Comparison of relaxation induced by glyceryl trinitrate, isosorbide dinitrate, and sodium nitroprusside in bovine airways.;Q3221044;P3781;Q162867
Comparison of relaxation induced by glyceryl trinitrate, isosorbide dinitrate, and sodium nitroprusside in bovine airways.;Q179748;P279;Q49916468
Comparative effects of isosorbide dinitrate, prednisolone, indomethacin, and elastase on the development of monocrotaline-induced pulmonary hypertension;Q179748;P279;Q49916468
[Drug therapy of coronary heart disease. Comparative effects of nifedipine and isosorbide dinitrate];Q179748;P279;Q49916468
[Drug therapy of coronary heart disease. Comparative effects of nifedipine and isosorbide dinitrate];Q1243800;P2175;Q844935
Pulmonary vascular effects of nitroglycerin and isosorbide dinitrate in patients with end-stage cardiomyopathies.;Q179748;P279;Q49916468
Comparative evaluation of a new formulation of isosorbide dinitrate oral spray and sublingual nitroglycerin tablets.;Q179748;P279;Q49916468
Ibuprofen plus isosorbide dinitrate treatment in the mdx mice ameliorates dystrophic heart structure.;Q179748;P279;Q49916468
[Hemodynamic effect of subchronic therapy with 120 mg isosorbide dinitrate in a slow release form in minimal to moderate post-infarct heart failure];Q179748;P279;Q49916468
Isosorbide dinitrate oral spray in acute exacerbation of chronic congestive heart failure secondary to coronary artery disease;Q179748;P279;Q49916468
Isosorbide dinitrate oral spray in acute exacerbation of chronic congestive heart failure secondary to coronary artery disease;Q1243800;P2175;Q844935
Isosorbide dinitrate oral spray in acute exacerbation of chronic congestive heart failure secondary to coronary artery disease;Q1243800;P2175;Q19000661
Plasma levels of isosorbide dinitrate and the isosorbide mononitrates after increasing doses of a retard preparation of isosorbide dinitrate;Q179748;P279;Q49916468
Plasma levels of isosorbide dinitrate and the isosorbide mononitrates after increasing doses of a retard preparation of isosorbide dinitrate;Q423401;P279;Q49916468
[Regional myocardial blood flow distribution (RMBF) and the influence of isosorbide dinitrate (ISDN) in patients with and without coronary heart disease (KHE)];Q179748;P279;Q49916468
[Regional myocardial blood flow distribution (RMBF) and the influence of isosorbide dinitrate (ISDN) in patients with and without coronary heart disease (KHE)];Q1243800;P2175;Q844935
Modification of platelet function by isosorbide dinitrate in patients with coronary artery disease;Q179748;P279;Q49916468
Modification of platelet function by isosorbide dinitrate in patients with coronary artery disease;Q1243800;P2175;Q844935
Effects and pharmacokinetics of isosorbide dinitrate in normal man.;Q179748;P279;Q49916468
Simultaneous determination of isosorbide dinitrate and its mononitrate metabolites in human plasma by capillary gas chromatography with electron-capture detection;Q183290;P703;Q15978631
Simultaneous determination of isosorbide dinitrate and its mononitrate metabolites in human plasma by capillary gas chromatography with electron-capture detection;Q179748;P279;Q49916468
Effects of isosorbide dinitrate on thromboxane A2 synthesis in carbon dioxide exposed platelets;Q218642;P527;Q623
Effects of isosorbide dinitrate on thromboxane A2 synthesis in carbon dioxide exposed platelets;Q179748;P279;Q49916468
Effects of isosorbide dinitrate on thromboxane A2 synthesis in carbon dioxide exposed platelets;Q1243800;P527;Q623
Antihypertensive effect of sustained-release isosorbide dinitrate for isolated systolic systemic hypertension in the elderly;Q179748;P279;Q49916468
No recovery of cold complex regional pain syndrome after transdermal isosorbide dinitrate: a small controlled trial.;Q179748;P279;Q49916468
[Vasodilator effects of intravenous isosorbide dinitrate in patients with heart failure--multi-center studies];Q179748;P279;Q49916468
[Effects of isosorbide dinitrate on left and right ventricular systolic time intervals in patients after myocardial infarction];Q179748;P279;Q49916468
Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris;Q39111;P2175;Q180762
Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris;Q179748;P279;Q49916468
Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris;Q1243800;P2175;Q180762
Effect of isosorbide dinitrate on hemodynamics and respiration of patients with coronary artery disease and of patients with chronic cor pulmonale.;Q179748;P279;Q49916468
Effect of isosorbide dinitrate on hemodynamics and respiration of patients with coronary artery disease and of patients with chronic cor pulmonale.;Q1243800;P2175;Q844935
Haemodynamics and plasma concentrations following sublingual GTN and intravenous, or inhaled, isosorbide dinitrate;Q179748;P279;Q49916468
Comparison of efficacy of nisoldipine, metoprolol, and isosorbide dinitrate in patients with stable exertional angina: a randomized, cross-over, placebo-controlled study;Q179748;P279;Q49916468
Comparison of efficacy of nisoldipine, metoprolol, and isosorbide dinitrate in patients with stable exertional angina: a randomized, cross-over, placebo-controlled study;Q3342150;P2175;Q180762
Comparison of efficacy of nisoldipine, metoprolol, and isosorbide dinitrate in patients with stable exertional angina: a randomized, cross-over, placebo-controlled study;Q1243800;P2175;Q180762
Randomized study to evaluate the relation between oral isosorbide dinitrate dosing interval and the development of early tolerance to its effect on left ventricular filling pressure in patients with chronic heart failure.;Q179748;P279;Q49916468
New association of nicardipine and isosorbide dinitrate to treat internal mammary artery vasopasm in DIEP breast reconstruction.;Q179748;P279;Q49916468
Hemodynamic and metabolic effects of isosorbide dinitrate in chronic congestive heart failure.;Q179748;P279;Q49916468
Hemodynamic and metabolic effects of isosorbide dinitrate in chronic congestive heart failure.;Q1243800;P2175;Q19000661
A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination.;Q179748;P279;Q49916468
The immediate effects of isosorbide dinitrate on right ventricular function in patients with acute hypoxemic respiratory failure. A combined invasive and radionuclide study.;Q179748;P279;Q49916468
Lack of oxidative stress during sustained therapy with isosorbide dinitrate and pentaerythrityl tetranitrate in healthy humans: a randomized, double-blind crossover study.;Q179748;P279;Q49916468
Lack of oxidative stress during sustained therapy with isosorbide dinitrate and pentaerythrityl tetranitrate in healthy humans: a randomized, double-blind crossover study.;Q483745;P703;Q15978631
Isosorbide dinitrate for treatment of preterm labor.;Q179748;P279;Q49916468
Plasma concentrations of isosorbide dinitrate after oral administration of a sustained-release formulation to human subjects;Q179748;P279;Q49916468
Plasma concentrations of isosorbide dinitrate after oral administration of a sustained-release formulation to human subjects;Q20035886;P703;Q15978631
Acute and subacute effects of nicorandil and isosorbide dinitrate on vessel wall properties of large arteries and hemodynamics in healthy volunteers;Q179748;P279;Q49916468
[Determination of isosorbide dinitrate and its degradation products in pharmaceuticals by gradient RP-HPLC];Q186474;P31;Q12140
[Determination of isosorbide dinitrate and its degradation products in pharmaceuticals by gradient RP-HPLC];Q485277;P31;Q12140
[Determination of isosorbide dinitrate and its degradation products in pharmaceuticals by gradient RP-HPLC];Q179748;P279;Q49916468
[Determination of isosorbide dinitrate and its degradation products in pharmaceuticals by gradient RP-HPLC];Q179748;P31;Q12140
[Determination of isosorbide dinitrate and its degradation products in pharmaceuticals by gradient RP-HPLC];Q173670;P31;Q12140
[Determination of isosorbide dinitrate and its degradation products in pharmaceuticals by gradient RP-HPLC];Q178450;P31;Q12140
[Determination of isosorbide dinitrate and its degradation products in pharmaceuticals by gradient RP-HPLC];Q20035886;P31;Q12140
[Determination of isosorbide dinitrate and its degradation products in pharmaceuticals by gradient RP-HPLC];Q483745;P31;Q12140
[Determination of isosorbide dinitrate and its degradation products in pharmaceuticals by gradient RP-HPLC];Q1243800;P31;Q12140
The effects of chewable isosorbide dinitrate in coronary insufficiency. A report on exercise electrocardiograms in 13 patients;Q179748;P279;Q49916468
Changes in myocardial ischaemia during isosorbide dinitrate or indoramin therapy in patients with stable angina using relations between the ST segment and heart rate.;Q179748;P279;Q49916468
Changes in myocardial ischaemia during isosorbide dinitrate or indoramin therapy in patients with stable angina using relations between the ST segment and heart rate.;Q1243800;P2175;Q180762
The effects of antianginal drugs on left ventricular function in patients with effort angina pectoris. Comparison among isosorbide dinitrate, nifedipine and propranolol by PANOVA.;Q218642;P31;Q12140
The effects of antianginal drugs on left ventricular function in patients with effort angina pectoris. Comparison among isosorbide dinitrate, nifedipine and propranolol by PANOVA.;Q186474;P31;Q12140
The effects of antianginal drugs on left ventricular function in patients with effort angina pectoris. Comparison among isosorbide dinitrate, nifedipine and propranolol by PANOVA.;Q186521;P31;Q12140
The effects of antianginal drugs on left ventricular function in patients with effort angina pectoris. Comparison among isosorbide dinitrate, nifedipine and propranolol by PANOVA.;Q7130425;P31;Q12140
The effects of antianginal drugs on left ventricular function in patients with effort angina pectoris. Comparison among isosorbide dinitrate, nifedipine and propranolol by PANOVA.;Q39111;P31;Q12140
The effects of antianginal drugs on left ventricular function in patients with effort angina pectoris. Comparison among isosorbide dinitrate, nifedipine and propranolol by PANOVA.;Q39111;P2175;Q180762
The effects of antianginal drugs on left ventricular function in patients with effort angina pectoris. Comparison among isosorbide dinitrate, nifedipine and propranolol by PANOVA.;Q207843;P31;Q12140
The effects of antianginal drugs on left ventricular function in patients with effort angina pectoris. Comparison among isosorbide dinitrate, nifedipine and propranolol by PANOVA.;Q179748;P31;Q12140
The effects of antianginal drugs on left ventricular function in patients with effort angina pectoris. Comparison among isosorbide dinitrate, nifedipine and propranolol by PANOVA.;Q179748;P279;Q49916468
The effects of antianginal drugs on left ventricular function in patients with effort angina pectoris. Comparison among isosorbide dinitrate, nifedipine and propranolol by PANOVA.;Q20035886;P31;Q12140
The effects of antianginal drugs on left ventricular function in patients with effort angina pectoris. Comparison among isosorbide dinitrate, nifedipine and propranolol by PANOVA.;Q483752;P31;Q12140
The effects of antianginal drugs on left ventricular function in patients with effort angina pectoris. Comparison among isosorbide dinitrate, nifedipine and propranolol by PANOVA.;Q1243800;P31;Q12140
The effects of antianginal drugs on left ventricular function in patients with effort angina pectoris. Comparison among isosorbide dinitrate, nifedipine and propranolol by PANOVA.;Q1243800;P2175;Q180762
Prevention of cardiac hypertrophy by long-term treatment with isosorbide dinitrate and prazosin but not by minoxidil in spontaneously hypertensive rats;Q179748;P279;Q49916468
Allergic reactions to glyceryl trinitrate and isosorbide dinitrate demonstrating cross-sensitivity.;Q3221044;P3781;Q162867
Allergic reactions to glyceryl trinitrate and isosorbide dinitrate demonstrating cross-sensitivity.;Q179748;P279;Q49916468
[Evaluation of antianginal efficacy of long-term therapy with low dose isosorbide dinitrate in patients with stable angina pectoris];Q179748;P279;Q49916468
[Evaluation of antianginal efficacy of long-term therapy with low dose isosorbide dinitrate in patients with stable angina pectoris];Q1243800;P2175;Q180762
What intervals in oral therapy of isosorbide dinitrate in various doses are sufficient to prevent nitrate tolerance?;Q179748;P279;Q49916468
Quantitative analysis of technetium 99m 2-methoxyisobutyl isonitrile single-photon emission computed tomography and isosorbide dinitrate infusion in assessment of myocardial viability before and after revascularization;Q179748;P279;Q49916468
Preparation and control-release kinetics of isosorbide dinitrate microspheres.;Q179748;P279;Q49916468
Serum concentrations of isosorbide dinitrate produced by a sustained-release capsule.;Q179748;P279;Q49916468
Comparative hemodynamic effects of placebo and oral isosorbide dinitrate in patients with significant coronary artery disease.;Q179748;P279;Q49916468
Comparative hemodynamic effects of placebo and oral isosorbide dinitrate in patients with significant coronary artery disease.;Q1243800;P2175;Q844935
High dose oral isosorbide dinitrate and ischemic heart pain: a preliminary report.;Q179748;P279;Q49916468
Metabolism of isosorbide dinitrate in the isolated perfused rabbit lung;Q179748;P279;Q49916468
Plasma concentrations and urinary excretion of isosorbide dinitrate and its metabolites in the dog;Q179748;P279;Q49916468
Absorption and excretion of isosorbide dinitrate and isosorbide-2-mononitrate in dogs;Q179748;P279;Q49916468
The action of amyl nitrite and isosorbide dinitrate on the contractility of sphincter of Oddi of guinea-pigs.;Q179748;P279;Q49916468
Recurrent catecholamine-induced coronary vasospam treated by intracoronary injection of isosorbide dinitrate in a patient with post-cardiac arrest syndrome.;Q179748;P279;Q49916468
Effect of a combination of pindolol and isosorbide dinitrate on ischemic ST-segment depression and exercise ability in angina pectoris.;Q179748;P279;Q49916468
Effect of a combination of pindolol and isosorbide dinitrate on ischemic ST-segment depression and exercise ability in angina pectoris.;Q418101;P2175;Q180762
Effect of a combination of pindolol and isosorbide dinitrate on ischemic ST-segment depression and exercise ability in angina pectoris.;Q1243800;P2175;Q180762
Comparison of acute haemodynamic effects of nifedipine and isosorbide dinitrate in patients with heart failure following acute myocardial infarction.;Q179748;P279;Q49916468
miRNA-130b is required for the ERK/FOXM1 pathway activation-mediated protective effects of isosorbide dinitrate against mesenchymal stem cell senescence induced by high glucose;Q179748;P279;Q49916468
Use of isosorbide dinitrate saliva concentrations for biopharmaceutical investigations;Q179748;P279;Q49916468
Use of isosorbide dinitrate saliva concentrations for biopharmaceutical investigations;Q179748;P31;Q12140
Use of isosorbide dinitrate saliva concentrations for biopharmaceutical investigations;Q1243800;P31;Q12140
In vivo three-dimensional EPR imaging of nitric oxide production from isosorbide dinitrate in mice;Q179748;P279;Q49916468
Comparative vasorelaxing profiles of nicorandil, isosorbide dinitrate and nitroglycerin in isolated coronary arteries of the dog.;Q179748;P279;Q49916468
Effects of propranolol and isosorbide dinitrate on exercise performance and adrenergic acitivity in patients with angina pectoris.;Q179748;P279;Q49916468
Effects of propranolol and isosorbide dinitrate on exercise performance and adrenergic acitivity in patients with angina pectoris.;Q1243800;P2175;Q180762
[Pharmacokinetics of isosorbide dinitrate studied by the extrapolation model];Q179748;P279;Q49916468
[Long term therapy of coronary heart disease with 120 mg slow release isosorbide dinitrate once a day. Study of duration of action and development of tolerance];Q179748;P279;Q49916468
[Long term therapy of coronary heart disease with 120 mg slow release isosorbide dinitrate once a day. Study of duration of action and development of tolerance];Q1243800;P2175;Q844935
[Relation of in vitro release of the isosorbide dinitrate to blood pressure changes after administration to anesthetized cats];Q179748;P279;Q49916468
A Double-Blind Randomized Trial Comparing the Effectiveness and Safety of Nifedipine and Isosorbide Dinitrate in Chronic Anal Fissure.;Q179748;P279;Q49916468
The efficiency of various doses of topical isosorbide dinitrate in the treatment of chronic anal fissure and the long-term results: a prospective, randomized and controlled clinical trial;Q179748;P279;Q49916468
Effects of isosorbide dinitrate on exercise capacity in cardiac patients--relationship between oxygen uptake responses and hemodynamic effects.;Q179748;P279;Q49916468
Effects of isosorbide dinitrate on exercise capacity in cardiac patients--relationship between oxygen uptake responses and hemodynamic effects.;Q1243800;P527;Q629
Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce Wave Reflections, Left Ventricular Hypertrophy, or Myocardial Fibrosis in Patients With Heart Failure With Preserved Ejection Fraction.;Q179748;P279;Q49916468
Differences in the antiischaemic effects of molsidomine and isosorbide dinitrate (ISDN) during acute and short-term administration in stable angina pectoris;Q179748;P279;Q49916468
Differences in the antiischaemic effects of molsidomine and isosorbide dinitrate (ISDN) during acute and short-term administration in stable angina pectoris;Q1243800;P2175;Q180762
The acute effects of low flow oxygen and isosorbide dinitrate on left and right ventricular ejection fractions in chronic obstructive pulmonary disease.;Q179748;P279;Q49916468
The acute effects of low flow oxygen and isosorbide dinitrate on left and right ventricular ejection fractions in chronic obstructive pulmonary disease.;Q1243800;P527;Q629
Continuous long-term dosing with oral slow-release isosorbide dinitrate does not reduce incidence of cardiac events in patients with healed myocardial infarction.;Q179748;P279;Q49916468
[Effects of isosorbide dinitrate on platelet aggregation and production of thromboxane B2];Q179748;P279;Q49916468
Isosorbide dinitrate plus hydralazine was effective for advanced heart failure in black patients.;Q179748;P279;Q49916468
High-dose isosorbide dinitrate for myocardial revascularization with composite arterial grafts;Q179748;P279;Q49916468
BiDil (isosorbide dinitrate and hydralazine): a new fixed-dose combination of two older medications for the treatment of heart failure in black patients.;Q179748;P31;Q12140
BiDil (isosorbide dinitrate and hydralazine): a new fixed-dose combination of two older medications for the treatment of heart failure in black patients.;Q179748;P279;Q49916468
BiDil (isosorbide dinitrate and hydralazine): a new fixed-dose combination of two older medications for the treatment of heart failure in black patients.;Q178450;P31;Q12140
BiDil (isosorbide dinitrate and hydralazine): a new fixed-dose combination of two older medications for the treatment of heart failure in black patients.;Q419987;P31;Q12140
BiDil (isosorbide dinitrate and hydralazine): a new fixed-dose combination of two older medications for the treatment of heart failure in black patients.;Q1243800;P31;Q12140
The acute effects of intravenous isosorbide dinitrate during cardiac surgery.;Q179748;P279;Q49916468
Identification of the urinary metabolites of isosorbide dinitrate in dogs;Q179748;P279;Q49916468
Comparison of the antianginal effectiveness of nifedipine, verapamil, and isosorbide dinitrate in patients receiving propranolol: a double-blind study;Q410291;P2175;Q180762
Comparison of the antianginal effectiveness of nifedipine, verapamil, and isosorbide dinitrate in patients receiving propranolol: a double-blind study;Q39111;P2175;Q180762
Comparison of the antianginal effectiveness of nifedipine, verapamil, and isosorbide dinitrate in patients receiving propranolol: a double-blind study;Q179748;P279;Q49916468
Comparison of the antianginal effectiveness of nifedipine, verapamil, and isosorbide dinitrate in patients receiving propranolol: a double-blind study;Q1243800;P2175;Q180762
Bioavailability and pharmacokinetics of a new isosorbide dinitrate spray preparation in healthy volunteers;Q179748;P279;Q49916468
[Dose-effect relationship of isosorbide dinitrate in the treatment of angina pectoris (author's transl)];Q179748;P279;Q49916468
[Dose-effect relationship of isosorbide dinitrate in the treatment of angina pectoris (author's transl)];Q1243800;P2175;Q180762
Efficacy and safety of the combination of isosorbide dinitrate spray and chitosan gel for the treatment of diabetic foot ulcers: A double-blind, randomized, clinical trial;Q179748;P279;Q49916468
Endoscopic papillary dilation by balloon and isosorbide dinitrate drip infusion for removing bile duct stone;Q179748;P279;Q49916468
Isosorbide dinitrate and pulsatile arterial haemodynamic variables in hypertension.;Q179748;P279;Q49916468
[Hemodynamic effects of intravenous isosorbide dinitrate in acute myocardial infarct];Q179748;P279;Q49916468
Comparison of the effects of molsidomine, nitroglycerin and isosorbide dinitrate on experimentally induced coronary artery thrombosis in the dog;Q179748;P279;Q49916468
[Haemodynamic effects of intravenous isosorbide dinitrate in congestive heart failure];Q179748;P279;Q49916468
[Haemodynamic effects of intravenous isosorbide dinitrate in congestive heart failure];Q1243800;P2175;Q19000661
Systemic and regional hemodynamic effects of isosorbide dinitrate in patients with liver cirrhosis and portal hypertension.;Q179748;P279;Q49916468
Transient pulsus alternans induced by isosorbide dinitrate: echocardiographic and hemodynamic evidence of reduced venous return--a case report;Q179748;P279;Q49916468
[Hemodynamic and isotope study of the effects of sublingual and oral administration of isosorbide dinitrate in cardiac insufficiency];Q179748;P279;Q49916468
Effect of chronic anal fissure components on isosorbide dinitrate treatment;Q179748;P279;Q49916468
[Comparison of the hypotensive effects of nitroglycerin (Nitrox-Spray) and isosorbide dinitrate (IsoMack-Spray) in rats];Q179748;P279;Q49916468
Alterations in myocardial perfusion during exercise after isosorbide dinitrate infusion in patients with coronary disease: assessment by thallium-201 scintigraphy;Q179748;P279;Q49916468
Altered hemodynamic response to isosorbide dinitrate in essential hypertension.;Q179748;P279;Q49916468
[The effects of isosorbide dinitrate spray on the coronary artery and its modification by the preceding chronic oral therapy with long acting isosorbide dinitrate];Q179748;P279;Q49916468
[Favorable results of conservative treatment with isosorbide dinitrate in 25 patients with fourth-degree hemorrhoids: a pilot study];Q179748;P279;Q49916468
[Patient compliance with a free and fixed combination of isosorbide dinitrate and bupranolol];Q179748;P279;Q49916468
[Possibility of developing tolerance to the anti-anginal effect of isosorbide dinitrate and verapamil];Q410291;P2175;Q180762
[Possibility of developing tolerance to the anti-anginal effect of isosorbide dinitrate and verapamil];Q179748;P279;Q49916468
[Possibility of developing tolerance to the anti-anginal effect of isosorbide dinitrate and verapamil];Q1243800;P2175;Q180762
Relationship between the pharmacodynamics and pharmacokinetics of two oral sustained-release formulations of isosorbide dinitrate in normal man;Q179748;P279;Q49916468
Antiischemic effects of a newly developed capsule containing 120 mg isosorbide dinitrate in sustained release form;Q179748;P279;Q49916468
The effect of isosorbide dinitrate and isosorbide-5-mononitrate on prostacyclin (PGI2) and thromboxane A2 (TXA2) generation in rat and human arteries;Q218642;P703;Q15978631
The effect of isosorbide dinitrate and isosorbide-5-mononitrate on prostacyclin (PGI2) and thromboxane A2 (TXA2) generation in rat and human arteries;Q186521;P703;Q15978631
The effect of isosorbide dinitrate and isosorbide-5-mononitrate on prostacyclin (PGI2) and thromboxane A2 (TXA2) generation in rat and human arteries;Q179748;P279;Q49916468
The effect of isosorbide dinitrate and isosorbide-5-mononitrate on prostacyclin (PGI2) and thromboxane A2 (TXA2) generation in rat and human arteries;Q20035886;P703;Q15978631
The effect of isosorbide dinitrate and isosorbide-5-mononitrate on prostacyclin (PGI2) and thromboxane A2 (TXA2) generation in rat and human arteries;Q620730;P703;Q15978631
The effect of isosorbide dinitrate and isosorbide-5-mononitrate on prostacyclin (PGI2) and thromboxane A2 (TXA2) generation in rat and human arteries;Q484940;P703;Q15978631
Bioequivalence of a sustained-release isosorbide dinitrate formulation at steady-state;Q179748;P279;Q49916468
Coronary MR imaging: effect of timing and dose of isosorbide dinitrate administration;Q179748;P279;Q49916468
Polarcardiographic (triaxicardiometric) study on the effect of isosorbide dinitrate on exercise-induced myocardial ischemia;Q179748;P279;Q49916468
[Solid phase extraction for GC detection analysis of isosorbide dinitrate and glycerol nitrate in human plasma];Q183290;P703;Q15978631
[Solid phase extraction for GC detection analysis of isosorbide dinitrate and glycerol nitrate in human plasma];Q186474;P703;Q15978631
[Solid phase extraction for GC detection analysis of isosorbide dinitrate and glycerol nitrate in human plasma];Q179748;P279;Q49916468
[Solid phase extraction for GC detection analysis of isosorbide dinitrate and glycerol nitrate in human plasma];Q620730;P703;Q15978631
[Prazosin in exercise-induced angina pectoris. An open study of work capacity after a single dose of prazosin, isosorbide dinitrate, atenolol and nifedipine];Q411325;P2175;Q180762
[Prazosin in exercise-induced angina pectoris. An open study of work capacity after a single dose of prazosin, isosorbide dinitrate, atenolol and nifedipine];Q39111;P2175;Q180762
[Prazosin in exercise-induced angina pectoris. An open study of work capacity after a single dose of prazosin, isosorbide dinitrate, atenolol and nifedipine];Q179748;P279;Q49916468
[Prazosin in exercise-induced angina pectoris. An open study of work capacity after a single dose of prazosin, isosorbide dinitrate, atenolol and nifedipine];Q1243800;P2175;Q180762
Loss of glyceryl trinitrate and of isosorbide dinitrate during infusion: a literature survey and practical recommendations;Q3221044;P3781;Q162867
Loss of glyceryl trinitrate and of isosorbide dinitrate during infusion: a literature survey and practical recommendations;Q179748;P279;Q49916468
Potentiation of isosorbide dinitrate effects with N-acetylcysteine in patients with chronic heart failure;Q179748;P279;Q49916468
[The effect of isosorbide dinitrate on the pulmonary arterial system in patients with pulmonary hypertension (author's transl)];Q179748;P279;Q49916468
Plasma disposition and hemodynamic effects of a single oral dose of isosorbide dinitrate in human males and females.;Q179748;P279;Q49916468
Plasma disposition and hemodynamic effects of a single oral dose of isosorbide dinitrate in human males and females.;Q20035886;P703;Q15978631
Effects of isosorbide dinitrate on pulmonary hypertension in chronic obstructive pulmonary disease.;Q179748;P279;Q49916468
Doppler diastolic transmitral flow patterns in severe heart failure: response to controlled changes in filling pressure using intravenous isosorbide dinitrate;Q179748;P279;Q49916468
[Effects of isosorbide dinitrate on systemic haemodynamics, regional coronary blood flow and ST-segment. A study on normal and/or ischaemic dog heart (author's transl)];Q179748;P279;Q49916468
Indomethacin increases the effect of isosorbide dinitrate on cerebral hemodynamic in migraine patients: pathogenetic and therapeutic implications;Q179748;P279;Q49916468
Indomethacin increases the effect of isosorbide dinitrate on cerebral hemodynamic in migraine patients: pathogenetic and therapeutic implications;Q484940;P703;Q177932
Isosorbide dinitrate in coronary heart disease. Effects of a delayed-action preparation during acute load and in chronic use;Q179748;P279;Q49916468
Isosorbide dinitrate in coronary heart disease. Effects of a delayed-action preparation during acute load and in chronic use;Q1243800;P2175;Q844935
Regional differences in the actions of verapamil and isosorbide dinitrate on rabbit and dog vascular smooth muscle.;Q179748;P279;Q49916468
Usefulness of intracoronary isosorbide dinitrate in alleviating myocardial ischaemia during coronary balloon angioplasty;Q179748;P279;Q49916468
Sustained hemodynamic and antianginal effects of high dose oral isosorbide dinitrate;Q179748;P279;Q49916468
Sustained hemodynamic and antianginal effects of high dose oral isosorbide dinitrate;Q1243800;P2175;Q180762
Sublingual isosorbide dinitrate for the detection of obstruction in hypertrophic cardiomyopathy;Q179748;P279;Q49916468
Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate;Q179748;P279;Q49916468
Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate;Q1243800;P2175;Q180762
[Experience in the use of isosorbide dinitrate (Carvanil), a drug for the treatment of angina pectoris.];Q186474;P31;Q12140
[Experience in the use of isosorbide dinitrate (Carvanil), a drug for the treatment of angina pectoris.];Q179748;P31;Q12140
[Experience in the use of isosorbide dinitrate (Carvanil), a drug for the treatment of angina pectoris.];Q179748;P279;Q49916468
[Experience in the use of isosorbide dinitrate (Carvanil), a drug for the treatment of angina pectoris.];Q1243800;P31;Q12140
[Experience in the use of isosorbide dinitrate (Carvanil), a drug for the treatment of angina pectoris.];Q1243800;P2175;Q180762
Hemodynamic effects of combined treatment with somatostatin analogue (SMS 201-995) and low-dose isosorbide dinitrate on portal hypertension in conscious cirrhotic rats.;Q179748;P279;Q49916468
The influence of isosorbide dinitrate and molsidomine on migration of polymorphonuclear neutrophils in vivo.;Q179748;P279;Q49916468
Regional myocardial dysfunction in patients with angina at rest and response to isosorbide dinitrate assessed by phase analysis of radionuclide ventriculograms.;Q179748;P279;Q49916468
Regional myocardial dysfunction in patients with angina at rest and response to isosorbide dinitrate assessed by phase analysis of radionuclide ventriculograms.;Q1243800;P2175;Q180762
Aminophylline 3%, Co-dergocrine Mesylate 0.05%, and Isosorbide Dinitrate 0.25% Cream for the Treatment of Orgasmic Dysfunction in Women;Q179748;P279;Q49916468
[The possibility of the development of isosorbide dinitrate and nifedipine withdrawal syndromes in patients with stable stenocardia of effort];Q179748;P279;Q49916468
Randomized double-blind comparison of isosorbide dinitrate and nifedipine in variant angina pectoris;Q39111;P2175;Q180762
Randomized double-blind comparison of isosorbide dinitrate and nifedipine in variant angina pectoris;Q179748;P279;Q49916468
Randomized double-blind comparison of isosorbide dinitrate and nifedipine in variant angina pectoris;Q1243800;P2175;Q180762
Effect of isosorbide dinitrate and atropine on the lower esophageal sphincter pressure in Chagasic patients.;Q179748;P279;Q49916468
Comparison of the immediate and long-term effects of captopril and isosorbide dinitrate as adjunctive treatment in mild heart failure.;Q179748;P279;Q49916468
[Effect of isosorbide dinitrate on esophageal emptying of chagasic megaesophagus: a therapeutic proposal?];Q179748;P279;Q49916468
Intracoronary administration of isosorbide dinitrate induced severely slow flow and transient ST-segment elevation.;Q179748;P279;Q49916468
Double-blind crossover comparison of the antianginal effects of nifedipine and isosorbide dinitrate in patients with exertional angina receiving propranolol;Q39111;P2175;Q180762
Double-blind crossover comparison of the antianginal effects of nifedipine and isosorbide dinitrate in patients with exertional angina receiving propranolol;Q179748;P279;Q49916468
Double-blind crossover comparison of the antianginal effects of nifedipine and isosorbide dinitrate in patients with exertional angina receiving propranolol;Q1243800;P2175;Q180762
Letter: Effectiveness of isosorbide dinitrate and nitroglycerin in relieving angina pectoris.;Q179748;P279;Q49916468
Letter: Effectiveness of isosorbide dinitrate and nitroglycerin in relieving angina pectoris.;Q1243800;P2175;Q180762
[Value of isosorbide dinitrate injection in the acute phase of myocardial infarction. Clinical and haemodynamic study (author's transl)];Q179748;P279;Q49916468
[Isosorbide dinitrate in the treatment of threatening myocardial infarction (author's transl)];Q179748;P279;Q49916468
Combined captopril and isosorbide dinitrate during healing after myocardial infarction. Effect on ventricular remodeling, function, mass and collagen;Q179748;P279;Q49916468
Intracervical application of the nitric oxide donor isosorbide dinitrate for induction of cervical ripening: a randomised controlled trial to determine clinical efficacy and safety prior to first trimester surgical evacuation of retained products of;Q179748;P279;Q49916468
Sublingual isosorbide dinitrate to improve technetium-99m-teboroxime perfusion defect reversibility;Q179748;P279;Q49916468
[Fendiline and isosorbide dinitrate in coronary heart disease (author's transl)];Q179748;P279;Q49916468
[Fendiline and isosorbide dinitrate in coronary heart disease (author's transl)];Q1243800;P2175;Q844935
Effect of sublingual isosorbide dinitrate on wedged hepatic venous pressure in cirrhotics with portal hypertension;Q179748;P279;Q49916468
Head-up tilt table testing with sublingual isosorbide dinitrate in the diagnosis of vasovagal syncope in children;Q179748;P279;Q49916468
[Continuous infusion of isosorbide dinitrate in intractable rest angina pectoris: report of a case];Q179748;P279;Q49916468
[Continuous infusion of isosorbide dinitrate in intractable rest angina pectoris: report of a case];Q1243800;P2175;Q180762
Nitrovasodilators ITF 296 and isosorbide dinitrate exert antiischemic activity by dilating coronary penetrating arteries.;Q179748;P2868;Q4008956
Nitrovasodilators ITF 296 and isosorbide dinitrate exert antiischemic activity by dilating coronary penetrating arteries.;Q179748;P279;Q49916468
Unmasking of an anomalous conduction pathway following isosorbide dinitrate;Q179748;P279;Q49916468
Perioperative sublingual isosorbide dinitrate for the prevention of cardiac complications in cardiac patients undergoing noncardiac surgery.;Q179748;P279;Q49916468
Nitroglycerin and isosorbide dinitrate stimulation of glutathione disulfide efflux from perfused rat liver;Q179748;P279;Q49916468
Efficacy of a single dose of slow-release isosorbide dinitrate in the treatment of silent or painful myocardial ischemia in stable angina pectoris.;Q179748;P279;Q49916468
Efficacy of a single dose of slow-release isosorbide dinitrate in the treatment of silent or painful myocardial ischemia in stable angina pectoris.;Q1243800;P2175;Q180762
Effect of isosorbide dinitrate on gastric blood flow in rats with liver cirrhosis determined by analyzing gastric blood flow, portal vein pressure and blood gas;Q179748;P279;Q49916468
[Effect of isosorbide dinitrate (isoket) on central hemodynamics and myocardial contraction in patients with ischemic heart disease].;Q179748;P279;Q49916468
[Effect of isosorbide dinitrate (isoket) on central hemodynamics and myocardial contraction in patients with ischemic heart disease].;Q1243800;P2175;Q844935
Effect of isosorbide dinitrate ointment on anal fissure.;Q179748;P279;Q49916468
Isosorbide dinitrate disposition in the rat: metabolite pharmacokinetics and interactions;Q179748;P279;Q49916468
Comparison of vaginal misoprostol, laminaria, and isosorbide dinitrate on cervical preparation and labor duration of term parturient: a randomized double-blind clinical trial.;Q179748;P279;Q49916468
Comparison of vaginal misoprostol, laminaria, and isosorbide dinitrate on cervical preparation and labor duration of term parturient: a randomized double-blind clinical trial.;Q416025;P636;Q4112929
Meta-Analysis of Randomized Controlled Trials on the Efficacy of Di'ao Xinxuekang Capsule and Isosorbide Dinitrate in Treating Angina Pectoris.;Q179748;P279;Q49916468
Solid-phase extraction of isosorbide dinitrate and two of its metabolites from plasma for gas chromatographic analysis;Q179748;P279;Q49916468
[The effect of a single administration of isosorbide dinitrate (Isoket ampules) in heart failure];Q179748;P279;Q49916468
Cost comparison analysis: pentaerythrithyl tetranitrate (PETN) and isosorbide dinitrate (ISDN) prescribed to diabetic patients in primary care practices in Germany.;Q179748;P279;Q49916468
Effects of vehicles and pressure sensitive adhesives on the penetration of isosorbide dinitrate across the hairless mouse skin.;Q179748;P279;Q49916468
[Determination of isosorbide dinitrate in human plasma after the administration of a newly-developed Czechoslovak preparation];Q186474;P703;Q15978631
[Determination of isosorbide dinitrate in human plasma after the administration of a newly-developed Czechoslovak preparation];Q179748;P279;Q49916468
[Determination of isosorbide dinitrate in human plasma after the administration of a newly-developed Czechoslovak preparation];Q178450;P703;Q15978631
Is tongxinluo more effective than isosorbide dinitrate in treating angina pectoris? A systematic review and meta-analysis of randomized controlled trials;Q179748;P279;Q49916468
Is tongxinluo more effective than isosorbide dinitrate in treating angina pectoris? A systematic review and meta-analysis of randomized controlled trials;Q1243800;P2175;Q180762
[Effects of intravenous infusion of isosorbide dinitrate (ISDN) on acute experimental congestive heart failure].;Q179748;P279;Q49916468
[Effects of intravenous infusion of isosorbide dinitrate (ISDN) on acute experimental congestive heart failure].;Q1243800;P2175;Q19000661
[The use of isosorbide dinitrate during open heart surgery].;Q179748;P279;Q49916468
Plasma concentrations of isosorbide dinitrate after administration of increasing doses of a sustained-release formulation to human subjects.;Q179748;P279;Q49916468
Plasma concentrations of isosorbide dinitrate after administration of increasing doses of a sustained-release formulation to human subjects.;Q20035886;P703;Q15978631
[Effect of isosorbide dinitrate on pulmonary artery pressure];Q179748;P279;Q49916468
[Comparison of isosorbide dinitrate and nifedipine in the treatment of variant angina pectoris. Randomized study];Q39111;P2175;Q180762
[Comparison of isosorbide dinitrate and nifedipine in the treatment of variant angina pectoris. Randomized study];Q179748;P279;Q49916468
[Comparison of isosorbide dinitrate and nifedipine in the treatment of variant angina pectoris. Randomized study];Q1243800;P2175;Q180762
Absorption of isosorbide dinitrate by PVC infusion bags and administration sets;Q179748;P279;Q49916468
[Isosorbide dinitrate in the treatment of coronary insufficiency];Q179748;P279;Q49916468
Hydralazine and isosorbide dinitrate: comparative central and regional hemodynamic effects when administered alone or in combination.;Q179748;P279;Q49916468
Preparation and characterization of niosomal gel for iontophoresis mediated transdermal delivery of isosorbide dinitrate;Q179748;P279;Q49916468
Antiplatelet effects of isosorbide dinitrate in man;Q179748;P279;Q49916468
Circadian investigation of interval therapy with isosorbide dinitrate in coronary heart disease.;Q179748;P279;Q49916468
Circadian investigation of interval therapy with isosorbide dinitrate in coronary heart disease.;Q1243800;P2175;Q844935
Effects of long-term molsidomine treatment versus isosorbide dinitrate and placebo on exercise tolerance in stable angina;Q179748;P279;Q49916468
Effects of long-term molsidomine treatment versus isosorbide dinitrate and placebo on exercise tolerance in stable angina;Q1243800;P2175;Q180762
Determination of isosorbide dinitrate biotransformation in various tissues of the rabbit by capillary column gas-liquid chromatography;Q179748;P279;Q49916468
Angina prophylaxis by chewable isosorbide dinitrate;Q179748;P279;Q49916468
Use of isosorbide dinitrate for the symptomatic treatment of patients with Chagas' disease achalasia. A double-blind, crossover trial.;Q179748;P279;Q49916468
Coronary artery distensibility in Kawasaki disease--evaluation by intracoronary infusion of isosorbide dinitrate in long-term follow-up.;Q179748;P279;Q49916468
[Isosorbide dinitrate tolerance in the treatment of patients with angina pectoris and the effect of addition of captopril on therapeutic results];Q179748;P279;Q49916468
[Isosorbide dinitrate tolerance in the treatment of patients with angina pectoris and the effect of addition of captopril on therapeutic results];Q1243800;P2175;Q180762
[Isosorbide dinitrate tolerance in the treatment of patients with angina pectoris and the effect of addition of captopril on therapeutic results];Q484940;P703;Q177932
[Pulmonary artery pressure measurement for assessment of bioavailability of isosorbide dinitrate and pentaerythritol tetranitrate (author's transl)];Q179748;P279;Q49916468
[Pulmonary artery pressure measurement for assessment of bioavailability of isosorbide dinitrate and pentaerythritol tetranitrate (author's transl)];Q3899224;P460;Q189334
Chronic treatment and tolerance with high doses of isosorbide dinitrate in a slow release form in patients with angina pectoris;Q179748;P279;Q49916468
Chronic treatment and tolerance with high doses of isosorbide dinitrate in a slow release form in patients with angina pectoris;Q1243800;P2175;Q180762
Potentiation of radiation-induced regrowth delay by isosorbide dinitrate in FSaII murine tumors;Q179748;P279;Q49916468
[The potential toxic action of the excipient of delayed-release isosorbide dinitrate];Q179748;P279;Q49916468
Isosorbide dinitrate and isoxsuprine in exercise induced asthma.;Q179748;P279;Q49916468
[Nitrite and methemoglobin formation in dogs following oral isosorbide dinitrate, isosorbide-2-mononitrate and isosorbide-5-mononitrate];Q179748;P279;Q49916468
Effect of sustained action isosorbide dinitrate on exercise performance in patients with ischemic heart disease;Q179748;P279;Q49916468
Effect of sustained action isosorbide dinitrate on exercise performance in patients with ischemic heart disease;Q1243800;P2175;Q844935
[Pharmacology of isosorbide dinitrate after transdermal application];Q179748;P279;Q49916468
[Comparison of the clinical and hemodynamic effects of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate in acute myocardial infarction];Q179748;P279;Q49916468
[Comparison of the clinical and hemodynamic effects of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate in acute myocardial infarction];Q905750;P2175;Q207550
Determination of isosorbide dinitrate and its metabolites in plasma by gas chromatography on a capillary column with electron-capture detection;Q179748;P279;Q49916468
Transdermal isosorbide dinitrate in angina pectoris: effect of acute and sustained therapy;Q179748;P279;Q49916468
Transdermal isosorbide dinitrate in angina pectoris: effect of acute and sustained therapy;Q1243800;P2175;Q180762
Randomized placebo-controlled comparative study of nifedipine, verapamil and isosorbide dinitrate in the treatment of angina at rest;Q410291;P2175;Q180762
Randomized placebo-controlled comparative study of nifedipine, verapamil and isosorbide dinitrate in the treatment of angina at rest;Q39111;P2175;Q180762
Randomized placebo-controlled comparative study of nifedipine, verapamil and isosorbide dinitrate in the treatment of angina at rest;Q179748;P279;Q49916468
Randomized placebo-controlled comparative study of nifedipine, verapamil and isosorbide dinitrate in the treatment of angina at rest;Q1243800;P2175;Q180762
A comparison of the effects of isosorbide dinitrate on isolated rabbit aorta and vena cava: role of guanosine 3',5'-cyclic monophosphate in vascular smooth muscle relaxation;Q179748;P279;Q49916468
Cooling down unstable angina with high dosage of isosorbide dinitrate (ISDN) continuously infused.;Q179748;P279;Q49916468
Cooling down unstable angina with high dosage of isosorbide dinitrate (ISDN) continuously infused.;Q1243800;P2175;Q180762
[Non-invasive methods in the study of the elastic properties of the thoracic aorta. Effect of isosorbide dinitrate];Q179748;P279;Q49916468
Effect of peroral administration of isosorbide dinitrate on portal pressure and blood flow in patients with cirrhosis of the liver;Q179748;P279;Q49916468
Is danshen (Salvia miltiorrhiza) dripping pill more effective than isosorbide dinitrate in treating angina pectoris? A systematic review of randomized controlled trials.;Q179748;P279;Q49916468
Is danshen (Salvia miltiorrhiza) dripping pill more effective than isosorbide dinitrate in treating angina pectoris? A systematic review of randomized controlled trials.;Q1243800;P2175;Q180762
Blood volume and right heart haemodynamics in abrupt hypotension following sublingual isosorbide dinitrate in acute myocardial infarction.;Q179748;P279;Q49916468
Release of isosorbide dinitrate from polymer film dosage forms and absorption of this drug through the oral mucosa of rats;Q179748;P279;Q49916468
Release of isosorbide dinitrate from polymer film dosage forms and absorption of this drug through the oral mucosa of rats;Q179748;P31;Q12140
Release of isosorbide dinitrate from polymer film dosage forms and absorption of this drug through the oral mucosa of rats;Q173670;P31;Q12140
Release of isosorbide dinitrate from polymer film dosage forms and absorption of this drug through the oral mucosa of rats;Q1243800;P31;Q12140
Attenuation by isosorbide dinitrate of coronary occlusion-induced acidosis in the dog myocardium.;Q179748;P279;Q49916468
Treatment of portal hypertension with isosorbide dinitrate alone and in combination with vasopressin;Q183011;P31;Q66571917
Treatment of portal hypertension with isosorbide dinitrate alone and in combination with vasopressin;Q179748;P279;Q49916468
Effects of isosorbide dinitrate on the pattern of arterial blood flow in healthy human subjects.;Q179748;P279;Q49916468
Effect of sublingual isosorbide dinitrate in portal hypertension;Q179748;P279;Q49916468
[Effect of isosorbide dinitrate on neutrophil migration in vivo];Q179748;P279;Q49916468
[Isosorbide dinitrate and bupranolol in the therapy of coronary heart disease (author's transl)];Q179748;P279;Q49916468
[Isosorbide dinitrate and bupranolol in the therapy of coronary heart disease (author's transl)];Q1243800;P2175;Q844935
Withdrawal effects of antianginal therapy: comparison of isosorbide dinitrate and nifedipine.;Q39111;P2175;Q180762
Withdrawal effects of antianginal therapy: comparison of isosorbide dinitrate and nifedipine.;Q179748;P279;Q49916468
Withdrawal effects of antianginal therapy: comparison of isosorbide dinitrate and nifedipine.;Q1243800;P2175;Q180762
Double blind controlled clinical trial of a long acting coronary vasodilator isosorbide dinitrate (sorbitrate);Q179748;P2868;Q4008956
Double blind controlled clinical trial of a long acting coronary vasodilator isosorbide dinitrate (sorbitrate);Q179748;P279;Q49916468
Pulmonary vascular effects of trinitroglycerin and isosorbide dinitrate after cardiopulmonary bypass.;Q179748;P279;Q49916468
The development and reversal of tolerance to antianginal effect of isosorbide dinitrate in patients with effort angina;Q179748;P279;Q49916468
The development and reversal of tolerance to antianginal effect of isosorbide dinitrate in patients with effort angina;Q1243800;P2175;Q180762
[Controlled clinical test of the antianginal action of the association of isosorbide dinitrate and prenylamine theophyllineacetate];Q179748;P279;Q49916468
[Controlled clinical test of the antianginal action of the association of isosorbide dinitrate and prenylamine theophyllineacetate];Q1243800;P2175;Q180762
Long-term effect of isosorbide dinitrate and nifedipine, singly and in association, in patients with chronic heart failure.;Q179748;P279;Q49916468
Propranolol and isosorbide dinitrate synergism in angina pectoris;Q179748;P279;Q49916468
Propranolol and isosorbide dinitrate synergism in angina pectoris;Q1243800;P2175;Q180762
A ten-year reevaluation. Nitroglycerin and isosorbide dinitrate in coronary insufficiency;Q179748;P279;Q49916468
Gas-liquid chromatographic determination of isosorbide dinitrate in tablets;Q179748;P279;Q49916468
Effects of isosorbide dinitrate on the urinary flow rate in patients with benign prostatic hyperplasia.;Q179748;P279;Q49916468
[Tolerance to a sustained release form of isosorbide dinitrate: comparison between 20 mg four times and 40 mg twice-daily administrations];Q179748;P279;Q49916468
[The effect of peroral administration of isosorbide dinitrate on portal pressure and flow in patients with liver cirrhosis];Q179748;P279;Q49916468
[Combination therapy with isosorbide dinitrate and verapamil in patients with coronary heart disease and hypertension: effect on blood pressure, ischemia and left ventricular function];Q410291;P2175;Q41861
[Combination therapy with isosorbide dinitrate and verapamil in patients with coronary heart disease and hypertension: effect on blood pressure, ischemia and left ventricular function];Q179748;P279;Q49916468
[Combination therapy with isosorbide dinitrate and verapamil in patients with coronary heart disease and hypertension: effect on blood pressure, ischemia and left ventricular function];Q1243800;P2175;Q844935
Kinetics of isosorbide dinitrate and relationships to pharmacological effects;Q179748;P279;Q49916468
[Anti-angina effectiveness of isosorbide dinitrate in an acute trial and following continuous 4-week therapy with 40 mg 6 times a day];Q179748;P279;Q49916468
[Anti-angina effectiveness of isosorbide dinitrate in an acute trial and following continuous 4-week therapy with 40 mg 6 times a day];Q1243800;P2175;Q180762
[Clinical evaluation of isosorbitol dinitrate (isosorbide dinitrate) in patients with critical stenosis of coronary arteries];Q179748;P279;Q49916468
Tolerance development during isosorbide dinitrate treatment: can it be circumvented?;Q179748;P279;Q49916468
Hemodynamic changes associated with angina pectoris induced by maximal treadmill exercise: effect of sublingual isosorbide dinitrate on systolic time intervals.;Q179748;P279;Q49916468
Hemodynamic changes associated with angina pectoris induced by maximal treadmill exercise: effect of sublingual isosorbide dinitrate on systolic time intervals.;Q1243800;P2175;Q180762
[Evaluation of the effectiveness of new delayed-action isosorbide dinitrate preparations in patients with exertion-induced stenocardia];Q179748;P279;Q49916468
Sublingual isosorbide dinitrate therapy versus sublingual acebo in angina pectoris;Q179748;P279;Q49916468
Sublingual isosorbide dinitrate therapy versus sublingual acebo in angina pectoris;Q1243800;P2175;Q180762
Influence of isosorbide dinitrate (ISDN) on compliance of the pulmonary venous system.;Q179748;P279;Q49916468
Clinical comparison of antiischemic efficacy of isosorbide dinitrate and molsidomine;Q179748;P279;Q49916468
[Comparative Assessment of Effects of Isosorbide Dinitrate, Isosorbide-5-Mononitrate and Nicorandil on the Frequency-of Angina Attacks and Vasoregulating Endothelial Function in Patients With Ischemic Heart Disease];Q179748;P279;Q49916468
[Comparative Assessment of Effects of Isosorbide Dinitrate, Isosorbide-5-Mononitrate and Nicorandil on the Frequency-of Angina Attacks and Vasoregulating Endothelial Function in Patients With Ischemic Heart Disease];Q423401;P279;Q49916468
[Hemodynamic effect of sublingual isosorbide dinitrate in acute myocardial infarct];Q179748;P279;Q49916468
Intravenous isosorbide dinitrate infusion in the management of unstable angina pectoris refractory to conventional medical therapy;Q179748;P279;Q49916468
Intravenous isosorbide dinitrate infusion in the management of unstable angina pectoris refractory to conventional medical therapy;Q1243800;P2175;Q180762
A case of vasospastic angina in which the ergonovine provocation test with intracoronary isosorbide dinitrate and nicorandil was effective in the diagnosis of microvascular spasm;Q179748;P279;Q49916468
A case of vasospastic angina in which the ergonovine provocation test with intracoronary isosorbide dinitrate and nicorandil was effective in the diagnosis of microvascular spasm;Q1243800;P2175;Q180762
Nitroglycerin and isosorbide dinitrate in coronary insufficiency;Q179748;P279;Q49916468
Intravenous isosorbide dinitrate in patients with refractory pump failure and acute myocardial infarction.;Q179748;P279;Q49916468
Isosorbide dinitrate in nephronophthisis treatment;Q179748;P279;Q49916468
Influence of systemically given placebo, trapidil and isosorbide dinitrate on norepinephrine-evoked hand vein constriction in healthy subjects.;Q186242;P1535;Q21098983
Influence of systemically given placebo, trapidil and isosorbide dinitrate on norepinephrine-evoked hand vein constriction in healthy subjects.;Q28163586;P3781;Q132621
Influence of systemically given placebo, trapidil and isosorbide dinitrate on norepinephrine-evoked hand vein constriction in healthy subjects.;Q179748;P279;Q49916468
Early hemodynamic effects at rest with acute and chronic isosorbide dinitrate treatment in patients with ischemic heart disease;Q179748;P279;Q49916468
Early hemodynamic effects at rest with acute and chronic isosorbide dinitrate treatment in patients with ischemic heart disease;Q1243800;P2175;Q844935
Assessment of dermal glyceryl trinitrate and isosorbide dinitrate for patients with angina pectoris;Q3221044;P3781;Q162867
Assessment of dermal glyceryl trinitrate and isosorbide dinitrate for patients with angina pectoris;Q3221044;P2175;Q180762
Assessment of dermal glyceryl trinitrate and isosorbide dinitrate for patients with angina pectoris;Q179748;P279;Q49916468
Assessment of dermal glyceryl trinitrate and isosorbide dinitrate for patients with angina pectoris;Q1243800;P2175;Q180762
Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina;Q179748;P279;Q49916468
Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina;Q1243800;P2175;Q180762
[The evaluation of viability in infarcted myocardium using gated blood pool scintigraphy during combined infusion of isosorbide dinitrate and dobutamine infusion];Q179748;P279;Q49916468
Effects of isosorbide dinitrate on pancreatic exocrine secretion in the dog;Q179748;P279;Q49916468
Improvement in exercise haemodynamics by isosorbide dinitrate in patients with severe congestive cardiac failure secondary to ischaemic heart disease.;Q179748;P279;Q49916468
Head-up tilt testing potentiated with low-dose sublingual isosorbide dinitrate: a simplified time-saving approach for the evaluation of unexplained syncope.;Q179748;P279;Q49916468
Comparison among the effects of arginine, a nitric oxide precursor, isosorbide dinitrate and molsidomine, two nitric oxide donors, on hormonal secretions and blood pressure in man;Q207843;P2868;Q50316227
Comparison among the effects of arginine, a nitric oxide precursor, isosorbide dinitrate and molsidomine, two nitric oxide donors, on hormonal secretions and blood pressure in man;Q179748;P279;Q49916468
Comparison among the effects of arginine, a nitric oxide precursor, isosorbide dinitrate and molsidomine, two nitric oxide donors, on hormonal secretions and blood pressure in man;Q179748;P2868;Q50316227
Comparison among the effects of arginine, a nitric oxide precursor, isosorbide dinitrate and molsidomine, two nitric oxide donors, on hormonal secretions and blood pressure in man;Q1243800;P2868;Q50316227
Hemodynamic effects of cutaneously administered isosorbide dinitrate ointment.;Q179748;P279;Q49916468
Left ventricular aneurysm and congestive heart failure: value of exercise stress and isosorbide dinitrate in predicting hemodynamic results of aneurysmectomy;Q179748;P279;Q49916468
Left ventricular aneurysm and congestive heart failure: value of exercise stress and isosorbide dinitrate in predicting hemodynamic results of aneurysmectomy;Q1243800;P2175;Q19000661
A study into the mucosal absorption of isosorbide dinitrate at different intraoral sites;Q179748;P279;Q49916468
Reduction of myocardial ischemic injury with sublingual isosorbide dinitrate;Q179748;P279;Q49916468
Management of acute heart failure following myocardial infarction: hemodynamic advantages of isosorbide dinitrate over frusemide;Q179748;P279;Q49916468
[Evaluation by means of atrial pacing of the hemodynamic and clinical effects of a delayed-action isosorbide dinitrate preparation in patients with angina pectoris];Q179748;P279;Q49916468
[Evaluation by means of atrial pacing of the hemodynamic and clinical effects of a delayed-action isosorbide dinitrate preparation in patients with angina pectoris];Q1243800;P2175;Q180762
[Bradycardia and hypotension induced by clonidine and isosorbide dinitrate (author's transl)];Q179748;P279;Q49916468
Measurement of plasma concentrations of isosorbide dinitrate;Q179748;P279;Q49916468
Plasma concentrations of isosorbide dinitrate after cutaneous and sublingual doses to human subjects.;Q179748;P279;Q49916468
Plasma concentrations of isosorbide dinitrate after cutaneous and sublingual doses to human subjects.;Q20035886;P703;Q15978631
Hemodynamic effects of oral and sublingual forms of isosorbide dinitrate in patients with acute coronary insufficiency;Q179748;P279;Q49916468
Effect of noradrenaline, sodium nitrite and isosorbide dinitrate on albumin transport in the wall of the excised rabbit common carotid artery;Q339975;P527;Q658
Effect of noradrenaline, sodium nitrite and isosorbide dinitrate on albumin transport in the wall of the excised rabbit common carotid artery;Q132621;P31;Q7279006
Effect of noradrenaline, sodium nitrite and isosorbide dinitrate on albumin transport in the wall of the excised rabbit common carotid artery;Q179748;P279;Q49916468
The effect of isosorbide dinitrate on the arterial vascular bed: a dose response study in dogs.;Q179748;P279;Q49916468
[Pulmonary extravascular water volume in heart diseases: the effect of isosorbide dinitrate on hemodynamic pulmonary edema];Q179748;P279;Q49916468
[Pulmonary extravascular water volume in heart diseases: the effect of isosorbide dinitrate on hemodynamic pulmonary edema];Q29053744;P366;Q7892
Topical application of isosorbide dinitrate in patients with persistent constipation after pull-through surgery for Hirschsprung's disease.;Q179748;P279;Q49916468
Beta-adrenergic-blocker LB46 and isosorbide dinitrate synergism in angina pectoris;Q179748;P279;Q49916468
Beta-adrenergic-blocker LB46 and isosorbide dinitrate synergism in angina pectoris;Q1243800;P2175;Q180762
Cardioprotective Effect of Isosorbide Dinitrate Postconditioning Against Rat Myocardial Ischemia-Reperfusion Injury In Vivo;Q179748;P279;Q49916468
[Hemodynamic study during 48 hours of delayed-release isosorbide dinitrate (repeated oral administration) in the acute phase of myocardial infarction complicated by left ventricular insufficiency];Q179748;P279;Q49916468
Effects of isosorbide dinitrate and diltiazem on Ca2+ flux and contraction in artery;Q179748;P279;Q49916468
[Pharmacokinetics of isosorbide dinitrate administered by intravenous infusion to hypertensive patients (author's transl)];Q179748;P279;Q49916468
Effect of swallowed isosorbide dinitrate on blood pressure, heart rate and exercise capacity in patients with coronary artery disease.;Q179748;P279;Q49916468
Effect of swallowed isosorbide dinitrate on blood pressure, heart rate and exercise capacity in patients with coronary artery disease.;Q1243800;P2175;Q844935
[Clinical and hemodynamic evaluation of isosorbide dinitrate therapy in heart failure (author's transl)];Q179748;P279;Q49916468
Nisoldipine versus isosorbide dinitrate in coronary heart disease: results of a double-masked study.;Q179748;P279;Q49916468
Nisoldipine versus isosorbide dinitrate in coronary heart disease: results of a double-masked study.;Q1243800;P2175;Q844935
[Treatment with isosorbide dinitrate of chronic myocardial infarction depending on the results of floating catheter-ergometer loading];Q179748;P279;Q49916468
Antagonism of cyanide toxicity by isosorbide dinitrate: possible role of nitric oxide.;Q179748;P279;Q49916468
Vasodilative effect of isosorbide dinitrate ointment in complex regional pain syndrome type 1.;Q179748;P279;Q49916468
Response to changing plasma concentrations of isosorbide-bound NO2 during acute and sustained treatment with isosorbide dinitrate in patients with coronary artery disease;Q179748;P279;Q49916468
Response to changing plasma concentrations of isosorbide-bound NO2 during acute and sustained treatment with isosorbide dinitrate in patients with coronary artery disease;Q1243800;P2175;Q844935
Nitrate tolerance: hemodynamic effects of intravenous isosorbide dinitrate after sustained oral isosorbide dinitrate administration.;Q179748;P279;Q49916468
[Comparative Assessment of Effects of Isosorbide Dinitrate, Isosorbide-5-Mononitrate and Nicorandil on the Frequency of Angina Attacks and Vasoregulating Endothelial Function in Patients With Ischemic Heart Disease].;Q179748;P279;Q49916468
[Comparative Assessment of Effects of Isosorbide Dinitrate, Isosorbide-5-Mononitrate and Nicorandil on the Frequency of Angina Attacks and Vasoregulating Endothelial Function in Patients With Ischemic Heart Disease].;Q423401;P279;Q49916468
Local effect of transdermal isosorbide dinitrate ointment on hand vein diameter.;Q179748;P279;Q49916468
Pharmacokinetics of isosorbide dinitrate in healthy volunteers after 24-hour intravenous infusion;Q179748;P279;Q49916468
Mechanism of ITF 296-induced vasorelaxation compared to nitroglycerin and isosorbide dinitrate: relationship between relaxation of rabbit aorta and tissue cGMP.;Q179748;P279;Q49916468
Influence of isosorbide dinitrate on superior mesenteric artery impedance in humans.;Q179748;P279;Q49916468
Influence of isosorbide dinitrate on superior mesenteric artery impedance in humans.;Q484940;P703;Q15978631
Biotransformation of glyceryl trinitrate and isosorbide dinitrate in vascular smooth muscle made tolerant to organic nitrates.;Q3221044;P3781;Q162867
Biotransformation of glyceryl trinitrate and isosorbide dinitrate in vascular smooth muscle made tolerant to organic nitrates.;Q179748;P279;Q49916468
Coronary MRI with induced vasodilation using isosorbide dinitrate;Q179748;P279;Q49916468
Isosorbide dinitrate alone and in association with intra-aortic balloon counterpulsation in acute myocardial infarction. A clinical study by precordial ECG mapping;Q179748;P279;Q49916468
Isosorbide dinitrate ointment vs botulinum toxin A (Dysport) as the primary treatment for chronic anal fissure: a randomized multicentre study;Q179748;P279;Q49916468
Comparison between isosorbide dinitrate in aerosol and in tablets for the treatment of hypertensive emergencies;Q179748;P279;Q49916468
Influence of standard and nicotine-reduced cigarette smoke on plasma concentrations of isosorbide dinitrate and its metabolites in rats;Q179748;P279;Q49916468
Influence of standard and nicotine-reduced cigarette smoke on plasma concentrations of isosorbide dinitrate and its metabolites in rats;Q28086552;P31;Q12144
[The effect of isosorbide dinitrate (Isoket Pharma-Schwartz) in patients with liver cirrhosis];Q179748;P279;Q49916468
Therapeutic effects of nitric oxide-donor isosorbide dinitrate on atherosclerosis-induced alterations in hemodynamics and arterial viscoelasticity are independent of the wall elastic component;Q186521;P703;Q177932
Therapeutic effects of nitric oxide-donor isosorbide dinitrate on atherosclerosis-induced alterations in hemodynamics and arterial viscoelasticity are independent of the wall elastic component;Q179748;P279;Q49916468
Differential inhibitory effects of isosorbide dinitrate and its mononitrate metabolites on platelet aggregation and thromboxane formation;Q179748;P279;Q49916468
The effect of pindolol and isosorbide dinitrate and their combination on exercise tolerance and ECG changes in angina pectoris;Q179748;P279;Q49916468
The effect of pindolol and isosorbide dinitrate and their combination on exercise tolerance and ECG changes in angina pectoris;Q418101;P2175;Q180762
The effect of pindolol and isosorbide dinitrate and their combination on exercise tolerance and ECG changes in angina pectoris;Q1243800;P2175;Q180762
Use of sublingual isosorbide dinitrate tablet for manual extraction of a retained placenta.;Q179748;P279;Q49916468
Influence of endothelium in dose-dependent inhibition and potentiation by isoniazid of isosorbide dinitrate relaxation of rat aorta.;Q179748;P279;Q49916468
Nitrate tolerance: influence of isosorbide dinitrate on the hemodynamic and antianginal effects of nitroglycerin;Q179748;P279;Q49916468
Nitrate tolerance: influence of isosorbide dinitrate on the hemodynamic and antianginal effects of nitroglycerin;Q1243800;P2175;Q180762
[The effect of isosorbide dinitrate spray on patients receiving coronary artery bypass grafting];Q179748;P279;Q49916468
The effects of an intravenous infusion of isosorbide dinitrate during open heart surgery.;Q179748;P279;Q49916468
Effect of sublingual isosorbide dinitrate on sputum volume and viscoelasticity in chronic obstructive lung disease;Q179748;P279;Q49916468
[Approaches to the personal antianginal therapy. Can we consider nitrosorbide as a drug of choice?];Q218642;P31;Q12140
[Approaches to the personal antianginal therapy. Can we consider nitrosorbide as a drug of choice?];Q186474;P31;Q12140
[Approaches to the personal antianginal therapy. Can we consider nitrosorbide as a drug of choice?];Q191924;P31;Q12140
[Approaches to the personal antianginal therapy. Can we consider nitrosorbide as a drug of choice?];Q905750;P31;Q12140
Sustained effect of orally administered isosorbide dinitrate on exercise performance of patients with angina pectoris.;Q179748;P279;Q49916468
Sustained effect of orally administered isosorbide dinitrate on exercise performance of patients with angina pectoris.;Q1243800;P2175;Q180762
Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial;Q179748;P279;Q49916468
[Influence of oral isosorbide dinitrate (ISDN) on parameters of blood flow in the coeliac trunk evaluated with doppler sonography].;Q179748;P279;Q49916468
Hemodynamic measurements and exercise testing to assess the development of tolerance against slow-release isosorbide dinitrate;Q179748;P279;Q49916468
Isosorbide dinitrate and exercise performance in patients with congestive heart failure.;Q179748;P279;Q49916468
Isosorbide dinitrate and exercise performance in patients with congestive heart failure.;Q1243800;P2175;Q19000661
Concentrations of isosorbide dinitrate, isosorbide-2-mononitrate and isosorbide-5-mononitrate in human vascular and muscle tissue under steady-state conditions.;Q186474;P703;Q15978631
Concentrations of isosorbide dinitrate, isosorbide-2-mononitrate and isosorbide-5-mononitrate in human vascular and muscle tissue under steady-state conditions.;Q179748;P279;Q49916468
Simultaneous determination of isosorbide dinitrate and its mononitrates in human plasma by capillary column GLC.;Q183290;P703;Q15978631
Simultaneous determination of isosorbide dinitrate and its mononitrates in human plasma by capillary column GLC.;Q186474;P703;Q15978631
Simultaneous determination of isosorbide dinitrate and its mononitrates in human plasma by capillary column GLC.;Q179748;P279;Q49916468
Simultaneous determination of isosorbide dinitrate and its mononitrates in human plasma by capillary column GLC.;Q620730;P703;Q15978631
Simultaneous determination of isosorbide dinitrate and its mononitrates in human plasma by capillary column GLC.;Q483745;P703;Q15978631
The effect of isosorbide dinitrate on uterine and ovarian blood flow in cycling and early pregnant mares: A pilot study.;Q179748;P279;Q49916468
Dose-response relation of antianginal activity of isosorbide dinitrate;Q179748;P279;Q49916468
Dose-response relation of antianginal activity of isosorbide dinitrate;Q1243800;P2175;Q180762
Isosorbide dinitrate in experimental portal hypertension: a study of factors that modulate the hemodynamic response.;Q179748;P279;Q49916468
Randomized double-blind comparison of nifedipine and isosorbide dinitrate in patients with coronary arterial spasm.;Q179748;P279;Q49916468
[Differential effects of isosorbide dinitrate and nitroprusside on pial vessel diameter in cats];Q179748;P279;Q49916468
[Comparative studies of the dissolution kinetics of 2 pharmaceutical forms of isosorbide dinitrate for sublingual administration: capsules and tablets];Q186474;P31;Q12140
[Comparative studies of the dissolution kinetics of 2 pharmaceutical forms of isosorbide dinitrate for sublingual administration: capsules and tablets];Q179748;P279;Q49916468
[Comparative studies of the dissolution kinetics of 2 pharmaceutical forms of isosorbide dinitrate for sublingual administration: capsules and tablets];Q179748;P31;Q12140
[Comparative studies of the dissolution kinetics of 2 pharmaceutical forms of isosorbide dinitrate for sublingual administration: capsules and tablets];Q1243800;P31;Q12140
The Endothelin Receptor Antagonist Macitentan Improves Isosorbide-5-Mononitrate (ISMN) and Isosorbide Dinitrate (ISDN) Induced Endothelial Dysfunction, Oxidative Stress, and Vascular Inflammation;Q179748;P279;Q49916468
The Endothelin Receptor Antagonist Macitentan Improves Isosorbide-5-Mononitrate (ISMN) and Isosorbide Dinitrate (ISDN) Induced Endothelial Dysfunction, Oxidative Stress, and Vascular Inflammation;Q423401;P279;Q49916468
[High-dose single administration of isosorbide dinitrate: effect on diurnal distribution of transitory myocardial ischemia in patients with stable angina pectoris];Q179748;P279;Q49916468
[High-dose single administration of isosorbide dinitrate: effect on diurnal distribution of transitory myocardial ischemia in patients with stable angina pectoris];Q1243800;P2175;Q180762
Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies: evidence from Phase I studies in healthy volunteers;Q179748;P279;Q49916468
Arteriographic demonstration of the release of coronary artery spasm by isosorbide dinitrate: a twenty-five-year retrospective.;Q179748;P279;Q49916468
Inhalation of carbon dioxide enhances the coronary vasodilating action of isosorbide dinitrate in the dog.;Q179748;P279;Q49916468
Inhalation of carbon dioxide enhances the coronary vasodilating action of isosorbide dinitrate in the dog.;Q484940;P527;Q623
Inhalation of carbon dioxide enhances the coronary vasodilating action of isosorbide dinitrate in the dog.;Q1243800;P527;Q623
[Therapy of angina pectoris with isosorbide dinitrate];Q179748;P279;Q49916468
[Therapy of angina pectoris with isosorbide dinitrate];Q1243800;P2175;Q180762
Refractory heart failure. Comparison of time course of action of sublingual nitroglycerin and isosorbide dinitrate, oral or sublingual.;Q179748;P279;Q49916468
Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure;Q179748;P279;Q49916468
Effect of isosorbide dinitrate on enzymatically estimated infarction size and on clinical condition of the patients of acute myocardial infarction.;Q179748;P279;Q49916468
Isosorbide dinitrate attenuated coronary artery spasm during general anesthesia for non-cardiac surgery.;Q179748;P279;Q49916468
Influence of the vasodilator drug isosorbide dinitrate on ocular circulation;Q179748;P2868;Q4008956
Influence of the vasodilator drug isosorbide dinitrate on ocular circulation;Q179748;P31;Q12140
Influence of the vasodilator drug isosorbide dinitrate on ocular circulation;Q179748;P279;Q49916468
Influence of the vasodilator drug isosorbide dinitrate on ocular circulation;Q484940;P31;Q12140
Influence of the vasodilator drug isosorbide dinitrate on ocular circulation;Q1243800;P31;Q12140
[Effect of nitroglycerin in acute myocardial infarction. III. Isosorbide dinitrate in patients with or without left-heart failure (author's transl)];Q179748;P279;Q49916468
[Effect of nitroglycerin in acute myocardial infarction. III. Isosorbide dinitrate in patients with or without left-heart failure (author's transl)];Q905750;P2175;Q207550
[Duration of effects of isosorbide dinitrate retard in coronary disease];Q179748;P279;Q49916468
Transdermal slow-release long-acting isosorbide dinitrate for 'nutcracker' oesophagus: an open study;Q179748;P279;Q49916468
Actions of isosorbide dinitrate on smooth muscle cells of rabbit vascular tissues.;Q179748;P279;Q49916468
[Effect of isosorbide dinitrate on the blood circulation system in patients with ischemic heart disease];Q179748;P279;Q49916468
[Effect of isosorbide dinitrate on the blood circulation system in patients with ischemic heart disease];Q1243800;P2175;Q844935
History of the synthesis and pharmacology of isosorbide dinitrate;Q179748;P279;Q49916468
Ask the doctor. My blood pressure has wide swings each day. It can go as high as 210/110 with even minor stress like grocery shopping, then fall to 100/50, which makes me tired and needing rest. I take 15 mg of isosorbide dinitrate and a slow-releas;Q179748;P279;Q49916468
A dose-finding study of the hemodynamic effect of isosorbide dinitrate spray in congestive heart failure;Q179748;P279;Q49916468
A dose-finding study of the hemodynamic effect of isosorbide dinitrate spray in congestive heart failure;Q1243800;P2175;Q19000661
Bioavailability and metabolism of isosorbide dinitrate from a transdermal spray;Q179748;P279;Q49916468
Comparative effects of theophylline and isosorbide dinitrate on exercise capacity in stable angina pectoris, and their mechanisms of action;Q179748;P279;Q49916468
Comparative effects of theophylline and isosorbide dinitrate on exercise capacity in stable angina pectoris, and their mechanisms of action;Q1243800;P2175;Q180762
Evidence for isosorbide dinitrate (ISDN) promoting effect on prostacyclin release by the lung and prostacyclin implication in ISDN-induced inhibition of platelet aggregation in humans;Q183290;P703;Q15978631
Evidence for isosorbide dinitrate (ISDN) promoting effect on prostacyclin release by the lung and prostacyclin implication in ISDN-induced inhibition of platelet aggregation in humans;Q179748;P279;Q49916468
Evidence for isosorbide dinitrate (ISDN) promoting effect on prostacyclin release by the lung and prostacyclin implication in ISDN-induced inhibition of platelet aggregation in humans;Q178450;P703;Q15978631
Evidence for isosorbide dinitrate (ISDN) promoting effect on prostacyclin release by the lung and prostacyclin implication in ISDN-induced inhibition of platelet aggregation in humans;Q484940;P703;Q15978631
Effects of long-term treatment with 120 mg of sustained-release isosorbide dinitrate and 60 mg of sustained-release nifedipine on myocardial perfusion;Q179748;P279;Q49916468
Decrease in plasma NOx concentration by isosorbide dinitrate, an organic nitrate ester.;Q179748;P279;Q49916468
An experimental and theoretical study of the vibrational spectra and structure of Isosorbide dinitrate;Q179748;P279;Q49916468
GLC determination of nitroglycerin and isosorbide dinitrate in human plasma.;Q186474;P703;Q15978631
GLC determination of nitroglycerin and isosorbide dinitrate in human plasma.;Q179748;P279;Q49916468
GLC determination of nitroglycerin and isosorbide dinitrate in human plasma.;Q620730;P703;Q15978631
GLC determination of nitroglycerin and isosorbide dinitrate in human plasma.;Q483745;P703;Q15978631
[Combined treatment of coronary heart disease with diltiazem and isosorbide dinitrate];Q179748;P279;Q49916468
[Combined treatment of coronary heart disease with diltiazem and isosorbide dinitrate];Q1243800;P2175;Q844935
[Molsidomine and isosorbide dinitrate: a comparative trial of tolerance in long-term intake by IHD patients with stable angina of effort];Q179748;P279;Q49916468
[Molsidomine and isosorbide dinitrate: a comparative trial of tolerance in long-term intake by IHD patients with stable angina of effort];Q1243800;P2175;Q180762
Cardiac arrest caused by coronary vasospasm treated with isosorbide dinitrate and left ventricular assistance.;Q179748;P279;Q49916468
Sublingual isosorbide dinitrate in the acute control of hypertension in patients with severe preeclampsia;Q179748;P279;Q49916468
Effects of captopril and a combination of hydralazine and isosorbide dinitrate on myocardial sympathetic tone in patients with severe congestive heart failure;Q179748;P279;Q49916468
Effects of captopril and a combination of hydralazine and isosorbide dinitrate on myocardial sympathetic tone in patients with severe congestive heart failure;Q419987;P2175;Q19000661
Effects of captopril and a combination of hydralazine and isosorbide dinitrate on myocardial sympathetic tone in patients with severe congestive heart failure;Q421119;P2175;Q19000661
Effects of captopril and a combination of hydralazine and isosorbide dinitrate on myocardial sympathetic tone in patients with severe congestive heart failure;Q1243800;P2175;Q19000661
Correlation between isosorbide dinitrate plasma levels and coronary vasodilation after chewing capsules.;Q179748;P279;Q49916468
Nitrate tolerance: comparison of nicorandil, isosorbide dinitrate, and nitroglycerin in anesthetized dogs.;Q179748;P279;Q49916468
Effect of isosorbide dinitrate on nitric oxide synthase under hypoxia.;Q179748;P279;Q49916468
Utilization of diethyl-beta-cyclodextrin as a sustained-release carrier for isosorbide dinitrate;Q179748;P279;Q49916468
[Extent of therapeutic effect and duration of 1 capsule of 120 mg isosorbide dinitrate in a slow release form];Q179748;P279;Q49916468
Comparative clinical trial of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate in ischaemic heart disease.;Q179748;P279;Q49916468
Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI;Q179748;P279;Q49916468
Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI;Q1243800;P527;Q629
Lack of pharmacokinetic interaction between isosorbide dinitrate and the beta-adrenergic receptor blockers atenolol and propranolol;Q179748;P279;Q49916468
[Effectiveness of isosorbide dinitrate and pentaerythritol tetranitrate by means of acute determination of the coronary reserve on cycloergometer in patients with stable angina pectoris];Q179748;P279;Q49916468
[Effectiveness of isosorbide dinitrate and pentaerythritol tetranitrate by means of acute determination of the coronary reserve on cycloergometer in patients with stable angina pectoris];Q3899224;P460;Q189334
[Effectiveness of isosorbide dinitrate and pentaerythritol tetranitrate by means of acute determination of the coronary reserve on cycloergometer in patients with stable angina pectoris];Q1243800;P2175;Q180762
[Treatment of ischemic heart disease with beta-receptor blockers and isosorbide dinitrate (author's transl)];Q179748;P279;Q49916468
[Treatment of ischemic heart disease with beta-receptor blockers and isosorbide dinitrate (author's transl)];Q1243800;P2175;Q844935
The interaction of alpha-human atrial natriuretic peptide (ANP) with salbutamol, sodium nitroprusside and isosorbide dinitrate in human bronchial smooth muscle;Q218642;P703;Q15978631
The interaction of alpha-human atrial natriuretic peptide (ANP) with salbutamol, sodium nitroprusside and isosorbide dinitrate in human bronchial smooth muscle;Q186521;P703;Q15978631
The interaction of alpha-human atrial natriuretic peptide (ANP) with salbutamol, sodium nitroprusside and isosorbide dinitrate in human bronchial smooth muscle;Q179748;P279;Q49916468
The interaction of alpha-human atrial natriuretic peptide (ANP) with salbutamol, sodium nitroprusside and isosorbide dinitrate in human bronchial smooth muscle;Q20035886;P703;Q15978631
[Dependence of a drop in blood pressure in pulmonary circulation and in the right heart on dosage of isosorbide dinitrate];Q179748;P279;Q49916468
[Hemodynamic and coronary effects of isosorbide dinitrate, by the intravenous route, before and after the cold test in chronic coronary insufficiency treated with a beta-blocker];Q179748;P279;Q49916468
Cardiorespiratory effects of isosorbide dinitrate and nifedipine in combination with nadolol: a double-blind comparative study of beneficial and adverse antianginal drug interactions;Q186474;P31;Q12140
Cardiorespiratory effects of isosorbide dinitrate and nifedipine in combination with nadolol: a double-blind comparative study of beneficial and adverse antianginal drug interactions;Q39111;P2175;Q180762
Cardiorespiratory effects of isosorbide dinitrate and nifedipine in combination with nadolol: a double-blind comparative study of beneficial and adverse antianginal drug interactions;Q39111;P31;Q12140
Cardiorespiratory effects of isosorbide dinitrate and nifedipine in combination with nadolol: a double-blind comparative study of beneficial and adverse antianginal drug interactions;Q179748;P31;Q12140
Cardiorespiratory effects of isosorbide dinitrate and nifedipine in combination with nadolol: a double-blind comparative study of beneficial and adverse antianginal drug interactions;Q179748;P279;Q49916468
Cardiorespiratory effects of isosorbide dinitrate and nifedipine in combination with nadolol: a double-blind comparative study of beneficial and adverse antianginal drug interactions;Q424952;P31;Q12140
Cardiorespiratory effects of isosorbide dinitrate and nifedipine in combination with nadolol: a double-blind comparative study of beneficial and adverse antianginal drug interactions;Q424952;P2175;Q180762
Cardiorespiratory effects of isosorbide dinitrate and nifedipine in combination with nadolol: a double-blind comparative study of beneficial and adverse antianginal drug interactions;Q1243800;P31;Q12140
Cardiorespiratory effects of isosorbide dinitrate and nifedipine in combination with nadolol: a double-blind comparative study of beneficial and adverse antianginal drug interactions;Q1243800;P2175;Q180762
[Evaluation using serial exercise tests of verapamil alone and combined with isosorbide dinitrate in exertional angina];Q410291;P2175;Q180762
[Evaluation using serial exercise tests of verapamil alone and combined with isosorbide dinitrate in exertional angina];Q179748;P279;Q49916468
[Evaluation using serial exercise tests of verapamil alone and combined with isosorbide dinitrate in exertional angina];Q1243800;P2175;Q180762
Isosorbide dinitrate plasma concentrations and bioavailability in human subjects after administration of standard oral and sublingual formulations;Q179748;P279;Q49916468
Isosorbide dinitrate plasma concentrations and bioavailability in human subjects after administration of standard oral and sublingual formulations;Q484940;P703;Q15978631
[Effects of injectable isosorbide dinitrate in perangiographic cerebral spasm];Q179748;P279;Q49916468
Effect of isosorbide dinitrate on gastroesophageal reflux in healthy volunteers and patients with Chagas' disease;Q179748;P279;Q49916468
Effect of isosorbide dinitrate on gastroesophageal reflux in healthy volunteers and patients with Chagas' disease;Q1243800;P2175;Q223591
[Effect of bupranolol in combination with isosorbide dinitrate in bronchial diseases];Q179748;P279;Q49916468
An unusual cause of cyanosis (isosorbide dinitrate induced methaemoglobinaemia);Q179748;P279;Q49916468
An unusual cause of cyanosis (isosorbide dinitrate induced methaemoglobinaemia);Q1243800;P2175;Q192120
Relative bioavailability of two isosorbide dinitrate sublingual tablet formulations administered as single doses in healthy subjects.;Q179748;P279;Q49916468
[Dynamic ECG evaluation of the activity of long-acting isosorbide dinitrate in patients with unstable angina (author's transl)];Q179748;P279;Q49916468
[Dynamic ECG evaluation of the activity of long-acting isosorbide dinitrate in patients with unstable angina (author's transl)];Q1243800;P2175;Q180762
Antianginal effect of isosorbide dinitrate spray in patients with exercise-induced stable angina;Q179748;P279;Q49916468
Antianginal effect of isosorbide dinitrate spray in patients with exercise-induced stable angina;Q1243800;P2175;Q180762
Effects of intracoronary isosorbide dinitrate during acute myocardial ischaemia: a study during angioplasty.;Q179748;P279;Q49916468
Effect of propranolol on hemodynamic responses to isosorbide dinitrate in anesthetized dogs.;Q179748;P279;Q49916468
[Evaluation of the efficacy of isosorbide-5-mononitrate in CHF patients unresponsive to isosorbide dinitrate therapy].;Q179748;P279;Q49916468
Isosorbide dinitrate in the treatment of anal fissure: a randomised, prospective, double blind, placebo-controlled trial.;Q179748;P279;Q49916468
Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations;Q179748;P279;Q49916468
Radionuclide and hemodynamic assessment of left ventricular functional reserve in patients with left ventricular aneurysm and congestive cardiac failure. Response to exercise stress and isosorbide dinitrate;Q179748;P279;Q49916468
[Effects of isosorbide dinitrate on coronary and systemic circulation in children: comparison with dipyridamole];Q179748;P279;Q49916468
Effect of intravenous isosorbide dinitrate versus nitroglycerin on elevated pulmonary arterial wedge pressure during acute myocardial infarction.;Q179748;P279;Q49916468
Effect of intravenous isosorbide dinitrate versus nitroglycerin on elevated pulmonary arterial wedge pressure during acute myocardial infarction.;Q905750;P2175;Q207550
Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT.;Q179748;P279;Q49916468
Improvement by isosorbide dinitrate of exercise-induced regional myocardial dysfunction;Q179748;P279;Q49916468
Plasma levels of isosorbide dinitrate and its main metabolites following oral administration of two sustained release formulations in normal man;Q179748;P279;Q49916468
Nitroglycerin and isosorbide dinitrate in pulmonary hypertension of chronic obstructive pulmonary disease.;Q179748;P279;Q49916468
[Disparate efficacy of isosorbide dinitrate, in sustained-release form, during acute and chronic administration (author's transl)];Q179748;P279;Q49916468
Immediate effect of sublingual isosorbide dinitrate in patients with coronary slow flow phenomenon (CSFP).;Q179748;P279;Q49916468
Comparison of the time to onset of action on myocardial ischaemia following intravenous administration of isosorbide dinitrate and 5-isosorbide mononitrate in Chinese patients.;Q179748;P279;Q49916468
Comparison of the time to onset of action on myocardial ischaemia following intravenous administration of isosorbide dinitrate and 5-isosorbide mononitrate in Chinese patients.;Q423401;P279;Q49916468
[Treatment of infantile hydrocephalus with isosorbide dinitrate (author's transl)];Q179748;P279;Q49916468
[The anti-anginal efficacy of the drug forms of isosorbide-5-mononitrate--Monocinque, Monocinque retard and isosorbide dinitrate];Q186521;P31;Q12140
[The anti-anginal efficacy of the drug forms of isosorbide-5-mononitrate--Monocinque, Monocinque retard and isosorbide dinitrate];Q179748;P31;Q12140
[The anti-anginal efficacy of the drug forms of isosorbide-5-mononitrate--Monocinque, Monocinque retard and isosorbide dinitrate];Q179748;P279;Q49916468
[The anti-anginal efficacy of the drug forms of isosorbide-5-mononitrate--Monocinque, Monocinque retard and isosorbide dinitrate];Q22124685;P31;Q12140
[The anti-anginal efficacy of the drug forms of isosorbide-5-mononitrate--Monocinque, Monocinque retard and isosorbide dinitrate];Q1243800;P31;Q12140
[The anti-anginal efficacy of the drug forms of isosorbide-5-mononitrate--Monocinque, Monocinque retard and isosorbide dinitrate];Q1243800;P2175;Q180762
[Doppler echocardiographic evaluation of vasodilator treatments in patients with cardiac insufficiency. Contribution to the combination of isosorbide dinitrate and captopril];Q179748;P2868;Q4008956
[Doppler echocardiographic evaluation of vasodilator treatments in patients with cardiac insufficiency. Contribution to the combination of isosorbide dinitrate and captopril];Q179748;P279;Q49916468
Efficacy of eccentric dosing with sustained-release isosorbide dinitrate in patients with angina pectoris;Q179748;P279;Q49916468
Efficacy of eccentric dosing with sustained-release isosorbide dinitrate in patients with angina pectoris;Q1243800;P2175;Q180762
Oral isosorbide dinitrate in angina pectoris: comparison of duration of action an dose-response relation during acute and sustained therapy.;Q179748;P279;Q49916468
Oral isosorbide dinitrate in angina pectoris: comparison of duration of action an dose-response relation during acute and sustained therapy.;Q1243800;P2175;Q180762
[Effects of isosorbide dinitrate tape (TY-0081) on congestive heart failure: results of multicenter study];Q179748;P279;Q49916468
[Effects of isosorbide dinitrate tape (TY-0081) on congestive heart failure: results of multicenter study];Q1243800;P2175;Q19000661
Pharmacokinetics of isosorbide dinitrate in rhesus monkey, cynomolgus monkey, and baboon;Q179748;P279;Q49916468
Comparison of the antianginal efficacy of isosorbide dinitrate (ISDN) 40 mg and verapamil 120 mg three times daily in the acute trial and following two-week treatment.;Q410291;P2175;Q180762
Comparison of the antianginal efficacy of isosorbide dinitrate (ISDN) 40 mg and verapamil 120 mg three times daily in the acute trial and following two-week treatment.;Q179748;P279;Q49916468
Comparison of the antianginal efficacy of isosorbide dinitrate (ISDN) 40 mg and verapamil 120 mg three times daily in the acute trial and following two-week treatment.;Q1243800;P2175;Q180762
Isosorbide dinitrate in angina pectoris. An evaluation of sublingual and oral administration;Q179748;P279;Q49916468
Isosorbide dinitrate in angina pectoris. An evaluation of sublingual and oral administration;Q1243800;P2175;Q180762
Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients;Q179748;P279;Q49916468
Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients;Q1243800;P2175;Q180762
Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients;Q1243800;P2175;Q844935
[Transcutaneous application of nitroglycerin and isosorbide dinitrate versus placebo: effect in myocardial ischemia];Q179748;P279;Q49916468
Effects of isosorbide dinitrate on oxygen uptake kinetics in cardiac patients;Q179748;P279;Q49916468
Effects of isosorbide dinitrate on oxygen uptake kinetics in cardiac patients;Q1243800;P527;Q629
Concentrations of the vasodilator isosorbide dinitrate and its metabolites in the blood of human subjects;Q186474;P703;Q15978631
Concentrations of the vasodilator isosorbide dinitrate and its metabolites in the blood of human subjects;Q179748;P2868;Q4008956
Concentrations of the vasodilator isosorbide dinitrate and its metabolites in the blood of human subjects;Q179748;P279;Q49916468
Treatment of elderly patients with isolated systolic hypertension with isosorbide dinitrate in an asymmetric dosing schedule;Q179748;P279;Q49916468
Prevention of contrast-induced nephropathy by adequate hydration combined with isosorbide dinitrate for patients with renal insufficiency and congestive heart failure;Q179748;P279;Q49916468
Prevention of contrast-induced nephropathy by adequate hydration combined with isosorbide dinitrate for patients with renal insufficiency and congestive heart failure;Q1243800;P2175;Q19000661
[Effect of isosorbide dinitrate on platelet aggregation and production of thromboxane B2];Q179748;P279;Q49916468
Letter by Taylor et al regarding article, "Hydralazine and isosorbide dinitrate in heart failure: historical perspectives, mechanisms, and future directions".;Q179748;P279;Q49916468
Enhancement by isosorbide dinitrate of haemodynamic effects of dopamine in chronic congestive cardiac failure.;Q179748;P279;Q49916468
[Effect of sublingual isosorbide dinitrate on hemodynamics in coronary patients with and without congestive heart failure (author's transl)];Q179748;P279;Q49916468
[Effect of sublingual isosorbide dinitrate on hemodynamics in coronary patients with and without congestive heart failure (author's transl)];Q1243800;P2175;Q19000661
A comparison of the haemodynamic effect of isosorbide-5-mononitrate and isosorbide dinitrate administered in intravenous injection to patients with acute myocardial infarction.;Q179748;P279;Q49916468
Topical treatment of erectile dysfunction: randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate, and co-dergocrine mesylate.;Q179748;P279;Q49916468
Differences in the antiischaemic effects of molsidomine and isosorbide dinitrate;Q179748;P279;Q49916468
Isosorbide dinitrate blocks thromboxane synthesis caused by CO2 in dog heart-lung preparation;Q179748;P279;Q49916468
Comparative study of time-course of hemodynamic effect of isosorbide dinitrate spray and sublingual tablets in patients with pulmonary congestion.;Q179748;P279;Q49916468
Different hemodynamic actions of trinitroglycerin and isosorbide dinitrate in patients with acute myocardial infarction.;Q179748;P279;Q49916468
Different hemodynamic actions of trinitroglycerin and isosorbide dinitrate in patients with acute myocardial infarction.;Q905750;P2175;Q207550
Hemodynamic effects of nicorandil, isosorbide dinitrate, and dihydralazine in healthy volunteers.;Q179748;P279;Q49916468
[Treatment of angina pectoris with beta-receptor blockaders a slow-releasing isosorbide dinitrate preparation];Q179748;P279;Q49916468
[Treatment of angina pectoris with beta-receptor blockaders a slow-releasing isosorbide dinitrate preparation];Q1243800;P2175;Q180762
Radionuclide confirmation of the therapeutic value of isosorbide dinitrate in relieving the dysphagia in achalasia;Q179748;P279;Q49916468
Radionuclide confirmation of the therapeutic value of isosorbide dinitrate in relieving the dysphagia in achalasia;Q173670;P703;Q177932
Radiocardiographic assessment of dobutamine and isosorbide dinitrate therapy in patients with mitral stenosis and pulmonary congestion;Q179748;P279;Q49916468
Identification of asynergic but viable myocardium in patients with chronic coronary artery disease by gated blood pool scintigraphy during isosorbide dinitrate and low-dose dobutamine infusion: comparison with thallium-201 scintigraphy with reinject;Q179748;P279;Q49916468
Identification of asynergic but viable myocardium in patients with chronic coronary artery disease by gated blood pool scintigraphy during isosorbide dinitrate and low-dose dobutamine infusion: comparison with thallium-201 scintigraphy with reinject;Q1243800;P2175;Q844935
A new isosorbide dinitrate extended-release formulation: pharmacokinetic and clinical parameters in patients with stable angina pectoris.;Q179748;P279;Q49916468
A new isosorbide dinitrate extended-release formulation: pharmacokinetic and clinical parameters in patients with stable angina pectoris.;Q1243800;P2175;Q180762
Quantitative and automatic polarographic determination of isosorbide dinitrate in pharmaceutical preparations;Q181619;P31;Q12140
Quantitative and automatic polarographic determination of isosorbide dinitrate in pharmaceutical preparations;Q179748;P31;Q12140
Quantitative and automatic polarographic determination of isosorbide dinitrate in pharmaceutical preparations;Q179748;P279;Q49916468
Quantitative and automatic polarographic determination of isosorbide dinitrate in pharmaceutical preparations;Q1243800;P31;Q12140
[Effects of intravenous infusion of isosorbide dinitrate on hemodynamics during anesthesia and surgery];Q179748;P279;Q49916468
[Development of tolerance with regard to the anti-ischemic effect of isosorbide dinitrate in regular multiple daily administration];Q179748;P279;Q49916468
Effect of repeated oral administration of isosorbide dinitrate on hepatic glutathione S-transferase activitiy in the rat;Q179748;P279;Q49916468
Tolerance to isosorbide dinitrate in isolated strips of rabbit corpus cavernosum;Q179748;P279;Q49916468
Vasodilator treatment with isosorbide dinitrate and hydralazine in chronic heart failure.;Q179748;P279;Q49916468
Comparison of exercise-rest-reinjection Tl-201 imaging and rest sublingual isosorbide dinitrate Tc-99m MIBI imaging for the assessment of myocardial viability.;Q179748;P279;Q49916468
Effects of intravenous injection of isosorbide dinitrate on the cardiovascular system.;Q179748;P279;Q49916468
Resistance to isosorbide dinitrate in patients with severe chronic heart failure: incidence and attempt at hemodynamic prediction.;Q179748;P279;Q49916468
Pathophysiological aspects and clinical outcome of intra-anal application of isosorbide dinitrate in patients with chronic anal fissure;Q179748;P279;Q49916468
[Isosorbide dinitrate in chronic cor pulmonale (author's transl)];Q179748;P279;Q49916468
Effects of a sustained-release form of isosorbide dinitrate on left atrial pressure in dogs with experimentally induced mitral valve regurgitation.;Q179748;P279;Q49916468
[Prevention of the development of tolerance to isosorbide dinitrate in interval therapy];Q179748;P279;Q49916468
Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial;Q179748;P279;Q49916468
Response of conductance and resistance vessels of the coronary artery to intracoronary isosorbide dinitrate in patients with variant angina;Q179748;P279;Q49916468
Response of conductance and resistance vessels of the coronary artery to intracoronary isosorbide dinitrate in patients with variant angina;Q1243800;P2175;Q180762
Effect of isosorbide dinitrate on submaximal exercise capacity of patients with chronic left ventricular failure;Q179748;P279;Q49916468
Comparison of Effects of Propofol and Isosorbide Dinitrate during Rewarming on Cardiopulmonary Bypass.;Q179748;P279;Q49916468
Does diabetes mellitus affect the progress of tolerance to isosorbide dinitrate (ISDN) in corporal tissue?;Q179748;P279;Q49916468
Acute effects of isosorbide dinitrate and nicorandil on the coronary slow flow phenomenon.;Q179748;P279;Q49916468
[Use of isosorbide dinitrate (Risordan) injection in left ventricular failure following acute myocardial infarction (author's transl)];Q179748;P279;Q49916468
[Long-term therapy of stress angina pectoris by a single daily administration of 120 mg isosorbide dinitrate in retard form. Comparison of monotherapy and combination therapy with atenolol and nifedipine];Q411325;P2175;Q180762
[Long-term therapy of stress angina pectoris by a single daily administration of 120 mg isosorbide dinitrate in retard form. Comparison of monotherapy and combination therapy with atenolol and nifedipine];Q39111;P2175;Q180762
[Long-term therapy of stress angina pectoris by a single daily administration of 120 mg isosorbide dinitrate in retard form. Comparison of monotherapy and combination therapy with atenolol and nifedipine];Q179748;P279;Q49916468
[Long-term therapy of stress angina pectoris by a single daily administration of 120 mg isosorbide dinitrate in retard form. Comparison of monotherapy and combination therapy with atenolol and nifedipine];Q1243800;P2175;Q180762
[The in vitro release rate of isosorbide dinitrate in a transdermal therapeutic membrane system];Q186521;P703;Q177932
[The in vitro release rate of isosorbide dinitrate in a transdermal therapeutic membrane system];Q179748;P279;Q49916468
Sex-related difference in the metabolism of isosorbide dinitrate following incubation in human blood;Q183290;P703;Q15978631
Sex-related difference in the metabolism of isosorbide dinitrate following incubation in human blood;Q179748;P279;Q49916468
The effect of nitrosorbide, korinfar and obzidan on the hemodynamics of patients with chronic hepatitis and liver cirrhosis based on the data acute drug trials;Q186521;P31;Q12140
The effect of nitrosorbide, korinfar and obzidan on the hemodynamics of patients with chronic hepatitis and liver cirrhosis based on the data acute drug trials;Q191924;P31;Q12140
The effect of nitrosorbide, korinfar and obzidan on the hemodynamics of patients with chronic hepatitis and liver cirrhosis based on the data acute drug trials;Q905750;P31;Q12140
Reduced infarct size in nonreperfused myocardial infarction by combined infusion of isosorbide dinitrate and streptokinase.;Q179748;P279;Q49916468
Underuse of hydralazine and isosorbide dinitrate for heart failure in patients of African ancestry: a cross-European survey;Q179748;P279;Q49916468
Determination of isosorbide dinitrate in arterial plasma, synthetic serum and pharmaceutical formulations by linear sweep voltammetry on a gold electrode.;Q179748;P31;Q12140
Determination of isosorbide dinitrate in arterial plasma, synthetic serum and pharmaceutical formulations by linear sweep voltammetry on a gold electrode.;Q179748;P279;Q49916468
Determination of isosorbide dinitrate in arterial plasma, synthetic serum and pharmaceutical formulations by linear sweep voltammetry on a gold electrode.;Q178450;P31;Q12140
Determination of isosorbide dinitrate in arterial plasma, synthetic serum and pharmaceutical formulations by linear sweep voltammetry on a gold electrode.;Q1243800;P31;Q12140
Effect of intervals between doses on the development of tolerance to isosorbide dinitrate;Q179748;P279;Q49916468
[The effect of isosorbide dinitrate on the dynamics of the left ventricle and on ischemic electrocardiographic changes during loading with supraventricular stimulation];Q179748;P279;Q49916468
[Effectiveness of sublingual isosorbide dinitrate in chest pain: coronary or esophageal angina?];Q179748;P279;Q49916468
[Effectiveness of sublingual isosorbide dinitrate in chest pain: coronary or esophageal angina?];Q1243800;P2175;Q180762
Long-term treatment of patients with coronary heart disease using isosorbide dinitrate, nifedipine and molsidomine;Q179748;P279;Q49916468
Long-term treatment of patients with coronary heart disease using isosorbide dinitrate, nifedipine and molsidomine;Q1243800;P2175;Q844935
Permeation-enhancing effects and mechanisms of O-acylterpineol on isosorbide dinitrate: mechanistic insights based on ATR-FTIR spectroscopy, molecular modeling, and CLSM images;Q179748;P279;Q49916468
Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients: long-term hemodynamic and renal effects.;Q179748;P279;Q49916468
Isosorbide dinitrate does not interfere with heparin anticoagulation: a placebo-controlled comparison with nitroglycerin in patients scheduled for coronary artery surgery.;Q179748;P279;Q49916468
Antianginal efficacy of oral therapy with isosorbide dinitrate capsules. Prolonged benefit shown by exercise testing in patients with ischemic heart disease.;Q179748;P279;Q49916468
Antianginal efficacy of oral therapy with isosorbide dinitrate capsules. Prolonged benefit shown by exercise testing in patients with ischemic heart disease.;Q1243800;P2175;Q844935
Antianginal efficacy of oral therapy with isosorbide dinitrate capsules. Prolonged benefit shown by exercise testing in patients with ischemic heart disease.;Q1243800;P2175;Q180762
[Intermittent claudication: effect of local treatment with isosorbide dinitrate paste];Q179748;P279;Q49916468
Effects of prostaglandin E1 and isosorbide dinitrate on acute hypoxic pulmonary vasoconstriction in conscious sheep.;Q179748;P279;Q49916468
Effects of prostaglandin E1 and isosorbide dinitrate on acute hypoxic pulmonary vasoconstriction in conscious sheep.;Q4860325;P279;Q209717
Effects of prostaglandin E1 and isosorbide dinitrate on acute hypoxic pulmonary vasoconstriction in conscious sheep.;Q4860325;P527;Q579348
Effects of prostaglandin E1 and isosorbide dinitrate on acute hypoxic pulmonary vasoconstriction in conscious sheep.;Q579348;P279;Q209717
[Hemodynamic effects of nitrate derivatives (trinitrine and isosorbide dinitrate)];Q179748;P279;Q49916468
Isosorbide dinitrate and glyceryl trinitrate: demonstration of cross tolerance in the capacitance vessels.;Q3221044;P3781;Q162867
Isosorbide dinitrate and glyceryl trinitrate: demonstration of cross tolerance in the capacitance vessels.;Q179748;P279;Q49916468
[Long-term treatment of chronic congestive heart failure with oral isosorbide dinitrate and phenotoline (author's transl)];Q179748;P279;Q49916468
[Long-term treatment of chronic congestive heart failure with oral isosorbide dinitrate and phenotoline (author's transl)];Q1243800;P2175;Q19000661
Reduced coronary vasodilation in patients with familial hypercholesterolemia following intracoronary injection of isosorbide dinitrate;Q179748;P279;Q49916468
Sorbide nitrate in the management of angina pectoris in general practice;Q179748;P279;Q49916468
A comparison of nifedipine and isosorbide dinitrate in angina pectoris with particular reference to arterial oxygen saturation;Q39111;P527;Q629
A comparison of nifedipine and isosorbide dinitrate in angina pectoris with particular reference to arterial oxygen saturation;Q39111;P2175;Q180762
A comparison of nifedipine and isosorbide dinitrate in angina pectoris with particular reference to arterial oxygen saturation;Q179748;P279;Q49916468
A comparison of nifedipine and isosorbide dinitrate in angina pectoris with particular reference to arterial oxygen saturation;Q1243800;P527;Q629
A comparison of nifedipine and isosorbide dinitrate in angina pectoris with particular reference to arterial oxygen saturation;Q1243800;P2175;Q180762
Fissurectomy and isosorbide dinitrate for chronic fissure in ano not responding to conservative treatment.;Q179748;P279;Q49916468
Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion;Q179748;P279;Q49916468
Influence of diet on the single-dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate;Q179748;P279;Q49916468
[Hemodynamic and coronary effects of isosorbide dinitrate: comparison of intravenous and intracoronary injection];Q179748;P279;Q49916468
The effect of isosorbide dinitrate on uterine artery and umbilical artery flow velocity waveforms at mid-pregnancy;Q179748;P279;Q49916468
Quantitative determination of isosorbide dinitrate and two metabolites in plasma;Q179748;P279;Q49916468
Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group;Q179748;P279;Q49916468
[ Combined therapy with isosorbide dinitrate, propranolol and nifedipine in patients with chronic ischemic heart disease].;Q179748;P279;Q49916468
[ Combined therapy with isosorbide dinitrate, propranolol and nifedipine in patients with chronic ischemic heart disease].;Q1243800;P2175;Q844935
Prolonged hemodynamic effectiveness of sustained release isosorbide dinitrate;Q179748;P279;Q49916468
Glyceryl trinitrate patches as an alternative to isosorbide dinitrate spray in the treatment of chronic painful diabetic neuropathy.;Q179748;P279;Q49916468
Hemodynamic evaluation of isosorbide dinitrate in alcoholic cirrhosis. Pharmacokinetic-hemodynamic interactions;Q179748;P279;Q49916468
Effect of isosorbide dinitrate on non-cirrhotic portal hypertension;Q179748;P279;Q49916468
[Hemodynamic effects of intravenous isosorbide dinitrate in chronic heart failure (author's transl)];Q179748;P279;Q49916468
Vascular effects of isosorbide dinitrate on the common carotid artery in human volunteers;Q179748;P279;Q49916468
Vascular effects of isosorbide dinitrate on the common carotid artery in human volunteers;Q483752;P703;Q15978631
Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.;Q179748;P279;Q49916468
The value of Tc-99m MIBI SPECT during isosorbide dinitrate infusion in assessment of viable myocardium in patients with myocardial infarction;Q179748;P279;Q49916468
Fate of orally given isosorbide dinitrate in cirrhotic patients;Q179748;P279;Q49916468
[The antianginal efficacy of verapamil and nitrosorbide used separately and jointly in patients with angina of effort];Q410291;P2175;Q180762
Enhanced effectiveness of combined sustained-release forms of isosorbide dinitrate and diltiazem for stable angina pectoris;Q179748;P279;Q49916468
Enhanced effectiveness of combined sustained-release forms of isosorbide dinitrate and diltiazem for stable angina pectoris;Q422229;P2175;Q180762
Enhanced effectiveness of combined sustained-release forms of isosorbide dinitrate and diltiazem for stable angina pectoris;Q1243800;P2175;Q180762
Propranolol combined with isosorbide dinitrate versus placebo in angina pectoris;Q179748;P279;Q49916468
Propranolol combined with isosorbide dinitrate versus placebo in angina pectoris;Q1243800;P2175;Q180762
Inhibition of platelet aggregation by isosorbide dinitrate;Q179748;P279;Q49916468
Hemodynamics and antianginal effects of high dose oral isosorbide dinitrate after chronic use.;Q179748;P279;Q49916468
Hemodynamics and antianginal effects of high dose oral isosorbide dinitrate after chronic use.;Q1243800;P2175;Q180762
Treatment of angina pectoris with a new coronary vasodilator, isosorbide dinitrate sublingual (Isordil Subloral);Q179748;P2868;Q4008956
Treatment of angina pectoris with a new coronary vasodilator, isosorbide dinitrate sublingual (Isordil Subloral);Q179748;P3780;Q48826195
Treatment of angina pectoris with a new coronary vasodilator, isosorbide dinitrate sublingual (Isordil Subloral);Q179748;P279;Q49916468
Treatment of angina pectoris with a new coronary vasodilator, isosorbide dinitrate sublingual (Isordil Subloral);Q1243800;P2175;Q180762
[Antianginal effect of transdermal isosorbide dinitrate (multicenter study)];Q179748;P279;Q49916468
[Antianginal effect of transdermal isosorbide dinitrate (multicenter study)];Q1243800;P2175;Q180762
Comparing the effect of oral and vaginal isosorbide dinitrate in pre-induction cervical ripening in term pregnancy: A controlled clinical trial.;Q179748;P279;Q49916468
Treatment of chronic anal fissure with isosorbide dinitrate: long-term results and dose determination.;Q179748;P279;Q49916468
[Influence of isosorbide dinitrate on haemodynamics and gas exchange in acute respiratory distress syndrome (author's transl)];Q179748;P279;Q49916468
[Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions];Q179748;P279;Q49916468
[Hemodynamic effects of isosorbide dinitrate (Isomack Retard capsules) in chronic heart failure];Q179748;P279;Q49916468
[Assay of plasma isosorbide dinitrate and its metabolites after oral administration of immediate and delayed-action forms];Q218642;P31;Q407595
[Assay of plasma isosorbide dinitrate and its metabolites after oral administration of immediate and delayed-action forms];Q179748;P279;Q49916468
Prolonged salutary effects of isosorbide dinitrate and nitroglycerin ointment on regional left ventricular function.;Q179748;P279;Q49916468
[Comparison of 2 recent isosorbide dinitrate preparations as new long-term galenicals with commonly used delayed-action preparations];Q179748;P279;Q49916468
[Use of isosorbide dinitrate in pearl form in the treatment of congestive heart failure. Phonomecanographic study];Q179748;P279;Q49916468
[Use of isosorbide dinitrate in pearl form in the treatment of congestive heart failure. Phonomecanographic study];Q1243800;P2175;Q19000661
[Effects of isosorbide dinitrate of prolonged action on the prevention of myocardial ischemia induced by exercise: correlation with nitrate blood levels];Q179748;P279;Q49916468
A comparison of carvedilol with a combination of propranolol and isosorbide dinitrate in the chronic treatment of stable angina.;Q412534;P2175;Q180762
A comparison of carvedilol with a combination of propranolol and isosorbide dinitrate in the chronic treatment of stable angina.;Q179748;P279;Q49916468
A comparison of carvedilol with a combination of propranolol and isosorbide dinitrate in the chronic treatment of stable angina.;Q1243800;P2175;Q180762
The Efficacy of the Transdermal Isosorbide Dinitrate Patch in Patients With Chronic Limb-Threatening Ischemia;Q179748;P279;Q49916468
[Transdermal nitroglycerin in stable effort angina. I. Therapeutic effect and duration of the action of a single dose. Comparison with placebo and isosorbide dinitrate];Q186474;P703;Q177932
[Transdermal nitroglycerin in stable effort angina. I. Therapeutic effect and duration of the action of a single dose. Comparison with placebo and isosorbide dinitrate];Q186521;P703;Q177932
[Transdermal nitroglycerin in stable effort angina. I. Therapeutic effect and duration of the action of a single dose. Comparison with placebo and isosorbide dinitrate];Q179748;P279;Q49916468
[Transdermal nitroglycerin in stable effort angina. I. Therapeutic effect and duration of the action of a single dose. Comparison with placebo and isosorbide dinitrate];Q484940;P703;Q177932
[Transdermal nitroglycerin in stable effort angina. I. Therapeutic effect and duration of the action of a single dose. Comparison with placebo and isosorbide dinitrate];Q1243800;P2175;Q180762
Modulation of inotropic therapy by venodilation in acute heart failure: a randomised comparison of four inotropic agents, alone and combined with isosorbide dinitrate;Q179748;P279;Q49916468
Bioadhesive polymer-grafted starch microspheres bearing isosorbide dinitrate for buccal administration;Q179748;P279;Q49916468
Isosorbide dinitrate bolus for heart failure in elderly emergency patients: a retrospective study.;Q179748;P279;Q49916468
The effects of intravenous nitroglycerin and isosorbide dinitrate on hemodynamics and myocardial metabolism.;Q179748;P279;Q49916468
[Antithrombotic effects of molsidomine, isosorbide dinitrate and verapamil in a laser-induced thrombosis model];Q179748;P279;Q49916468
The use of isosorbide dinitrate in status anginosus;Q179748;P279;Q49916468
Improved diagnostic yield of radionuclide angiography by quantitative phase analysis during resting angina and following isosorbide dinitrate;Q179748;P279;Q49916468
Improved diagnostic yield of radionuclide angiography by quantitative phase analysis during resting angina and following isosorbide dinitrate;Q1243800;P2175;Q180762
Effects of isosorbide dinitrate and nitroglycerin on central circulatory dynamics in coronary artery disease.;Q179748;P279;Q49916468
Effects of isosorbide dinitrate and nitroglycerin on central circulatory dynamics in coronary artery disease.;Q1243800;P2175;Q844935
Head-up tilt table testing with low dose sublingual isosorbide dinitrate in the evaluation of unexplained syncope: a comparison with isoproterenol infusion;Q179748;P279;Q49916468
Treatment of acute myocardial infarction with sodium nitroprusside during 24 hours, followed by isosorbide dinitrate;Q179748;P279;Q49916468
Treatment of acute myocardial infarction with sodium nitroprusside during 24 hours, followed by isosorbide dinitrate;Q905750;P2175;Q207550
A controlled comparison of oxyfedrine, isosorbide dinitrate and placebo in the treatment of patients suffering attacks of angina pectoris;Q179748;P279;Q49916468
A controlled comparison of oxyfedrine, isosorbide dinitrate and placebo in the treatment of patients suffering attacks of angina pectoris;Q1243800;P2175;Q180762
[Efficacy of a new slow-release isosorbide dinitrate preparation in myocardial infarction (author's transl)];Q179748;P279;Q49916468
[Effects of sublingual isosorbide dinitrate on systolic time intervals in normal subjects and those with coronary disease];Q179748;P279;Q49916468
Adenosine, dipyridamole and isosorbide dinitrate are ineffective to prevent the sympathetic initiation of poststenotic myocardial ischemia.;Q179748;P279;Q49916468
[Effect of i.v. nitroglycerin on the hemodynamics and size of infarct. Comparison with isosorbide dinitrate];Q179748;P279;Q49916468
Comparison of the therapeutic efficacy of continuous and intermittent injection of isosorbide dinitrate: a randomized study on unstable angina;Q186474;P703;Q177932
Comparison of the therapeutic efficacy of continuous and intermittent injection of isosorbide dinitrate: a randomized study on unstable angina;Q179748;P279;Q49916468
Comparison of the therapeutic efficacy of continuous and intermittent injection of isosorbide dinitrate: a randomized study on unstable angina;Q1243800;P2175;Q180762
Effects of nitro compounds, isosorbide dinitrate, 5-isosorbide mononitrate and glyceryl trinitrate on Ca-uptake into Ca-stores and Ca-release from Ca-stores in rabbit isolated femoral veins and femoral arteries;Q186474;P31;Q11173
Effects of nitro compounds, isosorbide dinitrate, 5-isosorbide mononitrate and glyceryl trinitrate on Ca-uptake into Ca-stores and Ca-release from Ca-stores in rabbit isolated femoral veins and femoral arteries;Q3221044;P3781;Q162867
Effects of nitro compounds, isosorbide dinitrate, 5-isosorbide mononitrate and glyceryl trinitrate on Ca-uptake into Ca-stores and Ca-release from Ca-stores in rabbit isolated femoral veins and femoral arteries;Q179748;P31;Q11173
Effects of nitro compounds, isosorbide dinitrate, 5-isosorbide mononitrate and glyceryl trinitrate on Ca-uptake into Ca-stores and Ca-release from Ca-stores in rabbit isolated femoral veins and femoral arteries;Q179748;P279;Q49916468
Effects of nitro compounds, isosorbide dinitrate, 5-isosorbide mononitrate and glyceryl trinitrate on Ca-uptake into Ca-stores and Ca-release from Ca-stores in rabbit isolated femoral veins and femoral arteries;Q905750;P31;Q11173
Effects of nitro compounds, isosorbide dinitrate, 5-isosorbide mononitrate and glyceryl trinitrate on Ca-uptake into Ca-stores and Ca-release from Ca-stores in rabbit isolated femoral veins and femoral arteries;Q423401;P279;Q49916468
Effects of nitro compounds, isosorbide dinitrate, 5-isosorbide mononitrate and glyceryl trinitrate on Ca-uptake into Ca-stores and Ca-release from Ca-stores in rabbit isolated femoral veins and femoral arteries;Q423401;P31;Q11173
Effects of nitro compounds, isosorbide dinitrate, 5-isosorbide mononitrate and glyceryl trinitrate on Ca-uptake into Ca-stores and Ca-release from Ca-stores in rabbit isolated femoral veins and femoral arteries;Q1243800;P31;Q11173
Role of hemoglobin in the differential biotransformation of glyceryl trinitrate and isosorbide dinitrate by human erythrocytes;Q3221044;P3781;Q162867
Role of hemoglobin in the differential biotransformation of glyceryl trinitrate and isosorbide dinitrate by human erythrocytes;Q179748;P279;Q49916468
Role of hemoglobin in the differential biotransformation of glyceryl trinitrate and isosorbide dinitrate by human erythrocytes;Q173670;P703;Q15978631
Evaluation of nitroglycerin in angina in patients on isosorbide dinitrate;Q179748;P279;Q49916468
Evaluation of nitroglycerin in angina in patients on isosorbide dinitrate;Q1243800;P2175;Q180762
[Ischemia tolerance of the heart in percutaneous transluminal coronary angioplasty. Controlled study of the effect of isosorbide dinitrate and nifedipine];Q179748;P279;Q49916468
Myocardial infarction following sublingual administration of isosorbide dinitrate;Q179748;P279;Q49916468
Intra-individual comparison of the action of equal doses of isosorbide-5-endomononitrate, slow-release isosorbide dinitrate and placebo in patients with coronary heart disease;Q179748;P279;Q49916468
Intra-individual comparison of the action of equal doses of isosorbide-5-endomononitrate, slow-release isosorbide dinitrate and placebo in patients with coronary heart disease;Q1243800;P2175;Q844935
Comparison of the inhibitory effects of nicorandil, nitroglycerin and isosorbide dinitrate on vascular smooth muscle of rabbit aorta.;Q179748;P279;Q49916468
The influence of isosorbide dinitrate on regional myocardial blood flow during acute coronary occlusion in the dog;Q179748;P279;Q49916468
[The ability of captopril to enhance the anti-anginal effect of isosorbide dinitrate in patients with stable exercise-induced angina pectoris];Q179748;P279;Q49916468
[The ability of captopril to enhance the anti-anginal effect of isosorbide dinitrate in patients with stable exercise-induced angina pectoris];Q1243800;P2175;Q180762
Isosorbide dinitrate sublingual therapy for inferior myocardial infarction: randomized trial to assess infarct size limitation.;Q179748;P279;Q49916468
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure;Q179748;P279;Q49916468
Determination of the two mononitrate metabolites of isosorbide dinitrate in human plasma and urine by gas chromatography with electron-capture detection;Q179748;P279;Q49916468
Determination of the two mononitrate metabolites of isosorbide dinitrate in human plasma and urine by gas chromatography with electron-capture detection;Q178450;P703;Q15978631
[Intermittent claudication: topical treatment with isosorbide dinitrate ointment. Preliminary results];Q179748;P279;Q49916468
Quantitative and qualitative modifications of lymphocyte subsets after sublingual administration of isosorbide dinitrate in migraineurs. Preliminary report.;Q179748;P279;Q49916468
[Effects of isosorbide dinitrate on body water spaces in chronic blood circulation insufficiency];Q179748;P279;Q49916468
[Effects of isosorbide dinitrate on body water spaces in chronic blood circulation insufficiency];Q29053744;P366;Q7892
Comparison of transdermal nitrate and isosorbide dinitrate in chronic stable angina;Q179748;P279;Q49916468
Comparison of transdermal nitrate and isosorbide dinitrate in chronic stable angina;Q1243800;P2175;Q180762
A patient with repeated syncopal attacks after using isosorbide dinitrate;Q179748;P279;Q49916468
Effect of intermittent administration of sustained release isosorbide dinitrate (sr-ISDN) in rats with pressure-overload heart;Q179748;P279;Q49916468
[Pharmacokinetics, effect and tolerance of isosorbide dinitrate and isosorbide-5-mononitrate in healthy persons];Q179748;P279;Q49916468
[Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration];Q179748;P279;Q49916468
Role of isosorbide dinitrate in management of chronic congestive heart failure.;Q179748;P279;Q49916468
Role of isosorbide dinitrate in management of chronic congestive heart failure.;Q1243800;P2175;Q19000661
Central and regional hemodynamic effects of intravenous isosorbide dinitrate, nitroglycerin and nitroprusside in patients with congestive heart failure;Q179748;P279;Q49916468
Central and regional hemodynamic effects of intravenous isosorbide dinitrate, nitroglycerin and nitroprusside in patients with congestive heart failure;Q1243800;P2175;Q19000661
Peripheral oedema in patients treated with isosorbide dinitrate;Q179748;P279;Q49916468
Impairment of platelet behaviour by isosorbide dinitrate;Q179748;P279;Q49916468
The effect of sublingual isosorbide dinitrate on acute urinary retention due to benign prostatic hyperplasia.;Q179748;P279;Q49916468
Can isosorbide dinitrate oral spray serve as an immediate bridging therapy for a mass cyanide poisoning?;Q179748;P279;Q49916468
Effects of chronic oral administration of isosorbide dinitrate on in vitro contractility of rat arterial smooth muscle;Q179748;P279;Q49916468
Plasma isosorbide dinitrate concentrations and effect after chewable and high-dose, sustained-release formulations.;Q179748;P279;Q49916468
[Effect of isosorbide dinitrate on the lower esophageal sphincter pressure in patients with Chagas' disease];Q179748;P279;Q49916468
Comparison of different absorption enhancers on the intranasal absorption of isosorbide dinitrate in rats.;Q179748;P279;Q49916468
Isosorbide di-nitrate (Sorbitrate) in the treatment of angina pectoris;Q179748;P3780;Q47521726
Isosorbide di-nitrate (Sorbitrate) in the treatment of angina pectoris;Q179748;P279;Q49916468
Isosorbide di-nitrate (Sorbitrate) in the treatment of angina pectoris;Q1243800;P2175;Q180762
Isosorbide dinitrate: relationship between pharmacokinetics and brachial artery hemodynamics in essential hypertension;Q179748;P279;Q49916468
Effects of isosorbide dinitrate and diltiazem used alone or combined on arterial hemodynamic and viscoelastic parameters. Experimental data in the rabbit;Q179748;P279;Q49916468
More rapid relief of pain with isosorbide dinitrate oral spray than with sublingual tablets in elderly patients with angina pectoris.;Q179748;P279;Q49916468
More rapid relief of pain with isosorbide dinitrate oral spray than with sublingual tablets in elderly patients with angina pectoris.;Q1243800;P2175;Q180762
Comparison of antianginal efficacy of nifedipine and isosorbide dinitrate in chronic stable angina: a long-term, randomized, double-blind, crossover study;Q39111;P2175;Q180762
Comparison of antianginal efficacy of nifedipine and isosorbide dinitrate in chronic stable angina: a long-term, randomized, double-blind, crossover study;Q179748;P279;Q49916468
Comparison of antianginal efficacy of nifedipine and isosorbide dinitrate in chronic stable angina: a long-term, randomized, double-blind, crossover study;Q1243800;P2175;Q180762
Systematic review and meta-analysis of randomized controlled trials comparing compound danshen dripping pills and isosorbide dinitrate in treating angina pectoris;Q183290;P31;Q11173
Systematic review and meta-analysis of randomized controlled trials comparing compound danshen dripping pills and isosorbide dinitrate in treating angina pectoris;Q179748;P31;Q11173
Systematic review and meta-analysis of randomized controlled trials comparing compound danshen dripping pills and isosorbide dinitrate in treating angina pectoris;Q179748;P279;Q49916468
Systematic review and meta-analysis of randomized controlled trials comparing compound danshen dripping pills and isosorbide dinitrate in treating angina pectoris;Q1243800;P2175;Q180762
Systematic review and meta-analysis of randomized controlled trials comparing compound danshen dripping pills and isosorbide dinitrate in treating angina pectoris;Q1243800;P31;Q11173
Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects;Q179748;P279;Q49916468
Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects;Q20035886;P703;Q15978631
[Effect of intra-arterial administration of isosorbide dinitrate on various hemodynamic parameters of pulmonary circulation and the right heart in patients with secondary pulmonary hypertension];Q179748;P279;Q49916468
Effects of sodium nitroprusside, isosorbide dinitrate, isoproterenol, phentolamine and prazosin on hepatic venous responses to sympathetic nerve stimulation in the cat.;Q179748;P279;Q49916468
[Absorption of isosorbide dinitrate in guinea-pig intestine and in the colon of sheep (author's transl)];Q179748;P279;Q49916468
Intravenous administration of isosorbide dinitrate attenuates the pressor response to laryngoscopy and tracheal intubation.;Q179748;P279;Q49916468
Dose- and time-related vasodilator response of conduit coronary arteries to intracoronary isosorbide dinitrate in human beings;Q179748;P2868;Q4008956
Dose- and time-related vasodilator response of conduit coronary arteries to intracoronary isosorbide dinitrate in human beings;Q179748;P279;Q49916468
Dose- and time-related vasodilator response of conduit coronary arteries to intracoronary isosorbide dinitrate in human beings;Q178450;P703;Q15978631
Effect of isosorbide dinitrate and its metabolites on rabbit atrial myocardial force-frequency relationships in vitro;Q179748;P279;Q49916468
G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT.;Q179748;P279;Q49916468
Abrupt cessation of short-term continuous treatment with isosorbide dinitrate may cause a rebound increase in silent myocardial ischaemia in patients with stable angina pectoris;Q179748;P279;Q49916468
Abrupt cessation of short-term continuous treatment with isosorbide dinitrate may cause a rebound increase in silent myocardial ischaemia in patients with stable angina pectoris;Q1243800;P2175;Q180762
[Successful management of a patient for cardiac surgery with difficulty in weaning from cardiopulmonary bypass by using both isosorbide dinitrate and olprinone hydrochloride].;Q179748;P279;Q49916468
Influence of electric foot shock on pharmacokinetics of isosorbide dinitrate orally administered to rats;Q179748;P279;Q49916468
Comparison of sublingual nitroglycerine and isosorbide dinitrate ointment by radionuclide ventriculography;Q179748;P279;Q49916468
[Experimental research on a delayed-release pharmaceutical preparation of isosorbide dinitrate];Q179748;P31;Q12140
[Experimental research on a delayed-release pharmaceutical preparation of isosorbide dinitrate];Q179748;P279;Q49916468
[Experimental research on a delayed-release pharmaceutical preparation of isosorbide dinitrate];Q1243800;P31;Q12140
[Effect of isosorbide dinitrate (sorbonit) on the exercise reaction in patients with coronary disease and in healthy individuals];Q179748;P279;Q49916468
Haemodynamic effects of oral salbutamol alone and in combination with sublingual isosorbide dinitrate in patients with severe congestive cardiac failure.;Q179748;P279;Q49916468
Short report: comparison of the effects of sublingual nifedipine and isosorbide dinitrate on oesophageal emptying in patients with Chagasic achalasia;Q179748;P279;Q49916468
Isosorbide dinitrate spray. Attenuation of cardiovascular responses to laryngoscopy and intubation.;Q179748;P279;Q49916468
[Chronic aortic and mitral valve regurgitation. Effects of isosorbide dinitrate on systolic function and passive elastic properties of the left ventricle (author's transl)];Q179748;P279;Q49916468
Sex- and species-related differences in the biotransformation of isosorbide dinitrate by various tissues of the rabbit and rat;Q179748;P279;Q49916468
[Plethysmographic researches on the beginning and duration of the pharmacological action of an isosorbide dinitrate drugs with prolonged action (author's transl)];Q179748;P31;Q12140
[Plethysmographic researches on the beginning and duration of the pharmacological action of an isosorbide dinitrate drugs with prolonged action (author's transl)];Q179748;P279;Q49916468
[Plethysmographic researches on the beginning and duration of the pharmacological action of an isosorbide dinitrate drugs with prolonged action (author's transl)];Q20035886;P31;Q12140
[Plethysmographic researches on the beginning and duration of the pharmacological action of an isosorbide dinitrate drugs with prolonged action (author's transl)];Q1243800;P31;Q12140
Adjuvant therapy of chronic refractory cardiac failure with oral hydralazine and isosorbide dinitrate;Q179748;P279;Q49916468
Isosorbide dinitrate in plasma and dialysate during haemodialysis;Q179748;P279;Q49916468
Clinical and circulatory effects of oral isosorbide dinitrate in patients with angina during exercise;Q179748;P279;Q49916468
Clinical and circulatory effects of oral isosorbide dinitrate in patients with angina during exercise;Q1243800;P2175;Q180762
Double-blind randomized multicenter study on the efficacy of trapidil versus isosorbide dinitrate in stable angina pectoris;Q179748;P279;Q49916468
Double-blind randomized multicenter study on the efficacy of trapidil versus isosorbide dinitrate in stable angina pectoris;Q1243800;P2175;Q180762
[Management of hypertension emergencies in elderly patients with isosorbide dinitrate aerosol];Q179748;P279;Q49916468
[Comparison of the efficacy and duration of action of 2 isosorbide dinitrate preparations];Q179748;P279;Q49916468
Differential effects of the novel NO-donating drug pirsidomine and isosorbide dinitrate on the venous vascular bed;Q207843;P31;Q12140
Differential effects of the novel NO-donating drug pirsidomine and isosorbide dinitrate on the venous vascular bed;Q179748;P31;Q12140
Differential effects of the novel NO-donating drug pirsidomine and isosorbide dinitrate on the venous vascular bed;Q179748;P279;Q49916468
Differential effects of the novel NO-donating drug pirsidomine and isosorbide dinitrate on the venous vascular bed;Q178450;P31;Q12140
Differential effects of the novel NO-donating drug pirsidomine and isosorbide dinitrate on the venous vascular bed;Q1243800;P31;Q12140
Effect of long-term octreotide and isosorbide dinitrate on haemodynamics in rats with portal vein stenosis;Q179748;P279;Q49916468
Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure;Q179748;P279;Q49916468
Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure;Q1243800;P2175;Q19000661
Effects of an oral dose of isosorbide dinitrate on platelet function and fibrinolysis in healthy volunteers.;Q179748;P279;Q49916468
Comparison of intracoronary adenosine and isosorbide dinitrate on no-reflow/slow flow during rotational atherectomy.;Q179748;P279;Q49916468
The effect of isosorbide dinitrate on exertional hypotension in old myocardial infarction;Q179748;P279;Q49916468
[Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations];Q179748;P279;Q49916468
The effect of intravenous isosorbide dinitrate in acute decompensated heart failure in hospital.;Q179748;P279;Q49916468
Effect of isosorbide dinitrate on cardiac output in severe cardiac failure: relation to initial hemodynamics, ventricular volume, and the preload reserve mechanism;Q179748;P279;Q49916468
Anti-ischemic effect of oligotide treatment in rat kidney: comparison with the effect of nifedipine and isosorbide dinitrate;Q179748;P279;Q49916468
Haemodynamic effects of intravenous isosorbide dinitrate in patients of cardiac failure following acute myocardial infarction;Q179748;P279;Q49916468
Influence of glyceryl trinitrate on venous and arterial effects of chronic, asymmetric isosorbide dinitrate treatment in patients with ischemic heart disease;Q3221044;P3781;Q162867
Influence of glyceryl trinitrate on venous and arterial effects of chronic, asymmetric isosorbide dinitrate treatment in patients with ischemic heart disease;Q3221044;P2175;Q1444550
Influence of glyceryl trinitrate on venous and arterial effects of chronic, asymmetric isosorbide dinitrate treatment in patients with ischemic heart disease;Q3221044;P2175;Q190805
Influence of glyceryl trinitrate on venous and arterial effects of chronic, asymmetric isosorbide dinitrate treatment in patients with ischemic heart disease;Q179748;P279;Q49916468
Influence of glyceryl trinitrate on venous and arterial effects of chronic, asymmetric isosorbide dinitrate treatment in patients with ischemic heart disease;Q1243800;P2175;Q844935
[Comparison of isosorbide dinitrate, isosorbide-5-mononitrate and sodium nitrite in isolated vascular preparations].;Q339975;P527;Q658
[Comparison of isosorbide dinitrate, isosorbide-5-mononitrate and sodium nitrite in isolated vascular preparations].;Q179748;P279;Q49916468
Determination of isosorbide dinitrate and its mononitrate metabolites in human plasma using Extrelut purification and capillary column gas-liquid chromatography;Q179748;P279;Q49916468
Determination of isosorbide dinitrate and its mononitrate metabolites in human plasma using Extrelut purification and capillary column gas-liquid chromatography;Q178450;P703;Q15978631
The effect of isosorbide dinitrate, a donor of nitric oxide, on maternal cerebral blood flow in gestational hypertension and preeclampsia.;Q179748;P279;Q49916468
[A case of vigorous achalasia, successfully treated with isosorbide dinitrate spray];Q179748;P279;Q49916468
Assessment of antianginal efficacy of long-acting sustained release isosorbide dinitrate in comparison with short-acting isosorbide dinitrate.;Q179748;P279;Q49916468
Assessment of antianginal efficacy of long-acting sustained release isosorbide dinitrate in comparison with short-acting isosorbide dinitrate.;Q1243800;P2175;Q180762
[Use of isosorbide dinitrate (isoket) in stenocardia and myocardial infarction];Q179748;P279;Q49916468
Separate and combined effects of pindolol and isosorbide dinitrate in standardized exercise tests of patients with angina pectoris.;Q179748;P279;Q49916468
Separate and combined effects of pindolol and isosorbide dinitrate in standardized exercise tests of patients with angina pectoris.;Q418101;P2175;Q180762
Separate and combined effects of pindolol and isosorbide dinitrate in standardized exercise tests of patients with angina pectoris.;Q1243800;P2175;Q180762
[Isosorbide dinitrate in exercise induced angina pectoris despite use of beta-blocking treatment. Clinical and hematological effects assessed by isotope angiocardiography];Q179748;P279;Q49916468
[Isosorbide dinitrate in exercise induced angina pectoris despite use of beta-blocking treatment. Clinical and hematological effects assessed by isotope angiocardiography];Q1243800;P2175;Q180762
Intravenous isosorbide dinitrate in the management of acute hypertension following cardiopulmonary bypass;Q179748;P279;Q49916468
[Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate];Q179748;P279;Q49916468
Isosorbide dinitrate for the relief of severe heart failure after myocardial infarction;Q179748;P279;Q49916468
Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure.;Q179748;P279;Q49916468
Controlled comparison of the pharmacodynamic effects of nicorandil (SG-75) and isosorbide dinitrate in man.;Q179748;P279;Q49916468
The effects of isosorbide dinitrate on exercise-induced ST-segment elevation at the infarcted area in old myocardial infarction;Q179748;P279;Q49916468
The effect of isosorbide dinitrate following experimental coronary occlusion;Q179748;P279;Q49916468
The long-acting hemodynamic effects of isosorbide dinitrate;Q179748;P279;Q49916468
Isosorbide dinitrate spray as therapeutic strategy for treatment of chronic venous ulcers.;Q179748;P279;Q49916468
Isosorbide dinitrate spray as therapeutic strategy for treatment of chronic venous ulcers.;Q484940;P703;Q177932
Double-blind randomised crossover trial comparing isosorbide dinitrate cream and oral sustained-release tablets in patients with angina pectoris;Q179748;P279;Q49916468
Double-blind randomised crossover trial comparing isosorbide dinitrate cream and oral sustained-release tablets in patients with angina pectoris;Q1243800;P2175;Q180762
Comparative evaluation of intravenous isosorbide dinitrate and nitroglycerin in patients with acute myocardial infarction.;Q179748;P279;Q49916468
Comparative evaluation of intravenous isosorbide dinitrate and nitroglycerin in patients with acute myocardial infarction.;Q905750;P2175;Q207550
The role of isosorbide dinitrate in the treatment of perioperative hypertension.;Q179748;P279;Q49916468
Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate;Q179748;P279;Q49916468
Effects of isosorbide dinitrate on portal hypertension in alcoholic cirrhosis;Q179748;P279;Q49916468
[Effects of isosorbide dinitrate on Oddi's sphincter];Q179748;P279;Q49916468
[Effect of isosorbide dinitrate on pulmonary venous compliance].;Q179748;P279;Q49916468
Determination of isosorbide as a metabolite of isosorbide dinitrate in human urine by capillary gas chromatography with electron-capture detection;Q179748;P279;Q49916468
Determination of isosorbide as a metabolite of isosorbide dinitrate in human urine by capillary gas chromatography with electron-capture detection;Q178450;P703;Q15978631
Intravenous isosorbide dinitrate during open-heart surgery and its role in the treatment of right-sided congestive heart failure.;Q179748;P279;Q49916468
Intravenous isosorbide dinitrate during open-heart surgery and its role in the treatment of right-sided congestive heart failure.;Q1243800;P2175;Q19000661
[Comparison of the effects of molsidomine retard and isosorbide dinitrate retard in patients with stable angina pectoris using an ergometry test];Q179748;P279;Q49916468
[Comparison of the effects of molsidomine retard and isosorbide dinitrate retard in patients with stable angina pectoris using an ergometry test];Q1243800;P2175;Q180762
The nitric oxide donor, isosorbide dinitrate, induces a cephalic cutaneous hypersensitivity, associated with sensitization of the medullary dorsal horn.;Q179748;P279;Q49916468
[Effects of isosorbide dinitrate on coronary and systemic circulation in children];Q179748;P279;Q49916468
Preparation, characterization and in vitro drug release of isosorbide dinitrate microspheres.;Q179748;P31;Q12140
Preparation, characterization and in vitro drug release of isosorbide dinitrate microspheres.;Q179748;P279;Q49916468
Preparation, characterization and in vitro drug release of isosorbide dinitrate microspheres.;Q20035886;P31;Q12140
Preparation, characterization and in vitro drug release of isosorbide dinitrate microspheres.;Q1243800;P31;Q12140
[Evaluation of tolerance during intravenous administration of low dose of isosorbide dinitrate in the treatment of unstable angina];Q179748;P279;Q49916468
[Evaluation of tolerance during intravenous administration of low dose of isosorbide dinitrate in the treatment of unstable angina];Q1243800;P2175;Q180762
Cardiovascular effects of isosorbide dinitrate infused intravenously into anaesthetized dogs.;Q179748;P279;Q49916468
Comparison of the hemodynamic responses to molsidomine and isosorbide dinitrate in congestive heart failure;Q179748;P279;Q49916468
Comparison of the hemodynamic responses to molsidomine and isosorbide dinitrate in congestive heart failure;Q1243800;P2175;Q19000661
[Acute hemodynamic effects of SIN-1 and isosorbide dinitrate in stable left ventricular failure: a comparative double-blind, cross-over study];Q179748;P279;Q49916468
Inactivation of human aldehyde dehydrogenase by isosorbide dinitrate;Q179748;P279;Q49916468
Inactivation of human aldehyde dehydrogenase by isosorbide dinitrate;Q484940;P703;Q15978631
Inactivation of human aldehyde dehydrogenase by isosorbide dinitrate;Q1243800;P527;Q556
Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man;Q179748;P279;Q49916468
Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man;Q423401;P279;Q49916468
[Coronary circulation, myocardial O2 consumption and left ventricular function after sublingual application of isosorbide dinitrate];Q179748;P279;Q49916468
Reduction of portal pressure by chronic administration of isosorbide dinitrate in patients with cirrhosis: effects on systemic and splanchnic hemodynamics and liver function.;Q179748;P279;Q49916468
[Sorption of isosorbide dinitrate on infusion sets];Q179748;P279;Q49916468
The combination of hydralazine and isosorbide dinitrate: the only antioxidant treatment recommended in the guidelines;Q179748;P279;Q49916468
Anti-ischemic effects of an 80-mg tablet of isosorbide dinitrate in sustained-release form before and after 2 weeks treatment with 80 mg once daily or twice daily;Q179748;P279;Q49916468
Influence of a Double-Lumen Extension Tube on Drug Delivery: Examples of Isosorbide Dinitrate and Diazepam;Q179748;P279;Q49916468
Dissolution rate studies. II. Modified column apparatus and its use in evaluating isosorbide dinitrate tablets;Q179748;P279;Q49916468
Comparison of antianginal efficacy of sustained release isosorbide dinitrate with short-acting isosorbide dinitrate.;Q179748;P279;Q49916468
Comparison of antianginal efficacy of sustained release isosorbide dinitrate with short-acting isosorbide dinitrate.;Q1243800;P2175;Q180762
Clinical effects of a sustained-release preparation of isosorbide dinitrate on angina pectoris;Q179748;P279;Q49916468
Clinical effects of a sustained-release preparation of isosorbide dinitrate on angina pectoris;Q1243800;P2175;Q180762
[Bioavailability of long-acting isosorbide dinitrate in humans];Q179748;P279;Q49916468
High-dose isosorbide dinitrate in management of angina pectoris.;Q179748;P279;Q49916468
High-dose isosorbide dinitrate in management of angina pectoris.;Q1243800;P2175;Q180762
[Arterial and venous dilation using nitroglycerin and isosorbide dinitrate during cardiopulmonary bypass];Q179748;P279;Q49916468
Anti-ischemic effects of first and second dose of 20 mg isosorbide dinitrate administered 5 hours apart: attenuation of effects despite rising plasma concentration;Q179748;P279;Q49916468
[Primary pulmonary hypertension in a brother and a sister--combined administration of prazosin and isosorbide dinitrate];Q179748;P279;Q49916468
[Primary pulmonary hypertension in a brother and a sister--combined administration of prazosin and isosorbide dinitrate];Q425296;P2175;Q41861
Role of pentobarbitone anaesthesia and sympathetic tone in the haemodynamic effects of isosorbide dinitrate in rats with cirrhosis.;Q179748;P279;Q49916468
Control of perioperative hypertension during coronary artery surgery. A randomised double-blind study comparing isosorbide dinitrate and nitroglycerin;Q179748;P279;Q49916468
Comparison of the effects of dopamine, hydralazine, and isosorbide dinitrate on myocardial hemodynamics in patients with refractory heart failure.;Q179748;P279;Q49916468
[Influence of combination therapy (isosorbide dinitrate and molsidomine) on the incidence of angina pectoris in patients with coronary heart disease];Q179748;P279;Q49916468
[Influence of combination therapy (isosorbide dinitrate and molsidomine) on the incidence of angina pectoris in patients with coronary heart disease];Q1243800;P2175;Q180762
[Influence of combination therapy (isosorbide dinitrate and molsidomine) on the incidence of angina pectoris in patients with coronary heart disease];Q1243800;P2175;Q844935
[Isosorbide dinitrate treatment of silent myocardial ischemia in patients after myocardial infarction];Q179748;P279;Q49916468
[Shall we Follow the Guidelines for Isosorbide Dinitrate in Acute Pulmonary Edema?];Q179748;P279;Q49916468
The utility of Nitroderm TTS in angina pectoris: long-term treatment after switching from long-acting oral isosorbide dinitrate;Q179748;P279;Q49916468
The utility of Nitroderm TTS in angina pectoris: long-term treatment after switching from long-acting oral isosorbide dinitrate;Q1243800;P2175;Q180762
Isosorbide dinitrate and intra-aortic balloon pumping in preinfarctional angina. Effects on central circulatory dynamics;Q179748;P279;Q49916468
Isosorbide dinitrate and intra-aortic balloon pumping in preinfarctional angina. Effects on central circulatory dynamics;Q1243800;P2175;Q180762
[Favourable results with local injections of botulinum-A toxin in patients with chronic isosorbide dinitrate ointment-resistant anal fissures];Q179748;P279;Q49916468
Effects of treatment with oral isosorbide dinitrate on platelet function in vivo: a double-blind placebo-controlled study in patients with stable angina pectoris.;Q179748;P279;Q49916468
Effects of treatment with oral isosorbide dinitrate on platelet function in vivo: a double-blind placebo-controlled study in patients with stable angina pectoris.;Q1243800;P2175;Q180762
Dilation of coronary artery stenoses after isosorbide dinitrate in man;Q179748;P279;Q49916468
Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group;Q179748;P279;Q49916468
Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group;Q419987;P2175;Q19000661
Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group;Q422185;P2175;Q19000661
Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group;Q1243800;P2175;Q19000661
Laryngeal oedema after isosorbide dinitrate spray and sublingual nifedipine.;Q179748;P279;Q49916468
Fate of orally given isosorbide dinitrate in man: factors of variability;Q179748;P279;Q49916468
Value of sublingual isosorbide dinitrate before isoproterenol tilt test for diagnosis of neurally mediated syncope;Q179748;P279;Q49916468
The effects of isosorbide dinitrate on methemoglobin reductase enzyme activity and antioxidant states.;Q179748;P279;Q49916468
Effects of amlodipine and isosorbide dinitrate on exercise-induced and ambulatory ischemia in patients with chronic stable angina pectoris;Q179748;P279;Q49916468
Effects of amlodipine and isosorbide dinitrate on exercise-induced and ambulatory ischemia in patients with chronic stable angina pectoris;Q1243800;P2175;Q180762
[Effect of isosorbide dinitrate on the capillaries of the myocardium];Q179748;P279;Q49916468
Duration of action of isosorbide dinitrate;Q179748;P279;Q49916468
Comparative haemodynamic and peripheral vasodilator effects of oral and chewable isosorbide dinitrate in patients with refractory congestive cardiac failure.;Q179748;P2868;Q4008956
Comparative haemodynamic and peripheral vasodilator effects of oral and chewable isosorbide dinitrate in patients with refractory congestive cardiac failure.;Q179748;P279;Q49916468
Isosorbide dinitrate and furosemide in the treatment of patients with severe pulmonary edema;Q388801;P2175;Q857667
Isosorbide dinitrate and furosemide in the treatment of patients with severe pulmonary edema;Q179748;P279;Q49916468
Acute and chronic isosorbide dinitrate therapy in congestive heart failure: demonstration of improved exercise capacity and differing arterial and venous tolerance during chronic administration.;Q179748;P279;Q49916468
Acute and chronic isosorbide dinitrate therapy in congestive heart failure: demonstration of improved exercise capacity and differing arterial and venous tolerance during chronic administration.;Q1243800;P2175;Q19000661
Finger pulse plethysmographic effects of two oral sustained-release formulations of isosorbide dinitrate in normal man;Q179748;P279;Q49916468
Inhibition of platelet function by injectable isosorbide dinitrate;Q179748;P279;Q49916468
Effects of sublingual nitrate in patients receiving sustained therapy of isosorbide dinitrate for coronary artery disease;Q179748;P279;Q49916468
Effects of sublingual nitrate in patients receiving sustained therapy of isosorbide dinitrate for coronary artery disease;Q1243800;P2175;Q844935
[Acute hemodynamic effects of intravenous bolus injection of isosorbide dinitrate in aged patients with congestive heart failure];Q179748;P279;Q49916468
[Acute hemodynamic effects of intravenous bolus injection of isosorbide dinitrate in aged patients with congestive heart failure];Q1243800;P2175;Q19000661
The effect of single and repeated oral doses of isosorbide dinitrate on plasma renin activity and plasma catecholamine levels in conscious dogs;Q179748;P279;Q49916468
Intravenous isosorbide dinitrate inhibits neutrophil aggregation and plasma-mediated stimulation of superoxide anion production;Q179748;P279;Q49916468
Biotransformation of isosorbide dinitrate in humans.;Q179748;P279;Q49916468
Hemodynamic effects of intravenous isosorbide dinitrate and nitroglycerine in acute myocardial infarction and elevated pulmonary artery wedge pressure.;Q179748;P279;Q49916468
Hemodynamic effects of intravenous isosorbide dinitrate and nitroglycerine in acute myocardial infarction and elevated pulmonary artery wedge pressure.;Q905750;P2175;Q207550
[Radionuclide angiocardiographic evaluation of the effect of isosorbide dinitrate in patients with Chagas' disease];Q179748;P279;Q49916468
Pharmacokinetics of isosorbide dinitrate, isosorbide-2-nitrate and isosorbide-5-nitrate in renal insufficiency after repeated oral dosage;Q179748;P279;Q49916468
Effect of sustained release isosorbide dinitrate (EV151) in dogs with experimentally-induced mitral insufficiency.;Q179748;P279;Q49916468
Plasma concentrations and coronary vasodilation after sublingual and intracoronary administration of isosorbide dinitrate;Q179748;P279;Q49916468
Combination therapy with isosorbide dinitrate: current status and the future.;Q179748;P279;Q49916468
Retracted: Cardioprotective Effect of Isosorbide Dinitrate Postconditioning Against Rat Myocardial Ischemia-Reperfusion Injury In Vivo;Q179748;P279;Q49916468
[Long-term therapy following myocardial infarct with isosorbide dinitrate in a low and high dose];Q179748;P279;Q49916468
Comparison of the effect of isosorbide-5-mononitrate and isosorbide dinitrate in a slow-release form on exercise-induced myocardial ischemia.;Q179748;P279;Q49916468
Comparative effects of nitroglycerin and isosorbide dinitrate on coronary collateral vessels and ischemic myocardium in dogs.;Q179748;P279;Q49916468
[Program for detection of patients with ineffective therapy with beta-adrenoblockers and comparative assessment of efficacy of addition of trimetazidine MB or isosorbide dinitrate in stable angina. Results of a Russian Study Parrallel];Q179748;P279;Q49916468
[Program for detection of patients with ineffective therapy with beta-adrenoblockers and comparative assessment of efficacy of addition of trimetazidine MB or isosorbide dinitrate in stable angina. Results of a Russian Study Parrallel];Q1243800;P2175;Q180762
Acute effects of sublingual isosorbide dinitrate on global and regional left ventricular diastolic filling in normal persons;Q179748;P279;Q49916468
[Prophylactic effect of isosorbide dinitrate on postoperative cardiac complications (author's transl)];Q179748;P279;Q49916468
[Comparison of isosorbide dinitrate and dinoprostone for induction of labor in term pregnancy];Q179748;P279;Q49916468
[Effectiveness and duration of effect of molsidomine and isosorbide dinitrate in peripheral circulation];Q179748;P279;Q49916468
Isosorbide dinitrate and hydralazine in blacks with heart failure.;Q179748;P279;Q49916468
Long-term Physicochemical Stability of Concentrated Solutions of Isosorbide Dinitrate in Polypropylene Syringes for Administration in the Intensive Care Unit;Q179748;P279;Q49916468
Effect of pertussis toxin and the cGMP lowering agent LY83583 on the relaxation induced by nitrates in isolated bovine mesenteric artery. A comparison between glyceryl trinitrate, isosorbide dinitrate and isosorbide 5-mononitrate;Q3221044;P3781;Q162867
Effect of pertussis toxin and the cGMP lowering agent LY83583 on the relaxation induced by nitrates in isolated bovine mesenteric artery. A comparison between glyceryl trinitrate, isosorbide dinitrate and isosorbide 5-mononitrate;Q179748;P279;Q49916468
Controlled observations on clinical efficacy of isosorbide dinitrate;Q179748;P279;Q49916468
[Comparative study of the vasodilator properties of linsidomine chlorhydrate versus isosorbide dinitrate by the intracoronary route];Q179748;P2868;Q4008956
[Comparative study of the vasodilator properties of linsidomine chlorhydrate versus isosorbide dinitrate by the intracoronary route];Q179748;P279;Q49916468
[Changes in the peripheral circulation pharmacologically induced with a combination based on isosorbide dinitrate and prenylamine-theophylline acetate];Q179748;P279;Q49916468
Sexually transferred drug adverse reaction to isosorbide dinitrate cream;Q183290;P31;Q12140
Sexually transferred drug adverse reaction to isosorbide dinitrate cream;Q179748;P31;Q12140
Sexually transferred drug adverse reaction to isosorbide dinitrate cream;Q179748;P279;Q49916468
Sexually transferred drug adverse reaction to isosorbide dinitrate cream;Q1243800;P31;Q12140
Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate.;Q179748;P279;Q49916468
Comparison of nifedipine and isosorbide dinitrate when added to maximal propranolol therapy in stable angina pectoris;Q39111;P2175;Q180762
Comparison of nifedipine and isosorbide dinitrate when added to maximal propranolol therapy in stable angina pectoris;Q179748;P279;Q49916468
Comparison of nifedipine and isosorbide dinitrate when added to maximal propranolol therapy in stable angina pectoris;Q1243800;P2175;Q180762
[Pharmacodynamic effects of VUFB's isosorbide dinitrate and Spofa's nitroglycerin];Q179748;P279;Q49916468
[Comparative invasive examination of the effect of isosorbide-5-mononitrate and isosorbide dinitrate in chronic coronary insufficiency];Q179748;P279;Q49916468
[Studies on isosorbide dinitrate. I. Determination of isosorbide dinitrate in human plasma by capillary column gas liquid chromatography];Q183290;P703;Q15978631
[Studies on isosorbide dinitrate. I. Determination of isosorbide dinitrate in human plasma by capillary column gas liquid chromatography];Q179748;P279;Q49916468
[Studies on isosorbide dinitrate. I. Determination of isosorbide dinitrate in human plasma by capillary column gas liquid chromatography];Q178450;P703;Q15978631
[Studies on isosorbide dinitrate. I. Determination of isosorbide dinitrate in human plasma by capillary column gas liquid chromatography];Q484940;P703;Q15978631
Tolerance to isosorbide dinitrate: rate of development and reversal;Q179748;P279;Q49916468
[Hemodynamic effects of oral dihydralazine and sublingual isosorbide dinitrate, alone and in combination in chronic heart failure];Q179748;P279;Q49916468
Nitro compounds (isosorbide dinitrate, 5-isosorbide mononitrate and glyceryl trinitrate) on the femoral vein and femoral artery;Q3221044;P3781;Q162867
Nitro compounds (isosorbide dinitrate, 5-isosorbide mononitrate and glyceryl trinitrate) on the femoral vein and femoral artery;Q179748;P31;Q11173
Nitro compounds (isosorbide dinitrate, 5-isosorbide mononitrate and glyceryl trinitrate) on the femoral vein and femoral artery;Q179748;P279;Q49916468
Nitro compounds (isosorbide dinitrate, 5-isosorbide mononitrate and glyceryl trinitrate) on the femoral vein and femoral artery;Q423401;P279;Q49916468
Nitro compounds (isosorbide dinitrate, 5-isosorbide mononitrate and glyceryl trinitrate) on the femoral vein and femoral artery;Q423401;P31;Q11173
Nitro compounds (isosorbide dinitrate, 5-isosorbide mononitrate and glyceryl trinitrate) on the femoral vein and femoral artery;Q1243800;P31;Q11173
NMR determination of isosorbide dinitrate and beta-adrenergic blocking agents in tablets;Q179748;P279;Q49916468
[Comparison of the anti-angina effect and effect duration of isosorbide dinitrate, isosorbide-2-mononitrate (IS-2-MN) and isosorbide-5-mononitrate (IS-5-MN)];Q179748;P279;Q49916468
[Comparison of the anti-angina effect and effect duration of isosorbide dinitrate, isosorbide-2-mononitrate (IS-2-MN) and isosorbide-5-mononitrate (IS-5-MN)];Q423401;P279;Q49916468
[Comparison of the anti-angina effect and effect duration of isosorbide dinitrate, isosorbide-2-mononitrate (IS-2-MN) and isosorbide-5-mononitrate (IS-5-MN)];Q1243800;P2175;Q180762
[Selection of therapy with nitrates in patients with stable effort angina: results of comparative study of common isosorbide dinitrate and long acting preparation of isosorbide-5-mononitrate].;Q179748;P279;Q49916468
[Selection of therapy with nitrates in patients with stable effort angina: results of comparative study of common isosorbide dinitrate and long acting preparation of isosorbide-5-mononitrate].;Q1243800;P2175;Q180762
Comparative effects of captopril and isosorbide dinitrate on the arterial wall of hypertensive human brachial arteries;Q186474;P703;Q15978631
Comparative effects of captopril and isosorbide dinitrate on the arterial wall of hypertensive human brachial arteries;Q179748;P279;Q49916468
Treatment of acute strangulated internal hemorrhoids by topical application of isosorbide dinitrate ointment.;Q179748;P279;Q49916468
Cluster headaches from isosorbide dinitrate;Q179748;P279;Q49916468
Determination of isosorbide dinitrate in pharmaceutical products by HPLC;Q186474;P31;Q12140
Determination of isosorbide dinitrate in pharmaceutical products by HPLC;Q485277;P31;Q12140
Determination of isosorbide dinitrate in pharmaceutical products by HPLC;Q179748;P279;Q49916468
Determination of isosorbide dinitrate in pharmaceutical products by HPLC;Q179748;P31;Q12140
Determination of isosorbide dinitrate in pharmaceutical products by HPLC;Q178450;P31;Q12140
Determination of isosorbide dinitrate in pharmaceutical products by HPLC;Q20035886;P31;Q12140
Determination of isosorbide dinitrate in pharmaceutical products by HPLC;Q483745;P31;Q12140
Determination of isosorbide dinitrate in pharmaceutical products by HPLC;Q1243800;P31;Q12140
Lateral internal sphincterotomy versus 0.25 % isosorbide dinitrate ointment for chronic anal fissures: a prospective randomized controlled trial;Q179748;P279;Q49916468
Fate of isosorbide dinitrate and mononitrates in patients with renal failure;Q179748;P279;Q49916468
[The effect of isosorbide dinitrate VUFB (intravenous injection) on pressure levels in the pulmonary artery (preliminary report)];Q179748;P279;Q49916468
[Pharmacokinetics of isosorbide dinitrate examined by physiologically-based pharmacokinetic model];Q179748;P279;Q49916468
Availability of isosorbide dinitrate, diazepam and chlormethiazole, from i.v. delivery systems.;Q179748;P279;Q49916468
[Experiences with isosorbide dinitrate in combination with a beta receptor blockader (Bupranolol)];Q179748;P279;Q49916468
Comparison between isosorbide dinitrate aerosol and nifedipine in the treatment of hypertensive emergencies;Q179748;P279;Q49916468
Quantitative analysis of 1,3,4,6-dianhydro-D-glucitol 2,5-dinitrate (isosorbide dinitrate) by infrared spectrometry;Q245280;P31;Q66589595
Quantitative analysis of 1,3,4,6-dianhydro-D-glucitol 2,5-dinitrate (isosorbide dinitrate) by infrared spectrometry;Q179748;P279;Q49916468
Nifedipine and isosorbide dinitrate alone and in combination for patients with chronic stable angina: a double-blind crossover study.;Q39111;P2175;Q180762
Nifedipine and isosorbide dinitrate alone and in combination for patients with chronic stable angina: a double-blind crossover study.;Q179748;P279;Q49916468
Nifedipine and isosorbide dinitrate alone and in combination for patients with chronic stable angina: a double-blind crossover study.;Q1243800;P2175;Q180762
Improvement in supine bicycle exercise performance in refractory congestive heart failure after isosorbide dinitrate: radionuclide and hemodynamic evaluation of acute effects.;Q179748;P279;Q49916468
Improvement in supine bicycle exercise performance in refractory congestive heart failure after isosorbide dinitrate: radionuclide and hemodynamic evaluation of acute effects.;Q1243800;P2175;Q19000661
Clinical evaluation of sublingual nitrates. Onset and duration of action of nitroglycerin and isosorbide dinitrate;Q179748;P279;Q49916468
Isosorbide dinitrate in treatment of angina pectoris. Preliminary clinical impression;Q179748;P279;Q49916468
Isosorbide dinitrate in treatment of angina pectoris. Preliminary clinical impression;Q1243800;P2175;Q180762
Protective effects of nipradilol, isosorbide dinitrate, and bunazosin on coronary artery constriction induced by intracoronary injection of acetylcholine in pigs;Q179748;P279;Q49916468
Efficacy of isosorbide dinitrate tape on exercise tolerance of patients with angina pectoris.;Q179748;P279;Q49916468
Efficacy of isosorbide dinitrate tape on exercise tolerance of patients with angina pectoris.;Q1243800;P2175;Q180762
Gas chromatographic determination of isosorbide dinitrate in human plasma and urine;Q179748;P279;Q49916468
Gas chromatographic determination of isosorbide dinitrate in human plasma and urine;Q620730;P703;Q15978631
Isosorbide dinitrate during acute coronary occlusion. Effects in the baboon;Q179748;P279;Q49916468
Development of a membrane-controlled transdermal therapeutic system containing isosorbide dinitrate;Q179748;P279;Q49916468
Development of a membrane-controlled transdermal therapeutic system containing isosorbide dinitrate;Q178450;P703;Q177932
Effect upon myocardial blood-flow in man of beta-blocking agents, isosorbide dinitrate, dipyridamole and their combination;Q179748;P279;Q49916468
Bioavailability of isosorbide dinitrate from an oral therapeutic system and from tablet Sorbonit Prolongatum 20,0 in human volunteers;Q245280;P703;Q15978631
Bioavailability of isosorbide dinitrate from an oral therapeutic system and from tablet Sorbonit Prolongatum 20,0 in human volunteers;Q183290;P703;Q15978631
Bioavailability of isosorbide dinitrate from an oral therapeutic system and from tablet Sorbonit Prolongatum 20,0 in human volunteers;Q183290;P703;Q177932
Bioavailability of isosorbide dinitrate from an oral therapeutic system and from tablet Sorbonit Prolongatum 20,0 in human volunteers;Q179748;P279;Q49916468
Bioavailability of isosorbide dinitrate from an oral therapeutic system and from tablet Sorbonit Prolongatum 20,0 in human volunteers;Q20035886;P703;Q15978631
Bioavailability of isosorbide dinitrate from an oral therapeutic system and from tablet Sorbonit Prolongatum 20,0 in human volunteers;Q20035886;P703;Q177932
The acute effect of sublingual nifedipine and isosorbide dinitrate on plasma viscosity in patients with acute myocardial infarction.;Q179748;P279;Q49916468
Nitrate tolerance: does tid isosorbide dinitrate mean dosing every eight hours?;Q179748;P279;Q49916468
Effects of angiotensin-converting enzyme inhibitor alacepril in patients with stable effort angina during chronic isosorbide dinitrate treatment.;Q179748;P279;Q49916468
Effects of angiotensin-converting enzyme inhibitor alacepril in patients with stable effort angina during chronic isosorbide dinitrate treatment.;Q1243800;P2175;Q180762
Sorption of isosorbide dinitrate to central venous catheters.;Q179748;P279;Q49916468
Prolonged plasma half-life after oral isosorbide dinitrate in patients with angina pectoris;Q179748;P279;Q49916468
Prolonged plasma half-life after oral isosorbide dinitrate in patients with angina pectoris;Q1243800;P2175;Q180762
Improved method for the rapid determination of isosorbide dinitrate in human plasma and its application in pharmacokinetic studies;Q179748;P279;Q49916468
Improved method for the rapid determination of isosorbide dinitrate in human plasma and its application in pharmacokinetic studies;Q484940;P703;Q15978631
Isosorbide dinitrate in the treatment of silent myocardial ischaemia in patients after myocardial infarction: an open pilot study.;Q179748;P279;Q49916468
[Effect of isosorbide dinitrate in relation to posture and age];Q179748;P279;Q49916468
[Importance of injectable isosorbide dinitrate after cardiac surgery under extracorporeal circulation];Q179748;P279;Q49916468
[Vasodilator therapy in congestive heart failure--hemodynamic effects of oral administered isosorbide dinitrate (author's transl)];Q179748;P279;Q49916468
[Vasodilator therapy in congestive heart failure--hemodynamic effects of oral administered isosorbide dinitrate (author's transl)];Q1243800;P2175;Q19000661
Pain scoring--a method for assessing acute antianginal therapy comparison of the response to acute sublingual administration of an isosorbide dinitrate tablet, isosorbide dinitrate spray and nitroglycerin spray in unstable angina.;Q179748;P279;Q49916468
Pain scoring--a method for assessing acute antianginal therapy comparison of the response to acute sublingual administration of an isosorbide dinitrate tablet, isosorbide dinitrate spray and nitroglycerin spray in unstable angina.;Q1243800;P2175;Q180762
Comparison of the effects of sublingual isosorbide dinitrate and cardiomyotomy on esophageal emptying in patients with chagasic megaesophagus;Q179748;P279;Q49916468
[Effects of isosorbide dinitrate on regional cerebral blood flow and intracranial pressure in cats];Q179748;P279;Q49916468
Membrane permeation-controlled transdermal delivery system design. Influence of controlling membrane and adhesive on skin permeation of isosorbide dinitrate;Q179748;P279;Q49916468
Anti-ischaemic response to sublingual nitroglycerin during oral administration of isosorbide dinitrate in patients with stable angina pectoris: when does cross-tolerance occur?;Q179748;P279;Q49916468
Anti-ischaemic response to sublingual nitroglycerin during oral administration of isosorbide dinitrate in patients with stable angina pectoris: when does cross-tolerance occur?;Q1243800;P2175;Q180762
Naproxen, isosorbide dinitrate and co-administration cannot prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: Randomized controlled trial;Q179748;P279;Q49916468
A comparative study on the effects of Gemfibrozil, Diltiazem and Isosorbide dinitrate on lipid profile in patients of ischemic heart disease in India;Q384295;P2175;Q844935
A comparative study on the effects of Gemfibrozil, Diltiazem and Isosorbide dinitrate on lipid profile in patients of ischemic heart disease in India;Q179748;P279;Q49916468
A comparative study on the effects of Gemfibrozil, Diltiazem and Isosorbide dinitrate on lipid profile in patients of ischemic heart disease in India;Q1243800;P2175;Q844935
[Hemodynamic effects of a new long-acting isosorbide dinitrate];Q179748;P279;Q49916468
Single administration of atenolol does not influence the kinetics of orally given isosorbide dinitrate;Q179748;P279;Q49916468
Influence of isosorbide dinitrate concentration on its skin permeability from adhesive matrix devices;Q179748;P279;Q49916468
The sorption of isosorbide dinitrate to intravenous delivery systems.;Q179748;P279;Q49916468
Effects of isosorbide dinitrate on electrocardiography, hemodynamics, and ventilation in patients with exercise-induced elevation of pulmonary artery wedge pressure;Q179748;P279;Q49916468
Randomized, prospective trial comparing 0.2 percent isosorbide dinitrate ointment with sphincterotomy in treatment of chronic anal fissure: a two-year follow-up.;Q179748;P279;Q49916468
Reduction of nitroglycerin and isosorbide dinitrate by hemodialysis in refractory angina pectoris after acute myocardial infarction;Q179748;P279;Q49916468
Reduction of nitroglycerin and isosorbide dinitrate by hemodialysis in refractory angina pectoris after acute myocardial infarction;Q905750;P2175;Q207550
Reduction of nitroglycerin and isosorbide dinitrate by hemodialysis in refractory angina pectoris after acute myocardial infarction;Q1243800;P2175;Q180762
[Isosorbide dinitrate spray: a comparative pharmacodynamic study with a sublingual preparation in patients with chronic cardiac insufficiency];Q179748;P279;Q49916468
Comments on 'A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily and isosorbide dinitrate twice daily in patients with stable angina';Q39111;P3780;Q47520879
Comments on 'A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily and isosorbide dinitrate twice daily in patients with stable angina';Q39111;P2175;Q180762
Comments on 'A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily and isosorbide dinitrate twice daily in patients with stable angina';Q179748;P279;Q49916468
Comments on 'A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily and isosorbide dinitrate twice daily in patients with stable angina';Q423401;P279;Q49916468
Comments on 'A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily and isosorbide dinitrate twice daily in patients with stable angina';Q1243800;P2175;Q180762
The effect of isosorbide dinitrate on left ventricular size, wall stress and left ventricular function in chronic refractory heart failure. An echocardiographic study.;Q179748;P279;Q49916468
[Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system];Q186474;P703;Q177932
[Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system];Q179748;P279;Q49916468
Effects of diltiazem alone or with isosorbide dinitrate or with atenolol both acutely and chronically for stable angina pectoris.;Q411325;P2175;Q180762
Effects of diltiazem alone or with isosorbide dinitrate or with atenolol both acutely and chronically for stable angina pectoris.;Q179748;P279;Q49916468
Effects of diltiazem alone or with isosorbide dinitrate or with atenolol both acutely and chronically for stable angina pectoris.;Q422229;P2175;Q180762
Effects of diltiazem alone or with isosorbide dinitrate or with atenolol both acutely and chronically for stable angina pectoris.;Q1243800;P2175;Q180762
Haemodynamic effects of isosorbide dinitrate in patients with congestive cardiac failure at rest and during submaximal supine exercise.;Q179748;P279;Q49916468
[In vivo penetration of isosorbide dinitrate from a transdermal therapeutic system in rat skin];Q179748;P279;Q49916468
[In vivo penetration of isosorbide dinitrate from a transdermal therapeutic system in rat skin];Q484940;P703;Q177932
Magnitude and nature of noncompliance with treatment using isosorbide dinitrate in patients with ischemic heart disease;Q179748;P279;Q49916468
Magnitude and nature of noncompliance with treatment using isosorbide dinitrate in patients with ischemic heart disease;Q1243800;P2175;Q844935
[Acute and long term action of isosorbide dinitrate on the pulmonary circulation, right ventricular function and arterial blood gases in patient with chronic cor pulmonale];Q179748;P279;Q49916468
[Echocardiographic evaluation of heart function before and after administration of isosorbide dinitrate in patients with acute myocardial infarct];Q179748;P279;Q49916468
Sublingual isosorbide dinitrate for treatment of acute pulmonary edema;Q179748;P279;Q49916468
Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions.;Q179748;P279;Q49916468
Effect of sustained-release isosorbide dinitrate on post-prandial gastric emptying and gastroduodenal motility in healthy humans.;Q179748;P279;Q49916468
The antianginal efficacy of isosorbide dinitrate: dose-response relation and long-term effects of high-dose treatment;Q179748;P279;Q49916468
The antianginal efficacy of isosorbide dinitrate: dose-response relation and long-term effects of high-dose treatment;Q1243800;P2175;Q180762
Hemodynamic effects of molsidomine, isosorbide dinitrate, and nifedipine at rest and during exercise;Q179748;P279;Q49916468
Isosorbide dinitrate inhibits mechanical stress-induced cardiac hypertrophy and autophagy through downregulation of angiotensin II type 1 receptor;Q179748;P279;Q49916468
The biotransformation of isosorbide dinitrate in dogs and humans;Q186521;P703;Q15978631
The biotransformation of isosorbide dinitrate in dogs and humans;Q179748;P279;Q49916468
Isosorbide dinitrate ointment in Raynaud's disease.;Q179748;P279;Q49916468
Effectiveness of isosorbide dinitrate and nitroglycerin in relieving angina pectoris during uninterrupted exercise.;Q179748;P279;Q49916468
Effectiveness of isosorbide dinitrate and nitroglycerin in relieving angina pectoris during uninterrupted exercise.;Q1243800;P2175;Q180762
Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: results from the African-American Heart Failure Trial.;Q179748;P279;Q49916468
[New drug forms of isosorbide dinitrate: the problem of an objective evaluation in patients with ischemic heart disease];Q179748;P31;Q12140
[New drug forms of isosorbide dinitrate: the problem of an objective evaluation in patients with ischemic heart disease];Q179748;P279;Q49916468
[New drug forms of isosorbide dinitrate: the problem of an objective evaluation in patients with ischemic heart disease];Q1243800;P31;Q12140
[New drug forms of isosorbide dinitrate: the problem of an objective evaluation in patients with ischemic heart disease];Q1243800;P2175;Q844935
Effects of isosorbide dinitrate on the response to atrial pacing in coronary heart disease;Q179748;P279;Q49916468
Effects of isosorbide dinitrate on the response to atrial pacing in coronary heart disease;Q1243800;P2175;Q844935
Oral isosorbide dinitrate in the treatment of angina pectoris. Dose-response relationship and duration of action during acute therapy;Q179748;P279;Q49916468
Oral isosorbide dinitrate in the treatment of angina pectoris. Dose-response relationship and duration of action during acute therapy;Q1243800;P2175;Q180762
Effects of nitric oxide donor, isosorbide dinitrate, on energy metabolism of rat reticulocytes;Q179748;P279;Q49916468
The effect of isosorbide dinitrate on placental blood flow and maternal blood pressure in women with pregnancy induced hypertension;Q179748;P279;Q49916468
[Clinical effects of isosorbide dinitrate in the transdermal spray (TD Spray Iso Mack) form];Q179748;P279;Q49916468
Conventional and slow release formulations of nifedipine and verapamil are more effective than slow release isosorbide dinitrate (ISDN) in preventing episodes of angina at rest;Q410291;P2175;Q180762
Conventional and slow release formulations of nifedipine and verapamil are more effective than slow release isosorbide dinitrate (ISDN) in preventing episodes of angina at rest;Q39111;P2175;Q180762
Conventional and slow release formulations of nifedipine and verapamil are more effective than slow release isosorbide dinitrate (ISDN) in preventing episodes of angina at rest;Q179748;P279;Q49916468
Conventional and slow release formulations of nifedipine and verapamil are more effective than slow release isosorbide dinitrate (ISDN) in preventing episodes of angina at rest;Q1243800;P2175;Q180762
Contribution of isosorbide-5-mononitrate, a major metabolite of isosorbide dinitrate (ISDN), to the hemodynamic effect of ISDN administered orally in conscious dogs;Q179748;P279;Q49916468
[Hemodynamic and anti-angina effects of transdermal nitroglycerin after acute and chronic administration. Additive effect of sublingual isosorbide dinitrate];Q179748;P279;Q49916468
[Hemodynamic and anti-angina effects of transdermal nitroglycerin after acute and chronic administration. Additive effect of sublingual isosorbide dinitrate];Q1243800;P2175;Q180762
Glyceryl trinitrate (nitroglycerin) ointment and isosorbide dinitrate: a review of their pharmacological properties and therapeutic use.;Q179748;P279;Q49916468
Glyceryl trinitrate (nitroglycerin) ointment and isosorbide dinitrate: a review of their pharmacological properties and therapeutic use.;Q620730;P703;Q177932
[Comparative efficacy, safety, cardio-hemodynamic effects of isosorbide dinitrate (ID) aerosol and sublingual tablets of nitroglycerin];Q179748;P279;Q49916468
[Long-term percutaneous therapy of angina pectoris with isosorbide dinitrate with reference to isosorbide dinitrate blood levels];Q179748;P279;Q49916468
[Long-term percutaneous therapy of angina pectoris with isosorbide dinitrate with reference to isosorbide dinitrate blood levels];Q1243800;P2175;Q180762
[The long-acting effects of isosorbide dinitrate on left ventricular performance in congestive heart insufficiency. Phonocardiographic study];Q179748;P279;Q49916468
Validation of high-performance liquid chromatographic methods for analysis of sustained-release preparations containing nitroglycerin, isosorbide dinitrate, or pentaerythritol tetranitrate;Q179748;P279;Q49916468
Validation of high-performance liquid chromatographic methods for analysis of sustained-release preparations containing nitroglycerin, isosorbide dinitrate, or pentaerythritol tetranitrate;Q3899224;P460;Q189334
Blinded randomized clinical trial of botulinum toxin versus isosorbide dinitrate ointment for treatment of anal fissure.;Q179748;P279;Q49916468
[Intra-anal application of isosorbide dinitrate in chronic anal fissure];Q179748;P279;Q49916468
Isosorbide dinitrate inhibits platelet adhesion and aggregation in nonthrombolyzed patients with acute myocardial infarction;Q179748;P279;Q49916468
[Trinitroglycerin ointment and oral isosorbide dinitrate: comparison of the hemodynamic effects induced in acute myocardial infarct with left ventricular insufficiency];Q179748;P279;Q49916468
Isosorbide dinitrate and nifedipine in variant angina pectoris.;Q1243800;P2175;Q180762
Oral administration of isosorbide dinitrate inhibits arterial thrombosis in rats;Q179748;P279;Q49916468
Effect of antispastic agents (calcium antagonists and/or isosorbide dinitrate) on high-sensitivity C-reactive protein in patients with coronary vasospastic angina pectoris and no hemodynamically significant coronary artery disease.;Q179748;P279;Q49916468
Effect of antispastic agents (calcium antagonists and/or isosorbide dinitrate) on high-sensitivity C-reactive protein in patients with coronary vasospastic angina pectoris and no hemodynamically significant coronary artery disease.;Q1243800;P2175;Q180762
Effect of antispastic agents (calcium antagonists and/or isosorbide dinitrate) on high-sensitivity C-reactive protein in patients with coronary vasospastic angina pectoris and no hemodynamically significant coronary artery disease.;Q1243800;P2175;Q844935
Isosorbide dinitrate or nifedipine: which is preferable in the medical therapy of achalasia?;Q179748;P279;Q49916468
Effects of isosorbide dinitrate spray on central hemodynamics. Comparison with sublingual glyceryl trinitrate and isosorbide dinitrate;Q3221044;P3781;Q162867
Effects of isosorbide dinitrate spray on central hemodynamics. Comparison with sublingual glyceryl trinitrate and isosorbide dinitrate;Q179748;P279;Q49916468
[Orally administered nitroderivates: efficacy and duration of the effects of isosorbide dinitrate (author's transl)];Q179748;P279;Q49916468
Improvement of walking distance in patients with intermittent claudication by chronic local therapy with isosorbide dinitrate ointment.;Q179748;P279;Q49916468
[Evaluation of long-term treatment with isosorbide dinitrate and prazosin in cardiac insufficiency];Q179748;P279;Q49916468
Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox;Q179748;P279;Q49916468
Coronary circulation in patients with and without coronary artery disease and the effects of chewable isosorbide dinitrate;Q179748;P279;Q49916468
Coronary circulation in patients with and without coronary artery disease and the effects of chewable isosorbide dinitrate;Q1243800;P2175;Q844935
[Hemodynamic effects of a transdermal formulation of isosorbide dinitrate and its pharmacokinetics in conscious dogs].;Q179748;P279;Q49916468
Effectiveness of sustained-action isosorbide dinitrate on exercise-induced myocardial ischemia;Q179748;P279;Q49916468
[Determination of the effect of a new anti-anginal drug, isosorbide dinitrate tape (TY0081), by Holter electrocardiography];Q188017;P31;Q12140
[Determination of the effect of a new anti-anginal drug, isosorbide dinitrate tape (TY0081), by Holter electrocardiography];Q186521;P31;Q12140
[Determination of the effect of a new anti-anginal drug, isosorbide dinitrate tape (TY0081), by Holter electrocardiography];Q485277;P31;Q12140
[Determination of the effect of a new anti-anginal drug, isosorbide dinitrate tape (TY0081), by Holter electrocardiography];Q179748;P31;Q12140
[Determination of the effect of a new anti-anginal drug, isosorbide dinitrate tape (TY0081), by Holter electrocardiography];Q179748;P279;Q49916468
[Determination of the effect of a new anti-anginal drug, isosorbide dinitrate tape (TY0081), by Holter electrocardiography];Q178450;P31;Q12140
[Determination of the effect of a new anti-anginal drug, isosorbide dinitrate tape (TY0081), by Holter electrocardiography];Q420439;P31;Q12140
[Determination of the effect of a new anti-anginal drug, isosorbide dinitrate tape (TY0081), by Holter electrocardiography];Q1243800;P31;Q12140
[Determination of the effect of a new anti-anginal drug, isosorbide dinitrate tape (TY0081), by Holter electrocardiography];Q1243800;P2175;Q180762
A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily, and isosorbide dinitrate twice daily in patients with chronic stable angina;Q39111;P3780;Q47520879
A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily, and isosorbide dinitrate twice daily in patients with chronic stable angina;Q39111;P2175;Q180762
A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily, and isosorbide dinitrate twice daily in patients with chronic stable angina;Q179748;P279;Q49916468
A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily, and isosorbide dinitrate twice daily in patients with chronic stable angina;Q423401;P279;Q49916468
A comparison of nifedipine once daily (Adalat LA), isosorbide mononitrate once daily, and isosorbide dinitrate twice daily in patients with chronic stable angina;Q1243800;P2175;Q180762
Coronary artery dilation and hemodynamic responses after isosorbide dinitrate therapy in patients with coronary artery disease.;Q179748;P279;Q49916468
Coronary artery dilation and hemodynamic responses after isosorbide dinitrate therapy in patients with coronary artery disease.;Q1243800;P2175;Q844935
[The anti-ischemic effect of isosorbide dinitrate alone and in combination with gallopamil and propranolol];Q179748;P279;Q49916468
Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations;Q179748;P279;Q49916468
Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations;Q20035886;P703;Q15978631
[Effect of digoxin, apressin and nitrosorbide on the hemodynamics in patients after myocardial infarction];Q905750;P2175;Q207550
Bronchodilator effect of sublingual isosorbide dinitrate in asthma.;Q179748;P279;Q49916468
[Pharmacodynamic effects of the sustained-release tablet of isosorbide dinitrate and its bioavailability in conscious dogs (author's transl)];Q179748;P279;Q49916468
A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization.;Q179748;P279;Q49916468
The effects of glyceryl trinitrate, isosorbide dinitrate and sodium nitroprusside on haemodynamics, coronary blood flow and myocardial oxygen consumption - an experimental study.;Q3221044;P3781;Q162867
The effects of glyceryl trinitrate, isosorbide dinitrate and sodium nitroprusside on haemodynamics, coronary blood flow and myocardial oxygen consumption - an experimental study.;Q179748;P279;Q49916468
The effects of glyceryl trinitrate, isosorbide dinitrate and sodium nitroprusside on haemodynamics, coronary blood flow and myocardial oxygen consumption - an experimental study.;Q905750;P527;Q629
The effects of glyceryl trinitrate, isosorbide dinitrate and sodium nitroprusside on haemodynamics, coronary blood flow and myocardial oxygen consumption - an experimental study.;Q1243800;P527;Q629
Prevention of creatine kinase-MB release in coronary artery disease and pacing-induced myocardial ischemia by isosorbide dinitrate spray;Q179748;P279;Q49916468
Prevention of creatine kinase-MB release in coronary artery disease and pacing-induced myocardial ischemia by isosorbide dinitrate spray;Q1243800;P2175;Q844935
Assessment of sublingual isosorbide dinitrate and intracoronary nifedipine during ergonovine provocation;Q179748;P279;Q49916468
The effectiveness of tenoxicam vs isosorbide dinitrate plus tenoxicam in the treatment of acute renal colic.;Q179748;P279;Q49916468
[Comparative effects of a single dose of isosorbide dinitrate by sublingual (10 mg) and oral (20 mg) routes in congestive left heart ventricle failure];Q179748;P279;Q49916468
Haemodynamic assessment of isosorbide dinitrate (sorbitrate) therapy in cases of acute myocardial infarction;Q179748;P279;Q49916468
Endoscopic retrograde extraction of common bile duct stones with drip infusion of isosorbide dinitrate;Q179748;P279;Q49916468
Drug plasma levels and coronary vasodilation after isosorbide dinitrate chewing capsules;Q179748;P279;Q49916468
Rapid clearance of isosorbide dinitrate from rabbit blood--determination by gas chromatography;Q179748;P279;Q49916468
Hemodynamic effects of isosorbide dinitrate vs nitroglycerin in patients with unstable angina;Q179748;P279;Q49916468
Hemodynamic effects of isosorbide dinitrate vs nitroglycerin in patients with unstable angina;Q1243800;P2175;Q180762
Plasma concentrations of isosorbide dinitrate and its metabolites after chronic high oral dosage in man.;Q179748;P279;Q49916468
Circulatory improvement after hydralazine or isosorbide dinitrate administration in patients with heart failure. Effect on metabolic responses to submaximal exercise;Q179748;P279;Q49916468
Salutary action of nicorandil, a new antianginal drug, on myocardial metabolism during ischemia and on postischemic function in a canine preparation of brief, repetitive coronary artery occlusions: comparison with isosorbide dinitrate;Q183290;P31;Q12140
Salutary action of nicorandil, a new antianginal drug, on myocardial metabolism during ischemia and on postischemic function in a canine preparation of brief, repetitive coronary artery occlusions: comparison with isosorbide dinitrate;Q179748;P31;Q12140
Salutary action of nicorandil, a new antianginal drug, on myocardial metabolism during ischemia and on postischemic function in a canine preparation of brief, repetitive coronary artery occlusions: comparison with isosorbide dinitrate;Q179748;P279;Q49916468
Salutary action of nicorandil, a new antianginal drug, on myocardial metabolism during ischemia and on postischemic function in a canine preparation of brief, repetitive coronary artery occlusions: comparison with isosorbide dinitrate;Q862989;P31;Q12140
Salutary action of nicorandil, a new antianginal drug, on myocardial metabolism during ischemia and on postischemic function in a canine preparation of brief, repetitive coronary artery occlusions: comparison with isosorbide dinitrate;Q1243800;P31;Q12140
Salutary action of nicorandil, a new antianginal drug, on myocardial metabolism during ischemia and on postischemic function in a canine preparation of brief, repetitive coronary artery occlusions: comparison with isosorbide dinitrate;Q1243800;P2175;Q180762
Letter: Efficacy of long-acting nitrates. II. Peroral isosorbide dinitrate;Q179748;P279;Q49916468
In vitro-in vivo correlation of percutaneous absorption: isosorbide dinitrate and morphine hydrochloride;Q179748;P279;Q49916468
[Treatment of advanced heart failure with hydralazine and isosorbide dinitrate (author's transl)];Q179748;P279;Q49916468
Comparison of coronary responses to intracoronary and intraaortic ergonovine and isosorbide dinitrate in patients with atypical chest pain;Q179748;P279;Q49916468
Sustained antianginal efficacy of oral high-dose isosorbide dinitrate in patients with coronary heart disease.;Q179748;P279;Q49916468
Sustained antianginal efficacy of oral high-dose isosorbide dinitrate in patients with coronary heart disease.;Q1243800;P2175;Q180762
Sustained antianginal efficacy of oral high-dose isosorbide dinitrate in patients with coronary heart disease.;Q1243800;P2175;Q844935
Determination of isosorbide dinitrate and its mononitrate metabolites in human plasma by high-performance liquid chromatography-thermal energy analysis;Q179748;P279;Q49916468
Determination of isosorbide dinitrate and its mononitrate metabolites in human plasma by high-performance liquid chromatography-thermal energy analysis;Q178450;P703;Q15978631
A simple and sensitive gas chromatography method for determination of isosorbide dinitrate and its metabolites in human plasma: application to pharmacokinetics study on oral spray.;Q218642;P703;Q15978631
A simple and sensitive gas chromatography method for determination of isosorbide dinitrate and its metabolites in human plasma: application to pharmacokinetics study on oral spray.;Q218642;P31;Q407595
A simple and sensitive gas chromatography method for determination of isosorbide dinitrate and its metabolites in human plasma: application to pharmacokinetics study on oral spray.;Q179748;P279;Q49916468
Development and validation of a chiral LC-ESI-MS/MS method for simultaneous determination of the enantiomeric metabolites isosorbide 2-mononitrate and isosorbide 5-mononitrate of isosorbide dinitrate in rat and human plasma;Q183290;P703;Q15978631
Development and validation of a chiral LC-ESI-MS/MS method for simultaneous determination of the enantiomeric metabolites isosorbide 2-mononitrate and isosorbide 5-mononitrate of isosorbide dinitrate in rat and human plasma;Q186474;P703;Q15978631
Development and validation of a chiral LC-ESI-MS/MS method for simultaneous determination of the enantiomeric metabolites isosorbide 2-mononitrate and isosorbide 5-mononitrate of isosorbide dinitrate in rat and human plasma;Q179748;P279;Q49916468
Development and validation of a chiral LC-ESI-MS/MS method for simultaneous determination of the enantiomeric metabolites isosorbide 2-mononitrate and isosorbide 5-mononitrate of isosorbide dinitrate in rat and human plasma;Q178450;P703;Q15978631
Development and validation of a chiral LC-ESI-MS/MS method for simultaneous determination of the enantiomeric metabolites isosorbide 2-mononitrate and isosorbide 5-mononitrate of isosorbide dinitrate in rat and human plasma;Q22124685;P703;Q15978631
Development and validation of a chiral LC-ESI-MS/MS method for simultaneous determination of the enantiomeric metabolites isosorbide 2-mononitrate and isosorbide 5-mononitrate of isosorbide dinitrate in rat and human plasma;Q483745;P703;Q15978631
Development and validation of a chiral LC-ESI-MS/MS method for simultaneous determination of the enantiomeric metabolites isosorbide 2-mononitrate and isosorbide 5-mononitrate of isosorbide dinitrate in rat and human plasma;Q484940;P703;Q15978631
Influence of electric foot shock on pharmacokinetics of isosorbide dinitrate subcutaneously administered to rats;Q179748;P279;Q49916468
Cardiopulmonary effects of glyceryl trinitrate and isosorbide dinitrate;Q3221044;P3781;Q162867
Cardiopulmonary effects of glyceryl trinitrate and isosorbide dinitrate;Q179748;P279;Q49916468
Nifedipine versus isosorbide dinitrate for angina pectoris.;Q39111;P2175;Q180762
Nifedipine versus isosorbide dinitrate for angina pectoris.;Q179748;P279;Q49916468
Nifedipine versus isosorbide dinitrate for angina pectoris.;Q1243800;P2175;Q180762
Effects of molsidomine, nitroglycerin, and isosorbide dinitrate on the coronary circulation, myocardial oxygen consumption, and haemodynamics in anaesthetized dogs;Q162867;P527;Q629
Effects of molsidomine, nitroglycerin, and isosorbide dinitrate on the coronary circulation, myocardial oxygen consumption, and haemodynamics in anaesthetized dogs;Q179748;P279;Q49916468
Effects of molsidomine, nitroglycerin, and isosorbide dinitrate on the coronary circulation, myocardial oxygen consumption, and haemodynamics in anaesthetized dogs;Q905750;P527;Q629
Effects of molsidomine, nitroglycerin, and isosorbide dinitrate on the coronary circulation, myocardial oxygen consumption, and haemodynamics in anaesthetized dogs;Q1243800;P527;Q629
Effects of long-term oral administration of isosorbide dinitrate on the antianginal response to nitroglycerin. Absence of nitrate cross-tolerance and self-tolerance shown by exercise testing.;Q162867;P361;Q22273164
Effects of long-term oral administration of isosorbide dinitrate on the antianginal response to nitroglycerin. Absence of nitrate cross-tolerance and self-tolerance shown by exercise testing.;Q179748;P279;Q49916468
Effects of long-term oral administration of isosorbide dinitrate on the antianginal response to nitroglycerin. Absence of nitrate cross-tolerance and self-tolerance shown by exercise testing.;Q1243800;P2175;Q180762
Haemodynamic advantages of isosorbide dinitrate over frusemide in acute heart-failure following myocardial infarction;Q179748;P279;Q49916468
A comparison between the effects of diltiazem and isosorbide dinitrate on digoxin pharmacodynamics and kinetics in the treatment of patients with chronic ischemic heart failure.;Q179748;P279;Q49916468
Comparison of buccal nitroglycerin and oral isosorbide dinitrate for nitrate tolerance in stable angina pectoris;Q179748;P279;Q49916468
Comparison of buccal nitroglycerin and oral isosorbide dinitrate for nitrate tolerance in stable angina pectoris;Q1243800;P2175;Q180762
Comparative hemodynamic effects of chewable isosorbide dinitrate and nitroglycerin in patients with congestive heart failure.;Q179748;P279;Q49916468
Comparative hemodynamic effects of chewable isosorbide dinitrate and nitroglycerin in patients with congestive heart failure.;Q1243800;P2175;Q19000661
[Clinical evaluation of isosorbide dinitrate (ISDN) spray: a study on the plasma concentrations of ISDN and on its hemodynamic effects using three administration routes];Q179748;P279;Q49916468
[Flow measurement characteristics in heart patients after the acute and protracted administration of 2 vasoactive drugs: prazosin hydrochloride and isosorbide dinitrate];Q170545;P31;Q12140
[Flow measurement characteristics in heart patients after the acute and protracted administration of 2 vasoactive drugs: prazosin hydrochloride and isosorbide dinitrate];Q179748;P31;Q12140
[Flow measurement characteristics in heart patients after the acute and protracted administration of 2 vasoactive drugs: prazosin hydrochloride and isosorbide dinitrate];Q179748;P279;Q49916468
[Flow measurement characteristics in heart patients after the acute and protracted administration of 2 vasoactive drugs: prazosin hydrochloride and isosorbide dinitrate];Q425296;P31;Q12140
[Flow measurement characteristics in heart patients after the acute and protracted administration of 2 vasoactive drugs: prazosin hydrochloride and isosorbide dinitrate];Q1243800;P31;Q12140
Effects of alprenolol and isosorbide dinitrate in angina pectoris. A comparative study with methodological considerations.;Q179748;P279;Q49916468
Effects of alprenolol and isosorbide dinitrate in angina pectoris. A comparative study with methodological considerations.;Q1243800;P2175;Q180762
Dose-response curve of angiographically smooth human epicardial vessel segments to intracoronary injections of isosorbide dinitrate;Q179748;P279;Q49916468
Dose-response curve of angiographically smooth human epicardial vessel segments to intracoronary injections of isosorbide dinitrate;Q178450;P703;Q15978631
[The effect of intravenous injection of isosorbide dinitrate on the hypertension during general anesthesia: a multi-center controlled study];Q179748;P279;Q49916468
In vitro evidence of an endothelial cell-dependent antiplatelet activity for isosorbide dinitrate, but not for its 2- and 5-mononitrate metabolites;Q179748;P279;Q49916468
Orally administered isosorbide dinitrate in patients with and without left ventricular failure due to acute myocardial infarction.;Q179748;P279;Q49916468
Controlled-release isosorbide dinitrate pellets. Part I: Design and evaluation of controlled-release capsule dosage form;Q179748;P279;Q49916468
Hemodynamic response to molsidomine in patients with ischemic cardiomyopathy tolerant to isosorbide dinitrate;Q179748;P279;Q49916468
Hemodynamic and hormonal response to induced hypotension with isosorbide dinitrate and nitroglycerin during anesthesia.;Q179748;P279;Q49916468
The comparison of the efficacy of atenolol and isosorbide dinitrate therapy in chronic hypotension patients with stable angina pectoris;Q411325;P2175;Q180762
The comparison of the efficacy of atenolol and isosorbide dinitrate therapy in chronic hypotension patients with stable angina pectoris;Q179748;P279;Q49916468
The comparison of the efficacy of atenolol and isosorbide dinitrate therapy in chronic hypotension patients with stable angina pectoris;Q1243800;P2175;Q180762
[Effects of isosorbide dinitrate injection on acute myocardial infarction. A haemodynamic and gamma-angiographic study (author's transl)];Q179748;P279;Q49916468
Gastrointestinal therapeutic system delivering of a water insoluble drug: isosorbide dinitrate (ISDN);Q183290;P31;Q12140
Gastrointestinal therapeutic system delivering of a water insoluble drug: isosorbide dinitrate (ISDN);Q183290;P703;Q177932
Gastrointestinal therapeutic system delivering of a water insoluble drug: isosorbide dinitrate (ISDN);Q411159;P31;Q12140
Gastrointestinal therapeutic system delivering of a water insoluble drug: isosorbide dinitrate (ISDN);Q179748;P31;Q12140
Gastrointestinal therapeutic system delivering of a water insoluble drug: isosorbide dinitrate (ISDN);Q179748;P279;Q49916468
Gastrointestinal therapeutic system delivering of a water insoluble drug: isosorbide dinitrate (ISDN);Q178450;P31;Q12140
Gastrointestinal therapeutic system delivering of a water insoluble drug: isosorbide dinitrate (ISDN);Q178450;P703;Q177932
Gastrointestinal therapeutic system delivering of a water insoluble drug: isosorbide dinitrate (ISDN);Q29053744;P31;Q12140
Gastrointestinal therapeutic system delivering of a water insoluble drug: isosorbide dinitrate (ISDN);Q29053744;P366;Q7892
Gastrointestinal therapeutic system delivering of a water insoluble drug: isosorbide dinitrate (ISDN);Q620730;P31;Q12140
Gastrointestinal therapeutic system delivering of a water insoluble drug: isosorbide dinitrate (ISDN);Q620730;P703;Q177932
Gastrointestinal therapeutic system delivering of a water insoluble drug: isosorbide dinitrate (ISDN);Q484940;P31;Q12140
Gastrointestinal therapeutic system delivering of a water insoluble drug: isosorbide dinitrate (ISDN);Q484940;P703;Q177932
Gastrointestinal therapeutic system delivering of a water insoluble drug: isosorbide dinitrate (ISDN);Q1243800;P31;Q12140
The therapeutic role of coronary vasodilators: glyceryl trinitrate, isosorbide dinitrate, and pentaerythritol tetranitrate;Q186521;P703;Q177932
The therapeutic role of coronary vasodilators: glyceryl trinitrate, isosorbide dinitrate, and pentaerythritol tetranitrate;Q3221044;P2868;Q4008956
The therapeutic role of coronary vasodilators: glyceryl trinitrate, isosorbide dinitrate, and pentaerythritol tetranitrate;Q3221044;P3781;Q162867
The therapeutic role of coronary vasodilators: glyceryl trinitrate, isosorbide dinitrate, and pentaerythritol tetranitrate;Q179748;P2868;Q4008956
The therapeutic role of coronary vasodilators: glyceryl trinitrate, isosorbide dinitrate, and pentaerythritol tetranitrate;Q179748;P279;Q49916468
The therapeutic role of coronary vasodilators: glyceryl trinitrate, isosorbide dinitrate, and pentaerythritol tetranitrate;Q3899224;P460;Q189334
Comparative effects of captopril and isosorbide dinitrate on pulmonary arteriolar resistance and right ventricular function in patients with severe left ventricular failure: results of a randomized crossover study.;Q179748;P279;Q49916468
Concomitant calcium antagonist plus isosorbide dinitrate therapy for markedly active variant angina;Q179748;P279;Q49916468
Concomitant calcium antagonist plus isosorbide dinitrate therapy for markedly active variant angina;Q1243800;P2175;Q180762
A novel permeation enhancer: N-succinyl chitosan on the intranasal absorption of isosorbide dinitrate in rats;Q179748;P279;Q49916468
[Comparison of the effects of depot isosorbide dinitrate (Isoket Retard 120) and diltiazem in patients with exertional angina pectoris];Q179748;P279;Q49916468
[Comparison of the effects of depot isosorbide dinitrate (Isoket Retard 120) and diltiazem in patients with exertional angina pectoris];Q422229;P2175;Q180762
[Comparison of the effects of depot isosorbide dinitrate (Isoket Retard 120) and diltiazem in patients with exertional angina pectoris];Q1243800;P2175;Q180762
Assay of glyceryl trinitrate, isosorbide dinitrate, and their metabolites in plasma by large-bore capillary column gas-liquid chromatography;Q218642;P31;Q407595
Assay of glyceryl trinitrate, isosorbide dinitrate, and their metabolites in plasma by large-bore capillary column gas-liquid chromatography;Q3221044;P3781;Q162867
Assay of glyceryl trinitrate, isosorbide dinitrate, and their metabolites in plasma by large-bore capillary column gas-liquid chromatography;Q179748;P279;Q49916468
Haemodynamic correlates of early and delayed responses to sublingual administration of isosorbide dinitrate in migraine patients: a transcranial Doppler study;Q179748;P279;Q49916468
Atrial natriuretic factor and isosorbide dinitrate modulate the gating of ATP-sensitive K+ channels in cultured vascular smooth muscle cells.;Q179748;P279;Q49916468
[Comparison of isosorbide dinitrate and nitroglycerin in patients with angina pectoris];Q179748;P279;Q49916468
[Comparison of isosorbide dinitrate and nitroglycerin in patients with angina pectoris];Q1243800;P2175;Q180762
Reassessment of vasodilator therapy in angina: effects of oral isosorbide dinitrate and hydralazine on exercise tolerance in patients receiving propranolol;Q179748;P2868;Q4008956
Reassessment of vasodilator therapy in angina: effects of oral isosorbide dinitrate and hydralazine on exercise tolerance in patients receiving propranolol;Q179748;P279;Q49916468
Reassessment of vasodilator therapy in angina: effects of oral isosorbide dinitrate and hydralazine on exercise tolerance in patients receiving propranolol;Q419987;P2868;Q4008956
Reassessment of vasodilator therapy in angina: effects of oral isosorbide dinitrate and hydralazine on exercise tolerance in patients receiving propranolol;Q1243800;P2175;Q180762
Comparative efficacy of the intravenous administration of linsidomine, a direct nitric oxide donor, and isosorbide dinitrate in severe unstable angina. A French multicentre study. French Group of Investigators.;Q179748;P279;Q49916468
Comparative efficacy of the intravenous administration of linsidomine, a direct nitric oxide donor, and isosorbide dinitrate in severe unstable angina. A French multicentre study. French Group of Investigators.;Q1243800;P2175;Q180762
Effects of isosorbide dinitrate on rheumatic and non-rheumatic mitral regurgitation;Q179748;P279;Q49916468
[Study of the bioequivalence of a new isosorbide dinitrate tablet formulation compared with the standard preparation];Q179748;P279;Q49916468
[The prophylactic effect of a combination of pindolol and isosorbide dinitrate on angina pectoris induced by arterial stimulation (author's transl)];Q179748;P279;Q49916468
[The prophylactic effect of a combination of pindolol and isosorbide dinitrate on angina pectoris induced by arterial stimulation (author's transl)];Q418101;P2175;Q180762
[The prophylactic effect of a combination of pindolol and isosorbide dinitrate on angina pectoris induced by arterial stimulation (author's transl)];Q1243800;P2175;Q180762
[Comparative hemodynamic studies with molsidomine and isosorbide dinitrate after aortocoronary bypass];Q179748;P279;Q49916468
Comparison between isosorbide dinitrate in aerosol and in tablet form for the treatment of hypertensive emergencies in the elderly;Q179748;P279;Q49916468
Sustained hemodynamic effects without tolerance during long-term isosorbide dinitrate treatment of chronic left ventricular failure;Q179748;P279;Q49916468
[The long-term treatment of angina pectoris with pindolol and isosorbide dinitrate in fixed combination. A multicenter trial (author's transl)];Q179748;P279;Q49916468
[The long-term treatment of angina pectoris with pindolol and isosorbide dinitrate in fixed combination. A multicenter trial (author's transl)];Q418101;P2175;Q180762
[The long-term treatment of angina pectoris with pindolol and isosorbide dinitrate in fixed combination. A multicenter trial (author's transl)];Q1243800;P2175;Q180762
Role of coronary spasm in the genesis of myocardial infarction: study of a case treated by isosorbide dinitrate in situ then by transluminal angioplasty.;Q179748;P279;Q49916468
[Long-acting isosorbide dinitrate and molsidomin in the treatment of effort angina in patients with arterial hypotension];Q179748;P279;Q49916468
[Long-acting isosorbide dinitrate and molsidomin in the treatment of effort angina in patients with arterial hypotension];Q1243800;P2175;Q180762
Intraoperative venesection and isosorbide dinitrate for postreperfusion syndrome during liver transplantation: A case report;Q179748;P279;Q49916468
Benefits from adding nifedipine to the treatment of unstable angina when beta-blockade and isosorbide dinitrate have proved inadequate;Q39111;P2175;Q180762
Benefits from adding nifedipine to the treatment of unstable angina when beta-blockade and isosorbide dinitrate have proved inadequate;Q179748;P279;Q49916468
Benefits from adding nifedipine to the treatment of unstable angina when beta-blockade and isosorbide dinitrate have proved inadequate;Q1243800;P2175;Q180762
[Ergometric and clinical results of treating coronary disease with isosorbide dinitrate and verapamil];Q179748;P279;Q49916468
Plasma concentrations and bioavailability of isosorbide dinitrate and pindolol from a combination formulation;Q179748;P279;Q49916468
[Effect of isosorbide dinitrate on vasomotricity-cytosolic calcium coupling during aging in the rat];Q179748;P279;Q49916468
Isosorbide-5-mononitrate and isosorbide dinitrate retard in the treatment of coronary heart disease: a multi-centre study.;Q179748;P279;Q49916468
Isosorbide-5-mononitrate and isosorbide dinitrate retard in the treatment of coronary heart disease: a multi-centre study.;Q423401;P279;Q49916468
Isosorbide-5-mononitrate and isosorbide dinitrate retard in the treatment of coronary heart disease: a multi-centre study.;Q1243800;P2175;Q844935
Nifedipine versus isosorbide dinitrate in patients with exertional angina receiving propranolol;Q39111;P2175;Q180762
Nifedipine versus isosorbide dinitrate in patients with exertional angina receiving propranolol;Q179748;P279;Q49916468
Nifedipine versus isosorbide dinitrate in patients with exertional angina receiving propranolol;Q1243800;P2175;Q180762
[The effect of diuretics on the magnitude of the effect of isosorbide dinitrate given as a single dose and after long-term administration. Ergometric study in patients with stable angina pectoris];Q179748;P279;Q49916468
[The effect of diuretics on the magnitude of the effect of isosorbide dinitrate given as a single dose and after long-term administration. Ergometric study in patients with stable angina pectoris];Q1243800;P2175;Q180762
High-dosage isosorbide dinitrate therapy for angina.;Q179748;P279;Q49916468
High-dosage isosorbide dinitrate therapy for angina.;Q1243800;P2175;Q180762
Effect of sustained release isosorbide dinitrate on exercise performance;Q179748;P279;Q49916468
[Early changes in left ventricular function after oral administration of isosorbide dinitrate studied with radionuclide ventriculography];Q179748;P279;Q49916468
Differences in the nitrite ion formation and the toxicological findings between isosorbide dinitrate and isosorbide-5-mononitrate;Q179748;P279;Q49916468
Absorption of nitroglycerin and isosorbide dinitrate by infusion tubing;Q179748;P279;Q49916468
[Bioavailability of 2 different depot formulations with 40 mg of isosorbide dinitrate];Q179748;P279;Q49916468
Early administration of isosorbide dinitrate improves survival of cyanide-poisoned rabbits.;Q179748;P279;Q49916468
Effect of isosorbide dinitrate, verapamil, and labetalol on portal pressure in cirrhosis.;Q179748;P279;Q49916468
Haemodynamic effects of Isodinit (isosorbide dinitrate) in acute myocardial infarction.;Q179748;P279;Q49916468
[Role of coronary spasm in the genesis of myocardial infarction. Apropos of a case treated with in situ isosorbide dinitrate and endoluminal dilatation];Q179748;P279;Q49916468
[The effect of nitroglycerin, nitrosorbide and nitroprusside on the intracellular content of Ca2+ ions in human lymphocytes];Q186474;P703;Q15978631
[The effect of nitroglycerin, nitrosorbide and nitroprusside on the intracellular content of Ca2+ ions in human lymphocytes];Q186521;P703;Q15978631
The haemodynamic and anti-ischaemic effects of a single tablet of 80 mg isosorbide dinitrate in slow-release formulation and a review of nitrate tolerance.;Q179748;P279;Q49916468
[Long-term tolerance and effect of isosorbide-5-mononitrate in comparison to isosorbide dinitrate (ISDN retard) in patients with coronary disease];Q179748;P279;Q49916468
Differences in the production of methemoglobin during high-dose treatment with isosorbide dinitrate or isosorbide 5-mononitrate;Q179748;P279;Q49916468
Regional blood flow and hemodynamics in the rabbit with adriamycin cardiomyopathy: effects of isosorbide dinitrate, dobutamine and captopril;Q179748;P279;Q49916468
Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure.;Q179748;P279;Q49916468
Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure.;Q1243800;P2175;Q19000661
Intravenous diltiazem versus isosorbide dinitrate for unstable angina: comparison of coronary angiographic morphology in the unstable and stabilized states;Q179748;P279;Q49916468
Intravenous diltiazem versus isosorbide dinitrate for unstable angina: comparison of coronary angiographic morphology in the unstable and stabilized states;Q422229;P2175;Q180762
Intravenous diltiazem versus isosorbide dinitrate for unstable angina: comparison of coronary angiographic morphology in the unstable and stabilized states;Q1243800;P2175;Q180762
Influence of emotional stress on pharmacokinetics of isosorbide dinitrate intraperitoneally administered to rats;Q179748;P279;Q49916468
Influence of emotional stress on pharmacokinetics of isosorbide dinitrate intraperitoneally administered to rats;Q484940;P703;Q177932
Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema;Q388801;P2175;Q857667
Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema;Q179748;P279;Q49916468
Comparison of sublingual isosorbide dinitrate and Valsalva maneuver for detection of obstruction in hypertrophic cardiomyopathy.;Q179748;P279;Q49916468
Evidence of interaction between fluoxetine and isosorbide dinitrate on neuroleptic-induced catalepsy in mice.;Q179748;P279;Q49916468
A comparison of the day-long antianginal effectiveness of nitroglycerin patches with that of three-times-daily isosorbide dinitrate: a double-blind study using dose titration;Q179748;P279;Q49916468
A comparison of the day-long antianginal effectiveness of nitroglycerin patches with that of three-times-daily isosorbide dinitrate: a double-blind study using dose titration;Q1243800;P2175;Q180762
[Hemodynamic effects of nitrate derivatives: effect of initial hemodynamic parameters on the nature of the responses observed after administration of isosorbide dinitrate and trinitrin];Q179748;P279;Q49916468
[Isosorbide dinitrate (ISDN) in the therapy of primary pulmonary hypertension];Q179748;P279;Q49916468
Enhancement of the efficacy of isosorbide dinitrate by captopril in stable angina pectoris;Q179748;P279;Q49916468
Enhancement of the efficacy of isosorbide dinitrate by captopril in stable angina pectoris;Q1243800;P2175;Q180762
Nicorandil versus isosorbide dinitrate as adjunctive treatment to direct balloon angioplasty in acute myocardial infarction.;Q179748;P279;Q49916468
Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety.;Q179748;P279;Q49916468
Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group;Q179748;P279;Q49916468
Vasodilator properties of nitroglycerin and isosorbide dinitrate during cardiopulmonary bypass.;Q179748;P279;Q49916468
[Comparison between the hemodynamic effects of nitroglycerine ointment and oral isosorbide dinitrate in the treatment of left ventricular failure (author's transl)];Q179748;P279;Q49916468
[Vasodilator therapy by isosorbide dinitrate for the patients with congestive heart failure (author's transl)];Q179748;P279;Q49916468
[Vasodilator therapy by isosorbide dinitrate for the patients with congestive heart failure (author's transl)];Q1243800;P2175;Q19000661
Pre- and afterload reduction in chronic mitral regurgitation: a double-blind randomized placebo-controlled trial of the acute and 2 weeks' effect of nifedipine or isosorbide dinitrate treatment on left ventricular function and the severity of mitral;Q179748;P279;Q49916468
Controlled, eight-hour haemodynamic study of a sustained-release formulation of isosorbide dinitrate in moderate left ventricular failure;Q179748;P279;Q49916468
Comparative effects of nifedipine, verapamil, isosorbide dinitrate and propranolol on exercise-induced angina pectoris;Q410291;P2175;Q180762
Comparative effects of nifedipine, verapamil, isosorbide dinitrate and propranolol on exercise-induced angina pectoris;Q39111;P2175;Q180762
Comparative effects of nifedipine, verapamil, isosorbide dinitrate and propranolol on exercise-induced angina pectoris;Q179748;P279;Q49916468
Comparative effects of nifedipine, verapamil, isosorbide dinitrate and propranolol on exercise-induced angina pectoris;Q1243800;P2175;Q180762
Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure.;Q179748;P279;Q49916468
Equal anti-ischemic properties of isosorbide dinitrate plus verapamil and isosorbide dinitrate plus propranolol. A randomized, double-blind and crossover study;Q179748;P279;Q49916468
Intratracheal administration of isosorbide dinitrate improves pulmonary artery pressure and ventricular remodeling in a rat model of heart failure following myocardial infarction.;Q179748;P279;Q49916468
Role of isosorbide dinitrate in patients with unstable angina pectoris;Q179748;P279;Q49916468
Role of isosorbide dinitrate in patients with unstable angina pectoris;Q1243800;P2175;Q180762
Effects of continuous intravenous infusion of isosorbide dinitrate on development of tolerance to vasodilating action in human epicardial coronary arteries;Q179748;P279;Q49916468
[Oral administration of isosorbide dinitrate in myocardial infarction without heart insufficiency. Its hemodynamic effects];Q179748;P279;Q49916468
Vascular hyporeactivity persists despite increased contractility after long-term administration of isosorbide dinitrate in portal hypertensive rats;Q179748;P279;Q49916468
[Experimental antithrombotic activity of oral isosorbide dinitrate];Q179748;P279;Q49916468
Preventive administration of intravenous N-acetylcysteine and development of tolerance to isosorbide dinitrate in patients with angina pectoris.;Q179748;P279;Q49916468
Preventive administration of intravenous N-acetylcysteine and development of tolerance to isosorbide dinitrate in patients with angina pectoris.;Q1243800;P2175;Q180762
Effects of isosorbide dinitrate and nicardipine hydrochloride on postprandial blood pressure in elderly patients with stable angina pectoris or healed myocardial infarction;Q179748;P279;Q49916468
Effects of isosorbide dinitrate and nicardipine hydrochloride on postprandial blood pressure in elderly patients with stable angina pectoris or healed myocardial infarction;Q729213;P2175;Q180762
Effects of isosorbide dinitrate and nicardipine hydrochloride on postprandial blood pressure in elderly patients with stable angina pectoris or healed myocardial infarction;Q1243800;P2175;Q180762
Lack of effect of verapamil and isosorbide dinitrate on the hepatic clearance of indocyanine green in cirrhosis;Q179748;P279;Q49916468
Sublingual isosorbide dinitrate in severe congestive heart failure;Q179748;P279;Q49916468
Sublingual isosorbide dinitrate in severe congestive heart failure;Q1243800;P2175;Q19000661
Studies on the mode of action of isosorbide dinitrate: a physiologic and biochemical approach.;Q179748;P279;Q49916468
Randomized double-blind comparison of nifedipine and isosorbide dinitrate therapy in variant angina pectoris due to coronary artery spasm;Q39111;P2175;Q180762
Randomized double-blind comparison of nifedipine and isosorbide dinitrate therapy in variant angina pectoris due to coronary artery spasm;Q179748;P279;Q49916468
Randomized double-blind comparison of nifedipine and isosorbide dinitrate therapy in variant angina pectoris due to coronary artery spasm;Q1243800;P2175;Q180762
Dilating effects of isosorbide dinitrate on diameter of internal thoracic artery graft;Q179748;P279;Q49916468
Metabolites decrease the plasma clearance of isosorbide dinitrate in rats;Q179748;P279;Q49916468
[Effect of isosorbide dinitrate on fresh myocardial infarct as compared with nifedipine (Bay a 1040)];Q179748;P279;Q49916468
The daylong pattern of the antianginal effect of long-term three times daily administered isosorbide dinitrate;Q179748;P279;Q49916468
The daylong pattern of the antianginal effect of long-term three times daily administered isosorbide dinitrate;Q1243800;P2175;Q180762
Isosorbide dinitrate bioavailability, kinetics, and metabolism.;Q179748;P279;Q49916468
Comparative quality tests of two types of sustained release preparation of isosorbide dinitrate;Q179748;P279;Q49916468
[Longterm effect and maintenance therapy with cutaneous isosorbide dinitrate in patients with coronary heart disease (author's transl)];Q179748;P279;Q49916468
[Longterm effect and maintenance therapy with cutaneous isosorbide dinitrate in patients with coronary heart disease (author's transl)];Q1243800;P2175;Q844935
The effect of intermittent administration of sustained release isosorbide dinitrate (sr-ISDN) in rats with volume overload heart.;Q179748;P279;Q49916468
Hemodynamic effects of orally administered isosorbide dinitrate in patients with congestive heart failure.;Q179748;P279;Q49916468
Hemodynamic effects of orally administered isosorbide dinitrate in patients with congestive heart failure.;Q1243800;P2175;Q19000661
[Isosorbide dinitrate: correlations between its anti-anginal effect, dosage form and administration schedule];Q179748;P279;Q49916468
[Isosorbide dinitrate: correlations between its anti-anginal effect, dosage form and administration schedule];Q1243800;P2175;Q180762
Influence and interference of isosorbide dinitrate and food intake on superior mesenteric artery impedance in humans.;Q179748;P279;Q49916468
Influence and interference of isosorbide dinitrate and food intake on superior mesenteric artery impedance in humans.;Q484940;P703;Q15978631
[Clinical studies of isosorbide dinitrate spray in postoperative patients];Q179748;P279;Q49916468
Evaluation of propranolol and of isosorbide dinitrate in angina pectoris;Q179748;P279;Q49916468
Evaluation of propranolol and of isosorbide dinitrate in angina pectoris;Q1243800;P2175;Q180762
[Pharmacokinetics and pharmacodynamics of a new 80 mg oral delayed-action isosorbide dinitrate preparation];Q179748;P279;Q49916468
[Effect of the vasodilator isosorbide dinitrate on ocular circulation];Q179748;P2868;Q4008956
[Effect of the vasodilator isosorbide dinitrate on ocular circulation];Q179748;P279;Q49916468
[Comparison of the anti-angina effectiveness of gallopamil to isosorbide dinitrate in long-term medication];Q186474;P31;Q12140
[Comparison of the anti-angina effectiveness of gallopamil to isosorbide dinitrate in long-term medication];Q179748;P31;Q12140
[Comparison of the anti-angina effectiveness of gallopamil to isosorbide dinitrate in long-term medication];Q179748;P279;Q49916468
[Comparison of the anti-angina effectiveness of gallopamil to isosorbide dinitrate in long-term medication];Q1243800;P31;Q12140
[Comparison of the anti-angina effectiveness of gallopamil to isosorbide dinitrate in long-term medication];Q1243800;P2175;Q180762
[Case of acute arterial hypotension with paradoxical bradycardia after administration of isosorbide dinitrate];Q179748;P279;Q49916468
Comparative study of the haemodynamic effects of oral molsidomine and isosorbide dinitrate in man.;Q179748;P279;Q49916468
[Changes in pressure in the pulmonary artery after administration of isosorbide dinitrate VUFB (sublingual tablets) in patients with acute myocardial infarct];Q179748;P279;Q49916468
Thin-layer chromatography of isosorbide dinitrate, nitroglycerin and their degradation products;Q179748;P279;Q49916468
[Pectanginose boring arrested by inhalation of isosorbide dinitrate (author's transl)];Q179748;P279;Q49916468
Isosorbide dinitrate: pharmacokinetics after intravenous administration;Q179748;P279;Q49916468
[Effects of inhalated isosorbide dinitrate on endothelin and nitric oxide and its therapeutic efficacy for experimental guinea-pigs with asthma];Q179748;P279;Q49916468
Plasma concentrations of isosorbide dinitrate and mononitrates after acute and chronic oral administration of isosorbide dinitrate in man;Q179748;P279;Q49916468
Recurrent administration of the nitric oxide donor, isosorbide dinitrate, induces a persistent cephalic cutaneous hypersensitivity: A model for migraine progression.;Q179748;P279;Q49916468
[Local treatment with isosorbide dinitrate ointment in Raynaud's phenomenon];Q179748;P279;Q49916468
Isosorbide dinitrate: its action on myocardial contractility in comparison with nitroglycerin.;Q179748;P279;Q49916468
Sorbitrate chewable;Q179748;P3780;Q47521726
[Effectiveness of oral isosorbide dinitrate and pentaerythritol tetranitrate in the light of long-term determinations of coronary reserve on cycloergometer in patients with stable angina pectoris];Q179748;P279;Q49916468
[Effectiveness of oral isosorbide dinitrate and pentaerythritol tetranitrate in the light of long-term determinations of coronary reserve on cycloergometer in patients with stable angina pectoris];Q3899224;P460;Q189334
[Effectiveness of oral isosorbide dinitrate and pentaerythritol tetranitrate in the light of long-term determinations of coronary reserve on cycloergometer in patients with stable angina pectoris];Q1243800;P2175;Q180762
Effect of isosorbide dinitrate on response to submaximal and maximal exercise in patients with congestive heart failure.;Q179748;P279;Q49916468
Effect of isosorbide dinitrate on response to submaximal and maximal exercise in patients with congestive heart failure.;Q1243800;P2175;Q19000661
Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris;Q410291;P2175;Q180762
Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris;Q179748;P279;Q49916468
Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris;Q1243800;P2175;Q180762
Effects of 3-days' intake of a sustained-release preparation of the nitric oxide donor, isosorbide dinitrate, on oesophageal motility;Q179748;P279;Q49916468
Effects of sublingual isosorbide dinitrate on left ventricular performance during exercise in patients with myocardial infarction;Q179748;P279;Q49916468
Hepatic extraction of isosorbide dinitrate in cardiac patients;Q179748;P279;Q49916468
Effect of isosorbide dinitrate infusion on the canine left ventricular force-length relationship;Q179748;P279;Q49916468
[Suppression of complex ventricular arrhythmias with isosorbide dinitrate in a case of congestive heart failure];Q179748;P279;Q49916468
[Suppression of complex ventricular arrhythmias with isosorbide dinitrate in a case of congestive heart failure];Q1243800;P2175;Q19000661
[Coronary artery dilatation induced by isosorbide dinitrate injection (author's transl)];Q179748;P279;Q49916468
Effectiveness of isosorbide dinitrate in cyanide poisoning as a function of the administration timing;Q179748;P279;Q49916468
Hemodynamic time course of acute and chronic isosorbide dinitrate treatment at rest and during exercise in patients with stable ischemic heart disease;Q179748;P279;Q49916468
Hemodynamic time course of acute and chronic isosorbide dinitrate treatment at rest and during exercise in patients with stable ischemic heart disease;Q1243800;P2175;Q844935
Polarographic determination of isosorbide dinitrate;Q179748;P279;Q49916468
Synergistic effect of prostaglandin E1 and isosorbide dinitrate in peripheral vascular disease;Q179748;P279;Q49916468
Synergistic effect of prostaglandin E1 and isosorbide dinitrate in peripheral vascular disease;Q4860325;P279;Q209717
Synergistic effect of prostaglandin E1 and isosorbide dinitrate in peripheral vascular disease;Q4860325;P527;Q579348
Synergistic effect of prostaglandin E1 and isosorbide dinitrate in peripheral vascular disease;Q579348;P279;Q209717
[Inhibitory effect of isosorbide dinitrate on whole blood aggregation];Q179748;P279;Q49916468
Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study.;Q179748;P279;Q49916468
[Changes in the antioxidant enzyme activity of the blood in patients with ischemic heart disease during treatment with nitrosorbide];Q186474;P366;Q133948
Randomized double-blind comparison of the effects of isosorbide dinitrate retard, verapamil sustained-release, and their combination on myocardial ischemic episodes;Q179748;P279;Q49916468
The antianginal efficacy of isosorbide dinitrate therapy is maintained during diuretic treatment.;Q179748;P279;Q49916468
The antianginal efficacy of isosorbide dinitrate therapy is maintained during diuretic treatment.;Q1243800;P2175;Q180762
[Hemodynamic effects of isosorbide dinitrate by intravenous infusion in subjects in hemodynamic equilibrium];Q179748;P279;Q49916468
Comparison of placebo, nitroglycerin, and isosorbide dinitrate for effectiveness of relief of angina and duration of action.;Q179748;P279;Q49916468
Comparison of placebo, nitroglycerin, and isosorbide dinitrate for effectiveness of relief of angina and duration of action.;Q1243800;P2175;Q180762
Patterns of isosorbide dinitrate and glyceryl trinitrate metabolites formed by selected segments of the rabbit gastrointestinal tract;Q3221044;P3781;Q162867
Patterns of isosorbide dinitrate and glyceryl trinitrate metabolites formed by selected segments of the rabbit gastrointestinal tract;Q179748;P279;Q49916468
Effect of penetration enhancers on isosorbide dinitrate penetration through rat skin from a transdermal therapeutic system;Q179748;P279;Q49916468
[The efficacy of isosorbide dinitrate administered in an intravenous bolus in acute cardiogenic pulmonary edema];Q179748;P279;Q49916468
[Significance of cardiac blood pool scintigraphy using intravenous injection of isosorbide dinitrate for the evaluation of viability of ischemic myocardium];Q179748;P279;Q49916468
Effects of isosorbide dinitrate and hydralazine on regional metabolic responses to arm exercise in patients with heart failure;Q179748;P279;Q49916468
Randomized controlled trial of vaginal misoprostol versus vaginal misoprostol and isosorbide dinitrate for termination of pregnancy at 13-29 weeks.;Q179748;P279;Q49916468
Randomized controlled trial of vaginal misoprostol versus vaginal misoprostol and isosorbide dinitrate for termination of pregnancy at 13-29 weeks.;Q416025;P636;Q4112929
[Use of isosorbide dinitrate and antagonists of angiotensin II in patients with stable angina pectoris in early stages of cardiac insufficiency].;Q179748;P279;Q49916468
[Use of isosorbide dinitrate and antagonists of angiotensin II in patients with stable angina pectoris in early stages of cardiac insufficiency].;Q1243800;P2175;Q180762
A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure.;Q179748;P279;Q49916468
A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure.;Q1243800;P2175;Q19000661
High-performance liquid chromatographic determination of the nitrate esters isosorbide dinitrate, pentaerythritol tetranitrate, and erythrityl tetranitrate in various tablet forms;Q179748;P279;Q49916468
High-performance liquid chromatographic determination of the nitrate esters isosorbide dinitrate, pentaerythritol tetranitrate, and erythrityl tetranitrate in various tablet forms;Q3899224;P460;Q189334
Comparative studies of the influence of dietary fat on plasma levels of isosorbide dinitrate from two sustained-release products.;Q179748;P279;Q49916468
Coronary dilating effects of intracoronary nicorandil. Comparison with isosorbide dinitrate;Q179748;P279;Q49916468
[Effects on the systemic and coronary circulation of 2 nitrate derivatives, intravenous trinitrin and sublingual isosorbide dinitrate, administered during atrial pacing];Q179748;P279;Q49916468
Simultaneous measurement of plasma isosorbide dinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate by gas-liquid chromatography;Q179748;P279;Q49916468
Clinical response and effects on left ventricular function of isosorbide dinitrate added to propranolol or diltiazem monotherapy in patients with chronic stable angina.;Q179748;P279;Q49916468
Clinical response and effects on left ventricular function of isosorbide dinitrate added to propranolol or diltiazem monotherapy in patients with chronic stable angina.;Q422229;P2175;Q180762
Clinical response and effects on left ventricular function of isosorbide dinitrate added to propranolol or diltiazem monotherapy in patients with chronic stable angina.;Q1243800;P2175;Q180762
Acute effects of nifedipine versus isosorbide dinitrate on exercise tolerance in patients with isolated coronary artery occlusion and collaterals;Q179748;P279;Q49916468
Intravaginal isosorbide dinitrate or misoprostol for cervical ripening prior to induction of labour: a randomised controlled trial.;Q179748;P279;Q49916468
Intravaginal isosorbide dinitrate or misoprostol for cervical ripening prior to induction of labour: a randomised controlled trial.;Q416025;P636;Q4112929
[Clinical and hemodynamic effects of an isosorbide dinitrate tape on patients with congestive heart failure--comparative study with nitroglycerin ointment];Q179748;P279;Q49916468
[Clinical and hemodynamic effects of an isosorbide dinitrate tape on patients with congestive heart failure--comparative study with nitroglycerin ointment];Q1243800;P2175;Q19000661
Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug.;Q179748;P31;Q12140
Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug.;Q179748;P279;Q49916468
Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug.;Q20035886;P31;Q12140
Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug.;Q1243800;P31;Q12140
Comparative effects of nifedipine, verapamil, isosorbide dinitrate and propranolol on exercise-induced angina pectoris.;Q410291;P2175;Q180762
Comparative effects of nifedipine, verapamil, isosorbide dinitrate and propranolol on exercise-induced angina pectoris.;Q39111;P2175;Q180762
Comparative effects of nifedipine, verapamil, isosorbide dinitrate and propranolol on exercise-induced angina pectoris.;Q179748;P279;Q49916468
Comparative effects of nifedipine, verapamil, isosorbide dinitrate and propranolol on exercise-induced angina pectoris.;Q1243800;P2175;Q180762
[Rapid attenuation of effects of isosorbide dinitrate during long-term treatment of chronic congestive heart failure];Q179748;P279;Q49916468
[Rapid attenuation of effects of isosorbide dinitrate during long-term treatment of chronic congestive heart failure];Q1243800;P2175;Q19000661
Isosorbide dinitrate and hydralazine as therapy for African Americans with heart failure: a failed paradigm?;Q179748;P279;Q49916468
Comparison of the effects of a controlled-release formulation of isosorbide-5-mononitrate and conventional isosorbide dinitrate on exercise performance in men with stable angina pectoris;Q179748;P279;Q49916468
Comparison of the effects of a controlled-release formulation of isosorbide-5-mononitrate and conventional isosorbide dinitrate on exercise performance in men with stable angina pectoris;Q1243800;P2175;Q180762
[Anti-arrhythmic effect of isosorbide dinitrate];Q179748;P279;Q49916468
[High performance liquid chromatographic assay and determination of the even distribution of active ingredients in nitroglycerin and isosorbide dinitrate tablets];Q179748;P279;Q49916468
[Comparative antianginal, hemodynamic and pharmacokinetic effects of isosorbide-2-mononitrate and isosorbide dinitrate in the rat];Q179748;P279;Q49916468
[Comparative antianginal, hemodynamic and pharmacokinetic effects of isosorbide-2-mononitrate and isosorbide dinitrate in the rat];Q1243800;P2175;Q180762
Determination of the partitioning, stability, and metabolite formation of isosorbide dinitrate in human and rat blood using an improved gas-liquid chromatographic assay;Q179748;P279;Q49916468
Determination of the partitioning, stability, and metabolite formation of isosorbide dinitrate in human and rat blood using an improved gas-liquid chromatographic assay;Q178450;P703;Q15978631
Comparison of effects of isosorbide dinitrate and hydralazine on left ventricular function by M-mode echocardiography;Q179748;P279;Q49916468
[Plasma levels of isosorbide dinitrate and its metabolites during intravenous infusion in surgical patients--effect of preoperative administration of isosorbide dinitrate].;Q179748;P279;Q49916468
Nitrate cross-tolerance: effect of sublingual isosorbide dinitrate and nitroglycerin during sustained nitrate therapy;Q179748;P279;Q49916468
[Isosorbide dinitrate ointment in the long-term treatment of intermittent claudication];Q179748;P279;Q49916468
Mechanisms for the in vivo antiplatelet effects of isosorbide dinitrate;Q179748;P279;Q49916468
A new multiple-unit oral floating dosage system. II: In vivo evaluation of floating and sustained-release characteristics with p-aminobenzoic acid and isosorbide dinitrate as model drugs.;Q218642;P31;Q12140
A new multiple-unit oral floating dosage system. II: In vivo evaluation of floating and sustained-release characteristics with p-aminobenzoic acid and isosorbide dinitrate as model drugs.;Q23118;P31;Q8386
A new multiple-unit oral floating dosage system. II: In vivo evaluation of floating and sustained-release characteristics with p-aminobenzoic acid and isosorbide dinitrate as model drugs.;Q191700;P1889;Q56085456
A new multiple-unit oral floating dosage system. II: In vivo evaluation of floating and sustained-release characteristics with p-aminobenzoic acid and isosorbide dinitrate as model drugs.;Q191700;P31;Q12140
A new multiple-unit oral floating dosage system. II: In vivo evaluation of floating and sustained-release characteristics with p-aminobenzoic acid and isosorbide dinitrate as model drugs.;Q179748;P31;Q12140
A new multiple-unit oral floating dosage system. II: In vivo evaluation of floating and sustained-release characteristics with p-aminobenzoic acid and isosorbide dinitrate as model drugs.;Q179748;P279;Q49916468
A new multiple-unit oral floating dosage system. II: In vivo evaluation of floating and sustained-release characteristics with p-aminobenzoic acid and isosorbide dinitrate as model drugs.;Q484940;P31;Q12140
A new multiple-unit oral floating dosage system. II: In vivo evaluation of floating and sustained-release characteristics with p-aminobenzoic acid and isosorbide dinitrate as model drugs.;Q1243800;P31;Q12140
Comparative evaluation of three dosages of slow-release isosorbide dinitrate (60, 80, 100 mg) in chronic angina of the aged;Q179748;P279;Q49916468
Comparative evaluation of three dosages of slow-release isosorbide dinitrate (60, 80, 100 mg) in chronic angina of the aged;Q1243800;P2175;Q180762
Gastric emptying of semisolid meal unaltered by 3 days' administration of a sustained-release preparation of the nitric oxide donor, isosorbide dinitrate;Q179748;P279;Q49916468
A sequential trial of isosorbide dinitrate ("sorbitrate") in angina pectoris;Q1243800;P2175;Q180762
Increased exercise tolerance and reduced duration of ischemia after isosorbide dinitrate oral spray in angina pectoris;Q179748;P279;Q49916468
Increased exercise tolerance and reduced duration of ischemia after isosorbide dinitrate oral spray in angina pectoris;Q1243800;P2175;Q180762
[Treatment of chronic anal fissures: diltiazem or isosorbide dinitrate as first choice?];Q179748;P279;Q49916468
Some remarks on the determination of isosorbide dinitrate and its metabolites in human plasma by GLC with electron capture detection;Q183290;P703;Q15978631
Some remarks on the determination of isosorbide dinitrate and its metabolites in human plasma by GLC with electron capture detection;Q186474;P703;Q15978631
Some remarks on the determination of isosorbide dinitrate and its metabolites in human plasma by GLC with electron capture detection;Q179748;P279;Q49916468
Some remarks on the determination of isosorbide dinitrate and its metabolites in human plasma by GLC with electron capture detection;Q620730;P703;Q15978631
Some remarks on the determination of isosorbide dinitrate and its metabolites in human plasma by GLC with electron capture detection;Q483745;P703;Q15978631
Nitrosamine formation from interaction of isosorbide dinitrate and hydroxyzine HCl, a tertiary amine;Q179748;P279;Q49916468
Hemodynamic effects of high-dose sustained-action oral isosorbide dinitrate in stable angina;Q179748;P279;Q49916468
Hemodynamic effects of high-dose sustained-action oral isosorbide dinitrate in stable angina;Q1243800;P2175;Q180762
Dose-Related Hepatic Blood Flow Effects Differentiate Nicorandil, Hydralazine, and Isosorbide Dinitrate in Healthy Subjects.;Q179748;P279;Q49916468
[Comparative evaluation of antianginal efficacy of isosorbide dinitrate in various doses in patients with stable angina];Q179748;P279;Q49916468
[Comparative evaluation of antianginal efficacy of isosorbide dinitrate in various doses in patients with stable angina];Q1243800;P2175;Q180762
[Plasma volume expansion may explain the attenuation of antianginal activity of oral isosorbide dinitrate in long-term therapy];Q179748;P279;Q49916468
[Plasma volume expansion may explain the attenuation of antianginal activity of oral isosorbide dinitrate in long-term therapy];Q1243800;P2175;Q180762
The additive antianginal action of oral isosorbide dinitrate in patients receiving propranolol. Magnitude and duration of effect;Q179748;P279;Q49916468
The additive antianginal action of oral isosorbide dinitrate in patients receiving propranolol. Magnitude and duration of effect;Q1243800;P2175;Q180762
Cutaneous pharmacodynamics of transdermally delivered isosorbide dinitrate;Q179748;P279;Q49916468
Isosorbide dinitrate in acute and chronic heart failure.;Q179748;P279;Q49916468
Co-administration of calcium gluconate and magnesium acetate effectively blocks the signs of morphine withdrawal in mice.;Q186474;P703;Q83310
Reevaluation of the usefulness of theobromine calcium gluconate for the management of congestive heart failure and anginal syndrome;Q206844;P1889;Q879
Ionization and hemodynamic effects of calcium chloride and calcium gluconate in the absence of hepatic function;Q208451;P527;Q706
Ionization and hemodynamic effects of calcium chloride and calcium gluconate in the absence of hepatic function;Q208451;P31;Q44791900
The influence of PTH, calcium gluconate and EDTA on the parotid saliva in the goat;Q408032;P1889;Q99239607
[Inhibition of anaphylactic reactions in the rabbit by adrenal cortex hormones, sodium salicylate and calcium gluconate];Q193572;P4149;Q3469744
[Inhibition of anaphylactic reactions in the rabbit by adrenal cortex hormones, sodium salicylate and calcium gluconate];Q414547;P527;Q658
[Protective action of ACTH, cortisone, calcium gluconate, pyrilamine (neoantergan), promethazine (fargan), and chlorpromazine (largactil) against experimental poisoning with Latrodectus venom in guinea pigs.];Q185690;P702;Q14819793
Therapeutic effect of topical calcium gluconate for hydrofluoric acid burn--time limit for the start of the treatment;Q186521;P703;Q177932
Prevention of citrate reactions during therapeutic plasma exchange by constant infusion of calcium gluconate with the return fluid;Q20035886;P703;Q177932
The use of calcium gluconate prior to verapamil in infants with paroxysmal supraventricular tachycardia.;Q410291;P2175;Q1598909
[Notes on the paper "Effects of calcium gluconate and calcium chloride on cardiovascular parameters", Anesthesist 27, p. 516];Q208451;P527;Q706
[Notes on the paper "Effects of calcium gluconate and calcium chloride on cardiovascular parameters", Anesthesist 27, p. 516];Q208451;P31;Q44791900
A prospective, randomized, double-blind comparison of calcium chloride and calcium gluconate therapies for hypocalcemia in critically ill children.;Q208451;P527;Q706
A prospective, randomized, double-blind comparison of calcium chloride and calcium gluconate therapies for hypocalcemia in critically ill children.;Q208451;P31;Q44791900
The effect of prostaglandin E2 and calcium gluconate on orthodontic tooth movement and root resorption in rats.;Q4860325;P279;Q209717
The effect of prostaglandin E2 and calcium gluconate on orthodontic tooth movement and root resorption in rats.;Q4860325;P527;Q416554
The effect of prostaglandin E2 and calcium gluconate on orthodontic tooth movement and root resorption in rats.;Q416554;P279;Q209717
[Recovery in aconite poisoning by intravenous administration of calcium gluconate and magnesium sulfate.];Q288266;P527;Q660
A Double-Blind, Active-Controlled Clinical Trial of Sodium Bicarbonate and Calcium Gluconate in the Treatment of Bilateral Osteoarthritis of the Knee.;Q218642;P527;Q623
A Double-Blind, Active-Controlled Clinical Trial of Sodium Bicarbonate and Calcium Gluconate in the Treatment of Bilateral Osteoarthritis of the Knee.;Q183290;P527;Q623
A Double-Blind, Active-Controlled Clinical Trial of Sodium Bicarbonate and Calcium Gluconate in the Treatment of Bilateral Osteoarthritis of the Knee.;Q186474;P527;Q623
A Double-Blind, Active-Controlled Clinical Trial of Sodium Bicarbonate and Calcium Gluconate in the Treatment of Bilateral Osteoarthritis of the Knee.;Q186521;P527;Q623
A Double-Blind, Active-Controlled Clinical Trial of Sodium Bicarbonate and Calcium Gluconate in the Treatment of Bilateral Osteoarthritis of the Knee.;Q179731;P527;Q623
A Double-Blind, Active-Controlled Clinical Trial of Sodium Bicarbonate and Calcium Gluconate in the Treatment of Bilateral Osteoarthritis of the Knee.;Q178450;P527;Q623
A Double-Blind, Active-Controlled Clinical Trial of Sodium Bicarbonate and Calcium Gluconate in the Treatment of Bilateral Osteoarthritis of the Knee.;Q620730;P527;Q623
Proceedings: Comparisons of phenobarbitone, magnesium sulphate, and calcium gluconate in treatment of neonatal hypocalcaemic convulsions.;Q288266;P527;Q660
Continuous infusion of calcium gluconate in 5% albumin is safe and prevents most hypocalcemic reactions during therapeutic plasma exchange;Q186474;P703;Q177932
A comparison of calcium gluconate and methocarbamol (Robaxin) in the treatment of Latrodectism (black widow spider envenomation);Q411456;P3780;Q47522096
Clinical arterial infusion of calcium gluconate: the preferred method for treating hydrofluoric acid burns of distal human limbs.;Q186474;P703;Q15978631
The use of hyaluronidase with calcium gluconate medication in sheep;Q186521;P31;Q12140
Safety of compounded calcium chloride admixtures for peripheral intravenous administration in the setting of a calcium gluconate shortage.;Q183290;P31;Q11173
Safety of compounded calcium chloride admixtures for peripheral intravenous administration in the setting of a calcium gluconate shortage.;Q208451;P527;Q706
Safety of compounded calcium chloride admixtures for peripheral intravenous administration in the setting of a calcium gluconate shortage.;Q208451;P31;Q11173
Safety of compounded calcium chloride admixtures for peripheral intravenous administration in the setting of a calcium gluconate shortage.;Q208451;P31;Q44791900
Change in plasma phosphate concentration on infusion of calcium gluconate or Na2EDTA;Q408032;P1889;Q99239607
Respiratory insufficiency after intraperitoneal administration of Kanamycin: failure of calcium gluconate to reverse toxic effects.;Q173670;P703;Q177932
Respiratory insufficiency after intraperitoneal administration of Kanamycin: failure of calcium gluconate to reverse toxic effects.;Q20816880;P703;Q177932
Calcium gluconate alleviates the toxic effect of hydrofluoric acid on human dermal fibroblasts through the Wnt/-catenin pathway;Q181003;P703;Q15978631
Calcium gluconate alleviates the toxic effect of hydrofluoric acid on human dermal fibroblasts through the Wnt/-catenin pathway;Q186474;P703;Q15978631
Erratum to: Effectiveness of intra-articular injections of sodium bicarbonate and calcium gluconate in the treatment of osteoarthritis of the knee: a randomized double-blind clinical trial.;Q179731;P527;Q623
Erratum to: Effectiveness of intra-articular injections of sodium bicarbonate and calcium gluconate in the treatment of osteoarthritis of the knee: a randomized double-blind clinical trial.;Q179731;P527;Q658
Prophylactic infusion of calcium gluconate to prevent a symptomatic fall in plasma ionized calcium during therapeutic plasma exchange: A comparison of two methods;Q218642;P703;Q177932
Prophylactic infusion of calcium gluconate to prevent a symptomatic fall in plasma ionized calcium during therapeutic plasma exchange: A comparison of two methods;Q20035886;P703;Q177932
Assay of calcium borogluconate veterinary medicines for calcium gluconate, boric acid, phosphorus, and magnesium by using inductively coupled plasma emission spectrometry.;Q218642;P31;Q12140
Assay of calcium borogluconate veterinary medicines for calcium gluconate, boric acid, phosphorus, and magnesium by using inductively coupled plasma emission spectrometry.;Q23118;P31;Q12140
Effect of calcium gluconate and adrenal steroids on sodium and water excretion in patients with cirrhosis and ascites;Q29053744;P366;Q7892
Calcium Gluconate in Cardiac Failure: Clinical Pharmacology and Therapeutics;Q186474;P703;Q177932
Calcium Gluconate in Cardiac Failure: Clinical Pharmacology and Therapeutics;Q186521;P703;Q177932
Calcium Gluconate in Cardiac Failure: Clinical Pharmacology and Therapeutics;Q20035886;P703;Q177932
Calcium Gluconate in Cardiac Failure: Clinical Pharmacology and Therapeutics;Q620730;P703;Q177932
Solubilizing effects of calcium salts upon calcium gluconate;Q2314;P1889;Q12370
Quality medicines in maternal health: results of oxytocin, misoprostol, magnesium sulfate and calcium gluconate quality audits.;Q181619;P31;Q12140
Quality medicines in maternal health: results of oxytocin, misoprostol, magnesium sulfate and calcium gluconate quality audits.;Q288266;P31;Q12140
Quality medicines in maternal health: results of oxytocin, misoprostol, magnesium sulfate and calcium gluconate quality audits.;Q288266;P527;Q660
Quality medicines in maternal health: results of oxytocin, misoprostol, magnesium sulfate and calcium gluconate quality audits.;Q416025;P31;Q12140
[Acidification of the urine after intravenous injection of calcium salts in man. II. Comparative effects of calcium gluconate and calcium chloride.];Q2314;P1889;Q12370
[Acidification of the urine after intravenous injection of calcium salts in man. II. Comparative effects of calcium gluconate and calcium chloride.];Q2314;P31;Q44791900
[Acidification of the urine after intravenous injection of calcium salts in man. II. Comparative effects of calcium gluconate and calcium chloride.];Q208451;P527;Q706
[Acidification of the urine after intravenous injection of calcium salts in man. II. Comparative effects of calcium gluconate and calcium chloride.];Q208451;P31;Q44791900
The application of ferrihydroxamic complexes to photocolorimetric determination of drugs. Part 2: Quantitative determination of calcium pangamate (vitamin B15) and its calcium gluconate mixtures;Q181619;P31;Q12140
The application of ferrihydroxamic complexes to photocolorimetric determination of drugs. Part 2: Quantitative determination of calcium pangamate (vitamin B15) and its calcium gluconate mixtures;Q186521;P31;Q12140
The application of ferrihydroxamic complexes to photocolorimetric determination of drugs. Part 2: Quantitative determination of calcium pangamate (vitamin B15) and its calcium gluconate mixtures;Q83187;P31;Q12140
The application of ferrihydroxamic complexes to photocolorimetric determination of drugs. Part 2: Quantitative determination of calcium pangamate (vitamin B15) and its calcium gluconate mixtures;Q83187;P2868;Q183206
The application of ferrihydroxamic complexes to photocolorimetric determination of drugs. Part 2: Quantitative determination of calcium pangamate (vitamin B15) and its calcium gluconate mixtures;Q83187;P361;Q27115611
The application of ferrihydroxamic complexes to photocolorimetric determination of drugs. Part 2: Quantitative determination of calcium pangamate (vitamin B15) and its calcium gluconate mixtures;Q20035886;P31;Q12140
[Therapy of acute infectious hepatitis with calcium gluconate Sandoz and magnesium sulfate Spofa.];Q288266;P527;Q660
Failure of calcium gluconate internal gelation for prolonging drug release from alginate-chitosan-based ocular insert of atenolol;Q411325;P31;Q12140
Failure of calcium gluconate internal gelation for prolonging drug release from alginate-chitosan-based ocular insert of atenolol;Q191924;P31;Q12140
Failure of calcium gluconate internal gelation for prolonging drug release from alginate-chitosan-based ocular insert of atenolol;Q170545;P31;Q12140
Determination of trace vitamin C by ion-pair HPLC with UV detection in calcium gluconate and vitamin C compound oral solution;Q186474;P31;Q11173
Determination of trace vitamin C by ion-pair HPLC with UV detection in calcium gluconate and vitamin C compound oral solution;Q485277;P31;Q11173
Determination of trace vitamin C by ion-pair HPLC with UV detection in calcium gluconate and vitamin C compound oral solution;Q199678;P31;Q34956
Determination of trace vitamin C by ion-pair HPLC with UV detection in calcium gluconate and vitamin C compound oral solution;Q199678;P31;Q11173
Determination of trace vitamin C by ion-pair HPLC with UV detection in calcium gluconate and vitamin C compound oral solution;Q178450;P31;Q11173
Determination of trace vitamin C by ion-pair HPLC with UV detection in calcium gluconate and vitamin C compound oral solution;Q20035886;P31;Q11173
Determination of trace vitamin C by ion-pair HPLC with UV detection in calcium gluconate and vitamin C compound oral solution;Q483745;P31;Q11173
Determination of trace vitamin C by ion-pair HPLC with UV detection in calcium gluconate and vitamin C compound oral solution;Q483752;P31;Q11173
The effect of intravenous calcium gluconate on the renal excretion of water and electrolytes;Q29053744;P155;Q23392
Comparison of parenterally administered calcium kinate gluconate with calcium gluconate and calcium chloride.;Q208451;P527;Q706
Comparison of parenterally administered calcium kinate gluconate with calcium gluconate and calcium chloride.;Q208451;P31;Q44791900
[Effects of calcium gluconate and calcium chloride on cardiocirculatory parameters in man (author's transl)];Q208451;P527;Q706
[Effects of calcium gluconate and calcium chloride on cardiocirculatory parameters in man (author's transl)];Q208451;P31;Q44791900
Physical compatibility of calcium gluconate and magnesium sulfate injections.;Q288266;P527;Q660
Comparison of renal clearance of calcium during infusion of calcium chloride and calcium gluconate;Q208451;P527;Q706
Comparison of renal clearance of calcium during infusion of calcium chloride and calcium gluconate;Q208451;P31;Q44791900
Influence of intravenous administration of calcium gluconate on the 11-hydroxycorticosteroid secretion by the adrenal cortex.;Q210420;P2849;Q19065
Multimodal assessment of human brain calcification with respect to parenteral calcium gluconate in stressed neonates;Q22124685;P703;Q15978631
Compatibility of calcium chloride and calcium gluconate with sodium phosphate in a mixed TPN solution;Q208451;P527;Q706
Compatibility of calcium chloride and calcium gluconate with sodium phosphate in a mixed TPN solution;Q208451;P31;Q44791900
Effectiveness of intra-articular injections of sodium bicarbonate and calcium gluconate in the treatment of osteoarthritis of the knee: a randomized double-blind clinical trial.;Q179731;P527;Q623
Effectiveness of intra-articular injections of sodium bicarbonate and calcium gluconate in the treatment of osteoarthritis of the knee: a randomized double-blind clinical trial.;Q179731;P527;Q658
Successful desensitization to oxaliplatin with incorporation of calcium gluconate and magnesium sulfate.;Q288266;P527;Q660
[Oscillopolarographic titration of calcium gluconate with EDTA];Q408032;P1889;Q99239607
[Iodine recovery as potassium iodide from the liquids resulted in iodometric determinations];Q121874;P527;Q703
[Treatment with potassium iodide following nuclear reactor accident];Q121874;P527;Q703
Treatment of cutaneous sporotrichosis with one daily dose of potassium iodide;Q121874;P527;Q703
Effect of potassium iodide and vitamin A on the thyroidal uptake and urinary excretion of I 131 in goitrous subjects on the island of Krk;Q121874;P527;Q703
Action of potassium iodide on thyroxine metabolism;Q121874;P527;Q703
Renin-angiotensin system in hypothyroid rats: effects of potassium iodide and triiodo-L-thyronine;Q121874;P527;Q703
Viability of the rat blastocyst following the oral administration of potassium perchlorate or potassium iodide to the mother;Q121874;P527;Q703
[Alteration of TSH secretion in children with goitre after short-term treatment with potassium iodide (author's transl)];Q121874;P527;Q703
[Effects of prophylactic doses of potassium iodide on the course of thyroid diseases (1986-1990) diagnosed due to the atomic accident at Czernobyl in adult patients at the outpatient endocrinologic hospital clinic in Lodz];Q121874;P527;Q703
Radio-sensitization with iodine compounds. II. Studies on mutant strains of Escherichia coli K12 resistant to radiation-induced toxic products from iodoacetic acid, potassium iodide or potassium iodate;Q183290;P31;Q11173
Radio-sensitization with iodine compounds. II. Studies on mutant strains of Escherichia coli K12 resistant to radiation-induced toxic products from iodoacetic acid, potassium iodide or potassium iodate;Q183290;P703;Q25419
Radio-sensitization with iodine compounds. II. Studies on mutant strains of Escherichia coli K12 resistant to radiation-induced toxic products from iodoacetic acid, potassium iodide or potassium iodate;Q23118;P31;Q11173
Radio-sensitization with iodine compounds. II. Studies on mutant strains of Escherichia coli K12 resistant to radiation-induced toxic products from iodoacetic acid, potassium iodide or potassium iodate;Q121874;P527;Q703
Radio-sensitization with iodine compounds. II. Studies on mutant strains of Escherichia coli K12 resistant to radiation-induced toxic products from iodoacetic acid, potassium iodide or potassium iodate;Q121874;P527;Q1103
Radio-sensitization with iodine compounds. II. Studies on mutant strains of Escherichia coli K12 resistant to radiation-induced toxic products from iodoacetic acid, potassium iodide or potassium iodate;Q121874;P31;Q11173
Radio-sensitization with iodine compounds. II. Studies on mutant strains of Escherichia coli K12 resistant to radiation-induced toxic products from iodoacetic acid, potassium iodide or potassium iodate;Q173670;P31;Q11173
Radio-sensitization with iodine compounds. II. Studies on mutant strains of Escherichia coli K12 resistant to radiation-induced toxic products from iodoacetic acid, potassium iodide or potassium iodate;Q173670;P703;Q25419
Radio-sensitization with iodine compounds. II. Studies on mutant strains of Escherichia coli K12 resistant to radiation-induced toxic products from iodoacetic acid, potassium iodide or potassium iodate;Q20816880;P703;Q25419
Radio-sensitization with iodine compounds. II. Studies on mutant strains of Escherichia coli K12 resistant to radiation-induced toxic products from iodoacetic acid, potassium iodide or potassium iodate;Q20816880;P31;Q11173
Radio-sensitization with iodine compounds. II. Studies on mutant strains of Escherichia coli K12 resistant to radiation-induced toxic products from iodoacetic acid, potassium iodide or potassium iodate;Q484940;P703;Q25419
Radio-sensitization with iodine compounds. II. Studies on mutant strains of Escherichia coli K12 resistant to radiation-induced toxic products from iodoacetic acid, potassium iodide or potassium iodate;Q484940;P31;Q11173
Use of potassium iodide as a chemical actinometer.;Q121874;P527;Q703
Oral potassium iodide for the treatment of sporotrichosis;Q121874;P527;Q703
A convenient procedure for the isolation of intact translatable mRNA by potassium iodide gradient centrifugation;Q121874;P527;Q703
Effects of potassium iodide, colchicine and dapsone on the generation of polymorphonuclear leukocyte-derived oxygen intermediates;Q121874;P527;Q703
[Focal reactions caused by potassium iodide and attempted immunization with methyl antigen in chronic pulmonary tuberculosis];Q121874;P527;Q703
Vitamins B1: a note on the stability of thiamine hydrochloride in aqueous solution in the presence of iodine and potassium iodide;Q83187;P31;Q46222910
Vitamins B1: a note on the stability of thiamine hydrochloride in aqueous solution in the presence of iodine and potassium iodide;Q121874;P527;Q703
Vitamins B1: a note on the stability of thiamine hydrochloride in aqueous solution in the presence of iodine and potassium iodide;Q121874;P527;Q1103
Metabolomics evaluation of repeated administration of potassium iodide on adult male rats;Q121874;P527;Q703
Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves' hyperthyroidism;Q121874;P527;Q1103
Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves' hyperthyroidism;Q121874;P527;Q703
Adverse reaction to potassium iodide from a cough syrup;Q121874;P527;Q703
Cutaneous cryptococcosis: report of a case treated with potassium iodide and x-ray therapy;Q121874;P527;Q703
Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma.;Q121874;P527;Q703
Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma.;Q484940;P703;Q177932
Recommendations on the use of potassium iodide as a thyroid-blocking agent in radiation accidents: an FDA update.;Q121874;P527;Q703
In vitro antibacterial effect of calcium hydroxide combined with chlorhexidine or iodine potassium iodide on Enterococcus faecalis.;Q121874;P527;Q703
In vitro antibacterial effect of calcium hydroxide combined with chlorhexidine or iodine potassium iodide on Enterococcus faecalis.;Q121874;P527;Q1103
In vitro antibacterial effect of calcium hydroxide combined with chlorhexidine or iodine potassium iodide on Enterococcus faecalis.;Q15646788;P279;Q804539
[The uptake of potassium iodide and its effect as an antioxidant in isolated rabbit eyes].;Q121874;P527;Q703
Effect of repetitive potassium iodide on thyroid and cardiovascular functions in elderly rats;Q121874;P527;Q703
Osseous sporotrichosis. Failure of treatment with potassium iodide and sulfadimethoxine and success with amphotericin B;Q412223;P2175;Q767327
Osseous sporotrichosis. Failure of treatment with potassium iodide and sulfadimethoxine and success with amphotericin B;Q121874;P527;Q703
An evaluation of potassium iodide as a therapeutic agent in the treatment of experimental hypercholesteremia and atherosclerosis.;Q218642;P703;Q177932
An evaluation of potassium iodide as a therapeutic agent in the treatment of experimental hypercholesteremia and atherosclerosis.;Q121874;P527;Q703
[Hypothyroidism following intermittent administration of potassium iodide];Q121874;P527;Q703
A gamma camera re-evaluation of potassium iodide blocking efficiency in mice.;Q121874;P527;Q703
Effect of potassium iodide and duodenal powder on the growth and organ weights of goitrogenfed rats;Q121874;P527;Q703
Nadolol and potassium iodide in combination in the surgical treatment of thyrotoxicosis;Q121874;P527;Q703
Effect of silver diamine fluoride and potassium iodide on residual bacteria in dentinal tubules.;Q121874;P527;Q703
[Crossed double-blind trial of potassium iodide and bromelain (Traumanase) in chronic bronchitis];Q121874;P527;Q703
[The effect of local administration of potassium iodide and methylthiouracil into rat adenohypophysis];Q121874;P527;Q703
A one step synthetic approach to L-pyrimidine nucleosides using natural phosphate coated with potassium iodide as catalyst.;Q121874;P527;Q703
Storage losses of potassium iodide in iodized salt and the possibility of their elimination;Q2314;P1889;Q12370
Storage losses of potassium iodide in iodized salt and the possibility of their elimination;Q121874;P527;Q703
Clinical dilemmas arising from the increased intake of iodine in the Spanish population and the recommendation for systematic prescription of potassium iodide in pregnant and lactating women (Consensus of the TDY Working Group of SEEN).;Q121874;P527;Q1103
Clinical dilemmas arising from the increased intake of iodine in the Spanish population and the recommendation for systematic prescription of potassium iodide in pregnant and lactating women (Consensus of the TDY Working Group of SEEN).;Q121874;P527;Q703
Inactivation of the antibacterial activity of iodine potassium iodide and chlorhexidine digluconate against Enterococcus faecalis by dentin, dentin matrix, type-I collagen, and heat-killed microbial whole cells.;Q121874;P527;Q703
Inactivation of the antibacterial activity of iodine potassium iodide and chlorhexidine digluconate against Enterococcus faecalis by dentin, dentin matrix, type-I collagen, and heat-killed microbial whole cells.;Q121874;P527;Q1103
Inactivation of the antibacterial activity of iodine potassium iodide and chlorhexidine digluconate against Enterococcus faecalis by dentin, dentin matrix, type-I collagen, and heat-killed microbial whole cells.;Q15646788;P279;Q804539
Treatment of disseminated granuloma annulare with potassium iodide;Q121874;P527;Q703
[On the effect of potassium iodide on the "total lipid" content of the aortic wall and the main atherogenic indices of the blood serum in experimental cholesterol atherosclerosis];Q121874;P527;Q703
[Essay of treatment of chronic pulmonary tuberculosis with streptomycin associated with potassium iodide and methyl antigen];Q121874;P527;Q703
[Value of potassium iodide trial therapy in grave gummatous syphilis and simple iodine-bismuth therapy during late latency];Q121874;P527;Q703
[Value of potassium iodide trial therapy in grave gummatous syphilis and simple iodine-bismuth therapy during late latency];Q121874;P527;Q1103
Serum iodine fractions in subjects receiving potassium iodide in small dosage;Q121874;P527;Q703
Serum iodine fractions in subjects receiving potassium iodide in small dosage;Q121874;P527;Q1103
Sporotrichoid Nocardia brasiliensis infection. Response to potassium iodide;Q121874;P527;Q703
Studies on the mechanism of action of potassium iodide on thyroid protein biosynthesis;Q121874;P527;Q703
New posology of potassium iodide for the treatment of cutaneous sporotrichosis: study of efficacy and safety in 102 patients.;Q121874;P527;Q703
[Clinical significance of potassium iodide test in children with inflammation of the gallbladder and bile tract];Q121874;P527;Q703
[Treatment of cervico-facial actinomycosis with massive doses of potassium iodide];Q121874;P527;Q703
[Effect of potassium iodide on tumor growth];Q121874;P527;Q703
[Microbiological studies on therapeutic action of certain antibiotics in suppurative states following antroatticotomy: thyrotricin and potassium iodide];Q121874;P527;Q703
[Microbiological studies on therapeutic action of certain antibiotics in suppurative states following antroatticotomy: thyrotricin and potassium iodide];Q22124685;P703;Q177932
Investigations regarding the wet decontamination of fluorescent lamp waste using iodine in potassium iodide solutions;Q121874;P527;Q1103
Investigations regarding the wet decontamination of fluorescent lamp waste using iodine in potassium iodide solutions;Q121874;P527;Q703
[Proceedings: Effect of potassium iodide on the non-specific hapten-IgG interaction, titrated by fluorescence quenching];Q121874;P527;Q703
[On the prescription of a potassium iodide ointment for the non-surgical removal of mycotic nails (author's transl)];Q121874;P527;Q703
Effect of storage conditions on potassium iodide stability in iodised table salt and collagen preparations;Q2314;P1889;Q11254
Effect of storage conditions on potassium iodide stability in iodised table salt and collagen preparations;Q2314;P1889;Q12370
Effect of storage conditions on potassium iodide stability in iodised table salt and collagen preparations;Q121874;P527;Q703
Effect of potassium iodide supplementation and teat-dipping on iodine status in dairy cows and milk iodine levels;Q121874;P527;Q703
Effect of potassium iodide supplementation and teat-dipping on iodine status in dairy cows and milk iodine levels;Q121874;P527;Q1103
The effectiveness of oral administration of potassium iodide to lactating goats in reducing the transfer of radioiodine to milk;Q121874;P527;Q703
The effectiveness of oral administration of potassium iodide to lactating goats in reducing the transfer of radioiodine to milk;Q121874;P527;Q1103
Association of itraconazole and potassium iodide in the treatment of feline sporotrichosis: a prospective study.;Q121874;P527;Q703
Effects of repeated potassium iodide administration on genes involved in synthesis and secretion of thyroid hormone in adult male rat.;Q121874;P527;Q703
Theoretical study of the molecular and electronic structure of one-dimensional crystals of potassium iodide and composites formed upon intercalation in single-walled carbon nanotubes;Q186521;P527;Q623
Theoretical study of the molecular and electronic structure of one-dimensional crystals of potassium iodide and composites formed upon intercalation in single-walled carbon nanotubes;Q191924;P527;Q623
Theoretical study of the molecular and electronic structure of one-dimensional crystals of potassium iodide and composites formed upon intercalation in single-walled carbon nanotubes;Q121874;P527;Q703
Penicillin alone and in combination with mercury succinimide and potassium iodide in the treatment of acute syphilitic orchitis of rabbits;Q121874;P527;Q703
Iodine potassium iodide improves the contrast-to-noise ratio of micro-computed tomography images of the human middle ear.;Q121874;P527;Q703
Iodine potassium iodide improves the contrast-to-noise ratio of micro-computed tomography images of the human middle ear.;Q484940;P703;Q15978631
Therapeutic effect of an alcohol solution of theophylline and potassium iodide in asthma;Q407308;P2175;Q35869
Therapeutic effect of an alcohol solution of theophylline and potassium iodide in asthma;Q186521;P703;Q177932
Therapeutic effect of an alcohol solution of theophylline and potassium iodide in asthma;Q121874;P527;Q703
[The effect of long-term external ionizing radiation on the functional activity of rat thyroid under enhanced potassium iodide consumption];Q121874;P527;Q703
Is potassium iodide solution necessary before total thyroidectomy for Graves disease?;Q121874;P527;Q703
Refractory feline sporotrichosis treated with itraconazole combined with potassium iodide;Q121874;P527;Q703
[The treatment of tinea capitis with potassium iodide];Q121874;P527;Q703
Control of severe thyrotoxicosis with potassium iodide and propranolol;Q121874;P527;Q703
[Determination of potassium iodide in calcium salicylate with theobromine calcium and potassium iodide];Q193572;P4149;Q3469744
[Determination of potassium iodide in calcium salicylate with theobromine calcium and potassium iodide];Q121874;P527;Q703
[Determination of potassium iodide in calcium salicylate with theobromine calcium and potassium iodide];Q206844;P1889;Q879
High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma.;Q121874;P527;Q703
Theory of thyroid hormone action: conclusions derived from differences in effect of sodium 1-thyroxine, sodium d-thyroxine, triiodothyronine and potassium iodide on uptake of radioactive iodine by thyroid gland of normal human subjects;Q186521;P703;Q15978631
Theory of thyroid hormone action: conclusions derived from differences in effect of sodium 1-thyroxine, sodium d-thyroxine, triiodothyronine and potassium iodide on uptake of radioactive iodine by thyroid gland of normal human subjects;Q121874;P527;Q703
Theory of thyroid hormone action: conclusions derived from differences in effect of sodium 1-thyroxine, sodium d-thyroxine, triiodothyronine and potassium iodide on uptake of radioactive iodine by thyroid gland of normal human subjects;Q121874;P527;Q1103
The effect of potassium iodide on photophobic responses in Euglena: evidence for two photoreceptor pigments;Q121874;P527;Q703
Safety and efficacy of oral potassium iodide in chromoblastomycosis.;Q121874;P527;Q703
[Efficacy of the association of PAS with potassium iodide in the treatment of experimental tuberculosis in the guinea pig.];Q121874;P527;Q703
[Efficacy of the association of PAS with potassium iodide in the treatment of experimental tuberculosis in the guinea pig.];Q229924;P2175;Q12204
Spectrophotometric determination of hydrogen peroxide in water with peroxidase-catalyzed oxidation of potassium iodide and its applications to hydroxylamine-involved Fenton and Fenton-like systems;Q121874;P527;Q703
Spectrophotometric determination of hydrogen peroxide in water with peroxidase-catalyzed oxidation of potassium iodide and its applications to hydroxylamine-involved Fenton and Fenton-like systems;Q170545;P527;Q556
Spectrophotometric determination of hydrogen peroxide in water with peroxidase-catalyzed oxidation of potassium iodide and its applications to hydroxylamine-involved Fenton and Fenton-like systems;Q29053744;P366;Q7892
Bacterial photodynamic inactivation mediated by methylene blue and red light is enhanced by synergistic effect of potassium iodide;Q121874;P527;Q703
Antibacterial efficacy of calcium hydroxide, iodine potassium iodide, betadine, and betadine scrub with and without surfactant against E faecalis in vitro.;Q121874;P527;Q703
Antibacterial efficacy of calcium hydroxide, iodine potassium iodide, betadine, and betadine scrub with and without surfactant against E faecalis in vitro.;Q121874;P527;Q1103
Silver diamine fluoride, potassium iodide, and esthetic perception: An in vitro pilot study.;Q121874;P527;Q703
[Efficacy of the association of streptomycin and potassium iodide in the treatment of experimental tuberculosis in the guinea pig.];Q121874;P527;Q703
[A case of chromomycosis treated with vitamin D2 and potassium iodide(with a 10-year follow-up)];Q121874;P527;Q703
Comparison of L-thyroxine and a saturated solution of potassium iodide in preventing damage to the thyroid following iodine-131-labeled antibody injection;Q121874;P527;Q703
Comparison of L-thyroxine and a saturated solution of potassium iodide in preventing damage to the thyroid following iodine-131-labeled antibody injection;Q121874;P527;Q1103
Comparison of L-thyroxine and a saturated solution of potassium iodide in preventing damage to the thyroid following iodine-131-labeled antibody injection;Q773449;P31;Q216852
Subclinical hypothyroidism during potassium iodide therapy for lymphocutaneous sporotrichosis.;Q121874;P527;Q703
[Neonatal hypothyroidism induced by the ingestion of potassium iodide during pregnancy (author's transl)];Q121874;P527;Q703
Levothyroxine and potassium iodide are both effective in treating benign solitary solid cold nodules of the thyroid.;Q121874;P527;Q703
Levothyroxine and potassium iodide are both effective in treating benign solitary solid cold nodules of the thyroid.;Q773449;P31;Q216852
[Liberation of active substances from ointment bases. IV. Influence of Tween 80, Span 60, water and the physico-chemical structure of the ointment on the liberation of potassium iodide from lard and white petrolatum];Q121874;P527;Q703
[Liberation of active substances from ointment bases. IV. Influence of Tween 80, Span 60, water and the physico-chemical structure of the ointment on the liberation of potassium iodide from lard and white petrolatum];Q29053744;P366;Q7892
Theophylline and potassium iodide in the treatment of chronic asthma;Q407308;P2175;Q35869
Theophylline and potassium iodide in the treatment of chronic asthma;Q121874;P527;Q703
Differences between normal and demineralized dentine pretreated with silver fluoride and potassium iodide after an in vitro challenge by Streptococcus mutans;Q121874;P527;Q703
[Studies on inhibiting effects of potassium iodide and of thyreoidin on experimental goiter.];Q121874;P527;Q703
Use of potassium iodide (KI) in a nuclear emergency.;Q121874;P527;Q703
Use of potassium iodide to mimic drought stress in triticale;Q121874;P527;Q703
Iodine in raw and pasteurized milk of dairy cows fed different amounts of potassium iodide;Q121874;P527;Q703
An in vitro model to measure the effect of a silver fluoride and potassium iodide treatment on the permeability of demineralized dentine to Streptococcus mutans;Q121874;P527;Q703
Thyroid uptake and radiation dose after (131)I-lipiodol treatment: is thyroid blocking by potassium iodide necessary?;Q121874;P527;Q703
[Effect of potassium iodide on efficiency of muscles];Q121874;P527;Q703
[On iodine sensitivity in Duhring's dermatitis herpetiformis: the epicutaneous potassium iodide test as a nonspecific example of the Hofmeister anion effect].;Q121874;P527;Q1103
[On iodine sensitivity in Duhring's dermatitis herpetiformis: the epicutaneous potassium iodide test as a nonspecific example of the Hofmeister anion effect].;Q121874;P527;Q703
Effects of methylmercaptoimidazole (MMI), propylthiouracil (PTU), potassium perchlorate (KClO4) and potassium iodide (KI) on the serum concentrations of thyrotrophin (TSH) and thyroid hormones in the rat.;Q184630;P527;Q703
Effects of methylmercaptoimidazole (MMI), propylthiouracil (PTU), potassium perchlorate (KClO4) and potassium iodide (KI) on the serum concentrations of thyrotrophin (TSH) and thyroid hormones in the rat.;Q121874;P527;Q703
Evaluation of potassium iodide (KI) and ammonium perchlorate (NH4ClO4) to ameliorate 131I- exposure in the rat;Q121874;P527;Q703
Entomophthoromycosis (basidiobolomycosis) presenting with "saxophone" penis and responding to potassium iodide;Q121874;P527;Q703
Treatment of erythematous dermatoses with potassium iodide;Q121874;P527;Q703
[Study of the reaction of alkaloids and potassium tetraiodomercurate (II). II. Selective detection of mercury (II) with the use of papaverine potassium iodide reagent];Q121874;P527;Q703
Effects of meso-2,3-dimercaptosuccinic acid, potassium iodide and chlorophyll on lead accumulation in male mice.;Q121874;P527;Q703
Effects of meso-2,3-dimercaptosuccinic acid, potassium iodide and chlorophyll on lead accumulation in male mice.;Q423814;P31;Q56604713
Ulcerative subcutaneous zygomycosis: development of hypothyroidism induced by potassium iodide (Wolff-Chaikoff effect);Q121874;P527;Q703
Concentration-dependent influence of various cytochalasins and chaetoglobosins on the phalloidin-induced polymerization of G-actin in 0.6 M potassium iodide;Q121874;P527;Q703
[Effect of potassium iodide on prevention of experimental lead nephropathy and expression of nuclear factor-kappaB and fibronectin];Q121874;P527;Q703
Combination of potassium iodide and propranolol in preparation of patients with Graves' disease for thyroid surgery;Q121874;P527;Q703
The electrophoretic mobility and fractionation of complexes of hydrolysis products of amylose with iodine and potassium iodide;Q121874;P527;Q703
The electrophoretic mobility and fractionation of complexes of hydrolysis products of amylose with iodine and potassium iodide;Q121874;P527;Q1103
The protective action of thyroid and potassium iodide in cholesterol induced atherosclerosis in chickens;Q121874;P527;Q703
The use of potassium iodide in combination with streptomycin in the treatment of experimental tuberculosis in guinea pigs.;Q121874;P527;Q703
[Production of stabilized potassium iodide tablets];Q121874;P527;Q703
[Effect of iodine on the thyroid: demonstration of the stimulating effect of potassium iodide and metallic iodine];Q121874;P527;Q703
[Effect of iodine on the thyroid: demonstration of the stimulating effect of potassium iodide and metallic iodine];Q121874;P527;Q1103
Instrumental measurements of different homeopathic dilutions of potassium iodide in water.;Q121874;P527;Q703
Instrumental measurements of different homeopathic dilutions of potassium iodide in water.;Q29053744;P1889;Q283
Erratum: Blastomycosis-like pyoderma: Novel use of potassium iodide;Q121874;P527;Q703
Toxicity of tetramethylammonium hydroxide to aquatic organisms and its synergistic action with potassium iodide;Q121874;P527;Q703
Enhancing nuclear emergency preparedness: Vermont's distribution program for potassium iodide;Q121874;P527;Q703
Absence of gradient of thyrotropin receptor antibody and T cell subset distribution between thyroid and peripheral venous blood in patients with Graves' disease prepared for surgery with carbimazole and potassium iodide;Q121874;P527;Q703
[Evaluation of equivalent body burden in the thyroid for the people of Poland on results of 131I absorption after the disaster in Czernobyl. Determination of thyroid blockade with potassium iodide];Q121874;P527;Q703
Age-dependent potassium iodide effect on the thyroid irradiation by 131I and 133I in the nuclear emergency;Q121874;P527;Q703
[Lipids metabolism in human arteriosclerosis and effect of potassium iodide on its modifications.];Q121874;P527;Q703
[Lipids metabolism in human arteriosclerosis and effect of potassium iodide on its modifications.];Q483745;P703;Q15978631
Orbital mucormycosis (phycomycosis) (a survival with amphotericin-B and potassium iodide);Q121874;P527;Q703
Sporotrichosis successfully treated with terbinafine and potassium iodide: case report and review of the literature.;Q121874;P527;Q703
[Worth of potassium iodide tablets in reactor accidents?];Q121874;P527;Q703
[Rare, severe hypersensitivity reaction to potassium iodide];Q121874;P527;Q703
D-xylose and potassium iodide absorption and serum carotene in pernicious anemia;Q121874;P527;Q703
Degradation of aqueous solution of potassium iodide and sodium cyanide in the presence of carbon tetrachloride;Q121874;P527;Q703
Degradation of aqueous solution of potassium iodide and sodium cyanide in the presence of carbon tetrachloride;Q178450;P527;Q623
Stimulation of wound healing with potassium iodide;Q121874;P527;Q703
Dihydrostreptomycin and potassium iodide in the treatment of tuberculosis verrucosa cutis;Q121874;P527;Q703
The antimicrobial effect of apical box versus apical cone preparation using iodine potassium iodide as root canal dressing: a pilot study.;Q121874;P527;Q1103
The antimicrobial effect of apical box versus apical cone preparation using iodine potassium iodide as root canal dressing: a pilot study.;Q121874;P527;Q703
Potassium iodate and its comparison to potassium iodide as a blocker of 131I uptake by the thyroid in rats;Q121874;P527;Q703
Hydration of potassium iodide dimer studied by photoelectron spectroscopy and ab initio calculations.;Q121874;P527;Q703
[Use of potassium iodide iontophoresis in the treatment of women suffering from candidiasis of the genital mucosa];Q121874;P527;Q703
On the distribution of potassium iodide to members of the public in anticipation of an accidental release of radioiodine;Q121874;P527;Q703
On the distribution of potassium iodide to members of the public in anticipation of an accidental release of radioiodine;Q121874;P527;Q1103
Successful treatment outcome with itraconazole and potassium iodide in disseminated sporotrichosis.;Q121874;P527;Q703
Sulfone compounds and potassium iodide alone and in combination with streptomycin in the treatment of experimental tuberculosis of guinea pigs.;Q183290;P31;Q11173
Sulfone compounds and potassium iodide alone and in combination with streptomycin in the treatment of experimental tuberculosis of guinea pigs.;Q192717;P31;Q11173
Sulfone compounds and potassium iodide alone and in combination with streptomycin in the treatment of experimental tuberculosis of guinea pigs.;Q121874;P527;Q703
Sulfone compounds and potassium iodide alone and in combination with streptomycin in the treatment of experimental tuberculosis of guinea pigs.;Q121874;P31;Q11173
Studies on mode of action of potassium iodide upon sporotrichosis;Q121874;P527;Q703
Experts advise on potassium iodide use: no protection against "dirty bombs";Q121874;P527;Q703
Thyroid protection gone awry: iododerma following potassium iodide administration prior to metaiodobenzylguanidine scintigraphy;Q121874;P527;Q703
Far-infrared difference-band absorption in potassium iodide;Q121874;P527;Q703
[Effect of potassium iodide and streptomycin on experimental tuberculosis in mice];Q121874;P527;Q703
[Action of urinary uric acid of potassium iodide];Q121874;P527;Q703
Effect of immunization and potassium iodide on polymorphonuclear leukocyte chemiluminescence in experimental murine sporotrichosis.;Q121874;P527;Q703
Ion uptake into demineralized dentine from glass ionomer cement following pretreatment with silver fluoride and potassium iodide;Q121874;P527;Q703
[Influence of the nature of the vehicles for pomades on the percutaneous absorption of potassium iodide, sodium salicylate and salicylic acid];Q193572;P4149;Q3469744
[Influence of the nature of the vehicles for pomades on the percutaneous absorption of potassium iodide, sodium salicylate and salicylic acid];Q121874;P527;Q703
[Influence of the nature of the vehicles for pomades on the percutaneous absorption of potassium iodide, sodium salicylate and salicylic acid];Q414547;P527;Q658
Serum and tissue iodine concentrations in rats fed diets supplemented with kombu powder or potassium iodide;Q121874;P527;Q703
Serum and tissue iodine concentrations in rats fed diets supplemented with kombu powder or potassium iodide;Q121874;P527;Q1103
[Quantitative determination of potassium iodide in antistrumin tablets];Q121874;P527;Q703
[The effect of potassium iodide on the pharmacokinetics of radioactive iodine-labelled antibodies];Q121874;P527;Q703
[The effect of potassium iodide on the pharmacokinetics of radioactive iodine-labelled antibodies];Q121874;P527;Q1103
Mechanism of antifungal action of potassium iodide on sporotrichosis;Q121874;P527;Q703
[On the effect of potassium iodide on light-enhanced endogenous respiration of algae].;Q121874;P527;Q703
The effect of pre-operative potassium iodide therapy on antibody production;Q121874;P527;Q703
Successful treatment of Pyoderma gangrenosum with potassium iodide;Q121874;P527;Q703
[Influence of dehydrofolliculin, thyroxine and potassium iodide on respiration of some Solanaceae];Q121874;P527;Q703
Formulation and optimization of potassium iodide tablets.;Q121874;P527;Q703
Effect of silver diamine fluoride and potassium iodide on bonding to demineralized dentin;Q121874;P527;Q703
[Research on the effects of antibiotics on pathogenic fungi. III. Experiments on the effect of combined tyrothricin and potassium iodide on various fungi.];Q121874;P527;Q703
[Efficacy of thyroxine and potassium iodide treatment of benign nodular thyroid lesions];Q121874;P527;Q703
125I-fibrinogen: thyroid blocking with 2.5 mg potassium iodide twice daily in patients after hip surgery.;Q121874;P527;Q703
Remission after potassium iodide therapy in patients with Graves' hyperthyroidism exhibiting thionamide-associated side effects;Q121874;P527;Q703
[Treatment of erythema nodosum and vasculitis nodularis using potassium iodide];Q121874;P527;Q703
[Quantitative and qualitative modalities of action of potassium iodide on the thyroid];Q121874;P527;Q703
Transition metal and base free synthesis of 2-aryl-2-oxazolines from aldehydes and -amino alcohols catalysed by potassium iodide;Q121874;P527;Q703
[Results of complex roentgen-free therapy of scalp mycoses with potassium iodide and vitamin A];Q121874;P527;Q703
Indications for using potassium iodide to protect the thyroid from low level internal irradiation;Q121874;P527;Q703
Thyroid failure after potassium iodide treatment of diffuse toxic goiter.;Q121874;P527;Q703
A powerful combination of copper-cysteamine nanoparticles with potassium iodide for bacterial destruction;Q121874;P527;Q703
Mild and efficient oxy-iodination of alkynes and phenols with potassium iodide and tert-butyl hydroperoxide;Q121874;P527;Q703
Mild and efficient oxy-iodination of alkynes and phenols with potassium iodide and tert-butyl hydroperoxide;Q130336;P31;Q407142
[Experience in the treatment of Demodex infection of the face by electrophoresis with potassium iodide solutions];Q121874;P527;Q703
[Blastic transformation of lymphocytes in the presence of potassium iodide];Q121874;P527;Q703
[Leukocyte phagocytic activity in gerbils with experimental sporotrichosis treated with potassium iodide];Q121874;P527;Q703
Risks in mass distribution of potassium iodide;Q121874;P527;Q703
Comment on article entitled "Randomized trial of a short course of preoperative potassium iodide in patients undergoing thyroidectomy for Graves' disease".;Q121874;P527;Q703
Direct emission of I2 molecule and IO radical from the heterogeneous reactions of gaseous ozone with aqueous potassium iodide solution;Q121874;P527;Q703
[Peroxidase activity of thyroid tissue in toxic diffuse goiter. Difference among thyroids administered antithyroid drugs and potassium iodide];Q121874;P527;Q703
[Peroxidase activity of thyroid tissue in toxic diffuse goiter. Difference among thyroids administered antithyroid drugs and potassium iodide];Q121874;P31;Q12140
[Peroxidase activity of thyroid tissue in toxic diffuse goiter. Difference among thyroids administered antithyroid drugs and potassium iodide];Q9358614;P31;Q12140
[Peroxidase activity of thyroid tissue in toxic diffuse goiter. Difference among thyroids administered antithyroid drugs and potassium iodide];Q178450;P31;Q12140
[Peroxidase activity of thyroid tissue in toxic diffuse goiter. Difference among thyroids administered antithyroid drugs and potassium iodide];Q20035886;P31;Q12140
[Release of active substances from ointment bases. The effect of ointment bases on the release of sulfathiazole and potassium iodide from the ointment];Q121874;P527;Q703
Effect of potassium iodide on plasma cholesterol of rats;Q121874;P527;Q703
One on one. I read that potassium iodide can protect me from cancer if I'm exposed to radiation from a nuclear power plant. Should I keep some of these pills on hand?;Q121874;P527;Q703
Properties of Physarum myosin purified by a potassium iodide procedure.;Q121874;P527;Q703
Hypercalcemic effect of potassium iodide on serum calcium in domestic fowl.;Q121874;P527;Q703
Tissue reactions to sodium hypochlorite and iodine potassium iodide under clinical conditions in monkey teeth;Q121874;P527;Q703
Tissue reactions to sodium hypochlorite and iodine potassium iodide under clinical conditions in monkey teeth;Q121874;P527;Q1103
Studies on the carcinogenicity of potassium iodide in F344 rats;Q121874;P527;Q703
Dacryocystitis due to Sporothrix brasiliensis: a case report of a successful clinical and serological outcome with low-dose potassium iodide treatment and oculoplastic surgery.;Q121874;P527;Q703
[Monilial granuloma of the buttocks cured by a combination of isoniazid and potassium iodide];Q121874;P527;Q703
Selective copper(II) acetate and potassium iodide catalyzed oxidation of aminals to dihydroquinazoline and quinazolinone alkaloids.;Q121874;P527;Q703
Assessment of potassium iodide (KI) distribution program among communities within the emergency planning zones (EPZ) of two nuclear power plants.;Q121874;P527;Q703
Iodine in milk and meat of dairy cows fed different amounts of potassium iodide or ethylenediamine dihydroiodide;Q121874;P527;Q703
Intermittent oral administration of potassium iodide solution for the correction of iodine deficiency;Q121874;P527;Q703
Intermittent oral administration of potassium iodide solution for the correction of iodine deficiency;Q121874;P527;Q1103
The antimicrobial effect of calcium hydroxide in root canals pretreated with 5% iodine potassium iodide;Q121874;P527;Q703
The antimicrobial effect of calcium hydroxide in root canals pretreated with 5% iodine potassium iodide;Q121874;P527;Q1103
Caries arrest and lesion appearance using two different silver fluoride therapies on primary teeth with and without potassium iodide: 12-month results;Q121874;P527;Q703
The effect of silver fluoride and potassium iodide on the bond strength of auto cure glass ionomer cement to dentine;Q121874;P527;Q703
An investigation of the inorganic iodine content of the saliva in hyperthyroidism following the administration of potassium iodide, and the effect of 2-thiouracil and 4-methyl thiouracil thereon;Q121874;P527;Q1103
An investigation of the inorganic iodine content of the saliva in hyperthyroidism following the administration of potassium iodide, and the effect of 2-thiouracil and 4-methyl thiouracil thereon;Q121874;P527;Q703
Potentiation by potassium iodide reveals that the anionic porphyrin TPPS4 is a surprisingly effective photosensitizer for antimicrobial photodynamic inactivation.;Q121874;P527;Q703
[Atherosclerosis, potassium iodide and lipid metabolism];Q121874;P527;Q703
[Effect of glutamic acid and potassium iodide on the course of experimental pneumoconiosis caused by coal and nepheline];Q121874;P527;Q703
[Clinical evaluation of intestinal absorption and use of potassium iodide in order to increase effectiveness of therapeutic measures in pneumoconiosis of coal miners].;Q186474;P703;Q177932
[Clinical evaluation of intestinal absorption and use of potassium iodide in order to increase effectiveness of therapeutic measures in pneumoconiosis of coal miners].;Q121874;P527;Q703
Comparison of two functionalized fullerenes for antimicrobial photodynamic inactivation: Potentiation by potassium iodide and photochemical mechanisms;Q121874;P527;Q703
[Chronic primary aspergillosis of the lung: effects of potassium iodide with delta-cortisone.];Q121874;P527;Q703
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by HELM AG;Q218642;P31;Q11173
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by HELM AG;Q183290;P31;Q11173
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by HELM AG;Q191924;P31;Q11173
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by HELM AG;Q485277;P31;Q11173
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by HELM AG;Q121874;P527;Q703
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by HELM AG;Q121874;P527;Q1103
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by HELM AG;Q121874;P31;Q11173
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by HELM AG;Q20817118;P31;Q11173
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by HELM AG;Q22124685;P31;Q11173
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by HELM AG;Q22124685;P366;Q5441186
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by HELM AG;Q422416;P31;Q11173
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by HELM AG;Q620730;P31;Q11173
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by HELM AG;Q483745;P31;Q11173
[Multiple subcutaneous abscess caused by potassium iodide (abscessing panniculitis due to potassium iodide).];Q121874;P527;Q703
Impact of potassium iodide on thyroidectomy for Graves' disease: implications for safety and operative difficulty;Q121874;P527;Q703
[Effect of potassium iodide on the immune response in the sporotrichosis.].;Q121874;P527;Q703
Efficient photodynamic inactivation of Candida albicans by porphyrin and potassium iodide co-encapsulation in micelles;Q186474;P703;Q310443
Efficient photodynamic inactivation of Candida albicans by porphyrin and potassium iodide co-encapsulation in micelles;Q186474;P703;Q83310
Efficient photodynamic inactivation of Candida albicans by porphyrin and potassium iodide co-encapsulation in micelles;Q121874;P527;Q703
Risk of severe allergic reactions from the use of potassium iodide for radiation emergencies;Q121874;P527;Q703
Congress considers stockpiling potassium iodide;Q121874;P527;Q703
[Potassium iodide and methyl antigen in chronic pulmonary tuberculosis after treatment with streptomycin and isoniazid: comparative study and counter-test];Q423169;P2175;Q13046587
[Potassium iodide and methyl antigen in chronic pulmonary tuberculosis after treatment with streptomycin and isoniazid: comparative study and counter-test];Q423169;P2175;Q12204
Acid potassium iodide method for determining atmospheric oxidants;Q121874;P527;Q703
Primary lymphocutaneous nocardiosis due to Nocardia brasiliensis which was successfully treated with only oral potassium iodide;Q121874;P527;Q703
The effect of environmental temperature and potassium iodide supplementation on the excretion of iodine by normal human subjects;Q186521;P703;Q15978631
The effect of environmental temperature and potassium iodide supplementation on the excretion of iodine by normal human subjects;Q121874;P527;Q703
The effect of environmental temperature and potassium iodide supplementation on the excretion of iodine by normal human subjects;Q121874;P527;Q1103
Neutrophil-poor Sweet's syndrome with response to potassium iodide;Q121874;P527;Q703
Effect of potassium iodide on aortic atherosclerosis in rabbits;Q121874;P527;Q703
Assessment of the effects of repeated doses of potassium iodide intake during pregnancy on male and female rat offspring using metabolomics and lipidomics;Q121874;P527;Q703
Prominent facial edema caused by potassium iodide solution in a patient with sporotrichosis.;Q121874;P527;Q703
Resolution concerning the stockpiling of potassium iodide in New York City in the event of a nuclear accident. The Committee on Public Health, The New York Academy of Medicine;Q121874;P527;Q703
Impact of potassium iodide on thyroidectomy for Graves' disease: Implications for safety and operative difficulty.;Q121874;P527;Q703
The effects of storage and of potassium iodide, urea, N-acetyl-cysteine and triton X-100 on the viscosity of bronchial mucus;Q121874;P527;Q703
The attempted treatment of the leukosis complex by intraperitoneal injection of potassium iodide;Q186521;P703;Q177932
The attempted treatment of the leukosis complex by intraperitoneal injection of potassium iodide;Q121874;P527;Q703
Refractory disseminated pyoderma gangrenosum, with dependence on corticosteroids, responding to potassium iodide;Q121874;P527;Q703
Intermittent therapy with potassium iodide in chronic obstructive disease of the airways. A review of 10 years' experience.;Q121874;P527;Q703
[Non-surgical removal of mycotic nails using potassium iodide];Q121874;P527;Q703
Solution complexation between potassium iodide and lariat ethers having pi-donor sidearms.;Q121874;P527;Q703
Pulmonary edema and iododerma induced by potassium iodide in the treatment of asthma;Q121874;P527;Q703
[Potassium iodide and methyl antigen in chronic pulmonary tuberculosis: variation of the number of radiologic and bacilloscopic improvements according to the method of treatment by streptomycin and isoniazid];Q423169;P2175;Q13046587
[Potassium iodide and methyl antigen in chronic pulmonary tuberculosis: variation of the number of radiologic and bacilloscopic improvements according to the method of treatment by streptomycin and isoniazid];Q423169;P2175;Q12204
Randomized trial of a short course of preoperative potassium iodide in patients undergoing thyroidectomy for Graves' disease.;Q121874;P527;Q703
Effect of silver diamine fluoride and potassium iodide on shear bond strength of glass ionomer cements to caries-affected dentine;Q121874;P527;Q703
The use of potassium iodide equilibrium density gradient centrifugation in the purification of RNA for hybridization with nonreiterated DNA sequences.;Q121874;P527;Q703
[Determination of potassium iodide in table salt by means of a reaction between the complex ion of 12C1 and brilliant green.];Q2314;P1889;Q12370
[Determination of potassium iodide in table salt by means of a reaction between the complex ion of 12C1 and brilliant green.];Q2314;P1889;Q11254
[Determination of potassium iodide in table salt by means of a reaction between the complex ion of 12C1 and brilliant green.];Q121874;P527;Q703
Wegener's granulomatosis successfully treated with prednisolone and potassium iodide;Q121874;P527;Q703
Wegener's granulomatosis successfully treated with prednisolone and potassium iodide;Q11426176;P2175;Q1161568
Treatment of granuloma annulare with potassium iodide;Q121874;P527;Q703
Sonochemical reactions at 640 kHz using an efficient reactor. Oxidation of potassium iodide;Q121874;P527;Q703
Longitudinal-optical phonons in thin films of rubidium iodide, potassium iodide, rubidium bromide, cesium iodide, and cesium bromide;Q121874;P527;Q703
Action of potassium iodide on thyroid acid protease;Q121874;P527;Q703
The combined effect of potassium iodide and streptomycin on far advanced chronic pulmonary tuberculosis;Q121874;P527;Q703
Synergistic effect of potassium iodide with phthalazone on the corrosion inhibition of mild steel in 1.0M HCl;Q121874;P527;Q703
[Effect of the excipient on the percutaneous resorption of potassium iodide & an organic iodine compound (iothion)];Q121874;P527;Q1103
[Effect of the excipient on the percutaneous resorption of potassium iodide & an organic iodine compound (iothion)];Q121874;P527;Q703
[Effect of the excipient on the percutaneous resorption of potassium iodide & an organic iodine compound (iothion)];Q121874;P31;Q11173
The Wolff-Chaikoff effect: hypothyroidism due to potassium iodide;Q121874;P527;Q703
Treatment of acute febrile neutrophilic dermatosis (Sweet's Syndrome) with potassium iodide;Q121874;P527;Q703
[Erythema nodosum. Treatment with potassium iodide];Q121874;P527;Q703
Treatment of hyperthyroidism with potassium iodide;Q121874;P527;Q703
Evaluation of potassium iodide prophylaxis knowledge and nuclear emergency preparedness: New Jersey 2005;Q121874;P527;Q703
Potentiometric titration of gold in ores with potassium iodide;Q121874;P527;Q703
The potassium iodide method for determining protection factors in open-fronted microbiological safety cabinets;Q121874;P527;Q703
[Experimental studies of skin sensitivity to potassium iodide in normal subjects, in dermatitis herpetiformis and pemphigus];Q121874;P527;Q703
Editorial: The use of potassium iodide in Graves' disease.;Q121874;P527;Q703
Hyperthyroidism induced by potassium iodide given in the course of 125I-fibrinogen test;Q121874;P527;Q703
[Determination of iodine and potassium iodide in iodine tincture according to the 6th issue of German pharmacopeia: hydrazine method];Q121874;P527;Q703
[Determination of iodine and potassium iodide in iodine tincture according to the 6th issue of German pharmacopeia: hydrazine method];Q121874;P527;Q1103
[Study on the stability of potassium iodide of the iodized salt];Q2314;P1889;Q11254
[Study on the stability of potassium iodide of the iodized salt];Q121874;P527;Q703
Physiological basis for the use of potassium iodide as a thyroid blocking agent logistic issues in its distribution;Q121874;P527;Q703
The role of desiccated thyroid and potassium iodide in the cholesterol-induced atherosclerosis of the chicken;Q121874;P527;Q703
[Effects of chronic administration of high doses of potassium iodide on iodine metabolism in the rat thyroid gland];Q121874;P527;Q703
[Effects of chronic administration of high doses of potassium iodide on iodine metabolism in the rat thyroid gland];Q121874;P527;Q1103
Controlling the crystal growth of potassium iodide with a 1,1-bis(pyridin-4-ylmethyl)-2,2-biimidazole ligand (L)  formation of a linear [K4I4L4]n polymer with cubic [K4I4] core units;Q121874;P527;Q703
Haematological staining methods using potassium iodide;Q121874;P527;Q703
A theory of thyroid hormone action derived from the differences in the effect of sodium-levothyroxine, sodium dextro-thyroxine, tri-iodothyronine, and potassium iodide on the uptake of radioactive iodine by the thyroid gland of normal human subjects;Q218642;P703;Q15978631
A theory of thyroid hormone action derived from the differences in the effect of sodium-levothyroxine, sodium dextro-thyroxine, tri-iodothyronine, and potassium iodide on the uptake of radioactive iodine by the thyroid gland of normal human subjects;Q121874;P527;Q703
A theory of thyroid hormone action derived from the differences in the effect of sodium-levothyroxine, sodium dextro-thyroxine, tri-iodothyronine, and potassium iodide on the uptake of radioactive iodine by the thyroid gland of normal human subjects;Q121874;P527;Q1103
[Effectiveness of potassium iodide in ovarian cysts in cows];Q121874;P527;Q703
Effects of potassium iodide on low avid immunological reactions: probable mechanism of action on selective fungal infections;Q121874;P527;Q703
Radiosensitization with iodine compounds. 3. Macromolecular synthesis and repair in Bacillus subtilis irradiated in the presence of iodoacetic acid, potassium iodide or potassium iodate;Q23118;P31;Q11173
Radiosensitization with iodine compounds. 3. Macromolecular synthesis and repair in Bacillus subtilis irradiated in the presence of iodoacetic acid, potassium iodide or potassium iodate;Q121874;P527;Q703
Radiosensitization with iodine compounds. 3. Macromolecular synthesis and repair in Bacillus subtilis irradiated in the presence of iodoacetic acid, potassium iodide or potassium iodate;Q121874;P527;Q1103
Radiosensitization with iodine compounds. 3. Macromolecular synthesis and repair in Bacillus subtilis irradiated in the presence of iodoacetic acid, potassium iodide or potassium iodate;Q121874;P31;Q11173
Radiosensitization with iodine compounds. 3. Macromolecular synthesis and repair in Bacillus subtilis irradiated in the presence of iodoacetic acid, potassium iodide or potassium iodate;Q173670;P31;Q11173
Radiosensitization with iodine compounds. 3. Macromolecular synthesis and repair in Bacillus subtilis irradiated in the presence of iodoacetic acid, potassium iodide or potassium iodate;Q22124685;P31;Q11173
Administration of potassium iodide to normal volunteers does not increase killing of Sporothrix schenckii by their neutrophils or monocytes;Q121874;P527;Q703
The Remarkable Effect of Potassium Iodide in Eosin and Rose Bengal Photodynamic Action against Salmonella Typhimurium and Staphylococcus aureus;Q218642;P703;Q188121
The Remarkable Effect of Potassium Iodide in Eosin and Rose Bengal Photodynamic Action against Salmonella Typhimurium and Staphylococcus aureus;Q183290;P703;Q188121
The Remarkable Effect of Potassium Iodide in Eosin and Rose Bengal Photodynamic Action against Salmonella Typhimurium and Staphylococcus aureus;Q186521;P703;Q188121
The Remarkable Effect of Potassium Iodide in Eosin and Rose Bengal Photodynamic Action against Salmonella Typhimurium and Staphylococcus aureus;Q20035886;P703;Q188121
The Remarkable Effect of Potassium Iodide in Eosin and Rose Bengal Photodynamic Action against Salmonella Typhimurium and Staphylococcus aureus;Q484940;P703;Q188121
Potassium iodide, but not potassium iodate, as a potential protective agent against oxidative damage to membrane lipids in porcine thyroid.;Q121874;P527;Q703
Consideration of potassium iodide in emergency plans.  Nuclear Regulatory Commission.  Final rule;Q121874;P527;Q703
A procedure for simultaneous preparation of large amounts of DNA and RNA by the use of potassium iodide gradients.;Q121874;P527;Q703
[Novel approaches in the therapy of leprosy: preliminary results with small doses of streptomycin by intradermal injection, either by itself or with PAS, or potassium iodide];Q121874;P527;Q703
Therapeutic efficacy and limitations of potassium iodide for patients newly diagnosed with Graves' disease;Q186521;P703;Q177932
Therapeutic efficacy and limitations of potassium iodide for patients newly diagnosed with Graves' disease;Q121874;P527;Q703
Therapeutic efficacy and limitations of potassium iodide for patients newly diagnosed with Graves' disease;Q620730;P703;Q177932
Developmental toxicity and psychotoxicity of potassium iodide in rats: a case for the inclusion of behaviour in toxicological assessment.;Q121874;P527;Q703
The Effect of Intraperitoneal Injection of Potassium Iodide on the Proliferative Activity of the Thyroid Gland in Guinea Pigs.;Q218642;P703;Q177932
The Effect of Intraperitoneal Injection of Potassium Iodide on the Proliferative Activity of the Thyroid Gland in Guinea Pigs.;Q186521;P703;Q177932
The Effect of Intraperitoneal Injection of Potassium Iodide on the Proliferative Activity of the Thyroid Gland in Guinea Pigs.;Q20035886;P703;Q177932
The Effect of Intraperitoneal Injection of Potassium Iodide on the Proliferative Activity of the Thyroid Gland in Guinea Pigs.;Q620730;P703;Q177932
The Effect of Intraperitoneal Injection of Potassium Iodide on the Proliferative Activity of the Thyroid Gland in Guinea Pigs.;Q484940;P703;Q177932
[Refractometric determination of glucose and potassium iodide in some complex prescriptions for eye drops];Q121874;P527;Q703
[Phonophoresis of fibrinolysin and potassium iodide in complex treatment of hemophthalmos];Q121874;P527;Q703
Successful therapy of refractory erythema nodosum associated with Crohn's disease using potassium iodide;Q121874;P527;Q703
[Combination of streptomycin, isoniazid and potassium iodide in therapy of experimental tuberculosis in guinea pigs.];Q121874;P527;Q703
[Combination of streptomycin, isoniazid and potassium iodide in therapy of experimental tuberculosis in guinea pigs.];Q423169;P2175;Q12204
Rhinofacial zygomycosis successfully treated with oral saturated solution of potassium iodide: a case report;Q121874;P527;Q703
Cutaneous sporotrichosis treatment with potassium iodide: a 24 year experience in So Paulo State, Brazil.;Q121874;P527;Q703
The effect of potassium iodide, sodium iodide, and iodethamine upon the concentration of alcohol-soluble and alcohol-insoluble fractions of blood iodine;Q121874;P527;Q703
The effect of potassium iodide, sodium iodide, and iodethamine upon the concentration of alcohol-soluble and alcohol-insoluble fractions of blood iodine;Q121874;P527;Q1103
Sensitivity of potassium iodide for hematologic staining;Q121874;P527;Q703
Reduction of thyroid irradiation from 131-I by potassium iodide;Q121874;P527;Q703
[Treatment of ulcero-membranous gingivo-stomatitis. Periodontitis or inflammatory gingivitis--aphthous pericoronitis with potassium iodide in combination with hydrogen peroxide];Q121874;P527;Q703
Conclusion on the peer review of the pesticide risk assessment of the active substance potassium iodide;Q121874;P527;Q703
The treatment of tinea capitis with oral potassium iodide;Q121874;P527;Q703
[Combination of PAS with isoniazid and potassium iodide in therapy of experimental tuberculosis in guinea pigs];Q121874;P527;Q703
[Combination of PAS with isoniazid and potassium iodide in therapy of experimental tuberculosis in guinea pigs];Q229924;P2175;Q12204
[Combination of PAS with isoniazid and potassium iodide in therapy of experimental tuberculosis in guinea pigs];Q423169;P2175;Q12204
[Reactions of some alkaloids with iodine dissolved in potassium iodide solutions and the determination of iodination products];Q121874;P527;Q703
[Reactions of some alkaloids with iodine dissolved in potassium iodide solutions and the determination of iodination products];Q121874;P527;Q1103
Effect of potassium iodide on relapse-rate of thyrotoxicosis treated with antithyroid drugs;Q121874;P527;Q703
Effect of potassium iodide on relapse-rate of thyrotoxicosis treated with antithyroid drugs;Q121874;P31;Q12140
Effect of potassium iodide on relapse-rate of thyrotoxicosis treated with antithyroid drugs;Q9358614;P31;Q12140
Granulomatous vasculitis as a complication of potassium iodide treatment for Sweet's syndrome.;Q121874;P527;Q703
The formation of thyroid hormones in vivo after the administration of I-131 labelled potassium iodide and thyrotropic hormone.;Q121874;P527;Q703
Antimicrobial photodynamic therapy mediated by methylene blue and potassium iodide to treat urinary tract infection in a female rat model.;Q121874;P527;Q703
Radio-sensitization with iodine compounds. I. Examination of damage in deoxyribonucleic acid with Bacillus subtilis transformation system by irradiation in the presence of potassium iodide;Q23118;P31;Q11173
Radio-sensitization with iodine compounds. I. Examination of damage in deoxyribonucleic acid with Bacillus subtilis transformation system by irradiation in the presence of potassium iodide;Q121874;P527;Q1103
Radio-sensitization with iodine compounds. I. Examination of damage in deoxyribonucleic acid with Bacillus subtilis transformation system by irradiation in the presence of potassium iodide;Q121874;P527;Q703
Radio-sensitization with iodine compounds. I. Examination of damage in deoxyribonucleic acid with Bacillus subtilis transformation system by irradiation in the presence of potassium iodide;Q121874;P31;Q11173
Radio-sensitization with iodine compounds. I. Examination of damage in deoxyribonucleic acid with Bacillus subtilis transformation system by irradiation in the presence of potassium iodide;Q173670;P31;Q11173
Radio-sensitization with iodine compounds. I. Examination of damage in deoxyribonucleic acid with Bacillus subtilis transformation system by irradiation in the presence of potassium iodide;Q484940;P31;Q11173
A potassium iodide stimulated peroxidase from goat submaxillary gland;Q121874;P527;Q703
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all animal species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by Ajay Europe SARL;Q218642;P31;Q11173
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all animal species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by Ajay Europe SARL;Q183290;P31;Q11173
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all animal species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by Ajay Europe SARL;Q191924;P31;Q11173
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all animal species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by Ajay Europe SARL;Q121874;P527;Q703
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all animal species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by Ajay Europe SARL;Q121874;P527;Q1103
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all animal species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by Ajay Europe SARL;Q121874;P31;Q11173
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all animal species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by Ajay Europe SARL;Q173670;P31;Q11173
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all animal species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by Ajay Europe SARL;Q20817118;P31;Q11173
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all animal species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by Ajay Europe SARL;Q422416;P31;Q11173
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all animal species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by Ajay Europe SARL;Q423423;P31;Q11173
Scientific Opinion on the safety and efficacy of iodine compounds (E2) as feed additives for all animal species: calcium iodate anhydrous and potassium iodide, based on a dossier submitted by Ajay Europe SARL;Q483745;P31;Q11173
Potassium perchlorate, potassium iodide, and propylthiouracil: promoting effect on the development of thyroid tumors in rats treated with N-bis(2-hydroxypropyl)-nitrosamine.;Q121874;P527;Q703
Colorimetric detection of peptides with tert.-butyl hypochlorite and potassium iodide;Q121874;P527;Q703
[Effect of potassium iodide and perchlorate on the process of thyroid hormone secretion];Q121874;P527;Q703
[Combination of thiosemicarbazone with isoniazid and potassium iodide in therapy of experimental tuberculosis in guinea pig.];Q121874;P527;Q703
[Combination of thiosemicarbazone with isoniazid and potassium iodide in therapy of experimental tuberculosis in guinea pig.];Q423169;P2175;Q12204
[A simplified method for the determination of potassium iodide in kitchen salt with the aid of a new iodine reaction];Q2314;P1889;Q12370
[A simplified method for the determination of potassium iodide in kitchen salt with the aid of a new iodine reaction];Q121874;P527;Q1103
[A simplified method for the determination of potassium iodide in kitchen salt with the aid of a new iodine reaction];Q121874;P527;Q703
The effect of galvanization and potassium iodide iontophoresis of the throat and larynx on thyroid parameters: a randomized controlled trial;Q121874;P527;Q703
The antibacterial efficacy of silver diamine fluoride (SDF) is not modulated by potassium iodide (KI) supplements: A study on in-situ plaque biofilms using viability real-time PCR with propidium monoazide;Q121874;P527;Q703
Caries arrest and lesion appearance using two different silver fluoride therapies with and without potassium iodide: 6-month results;Q121874;P527;Q703
The potassium iodide patch test in the dermatitis herpetiformis in relation to treatment with a gluten-free diet and dapsone;Q121874;P527;Q703
The potassium iodide patch test in the dermatitis herpetiformis in relation to treatment with a gluten-free diet and dapsone;Q422226;P2175;Q1151507
[Attempted therapy of experimental tuberculosis in white mice with streptomycin associated with potassium iodide];Q121874;P527;Q703
[Determination of potassium iodide in Polish edible salt];Q2314;P1889;Q11254
[Determination of potassium iodide in Polish edible salt];Q121874;P527;Q703
[Follicular pustules in potassium iodide patch-test-reactions];Q121874;P527;Q703
Synergistic inhibition effect of potassium iodide and novel Schiff bases on X65 steel corrosion in 0.5M H2SO4;Q121874;P527;Q703
[Use of general galvano-ionization with potassium iodide and magnesium sulfate in hypertension in aged in conditions of a policlinic];Q288266;P527;Q660
[Use of general galvano-ionization with potassium iodide and magnesium sulfate in hypertension in aged in conditions of a policlinic];Q121874;P527;Q703
[Evaluation of potassium iodide in Polish dietary salt];Q2314;P1889;Q12370
[Evaluation of potassium iodide in Polish dietary salt];Q2314;P1889;Q11254
[Evaluation of potassium iodide in Polish dietary salt];Q121874;P527;Q703
[Positive reaction of patch tests to potassium iodide in pemphigus foliaceus.];Q121874;P527;Q703
[Regeneration of used mercuric and potassium iodide for an economical use in egg-counts routines (author's transl)];Q121874;P527;Q703
Calorimetric studies of the interactions of guanidinium hydrochloride and potassium iodide with model amides in aqueous solution.;Q121874;P527;Q703
Effect of varying dosages of potassium iodide in experimental atherosclerosis;Q121874;P527;Q703
Effects of short-term potassium iodide treatment for thyrotoxicosis due to Graves disease in children and adolescents;Q121874;P527;Q703
Percutaneous absorption of mercuric chloride in guinea-pigs. Effect of potassium iodide and the pretreatment of the skin with irritant concentrations of mercury.;Q121874;P527;Q703
Analytical applications of condensed phosphoric acid-III Iodometric determination of sulphur after reduction of sulphate with sodium hypophosphite and either tin metal or potassium iodide in condensed phosphoric acid;Q121874;P527;Q703
Long-path infrared spectroscopic investigation at ambient concentrations of the 2% neutral buffered potassium iodide method for determination of ozone.;Q121874;P527;Q703
Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking.;Q121874;P527;Q703
Repeated potassium iodide exposure during pregnancy impairs progeny's brain development;Q121874;P527;Q703
[Determination of potassium iodide and hydroiodic acid in iodine tincture];Q121874;P527;Q703
[Determination of potassium iodide and hydroiodic acid in iodine tincture];Q121874;P527;Q1103
Failure to reach euthyroidism with potassium iodide and propranolol in preparation of patient with Graves' disease for surgery;Q121874;P527;Q703
Thyroid dose estimation with potassium iodide (KI) administration in a nuclear emergency;Q121874;P527;Q703
Oral potassium iodide for the treatment of sporotrichosis.;Q121874;P527;Q703
Erythema annulare centrifugum-like neutrophilic dermatosis: effects of potassium iodide;Q121874;P527;Q703
Multiple subcutaneous mycetomas caused by Pseudallescheria boydii: response to therapy with oral potassium iodide solution;Q121874;P527;Q703
Effects of time of administration and dietary iodine levels on potassium iodide (KI) blockade of thyroid irradiation by 131I from radioactive fallout;Q121874;P527;Q703
Effects of time of administration and dietary iodine levels on potassium iodide (KI) blockade of thyroid irradiation by 131I from radioactive fallout;Q121874;P527;Q1103
A prospective case series evaluating efficacy and safety of combination of itraconazole and potassium iodide in rhinofacial conidiobolomycosis.;Q121874;P527;Q703
[Research on the effect of antibiotics on pathogenic fungi.  IV.  Antimycotic activity of antibiotics and drugs, alone and combined with potassium iodide];Q218642;P31;Q12140
[Research on the effect of antibiotics on pathogenic fungi.  IV.  Antimycotic activity of antibiotics and drugs, alone and combined with potassium iodide];Q12187;P279;Q12140
[Research on the effect of antibiotics on pathogenic fungi.  IV.  Antimycotic activity of antibiotics and drugs, alone and combined with potassium iodide];Q121874;P527;Q703
[Research on the effect of antibiotics on pathogenic fungi.  IV.  Antimycotic activity of antibiotics and drugs, alone and combined with potassium iodide];Q121874;P31;Q12140
[Research on the effect of antibiotics on pathogenic fungi.  IV.  Antimycotic activity of antibiotics and drugs, alone and combined with potassium iodide];Q173670;P31;Q12140
[Research on the effect of antibiotics on pathogenic fungi.  IV.  Antimycotic activity of antibiotics and drugs, alone and combined with potassium iodide];Q483752;P31;Q12140
[Research on the effect of antibiotics on pathogenic fungi.  IV.  Antimycotic activity of antibiotics and drugs, alone and combined with potassium iodide];Q484940;P31;Q12140
National surveillance for radiological exposures and intentional potassium iodide and iodine product ingestions in the United States associated with the 2011 Japan radiological incident.;Q121874;P527;Q703
National surveillance for radiological exposures and intentional potassium iodide and iodine product ingestions in the United States associated with the 2011 Japan radiological incident.;Q121874;P527;Q1103
Metabolic, isotopic, and pathological differences between sodium-5-iodo-2-thiouracil and thiouracil plus potassium iodide;Q121874;P527;Q703
[Thyroidal autoregulation in nontoxic goiter patients: normalization of the T3/T4 ratio in serum by treatment with potassium iodide (author's transl)].;Q327362;P2175;Q165135
[Thyroidal autoregulation in nontoxic goiter patients: normalization of the T3/T4 ratio in serum by treatment with potassium iodide (author's transl)].;Q121874;P527;Q703
[Thyroidal autoregulation in nontoxic goiter patients: normalization of the T3/T4 ratio in serum by treatment with potassium iodide (author's transl)].;Q773449;P2175;Q165135
Cytochemical identification of turbot myeloperoxidase-positive granulocytes by potassium iodide and oxidized pyronine Y staining.;Q121874;P527;Q703
Effects of theophylline-alcohol with potassium iodide in asthmatic patients;Q407308;P2175;Q35869
Effects of theophylline-alcohol with potassium iodide in asthmatic patients;Q121874;P527;Q703
[The test with potassium iodide in the differentiation of some forms of bronchial asthma.];Q121874;P527;Q703
Tuberculous meningitis in children treated with combined streptomycin and potassium iodide;Q121874;P527;Q703
[Early clinical findings on the use of P.A.S. associated with potassium iodide in cases of tuberculosis in children];Q121874;P527;Q703
[Clinical and metabolic response in goats with iodopenia after administration of potassium iodide];Q121874;P527;Q703
[Photochemiluminescence of tryptophan-containing peptides and proteins during photooxidation. 3. Effect of oxygen and potassium iodide on the photochemiluminescence of glycyltryptophan solutions];Q121874;P527;Q703
The effect of various concentrations of iodine potassium iodide on the antimicrobial properties of mineral trioxide aggregate--a pilot study.;Q121874;P527;Q703
The effect of various concentrations of iodine potassium iodide on the antimicrobial properties of mineral trioxide aggregate--a pilot study.;Q121874;P527;Q1103
Nuclear detonation, thyroid cancer and potassium iodide prophylaxis;Q121874;P527;Q703
Potassium iodide and acrylamide fluorescence quenching studies on gamma-crystallins of human lenses in development and aging;Q20035886;P703;Q15978631
Metabolism of ethylenediaminedihydriodide and sodium or potassium iodide by dairy cows;Q121874;P527;Q703
Effects of potassium iodide on aspartate aminotransferase.;Q121874;P527;Q703
[Chromoblastomycosis. Treatment of a case with potassium iodide and calciferol.];Q121874;P527;Q703
EFFECT of potassium iodide on lactation;Q121874;P527;Q703
Translation of specific vaccinia virus RNAs purified as RNA-DNA hybrids on potassium iodide gradients;Q121874;P527;Q703
Final recommendations issued on potassium iodide;Q121874;P527;Q703
Synthesis of sulfonated oxindoles by potassium iodide catalyzed arylsulfonylation of activated alkenes with sulfonylhydrazides in water.;Q121874;P527;Q703
Synthesis of sulfonated oxindoles by potassium iodide catalyzed arylsulfonylation of activated alkenes with sulfonylhydrazides in water.;Q29053744;P366;Q7892
[Double-blind study on the effectiveness of potassium iodide in the treatment of senile cataract];Q121874;P527;Q703
The role of potassium iodide in asthmatic children;Q121874;P527;Q703
[Restoration of cardiac function following its arrest induced by potassium iodide after stimulation of the vagus nerve];Q121874;P527;Q703
[Effect of streptomycin or isonicotinic and hydrazide with potassium iodide and methyl antigen on pulmonary foci of chronic tuberculosis];Q121874;P527;Q703
Use of potassium iodide in deep mycosis;Q121874;P527;Q703
[Congenital struma caused by use of potassium iodide during pregnancy];Q121874;P527;Q703
Palmoplantar pustulosis and pustulotic arthro-osteitis treatment with potassium iodide and tetracycline, a novel remedy with an old drug: a review of 25 patients.;Q193045;P31;Q12140
Palmoplantar pustulosis and pustulotic arthro-osteitis treatment with potassium iodide and tetracycline, a novel remedy with an old drug: a review of 25 patients.;Q121874;P527;Q703
Palmoplantar pustulosis and pustulotic arthro-osteitis treatment with potassium iodide and tetracycline, a novel remedy with an old drug: a review of 25 patients.;Q121874;P31;Q12140
Palmoplantar pustulosis and pustulotic arthro-osteitis treatment with potassium iodide and tetracycline, a novel remedy with an old drug: a review of 25 patients.;Q20035886;P31;Q12140
Transient myxedema produced by prolonged ingestion of saturated solution of potassium iodide;Q121874;P527;Q703
Nuclear power plant emergency preparedness: results from an evaluation of Michigan's potassium iodide distribution program;Q121874;P527;Q703
Clinical experience of treating Graves' hyperthyroidism complicated with malignancy-The possible role of potassium iodide for avoiding the risk of thionamide-associated neutropenia;Q121874;P527;Q703
Does potassium iodide application following silver diamine fluoride reduce staining of tooth? A systematic review;Q121874;P527;Q703
Radioactive iodide (131 I-) excretion profiles in response to potassium iodide (KI) and ammonium perchlorate (NH4ClO4) prophylaxis.;Q121874;P527;Q703
Synthesis of cyclic carbonates from epoxides and CO2 catalyzed by potassium iodide and amino alcohols;Q153;P2670;Q623
Synthesis of cyclic carbonates from epoxides and CO2 catalyzed by potassium iodide and amino alcohols;Q183290;P527;Q623
Synthesis of cyclic carbonates from epoxides and CO2 catalyzed by potassium iodide and amino alcohols;Q186474;P527;Q623
Synthesis of cyclic carbonates from epoxides and CO2 catalyzed by potassium iodide and amino alcohols;Q121874;P527;Q703
Dynamical properties of iodine release in potassium iodide solution under combination of ultrasound and light irradiations;Q121874;P527;Q703
Dynamical properties of iodine release in potassium iodide solution under combination of ultrasound and light irradiations;Q121874;P527;Q1103
Monensin and verapamil do not alter intracellular localisation of daunorubicin in multidrug resistant human KB cells;Q410291;P31;Q12140
Monensin and verapamil do not alter intracellular localisation of daunorubicin in multidrug resistant human KB cells;Q411659;P31;Q12140
Monensin and verapamil do not alter intracellular localisation of daunorubicin in multidrug resistant human KB cells;Q20816880;P703;Q15978631
Monensin and verapamil do not alter intracellular localisation of daunorubicin in multidrug resistant human KB cells;Q20816880;P31;Q12140
Monensin and verapamil do not alter intracellular localisation of daunorubicin in multidrug resistant human KB cells;Q22124685;P31;Q12140
Monensin and verapamil do not alter intracellular localisation of daunorubicin in multidrug resistant human KB cells;Q22124685;P703;Q15978631
Cardio-toxicity of Daunomycin and Adriamycin.;Q18936;P3780;Q47520887
Adriamycin and daunomycin semiquinone membrane/buffer partition constants using the spin-broadening technique;Q18936;P3780;Q47520887
Treatment of adult acute non-lymphoblastic leukemia using intermittent combination chemotherapy with daunomycin, cytosine arabinoside, 6-mercaptopurine and prednisolone-DCMP two step therapy;Q180983;P2175;Q29496
Treatment of adult acute non-lymphoblastic leukemia using intermittent combination chemotherapy with daunomycin, cytosine arabinoside, 6-mercaptopurine and prednisolone-DCMP two step therapy;Q186474;P1889;Q178425
Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.;Q186474;P31;Q12140
Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.;Q411659;P31;Q12140
Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.;Q1063862;P31;Q12140
Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.;Q483745;P31;Q12140
Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.;Q483752;P31;Q12140
Protein kinase C isoforms in multidrug resistant P388/ADR cells: a possible role in daunorubicin transport.;Q218642;P31;Q12140
Protein kinase C isoforms in multidrug resistant P388/ADR cells: a possible role in daunorubicin transport.;Q186474;P31;Q12140
Protein kinase C isoforms in multidrug resistant P388/ADR cells: a possible role in daunorubicin transport.;Q411659;P31;Q12140
Protein kinase C isoforms in multidrug resistant P388/ADR cells: a possible role in daunorubicin transport.;Q411659;P361;Q22290410
Protein kinase C isoforms in multidrug resistant P388/ADR cells: a possible role in daunorubicin transport.;Q173670;P31;Q12140
Protein kinase C isoforms in multidrug resistant P388/ADR cells: a possible role in daunorubicin transport.;Q178450;P31;Q12140
Protein kinase C isoforms in multidrug resistant P388/ADR cells: a possible role in daunorubicin transport.;Q20035886;P31;Q12140
A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncolog;Q180983;P2175;Q29496
A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncolog;Q408977;P2175;Q29496
A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncolog;Q408977;P2175;Q18553852
Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cells.;Q258450;P31;Q12140
Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cells.;Q411659;P31;Q12140
Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cells.;Q20035886;P31;Q12140
Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cells.;Q620730;P31;Q12140
Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cells.;Q484940;P31;Q12140
Cytotoxicity of daunorubicin in trisomic (+21) human fibroblasts: relation to drug uptake and cell membrane fluidity;Q186474;P31;Q12140
Cytotoxicity of daunorubicin in trisomic (+21) human fibroblasts: relation to drug uptake and cell membrane fluidity;Q186474;P703;Q15978631
Cytotoxicity of daunorubicin in trisomic (+21) human fibroblasts: relation to drug uptake and cell membrane fluidity;Q411659;P31;Q12140
Cytotoxicity of daunorubicin in trisomic (+21) human fibroblasts: relation to drug uptake and cell membrane fluidity;Q413961;P31;Q12140
Cytotoxicity of daunorubicin in trisomic (+21) human fibroblasts: relation to drug uptake and cell membrane fluidity;Q420439;P31;Q12140
Relationship between the intracellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia.;Q411659;P31;Q109603820
P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport.;Q153;P31;Q12140
P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport.;Q411659;P31;Q12140
P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport.;Q411659;P361;Q22290410
P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for a saturation of active daunorubicin transport.;Q20035886;P31;Q12140
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia;Q180983;P2175;Q264118
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia;Q411659;P2175;Q264118
Proceedings: Daunorubicin cardiac toxicity in children with acute lymphocytic leukemia.;Q411659;P2175;Q6708277
Association of daunorubicin to a lipid nanoemulsion that binds to low-density lipoprotein receptors enhances the antitumour action and decreases the toxicity of the drug in melanoma-bearing mice.;Q218642;P31;Q12140
Association of daunorubicin to a lipid nanoemulsion that binds to low-density lipoprotein receptors enhances the antitumour action and decreases the toxicity of the drug in melanoma-bearing mice.;Q411659;P31;Q12140
Association of daunorubicin to a lipid nanoemulsion that binds to low-density lipoprotein receptors enhances the antitumour action and decreases the toxicity of the drug in melanoma-bearing mice.;Q191924;P366;Q8386
[In vitro changes in the lens epithelium and corneal endothelium caused by the cytostatic drug daunomycin];Q411659;P31;Q12140
[In vitro changes in the lens epithelium and corneal endothelium caused by the cytostatic drug daunomycin];Q484940;P31;Q12140
Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.;Q183290;P31;Q12140
Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.;Q186474;P31;Q12140
Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.;Q411659;P31;Q12140
Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.;Q192717;P31;Q12140
Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.;Q173670;P31;Q12140
Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.;Q19856779;P31;Q12140
Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.;Q22124685;P31;Q12140
Antimicrobial activities of daunorubicin and adriamycin derivatives on bacterial and protoplast type L-form cells of Bacillus subtilis 170, Escherichia coli B, and Proteus mirabilis VI. Structure--activity relationship;Q218642;P703;Q25419
Antimicrobial activities of daunorubicin and adriamycin derivatives on bacterial and protoplast type L-form cells of Bacillus subtilis 170, Escherichia coli B, and Proteus mirabilis VI. Structure--activity relationship;Q183290;P703;Q25419
Antimicrobial activities of daunorubicin and adriamycin derivatives on bacterial and protoplast type L-form cells of Bacillus subtilis 170, Escherichia coli B, and Proteus mirabilis VI. Structure--activity relationship;Q20035886;P703;Q25419
Antimicrobial activities of daunorubicin and adriamycin derivatives on bacterial and protoplast type L-form cells of Bacillus subtilis 170, Escherichia coli B, and Proteus mirabilis VI. Structure--activity relationship;Q483745;P703;Q25419
Antimicrobial activities of daunorubicin and adriamycin derivatives on bacterial and protoplast type L-form cells of Bacillus subtilis 170, Escherichia coli B, and Proteus mirabilis VI. Structure--activity relationship;Q483752;P703;Q25419
Antimicrobial activities of daunorubicin and adriamycin derivatives on bacterial and protoplast type L-form cells of Bacillus subtilis 170, Escherichia coli B, and Proteus mirabilis VI. Structure--activity relationship;Q484940;P703;Q25419
Interaction of daunomycin antibiotic with human serum albumin: investigation by resonant mirror biosensor technique, fluorescence spectroscopy and molecular modeling methods.;Q484940;P703;Q15978631
A novel extracellular protein of Streptomyces peucetius binds to daunorubicin but does not inhibit the bioactivity of the antibiotic.;Q218642;P703;Q1144013
A novel extracellular protein of Streptomyces peucetius binds to daunorubicin but does not inhibit the bioactivity of the antibiotic.;Q411659;P703;Q1144013
A novel extracellular protein of Streptomyces peucetius binds to daunorubicin but does not inhibit the bioactivity of the antibiotic.;Q411659;P703;Q7623394
Isolation of a chitinase overproducing mutant of Streptomyces peucetius defective in daunorubicin biosynthesis.;Q411659;P361;Q22277880
Isolation of a chitinase overproducing mutant of Streptomyces peucetius defective in daunorubicin biosynthesis.;Q411659;P703;Q1144013
Isolation of a chitinase overproducing mutant of Streptomyces peucetius defective in daunorubicin biosynthesis.;Q411659;P703;Q7623394
Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system.;Q411659;P31;Q12140
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study;Q180983;P2175;Q29496
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study;Q180983;P2175;Q264118
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study;Q411659;P2175;Q264118
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study;Q239426;P2175;Q264118
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study;Q418817;P2175;Q264118
MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin;Q411659;P2175;Q264118
In vitro cytotoxicity of the LDE: daunorubicin complex in acute myelogenous leukemia blast cells;Q411659;P2175;Q264118
Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia;Q180983;P2175;Q29496
Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia;Q180983;P2175;Q264118
Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia;Q411659;P2175;Q264118
Inhibition of thymidylate synthase in intact L1210 cells by ara-C, daunomycin, hydroxyurea and 3,4-dihydroxybenzylamine;Q212272;P279;Q48318
Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia;Q218642;P31;Q407595
Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia;Q411659;P2175;Q264118
High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission;Q180983;P2175;Q29496
High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission;Q180983;P2175;Q264118
High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission;Q411659;P2175;Q264118
A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.;Q218642;P31;Q12140
A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.;Q411659;P31;Q12140
[Daunomycin and rubidomycin (new antiblastic drugs)];Q411659;P31;Q12140
[Daunomycin and rubidomycin (new antiblastic drugs)];Q178450;P31;Q12140
Reversal of daunomycin and vinblastine resistance in multidrug-resistant P388 leukemia in vitro through enhanced cytotoxicity by triterpenoids.;Q411659;P31;Q12140
Reversal of daunomycin and vinblastine resistance in multidrug-resistant P388 leukemia in vitro through enhanced cytotoxicity by triterpenoids.;Q173670;P31;Q12140
Reversal of daunomycin and vinblastine resistance in multidrug-resistant P388 leukemia in vitro through enhanced cytotoxicity by triterpenoids.;Q20035886;P31;Q12140
Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia;Q180983;P2175;Q29496
Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia;Q186474;P1889;Q178425
Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia;Q411659;P2175;Q6708277
Anthracyclic products from Streptomyces erythromogenes nov. sp. Biotransformation of daunomycin (Dn) by an acellular preparation and synergism between Dn and some known antibiotics;Q218642;P703;Q1144013
Anthracyclic products from Streptomyces erythromogenes nov. sp. Biotransformation of daunomycin (Dn) by an acellular preparation and synergism between Dn and some known antibiotics;Q411659;P703;Q1144013
Curcumin is a tight-binding inhibitor of the most efficient human daunorubicin reductase--Carbonyl reductase 1.;Q186474;P703;Q15978631
Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia.;Q180983;P2175;Q264118
Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia.;Q180983;P2175;Q29496
Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia.;Q411659;P2175;Q264118
Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia.;Q418817;P2175;Q264118
Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia.;Q411659;P2175;Q264118
Cloning and characterization of the Streptomyces peucetius dnmZUV genes encoding three enzymes required for biosynthesis of the daunorubicin precursor thymidine diphospho-L-daunosamine;Q411659;P703;Q1144013
Cloning and characterization of the Streptomyces peucetius dnmZUV genes encoding three enzymes required for biosynthesis of the daunorubicin precursor thymidine diphospho-L-daunosamine;Q411659;P703;Q7623394
Cloning and characterization of the Streptomyces peucetius dnmZUV genes encoding three enzymes required for biosynthesis of the daunorubicin precursor thymidine diphospho-L-daunosamine;Q483752;P703;Q1144013
[Effect of cisplatin, topotecan, daunorubicin and hydroxyurea on human mesenchymal stem cells].;Q212272;P279;Q48318
Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells (CFUc) by daunorubicin, daunorubicinol, and daunorubicin-DNA complex;Q218642;P703;Q15978631
Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells (CFUc) by daunorubicin, daunorubicinol, and daunorubicin-DNA complex;Q186474;P703;Q15978631
Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells (CFUc) by daunorubicin, daunorubicinol, and daunorubicin-DNA complex;Q170545;P703;Q15978631
Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells (CFUc) by daunorubicin, daunorubicinol, and daunorubicin-DNA complex;Q178450;P703;Q15978631
Correlation of MDR1 /P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia;Q411659;P2175;Q264118
Effect of Dose Ratio on Mitoxantrone and Daunorubicin in Acute Myeloid Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials;Q411659;P2175;Q264118
Effect of Dose Ratio on Mitoxantrone and Daunorubicin in Acute Myeloid Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials;Q239426;P2175;Q264118
High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group;Q180983;P2175;Q29496
High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group;Q180983;P2175;Q264118
High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group;Q186474;P1889;Q178425
High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group;Q411659;P2175;Q264118
Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells.;Q412178;P2175;Q128581
Daunorubicin (NSC-82151), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) combination therapy for advanced adult acute leukemia;Q180983;P2175;Q29496
Daunorubicin (NSC-82151), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) combination therapy for advanced adult acute leukemia;Q180983;P2175;Q976388
Daunorubicin (NSC-82151), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) combination therapy for advanced adult acute leukemia;Q186474;P1889;Q178425
Daunorubicin (NSC-82151), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) combination therapy for advanced adult acute leukemia;Q408977;P2175;Q29496
High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results;Q180983;P2175;Q29496
High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results;Q180983;P2175;Q264118
High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results;Q411659;P2175;Q264118
Analysis of efficacy and cost-effectiveness of high-dose arabinoside versus daunorubicin chemotherapy in older adult patients with acute myeloid leukemia by cytogenetic risk profile: retrospective review from China.;Q411659;P2175;Q264118
The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression;Q188017;P527;Q623
The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression;Q188017;P703;Q15978631
The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression;Q186521;P527;Q623
The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression;Q186521;P703;Q15978631
Design and conduct of a double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: a Southwest Oncology Group study.;Q180983;P2175;Q29496
Design and conduct of a double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: a Southwest Oncology Group study.;Q180983;P2175;Q264118
Design and conduct of a double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: a Southwest Oncology Group study.;Q411659;P2175;Q264118
Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.;Q180983;P2175;Q29496
Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.;Q180983;P2175;Q264118
Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.;Q411659;P2175;Q264118
Intensified daunorubicin in induction therapy and autologous peripheral blood stem cell transplantation in postremission therapy (Double-7 protocol) for adult acute myeloid leukemia.;Q411659;P2175;Q264118
Comparison of daunomycin effects on human keratinocytes and melanoma HTB 1410 cells. Image cytometry study;Q186474;P703;Q15978631
Comparison of daunomycin effects on human keratinocytes and melanoma HTB 1410 cells. Image cytometry study;Q186521;P703;Q15978631
Comparison of daunomycin effects on human keratinocytes and melanoma HTB 1410 cells. Image cytometry study;Q485277;P703;Q15978631
Comparison of daunomycin effects on human keratinocytes and melanoma HTB 1410 cells. Image cytometry study;Q484940;P703;Q15978631
Daunorubicin (NSC-83142) versus daunorubicin plus prednisone (NSC-10023) versus daunorubicin plus vincristine (NSC-67574) plus prednisone in advanced childhood acute lymphocytic leukemia;Q408977;P2175;Q29496
Daunorubicin (NSC-83142) versus daunorubicin plus prednisone (NSC-10023) versus daunorubicin plus vincristine (NSC-67574) plus prednisone in advanced childhood acute lymphocytic leukemia;Q411659;P2175;Q6708277
Genomic sequence and expression of a cloned human carbonyl reductase gene with daunorubicin reductase activity;Q620730;P527;Q623
Genomic sequence and expression of a cloned human carbonyl reductase gene with daunorubicin reductase activity;Q620730;P703;Q15978631
[Effect of arsenic trioxide and daunorubicin on procoagulant activity of acute promyelocytic leukemia cells].;Q7739;P527;Q871
[Effect of arsenic trioxide and daunorubicin on procoagulant activity of acute promyelocytic leukemia cells].;Q7739;P2175;Q612108
Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes;Q178450;P703;Q15978631
Metabolism of the anthracycline antibiotic daunorubicin to daunorubicinol and deoxydaunorubicinol aglycone in hepatocytes isolated from the rat and the rabbit;Q411659;P279;Q417589
Rapid high-performance liquid chromatographic assay for the anthracyclines daunorubicin and 7-con-O-methylnogarol in plasma;Q411659;P31;Q109603820
Sequential vincristine, arabinosylcytosine and daunomycin induction therapy in adult acute leukemia;Q408977;P2175;Q29496
Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin.;Q411659;P2175;Q6708277
Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia.;Q411659;P2175;Q264118
Successful treatment of hepatosplenic candidiasis in an elderly patient with acute myeloid leukemia using liposomal daunorubicin and fluconazole.;Q411478;P2175;Q273510
Successful treatment of hepatosplenic candidiasis in an elderly patient with acute myeloid leukemia using liposomal daunorubicin and fluconazole.;Q411478;P279;Q419639
Successful treatment of hepatosplenic candidiasis in an elderly patient with acute myeloid leukemia using liposomal daunorubicin and fluconazole.;Q411659;P2175;Q264118
The effect of daunomycin on cell proliferation and protein synthesis of human leukemic blast cells.;Q186521;P703;Q15978631
ROS production and their influence on the cellular antioxidative system in human erythrocytes incubated with daunorubicin and glutaraldehyde.;Q183290;P703;Q15978631
ROS production and their influence on the cellular antioxidative system in human erythrocytes incubated with daunorubicin and glutaraldehyde.;Q173670;P703;Q15978631
Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion;Q183290;P31;Q12140
Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion;Q180983;P31;Q12140
Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion;Q411659;P31;Q12140
Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion;Q418817;P31;Q12140
Susceptibility of acute myeloid leukemia (AML) cells from clinically resistant and sensitive patients to daunomycin (DNR): assessment in vitro after stimulation with colony stimulating factors (CSFs).;Q411659;P2175;Q264118
High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity.;Q411659;P2175;Q6708277
Daunomycin accumulation in resistant tumor cells as a screening model for resistance modifying drugs: role of protein binding;Q411659;P31;Q12140
Daunomycin accumulation in resistant tumor cells as a screening model for resistance modifying drugs: role of protein binding;Q178450;P31;Q12140
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.;Q180983;P2175;Q29496
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.;Q180983;P2175;Q264118
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.;Q411659;P2175;Q264118
Evaluation of flow cytometry for multidrug resistance detection in low resistance K562 cells using daunorubicin and monoclonal antibodies.;Q411659;P31;Q12140
Evaluation of flow cytometry for multidrug resistance detection in low resistance K562 cells using daunorubicin and monoclonal antibodies.;Q20816880;P31;Q12140
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study;Q180983;P2175;Q29496
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study;Q180983;P2175;Q264118
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study;Q411659;P2175;Q264118
Daunomycin, cytosine arabinoside and 6-thioguanine (DAT) vs vincristine, cytosine arabinoside and 6-thioguanine (VAT) in the induction treatment of acute nonlymphocyte leukemia: a randomized collaborative study.;Q180983;P2175;Q29496
Daunomycin, cytosine arabinoside and 6-thioguanine (DAT) vs vincristine, cytosine arabinoside and 6-thioguanine (VAT) in the induction treatment of acute nonlymphocyte leukemia: a randomized collaborative study.;Q408977;P2175;Q29496
[Therapeutic experience with daunomycin in malignant lymphoma];Q186521;P703;Q177932
Combination chemotherapy with cytosine arabinoside and rubidomycin in 30 cases of acute granulocytic leukemia;Q180983;P2175;Q29496
Combination chemotherapy with cytosine arabinoside and rubidomycin in 30 cases of acute granulocytic leukemia;Q186474;P1889;Q178425
The carboxylic ionophore monensin inhibits active drug efflux and modulates in vitro resistance in daunorubicin resistant Ehrlich ascites tumor cells.;Q153;P31;Q12140
The carboxylic ionophore monensin inhibits active drug efflux and modulates in vitro resistance in daunorubicin resistant Ehrlich ascites tumor cells.;Q186521;P31;Q12140
The carboxylic ionophore monensin inhibits active drug efflux and modulates in vitro resistance in daunorubicin resistant Ehrlich ascites tumor cells.;Q411659;P31;Q12140
Comparison of the interactions of daunorubicin in a free form and attached to single-walled carbon nanotubes with model lipid membranes.;Q186474;P527;Q623
Phase 1 Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia;Q180983;P2175;Q264118
Phase 1 Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia;Q411659;P2175;Q264118
Leukemia cell lines resistant to cytosine arabinoside, cyclophosphamide or daunomycin are equally sensitive to the drug acetyldinaline as the parental cell line;Q180983;P31;Q12140
Leukemia cell lines resistant to cytosine arabinoside, cyclophosphamide or daunomycin are equally sensitive to the drug acetyldinaline as the parental cell line;Q411659;P31;Q12140
Leukemia cell lines resistant to cytosine arabinoside, cyclophosphamide or daunomycin are equally sensitive to the drug acetyldinaline as the parental cell line;Q483745;P31;Q12140
The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials;Q180983;P2175;Q29496
The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials;Q180983;P2175;Q264118
The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials;Q411659;P2175;Q264118
The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials;Q1063862;P2175;Q264118
Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells;Q186474;P31;Q12140
Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells;Q411659;P31;Q12140
Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells;Q485277;P31;Q12140
Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells;Q1063862;P31;Q12140
Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells;Q483745;P31;Q12140
Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?;Q411659;P31;Q12140
Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?;Q484940;P31;Q12140
Cloning and expression of daunorubicin biosynthesis genes from Streptomyces peucetius and S. peucetius subsp. caesius;Q411659;P361;Q22277880
Cloning and expression of daunorubicin biosynthesis genes from Streptomyces peucetius and S. peucetius subsp. caesius;Q411659;P703;Q1144013
Cloning and expression of daunorubicin biosynthesis genes from Streptomyces peucetius and S. peucetius subsp. caesius;Q411659;P703;Q7623394
Drug targeting to decrease cardiotoxicity - determination of the cytotoxic effect of GnRH-based conjugates containing doxorubicin, daunorubicin and methotrexate on human cardiomyocytes and endothelial cells;Q485277;P703;Q15978631
Drug targeting to decrease cardiotoxicity - determination of the cytotoxic effect of GnRH-based conjugates containing doxorubicin, daunorubicin and methotrexate on human cardiomyocytes and endothelial cells;Q173670;P703;Q15978631
Drug targeting to decrease cardiotoxicity - determination of the cytotoxic effect of GnRH-based conjugates containing doxorubicin, daunorubicin and methotrexate on human cardiomyocytes and endothelial cells;Q178450;P703;Q15978631
Drug targeting to decrease cardiotoxicity - determination of the cytotoxic effect of GnRH-based conjugates containing doxorubicin, daunorubicin and methotrexate on human cardiomyocytes and endothelial cells;Q620730;P703;Q15978631
DAE (daunorubicin, Ara-C, and etoposide) and intermediate dose Ara-C for remission induction and consolidation treatment of adult patients with acute myeloid leukemia.;Q411659;P2175;Q264118
DAE (daunorubicin, Ara-C, and etoposide) and intermediate dose Ara-C for remission induction and consolidation treatment of adult patients with acute myeloid leukemia.;Q418817;P2175;Q264118
Cellular pharmacokinetics of daunomycin in human leukemic blasts in vitro and in vivo;Q186474;P703;Q15978631
Intercalation with DNA is a prerequisite for Daunomycin, Adriamycin and its congeners in inhibiting DNAase I;Q18936;P3780;Q47520887
Therapy of acute myelogenous leukemia: results of combination chemotherapy with cytarabine, daunorubicin and 6-mercaptopurine;Q180983;P2175;Q29496
Therapy of acute myelogenous leukemia: results of combination chemotherapy with cytarabine, daunorubicin and 6-mercaptopurine;Q180983;P2175;Q264118
Therapy of acute myelogenous leukemia: results of combination chemotherapy with cytarabine, daunorubicin and 6-mercaptopurine;Q411659;P2175;Q264118
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia;Q180983;P2175;Q29496
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia;Q180983;P2175;Q264118
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia;Q411659;P2175;Q264118
Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells;Q186474;P703;Q15978631
Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells;Q186474;P31;Q12140
Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells;Q1063862;P31;Q12140
Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.;Q218642;P703;Q15978631
Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.;Q218642;P31;Q12140
Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.;Q186474;P31;Q12140
Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.;Q186474;P703;Q15978631
Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.;Q411659;P31;Q12140
Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.;Q178450;P31;Q12140
Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.;Q178450;P703;Q15978631
Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.;Q20816880;P703;Q15978631
Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.;Q20816880;P31;Q12140
Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.;Q1063862;P31;Q12140
Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein.;Q411659;P361;Q22290410
Daunomycin: an anthracycline antibiotic effective in acute leukemia.;Q411659;P279;Q417589
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study.;Q180983;P2175;Q29496
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study.;Q180983;P2175;Q264118
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study.;Q411659;P2175;Q264118
Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors.;Q415588;P2175;Q9303627
Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors.;Q418817;P2175;Q9303627
Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia;Q411659;P2175;Q264118
Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon.;Q186521;P31;Q12140
Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon.;Q411659;P31;Q12140
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study;Q411659;P2175;Q264118
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study;Q1063862;P2175;Q264118
Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags.;Q18936;P31;Q109603820
Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags.;Q411659;P31;Q109603820
Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags.;Q425122;P279;Q417589
Apoptosis and resistance to daunorubicin in human leukemic cells.;Q218642;P703;Q15978631
Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells;Q153;P31;Q12140
Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells;Q183290;P31;Q12140
Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells;Q18936;P31;Q12140
Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells;Q411659;P31;Q12140
Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells;Q173670;P31;Q12140
Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells;Q20816880;P31;Q12140
Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells;Q20035886;P31;Q12140
Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells;Q1063862;P31;Q12140
Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.;Q411659;P2175;Q264118
Hexokinase II inhibition by 3-bromopyruvate sensitizes myeloid leukemic cells K-562 to anti-leukemic drug, daunorubicin;Q411659;P31;Q12140
Hexokinase II inhibition by 3-bromopyruvate sensitizes myeloid leukemic cells K-562 to anti-leukemic drug, daunorubicin;Q485277;P31;Q12140
Hexokinase II inhibition by 3-bromopyruvate sensitizes myeloid leukemic cells K-562 to anti-leukemic drug, daunorubicin;Q213580;P31;Q12140
Hexokinase II inhibition by 3-bromopyruvate sensitizes myeloid leukemic cells K-562 to anti-leukemic drug, daunorubicin;Q20816880;P31;Q12140
Hexokinase II inhibition by 3-bromopyruvate sensitizes myeloid leukemic cells K-562 to anti-leukemic drug, daunorubicin;Q484940;P31;Q12140
Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro.;Q218642;P31;Q12140
Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro.;Q218642;P703;Q15978631
Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro.;Q183290;P31;Q12140
Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro.;Q183290;P703;Q15978631
Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro.;Q410291;P31;Q12140
Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro.;Q408977;P31;Q12140
Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro.;Q408977;P2175;Q29496
Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro.;Q411659;P31;Q12140
Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro.;Q367700;P31;Q12140
Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro.;Q367700;P703;Q15978631
[Cytotoxic action of doxorubicin and daunomycin on human lung cancer cells];Q186474;P703;Q15978631
Long term follow-up of patients with acute myelogenous leukemia who received the daunorubicin, vincristine, and cytosine arabinoside regimen.;Q180983;P2175;Q29496
Long term follow-up of patients with acute myelogenous leukemia who received the daunorubicin, vincristine, and cytosine arabinoside regimen.;Q180983;P2175;Q264118
Long term follow-up of patients with acute myelogenous leukemia who received the daunorubicin, vincristine, and cytosine arabinoside regimen.;Q408977;P2175;Q29496
Long term follow-up of patients with acute myelogenous leukemia who received the daunorubicin, vincristine, and cytosine arabinoside regimen.;Q411659;P2175;Q264118
Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates;Q183290;P31;Q12140
Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates;Q18936;P31;Q12140
Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates;Q186474;P31;Q12140
Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates;Q411659;P31;Q12140
Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates;Q191924;P366;Q8386
Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates;Q19856779;P31;Q12140
Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates;Q19856779;P1889;Q417625
Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates;Q422232;P31;Q12140
Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells;Q183290;P31;Q12140
Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells;Q411659;P31;Q12140
Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells;Q485277;P31;Q12140
Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells;Q178450;P31;Q12140
Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells;Q483745;P31;Q12140
Reduction of daunorubicin in the presence of sulfur-containing peptides;Q84587774;P3781;Q682
A novel nanohybrid of daunomycin and single-walled carbon nanotubes: photophysical properties and enhanced electrochemical activity.;Q218642;P527;Q623
[Clinical management of acute lymphocytic leukemia in adults. 1. Treatment of acute lymphocytic leukemia with VP (vincristine, prednisolone)--DVMP (daunorubicin, vincristine 6-mercaptopurine, prednisolone) regimen];Q408977;P2175;Q29496
[Clinical management of acute lymphocytic leukemia in adults. 1. Treatment of acute lymphocytic leukemia with VP (vincristine, prednisolone)--DVMP (daunorubicin, vincristine 6-mercaptopurine, prednisolone) regimen];Q411659;P2175;Q6708277
[Clinical management of acute lymphocytic leukemia in adults. 1. Treatment of acute lymphocytic leukemia with VP (vincristine, prednisolone)--DVMP (daunorubicin, vincristine 6-mercaptopurine, prednisolone) regimen];Q418529;P2175;Q6708277
Perturbation of generation cycle of human leukaemic blast cells in vivo by daunomycin;Q20035886;P703;Q15978631
Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study;Q16965066;P527;Q411659
Adriamycin and daunomycin generate reactive oxygen compounds in erythrocytes;Q218642;P31;Q11173
Adriamycin and daunomycin generate reactive oxygen compounds in erythrocytes;Q18936;P31;Q11173
Adriamycin and daunomycin generate reactive oxygen compounds in erythrocytes;Q18936;P3780;Q47520887
Adriamycin and daunomycin generate reactive oxygen compounds in erythrocytes;Q411659;P31;Q11173
HPLC determination of daunorubicin and daunorubicinol in human plasma.;Q186474;P703;Q15978631
HPLC determination of daunorubicin and daunorubicinol in human plasma.;Q20035886;P703;Q15978631
HPLC determination of daunorubicin and daunorubicinol in human plasma.;Q483745;P703;Q15978631
[Effect of PDMP, a glucosylceramide synthase inhibitor, on reversion of daunorubicin resistance in human leukemia cell line K562/A02].;Q218642;P703;Q15978631
[Effect of PDMP, a glucosylceramide synthase inhibitor, on reversion of daunorubicin resistance in human leukemia cell line K562/A02].;Q178450;P703;Q15978631
[Effect of PDMP, a glucosylceramide synthase inhibitor, on reversion of daunorubicin resistance in human leukemia cell line K562/A02].;Q20816880;P703;Q15978631
[Effect of PDMP, a glucosylceramide synthase inhibitor, on reversion of daunorubicin resistance in human leukemia cell line K562/A02].;Q20035886;P703;Q15978631
[Effect of PDMP, a glucosylceramide synthase inhibitor, on reversion of daunorubicin resistance in human leukemia cell line K562/A02].;Q22124685;P703;Q15978631
[Effects of all-trans retinoic acid, arsenic trioxide and daunorubicin on tissue factor expression in NB4 cells];Q7739;P527;Q871
[Effects of all-trans retinoic acid, arsenic trioxide and daunorubicin on tissue factor expression in NB4 cells];Q287029;P31;Q425517
Effect of doxorubicin, daunorubicin, and idarubicin on the growth rate of human leukemia cells (K562) studied with image analysis;Q20816880;P703;Q15978631
Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil.;Q153;P31;Q12140
Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil.;Q410291;P31;Q12140
Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil.;Q411659;P31;Q12140
Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil.;Q20035886;P31;Q12140
Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil.;Q484940;P31;Q12140
Intercalation and induction of strand breaks by adriamycin and daunomycin: a study with human genomic DNA;Q218642;P703;Q15978631
Intercalation and induction of strand breaks by adriamycin and daunomycin: a study with human genomic DNA;Q178450;P703;Q15978631
Intercalation and induction of strand breaks by adriamycin and daunomycin: a study with human genomic DNA;Q484940;P703;Q15978631
The Streptomyces peucetius dpsY and dnrX genes govern early and late steps of daunorubicin and doxorubicin biosynthesis;Q18936;P703;Q1144013
The Streptomyces peucetius dpsY and dnrX genes govern early and late steps of daunorubicin and doxorubicin biosynthesis;Q18936;P703;Q7623394
The Streptomyces peucetius dpsY and dnrX genes govern early and late steps of daunorubicin and doxorubicin biosynthesis;Q186521;P703;Q1144013
The Streptomyces peucetius dpsY and dnrX genes govern early and late steps of daunorubicin and doxorubicin biosynthesis;Q411659;P703;Q7623394
The Streptomyces peucetius dpsY and dnrX genes govern early and late steps of daunorubicin and doxorubicin biosynthesis;Q411659;P703;Q1144013
Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.;Q180983;P2175;Q29496
Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.;Q180983;P2175;Q264118
Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.;Q411659;P2175;Q264118
Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.;Q5134875;P2175;Q264118
Enhancing cytotoxicity of daunorubicin on drug-resistant leukaemia cells with microparticle-mediated drug delivery system;Q411659;P31;Q12140
[Action of surface-active agents (Triton X 100, Osofor) and of an antimitotic drug (Daunomycin) on cells of ascites tumors];Q218642;P31;Q12140
[Action of surface-active agents (Triton X 100, Osofor) and of an antimitotic drug (Daunomycin) on cells of ascites tumors];Q186521;P31;Q12140
[Action of surface-active agents (Triton X 100, Osofor) and of an antimitotic drug (Daunomycin) on cells of ascites tumors];Q411659;P31;Q12140
[Action of surface-active agents (Triton X 100, Osofor) and of an antimitotic drug (Daunomycin) on cells of ascites tumors];Q178450;P31;Q12140
Outpatient ADE (cytarabine, daunorubicin, and etoposide) is feasible and effective for the first relapse of pediatric acute myeloid leukemia: A prospective, phase II study;Q180983;P2175;Q29496
Outpatient ADE (cytarabine, daunorubicin, and etoposide) is feasible and effective for the first relapse of pediatric acute myeloid leukemia: A prospective, phase II study;Q180983;P2175;Q264118
Outpatient ADE (cytarabine, daunorubicin, and etoposide) is feasible and effective for the first relapse of pediatric acute myeloid leukemia: A prospective, phase II study;Q411659;P2175;Q264118
Outpatient ADE (cytarabine, daunorubicin, and etoposide) is feasible and effective for the first relapse of pediatric acute myeloid leukemia: A prospective, phase II study;Q418817;P2175;Q264118
Study of the interaction between daunorubicin and human serum albumin, and the determination of daunorubicin in blood serum samples;Q183290;P703;Q15978631
[Efficacy of a new antineoplastic antibiotic, daunomycin, in the therapy of malignant tumors in children];Q411659;P2868;Q4381760
A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor.;Q411659;P2175;Q264118
Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs.;Q153;P31;Q12140
Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs.;Q183290;P31;Q12140
Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs.;Q410291;P31;Q12140
Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs.;Q411659;P31;Q12140
Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs.;Q20816880;P31;Q12140
[Cytochemical modifications in the blood of patients with acute leukemia treated with daunomycin, vincristine and cortisone];Q408977;P2175;Q29496
[Experiences with daunomycin and cytosine arabinoside in the therapy of acute myeloid leukemias];Q180983;P2175;Q29496
[Experiences with daunomycin and cytosine arabinoside in the therapy of acute myeloid leukemias];Q180983;P2175;Q264118
[Experiences with daunomycin and cytosine arabinoside in the therapy of acute myeloid leukemias];Q411659;P2175;Q264118
A phase I-II study of cytosine arabinoside, daunorubicin, and VP16-213 in adult patients with acute non-lymphocytic leukemia;Q180983;P2175;Q29496
A phase I-II study of cytosine arabinoside, daunorubicin, and VP16-213 in adult patients with acute non-lymphocytic leukemia;Q411659;P2175;Q6708277
A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.;Q411659;P2175;Q264118
A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.;Q1063862;P2175;Q264118
Interaction of actinomycin D, ethidium, quinacrine, daunorubicin, and tetralysine with DNA: 31P NMR chemical shift and relaxation investigation;Q20816880;P31;Q178430
Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia.;Q411659;P2175;Q264118
Effects of verapamil on in vitro intracellular accumulation and retention of daunorubicin in blast cells from patients with acute nonlymphocytic leukemia;Q411659;P2175;Q6708277
Chemotherapy for adult acute nonlymphocytic leukemia with daunorubicin and cytosine arabinoside;Q180983;P2175;Q29496
Chemotherapy for adult acute nonlymphocytic leukemia with daunorubicin and cytosine arabinoside;Q186474;P1889;Q178425
Chemotherapy for adult acute nonlymphocytic leukemia with daunorubicin and cytosine arabinoside;Q411659;P2175;Q6708277
A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia.;Q180983;P2175;Q29496
A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia.;Q411659;P2175;Q6708277
A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia.;Q1063862;P2175;Q6708277
Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia;Q411659;P2175;Q264118
Changes in the toxicity and therapeutic efficacy of daunorubicin linked with a biodegradable carrier;Q186474;P703;Q177932
Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation.;Q12187;P279;Q12140
Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation.;Q411659;P31;Q12140
Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation.;Q485277;P31;Q12140
Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation.;Q419164;P31;Q12140
Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation.;Q20035886;P31;Q12140
Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation.;Q484940;P31;Q12140
The effect of macromolecular conjugates of daunorubicin on nuclear ultrastructure in Trypanosoma brucei rhodesiense;Q186521;P703;Q33244
[High-density lipoproteins as a form of daunorubicin transport in hepatoma cells of mice];Q411659;P361;Q22290410
Encapsulation of daunorubicin into Saccharomyces cerevisiae-derived lysosome as drug delivery vehicles for acute myeloid leukemia (AML) treatment;Q218642;P31;Q12140
Encapsulation of daunorubicin into Saccharomyces cerevisiae-derived lysosome as drug delivery vehicles for acute myeloid leukemia (AML) treatment;Q183290;P31;Q12140
Encapsulation of daunorubicin into Saccharomyces cerevisiae-derived lysosome as drug delivery vehicles for acute myeloid leukemia (AML) treatment;Q411659;P31;Q12140
Encapsulation of daunorubicin into Saccharomyces cerevisiae-derived lysosome as drug delivery vehicles for acute myeloid leukemia (AML) treatment;Q411659;P2175;Q264118
Encapsulation of daunorubicin into Saccharomyces cerevisiae-derived lysosome as drug delivery vehicles for acute myeloid leukemia (AML) treatment;Q22124685;P31;Q12140
Encapsulation of daunorubicin into Saccharomyces cerevisiae-derived lysosome as drug delivery vehicles for acute myeloid leukemia (AML) treatment;Q483745;P31;Q12140
Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia;Q411659;P2175;Q264118
Daunorubicin and gambogic acid coloaded cysteamine-CdTe quantum dots minimizing the multidrug resistance of lymphoma in vitro and in vivo.;Q186474;P31;Q12140
Daunorubicin and gambogic acid coloaded cysteamine-CdTe quantum dots minimizing the multidrug resistance of lymphoma in vitro and in vivo.;Q23118;P31;Q8386
Daunorubicin and gambogic acid coloaded cysteamine-CdTe quantum dots minimizing the multidrug resistance of lymphoma in vitro and in vivo.;Q186521;P31;Q12140
Daunorubicin and gambogic acid coloaded cysteamine-CdTe quantum dots minimizing the multidrug resistance of lymphoma in vitro and in vivo.;Q411659;P31;Q12140
Daunorubicin and gambogic acid coloaded cysteamine-CdTe quantum dots minimizing the multidrug resistance of lymphoma in vitro and in vivo.;Q178450;P31;Q12140
Daunorubicin and gambogic acid coloaded cysteamine-CdTe quantum dots minimizing the multidrug resistance of lymphoma in vitro and in vivo.;Q617563;P31;Q12140
Increased efflux of vincristine, but not of daunorubicin, associated with the murine multidrug resistance protein (MRP).;Q153;P31;Q12140
Increased efflux of vincristine, but not of daunorubicin, associated with the murine multidrug resistance protein (MRP).;Q408977;P31;Q12140
Increased efflux of vincristine, but not of daunorubicin, associated with the murine multidrug resistance protein (MRP).;Q411659;P31;Q12140
Increased efflux of vincristine, but not of daunorubicin, associated with the murine multidrug resistance protein (MRP).;Q173670;P31;Q12140
Increased efflux of vincristine, but not of daunorubicin, associated with the murine multidrug resistance protein (MRP).;Q20035886;P31;Q12140
Increased efflux of vincristine, but not of daunorubicin, associated with the murine multidrug resistance protein (MRP).;Q22124685;P31;Q12140
Increased efflux of vincristine, but not of daunorubicin, associated with the murine multidrug resistance protein (MRP).;Q484940;P31;Q12140
Nucleic acid binding drugs. Some conformational properties of the anti-cancer drug daunomycin and several of its derivatives: implications for DNA-binding;Q218642;P31;Q12140
Nucleic acid binding drugs. Some conformational properties of the anti-cancer drug daunomycin and several of its derivatives: implications for DNA-binding;Q183290;P31;Q12140
Nucleic acid binding drugs. Some conformational properties of the anti-cancer drug daunomycin and several of its derivatives: implications for DNA-binding;Q23118;P31;Q12140
Nucleic acid binding drugs. Some conformational properties of the anti-cancer drug daunomycin and several of its derivatives: implications for DNA-binding;Q23118;P31;Q8386
Nucleic acid binding drugs. Some conformational properties of the anti-cancer drug daunomycin and several of its derivatives: implications for DNA-binding;Q411659;P31;Q12140
Nucleic acid binding drugs. Some conformational properties of the anti-cancer drug daunomycin and several of its derivatives: implications for DNA-binding;Q178450;P31;Q12140
[The role of daunorubicin in induction therapy for adult acute myeloid leukemia];Q411659;P2175;Q264118
[Consolidation therapy with high-dose cytarabine and daunorubicin for prolonged disease free survival in acute myelocytic leukemia];Q180983;P2175;Q29496
Specificity of daunomycin in causing chromosome aberrations in human leukocytes;Q183290;P703;Q15978631
Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin;Q218642;P31;Q12140
Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin;Q411659;P31;Q12140
Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin;Q173670;P31;Q12140
Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin;Q178450;P31;Q12140
Multidrug resistance-associated protein (MRP) mediated transport of daunomycin and leukotriene C4 (LTC4) in isolated plasma membrane vesicles;Q186474;P31;Q12140
Multidrug resistance-associated protein (MRP) mediated transport of daunomycin and leukotriene C4 (LTC4) in isolated plasma membrane vesicles;Q186521;P31;Q12140
Multidrug resistance-associated protein (MRP) mediated transport of daunomycin and leukotriene C4 (LTC4) in isolated plasma membrane vesicles;Q411659;P31;Q12140
Multidrug resistance-associated protein (MRP) mediated transport of daunomycin and leukotriene C4 (LTC4) in isolated plasma membrane vesicles;Q173670;P31;Q12140
Multidrug resistance-associated protein (MRP) mediated transport of daunomycin and leukotriene C4 (LTC4) in isolated plasma membrane vesicles;Q418386;P31;Q12140
Multidrug resistance-associated protein (MRP) mediated transport of daunomycin and leukotriene C4 (LTC4) in isolated plasma membrane vesicles;Q20035886;P31;Q12140
Multidrug resistance-associated protein (MRP) mediated transport of daunomycin and leukotriene C4 (LTC4) in isolated plasma membrane vesicles;Q22124685;P31;Q12140
Multidrug resistance-associated protein (MRP) mediated transport of daunomycin and leukotriene C4 (LTC4) in isolated plasma membrane vesicles;Q483745;P31;Q12140
A dose intensive regimen of cytosine arabinoside and daunorubicin for chronic myelogenous leukemia in blast crisis.;Q180983;P2175;Q29496
Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.;Q180983;P2175;Q29496
Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.;Q180983;P2175;Q264118
Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.;Q411659;P2175;Q264118
[Chemotherapy with cytosine arabinoside, daunomycin and vincristine in refractory leukemia of childhood (author's transl)];Q180983;P2175;Q29496
[Chemotherapy with cytosine arabinoside, daunomycin and vincristine in refractory leukemia of childhood (author's transl)];Q186474;P1889;Q178425
[Chemotherapy with cytosine arabinoside, daunomycin and vincristine in refractory leukemia of childhood (author's transl)];Q408977;P2175;Q29496
Chromosome aberrations induced by daunomycin in human leukocyte cultures, with the apparent synergistic effect of arginine;Q186474;P703;Q15978631
Immunotargeting of daunomycin to localized and metastatic human colon adenocarcinoma in athymic mice;Q484940;P703;Q15978631
Investigations of calsequestrin as a target for anthracyclines: comparison of functional effects of daunorubicin, daunorubicinol, and trifluoperazine.;Q411659;P31;Q109603820
Resistance to oxidants associated with elevated catalase activity in HL-60 leukemia cells that overexpress multidrug-resistance protein does not contribute to the resistance to daunorubicin manifested by these cells.;Q411659;P31;Q12140
Resistance to oxidants associated with elevated catalase activity in HL-60 leukemia cells that overexpress multidrug-resistance protein does not contribute to the resistance to daunorubicin manifested by these cells.;Q485277;P31;Q12140
Resistance to oxidants associated with elevated catalase activity in HL-60 leukemia cells that overexpress multidrug-resistance protein does not contribute to the resistance to daunorubicin manifested by these cells.;Q173670;P31;Q12140
Resistance to oxidants associated with elevated catalase activity in HL-60 leukemia cells that overexpress multidrug-resistance protein does not contribute to the resistance to daunorubicin manifested by these cells.;Q483745;P31;Q12140
Comparison of daunorubicin and Fluo-3 for detection of multidrug resistance in human tumor cells;Q186474;P703;Q15978631
Comparison of daunorubicin and Fluo-3 for detection of multidrug resistance in human tumor cells;Q186474;P31;Q12140
Comparison of daunorubicin and Fluo-3 for detection of multidrug resistance in human tumor cells;Q411659;P31;Q12140
Comparison of daunorubicin and Fluo-3 for detection of multidrug resistance in human tumor cells;Q170545;P31;Q12140
Comparison of daunorubicin and Fluo-3 for detection of multidrug resistance in human tumor cells;Q170545;P703;Q15978631
Immunocytochemistry for drugs containing an aliphatic primary amino group in the molecule, anticancer antibiotic daunomycin as a model.;Q12187;P279;Q12140
Immunocytochemistry for drugs containing an aliphatic primary amino group in the molecule, anticancer antibiotic daunomycin as a model.;Q411659;P31;Q12140
Immunocytochemistry for drugs containing an aliphatic primary amino group in the molecule, anticancer antibiotic daunomycin as a model.;Q484940;P31;Q12140
Induction of daunorubicin carbonyl reducing enzymes by daunorubicin in sensitive and resistant pancreas carcinoma cells;Q484940;P527;Q623
[Suppression of DNA synthesis in mice by the anthracycline antibiotics daunorubicin, carminomycin and doxorubicin].;Q18936;P279;Q417589
[Suppression of DNA synthesis in mice by the anthracycline antibiotics daunorubicin, carminomycin and doxorubicin].;Q411659;P279;Q417589
Daunorubicin reductase activity in human normal lymphocytes, myeloblasts and leukemic cell lines;Q178450;P703;Q15978631
Rapid kinetics of the interaction between daunomycin and drug-sensitive or drug-resistant P388 leukemia cells;Q411659;P31;Q12140
Rapid kinetics of the interaction between daunomycin and drug-sensitive or drug-resistant P388 leukemia cells;Q173670;P31;Q12140
Rapid kinetics of the interaction between daunomycin and drug-sensitive or drug-resistant P388 leukemia cells;Q20035886;P31;Q12140
Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model;Q20035886;P703;Q15978631
Syntheses and biological activities of 3'-azido disaccharide analogues of daunorubicin against drug-resistant leukemia.;Q183290;P31;Q12140
Syntheses and biological activities of 3'-azido disaccharide analogues of daunorubicin against drug-resistant leukemia.;Q411659;P31;Q12140
Liposomal daunorubicin marketed for HIV-related Kaposi's sarcoma;Q16965066;P527;Q411659
Adriamycin and daunorubicin bind in a cooperative manner to deoxyribonucleic acid;Q18936;P3780;Q47520887
Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?;Q412685;P527;Q105946712
Genetic toxicology of mitomycin C, actinomycins, daunomycin and adriamycin.;Q19856779;P1889;Q417625
A differential interaction of daunomycin, adriamycin and their derivatives with human erythrocytes and phospholipid bilayers;Q218642;P703;Q15978631
Distribution and metabolism of adriamycin in mice. Comparison with daunomycin;Q186474;P703;Q83310
Letter: Digoxin does not prevent daunorubicin or adriamycin from binding to rat heart muscle.;Q422222;P3780;Q48826409
A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.;Q180983;P2175;Q29496
A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.;Q180983;P2175;Q264118
A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.;Q411659;P2175;Q264118
Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin;Q180983;P31;Q12140
Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin;Q183290;P31;Q12140
Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin;Q411659;P31;Q12140
Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin;Q178450;P31;Q12140
Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin;Q20035886;P31;Q12140
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review;Q180983;P2175;Q29496
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review;Q180983;P2175;Q264118
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review;Q411659;P2175;Q264118
Modifying the sugar moieties of daunorubicin overcomes P-gp-mediated multidrug resistance.;Q23118;P31;Q8386
Modifying the sugar moieties of daunorubicin overcomes P-gp-mediated multidrug resistance.;Q411659;P31;Q12140
Modifying the sugar moieties of daunorubicin overcomes P-gp-mediated multidrug resistance.;Q20035886;P31;Q12140
Modifying the sugar moieties of daunorubicin overcomes P-gp-mediated multidrug resistance.;Q22124685;P31;Q12140
A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia;Q180983;P2175;Q29496
A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia;Q180983;P2175;Q264118
A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia;Q411659;P2175;Q264118
A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia;Q1063862;P2175;Q264118
Binding of anticancer drug daunomycin to parallel G-quadruplex DNA [d-(TTGGGGT)] leads to thermal stabilization: A multispectroscopic investigation;Q385347;P31;Q12140
Binding of anticancer drug daunomycin to parallel G-quadruplex DNA [d-(TTGGGGT)] leads to thermal stabilization: A multispectroscopic investigation;Q218642;P31;Q12140
Binding of anticancer drug daunomycin to parallel G-quadruplex DNA [d-(TTGGGGT)] leads to thermal stabilization: A multispectroscopic investigation;Q186521;P31;Q12140
Binding of anticancer drug daunomycin to parallel G-quadruplex DNA [d-(TTGGGGT)] leads to thermal stabilization: A multispectroscopic investigation;Q411659;P31;Q12140
Binding of anticancer drug daunomycin to parallel G-quadruplex DNA [d-(TTGGGGT)] leads to thermal stabilization: A multispectroscopic investigation;Q178450;P31;Q12140
Binding of anticancer drug daunomycin to parallel G-quadruplex DNA [d-(TTGGGGT)] leads to thermal stabilization: A multispectroscopic investigation;Q620730;P31;Q12140
[Distribution and chemotherapeutic activity of daunomycin and adriamycin in spontaneous mammary carcinoma of mice];Q178450;P703;Q177932
Partitioning and structural effects of the antitumor drug daunomycin on model membranes;Q411659;P31;Q12140
Partitioning and structural effects of the antitumor drug daunomycin on model membranes;Q20035886;P31;Q12140
CdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluation;Q218642;P703;Q15978631
CdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluation;Q218642;P31;Q12140
CdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluation;Q186474;P31;Q12140
CdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluation;Q186474;P703;Q15978631
CdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluation;Q23118;P31;Q8386
CdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluation;Q186521;P703;Q15978631
CdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluation;Q186521;P31;Q12140
CdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluation;Q411659;P31;Q12140
CdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluation;Q407781;P31;Q12140
CdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluation;Q485277;P703;Q15978631
CdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluation;Q485277;P31;Q12140
CdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluation;Q178450;P31;Q12140
CdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluation;Q178450;P703;Q15978631
CdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluation;Q22124685;P31;Q12140
CdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluation;Q22124685;P703;Q15978631
CdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluation;Q620730;P31;Q12140
CdTe quantum dots with daunorubicin induce apoptosis of multidrug-resistant human hepatoma HepG2/ADM cells: in vitro and in vivo evaluation;Q620730;P703;Q15978631
High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long-term follow-up of a prospective multicenter trial;Q180983;P2175;Q29496
High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long-term follow-up of a prospective multicenter trial;Q180983;P2175;Q264118
High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long-term follow-up of a prospective multicenter trial;Q411659;P2175;Q264118
Sequencing of cytosine arabinoside (NSC-63878) and daunorubicin (NSC-82151) in acute myelogenous leukemia;Q180983;P2175;Q29496
Sequencing of cytosine arabinoside (NSC-63878) and daunorubicin (NSC-82151) in acute myelogenous leukemia;Q180983;P2175;Q264118
Sequencing of cytosine arabinoside (NSC-63878) and daunorubicin (NSC-82151) in acute myelogenous leukemia;Q186474;P1889;Q178425
Sequencing of cytosine arabinoside (NSC-63878) and daunorubicin (NSC-82151) in acute myelogenous leukemia;Q411659;P2175;Q264118
Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia;Q180983;P2175;Q29496
Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia;Q186474;P1889;Q178425
Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia;Q411659;P2175;Q6708277
Regulation of secondary metabolism in Streptomyces spp. and overproduction of daunorubicin in Streptomyces peucetius;Q411659;P703;Q7623394
Regulation of secondary metabolism in Streptomyces spp. and overproduction of daunorubicin in Streptomyces peucetius;Q411659;P703;Q1144013
Regulation of secondary metabolism in Streptomyces spp. and overproduction of daunorubicin in Streptomyces peucetius;Q173670;P703;Q1144013
Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation.;Q411659;P2175;Q264118
High-dose cytosine arabinoside and daunomycin as primary therapy for adults with acute nonlymphoblastic leukemia: a pilot study;Q180983;P2175;Q29496
Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of daunorubicin and doxorubicin in HL60 and its resistant cells and comparison with those of pirarubicin;Q153;P703;Q15978631
Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of daunorubicin and doxorubicin in HL60 and its resistant cells and comparison with those of pirarubicin;Q186521;P703;Q15978631
Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of daunorubicin and doxorubicin in HL60 and its resistant cells and comparison with those of pirarubicin;Q485277;P703;Q15978631
Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of daunorubicin and doxorubicin in HL60 and its resistant cells and comparison with those of pirarubicin;Q483745;P703;Q15978631
Biosynthetic relationships among daunorubicin, doxorubicin and 13-dihydrodaunorubicin in Streptomyces peucetius;Q18936;P703;Q7623394
Biosynthetic relationships among daunorubicin, doxorubicin and 13-dihydrodaunorubicin in Streptomyces peucetius;Q18936;P703;Q1144013
Biosynthetic relationships among daunorubicin, doxorubicin and 13-dihydrodaunorubicin in Streptomyces peucetius;Q411659;P703;Q1144013
Biosynthetic relationships among daunorubicin, doxorubicin and 13-dihydrodaunorubicin in Streptomyces peucetius;Q411659;P703;Q7623394
L-asparaginase and prednisolone pretreatment followed by rubidomycin and cytosine arabinoside for induction of remission in adult patients with acute myeloblastic leukaemia;Q180983;P2175;Q29496
Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia;Q16965066;P527;Q411659
Daunorubicin, vincristine, and prednisone for remission induction in patients with acute lymphoblastic leukemia in relapse;Q408977;P2175;Q29496
Daunorubicin, vincristine, and prednisone for remission induction in patients with acute lymphoblastic leukemia in relapse;Q408977;P2175;Q18553852
Spectroscopic studies of cutaneous photosensitizing agents--X. A spin-trapping and direct electron spin resonance study of the photochemical pathways of daunomycin and adriamycin.;Q218642;P703;Q2046782
Binding of anticancer drug daunomycin to a TGGGGT G-quadruplex DNA probed by all-atom molecular dynamics simulations: additional pure groove binding mode and implications on designing more selective G-quadruplex ligands.;Q385347;P31;Q12140
Binding of anticancer drug daunomycin to a TGGGGT G-quadruplex DNA probed by all-atom molecular dynamics simulations: additional pure groove binding mode and implications on designing more selective G-quadruplex ligands.;Q218642;P31;Q12140
Binding of anticancer drug daunomycin to a TGGGGT G-quadruplex DNA probed by all-atom molecular dynamics simulations: additional pure groove binding mode and implications on designing more selective G-quadruplex ligands.;Q186521;P31;Q12140
Binding of anticancer drug daunomycin to a TGGGGT G-quadruplex DNA probed by all-atom molecular dynamics simulations: additional pure groove binding mode and implications on designing more selective G-quadruplex ligands.;Q411659;P31;Q12140
Binding of anticancer drug daunomycin to a TGGGGT G-quadruplex DNA probed by all-atom molecular dynamics simulations: additional pure groove binding mode and implications on designing more selective G-quadruplex ligands.;Q191924;P31;Q12140
Binding of anticancer drug daunomycin to a TGGGGT G-quadruplex DNA probed by all-atom molecular dynamics simulations: additional pure groove binding mode and implications on designing more selective G-quadruplex ligands.;Q178450;P31;Q12140
Binding of anticancer drug daunomycin to a TGGGGT G-quadruplex DNA probed by all-atom molecular dynamics simulations: additional pure groove binding mode and implications on designing more selective G-quadruplex ligands.;Q620730;P31;Q12140
The interaction of daunorubicin and mitoxantrone with the red blood cells of acute myeloid leukemia patients.;Q411659;P2175;Q264118
The interaction of daunorubicin and mitoxantrone with the red blood cells of acute myeloid leukemia patients.;Q239426;P2175;Q264118
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.;Q411659;P2175;Q264118
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.;Q239426;P2175;Q264118
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.;Q1063862;P2175;Q264118
Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals;Q178450;P703;Q177932
A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia;Q411659;P2175;Q264118
The protein kinase C inhibitor, CGP 41 251, reverses decreased daunomycin uptake in a human drug-resistant ovarian carcinoma cell line.;Q186474;P31;Q12140
The protein kinase C inhibitor, CGP 41 251, reverses decreased daunomycin uptake in a human drug-resistant ovarian carcinoma cell line.;Q186474;P703;Q15978631
The protein kinase C inhibitor, CGP 41 251, reverses decreased daunomycin uptake in a human drug-resistant ovarian carcinoma cell line.;Q186521;P31;Q12140
The protein kinase C inhibitor, CGP 41 251, reverses decreased daunomycin uptake in a human drug-resistant ovarian carcinoma cell line.;Q186521;P703;Q15978631
The protein kinase C inhibitor, CGP 41 251, reverses decreased daunomycin uptake in a human drug-resistant ovarian carcinoma cell line.;Q411659;P31;Q12140
The protein kinase C inhibitor, CGP 41 251, reverses decreased daunomycin uptake in a human drug-resistant ovarian carcinoma cell line.;Q20035886;P31;Q12140
The protein kinase C inhibitor, CGP 41 251, reverses decreased daunomycin uptake in a human drug-resistant ovarian carcinoma cell line.;Q20035886;P703;Q15978631
The protein kinase C inhibitor, CGP 41 251, reverses decreased daunomycin uptake in a human drug-resistant ovarian carcinoma cell line.;Q620730;P31;Q12140
The protein kinase C inhibitor, CGP 41 251, reverses decreased daunomycin uptake in a human drug-resistant ovarian carcinoma cell line.;Q620730;P703;Q15978631
[Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia];Q180983;P2175;Q29496
[Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia];Q186474;P1889;Q178425
[Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia];Q411659;P2175;Q6708277
[Effects of daunomycin and other tetracycline compounds on fibroblast cultures];Q411659;P31;Q11173
[Effects of daunomycin and other tetracycline compounds on fibroblast cultures];Q193045;P31;Q11173
Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative.;Q183290;P31;Q12140
Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative.;Q186474;P31;Q12140
Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative.;Q411659;P31;Q12140
Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative.;Q173670;P31;Q12140
Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative.;Q178450;P31;Q12140
Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative.;Q20035886;P31;Q12140
Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative.;Q2354337;P31;Q12140
Methylxanthines (caffeine, pentoxifylline and theophylline) decrease the mutagenic effect of daunomycin, doxorubicin and mitoxantrone.;Q407308;P279;Q49922434
Methylxanthines (caffeine, pentoxifylline and theophylline) decrease the mutagenic effect of daunomycin, doxorubicin and mitoxantrone.;Q60235;P279;Q49922434
Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B.;Q411659;P2175;Q6708277
Daunorubicinol, a major metabolite of daunorubicin: isolation from human urine and enzymatic reactions;Q178450;P703;Q15978631
Effects of cytosine arabinoside and daunorubicin on survival and cell cycle progression of Chinese hamster ovary cells;Q186474;P1889;Q178425
Remission induction in children with acute non-lymphocytic leukemia using cytosine arabinoside and doxorubicin or daunorubicin: a report from the Childrens Cancer Study Group.;Q180983;P2175;Q29496
Remission induction in children with acute non-lymphocytic leukemia using cytosine arabinoside and doxorubicin or daunorubicin: a report from the Childrens Cancer Study Group.;Q186474;P1889;Q178425
Remission induction in children with acute non-lymphocytic leukemia using cytosine arabinoside and doxorubicin or daunorubicin: a report from the Childrens Cancer Study Group.;Q411659;P2175;Q6708277
Mechanism of action of the anthracycline anti-tumor antibiotics, doxorubicin, daunomycin and rubidazone: preferential inhibition of DNA polymerase alpha;Q12187;P138;Q41579184
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin;Q411659;P279;Q417589
Treatment of acute myeloid leukemia of childhood with cytosine arabinoside, daunorubicin, prednisolone, and mercaptopurine or thioguanine.;Q385347;P2175;Q264118
Treatment of acute myeloid leukemia of childhood with cytosine arabinoside, daunorubicin, prednisolone, and mercaptopurine or thioguanine.;Q180983;P2175;Q29496
Treatment of acute myeloid leukemia of childhood with cytosine arabinoside, daunorubicin, prednisolone, and mercaptopurine or thioguanine.;Q180983;P2175;Q264118
Treatment of acute myeloid leukemia of childhood with cytosine arabinoside, daunorubicin, prednisolone, and mercaptopurine or thioguanine.;Q411659;P2175;Q264118
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia;Q180983;P2175;Q264118
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia;Q411659;P2175;Q264118
Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics;Q411659;P2175;Q264118
Adenosine triphosphate-dependent transport of doxorubicin, daunomycin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein;Q218642;P703;Q15978631
Adenosine triphosphate-dependent transport of doxorubicin, daunomycin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein;Q15277;P703;Q15978631
Adenosine triphosphate-dependent transport of doxorubicin, daunomycin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein;Q190012;P703;Q15978631
Adenosine triphosphate-dependent transport of doxorubicin, daunomycin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein;Q20035886;P703;Q15978631
Enhanced response to daunomycin of normal, tumor and metastatic cell lines via drug photoactivation.;Q411659;P31;Q12140
Liposome encapsulated daunorubicin doubles anthracycline toxicity in cell lines showing a non-PGP related multidrug resistance;Q258450;P31;Q12140
Liposome encapsulated daunorubicin doubles anthracycline toxicity in cell lines showing a non-PGP related multidrug resistance;Q411659;P31;Q12140
Liposome encapsulated daunorubicin doubles anthracycline toxicity in cell lines showing a non-PGP related multidrug resistance;Q20035886;P31;Q12140
Liposome encapsulated daunorubicin doubles anthracycline toxicity in cell lines showing a non-PGP related multidrug resistance;Q620730;P31;Q12140
Liposome encapsulated daunorubicin doubles anthracycline toxicity in cell lines showing a non-PGP related multidrug resistance;Q483745;P31;Q12140
[Treatment of acute myeloblastic leukemia by the combination of daunorubicin (or rubidazone) and cytosine arabinoside (apropos of 76 cases)];Q180983;P2175;Q264118
[Treatment of acute myeloblastic leukemia by the combination of daunorubicin (or rubidazone) and cytosine arabinoside (apropos of 76 cases)];Q180983;P2175;Q29496
[Treatment of acute myeloblastic leukemia by the combination of daunorubicin (or rubidazone) and cytosine arabinoside (apropos of 76 cases)];Q411659;P2175;Q264118
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.;Q180983;P2175;Q29496
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.;Q180983;P2175;Q976388
The Streptomyces peucetius drrC gene encodes a UvrA-like protein involved in daunorubicin resistance and production;Q218642;P703;Q1144013
The Streptomyces peucetius drrC gene encodes a UvrA-like protein involved in daunorubicin resistance and production;Q186521;P703;Q1144013
The Streptomyces peucetius drrC gene encodes a UvrA-like protein involved in daunorubicin resistance and production;Q411659;P703;Q1144013
The Streptomyces peucetius drrC gene encodes a UvrA-like protein involved in daunorubicin resistance and production;Q411659;P703;Q7623394
Regulation of daunorubicin production in Streptomyces peucetius by the dnrR2 locus.;Q411659;P703;Q7623394
Regulation of daunorubicin production in Streptomyces peucetius by the dnrR2 locus.;Q411659;P703;Q1144013
Regulation of daunorubicin production in Streptomyces peucetius by the dnrR2 locus.;Q173670;P703;Q1144013
Uptake of free and DNA-bound daunorubicin and doxorubicin into human leukemic cells;Q218642;P703;Q15978631
Uptake of free and DNA-bound daunorubicin and doxorubicin into human leukemic cells;Q178450;P703;Q15978631
Effects of mithramycin, mitomycin, daunorubicin, and bleomycin on human subconjunctival fibroblast attachment and proliferation;Q19856779;P1889;Q417625
Pharmacokinetic, toxicologic, and chemotherapeutic properties of detorubicin in mice: a comparative study with daunorubicin and adriamycin.;Q20035886;P703;Q177932
Daunomycin as an inhibitor of human lens epithelial cell proliferation in culture;Q178450;P703;Q15978631
Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.;Q411659;P2175;Q264118
Dendrimer modified graphite sensors for detection of anticancer drug Daunorubicin by voltammetry and electrochemical impedance spectroscopy;Q411659;P31;Q12140
Dendrimer modified graphite sensors for detection of anticancer drug Daunorubicin by voltammetry and electrochemical impedance spectroscopy;Q178450;P31;Q12140
[Study on pharmaceutical characterization and pharmacokinetics of daunorubicin long-circulating liposomes in rat].;Q183290;P31;Q12140
[Study on pharmaceutical characterization and pharmacokinetics of daunorubicin long-circulating liposomes in rat].;Q411659;P31;Q12140
Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study;Q411659;P2175;Q6708277
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7+3) in newly diagnosed high-risk acute myeloid leukemia (AML);Q180983;P2175;Q29496
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7+3) in newly diagnosed high-risk acute myeloid leukemia (AML);Q180983;P2175;Q264118
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7+3) in newly diagnosed high-risk acute myeloid leukemia (AML);Q411659;P2175;Q264118
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7+3) in newly diagnosed high-risk acute myeloid leukemia (AML);Q239426;P2175;Q264118
Adriamycin and daunomycin dose-dependent effects upon contractions of isolated rat myocytes;Q18936;P3780;Q47520887
[Daunomycin alone and in association with other drugs in the therapy of acute myelomonoblastic leukemia in the adult];Q411659;P31;Q12140
[Daunomycin alone and in association with other drugs in the therapy of acute myelomonoblastic leukemia in the adult];Q178450;P31;Q12140
Study of the interaction of aglycon of daunorubicin with human serum albumin by spectroscopy and modeling.;Q183290;P703;Q15978631
Sequential studies of daunorubicin and adriamycin in acute nonlymphocytic leukemia.;Q411659;P2175;Q6708277
Effect of daunomycin on cardiovascular responses to isoproterenol and norepinephrine;Q186242;P1535;Q21098983
Effect of daunomycin on cardiovascular responses to isoproterenol and norepinephrine;Q28163586;P3781;Q132621
Conventional and high-dose daunorubicin and idarubicin in acute myeloid leukaemia remission induction treatment: a mixed treatment comparison meta-analysis of 7258 patients.;Q411659;P2175;Q264118
Conventional and high-dose daunorubicin and idarubicin in acute myeloid leukaemia remission induction treatment: a mixed treatment comparison meta-analysis of 7258 patients.;Q1063862;P2175;Q264118
The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities;Q186521;P31;Q12140
The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities;Q411659;P31;Q12140
Liposomal daunorubicin (Daunoxome) and polyethylated glycol conjugated asparaginase (PEG-ASPA) in children with relapsed and refractory acute lymphoblastic leukemia treated on compassionate basis.;Q16965066;P527;Q411659
Polarographic determination of doxorubicin and daunorubicin in pharmaceutical preparations and biological media;Q18936;P31;Q12140
Polarographic determination of doxorubicin and daunorubicin in pharmaceutical preparations and biological media;Q411659;P31;Q12140
Polarographic determination of doxorubicin and daunorubicin in pharmaceutical preparations and biological media;Q20035886;P31;Q12140
Relationship between expression level of P-glycoprotein and daunorubicin transport in LLC-PK1 cells transfected with human MDR1 gene.;Q186474;P703;Q15978631
Relationship between expression level of P-glycoprotein and daunorubicin transport in LLC-PK1 cells transfected with human MDR1 gene.;Q411659;P361;Q22290410
Relationship between expression level of P-glycoprotein and daunorubicin transport in LLC-PK1 cells transfected with human MDR1 gene.;Q173670;P703;Q15978631
Relationship between expression level of P-glycoprotein and daunorubicin transport in LLC-PK1 cells transfected with human MDR1 gene.;Q178450;P703;Q15978631
Relationship between expression level of P-glycoprotein and daunorubicin transport in LLC-PK1 cells transfected with human MDR1 gene.;Q20816880;P703;Q15978631
Relationship between expression level of P-glycoprotein and daunorubicin transport in LLC-PK1 cells transfected with human MDR1 gene.;Q20035886;P703;Q15978631
Relationship between expression level of P-glycoprotein and daunorubicin transport in LLC-PK1 cells transfected with human MDR1 gene.;Q22124685;P703;Q15978631
Relationship between expression level of P-glycoprotein and daunorubicin transport in LLC-PK1 cells transfected with human MDR1 gene.;Q483745;P703;Q15978631
A plasma membrane 'vacuum cleaner' for daunorubicin in non-P-glycoprotein multidrug-resistant SW-1573 human non-small cell lung carcinoma cells. A study using fluorescence resonance energy transfer.;Q181003;P31;Q12140
A plasma membrane 'vacuum cleaner' for daunorubicin in non-P-glycoprotein multidrug-resistant SW-1573 human non-small cell lung carcinoma cells. A study using fluorescence resonance energy transfer.;Q181003;P703;Q15978631
A plasma membrane 'vacuum cleaner' for daunorubicin in non-P-glycoprotein multidrug-resistant SW-1573 human non-small cell lung carcinoma cells. A study using fluorescence resonance energy transfer.;Q183290;P31;Q12140
A plasma membrane 'vacuum cleaner' for daunorubicin in non-P-glycoprotein multidrug-resistant SW-1573 human non-small cell lung carcinoma cells. A study using fluorescence resonance energy transfer.;Q183290;P703;Q15978631
A plasma membrane 'vacuum cleaner' for daunorubicin in non-P-glycoprotein multidrug-resistant SW-1573 human non-small cell lung carcinoma cells. A study using fluorescence resonance energy transfer.;Q411659;P31;Q12140
A plasma membrane 'vacuum cleaner' for daunorubicin in non-P-glycoprotein multidrug-resistant SW-1573 human non-small cell lung carcinoma cells. A study using fluorescence resonance energy transfer.;Q20035886;P31;Q12140
A plasma membrane 'vacuum cleaner' for daunorubicin in non-P-glycoprotein multidrug-resistant SW-1573 human non-small cell lung carcinoma cells. A study using fluorescence resonance energy transfer.;Q20035886;P703;Q15978631
Involvement of glutathione and glutathione-related enzymes in the protection of normal and trisomic human fibroblasts against daunorubicin;Q116907;P703;Q15978631
Involvement of glutathione and glutathione-related enzymes in the protection of normal and trisomic human fibroblasts against daunorubicin;Q484940;P703;Q15978631
Increased excretion of urine coproporphyrins during daunorubicin administration in patients affected by acute myelogenous leukemia.;Q411659;P2175;Q264118
[A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group];Q180983;P2175;Q29496
[A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group];Q411659;P2175;Q6708277
[A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group];Q1063862;P2175;Q6708277
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q218642;P31;Q12140
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q218642;P703;Q15978631
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q218642;P31;Q407595
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q218642;P703;Q177932
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q18936;P31;Q12140
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q186474;P31;Q12140
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q186474;P703;Q177932
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q186474;P703;Q15978631
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q411659;P31;Q12140
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q191924;P366;Q8386
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q485277;P31;Q12140
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q485277;P703;Q15978631
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q485277;P703;Q177932
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q20035886;P31;Q12140
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q20035886;P703;Q15978631
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q20035886;P703;Q177932
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q425122;P31;Q12140
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q1063862;P31;Q12140
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q483745;P31;Q12140
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q483745;P703;Q15978631
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma;Q483745;P703;Q177932
Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia.;Q180983;P2175;Q29496
Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia.;Q186474;P1889;Q178425
A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.;Q180983;P2175;Q29496
A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.;Q180983;P2175;Q264118
A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.;Q411659;P2175;Q264118
A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.;Q1063862;P2175;Q264118
The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).;Q180983;P2175;Q29496
The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).;Q177094;P2175;Q29496
Ultrastructural localization of daunomycin in multidrug-resistant cultured cells with modulation of the multidrug transporter.;Q411659;P31;Q12140
Kinetic evaluation of the effect of actinomycin D, daunomycin, and mitomycin C on proliferating cultured leukemia L 1210 cells;Q19856779;P1889;Q417625
A comparative trial of remission induction (by cytosine arabinoside, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia;Q385347;P2175;Q264118
A comparative trial of remission induction (by cytosine arabinoside, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia;Q180983;P2175;Q29496
A comparative trial of remission induction (by cytosine arabinoside, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia;Q180983;P2175;Q264118
A comparative trial of remission induction (by cytosine arabinoside, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia;Q218642;P703;Q2046782
A comparative trial of remission induction (by cytosine arabinoside, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia;Q186474;P1889;Q178425
A comparative trial of remission induction (by cytosine arabinoside, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia;Q411659;P2175;Q264118
Different distribution of daunomycin in plasma membranes from drug-sensitive and drug-resistant P388 leukemia cells.;Q411659;P31;Q12140
Different distribution of daunomycin in plasma membranes from drug-sensitive and drug-resistant P388 leukemia cells.;Q178450;P31;Q12140
Different distribution of daunomycin in plasma membranes from drug-sensitive and drug-resistant P388 leukemia cells.;Q20035886;P31;Q12140
Serine protease inhibitors block neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin;Q183290;P31;Q26997410
Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.;Q180983;P2175;Q29496
Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.;Q180983;P2175;Q264118
Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.;Q411659;P2175;Q264118
[Treatment of acute myeloid leukemia with daunomycin (38 cases)];Q411659;P2175;Q264118
[Predictive value of intracellular accumulation of daunorubicin and P-glycoprotein expression simultaneously determined by flow cytometry in adult acute myeloid leukemias].;Q411659;P2175;Q264118
GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate;Q411659;P31;Q12140
GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate;Q191924;P366;Q8386
GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate;Q485277;P31;Q12140
GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate;Q173670;P31;Q12140
GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate;Q20817116;P31;Q12140
GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate;Q620730;P31;Q12140
GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate;Q484940;P31;Q12140
GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate;Q422232;P31;Q12140
The comparative study of influence of lactic and glycolic acids copolymers type on properties of daunorubicin loaded nanoparticles and drug release;Q23118;P31;Q8386
The comparative study of influence of lactic and glycolic acids copolymers type on properties of daunorubicin loaded nanoparticles and drug release;Q186521;P31;Q12140
The comparative study of influence of lactic and glycolic acids copolymers type on properties of daunorubicin loaded nanoparticles and drug release;Q411659;P31;Q12140
Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia.;Q411659;P2175;Q264118
What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?;Q411659;P2175;Q264118
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.;Q287029;P2175;Q29496
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.;Q287029;P31;Q425517
Vincristine (NSC-67574), cytosine arabinoside (NSC-63878), 6 thioguanine (NSC-752) and daunorubicin (NSC-82151) (VAT-D): a pilot study of combination chemotherapy for remission induction in acute myeloid leukemia in adults.;Q385347;P2175;Q264118
Vincristine (NSC-67574), cytosine arabinoside (NSC-63878), 6 thioguanine (NSC-752) and daunorubicin (NSC-82151) (VAT-D): a pilot study of combination chemotherapy for remission induction in acute myeloid leukemia in adults.;Q180983;P2175;Q29496
Vincristine (NSC-67574), cytosine arabinoside (NSC-63878), 6 thioguanine (NSC-752) and daunorubicin (NSC-82151) (VAT-D): a pilot study of combination chemotherapy for remission induction in acute myeloid leukemia in adults.;Q180983;P2175;Q264118
Vincristine (NSC-67574), cytosine arabinoside (NSC-63878), 6 thioguanine (NSC-752) and daunorubicin (NSC-82151) (VAT-D): a pilot study of combination chemotherapy for remission induction in acute myeloid leukemia in adults.;Q186474;P1889;Q178425
Vincristine (NSC-67574), cytosine arabinoside (NSC-63878), 6 thioguanine (NSC-752) and daunorubicin (NSC-82151) (VAT-D): a pilot study of combination chemotherapy for remission induction in acute myeloid leukemia in adults.;Q411659;P2175;Q264118
Vincristine (NSC-67574), cytosine arabinoside (NSC-63878), 6 thioguanine (NSC-752) and daunorubicin (NSC-82151) (VAT-D): a pilot study of combination chemotherapy for remission induction in acute myeloid leukemia in adults.;Q408977;P2175;Q29496
Affinity of anticancer drug, daunomycin, to core histones in solution: comparison of free and cross-linked proteins;Q218642;P31;Q12140
Affinity of anticancer drug, daunomycin, to core histones in solution: comparison of free and cross-linked proteins;Q411659;P31;Q12140
DNA-drug interactions. The crystal structure of d(CGATCG) complexed with daunomycin;Q218642;P31;Q12140
DNA-drug interactions. The crystal structure of d(CGATCG) complexed with daunomycin;Q186474;P31;Q12140
DNA-drug interactions. The crystal structure of d(CGATCG) complexed with daunomycin;Q186521;P31;Q12140
DNA-drug interactions. The crystal structure of d(CGATCG) complexed with daunomycin;Q411659;P31;Q12140
DNA-drug interactions. The crystal structure of d(CGATCG) complexed with daunomycin;Q191924;P31;Q12140
DNA-drug interactions. The crystal structure of d(CGATCG) complexed with daunomycin;Q178450;P31;Q12140
DNA-drug interactions. The crystal structure of d(CGATCG) complexed with daunomycin;Q620730;P31;Q12140
["Chimeric" antibiotics, daunorubicin and its analogs N-acylated with bruneomycin (Streptonigrin)];Q423098;P2868;Q12187
Effects of anthracycline antibiotic, daunomycin on thymus chromatin: the role of chromosomal proteins.;Q411659;P279;Q417589
P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia;Q411659;P2175;Q264118
Microbial metabolism of anthracycline antibiotics daunomycin and adriamycin.;Q411659;P279;Q417589
Model for calculating chromatographic mobility of anthracycline antibiotics of the series of daunorubicin and its polysynthetic analogs;Q411659;P279;Q417589
[Therapeutic study of leukemia by pegylated liposomal daunorubicin];Q186521;P703;Q177932
GLC--mass spectrometry of several important anticancer drugs II: doxorubicin and daunorubicin aglycone analogs.;Q18936;P31;Q12140
GLC--mass spectrometry of several important anticancer drugs II: doxorubicin and daunorubicin aglycone analogs.;Q186474;P31;Q12140
GLC--mass spectrometry of several important anticancer drugs II: doxorubicin and daunorubicin aglycone analogs.;Q411659;P31;Q12140
GLC--mass spectrometry of several important anticancer drugs II: doxorubicin and daunorubicin aglycone analogs.;Q620730;P31;Q12140
GLC--mass spectrometry of several important anticancer drugs II: doxorubicin and daunorubicin aglycone analogs.;Q483745;P31;Q12140
GLC--mass spectrometry of several important anticancer drugs II: doxorubicin and daunorubicin aglycone analogs.;Q484940;P31;Q12140
Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia.;Q411659;P2175;Q264118
Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia.;Q1063862;P2175;Q264118
Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institute experience.;Q411659;P2175;Q264118
[Early daunorubicin cardiotoxicity and fatal outcome in a child with acute myeloblastic leukemia (M2)];Q411659;P2175;Q264118
Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.;Q180983;P2175;Q29496
Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.;Q180983;P2175;Q264118
Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.;Q411659;P2175;Q264118
Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study.;Q411659;P2175;Q264118
Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study.;Q412685;P527;Q105946712
Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study.;Q412685;P2175;Q264118
The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.;Q18936;P31;Q109603820
The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.;Q411659;P31;Q109603820
High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia.;Q411659;P31;Q11173
High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia.;Q485277;P31;Q11173
High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia.;Q178450;P31;Q11173
[The effects of cytosine arabinoside and daunomycin on cell kinetics in childhood acute myeloblastic leukemia];Q180983;P2175;Q264118
[The effects of cytosine arabinoside and daunomycin on cell kinetics in childhood acute myeloblastic leukemia];Q180983;P2175;Q29496
[The effects of cytosine arabinoside and daunomycin on cell kinetics in childhood acute myeloblastic leukemia];Q411659;P2175;Q264118
Mapping the DNA-binding domain and target sequences of the Streptomyces peucetius daunorubicin biosynthesis regulatory protein, DnrI.;Q218642;P703;Q1144013
Mapping the DNA-binding domain and target sequences of the Streptomyces peucetius daunorubicin biosynthesis regulatory protein, DnrI.;Q411659;P703;Q1144013
Mapping the DNA-binding domain and target sequences of the Streptomyces peucetius daunorubicin biosynthesis regulatory protein, DnrI.;Q411659;P703;Q7623394
Mapping the DNA-binding domain and target sequences of the Streptomyces peucetius daunorubicin biosynthesis regulatory protein, DnrI.;Q411659;P361;Q22277880
Double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without recombinant human granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: economic evaluation with attention to inpatient and outpat;Q180983;P2175;Q29496
Double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without recombinant human granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: economic evaluation with attention to inpatient and outpat;Q180983;P2175;Q264118
Double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without recombinant human granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: economic evaluation with attention to inpatient and outpat;Q411659;P2175;Q264118
Double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without recombinant human granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: economic evaluation with attention to inpatient and outpat;Q178450;P703;Q15978631
Liposomal daunorubicin (DaunoXome) in children with recurrent or progressive brain tumors;Q16965066;P527;Q411659
Combined effects of bortezomib and daunorubicin on multiple myeloma cell KM3 in vitro.;Q419319;P2175;Q467635
Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia;Q411659;P2175;Q264118
Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia;Q1063862;P2175;Q264118
Daunorubicin efflux assay in determining multidrug resistance of patients with acute myeloid leukemia.;Q153;P31;Q12140
Daunorubicin efflux assay in determining multidrug resistance of patients with acute myeloid leukemia.;Q411659;P31;Q12140
Daunorubicin efflux assay in determining multidrug resistance of patients with acute myeloid leukemia.;Q411659;P2175;Q264118
Daunorubicin efflux assay in determining multidrug resistance of patients with acute myeloid leukemia.;Q178450;P31;Q12140
Trypanocidal activity of daunorubicin and related compounds;Q186521;P31;Q11173
Trypanocidal activity of daunorubicin and related compounds;Q411659;P31;Q11173
In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry.;Q411659;P2175;Q264118
[Quadruple combination chemotherapy of acute leukemia using daunomycin, cytosine arabinoside, 6-mercaptopurine riboside and prednisolone];Q180983;P2175;Q29496
[Quadruple combination chemotherapy of acute leukemia using daunomycin, cytosine arabinoside, 6-mercaptopurine riboside and prednisolone];Q180983;P2175;Q976388
Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine.;Q180983;P2175;Q29496
Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine.;Q180983;P2175;Q264118
Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine.;Q411659;P2175;Q264118
Age and cytogenetics as predictors of event free survival in patients with acute non-lymphocytic leukemia receiving high dose cytosine arabinoside and daunorubicin as consolidation chemotherapy.;Q180983;P2175;Q29496
Age and cytogenetics as predictors of event free survival in patients with acute non-lymphocytic leukemia receiving high dose cytosine arabinoside and daunorubicin as consolidation chemotherapy.;Q411659;P2175;Q6708277
High-dose daunorubicin in older patients with acute myeloid leukemia;Q411659;P2175;Q264118
The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia.;Q186521;P31;Q12140
The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia.;Q411659;P31;Q12140
The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia.;Q1063862;P31;Q12140
Nucleic Acid Biohybrid Nanocarriers with High Therapeutic Payload and Controllable Extended Release of Daunomycin for Cancer Therapy;Q218642;P703;Q177932
Nucleic Acid Biohybrid Nanocarriers with High Therapeutic Payload and Controllable Extended Release of Daunomycin for Cancer Therapy;Q186474;P703;Q177932
Nucleic Acid Biohybrid Nanocarriers with High Therapeutic Payload and Controllable Extended Release of Daunomycin for Cancer Therapy;Q186521;P703;Q177932
Nucleic Acid Biohybrid Nanocarriers with High Therapeutic Payload and Controllable Extended Release of Daunomycin for Cancer Therapy;Q485277;P703;Q177932
Nucleic Acid Biohybrid Nanocarriers with High Therapeutic Payload and Controllable Extended Release of Daunomycin for Cancer Therapy;Q173670;P703;Q177932
Nucleic Acid Biohybrid Nanocarriers with High Therapeutic Payload and Controllable Extended Release of Daunomycin for Cancer Therapy;Q178450;P703;Q177932
Nucleic Acid Biohybrid Nanocarriers with High Therapeutic Payload and Controllable Extended Release of Daunomycin for Cancer Therapy;Q20035886;P703;Q177932
Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma;Q16965066;P527;Q411659
A simplified method for determination of daunorubicin, adriamycin, and their chief fluorescent metabolites in human plasma by high-pressure liquid chromatography;Q218642;P703;Q15978631
A simplified method for determination of daunorubicin, adriamycin, and their chief fluorescent metabolites in human plasma by high-pressure liquid chromatography;Q218642;P31;Q407595
Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin;Q180983;P2175;Q29496
Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin;Q180983;P2175;Q264118
Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin;Q186474;P1889;Q178425
Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin;Q411659;P2175;Q264118
Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin;Q1063862;P2175;Q264118
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leuk;Q183290;P31;Q12140
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leuk;Q186474;P31;Q12140
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leuk;Q180983;P31;Q12140
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leuk;Q180983;P2175;Q29496
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leuk;Q180983;P2175;Q264118
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leuk;Q411659;P31;Q12140
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leuk;Q411659;P2175;Q264118
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leuk;Q418817;P31;Q12140
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leuk;Q418817;P2175;Q264118
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leuk;Q20035886;P31;Q12140
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leuk;Q424342;P31;Q12140
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leuk;Q484940;P31;Q12140
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leuk;Q2354337;P31;Q12140
Reversible targeting and controlled release delivery of daunorubicin to cancer cells by aptamer-wrapped carbon nanotubes.;Q173670;P527;Q623
Role of apoptosis in the cytotoxic effect mediated by daunorubicin in cultured human retinal pigment epithelial cells.;Q173670;P703;Q15978631
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16);Q218642;P31;Q12140
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16);Q186474;P31;Q12140
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16);Q411659;P31;Q12140
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16);Q170545;P31;Q12140
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16);Q173670;P31;Q12140
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16);Q418817;P31;Q12140
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16);Q178450;P31;Q12140
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16);Q20035886;P31;Q12140
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16);Q483752;P31;Q12140
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16);Q484940;P31;Q12140
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16);Q524995;P31;Q12140
Combination chemotherapy with daunorubicin, cytosine arabinoside and prednisolone (DAP) in acute nonlymphocytic leukemia;Q180983;P2175;Q29496
Combination chemotherapy with daunorubicin, cytosine arabinoside and prednisolone (DAP) in acute nonlymphocytic leukemia;Q186474;P1889;Q178425
Combination chemotherapy with daunorubicin, cytosine arabinoside and prednisolone (DAP) in acute nonlymphocytic leukemia;Q411659;P2175;Q6708277
Isolation and characterization of stable mutants of Streptomyces peucetius defective in daunorubicin biosynthesis;Q411659;P361;Q22277880
Isolation and characterization of stable mutants of Streptomyces peucetius defective in daunorubicin biosynthesis;Q411659;P703;Q7623394
Isolation and characterization of stable mutants of Streptomyces peucetius defective in daunorubicin biosynthesis;Q411659;P703;Q1144013
Daunorubicin, cytosine arabinoside, 6-mercaptopurine riboside, and prednisolone (DCMP) combination chemotherapy for acute myelogenous leukemia in adults;Q180983;P2175;Q29496
Daunorubicin, cytosine arabinoside, 6-mercaptopurine riboside, and prednisolone (DCMP) combination chemotherapy for acute myelogenous leukemia in adults;Q180983;P2175;Q264118
Daunorubicin, cytosine arabinoside, 6-mercaptopurine riboside, and prednisolone (DCMP) combination chemotherapy for acute myelogenous leukemia in adults;Q186474;P1889;Q178425
Daunorubicin, cytosine arabinoside, 6-mercaptopurine riboside, and prednisolone (DCMP) combination chemotherapy for acute myelogenous leukemia in adults;Q411659;P2175;Q264118
Fate of 5-fluorouracil, doxorubicin, epirubicin, and daunorubicin in hospital wastewater and their elimination by activated sludge and treatment in a membrane-bio-reactor system.;Q29053744;P155;Q23392
The Streptomyces peucetius dpsC gene determines the choice of starter unit in biosynthesis of the daunorubicin polyketide.;Q186521;P703;Q1144013
The Streptomyces peucetius dpsC gene determines the choice of starter unit in biosynthesis of the daunorubicin polyketide.;Q411659;P703;Q7623394
The Streptomyces peucetius dpsC gene determines the choice of starter unit in biosynthesis of the daunorubicin polyketide.;Q411659;P703;Q1144013
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.;Q180983;P2175;Q29496
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.;Q180983;P2175;Q264118
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.;Q411659;P2175;Q264118
Influence of continuous infusion of cytosine arabinoside on sequencing with daunorubicin in L1210 leukemia;Q180983;P2175;Q29496
Metabolism of daunomycin (NSC-82151) in vitro and the chemotherapeutic activity of isolated metabolites in vivo;Q183290;P703;Q177932
Metabolism of daunomycin (NSC-82151) in vitro and the chemotherapeutic activity of isolated metabolites in vivo;Q186474;P703;Q177932
Metabolism of daunomycin (NSC-82151) in vitro and the chemotherapeutic activity of isolated metabolites in vivo;Q22124685;P703;Q177932
Effect of idarubicin and epirubicin on in vitro polymorphonuclear function: diminished superoxide radical formation compared to their parent compounds daunorubicin and doxorubicin;Q18936;P31;Q11173
Effect of idarubicin and epirubicin on in vitro polymorphonuclear function: diminished superoxide radical formation compared to their parent compounds daunorubicin and doxorubicin;Q411659;P31;Q11173
Effect of idarubicin and epirubicin on in vitro polymorphonuclear function: diminished superoxide radical formation compared to their parent compounds daunorubicin and doxorubicin;Q425122;P31;Q11173
Effect of idarubicin and epirubicin on in vitro polymorphonuclear function: diminished superoxide radical formation compared to their parent compounds daunorubicin and doxorubicin;Q1063862;P31;Q11173
Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test.;Q411659;P2868;Q281044
Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test.;Q1063862;P2868;Q281044
[Therapeutic trials in acute myeloblastic leukosis. Analysis of a group of 51 patients treated with daunomycin];Q218642;P703;Q177932
[Therapeutic trials in acute myeloblastic leukosis. Analysis of a group of 51 patients treated with daunomycin];Q186521;P703;Q177932
A new anthracycline metabolite D788-1 (10-carboxy-13-deoxocarminomycin) in daunorubicin beer;Q218642;P31;Q407595
High-dose versus standard-dose daunorubicin in induction therapy for young patients with de novo acute myeloid leukaemia: a meta-analysis of randomised trials.;Q411659;P2175;Q264118
Targeted inhibition of ULK1 enhances daunorubicin sensitivity in acute myeloid leukemia;Q411659;P2175;Q264118
A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.;Q180983;P2175;Q29496
A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.;Q180983;P2175;Q264118
A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.;Q411659;P2175;Q264118
Adriamycin analogues. Preparation and biological evaluation of some N-perfluoroacyl analogues of daunorubicin, adriamycin, and N-(trifluoroacetyl)adriamycin 14-valerate and their 9,10-anhydro derivatives;Q18936;P3780;Q47520887
Inhibitory effects of daunorubicin on endothelium-dependent vasorelaxing response to acetylcholine of rat aorta;Q180623;P361;Q24460665
Treatment of acute non lymphocytic leukemia. Results of a prospective trial of daunorubicin, arabinosylcytosine and 6-thioguanine (DAT) versus DAT plus vindesine and etoposide;Q411659;P2175;Q6708277
Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro;Q408977;P2175;Q29496
Influence of pokeweed mitogen, phytohemagglutinin, and Bacillus Calmette-Gurin on the toxicity of rubidomycin on DBA-2 mice.;Q186474;P703;Q83310
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice;Q411659;P31;Q12140
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice;Q191924;P31;Q12140
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice;Q170545;P31;Q12140
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice;Q173670;P31;Q12140
Induction chemotherapy for newly diagnosed acute myeloid leukaemia using a regime containing cytosine arabinoside, daunorubicin and etoposide.;Q180983;P2175;Q29496
Induction chemotherapy for newly diagnosed acute myeloid leukaemia using a regime containing cytosine arabinoside, daunorubicin and etoposide.;Q180983;P2175;Q264118
Induction chemotherapy for newly diagnosed acute myeloid leukaemia using a regime containing cytosine arabinoside, daunorubicin and etoposide.;Q411659;P2175;Q264118
Induction chemotherapy for newly diagnosed acute myeloid leukaemia using a regime containing cytosine arabinoside, daunorubicin and etoposide.;Q418817;P2175;Q264118
Synthetic anthracyclines: regiospecific total synthesis of D-ring thiophene analogues of daunomycin;Q411659;P31;Q109603820
Functional characterization and transcriptional analysis of the dnrR1 locus, which controls daunorubicin biosynthesis in Streptomyces peucetius.;Q411659;P703;Q7623394
Functional characterization and transcriptional analysis of the dnrR1 locus, which controls daunorubicin biosynthesis in Streptomyces peucetius.;Q411659;P703;Q1144013
Functional characterization and transcriptional analysis of the dnrR1 locus, which controls daunorubicin biosynthesis in Streptomyces peucetius.;Q411659;P361;Q22277880
Functional characterization and transcriptional analysis of the dnrR1 locus, which controls daunorubicin biosynthesis in Streptomyces peucetius.;Q173670;P703;Q1144013
A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia;Q180983;P2175;Q29496
A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia;Q411659;P2175;Q6708277
Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review.;Q18936;P279;Q417589
Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review.;Q411659;P279;Q417589
Daunorubicin metabolism by human hematological components;Q178450;P703;Q15978631
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells;Q218642;P31;Q12140
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells;Q411659;P31;Q12140
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells;Q170545;P31;Q12140
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells;Q173670;P31;Q12140
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells;Q178450;P31;Q12140
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells;Q22124685;P31;Q12140
Drug-induced kinetic perturbations of the marrow blasts in acute leukemia. Effects of the daunorubicin, cytosine arabinoside and 6-thioguanine combination.;Q180983;P2175;Q29496
Drug-induced kinetic perturbations of the marrow blasts in acute leukemia. Effects of the daunorubicin, cytosine arabinoside and 6-thioguanine combination.;Q180983;P2175;Q976388
Association of daunomycin to membrane domains studied by fluorescence resonance energy transfer;Q218642;P703;Q2046782
In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.;Q180983;P2175;Q29496
In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.;Q180983;P2175;Q264118
In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.;Q411659;P2175;Q264118
Activity of adriamycin (NSC-123127) and daunomycin (NSC-82151) against mouse mammary carcinoma;Q186474;P703;Q83310
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia.;Q180983;P2175;Q29496
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia.;Q180983;P2175;Q264118
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia.;Q411659;P2175;Q264118
Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results;Q385347;P2175;Q264118
Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results;Q180983;P2175;Q29496
Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results;Q180983;P2175;Q264118
Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results;Q411659;P2175;Q264118
Biodistribution of intravenously injected [14C] doxorubicin and [14C] daunorubicin in mice: concise communication;Q186474;P703;Q83310
Preparation and utility of a radioiodinated analogue of daunomycin in the study of multidrug resistance.;Q411659;P31;Q12140
Preparation and utility of a radioiodinated analogue of daunomycin in the study of multidrug resistance.;Q20035886;P31;Q12140
Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial;Q180983;P2175;Q29496
Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial;Q411659;P2175;Q6708277
Modeling Drug-Drug Interactions of AZD1208 with Vincristine and Daunorubicin on Ligand-Extrusion Binding TMD-Domains of multidrug resistance P-glycoprotein (ABCB1);Q218642;P31;Q12140
Modeling Drug-Drug Interactions of AZD1208 with Vincristine and Daunorubicin on Ligand-Extrusion Binding TMD-Domains of multidrug resistance P-glycoprotein (ABCB1);Q186474;P31;Q12140
Modeling Drug-Drug Interactions of AZD1208 with Vincristine and Daunorubicin on Ligand-Extrusion Binding TMD-Domains of multidrug resistance P-glycoprotein (ABCB1);Q186521;P31;Q12140
Modeling Drug-Drug Interactions of AZD1208 with Vincristine and Daunorubicin on Ligand-Extrusion Binding TMD-Domains of multidrug resistance P-glycoprotein (ABCB1);Q411659;P31;Q12140
Modeling Drug-Drug Interactions of AZD1208 with Vincristine and Daunorubicin on Ligand-Extrusion Binding TMD-Domains of multidrug resistance P-glycoprotein (ABCB1);Q408977;P31;Q12140
Modeling Drug-Drug Interactions of AZD1208 with Vincristine and Daunorubicin on Ligand-Extrusion Binding TMD-Domains of multidrug resistance P-glycoprotein (ABCB1);Q304330;P31;Q12140
Modeling Drug-Drug Interactions of AZD1208 with Vincristine and Daunorubicin on Ligand-Extrusion Binding TMD-Domains of multidrug resistance P-glycoprotein (ABCB1);Q178450;P31;Q12140
Modeling Drug-Drug Interactions of AZD1208 with Vincristine and Daunorubicin on Ligand-Extrusion Binding TMD-Domains of multidrug resistance P-glycoprotein (ABCB1);Q20035886;P31;Q12140
Modeling Drug-Drug Interactions of AZD1208 with Vincristine and Daunorubicin on Ligand-Extrusion Binding TMD-Domains of multidrug resistance P-glycoprotein (ABCB1);Q22124685;P31;Q12140
Modeling Drug-Drug Interactions of AZD1208 with Vincristine and Daunorubicin on Ligand-Extrusion Binding TMD-Domains of multidrug resistance P-glycoprotein (ABCB1);Q420439;P31;Q12140
Modeling Drug-Drug Interactions of AZD1208 with Vincristine and Daunorubicin on Ligand-Extrusion Binding TMD-Domains of multidrug resistance P-glycoprotein (ABCB1);Q483745;P31;Q12140
Modeling Drug-Drug Interactions of AZD1208 with Vincristine and Daunorubicin on Ligand-Extrusion Binding TMD-Domains of multidrug resistance P-glycoprotein (ABCB1);Q483752;P31;Q12140
Modeling Drug-Drug Interactions of AZD1208 with Vincristine and Daunorubicin on Ligand-Extrusion Binding TMD-Domains of multidrug resistance P-glycoprotein (ABCB1);Q484940;P31;Q12140
Quantitative evaluation of intracellular uptake of daunorubicin in acute myeloid leukemia: a method analysis.;Q411659;P2175;Q264118
Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells.;Q218642;P703;Q15978631
Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells.;Q218642;P527;Q623
Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells.;Q178450;P527;Q623
Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells.;Q178450;P703;Q15978631
Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells.;Q20816880;P703;Q15978631
Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells.;Q20035886;P703;Q15978631
The multidrug transporter: rapid modulation of efflux activity monitored in single cells by the morphologic effects of vinblastine and daunomycin;Q153;P31;Q12140
The multidrug transporter: rapid modulation of efflux activity monitored in single cells by the morphologic effects of vinblastine and daunomycin;Q186521;P31;Q12140
The multidrug transporter: rapid modulation of efflux activity monitored in single cells by the morphologic effects of vinblastine and daunomycin;Q411659;P31;Q12140
High-dose cytosine arabinoside, daunomycin and 6-thioguanine in relapsed or refractory acute nonlymphocytic leukemia.;Q180983;P2175;Q29496
High-dose cytosine arabinoside, daunomycin and 6-thioguanine in relapsed or refractory acute nonlymphocytic leukemia.;Q411659;P2175;Q6708277
Electrochemical study of the anticancer drug daunorubicin at a water/oil interface: drug lipophilicity and quantification;Q411659;P31;Q12140
Electrochemical study of the anticancer drug daunorubicin at a water/oil interface: drug lipophilicity and quantification;Q29053744;P366;Q7892
Electrochemical study of the anticancer drug daunorubicin at a water/oil interface: drug lipophilicity and quantification;Q29053744;P31;Q12140
Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.;Q180983;P2175;Q264118
Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.;Q180983;P2175;Q29496
Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.;Q411659;P2175;Q264118
No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group;Q180983;P2175;Q29496
No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group;Q180983;P2175;Q264118
No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group;Q411659;P2175;Q264118
No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group;Q418817;P2175;Q264118
The Streptomyces peucetius dpsC Gene Determines the Choice of Starter Unit in Biosynthesis of the Daunorubicin Polyketide;Q186521;P703;Q1144013
The Streptomyces peucetius dpsC Gene Determines the Choice of Starter Unit in Biosynthesis of the Daunorubicin Polyketide;Q411659;P703;Q7623394
The Streptomyces peucetius dpsC Gene Determines the Choice of Starter Unit in Biosynthesis of the Daunorubicin Polyketide;Q411659;P703;Q1144013
The Streptomyces peucetius dpsC Gene Determines the Choice of Starter Unit in Biosynthesis of the Daunorubicin Polyketide;Q620730;P703;Q1144013
[Influence of perfluorodecalin on growth of actinomycetes and intensification of Streptomycin and daunorubicin production by the genus Streptomyces kind bacteria in submerged culture];Q411659;P703;Q1144013
[Influence of perfluorodecalin on growth of actinomycetes and intensification of Streptomycin and daunorubicin production by the genus Streptomyces kind bacteria in submerged culture];Q192717;P703;Q1144013
Successful re-induction therapy for acute myelogenous leukemia with cytosine arabinoside and daunorubicin;Q180983;P2175;Q264118
Successful re-induction therapy for acute myelogenous leukemia with cytosine arabinoside and daunorubicin;Q180983;P2175;Q29496
Successful re-induction therapy for acute myelogenous leukemia with cytosine arabinoside and daunorubicin;Q411659;P2175;Q264118
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.;Q183290;P31;Q12140
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.;Q186474;P31;Q12140
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.;Q180983;P31;Q12140
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.;Q180983;P2175;Q29496
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.;Q180983;P2175;Q264118
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.;Q411659;P31;Q12140
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.;Q411659;P2175;Q264118
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.;Q178450;P31;Q12140
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.;Q20035886;P31;Q12140
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.;Q2354337;P31;Q12140
Determination of daunorubicin, doxorubicin and their fluorescent metabolites by high-pressure liquid chromatography: plasma levels in DBA2 mice;Q218642;P31;Q407595
High concentration of Daunorubicin and Daunorubicinol in human malignant astrocytomas after systemic administration of liposomal Daunorubicin.;Q485277;P703;Q15978631
High concentration of Daunorubicin and Daunorubicinol in human malignant astrocytomas after systemic administration of liposomal Daunorubicin.;Q178450;P703;Q15978631
The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicin;Q186474;P703;Q15978631
The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicin;Q186474;P31;Q12140
The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicin;Q186521;P703;Q15978631
The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicin;Q186521;P31;Q12140
The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicin;Q411659;P31;Q12140
Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: implications for liposome-encapsulated daunorubicin.;Q411659;P31;Q12140
Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: implications for liposome-encapsulated daunorubicin.;Q22124685;P31;Q12140
Competitive interaction of the antitumor drug daunorubicin and the fluorescence probe ethidium bromide with DNA as studied by resolving trilinear fluorescence data: the use of PARAFAC and its modification;Q218642;P31;Q12140
Competitive interaction of the antitumor drug daunorubicin and the fluorescence probe ethidium bromide with DNA as studied by resolving trilinear fluorescence data: the use of PARAFAC and its modification;Q186474;P31;Q12140
Competitive interaction of the antitumor drug daunorubicin and the fluorescence probe ethidium bromide with DNA as studied by resolving trilinear fluorescence data: the use of PARAFAC and its modification;Q7130425;P31;Q12140
Competitive interaction of the antitumor drug daunorubicin and the fluorescence probe ethidium bromide with DNA as studied by resolving trilinear fluorescence data: the use of PARAFAC and its modification;Q411659;P31;Q12140
Competitive interaction of the antitumor drug daunorubicin and the fluorescence probe ethidium bromide with DNA as studied by resolving trilinear fluorescence data: the use of PARAFAC and its modification;Q170545;P31;Q12140
Competitive interaction of the antitumor drug daunorubicin and the fluorescence probe ethidium bromide with DNA as studied by resolving trilinear fluorescence data: the use of PARAFAC and its modification;Q173670;P31;Q12140
Competitive interaction of the antitumor drug daunorubicin and the fluorescence probe ethidium bromide with DNA as studied by resolving trilinear fluorescence data: the use of PARAFAC and its modification;Q178450;P31;Q12140
Competitive interaction of the antitumor drug daunorubicin and the fluorescence probe ethidium bromide with DNA as studied by resolving trilinear fluorescence data: the use of PARAFAC and its modification;Q20035886;P31;Q12140
Induction therapy and intensive consolidation with daunorubicin, cytosine arabinoside, and 6-thioguanine in adult acute nonlymphoblastic leukemia;Q180983;P2175;Q29496
Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes;Q180983;P2175;Q264118
Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes;Q180983;P2175;Q954625
Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes;Q411659;P2175;Q264118
The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.;Q186521;P31;Q12140
The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.;Q411659;P31;Q12140
The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.;Q483745;P31;Q12140
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation;Q218642;P703;Q2046782
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation;Q178450;P703;Q2046782
Improvement of flow-cytometric detection of multidrug-resistant cells by cell-volume normalization of intracellular daunorubicin content.;Q411659;P31;Q12140
Improvement of flow-cytometric detection of multidrug-resistant cells by cell-volume normalization of intracellular daunorubicin content.;Q484940;P31;Q12140
Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500);Q180983;P2175;Q29496
Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500);Q180983;P2175;Q264118
Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500);Q411659;P2175;Q264118
Inhibition of nucleic acid synthesis by daunomycin and its relationship to the uptake of the drug in HeLa cells;Q23118;P31;Q8386
Inhibition of nucleic acid synthesis by daunomycin and its relationship to the uptake of the drug in HeLa cells;Q411659;P31;Q12140
Inhibition of nucleic acid synthesis by daunomycin and its relationship to the uptake of the drug in HeLa cells;Q485277;P31;Q12140
Inhibition of nucleic acid synthesis by daunomycin and its relationship to the uptake of the drug in HeLa cells;Q483745;P31;Q12140
Inhibition of nucleic acid synthesis by daunomycin and its relationship to the uptake of the drug in HeLa cells;Q484940;P31;Q12140
Two years' experience in the treatment of acute myeloid leukaemia using a three-drug regimen: daunorubicin, cytosine arabinoside and 6-thioguanine;Q385347;P31;Q12140
Two years' experience in the treatment of acute myeloid leukaemia using a three-drug regimen: daunorubicin, cytosine arabinoside and 6-thioguanine;Q385347;P2175;Q264118
Two years' experience in the treatment of acute myeloid leukaemia using a three-drug regimen: daunorubicin, cytosine arabinoside and 6-thioguanine;Q180983;P31;Q12140
Two years' experience in the treatment of acute myeloid leukaemia using a three-drug regimen: daunorubicin, cytosine arabinoside and 6-thioguanine;Q180983;P2175;Q29496
Two years' experience in the treatment of acute myeloid leukaemia using a three-drug regimen: daunorubicin, cytosine arabinoside and 6-thioguanine;Q180983;P2175;Q264118
Two years' experience in the treatment of acute myeloid leukaemia using a three-drug regimen: daunorubicin, cytosine arabinoside and 6-thioguanine;Q186521;P31;Q12140
Two years' experience in the treatment of acute myeloid leukaemia using a three-drug regimen: daunorubicin, cytosine arabinoside and 6-thioguanine;Q411659;P31;Q12140
Two years' experience in the treatment of acute myeloid leukaemia using a three-drug regimen: daunorubicin, cytosine arabinoside and 6-thioguanine;Q411659;P2175;Q264118
Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients.;Q218642;P31;Q12140
Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients.;Q411659;P31;Q12140
Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients.;Q178450;P31;Q12140
Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients.;Q20035886;P31;Q12140
2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia.;Q411659;P2175;Q264118
miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2.;Q218642;P31;Q12140
miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2.;Q186474;P31;Q12140
miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2.;Q411659;P31;Q12140
miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2.;Q173670;P31;Q12140
miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2.;Q20816880;P31;Q12140
miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2.;Q483745;P31;Q12140
Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo);Q218642;P703;Q15978631
Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo);Q218642;P31;Q12140
Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo);Q18936;P31;Q12140
Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo);Q186474;P703;Q15978631
Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo);Q186474;P31;Q12140
Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo);Q411659;P31;Q12140
Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo);Q178450;P31;Q12140
Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo);Q178450;P703;Q15978631
Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo);Q483745;P31;Q12140
Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo);Q483745;P703;Q15978631
Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo);Q483752;P703;Q15978631
Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo);Q483752;P31;Q12140
[Combined effect of recombinant mutant human TRAIL and daunorubicin in inducing apoptosis of leukemia cell and its mechanism];Q218642;P703;Q15978631
[Combined effect of recombinant mutant human TRAIL and daunorubicin in inducing apoptosis of leukemia cell and its mechanism];Q186474;P703;Q15978631
[Combined effect of recombinant mutant human TRAIL and daunorubicin in inducing apoptosis of leukemia cell and its mechanism];Q186521;P703;Q15978631
[Combined effect of recombinant mutant human TRAIL and daunorubicin in inducing apoptosis of leukemia cell and its mechanism];Q173670;P703;Q15978631
[Combined effect of recombinant mutant human TRAIL and daunorubicin in inducing apoptosis of leukemia cell and its mechanism];Q483745;P703;Q15978631
[Combined effect of recombinant mutant human TRAIL and daunorubicin in inducing apoptosis of leukemia cell and its mechanism];Q484940;P703;Q15978631
Melanoma-specific cytotoxicity of a human MGSA/GRO alpha C-terminal peptide conjugated to daunorubicin;Q218642;P703;Q15978631
Melanoma-specific cytotoxicity of a human MGSA/GRO alpha C-terminal peptide conjugated to daunorubicin;Q183290;P703;Q15978631
Melanoma-specific cytotoxicity of a human MGSA/GRO alpha C-terminal peptide conjugated to daunorubicin;Q186474;P703;Q15978631
Melanoma-specific cytotoxicity of a human MGSA/GRO alpha C-terminal peptide conjugated to daunorubicin;Q173670;P703;Q15978631
Melanoma-specific cytotoxicity of a human MGSA/GRO alpha C-terminal peptide conjugated to daunorubicin;Q22124685;P703;Q15978631
Melanoma-specific cytotoxicity of a human MGSA/GRO alpha C-terminal peptide conjugated to daunorubicin;Q620730;P703;Q15978631
Continuous-infusion daunorubicin and carboplatin for high-risk acute myeloid leukemia in the elderly;Q411659;P2175;Q264118
Phase II study of 5-fluorouracil, methyl-CCNU, and daunorubicin in colorectal cancer: a Cancer and Leukemia Group B study.;Q139347;P2175;Q12078
Phase II study of 5-fluorouracil, methyl-CCNU, and daunorubicin in colorectal cancer: a Cancer and Leukemia Group B study.;Q238512;P2175;Q2739660
Cytotoxic and cytokinetic effects of 1-beta-D-arabinofuranosylcytosine, daunorubicin, and 6-thioguanine on HeLa cells in culture;Q186474;P1889;Q178425
Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells.;Q218642;P703;Q15978631
Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells.;Q186474;P703;Q15978631
Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells.;Q186521;P703;Q15978631
Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells.;Q411659;P361;Q22290410
Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells.;Q80863;P703;Q15978631
Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells.;Q173670;P703;Q15978631
Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells.;Q20035886;P703;Q15978631
Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells.;Q22124685;P703;Q15978631
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr;Q183290;P31;Q12140
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr;Q186474;P31;Q12140
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr;Q180983;P31;Q12140
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr;Q180983;P2175;Q29496
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr;Q180983;P2175;Q264118
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr;Q411659;P31;Q12140
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr;Q411659;P2175;Q264118
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr;Q178450;P31;Q12140
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr;Q418817;P31;Q12140
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr;Q418817;P2175;Q264118
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr;Q20035886;P31;Q12140
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr;Q620730;P31;Q12140
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr;Q483745;P31;Q12140
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr;Q2354337;P31;Q12140
Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma;Q239426;P2175;Q208414
The phosphoinositide 3-kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukemia cell lines.;Q218642;P703;Q15978631
The phosphoinositide 3-kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukemia cell lines.;Q186521;P703;Q15978631
The phosphoinositide 3-kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukemia cell lines.;Q411659;P2175;Q264118
High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China.;Q411659;P2175;Q264118
Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.;Q186521;P527;Q623
Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.;Q186521;P703;Q15978631
The effects of daunomycin and ethidium bromide on Escherichia coli;Q186521;P703;Q25419
Identification of the subcellular localization of daunorubicin in multidrug-resistant K562 cell line;Q411659;P31;Q12140
Identification of the subcellular localization of daunorubicin in multidrug-resistant K562 cell line;Q20816880;P31;Q12140
Identification of the subcellular localization of daunorubicin in multidrug-resistant K562 cell line;Q484940;P31;Q12140
[Therapy of acute leukemia in childhood with the new association of daunomycin, vincristine and prednisone];Q408977;P2175;Q29496
Fluorometric determination of serum levels and urinary excretion of daunomycin (NSC-82151) in mice and rats;Q186474;P703;Q83310
Letter: A 13C nuclear magnetic resonance study of the biosynthesis of daunomycin from 13CH313CO2Na;Q218642;P703;Q2046782
A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group;Q411659;P31;Q109603820
A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group;Q411659;P2175;Q264118
A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group;Q1063862;P2175;Q264118
A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group;Q1063862;P279;Q417589
Metabolism of doxorubicin, daunorubicin and epirubicin in human and rat hepatoma cells;Q22124685;P703;Q15978631
[Treatment of acute myeloblastic leukemia with cytosine arabinoside combined with daunorubicin or ifosfamide or thioguanine];Q385347;P2175;Q264118
[Treatment of acute myeloblastic leukemia with cytosine arabinoside combined with daunorubicin or ifosfamide or thioguanine];Q180983;P2175;Q264118
[Treatment of acute myeloblastic leukemia with cytosine arabinoside combined with daunorubicin or ifosfamide or thioguanine];Q180983;P2175;Q29496
[Treatment of acute myeloblastic leukemia with cytosine arabinoside combined with daunorubicin or ifosfamide or thioguanine];Q411659;P2175;Q264118
The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate.;Q410291;P31;Q12140
The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate.;Q186521;P31;Q12140
The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate.;Q411659;P31;Q12140
The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate.;Q20035886;P31;Q12140
Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia.;Q411659;P2175;Q264118
Effects of daunorubicin, mitomycin C, azathioprine and cyclosporin A on human retinal pigmented epithelial, corneal endothelial and conjunctival cell lines.;Q218642;P703;Q15978631
Effects of daunorubicin, mitomycin C, azathioprine and cyclosporin A on human retinal pigmented epithelial, corneal endothelial and conjunctival cell lines.;Q186474;P703;Q15978631
Effects of daunorubicin, mitomycin C, azathioprine and cyclosporin A on human retinal pigmented epithelial, corneal endothelial and conjunctival cell lines.;Q367700;P703;Q15978631
Effects of daunorubicin, mitomycin C, azathioprine and cyclosporin A on human retinal pigmented epithelial, corneal endothelial and conjunctival cell lines.;Q19856779;P1889;Q417625
Demonstration of differences in drug resistance by direct testing of DNA excision repair activity following standard and liposomal daunorubicin exposure in normal paediatric marrow using high resolution CLSM.;Q218642;P31;Q12140
Demonstration of differences in drug resistance by direct testing of DNA excision repair activity following standard and liposomal daunorubicin exposure in normal paediatric marrow using high resolution CLSM.;Q183290;P31;Q12140
Demonstration of differences in drug resistance by direct testing of DNA excision repair activity following standard and liposomal daunorubicin exposure in normal paediatric marrow using high resolution CLSM.;Q186474;P31;Q12140
Demonstration of differences in drug resistance by direct testing of DNA excision repair activity following standard and liposomal daunorubicin exposure in normal paediatric marrow using high resolution CLSM.;Q411659;P31;Q12140
Demonstration of differences in drug resistance by direct testing of DNA excision repair activity following standard and liposomal daunorubicin exposure in normal paediatric marrow using high resolution CLSM.;Q192717;P31;Q12140
Demonstration of differences in drug resistance by direct testing of DNA excision repair activity following standard and liposomal daunorubicin exposure in normal paediatric marrow using high resolution CLSM.;Q178450;P31;Q12140
Demonstration of differences in drug resistance by direct testing of DNA excision repair activity following standard and liposomal daunorubicin exposure in normal paediatric marrow using high resolution CLSM.;Q22124685;P31;Q12140
Demonstration of differences in drug resistance by direct testing of DNA excision repair activity following standard and liposomal daunorubicin exposure in normal paediatric marrow using high resolution CLSM.;Q483745;P31;Q12140
Potentiation of the biological activities of daunomycin and adriamycin by ascorbic acid and dimethylsulfoxide;Q407927;P31;Q408395
Potentiation of the biological activities of daunomycin and adriamycin by ascorbic acid and dimethylsulfoxide;Q407927;P527;Q4407
[Liposomal daunorubicin (daunosom) in the treatment of recurrent acute promyelocytic leukemia];Q16965066;P527;Q411659
Role of membrane lipids in the interaction of daunomycin with plasma membranes from tumor cells: implications in drug-resistance phenomena.;Q411659;P31;Q12140
Role of membrane lipids in the interaction of daunomycin with plasma membranes from tumor cells: implications in drug-resistance phenomena.;Q173670;P31;Q12140
Acute Myeloblastic Leukemia: Management with High-Dose Cytosine Arabinoside, Daunorubicin and Marrow Transplantation: Malignancy: Current Clinical Practice.;Q186474;P1889;Q178425
[The therapeutic efficacy and toxicity of the liposomal form of daunorubicin (Daunoxome) in lymphosarcoma patients];Q186521;P703;Q177932
[The therapeutic efficacy and toxicity of the liposomal form of daunorubicin (Daunoxome) in lymphosarcoma patients];Q178450;P703;Q177932
[Liposomal daunorubicin and interferon-alfa in combination with all-retinoic acid--a new regime for the treatment of acute promyelocytic leukemia];Q287029;P2175;Q29496
[Liposomal daunorubicin and interferon-alfa in combination with all-retinoic acid--a new regime for the treatment of acute promyelocytic leukemia];Q287029;P31;Q425517
[Liposomal daunorubicin and interferon-alfa in combination with all-retinoic acid--a new regime for the treatment of acute promyelocytic leukemia];Q16965066;P527;Q411659
Long-term remission in a case of acute promyelocytic leukemia patient with marked myelofibrosis treated with arsenic trioxide, all-trans retinoic acid and consolidation therapy with daunorubicin plus cytarabine;Q7739;P527;Q871
Long-term remission in a case of acute promyelocytic leukemia patient with marked myelofibrosis treated with arsenic trioxide, all-trans retinoic acid and consolidation therapy with daunorubicin plus cytarabine;Q7739;P2175;Q612108
Long-term remission in a case of acute promyelocytic leukemia patient with marked myelofibrosis treated with arsenic trioxide, all-trans retinoic acid and consolidation therapy with daunorubicin plus cytarabine;Q180983;P2175;Q29496
Long-term remission in a case of acute promyelocytic leukemia patient with marked myelofibrosis treated with arsenic trioxide, all-trans retinoic acid and consolidation therapy with daunorubicin plus cytarabine;Q287029;P2175;Q29496
Long-term remission in a case of acute promyelocytic leukemia patient with marked myelofibrosis treated with arsenic trioxide, all-trans retinoic acid and consolidation therapy with daunorubicin plus cytarabine;Q287029;P31;Q425517
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients;Q412685;P527;Q105946712
Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized f;Q385347;P2175;Q264118
Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized f;Q180983;P2175;Q29496
Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized f;Q180983;P2175;Q264118
Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized f;Q411659;P2175;Q264118
Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia.;Q411659;P2175;Q264118
Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia.;Q1063862;P2175;Q264118
Comparative uptake, retention and cytotoxicity of daunorubicin by human myeloid cells.;Q186474;P703;Q15978631
[Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].;Q180983;P2175;Q29496
[Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].;Q180983;P2175;Q264118
[Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].;Q411659;P2175;Q264118
[Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].;Q1063862;P2175;Q264118
Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG).;Q180983;P2175;Q29496
Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG).;Q180983;P2175;Q264118
Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG).;Q411659;P2175;Q264118
Outpatient administration of liposomal daunorubicin and cytarabine (Vyxeos) in patients with secondary acute myeloid leukemia;Q180983;P2175;Q29496
Outpatient administration of liposomal daunorubicin and cytarabine (Vyxeos) in patients with secondary acute myeloid leukemia;Q180983;P2175;Q264118
Outpatient administration of liposomal daunorubicin and cytarabine (Vyxeos) in patients with secondary acute myeloid leukemia;Q411659;P2175;Q264118
Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.;Q180983;P2175;Q264118
Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.;Q411659;P2175;Q264118
Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.;Q1063862;P2175;Q264118
High-affinity binding of silybin derivatives to the nucleotide-binding domain of a Leishmania tropica P-glycoprotein-like transporter and chemosensitization of a multidrug-resistant parasite to daunomycin;Q411659;P31;Q12140
High-affinity binding of silybin derivatives to the nucleotide-binding domain of a Leishmania tropica P-glycoprotein-like transporter and chemosensitization of a multidrug-resistant parasite to daunomycin;Q485277;P31;Q12140
High-affinity binding of silybin derivatives to the nucleotide-binding domain of a Leishmania tropica P-glycoprotein-like transporter and chemosensitization of a multidrug-resistant parasite to daunomycin;Q20035886;P31;Q12140
High-affinity binding of silybin derivatives to the nucleotide-binding domain of a Leishmania tropica P-glycoprotein-like transporter and chemosensitization of a multidrug-resistant parasite to daunomycin;Q483745;P31;Q12140
Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia;Q180983;P2175;Q29496
Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia;Q180983;P2175;Q264118
Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia;Q411659;P2175;Q264118
Nuclear factor - kappaB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug.;Q411659;P31;Q12140
cis-Aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate;Q218642;P31;Q12140
cis-Aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate;Q411659;P31;Q12140
cis-Aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate;Q485277;P31;Q12140
Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia.;Q411659;P2175;Q264118
Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia.;Q1063862;P2175;Q264118
Niemann-Pick C1 protein facilitates the efflux of the anticancer drug daunorubicin from cells according to a novel vesicle-mediated pathway.;Q153;P31;Q12140
Niemann-Pick C1 protein facilitates the efflux of the anticancer drug daunorubicin from cells according to a novel vesicle-mediated pathway.;Q186474;P31;Q12140
Niemann-Pick C1 protein facilitates the efflux of the anticancer drug daunorubicin from cells according to a novel vesicle-mediated pathway.;Q411659;P31;Q12140
Niemann-Pick C1 protein facilitates the efflux of the anticancer drug daunorubicin from cells according to a novel vesicle-mediated pathway.;Q20035886;P31;Q12140
Remission induction with cytarabine and daunorubicin with or without 6-thioguanine in adult patients with acute myelocytic leukemia;Q180983;P2175;Q29496
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia.;Q180983;P2175;Q29496
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia.;Q180983;P2175;Q264118
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia.;Q411659;P2175;Q264118
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia.;Q412685;P527;Q105946712
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia.;Q412685;P2175;Q264118
[Treatment of acute promyelocytic leukemia: comparison of the therapeutic effect of daunorubicin and "DCMP" regimen in remission induction treatment];Q186474;P703;Q177932
[Treatment of acute promyelocytic leukemia: comparison of the therapeutic effect of daunorubicin and "DCMP" regimen in remission induction treatment];Q186521;P703;Q177932
[Treatment of acute promyelocytic leukemia: comparison of the therapeutic effect of daunorubicin and "DCMP" regimen in remission induction treatment];Q178450;P703;Q177932
[Treatment of acute promyelocytic leukemia: comparison of the therapeutic effect of daunorubicin and "DCMP" regimen in remission induction treatment];Q20035886;P703;Q177932
[Treatment of acute promyelocytic leukemia: comparison of the therapeutic effect of daunorubicin and "DCMP" regimen in remission induction treatment];Q22124685;P703;Q177932
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicine for acute myeloid leukemia in elderly patients.;Q239426;P2175;Q264118
A stability-indicating, ion-pairing, reversed-phase liquid chromatography method for studies of daunorubicin degradation in i.v. infusion fluids.;Q411659;P361;Q22277889
High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials.;Q411659;P2175;Q264118
G-quadruplex forming region within WT1 promoter is selectively targeted by daunorubicin and mitoxantrone: A possible mechanism for anti-leukemic effect of drugs;Q181003;P31;Q12140
G-quadruplex forming region within WT1 promoter is selectively targeted by daunorubicin and mitoxantrone: A possible mechanism for anti-leukemic effect of drugs;Q218642;P31;Q12140
G-quadruplex forming region within WT1 promoter is selectively targeted by daunorubicin and mitoxantrone: A possible mechanism for anti-leukemic effect of drugs;Q186521;P31;Q12140
G-quadruplex forming region within WT1 promoter is selectively targeted by daunorubicin and mitoxantrone: A possible mechanism for anti-leukemic effect of drugs;Q411659;P31;Q12140
G-quadruplex forming region within WT1 promoter is selectively targeted by daunorubicin and mitoxantrone: A possible mechanism for anti-leukemic effect of drugs;Q239426;P31;Q12140
G-quadruplex forming region within WT1 promoter is selectively targeted by daunorubicin and mitoxantrone: A possible mechanism for anti-leukemic effect of drugs;Q620730;P31;Q12140
Altered subcellular distribution of daunorubicin in the non-P-glycoprotein-mediated multidrug-resistant cell line HL-60/ADR;Q218642;P31;Q12140
Altered subcellular distribution of daunorubicin in the non-P-glycoprotein-mediated multidrug-resistant cell line HL-60/ADR;Q411659;P31;Q12140
Altered subcellular distribution of daunorubicin in the non-P-glycoprotein-mediated multidrug-resistant cell line HL-60/ADR;Q485277;P31;Q12140
Altered subcellular distribution of daunorubicin in the non-P-glycoprotein-mediated multidrug-resistant cell line HL-60/ADR;Q173670;P31;Q12140
Altered subcellular distribution of daunorubicin in the non-P-glycoprotein-mediated multidrug-resistant cell line HL-60/ADR;Q178450;P31;Q12140
Altered subcellular distribution of daunorubicin in the non-P-glycoprotein-mediated multidrug-resistant cell line HL-60/ADR;Q20035886;P31;Q12140
Altered subcellular distribution of daunorubicin in the non-P-glycoprotein-mediated multidrug-resistant cell line HL-60/ADR;Q483745;P31;Q12140
Laser and daunomycin chemophototherapy of human carcinoma cells;Q483745;P703;Q15978631
[Clinical evaluation of daunomycin combined with vincristine and prednisone in the treatment of acute leukemias];Q408977;P2175;Q29496
Alteration of rat bone marrow megakaryocytes following administration of cytosine arabinoside, daunomycin and hydroxyurea;Q212272;P279;Q48318
Daunomycin binding to detergent micelles: a model system for evaluating the hydrophobic contribution to drug-DNA interactions;Q218642;P31;Q12140
Daunomycin binding to detergent micelles: a model system for evaluating the hydrophobic contribution to drug-DNA interactions;Q411659;P31;Q12140
Daunomycin binding to detergent micelles: a model system for evaluating the hydrophobic contribution to drug-DNA interactions;Q191924;P31;Q12140
Daunomycin binding to detergent micelles: a model system for evaluating the hydrophobic contribution to drug-DNA interactions;Q178450;P31;Q12140
Intensive chemotherapy with daunorubicin, 5-azacytidine, 6-thioguanine, and cytarabine (DATA) for the blastic transformation of chronic granulocytic leukemia.;Q180983;P2175;Q29496
Improved antitumor activity of basic amino acid and dipeptide derivatives of daunorubicin on EL4 leukemia cells in mice;Q484940;P31;Q8066
A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia.;Q180983;P2175;Q29496
A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.;Q180983;P2175;Q29496
A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.;Q411659;P2175;Q264118
A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.;Q5134875;P2175;Q264118
Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia.;Q180983;P2175;Q29496
Daunomycin delivery by ultrasmall graphene quantum dots to DNA duplexes: understanding the dynamics by resonance energy transfer;Q218642;P703;Q2046782
Daunomycin delivery by ultrasmall graphene quantum dots to DNA duplexes: understanding the dynamics by resonance energy transfer;Q178450;P703;Q2046782
Efficacy of multi-functional liposomes containing daunorubicin and emetine for treatment of acute myeloid leukaemia.;Q411659;P2175;Q264118
Effect of 12-deoxyphorbol 13-phenylacetate on daunorubicin resistance and calcium-independent protein-kinase-C isozymes in drug-sensitive murine leukemia p388 cells.;Q186474;P31;Q12140
Effect of 12-deoxyphorbol 13-phenylacetate on daunorubicin resistance and calcium-independent protein-kinase-C isozymes in drug-sensitive murine leukemia p388 cells.;Q411659;P31;Q12140
Interaction of antileukemia agents adriamycin and daunomycin with sphinganine on the differentiation of human leukemia cell line HL-60.;Q485277;P703;Q15978631
Interaction of antileukemia agents adriamycin and daunomycin with sphinganine on the differentiation of human leukemia cell line HL-60.;Q483745;P703;Q15978631
Interaction of antileukemia agents adriamycin and daunomycin with sphinganine on the differentiation of human leukemia cell line HL-60.;Q484940;P703;Q15978631
Cardiotoxicity of free and liposomally encapsulated rubomycin (daunorubicin) in mice;Q186474;P703;Q83310
Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III t;Q180983;P2175;Q29496
Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III t;Q180983;P2175;Q264118
Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III t;Q411659;P2175;Q264118
Adriamycin, an antitumour antibiotic: a review with special reference to daunomycin;Q18936;P3780;Q47520887
Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells.;Q186474;P31;Q12140
Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells.;Q186474;P703;Q15978631
Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells.;Q411659;P31;Q12140
Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myelobla;Q186474;P1889;Q178425
Subcellular distribution of daunorubicin in the P-glycoprotein-mediated multidrug-resistant cell line K562/ADR;Q218642;P31;Q12140
Subcellular distribution of daunorubicin in the P-glycoprotein-mediated multidrug-resistant cell line K562/ADR;Q183290;P31;Q12140
Subcellular distribution of daunorubicin in the P-glycoprotein-mediated multidrug-resistant cell line K562/ADR;Q411659;P31;Q12140
Subcellular distribution of daunorubicin in the P-glycoprotein-mediated multidrug-resistant cell line K562/ADR;Q173670;P31;Q12140
Subcellular distribution of daunorubicin in the P-glycoprotein-mediated multidrug-resistant cell line K562/ADR;Q178450;P31;Q12140
Subcellular distribution of daunorubicin in the P-glycoprotein-mediated multidrug-resistant cell line K562/ADR;Q20816880;P31;Q12140
Subcellular distribution of daunorubicin in the P-glycoprotein-mediated multidrug-resistant cell line K562/ADR;Q20035886;P31;Q12140
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.;Q417542;P129;Q5009781
[Quadruple combination chemotherapy of acute leukemia using daunomycin, cytosine arabinoside, vincristine and prednisolone (author's transl)];Q180983;P2175;Q29496
[Quadruple combination chemotherapy of acute leukemia using daunomycin, cytosine arabinoside, vincristine and prednisolone (author's transl)];Q180983;P2175;Q976388
[Quadruple combination chemotherapy of acute leukemia using daunomycin, cytosine arabinoside, vincristine and prednisolone (author's transl)];Q408977;P2175;Q29496
Etoposide and mitoxantrone as a second cycle of consolidation therapy following high dose cytosine arabinoside and daunorubicin in patients with acute non-lymphocytic leukemia in remission: a pilot study;Q180983;P2175;Q29496
Etoposide and mitoxantrone as a second cycle of consolidation therapy following high dose cytosine arabinoside and daunorubicin in patients with acute non-lymphocytic leukemia in remission: a pilot study;Q411659;P2175;Q6708277
The influence of joint application of arsenic trioxide and daunorubicin on primary acute promyelocytic leukaemia cells and apoptosis and blood coagulation of cell strain.;Q7739;P527;Q871
Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells.;Q410291;P31;Q12140
Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells.;Q186521;P31;Q12140
Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells.;Q411659;P31;Q12140
[Treatment of acute myeloblastic leukemia with daunorubicin and cytosine-arabinoside];Q411659;P2175;Q264118
Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry.;Q218642;P31;Q12140
Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry.;Q411659;P31;Q12140
Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry.;Q367700;P31;Q12140
Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry.;Q20035886;P31;Q12140
Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin;Q180983;P2175;Q29496
Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin;Q180983;P2175;Q264118
Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin;Q411659;P2175;Q264118
Determination of the cellular uptake of daunorubicin in human leukemia in vivo: method of examination and first results;Q178450;P703;Q15978631
Two distinct modes of oncoprotein expression during apoptosis resistance in vincristine and daunorubicin multidrug-resistant HL60 cells.;Q186521;P31;Q12140
Two distinct modes of oncoprotein expression during apoptosis resistance in vincristine and daunorubicin multidrug-resistant HL60 cells.;Q408977;P31;Q12140
Two distinct modes of oncoprotein expression during apoptosis resistance in vincristine and daunorubicin multidrug-resistant HL60 cells.;Q411659;P31;Q12140
Two distinct modes of oncoprotein expression during apoptosis resistance in vincristine and daunorubicin multidrug-resistant HL60 cells.;Q485277;P31;Q12140
Two distinct modes of oncoprotein expression during apoptosis resistance in vincristine and daunorubicin multidrug-resistant HL60 cells.;Q483745;P31;Q12140
Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.;Q411659;P361;Q22290410
Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.;Q411659;P31;Q12140
Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.;Q485277;P31;Q12140
Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.;Q484940;P31;Q12140
Purification and characterization of the DNA-binding protein DnrI, a transcriptional factor of daunorubicin biosynthesis in Streptomyces peucetius;Q218642;P703;Q1144013
Purification and characterization of the DNA-binding protein DnrI, a transcriptional factor of daunorubicin biosynthesis in Streptomyces peucetius;Q411659;P361;Q22277880
Purification and characterization of the DNA-binding protein DnrI, a transcriptional factor of daunorubicin biosynthesis in Streptomyces peucetius;Q411659;P703;Q1144013
Purification and characterization of the DNA-binding protein DnrI, a transcriptional factor of daunorubicin biosynthesis in Streptomyces peucetius;Q411659;P703;Q7623394
Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines.;Q408977;P2175;Q208414
Degradation of doxorubicin and daunorubicin in human and rabbit biological fluids;Q178450;P703;Q15978631
Glucose-6-phosphate dehydrogenase deficiency severely restricts the biotransformation of daunorubicin in human erythrocytes;Q620730;P703;Q15978631
Induction of resistance to daunorubicin in drug-sensitive leukemia p388 cells - a role of pkc-Beta-I isozyme.;Q411659;P31;Q12140
Induction of resistance to daunorubicin in drug-sensitive leukemia p388 cells - a role of pkc-Beta-I isozyme.;Q484940;P31;Q12140
Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein.;Q218642;P31;Q12140
Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein.;Q186474;P31;Q12140
Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein.;Q411659;P31;Q12140
Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein.;Q485277;P31;Q12140
Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein.;Q173670;P31;Q12140
Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein.;Q178450;P31;Q12140
Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein.;Q20816880;P31;Q12140
Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein.;Q20035886;P31;Q12140
Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein.;Q483745;P31;Q12140
Equilibrium, kinetic and photoaffinity labeling studies of daunomycin binding to P-glycoprotein-containing membranes of multidrug-resistant Chinese hamster ovary cells.;Q186474;P31;Q12140
Equilibrium, kinetic and photoaffinity labeling studies of daunomycin binding to P-glycoprotein-containing membranes of multidrug-resistant Chinese hamster ovary cells.;Q411659;P31;Q12140
Equilibrium, kinetic and photoaffinity labeling studies of daunomycin binding to P-glycoprotein-containing membranes of multidrug-resistant Chinese hamster ovary cells.;Q20035886;P31;Q12140
Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia.;Q180983;P2175;Q29496
Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia.;Q180983;P2175;Q264118
Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia.;Q411659;P2175;Q264118
Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia.;Q418817;P2175;Q264118
EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes;Q180983;P2175;Q264118
EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes;Q180983;P2175;Q954625
EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes;Q411659;P2175;Q264118
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party;Q385347;P31;Q12140
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party;Q385347;P2175;Q264118
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party;Q180983;P31;Q12140
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party;Q180983;P2175;Q29496
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party;Q180983;P2175;Q264118
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party;Q181003;P31;Q12140
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party;Q186474;P1889;Q178425
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party;Q186474;P31;Q12140
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party;Q186521;P31;Q12140
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party;Q411659;P31;Q12140
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party;Q411659;P2175;Q264118
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party;Q418529;P31;Q12140
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party;Q173670;P31;Q12140
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party;Q20035886;P31;Q12140
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party;Q22124685;P31;Q12140
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party;Q424972;P31;Q12140
Treatment of acute myeloid leukaemia with daunorubicin, cytosine arabinoside, mercaptopurine, L-asparaginase, prednisone and thioguanine: results of treatment with five multiple-drug schedules. Report of the Medical Research Council's Working Party;Q483745;P31;Q12140
Single-nucleotide polymorphisms in aldo-keto and carbonyl reductase genes are not associated with acute cardiotoxicity after daunorubicin chemotherapy;Q183290;P527;Q623
Femtosecond dynamics of a drug-protein complex: daunomycin with Apo riboflavin-binding protein;Q218642;P31;Q12140
Femtosecond dynamics of a drug-protein complex: daunomycin with Apo riboflavin-binding protein;Q411659;P31;Q12140
Femtosecond dynamics of a drug-protein complex: daunomycin with Apo riboflavin-binding protein;Q130365;P31;Q12140
Femtosecond dynamics of a drug-protein complex: daunomycin with Apo riboflavin-binding protein;Q170545;P31;Q12140
Femtosecond dynamics of a drug-protein complex: daunomycin with Apo riboflavin-binding protein;Q28852357;P31;Q12140
Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells;Q180983;P2175;Q264118
Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells;Q180983;P2175;Q29496
Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells;Q411659;P2175;Q264118
Daunorubicin, cytarabine, and cladribine regimen plus radiotherapy and donor lymphocyte infusion for extramedullary relapse of acute myeloid leukemia after hematopoietic stem cell transplantation;Q180983;P2175;Q29496
Daunorubicin, cytarabine, and cladribine regimen plus radiotherapy and donor lymphocyte infusion for extramedullary relapse of acute myeloid leukemia after hematopoietic stem cell transplantation;Q180983;P2175;Q264118
Daunorubicin, cytarabine, and cladribine regimen plus radiotherapy and donor lymphocyte infusion for extramedullary relapse of acute myeloid leukemia after hematopoietic stem cell transplantation;Q411659;P2175;Q264118
Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer.;Q426921;P1889;Q27105849
o-Methylation on anthracyclines and anthracyclinones. New o-methyl ethers of daunorubicin and its analogues;Q411659;P31;Q109603820
Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin;Q218642;P31;Q12140
Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin;Q18936;P31;Q12140
Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin;Q411659;P31;Q12140
Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin;Q407781;P31;Q12140
Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin;Q178450;P31;Q12140
Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin;Q418817;P31;Q12140
Uptake of adriamycin and daunomycin in L1210 and human leukemia cells: a comparative study.;Q483745;P703;Q15978631
Determination of anthracycline antibiotics doxorubicin and daunorubicin by capillary electrophoresis with UV absorption detection.;Q18936;P279;Q417589
Determination of anthracycline antibiotics doxorubicin and daunorubicin by capillary electrophoresis with UV absorption detection.;Q411659;P279;Q417589
A novel method of conjugation of daunomycin with antibody with a poly-L-glutamic acid derivative as intermediate drug carrier. An anti-alpha-fetoprotein antibody-daunomycin conjugate;Q218642;P31;Q12140
A novel method of conjugation of daunomycin with antibody with a poly-L-glutamic acid derivative as intermediate drug carrier. An anti-alpha-fetoprotein antibody-daunomycin conjugate;Q23118;P31;Q8386
A novel method of conjugation of daunomycin with antibody with a poly-L-glutamic acid derivative as intermediate drug carrier. An anti-alpha-fetoprotein antibody-daunomycin conjugate;Q411659;P31;Q12140
A novel method of conjugation of daunomycin with antibody with a poly-L-glutamic acid derivative as intermediate drug carrier. An anti-alpha-fetoprotein antibody-daunomycin conjugate;Q191924;P31;Q12140
A novel method of conjugation of daunomycin with antibody with a poly-L-glutamic acid derivative as intermediate drug carrier. An anti-alpha-fetoprotein antibody-daunomycin conjugate;Q483745;P31;Q12140
BET Inhibition Suppresses S100A8 and S100A9 Expression in Acute Myeloid Leukemia Cells and Synergises with Daunorubicin in Causing Cell Death.;Q411659;P2175;Q264118
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.;Q411659;P2175;Q264118
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.;Q418817;P2175;Q264118
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group;Q385347;P2175;Q264118
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group;Q180983;P2175;Q29496
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group;Q180983;P2175;Q264118
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group;Q411659;P2175;Q264118
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group;Q239426;P2175;Q264118
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.;Q180983;P2175;Q29496
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.;Q180983;P2175;Q264118
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.;Q411659;P2175;Q264118
Individual nuclear uptake patterns for adriamycin and daunomycin in human leukemia and lymphoma cells;Q484940;P703;Q15978631
Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells;Q411659;P2175;Q264118
Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells;Q5984881;P2175;Q29496
Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression.;Q18936;P3780;Q47520887
Apoptotic mechanism of human leukemia K562/A02 cells induced by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin;Q218642;P703;Q15978631
Apoptotic mechanism of human leukemia K562/A02 cells induced by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin;Q20816880;P703;Q15978631
Kinetics of daunorubicin transport by P-glycoprotein of intact cancer cells.;Q411659;P361;Q22290410
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia;Q180983;P2175;Q264118
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia;Q411659;P2175;Q264118
Adriamycin and daunorubicin inhibition of mutant T4 DNA polymerases.;Q18936;P3780;Q47520887
Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression;Q411659;P2175;Q264118
Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression;Q1063862;P2175;Q264118
Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma.;Q408977;P2175;Q208414
Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma.;Q11426176;P2175;Q208414
Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma.;Q16965066;P527;Q411659
[Current treatment of acute lymphoblastic leukemia. Effects of the reinduction method. New medicines (rubidomycin)];Q186474;P31;Q12140
[Current treatment of acute lymphoblastic leukemia. Effects of the reinduction method. New medicines (rubidomycin)];Q191924;P31;Q12140
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study;Q180983;P2175;Q29496
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study;Q186474;P1889;Q178425
Cellular daunomycin fluorescence in multidrug resistant 2780AD cells and its relation to cellular drug localisation.;Q186474;P31;Q12140
Cellular daunomycin fluorescence in multidrug resistant 2780AD cells and its relation to cellular drug localisation.;Q411659;P31;Q12140
Cellular daunomycin fluorescence in multidrug resistant 2780AD cells and its relation to cellular drug localisation.;Q178450;P31;Q12140
Ag-4-ATP-MWCNT electrode modified with dsDNA as label-free electrochemical sensor for the detection of daunorubicin anticancer drug.;Q181003;P31;Q12140
Ag-4-ATP-MWCNT electrode modified with dsDNA as label-free electrochemical sensor for the detection of daunorubicin anticancer drug.;Q218642;P31;Q12140
Ag-4-ATP-MWCNT electrode modified with dsDNA as label-free electrochemical sensor for the detection of daunorubicin anticancer drug.;Q186474;P31;Q12140
Ag-4-ATP-MWCNT electrode modified with dsDNA as label-free electrochemical sensor for the detection of daunorubicin anticancer drug.;Q186521;P31;Q12140
Ag-4-ATP-MWCNT electrode modified with dsDNA as label-free electrochemical sensor for the detection of daunorubicin anticancer drug.;Q411659;P31;Q12140
Ag-4-ATP-MWCNT electrode modified with dsDNA as label-free electrochemical sensor for the detection of daunorubicin anticancer drug.;Q80863;P31;Q12140
Ag-4-ATP-MWCNT electrode modified with dsDNA as label-free electrochemical sensor for the detection of daunorubicin anticancer drug.;Q178450;P31;Q12140
Ag-4-ATP-MWCNT electrode modified with dsDNA as label-free electrochemical sensor for the detection of daunorubicin anticancer drug.;Q20035886;P31;Q12140
Ag-4-ATP-MWCNT electrode modified with dsDNA as label-free electrochemical sensor for the detection of daunorubicin anticancer drug.;Q22124685;P31;Q12140
On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP);Q411659;P31;Q12140
On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP);Q116907;P31;Q12140
On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP);Q173670;P31;Q12140
On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP);Q20035886;P31;Q12140
On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP);Q22124685;P31;Q12140
On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP);Q900898;P31;Q12140
Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length.;Q180983;P2175;Q264118
Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length.;Q180983;P2175;Q29496
Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length.;Q411659;P2175;Q264118
FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.;Q411659;P2175;Q264118
[Effects of anthracycline drugs (aclarubicin, daunorubicin, doxorubicin, epirubicin, pirarubicin) on mouse acute toxicity and rat liver microsomal lipid peroxidation];Q18936;P31;Q12140
[Effects of anthracycline drugs (aclarubicin, daunorubicin, doxorubicin, epirubicin, pirarubicin) on mouse acute toxicity and rat liver microsomal lipid peroxidation];Q411659;P31;Q12140
[Effects of anthracycline drugs (aclarubicin, daunorubicin, doxorubicin, epirubicin, pirarubicin) on mouse acute toxicity and rat liver microsomal lipid peroxidation];Q425122;P31;Q12140
Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia.;Q180983;P2175;Q29496
Cytosine arabinoside and daunorubicin induction therapy in a patient with acute myeloid leukemia on chronic hemodialysis.;Q180983;P2175;Q264118
Cytosine arabinoside and daunorubicin induction therapy in a patient with acute myeloid leukemia on chronic hemodialysis.;Q180983;P2175;Q29496
Cytosine arabinoside and daunorubicin induction therapy in a patient with acute myeloid leukemia on chronic hemodialysis.;Q186474;P1889;Q178425
Cytosine arabinoside and daunorubicin induction therapy in a patient with acute myeloid leukemia on chronic hemodialysis.;Q411659;P2175;Q264118
Fluorescent double labeling of normal and malignant hematopoietic cells by monoclonal antibodies (FITC) and anthracycline cytostatic drug (Daunomycin): a cytometric technique for analysis of drug uptake in hematopoietic cell subpopulations.;Q186474;P31;Q12140
Fluorescent double labeling of normal and malignant hematopoietic cells by monoclonal antibodies (FITC) and anthracycline cytostatic drug (Daunomycin): a cytometric technique for analysis of drug uptake in hematopoietic cell subpopulations.;Q186521;P31;Q12140
Fluorescent double labeling of normal and malignant hematopoietic cells by monoclonal antibodies (FITC) and anthracycline cytostatic drug (Daunomycin): a cytometric technique for analysis of drug uptake in hematopoietic cell subpopulations.;Q411659;P31;Q12140
Fluorescent double labeling of normal and malignant hematopoietic cells by monoclonal antibodies (FITC) and anthracycline cytostatic drug (Daunomycin): a cytometric technique for analysis of drug uptake in hematopoietic cell subpopulations.;Q170545;P31;Q12140
Fluorescent double labeling of normal and malignant hematopoietic cells by monoclonal antibodies (FITC) and anthracycline cytostatic drug (Daunomycin): a cytometric technique for analysis of drug uptake in hematopoietic cell subpopulations.;Q178450;P31;Q12140
Fluorescent double labeling of normal and malignant hematopoietic cells by monoclonal antibodies (FITC) and anthracycline cytostatic drug (Daunomycin): a cytometric technique for analysis of drug uptake in hematopoietic cell subpopulations.;Q484940;P31;Q12140
[The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)].;Q177094;P2175;Q29496
Correlations between cytotoxicity, biochemical effects, drug levels, and therapeutic effectiveness of daunomycin and adriamycin on Sarcoma 180 ascites in mice.;Q183290;P31;Q12140
Correlations between cytotoxicity, biochemical effects, drug levels, and therapeutic effectiveness of daunomycin and adriamycin on Sarcoma 180 ascites in mice.;Q183290;P703;Q177932
Correlations between cytotoxicity, biochemical effects, drug levels, and therapeutic effectiveness of daunomycin and adriamycin on Sarcoma 180 ascites in mice.;Q186474;P703;Q177932
Correlations between cytotoxicity, biochemical effects, drug levels, and therapeutic effectiveness of daunomycin and adriamycin on Sarcoma 180 ascites in mice.;Q186474;P31;Q12140
Correlations between cytotoxicity, biochemical effects, drug levels, and therapeutic effectiveness of daunomycin and adriamycin on Sarcoma 180 ascites in mice.;Q186474;P703;Q83310
Correlations between cytotoxicity, biochemical effects, drug levels, and therapeutic effectiveness of daunomycin and adriamycin on Sarcoma 180 ascites in mice.;Q411659;P31;Q12140
Correlations between cytotoxicity, biochemical effects, drug levels, and therapeutic effectiveness of daunomycin and adriamycin on Sarcoma 180 ascites in mice.;Q191924;P31;Q12140
Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and Meta-analysis;Q411659;P2175;Q264118
Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and Meta-analysis;Q1063862;P2175;Q264118
Selected studies of daunorubicin in adult acute nonlymphocytic leukemia;Q411659;P2175;Q6708277
Clinical and cell kinetic data on the combination of cytosine arabinoside with daunorubicin, isosfamide, thioguanine, and vincristine for remission induction and maintenance in patients with acute myelocytic leukaemia (author's transl);Q180983;P2175;Q29496
Clinical and cell kinetic data on the combination of cytosine arabinoside with daunorubicin, isosfamide, thioguanine, and vincristine for remission induction and maintenance in patients with acute myelocytic leukaemia (author's transl);Q186474;P1889;Q178425
Clinical and cell kinetic data on the combination of cytosine arabinoside with daunorubicin, isosfamide, thioguanine, and vincristine for remission induction and maintenance in patients with acute myelocytic leukaemia (author's transl);Q408977;P2175;Q29496
Enhancing the Therapeutic Efficacy of Daunorubicin and Mitoxantrone with Bavachinin, Candidone, and Tephrosin;Q186474;P703;Q177932
Enhancing the Therapeutic Efficacy of Daunorubicin and Mitoxantrone with Bavachinin, Candidone, and Tephrosin;Q186521;P703;Q177932
Enhancing the Therapeutic Efficacy of Daunorubicin and Mitoxantrone with Bavachinin, Candidone, and Tephrosin;Q178450;P703;Q177932
Enhancing the Therapeutic Efficacy of Daunorubicin and Mitoxantrone with Bavachinin, Candidone, and Tephrosin;Q22124685;P703;Q177932
Overexpression of a pathway specific negative regulator enhances production of daunorubicin in bldA deficient Streptomyces peucetius ATCC 27952.;Q218642;P703;Q1144013
Overexpression of a pathway specific negative regulator enhances production of daunorubicin in bldA deficient Streptomyces peucetius ATCC 27952.;Q186521;P703;Q1144013
Overexpression of a pathway specific negative regulator enhances production of daunorubicin in bldA deficient Streptomyces peucetius ATCC 27952.;Q411659;P703;Q7623394
Overexpression of a pathway specific negative regulator enhances production of daunorubicin in bldA deficient Streptomyces peucetius ATCC 27952.;Q411659;P703;Q1144013
Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia.;Q411659;P31;Q12140
Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia.;Q620730;P31;Q12140
Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance;Q153;P31;Q12140
Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance;Q183290;P31;Q12140
Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance;Q186474;P31;Q12140
Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance;Q411659;P31;Q12140
Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance;Q1063862;P31;Q12140
Sequential induction chemotherapy with vincristine, daunorubicin, cyclophosphamide, and prednisone in adult acute lymphoblastic leukemia.;Q408977;P2175;Q29496
Sequential induction chemotherapy with vincristine, daunorubicin, cyclophosphamide, and prednisone in adult acute lymphoblastic leukemia.;Q408977;P2175;Q18553852
Structure of daunomycin complexed to d-TGATCA by two-dimensional nuclear magnetic resonance spectroscopy.;Q218642;P703;Q2046782
Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943);Q186474;P703;Q83310
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.;Q180983;P2175;Q264118
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.;Q180983;P2175;Q29496
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.;Q411659;P2175;Q264118
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.;Q419319;P2175;Q264118
Differences in accumulation of anthracyclines daunorubicin, doxorubicin and epirubicin in rat tissues revealed by immunocytochemistry.;Q18936;P31;Q109603820
Differences in accumulation of anthracyclines daunorubicin, doxorubicin and epirubicin in rat tissues revealed by immunocytochemistry.;Q411659;P31;Q109603820
Differences in accumulation of anthracyclines daunorubicin, doxorubicin and epirubicin in rat tissues revealed by immunocytochemistry.;Q425122;P279;Q417589
Increasing the accumulation of daunorubicin in human leukemic cells by prolonging the infusion time.;Q484940;P703;Q15978631
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia;Q180983;P2175;Q264118
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia;Q180983;P2175;Q29496
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia;Q411659;P2175;Q264118
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia;Q1063862;P2175;Q264118
Effects of 3'-(4-morpholinyl)-3'-deaminodaunorubicin,3'- (4-methoxy-1-piperidinyl)-3'-deaminodaunorubicin and daunorubicin on nuclear and polysomal RNA synthesis in human colon carcinoma cells in vitro;Q218642;P703;Q15978631
Effects of 3'-(4-morpholinyl)-3'-deaminodaunorubicin,3'- (4-methoxy-1-piperidinyl)-3'-deaminodaunorubicin and daunorubicin on nuclear and polysomal RNA synthesis in human colon carcinoma cells in vitro;Q173670;P703;Q15978631
Reduced daunomycin accumulation in drug-sensitive and multidrug-resistant human carcinoma KB cells following phorbol ester treatment: a potential role for protein kinase C in reducing drug influx.;Q153;P31;Q12140
Reduced daunomycin accumulation in drug-sensitive and multidrug-resistant human carcinoma KB cells following phorbol ester treatment: a potential role for protein kinase C in reducing drug influx.;Q153;P703;Q15978631
Reduced daunomycin accumulation in drug-sensitive and multidrug-resistant human carcinoma KB cells following phorbol ester treatment: a potential role for protein kinase C in reducing drug influx.;Q186474;P31;Q12140
Reduced daunomycin accumulation in drug-sensitive and multidrug-resistant human carcinoma KB cells following phorbol ester treatment: a potential role for protein kinase C in reducing drug influx.;Q186474;P703;Q15978631
Reduced daunomycin accumulation in drug-sensitive and multidrug-resistant human carcinoma KB cells following phorbol ester treatment: a potential role for protein kinase C in reducing drug influx.;Q411659;P31;Q12140
Reduced daunomycin accumulation in drug-sensitive and multidrug-resistant human carcinoma KB cells following phorbol ester treatment: a potential role for protein kinase C in reducing drug influx.;Q173670;P31;Q12140
Reduced daunomycin accumulation in drug-sensitive and multidrug-resistant human carcinoma KB cells following phorbol ester treatment: a potential role for protein kinase C in reducing drug influx.;Q173670;P703;Q15978631
Reduced daunomycin accumulation in drug-sensitive and multidrug-resistant human carcinoma KB cells following phorbol ester treatment: a potential role for protein kinase C in reducing drug influx.;Q20816880;P31;Q12140
Reduced daunomycin accumulation in drug-sensitive and multidrug-resistant human carcinoma KB cells following phorbol ester treatment: a potential role for protein kinase C in reducing drug influx.;Q20816880;P703;Q15978631
Efficacy and morbidity of daunomycin (NSC-82151) added to vincristine (NSC-67574) and prednisone (NSC-10023) for remission induction of childhood acute lymphocytic leukemia;Q408977;P2175;Q29496
Efficacy and morbidity of daunomycin (NSC-82151) added to vincristine (NSC-67574) and prednisone (NSC-10023) for remission induction of childhood acute lymphocytic leukemia;Q411659;P2175;Q6708277
Preliminary results of a trial on acute myeloid leukemia comparing the effect of cytosine arabinoside, the combination of cytosine arabinoside and thioguanine and the combination of cytosine arabinoside and daunorubicine;Q385347;P2175;Q264118
Preliminary results of a trial on acute myeloid leukemia comparing the effect of cytosine arabinoside, the combination of cytosine arabinoside and thioguanine and the combination of cytosine arabinoside and daunorubicine;Q180983;P2175;Q264118
Preliminary results of a trial on acute myeloid leukemia comparing the effect of cytosine arabinoside, the combination of cytosine arabinoside and thioguanine and the combination of cytosine arabinoside and daunorubicine;Q180983;P2175;Q29496
Preliminary results of a trial on acute myeloid leukemia comparing the effect of cytosine arabinoside, the combination of cytosine arabinoside and thioguanine and the combination of cytosine arabinoside and daunorubicine;Q411659;P2175;Q264118
A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia;Q411659;P2175;Q264118
In vitro and in vivo cytotoxic activity of anti-human leukemia monoclonal antibodies SN5c and SN6 daunorubicin conjugates.;Q183290;P703;Q15978631
In vitro and in vivo cytotoxic activity of anti-human leukemia monoclonal antibodies SN5c and SN6 daunorubicin conjugates.;Q484940;P703;Q15978631
Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response.;Q411659;P31;Q12140
[Inhibitory effect of daunorubicin enhanced by PDTC on drug-resistant leukemic cells in vitro].;Q186474;P31;Q12140
[Inhibitory effect of daunorubicin enhanced by PDTC on drug-resistant leukemic cells in vitro].;Q186521;P31;Q12140
[Inhibitory effect of daunorubicin enhanced by PDTC on drug-resistant leukemic cells in vitro].;Q411659;P31;Q12140
[Inhibitory effect of daunorubicin enhanced by PDTC on drug-resistant leukemic cells in vitro].;Q178450;P31;Q12140
[Inhibitory effect of daunorubicin enhanced by PDTC on drug-resistant leukemic cells in vitro].;Q20035886;P31;Q12140
[Inhibitory effect of daunorubicin enhanced by PDTC on drug-resistant leukemic cells in vitro].;Q1187179;P31;Q12140
[Inhibitory effect of daunorubicin enhanced by PDTC on drug-resistant leukemic cells in vitro].;Q484940;P31;Q12140
5'-Deoxy-5-fluorouridine increases daunorubicin uptake in multidrug-resistant cells and its activity is related with P-gp 170 expression.;Q411659;P31;Q12140
5'-Deoxy-5-fluorouridine increases daunorubicin uptake in multidrug-resistant cells and its activity is related with P-gp 170 expression.;Q178450;P31;Q12140
5'-Deoxy-5-fluorouridine increases daunorubicin uptake in multidrug-resistant cells and its activity is related with P-gp 170 expression.;Q20035886;P31;Q12140
Activity of (7) anthracycline related compounds in an doxorubicin sensitive human small cell lung cancer line and its doxorubicin resistant descendant. Activity of doxorubicin, daunorubicin, 4-deoxyrubicin, 4-demethoxydaunorubicin, detorubicin, 4'-e;Q218642;P31;Q11173
Activity of (7) anthracycline related compounds in an doxorubicin sensitive human small cell lung cancer line and its doxorubicin resistant descendant. Activity of doxorubicin, daunorubicin, 4-deoxyrubicin, 4-demethoxydaunorubicin, detorubicin, 4'-e;Q218642;P703;Q15978631
Activity of (7) anthracycline related compounds in an doxorubicin sensitive human small cell lung cancer line and its doxorubicin resistant descendant. Activity of doxorubicin, daunorubicin, 4-deoxyrubicin, 4-demethoxydaunorubicin, detorubicin, 4'-e;Q18936;P31;Q11173
Activity of (7) anthracycline related compounds in an doxorubicin sensitive human small cell lung cancer line and its doxorubicin resistant descendant. Activity of doxorubicin, daunorubicin, 4-deoxyrubicin, 4-demethoxydaunorubicin, detorubicin, 4'-e;Q411659;P31;Q11173
Activity of (7) anthracycline related compounds in an doxorubicin sensitive human small cell lung cancer line and its doxorubicin resistant descendant. Activity of doxorubicin, daunorubicin, 4-deoxyrubicin, 4-demethoxydaunorubicin, detorubicin, 4'-e;Q191924;P31;Q11173
Daunorubicin conjugated to a monoclonal anti-CA125 antibody selectively kills human ovarian cancer cells.;Q218642;P703;Q15978631
Daunorubicin conjugated to a monoclonal anti-CA125 antibody selectively kills human ovarian cancer cells.;Q186474;P703;Q15978631
Daunorubicin conjugated to a monoclonal anti-CA125 antibody selectively kills human ovarian cancer cells.;Q287415;P703;Q15978631
Daunorubicin conjugated to a monoclonal anti-CA125 antibody selectively kills human ovarian cancer cells.;Q178450;P703;Q15978631
N-terminal tail domains of core histones in nucleosome block the access of anticancer drugs, mithramycin and daunomycin, to the nucleosomal DNA.;Q218642;P31;Q12140
N-terminal tail domains of core histones in nucleosome block the access of anticancer drugs, mithramycin and daunomycin, to the nucleosomal DNA.;Q411659;P31;Q12140
N-terminal tail domains of core histones in nucleosome block the access of anticancer drugs, mithramycin and daunomycin, to the nucleosomal DNA.;Q178450;P31;Q12140
The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia;Q180983;P2175;Q29496
The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia;Q180983;P2175;Q264118
The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia;Q411659;P2175;Q264118
The effect of daunomycin on human cells in vivo and in vitro;Q186521;P703;Q15978631
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.;Q180983;P2175;Q29496
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.;Q180983;P2175;Q264118
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.;Q411659;P2175;Q264118
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.;Q1063862;P2175;Q264118
The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia.;Q411659;P2175;Q264118
Determination of intracellular organelles implicated in daunorubicin cytoplasmic sequestration in multidrug-resistant MCF-7 cells using fluorescence microscopy image analysis.;Q186474;P31;Q12140
Determination of intracellular organelles implicated in daunorubicin cytoplasmic sequestration in multidrug-resistant MCF-7 cells using fluorescence microscopy image analysis.;Q411659;P31;Q12140
Determination of intracellular organelles implicated in daunorubicin cytoplasmic sequestration in multidrug-resistant MCF-7 cells using fluorescence microscopy image analysis.;Q170545;P31;Q12140
Determination of intracellular organelles implicated in daunorubicin cytoplasmic sequestration in multidrug-resistant MCF-7 cells using fluorescence microscopy image analysis.;Q178450;P31;Q12140
Determination of intracellular organelles implicated in daunorubicin cytoplasmic sequestration in multidrug-resistant MCF-7 cells using fluorescence microscopy image analysis.;Q22124685;P31;Q12140
Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS;Q183290;P703;Q177932
Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS;Q186474;P703;Q177932
Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS;Q485277;P703;Q177932
Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS;Q20035886;P703;Q177932
Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS;Q22124685;P703;Q177932
Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS;Q620730;P703;Q177932
Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03;Q218642;P703;Q177932
Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03;Q186474;P703;Q177932
Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03;Q178450;P703;Q177932
Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03;Q483745;P703;Q177932
Modulation of daunorubicin intracellular accumulation in P-glycoprotein expressing MCF-7 human breast adenocarcinoma cells by thermosensitive-liposome encapsulation and hyperthermia.;Q186474;P703;Q15978631
Modulation of daunorubicin intracellular accumulation in P-glycoprotein expressing MCF-7 human breast adenocarcinoma cells by thermosensitive-liposome encapsulation and hyperthermia.;Q170545;P703;Q15978631
Modulation of daunorubicin intracellular accumulation in P-glycoprotein expressing MCF-7 human breast adenocarcinoma cells by thermosensitive-liposome encapsulation and hyperthermia.;Q20035886;P703;Q15978631
Modulation of daunorubicin intracellular accumulation in P-glycoprotein expressing MCF-7 human breast adenocarcinoma cells by thermosensitive-liposome encapsulation and hyperthermia.;Q22124685;P703;Q15978631
Abrogation of G(2)/M-phase block enhances the cytotoxicity of daunorubicin, melphalan and cisplatin in TP53 mutant human tumor cells.;Q218642;P703;Q15978631
Abrogation of G(2)/M-phase block enhances the cytotoxicity of daunorubicin, melphalan and cisplatin in TP53 mutant human tumor cells.;Q186521;P703;Q15978631
Abrogation of G(2)/M-phase block enhances the cytotoxicity of daunorubicin, melphalan and cisplatin in TP53 mutant human tumor cells.;Q20035886;P703;Q15978631
Abrogation of G(2)/M-phase block enhances the cytotoxicity of daunorubicin, melphalan and cisplatin in TP53 mutant human tumor cells.;Q22124685;P703;Q15978631
Abrogation of G(2)/M-phase block enhances the cytotoxicity of daunorubicin, melphalan and cisplatin in TP53 mutant human tumor cells.;Q620730;P703;Q15978631
Reversal of multidrug resistance in xenograft nude-mice by magnetic Fe(3)O(4) nanoparticles combined with daunorubicin and 5-bromotetrandrine.;Q411659;P31;Q12140
Reversal of multidrug resistance in xenograft nude-mice by magnetic Fe(3)O(4) nanoparticles combined with daunorubicin and 5-bromotetrandrine.;Q191924;P31;Q12140
Reversal of multidrug resistance in xenograft nude-mice by magnetic Fe(3)O(4) nanoparticles combined with daunorubicin and 5-bromotetrandrine.;Q170545;P31;Q12140
Reversal of multidrug resistance in xenograft nude-mice by magnetic Fe(3)O(4) nanoparticles combined with daunorubicin and 5-bromotetrandrine.;Q173670;P31;Q12140
Decitabine (5-Aza-2'-deoxycytidine: DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations;Q411659;P2175;Q264118
Decitabine (5-Aza-2'-deoxycytidine: DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations;Q1181878;P2175;Q264118
Evidence for daunomycin efflux from multidrug-resistant 2780AD human ovarian carcinoma cells against a concentration gradient.;Q153;P31;Q12140
Evidence for daunomycin efflux from multidrug-resistant 2780AD human ovarian carcinoma cells against a concentration gradient.;Q153;P703;Q15978631
Evidence for daunomycin efflux from multidrug-resistant 2780AD human ovarian carcinoma cells against a concentration gradient.;Q218642;P703;Q15978631
Evidence for daunomycin efflux from multidrug-resistant 2780AD human ovarian carcinoma cells against a concentration gradient.;Q218642;P31;Q12140
Evidence for daunomycin efflux from multidrug-resistant 2780AD human ovarian carcinoma cells against a concentration gradient.;Q411659;P31;Q12140
Evidence for daunomycin efflux from multidrug-resistant 2780AD human ovarian carcinoma cells against a concentration gradient.;Q178450;P31;Q12140
Evidence for daunomycin efflux from multidrug-resistant 2780AD human ovarian carcinoma cells against a concentration gradient.;Q178450;P703;Q15978631
Simultaneous determination of cyclophosphamide, ifosfamide, doxorubicin, epirubicin and daunorubicin in human urine using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry: bioanalytical method validation.;Q183290;P703;Q15978631
Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.;Q218642;P703;Q15978631
Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.;Q186474;P703;Q15978631
Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.;Q412327;P2175;Q29496
Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.;Q177094;P2175;Q29496
Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.;Q173670;P703;Q15978631
Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.;Q620730;P703;Q15978631
Effects of cyclosporin A and verapamil on the intracellular daunorubicin accumulation in Chinese hamster ovary cells with increasing levels of drug-resistance.;Q218642;P31;Q12140
Effects of cyclosporin A and verapamil on the intracellular daunorubicin accumulation in Chinese hamster ovary cells with increasing levels of drug-resistance.;Q186474;P31;Q12140
Effects of cyclosporin A and verapamil on the intracellular daunorubicin accumulation in Chinese hamster ovary cells with increasing levels of drug-resistance.;Q410291;P31;Q12140
Effects of cyclosporin A and verapamil on the intracellular daunorubicin accumulation in Chinese hamster ovary cells with increasing levels of drug-resistance.;Q411659;P31;Q12140
Effects of cyclosporin A and verapamil on the intracellular daunorubicin accumulation in Chinese hamster ovary cells with increasing levels of drug-resistance.;Q367700;P31;Q12140
[Poor response in patients with de novo acute myeloid leukemia and erythroblastic or megakaryocytic dysplasia to treatment with standard doses of cytosine arabinoside and daunorubicin];Q180983;P2175;Q264118
[Poor response in patients with de novo acute myeloid leukemia and erythroblastic or megakaryocytic dysplasia to treatment with standard doses of cytosine arabinoside and daunorubicin];Q180983;P2175;Q29496
[Poor response in patients with de novo acute myeloid leukemia and erythroblastic or megakaryocytic dysplasia to treatment with standard doses of cytosine arabinoside and daunorubicin];Q411659;P2175;Q264118
[Embelin Reverses the Multi-drug Resistance of K562/D to Daunorubicin Independently of P-gp and MDR1 mRNA].;Q218642;P31;Q12140
[Embelin Reverses the Multi-drug Resistance of K562/D to Daunorubicin Independently of P-gp and MDR1 mRNA].;Q411659;P31;Q12140
[Embelin Reverses the Multi-drug Resistance of K562/D to Daunorubicin Independently of P-gp and MDR1 mRNA].;Q173670;P31;Q12140
[Embelin Reverses the Multi-drug Resistance of K562/D to Daunorubicin Independently of P-gp and MDR1 mRNA].;Q178450;P31;Q12140
[Embelin Reverses the Multi-drug Resistance of K562/D to Daunorubicin Independently of P-gp and MDR1 mRNA].;Q20816880;P31;Q12140
[Embelin Reverses the Multi-drug Resistance of K562/D to Daunorubicin Independently of P-gp and MDR1 mRNA].;Q20035886;P31;Q12140
[Embelin Reverses the Multi-drug Resistance of K562/D to Daunorubicin Independently of P-gp and MDR1 mRNA].;Q22124685;P31;Q12140
[Embelin Reverses the Multi-drug Resistance of K562/D to Daunorubicin Independently of P-gp and MDR1 mRNA].;Q484940;P31;Q12140
Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: equilibrium binding studies on interaction of daunomycin with deoxyribonucleic acid;Q411659;P279;Q417589
Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin;Q180983;P2175;Q29496
Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin;Q180983;P2175;Q264118
Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin;Q411659;P2175;Q264118
Simultaneous determination of cytosine arabinoside, daunorubicin and etoposide in human plasma.;Q183290;P703;Q15978631
[In vivo concentrations of an antimitotic, daunorubicin, in peripheral and bone marrow human leukemia cells];Q484940;P703;Q15978631
Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin;Q411659;P2175;Q264118
Therapy of acute myelocytic leukemia. Daunomycin contrasted with a combination of cytosine arabinoside and 6-thioguanine.;Q180983;P2175;Q29496
Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML.;Q180983;P2175;Q29496
Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML.;Q180983;P2175;Q264118
Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML.;Q411659;P2175;Q264118
Efficacy and tolerance of liposomal daunorubicin in Kaposi sarcoma associated with human immunodeficiency virus infection.;Q20816880;P703;Q15978631
Immobilization and properties of carminomycin 4-O-methyltranferase, the enzyme which catalyzes the final step in the biosynthesis of daunorubicin in Streptomyces peucetius.;Q411659;P703;Q7623394
Immobilization and properties of carminomycin 4-O-methyltranferase, the enzyme which catalyzes the final step in the biosynthesis of daunorubicin in Streptomyces peucetius.;Q411659;P703;Q1144013
Comparison of the antileukemic effect in mice of adriamycin (NSC-123127) with daunomycin (NSC-82151).;Q186474;P703;Q83310
High dose daunorubicin (NSC-83142) in the treatment of advanced acute myelogenous leukemia.;Q411659;P2175;Q264118
Probing daunorubicin accumulation defects in non-P-glycoprotein expressing multidrug-resistant cell lines using digitonin.;Q411659;P31;Q12140
Probing daunorubicin accumulation defects in non-P-glycoprotein expressing multidrug-resistant cell lines using digitonin.;Q20035886;P31;Q12140
Adriamycin and daunorubicin disposition in the rabbit.;Q18936;P3780;Q47520887
Alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin;Q218642;P31;Q12140
Alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin;Q411659;P31;Q12140
Alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin;Q178450;P31;Q12140
Binding of the alkaloid aristololactam--D-glucoside and daunomycin to human hemoglobin: spectroscopy and calorimetry studies;Q178450;P703;Q15978631
DrrC protein of Streptomyces peucetius removes daunorubicin from intercalated dnrI promoter.;Q411659;P703;Q1144013
DrrC protein of Streptomyces peucetius removes daunorubicin from intercalated dnrI promoter.;Q411659;P703;Q7623394
Electron spin resonance study on the mode of generation of free radicals of daunomycin, adriamycin, and carboquone in NAD(P)H-microsome system.;Q218642;P703;Q2046782
Electron spin resonance study on the mode of generation of free radicals of daunomycin, adriamycin, and carboquone in NAD(P)H-microsome system.;Q178450;P703;Q2046782
Differential fluorescent staining of human chromosomes with daunomycin and adriamycin--the d-bands.;Q178450;P703;Q15978631
[Restorative effect of quercetin on subcellular distribution of daunorubicin in multidrug resistant leukemia cell lines K562/ADM and HL-60/ADM];Q218642;P31;Q12140
[Restorative effect of quercetin on subcellular distribution of daunorubicin in multidrug resistant leukemia cell lines K562/ADM and HL-60/ADM];Q411659;P31;Q12140
[Restorative effect of quercetin on subcellular distribution of daunorubicin in multidrug resistant leukemia cell lines K562/ADM and HL-60/ADM];Q407781;P31;Q12140
[Restorative effect of quercetin on subcellular distribution of daunorubicin in multidrug resistant leukemia cell lines K562/ADM and HL-60/ADM];Q485277;P31;Q12140
[Restorative effect of quercetin on subcellular distribution of daunorubicin in multidrug resistant leukemia cell lines K562/ADM and HL-60/ADM];Q173670;P31;Q12140
[Restorative effect of quercetin on subcellular distribution of daunorubicin in multidrug resistant leukemia cell lines K562/ADM and HL-60/ADM];Q178450;P31;Q12140
[Restorative effect of quercetin on subcellular distribution of daunorubicin in multidrug resistant leukemia cell lines K562/ADM and HL-60/ADM];Q20816880;P31;Q12140
[Restorative effect of quercetin on subcellular distribution of daunorubicin in multidrug resistant leukemia cell lines K562/ADM and HL-60/ADM];Q22124685;P31;Q12140
[Restorative effect of quercetin on subcellular distribution of daunorubicin in multidrug resistant leukemia cell lines K562/ADM and HL-60/ADM];Q483745;P31;Q12140
Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia;Q408977;P2175;Q29496
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.;Q180983;P2175;Q29496
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.;Q180983;P2175;Q264118
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.;Q411659;P2175;Q264118
A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: validation with daunomycin, doxorubicin, and the alpha particle emitter (210)Po.;Q218642;P31;Q12140
A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: validation with daunomycin, doxorubicin, and the alpha particle emitter (210)Po.;Q218642;P703;Q177932
A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: validation with daunomycin, doxorubicin, and the alpha particle emitter (210)Po.;Q18936;P31;Q12140
A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: validation with daunomycin, doxorubicin, and the alpha particle emitter (210)Po.;Q411659;P31;Q12140
A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: validation with daunomycin, doxorubicin, and the alpha particle emitter (210)Po.;Q191924;P31;Q12140
A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: validation with daunomycin, doxorubicin, and the alpha particle emitter (210)Po.;Q20035886;P31;Q12140
A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: validation with daunomycin, doxorubicin, and the alpha particle emitter (210)Po.;Q20035886;P703;Q177932
A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3.;Q180983;P2175;Q264118
A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3.;Q180983;P2175;Q29496
A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3.;Q411659;P2175;Q264118
Cytostatic drug resistance. Role of phase-I daunorubicin metabolism in cancer cells.;Q186474;P31;Q12140
Cytostatic drug resistance. Role of phase-I daunorubicin metabolism in cancer cells.;Q411659;P31;Q12140
Cytostatic drug resistance. Role of phase-I daunorubicin metabolism in cancer cells.;Q173670;P31;Q12140
Cytostatic drug resistance. Role of phase-I daunorubicin metabolism in cancer cells.;Q484940;P31;Q12140
Addition of rubidomycin to induction treatment with vincristine, prednisone, and L-asparaginase in standard-risk childhood acute lymphocytic leukemia (study ALL V): a report on behalf of the Dutch Childhood Leukemia Study Group;Q408977;P2175;Q29496
Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.;Q186521;P703;Q15978631
Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.;Q186521;P31;Q12140
Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.;Q411659;P31;Q12140
Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.;Q20035886;P31;Q12140
Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.;Q20035886;P703;Q15978631
Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.;Q22124685;P31;Q12140
Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.;Q22124685;P703;Q15978631
Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.;Q483745;P31;Q12140
Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.;Q483745;P703;Q15978631
In vitro sensitivity of leukemic clonogenic cells to four anthracyclines (adriamycin, daunorubicin, rubidazone and aclacinomycin) in human acute myeloid leukemia;Q411659;P31;Q109603820
In vitro sensitivity of leukemic clonogenic cells to four anthracyclines (adriamycin, daunorubicin, rubidazone and aclacinomycin) in human acute myeloid leukemia;Q411659;P2175;Q264118
In vitro sensitivity of leukemic clonogenic cells to four anthracyclines (adriamycin, daunorubicin, rubidazone and aclacinomycin) in human acute myeloid leukemia;Q484940;P703;Q15978631
TRIM31 promotes acute myeloid leukemia progression and sensitivity to daunorubicin through the Wnt/-catenin signaling;Q411659;P2175;Q264118
[Treatment of acute myeloid leukemia in adults with a combination of daunomycin and cytosine-arabinoside];Q411659;P2175;Q264118
[Acute refractory lymphoblastic leukemia in the adult. Treatment with daunorubicin, cytosine arabinoside, 6-thioguanine, vincristine and prednisone];Q180983;P2175;Q29496
[Acute refractory lymphoblastic leukemia in the adult. Treatment with daunorubicin, cytosine arabinoside, 6-thioguanine, vincristine and prednisone];Q408977;P2175;Q18553852
[Acute refractory lymphoblastic leukemia in the adult. Treatment with daunorubicin, cytosine arabinoside, 6-thioguanine, vincristine and prednisone];Q408977;P2175;Q29496
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.;Q180983;P2175;Q29496
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.;Q180983;P2175;Q264118
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.;Q411659;P2175;Q264118
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.;Q177094;P2175;Q264118
A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.;Q177094;P2175;Q29496
Kinetics of glutathione and daunorubicin efflux from multidrug resistance protein overexpressing small-cell lung cancer cells.;Q153;P31;Q12140
Kinetics of glutathione and daunorubicin efflux from multidrug resistance protein overexpressing small-cell lung cancer cells.;Q411659;P31;Q12140
Kinetics of glutathione and daunorubicin efflux from multidrug resistance protein overexpressing small-cell lung cancer cells.;Q116907;P31;Q12140
Kinetics of glutathione and daunorubicin efflux from multidrug resistance protein overexpressing small-cell lung cancer cells.;Q20816880;P31;Q12140
A biophysical approach to daunorubicin interaction with model membranes: relevance for the drug's biological activity.;Q218642;P31;Q12140
A biophysical approach to daunorubicin interaction with model membranes: relevance for the drug's biological activity.;Q411659;P31;Q12140
Comparison of antitumor effects of daunorubicin covalently linked to poly-L-amino acid carriers;Q186474;P31;Q24301658
Comparison of antitumor effects of daunorubicin covalently linked to poly-L-amino acid carriers;Q483745;P31;Q24301658
Increased pressure alters plasma membrane dynamics and renders acute myeloid leukemia cells resistant to daunorubicin;Q411659;P2175;Q264118
Daunorubicin versus aclarubicin in combination with cytarabine and thioguanine in elderly patients with acute nonlymphocytic leukemia, a preliminary report;Q180983;P2175;Q29496
Daunorubicin versus aclarubicin in combination with cytarabine and thioguanine in elderly patients with acute nonlymphocytic leukemia, a preliminary report;Q411659;P2175;Q6708277
Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukemia with cytosine arabinoside, daunorubicin, andm-AMSA;Q180983;P2175;Q264118
Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukemia with cytosine arabinoside, daunorubicin, andm-AMSA;Q180983;P2175;Q29496
Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukemia with cytosine arabinoside, daunorubicin, andm-AMSA;Q411659;P2175;Q264118
Distribution of daunorubicin intravenously injected or intravenously infused as free drug and as a complex with DNA in rabbits;Q218642;P31;Q12140
Distribution of daunorubicin intravenously injected or intravenously infused as free drug and as a complex with DNA in rabbits;Q411659;P31;Q12140
Distribution of daunorubicin intravenously injected or intravenously infused as free drug and as a complex with DNA in rabbits;Q178450;P31;Q12140
Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organiz;Q180983;P2175;Q29496
Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organiz;Q180983;P2175;Q264118
Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organiz;Q411659;P2175;Q264118
Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organiz;Q239426;P2175;Q264118
Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association;Q180983;P2175;Q264118
Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association;Q180983;P2175;Q29496
Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association;Q180983;P2175;Q976388
Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association;Q411659;P2175;Q264118
Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association;Q412685;P2175;Q264118
Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association;Q412685;P527;Q105946712
Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells.;Q411659;P31;Q12140
Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells.;Q16965066;P31;Q12140
Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells.;Q16965066;P527;Q411659
Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells.;Q483745;P703;Q15978631
Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells.;Q483745;P31;Q12140
Vincristine, prednisone, and daunomycin in acute leukemia of childhood.;Q408977;P2175;Q29496
Determination of daunomycin in human plasma and urine by using an interference-free analysis of excitation-emission matrix fluorescence data with second-order calibration;Q178450;P703;Q15978631
Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells.;Q183290;P31;Q12140
Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells.;Q183290;P703;Q15978631
Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells.;Q186474;P31;Q12140
Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells.;Q186474;P703;Q15978631
Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells.;Q411659;P31;Q12140
Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells.;Q170545;P31;Q12140
Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells.;Q170545;P703;Q15978631
Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells.;Q20035886;P31;Q12140
Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells.;Q20035886;P703;Q15978631
Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells.;Q22124685;P703;Q15978631
Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells.;Q22124685;P31;Q12140
Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells.;Q484940;P31;Q12140
Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells.;Q484940;P703;Q15978631
Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins;Q180983;P2175;Q29496
Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins;Q180983;P31;Q12140
Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins;Q411659;P31;Q12140
Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group;Q180983;P2175;Q264118
Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group;Q180983;P2175;Q29496
Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group;Q186474;P1889;Q178425
Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group;Q411659;P2175;Q264118
Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group;Q411659;P2175;Q6708277
Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group;Q239426;P2175;Q264118
Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex;Q218642;P31;Q12140
Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex;Q411659;P31;Q12140
Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex;Q178450;P31;Q12140
Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex;Q483745;P31;Q12140
Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia.;Q180983;P2175;Q29496
Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia.;Q180983;P2175;Q264118
Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia.;Q411659;P2175;Q264118
Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia.;Q239426;P2175;Q264118
A rapid chromatographic procedure for the determination of adriamycin, daunomycin and their 13-OH metabolites adriamycinol and daunomycinol;Q218642;P31;Q407595
Responder versus nonresponder comparisons: daunorubicin plus prednisone in treatment of acute nonlymphocytic leukemia;Q411659;P2175;Q6708277
Lack of oncogenic activity of doxorubicin and daunorubicin in BALB/C mice;Q186474;P703;Q83310
Lack of oncogenic activity of doxorubicin and daunorubicin in BALB/C mice;Q411659;P31;Q187661
High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update;Q180983;P2175;Q29496
High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update;Q411659;P2175;Q6708277
Interactions between an anthracycline antibiotic and DNA: molecular structure of daunomycin complexed to d(CpGpTpApCpG) at 1.2-A resolution;Q411659;P279;Q417589
Inadvertent intrathecal administration of daunomycin resulting in fatality: Case report and therapeutic considerations;Q186474;P703;Q177932
Inadvertent intrathecal administration of daunomycin resulting in fatality: Case report and therapeutic considerations;Q484940;P703;Q177932
Evaluation of daunorubicin (NSC-82151) and methotrexate (NSC-740) in combination as a remission maintenance regimen in the treatment of acute leukemia.;Q422232;P2175;Q29496
Growth conditions, physiological properties, and selection of optimal parameters of biodegradation of anticancer drug daunomycin in industrial effluents by Bjerkandera adusta CCBAS930;Q218642;P31;Q12140
Growth conditions, physiological properties, and selection of optimal parameters of biodegradation of anticancer drug daunomycin in industrial effluents by Bjerkandera adusta CCBAS930;Q183290;P31;Q12140
Growth conditions, physiological properties, and selection of optimal parameters of biodegradation of anticancer drug daunomycin in industrial effluents by Bjerkandera adusta CCBAS930;Q186474;P31;Q12140
Growth conditions, physiological properties, and selection of optimal parameters of biodegradation of anticancer drug daunomycin in industrial effluents by Bjerkandera adusta CCBAS930;Q411659;P31;Q12140
Growth conditions, physiological properties, and selection of optimal parameters of biodegradation of anticancer drug daunomycin in industrial effluents by Bjerkandera adusta CCBAS930;Q139347;P31;Q12140
Growth conditions, physiological properties, and selection of optimal parameters of biodegradation of anticancer drug daunomycin in industrial effluents by Bjerkandera adusta CCBAS930;Q139347;P2175;Q12078
Growth conditions, physiological properties, and selection of optimal parameters of biodegradation of anticancer drug daunomycin in industrial effluents by Bjerkandera adusta CCBAS930;Q620730;P31;Q12140
Growth conditions, physiological properties, and selection of optimal parameters of biodegradation of anticancer drug daunomycin in industrial effluents by Bjerkandera adusta CCBAS930;Q707939;P31;Q12140
Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin;Q186474;P703;Q83310
Analysis of heterogeneity in daunorubicin uptake by human leukemia cells using laser flow cytometry.;Q218642;P703;Q15978631
The efficacy of WGA modified daunorubicin anti-resistant liposomes in treatment of drug-resistant MCF-7 breast cancer.;Q181003;P31;Q12140
The efficacy of WGA modified daunorubicin anti-resistant liposomes in treatment of drug-resistant MCF-7 breast cancer.;Q218642;P31;Q12140
The efficacy of WGA modified daunorubicin anti-resistant liposomes in treatment of drug-resistant MCF-7 breast cancer.;Q186474;P31;Q12140
The efficacy of WGA modified daunorubicin anti-resistant liposomes in treatment of drug-resistant MCF-7 breast cancer.;Q186521;P31;Q12140
The efficacy of WGA modified daunorubicin anti-resistant liposomes in treatment of drug-resistant MCF-7 breast cancer.;Q411659;P31;Q12140
The efficacy of WGA modified daunorubicin anti-resistant liposomes in treatment of drug-resistant MCF-7 breast cancer.;Q170545;P31;Q12140
The efficacy of WGA modified daunorubicin anti-resistant liposomes in treatment of drug-resistant MCF-7 breast cancer.;Q22124685;P31;Q12140
The efficacy of WGA modified daunorubicin anti-resistant liposomes in treatment of drug-resistant MCF-7 breast cancer.;Q620730;P31;Q12140
[Clinical observations on the therapy of acute leukemia in childhood. Comparative study of 2 drug associations: vincristine with prednisone and daunomycin with vincristine and prednisone];Q186474;P31;Q12140
[Clinical observations on the therapy of acute leukemia in childhood. Comparative study of 2 drug associations: vincristine with prednisone and daunomycin with vincristine and prednisone];Q408977;P31;Q12140
[Clinical observations on the therapy of acute leukemia in childhood. Comparative study of 2 drug associations: vincristine with prednisone and daunomycin with vincristine and prednisone];Q408977;P2175;Q29496
[Clinical observations on the therapy of acute leukemia in childhood. Comparative study of 2 drug associations: vincristine with prednisone and daunomycin with vincristine and prednisone];Q411659;P31;Q12140
[Clinical observations on the therapy of acute leukemia in childhood. Comparative study of 2 drug associations: vincristine with prednisone and daunomycin with vincristine and prednisone];Q424972;P31;Q12140
Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities.;Q180983;P2175;Q29496
Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities.;Q180983;P2175;Q264118
Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities.;Q411659;P2175;Q264118
Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities.;Q418817;P2175;Q264118
Spectroelectrochemical study of the interaction between antitumor drug daunomycin and DNA in the presence of antioxidants.;Q218642;P31;Q12140
Spectroelectrochemical study of the interaction between antitumor drug daunomycin and DNA in the presence of antioxidants.;Q183290;P31;Q12140
Spectroelectrochemical study of the interaction between antitumor drug daunomycin and DNA in the presence of antioxidants.;Q411659;P31;Q12140
Spectroelectrochemical study of the interaction between antitumor drug daunomycin and DNA in the presence of antioxidants.;Q178450;P31;Q12140
Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.;Q18936;P31;Q12140
Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.;Q411659;P31;Q12140
Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.;Q20035886;P31;Q12140
Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.;Q20035886;P703;Q15978631
Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.;Q1063862;P31;Q12140
Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.;Q484940;P31;Q12140
Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.;Q484940;P703;Q15978631
Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia;Q411659;P2175;Q264118
Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia;Q1063862;P2175;Q264118
Nucleotide sequence analysis of five putative Streptomyces griseus genes, one of which complements an early function in daunorubicin biosynthesis that is linked to a putative gene cluster involved in TDP-daunosamine formation.;Q186521;P703;Q1144013
Nucleotide sequence analysis of five putative Streptomyces griseus genes, one of which complements an early function in daunorubicin biosynthesis that is linked to a putative gene cluster involved in TDP-daunosamine formation.;Q411659;P361;Q22277880
Nucleotide sequence analysis of five putative Streptomyces griseus genes, one of which complements an early function in daunorubicin biosynthesis that is linked to a putative gene cluster involved in TDP-daunosamine formation.;Q411659;P703;Q1144013
Nucleotide sequence analysis of five putative Streptomyces griseus genes, one of which complements an early function in daunorubicin biosynthesis that is linked to a putative gene cluster involved in TDP-daunosamine formation.;Q411659;P703;Q7623385
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.;Q180983;P2175;Q264118
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.;Q180983;P2175;Q29496
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.;Q411659;P2175;Q264118
Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein.;Q218642;P31;Q12140
Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein.;Q186474;P31;Q12140
Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein.;Q186521;P31;Q12140
Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein.;Q411659;P31;Q12140
Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein.;Q485277;P31;Q12140
Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein.;Q80863;P31;Q12140
Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein.;Q170545;P31;Q12140
Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein.;Q173670;P31;Q12140
Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein.;Q418817;P31;Q12140
Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein.;Q20035886;P31;Q12140
Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein.;Q22124685;P31;Q12140
Flow cytometry evaluation of the multidrug-resistant phenotype with functional tests involving uptake of daunorubicin, Hoechst 33342, or rhodamine 123: a comparative study.;Q411659;P31;Q12140
Flow cytometry evaluation of the multidrug-resistant phenotype with functional tests involving uptake of daunorubicin, Hoechst 33342, or rhodamine 123: a comparative study.;Q485277;P31;Q12140
Flow cytometry evaluation of the multidrug-resistant phenotype with functional tests involving uptake of daunorubicin, Hoechst 33342, or rhodamine 123: a comparative study.;Q170545;P31;Q12140
[Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia].;Q180983;P2175;Q264118
[Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia].;Q180983;P2175;Q29496
[Intensive induction chemotherapy of adult acute myelogenous leukemia by continuing daunorubicin, behenoyl-cytosine arabinoside, 6-mercaptopurine and prednisolone until marrow aplasia].;Q411659;P2175;Q264118
Sequential mitoxantrone, daunorubicin, and cytosine arabinoside for patients with newly diagnosed acute myelocytic leukemia;Q180983;P2175;Q29496
Noradrenaline and alpha blockers in daunomycin cardiotoxicity;Q132621;P31;Q7279006
1,4-Anthraquinone: an anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of L1210 leukemic cells in the same nanomolar range as daunorubicin in vitro;Q218642;P31;Q12140
1,4-Anthraquinone: an anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of L1210 leukemic cells in the same nanomolar range as daunorubicin in vitro;Q411659;P31;Q12140
1,4-Anthraquinone: an anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of L1210 leukemic cells in the same nanomolar range as daunorubicin in vitro;Q178450;P31;Q12140
1,4-Anthraquinone: an anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of L1210 leukemic cells in the same nanomolar range as daunorubicin in vitro;Q179748;P31;Q12140
1,4-Anthraquinone: an anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of L1210 leukemic cells in the same nanomolar range as daunorubicin in vitro;Q483745;P31;Q12140
In-vitro prediction of clinical response to chemotherapy in childhood acute leukaemia. I. Combination of daunorubicin, vincristine and prednisolone;Q408977;P2175;Q29496
Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.;Q180983;P2175;Q29496
Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.;Q180983;P2175;Q264118
Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.;Q411659;P2175;Q264118
6-mercaptopurine and daunorubicin double drug liposomes-preparation, drug-drug interaction and characterization.;Q411659;P31;Q12140
6-mercaptopurine and daunorubicin double drug liposomes-preparation, drug-drug interaction and characterization.;Q418529;P31;Q12140
Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells;Q153;P703;Q15978631
Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells;Q218642;P31;Q407595
Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells;Q218642;P703;Q15978631
Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells;Q218642;P703;Q177932
Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells;Q186474;P703;Q177932
Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells;Q186474;P703;Q15978631
Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells;Q367700;P703;Q15978631
Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells;Q173670;P703;Q15978631
Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells;Q173670;P703;Q177932
Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells;Q178450;P703;Q15978631
Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells;Q178450;P703;Q177932
Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells;Q22124685;P703;Q15978631
Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells;Q22124685;P703;Q177932
P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.;Q411659;P31;Q12140
P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.;Q20035886;P31;Q12140
[Clinico-pharmacologic, cytochemical and Feulgen photometric studies in adult undifferentiated cell leukemias under combination chemotherapy with vincristine, daunorubicine and prednisone];Q408977;P2175;Q29496
Correlation of MDR1/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia.;Q411659;P2175;Q264118
Daunorubicin 90 mg/m2 in Acute Myeloid Leukemia Induction: Increased Toxicity in YoungPatients.;Q411659;P2175;Q264118
The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts.;Q186521;P703;Q15978631
Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.;Q411659;P31;Q12140
Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.;Q412178;P31;Q12140
Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.;Q20035886;P31;Q12140
Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.;Q484940;P31;Q12140
Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol;Q180983;P2175;Q29496
Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol;Q411659;P2175;Q6708277
PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation;Q411659;P2175;Q264118
Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction.;Q178450;P527;Q623
Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin.;Q178450;P703;Q15978631
Purification, cloning, and DNA sequence analysis of a chitinase from an overproducing mutant of Streptomyces peucetius defective in daunorubicin biosynthesis;Q218642;P703;Q1144013
Purification, cloning, and DNA sequence analysis of a chitinase from an overproducing mutant of Streptomyces peucetius defective in daunorubicin biosynthesis;Q411659;P361;Q22277880
Purification, cloning, and DNA sequence analysis of a chitinase from an overproducing mutant of Streptomyces peucetius defective in daunorubicin biosynthesis;Q411659;P703;Q1144013
Purification, cloning, and DNA sequence analysis of a chitinase from an overproducing mutant of Streptomyces peucetius defective in daunorubicin biosynthesis;Q411659;P703;Q7623394
Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin;Q218642;P31;Q12140
Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin;Q183290;P31;Q12140
Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin;Q411659;P31;Q12140
Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin;Q178450;P31;Q12140
Therapeutic effect of treatment with polyclonal or monoclonal antibodies to alpha-fetoprotein that have been conjugated to daunomycin via a dextran bridge: studies with an alpha-fetoprotein-producing rat hepatoma tumor model;Q186521;P703;Q177932
The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B;Q180983;P2175;Q29496
The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B;Q411659;P2175;Q6708277
Functional characterization and transcriptional analysis of a gene cluster governing early and late steps in daunorubicin biosynthesis in Streptomyces peucetius.;Q411659;P703;Q1144013
Functional characterization and transcriptional analysis of a gene cluster governing early and late steps in daunorubicin biosynthesis in Streptomyces peucetius.;Q411659;P703;Q7623394
Functional characterization and transcriptional analysis of a gene cluster governing early and late steps in daunorubicin biosynthesis in Streptomyces peucetius.;Q411659;P361;Q22277880
Preparative procedures for conversion of daunorubicin into doxorubicin (Adriamycin) and 14-O-acetyldoxorubicin by way of 14-bromodaunorubicin;Q18936;P3780;Q47520887
Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly;Q180983;P2175;Q29496
Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly;Q411659;P2175;Q6708277
Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo;Q183290;P31;Q12140
Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo;Q411659;P31;Q12140
Intramolecular electron transfer in proteins. Radiolysis study of the reductive activation of daunorubicin complexed in egg white apo-riboflavin binding protein;Q130365;P361;Q22313814
Effects of leukemic bone marrow stromal cells on gene differential expression in human leukemic Jurkat T-cell line exposed to daunorubicin;Q186521;P703;Q15978631
Assay for determination of daunorubicin in cancer cells with multidrug resistance phenotype;Q218642;P31;Q12140
Assay for determination of daunorubicin in cancer cells with multidrug resistance phenotype;Q411659;P31;Q12140
Hydration of drug-DNA complexes: greater water uptake for adriamycin compared to daunomycin;Q218642;P31;Q12140
Hydration of drug-DNA complexes: greater water uptake for adriamycin compared to daunomycin;Q411659;P31;Q12140
Hydration of drug-DNA complexes: greater water uptake for adriamycin compared to daunomycin;Q485277;P31;Q12140
Hydration of drug-DNA complexes: greater water uptake for adriamycin compared to daunomycin;Q178450;P31;Q12140
Hydration of drug-DNA complexes: greater water uptake for adriamycin compared to daunomycin;Q29053744;P31;Q12140
Hydration of drug-DNA complexes: greater water uptake for adriamycin compared to daunomycin;Q29053744;P155;Q23392
Functional multidrug resistance in acute myeloblastic leukaemia: a standardized flow cytometric assay for intracellular daunorubicin accumulation;Q411659;P31;Q12140
Daunorubicin metabolism in acute nonlymphocytic leukemia.;Q411659;P2175;Q6708277
Effect of verapamil on daunorubicin accumulation in human leukemic cells with different levels of MDR1 gene expression.;Q173670;P703;Q15978631
Effect of verapamil on daunorubicin accumulation in human leukemic cells with different levels of MDR1 gene expression.;Q178450;P703;Q15978631
Effect of verapamil on daunorubicin accumulation in human leukemic cells with different levels of MDR1 gene expression.;Q22124685;P703;Q15978631
An electrochemical daunorubicin sensor based on the use of platinum nanoparticles loaded onto a nanocomposite prepared from nitrogen decorated reduced graphene oxide and single-walled carbon nanotubes;Q218642;P527;Q623
An electrochemical daunorubicin sensor based on the use of platinum nanoparticles loaded onto a nanocomposite prepared from nitrogen decorated reduced graphene oxide and single-walled carbon nanotubes;Q218642;P527;Q627
An electrochemical daunorubicin sensor based on the use of platinum nanoparticles loaded onto a nanocomposite prepared from nitrogen decorated reduced graphene oxide and single-walled carbon nanotubes;Q191924;P527;Q623
An electrochemical daunorubicin sensor based on the use of platinum nanoparticles loaded onto a nanocomposite prepared from nitrogen decorated reduced graphene oxide and single-walled carbon nanotubes;Q191924;P527;Q627
[Combination chemotherapy with cytosine arabinoside and daunomycin in childhood acute leukemia];Q180983;P2175;Q29496
[Combination chemotherapy with cytosine arabinoside and daunomycin in childhood acute leukemia];Q180983;P2175;Q976388
[Combination chemotherapy with cytosine arabinoside and daunomycin in childhood acute leukemia];Q186474;P1889;Q178425
Comparison of 60 and 80mg/m2 of daunorubicin in induction therapy of acute myeloid leukaemia.;Q411659;P2175;Q264118
Substitutions at C2' of daunosamine in the anticancer drug daunorubicin alter its DNA-binding sequence specificity;Q218642;P31;Q12140
Substitutions at C2' of daunosamine in the anticancer drug daunorubicin alter its DNA-binding sequence specificity;Q183290;P31;Q12140
Substitutions at C2' of daunosamine in the anticancer drug daunorubicin alter its DNA-binding sequence specificity;Q186474;P31;Q12140
Substitutions at C2' of daunosamine in the anticancer drug daunorubicin alter its DNA-binding sequence specificity;Q411659;P31;Q12140
Substitutions at C2' of daunosamine in the anticancer drug daunorubicin alter its DNA-binding sequence specificity;Q178450;P31;Q12140
Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.;Q218642;P31;Q12140
Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.;Q183290;P31;Q12140
Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.;Q186474;P31;Q12140
Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.;Q410291;P31;Q12140
Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.;Q411659;P31;Q12140
Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.;Q173670;P31;Q12140
Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.;Q178450;P31;Q12140
Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.;Q20035886;P31;Q12140
Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.;Q1063862;P31;Q12140
Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.;Q2354337;P31;Q12140
Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin.;Q411659;P31;Q12140
Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin.;Q173670;P31;Q12140
Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin.;Q419964;P31;Q12140
Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in Golgi vesicles.;Q153;P31;Q12140
Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in Golgi vesicles.;Q411659;P31;Q12140
Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in Golgi vesicles.;Q20035886;P31;Q12140
Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in Golgi vesicles.;Q22124685;P31;Q12140
Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in Golgi vesicles.;Q620730;P31;Q12140
Effects of cytochalasins and colchicine on the accumulation and retention of daunomycin and vincristine in drug resistant tumor cells.;Q408977;P31;Q12140
Effects of cytochalasins and colchicine on the accumulation and retention of daunomycin and vincristine in drug resistant tumor cells.;Q411659;P31;Q12140
Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein.;Q408977;P31;Q12140
Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein.;Q411659;P31;Q12140
Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein.;Q20035886;P31;Q12140
Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein.;Q20035886;P703;Q15978631
Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein.;Q484940;P703;Q15978631
Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein.;Q484940;P31;Q12140
Plasma membrane as a site of redox activation of daunomycin in intact human erythrocytes. Quantitative evaluation of the hydrogen peroxide produced by the membrane with respect to the cytosol.;Q181619;P703;Q15978631
Plasma membrane as a site of redox activation of daunomycin in intact human erythrocytes. Quantitative evaluation of the hydrogen peroxide produced by the membrane with respect to the cytosol.;Q20035886;P703;Q15978631
Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia.;Q411659;P2175;Q264118
Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.;Q411659;P2175;Q264118
Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.;Q1063862;P2175;Q264118
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial;Q411659;P2175;Q264118
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial;Q5134875;P2175;Q264118
Liposomal daunorubicin (DaunoXome) in multiple myeloma: a modified VAD regimen using short-term infusion.;Q16965066;P527;Q411659
Adriamycin analogues. Novel anomeric ribofuranoside analogues of daunorubicin;Q18936;P3780;Q47520887
Interaction of 3'-azido-3'-deamino daunorubicin with human serum albumin: investigation by fluorescence spectroscopy and molecular modeling methods.;Q484940;P703;Q15978631
Modulation of antitumoral antibody-dependent cellular cytotoxicity and natural killer activity by Adriamycin and daunorubicin;Q18936;P3780;Q47520887
Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?;Q411659;P2175;Q264118
Synergistic antitumoral efficacy of a novel replicative adenovirus SG611-PDCD5 and daunorubicin in human leukemic cells;Q183290;P703;Q15978631
Synergistic antitumoral efficacy of a novel replicative adenovirus SG611-PDCD5 and daunorubicin in human leukemic cells;Q186474;P703;Q15978631
Synergistic antitumoral efficacy of a novel replicative adenovirus SG611-PDCD5 and daunorubicin in human leukemic cells;Q178450;P703;Q15978631
Synergistic antitumoral efficacy of a novel replicative adenovirus SG611-PDCD5 and daunorubicin in human leukemic cells;Q20035886;P703;Q15978631
Synergistic antitumoral efficacy of a novel replicative adenovirus SG611-PDCD5 and daunorubicin in human leukemic cells;Q620730;P703;Q15978631
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia;Q180983;P2175;Q29496
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia;Q180983;P2175;Q976388
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia;Q16965066;P527;Q411659
Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.;Q411659;P2175;Q264118
Daunomycin and doxorubicin Lym-1-drug conjugates for the treatment of malignant lymphomas;Q18936;P31;Q12140
Daunomycin and doxorubicin Lym-1-drug conjugates for the treatment of malignant lymphomas;Q18936;P2175;Q208414
Daunomycin and doxorubicin Lym-1-drug conjugates for the treatment of malignant lymphomas;Q411659;P31;Q12140
Daunomycin and doxorubicin Lym-1-drug conjugates for the treatment of malignant lymphomas;Q178450;P31;Q12140
Daunomycin and doxorubicin Lym-1-drug conjugates for the treatment of malignant lymphomas;Q483745;P31;Q12140
Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation.;Q186474;P31;Q12140
Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation.;Q411659;P31;Q12140
Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation.;Q20035886;P31;Q12140
Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation.;Q484940;P31;Q12140
Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study.;Q411659;P2175;Q264118
Cooperativity in the inhibition of P-glycoprotein-mediated daunorubicin transport: evidence for half-of-the-sites reactivity;Q411659;P361;Q22290410
Daunorubicin metabolism in leukemic cells isolated from patients with acute myeloid leukemia.;Q411659;P2175;Q264118
Enhanced daunomycin accumulation in human intestinal Caco-2 cells from non-ionic food emulsifiers unrelated to the p-glycoprotein inhibitory mechanism.;Q186474;P703;Q15978631
Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia;Q180983;P2175;Q29496
Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia;Q180983;P2175;Q264118
Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia;Q411659;P2175;Q264118
Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia;Q1063862;P2175;Q264118
Daunomycin inhibits the uptake of adenine, amino acids, and glucose into cardiac myocytes;Q178450;P31;Q8066
Daunorubicin accumulation by human myeloblasts varying in anthracycline resistance.;Q178450;P703;Q15978631
Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells;Q18936;P3780;Q47520887
Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin, and asparaginase consolidation for acute nonlymphocytic leukemia.;Q180983;P2175;Q29496
Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin, and asparaginase consolidation for acute nonlymphocytic leukemia.;Q411659;P2175;Q6708277
Tissue distribution and disposition of daunomycin (NCS-82151) in mice: fluorometric and isotopic methods.;Q186474;P703;Q83310
Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma--the DD Protocol;Q16965066;P527;Q411659
A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.;Q218642;P31;Q12140
A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.;Q180983;P31;Q12140
A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.;Q180983;P2175;Q29496
A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.;Q180983;P2175;Q264118
A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.;Q411659;P31;Q12140
A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.;Q411659;P2175;Q264118
A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.;Q484940;P31;Q12140
Accumulation of daunomycin and fluorescent dyes by drug-transporting Malpighian tubule cells of the tobacco hornworn, Manduca sexta.;Q218642;P31;Q12140
Accumulation of daunomycin and fluorescent dyes by drug-transporting Malpighian tubule cells of the tobacco hornworn, Manduca sexta.;Q411659;P31;Q12140
Accumulation of daunomycin and fluorescent dyes by drug-transporting Malpighian tubule cells of the tobacco hornworn, Manduca sexta.;Q22124685;P31;Q12140
Differential sensitivity of acute myeloid leukemia cells to daunorubicin depends on P2X7A versus P2X7B receptor expression;Q411659;P2175;Q264118
Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia.;Q411659;P2175;Q264118
[Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia];Q385347;P2175;Q264118
[Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia];Q180983;P2175;Q29496
[Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia];Q180983;P2175;Q264118
[Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia];Q186474;P1889;Q178425
[Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia];Q411659;P2175;Q264118
Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: geometry of intercalation of iremycin and daunomycin;Q411659;P279;Q417589
Eradication of Biofilm-Like Microcolony Structures of Borrelia burgdorferi by Daunomycin and Daptomycin but not Mitomycin C in Combination with Doxycycline and Cefuroxime.;Q413728;P2175;Q201989
Eradication of Biofilm-Like Microcolony Structures of Borrelia burgdorferi by Daunomycin and Daptomycin but not Mitomycin C in Combination with Doxycycline and Cefuroxime.;Q422442;P2175;Q201989
Adriamycin and daunomycin induce interstrand DNA crosslinks in Hela S3 Cells;Q18936;P3780;Q47520887
Remission induction with daunomycin, vincristine, and prednisone in adult acute lymphocytic leukemia.;Q408977;P2175;Q29496
Remission induction with daunomycin, vincristine, and prednisone in adult acute lymphocytic leukemia.;Q411659;P2175;Q6708277
Effects on leukemic clonogenic cells in murine myeloid leukemia of 1-beta-D-arabinofuranosylcytosine and the anthracyclines adriamycin, daunomycin, aclacinomycin A, and 4'-epidoxorubicin;Q18936;P31;Q109603820
Effects on leukemic clonogenic cells in murine myeloid leukemia of 1-beta-D-arabinofuranosylcytosine and the anthracyclines adriamycin, daunomycin, aclacinomycin A, and 4'-epidoxorubicin;Q411659;P31;Q109603820
An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and daunorubicin by induction of both necrosis and apoptosis.;Q218642;P703;Q15978631
An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and daunorubicin by induction of both necrosis and apoptosis.;Q423762;P703;Q15978631
The anthracycline antitumor agents doxorubicin and daunorubicin reduce the activity of Candida albicans phospholipase B;Q186474;P703;Q310443
The anthracycline antitumor agents doxorubicin and daunorubicin reduce the activity of Candida albicans phospholipase B;Q186521;P703;Q310443
Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein;Q186474;P703;Q15978631
Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein;Q186474;P31;Q12140
Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein;Q411659;P31;Q12140
Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein;Q116907;P31;Q12140
Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein;Q116907;P703;Q15978631
Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein;Q170545;P31;Q12140
Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein;Q170545;P703;Q15978631
Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein;Q173670;P31;Q12140
Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein;Q173670;P703;Q15978631
Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein;Q22124685;P31;Q12140
Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein;Q22124685;P703;Q15978631
Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia;Q411659;P2175;Q264118
[Influence of arsenic trioxide and daunorubicin on the expression of annexin II and fibrinolytic activity in NB4 cells].;Q7739;P527;Q871
Daunorubicin attenuates tumor necrosis factor-alpha-induced biosynthesis of plasminogen activator inhibitor-1 in human umbilical vein endothelial cells.;Q178450;P703;Q15978631
[High frequency and quality of remissions in acute lymphoblastic leukemia in children induced by the association of delta-1-cortisone, leurocristine and rubidomycin importance of rooms free of pathogenic germs];Q408977;P2175;Q29496
[High frequency and quality of remissions in acute lymphoblastic leukemia in children induced by the association of delta-1-cortisone, leurocristine and rubidomycin importance of rooms free of pathogenic germs];Q408977;P2175;Q18553852
Cooperative P-glycoprotein mediated daunorubicin transport into DNA-loaded plasma membrane vesicles;Q411659;P361;Q22290410
Disseminated Langerhans cell histiocytosis associated with acute myeloid leukaemia: complete remission with daunorubicin and cytarabine.;Q180983;P2175;Q29496
Disseminated Langerhans cell histiocytosis associated with acute myeloid leukaemia: complete remission with daunorubicin and cytarabine.;Q180983;P2175;Q264118
Disseminated Langerhans cell histiocytosis associated with acute myeloid leukaemia: complete remission with daunorubicin and cytarabine.;Q411659;P2175;Q264118
New Natural Sesquiterpenes as Modulators of Daunomycin Resistance in a Multidrug-ResistantLeishmaniatropicaLine,;Q183290;P31;Q12140
New Natural Sesquiterpenes as Modulators of Daunomycin Resistance in a Multidrug-ResistantLeishmaniatropicaLine,;Q411659;P31;Q12140
New Natural Sesquiterpenes as Modulators of Daunomycin Resistance in a Multidrug-ResistantLeishmaniatropicaLine,;Q173670;P31;Q12140
New Natural Sesquiterpenes as Modulators of Daunomycin Resistance in a Multidrug-ResistantLeishmaniatropicaLine,;Q178450;P31;Q12140
New Natural Sesquiterpenes as Modulators of Daunomycin Resistance in a Multidrug-ResistantLeishmaniatropicaLine,;Q22124685;P31;Q12140
New Natural Sesquiterpenes as Modulators of Daunomycin Resistance in a Multidrug-ResistantLeishmaniatropicaLine,;Q483745;P31;Q12140
Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells;Q218642;P703;Q15978631
Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells;Q218642;P31;Q12140
Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells;Q18936;P31;Q12140
Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells;Q186521;P31;Q12140
Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells;Q186521;P703;Q15978631
Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells;Q411659;P31;Q12140
Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells;Q407781;P31;Q12140
Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells;Q178450;P31;Q12140
Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells;Q178450;P703;Q15978631
Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells;Q20816880;P703;Q15978631
Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells;Q20816880;P31;Q12140
Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells;Q22124685;P31;Q12140
Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells;Q22124685;P703;Q15978631
[On the use of daunomycin in association with other drugs in the therapy of infantile acute leukemia];Q411659;P31;Q12140
Apoferritin-based nanomedicine platform for drug delivery: equilibrium binding study of daunomycin with DNA;Q218642;P31;Q12140
Apoferritin-based nanomedicine platform for drug delivery: equilibrium binding study of daunomycin with DNA;Q411659;P31;Q12140
Apoferritin-based nanomedicine platform for drug delivery: equilibrium binding study of daunomycin with DNA;Q191924;P366;Q8386
Apoferritin-based nanomedicine platform for drug delivery: equilibrium binding study of daunomycin with DNA;Q191924;P31;Q12140
Apoferritin-based nanomedicine platform for drug delivery: equilibrium binding study of daunomycin with DNA;Q178450;P31;Q12140
[Newly Diagnosed Acute Myeloid Leukemia Patients-Derived Bone Marrow Mesenchymal Stem Cells Suppress Daunorubicin Induced HL-60 Cell Apoptosis via Modulating Caspase-3/Survivin];Q411659;P2175;Q264118
[Derivatives of antineoplastic antibiotics of the daunorubicin series containing methylurea or nitrosomethylurea residues];Q411659;P2868;Q4381760
[Detrimental effects of Daunorubicin and Doxorubicin on human erythrocytes in vitro];Q178450;P703;Q15978631
Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.;Q180983;P2175;Q29496
Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age.;Q411659;P2175;Q264118
Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age.;Q5134875;P2175;Q264118
Multistep drug intercalation: molecular dynamics and free energy studies of the binding of daunomycin to DNA;Q218642;P31;Q12140
Multistep drug intercalation: molecular dynamics and free energy studies of the binding of daunomycin to DNA;Q411659;P31;Q12140
Multistep drug intercalation: molecular dynamics and free energy studies of the binding of daunomycin to DNA;Q178450;P31;Q12140
Multistep drug intercalation: molecular dynamics and free energy studies of the binding of daunomycin to DNA;Q22124685;P31;Q12140
Enhanced potency of daunorubicin against multidrug resistant subline KB-ChR-8-5-11 by a pulsed magnetic field.;Q186474;P31;Q12140
Enhanced potency of daunorubicin against multidrug resistant subline KB-ChR-8-5-11 by a pulsed magnetic field.;Q411659;P31;Q12140
Enhanced potency of daunorubicin against multidrug resistant subline KB-ChR-8-5-11 by a pulsed magnetic field.;Q173670;P31;Q12140
Enhanced potency of daunorubicin against multidrug resistant subline KB-ChR-8-5-11 by a pulsed magnetic field.;Q20816880;P31;Q12140
[Conbined treatment with rubidomycin and vincristine in acute leukemia in children];Q408977;P2175;Q29496
Cytostatic efficacy of DNA-complexes of adriamycin, daunomycin and actinomycin D. I. Comparative studies in Novikoff hepatoma, human mammary carcinoma cells and human leukemic leukocytes.;Q218642;P703;Q15978631
Cytostatic efficacy of DNA-complexes of adriamycin, daunomycin and actinomycin D. I. Comparative studies in Novikoff hepatoma, human mammary carcinoma cells and human leukemic leukocytes.;Q186474;P703;Q15978631
Cytostatic efficacy of DNA-complexes of adriamycin, daunomycin and actinomycin D. I. Comparative studies in Novikoff hepatoma, human mammary carcinoma cells and human leukemic leukocytes.;Q178450;P703;Q15978631
Cytostatic efficacy of DNA-complexes of adriamycin, daunomycin and actinomycin D. I. Comparative studies in Novikoff hepatoma, human mammary carcinoma cells and human leukemic leukocytes.;Q484940;P703;Q15978631
[The study of mechanisms of accumulation of daunorubicin and rodamin-123 in cells of human venous blood using cytometry technique];Q186521;P703;Q15978631
A randomized clinical trial of daunorubicin and a combination of prednisone, vincristine, 6-mercaptopurine, and methotrexate in adult acute nonlymphocytic leukemia;Q408977;P2175;Q29496
A randomized clinical trial of daunorubicin and a combination of prednisone, vincristine, 6-mercaptopurine, and methotrexate in adult acute nonlymphocytic leukemia;Q411659;P2175;Q6708277
A randomized clinical trial of daunorubicin and a combination of prednisone, vincristine, 6-mercaptopurine, and methotrexate in adult acute nonlymphocytic leukemia;Q418529;P2175;Q6708277
A randomized clinical trial of daunorubicin and a combination of prednisone, vincristine, 6-mercaptopurine, and methotrexate in adult acute nonlymphocytic leukemia;Q422232;P2175;Q29496
[Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children];Q180983;P2175;Q29496
[Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children];Q180983;P2175;Q264118
[Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children];Q411659;P2175;Q264118
[Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children];Q16965066;P527;Q411659
Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia.;Q16965066;P527;Q411659
The preparation of mitomycin C, adriamycin and daunomycin covalently bound to antibodies as improved cancer chemotherapeutic agents;Q186474;P703;Q177932
The preparation of mitomycin C, adriamycin and daunomycin covalently bound to antibodies as improved cancer chemotherapeutic agents;Q186521;P703;Q177932
The preparation of mitomycin C, adriamycin and daunomycin covalently bound to antibodies as improved cancer chemotherapeutic agents;Q19856779;P1889;Q417625
Chemotherapy of acute leukemia: a comparison of vincristine, cytarabine, and prednisone alone and in combination with cyclophosphamide or daunorubicin;Q180983;P2175;Q29496
Chemotherapy of acute leukemia: a comparison of vincristine, cytarabine, and prednisone alone and in combination with cyclophosphamide or daunorubicin;Q180983;P2175;Q976388
Chemotherapy of acute leukemia: a comparison of vincristine, cytarabine, and prednisone alone and in combination with cyclophosphamide or daunorubicin;Q408977;P2175;Q29496
Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma.;Q16965066;P527;Q411659
Molecular structure of an anticancer drug-DNA complex: daunomycin plus d(CpGpTpApCpG).;Q411659;P31;Q12140
Molecular structure of an anticancer drug-DNA complex: daunomycin plus d(CpGpTpApCpG).;Q178450;P31;Q12140
Molecular structure of an anticancer drug-DNA complex: daunomycin plus d(CpGpTpApCpG).;Q620730;P31;Q12140
A second comparative trial of remission induction (by cytosine arabinoside given every 12 hours, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia;Q385347;P2175;Q264118
A second comparative trial of remission induction (by cytosine arabinoside given every 12 hours, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia;Q180983;P2175;Q29496
A second comparative trial of remission induction (by cytosine arabinoside given every 12 hours, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia;Q180983;P2175;Q264118
A second comparative trial of remission induction (by cytosine arabinoside given every 12 hours, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia;Q218642;P703;Q2046782
A second comparative trial of remission induction (by cytosine arabinoside given every 12 hours, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia;Q186474;P1889;Q178425
A second comparative trial of remission induction (by cytosine arabinoside given every 12 hours, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia;Q411659;P2175;Q264118
Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older;Q411659;P2175;Q264118
Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older;Q1063862;P2175;Q264118
Inhibitory effects of ginsenosides and their hydrolyzed metabolites on daunorubicin transport in KB-C2 cells.;Q411659;P361;Q22290410
Role of daunorubicin in the induction therapy for adult acute myeloid leukemia;Q411659;P2175;Q264118
Crystal structure of a ternary complex of DnrK, a methyltransferase in daunorubicin biosynthesis, with bound products;Q411659;P361;Q22277880
Co-delivery of IR-768 and daunorubicin using mPEG-b-PLGA micelles for synergistic enhancement of combination therapy of melanoma;Q186474;P703;Q83310
Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.;Q411659;P31;Q12140
Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.;Q178450;P31;Q12140
Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.;Q20035886;P31;Q12140
A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma.;Q408977;P2175;Q208414
A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma.;Q408977;P2175;Q1138590
A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma.;Q11426176;P2175;Q1138590
A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma.;Q11426176;P2175;Q208414
Changes in GSH-antioxidant system induced by daunorubicin in human normal and diabetic fibroblasts.;Q183290;P703;Q15978631
Changes in GSH-antioxidant system induced by daunorubicin in human normal and diabetic fibroblasts.;Q186474;P703;Q15978631
Changes in GSH-antioxidant system induced by daunorubicin in human normal and diabetic fibroblasts.;Q186474;P366;Q133948
Changes in GSH-antioxidant system induced by daunorubicin in human normal and diabetic fibroblasts.;Q485277;P703;Q15978631
Changes in GSH-antioxidant system induced by daunorubicin in human normal and diabetic fibroblasts.;Q116907;P366;Q133948
Changes in GSH-antioxidant system induced by daunorubicin in human normal and diabetic fibroblasts.;Q116907;P703;Q15978631
Changes in GSH-antioxidant system induced by daunorubicin in human normal and diabetic fibroblasts.;Q620730;P703;Q15978631
Some determinants of the therapeutic efficacy of actinomycin D (NSC-3053), adriamycin (NSC-123127), and daunorubicin (NSC-83142);Q183290;P703;Q177932
Some determinants of the therapeutic efficacy of actinomycin D (NSC-3053), adriamycin (NSC-123127), and daunorubicin (NSC-83142);Q186474;P703;Q177932
Some determinants of the therapeutic efficacy of actinomycin D (NSC-3053), adriamycin (NSC-123127), and daunorubicin (NSC-83142);Q178450;P703;Q177932
Treatment of acute myeloid leukaemia with cytosine arabinoside and daunomycin in combination;Q180983;P2175;Q29496
Treatment of acute myeloid leukaemia with cytosine arabinoside and daunomycin in combination;Q180983;P2175;Q264118
Treatment of acute myeloid leukaemia with cytosine arabinoside and daunomycin in combination;Q411659;P2175;Q264118
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.;Q180983;P2175;Q29496
Acyclovir bioavailability in patients with acute myelogenous leukemia treated with daunorubicin and cytarabine.;Q180983;P2175;Q29496
Acyclovir bioavailability in patients with acute myelogenous leukemia treated with daunorubicin and cytarabine.;Q180983;P2175;Q264118
Acyclovir bioavailability in patients with acute myelogenous leukemia treated with daunorubicin and cytarabine.;Q411659;P2175;Q264118
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.;Q180983;P2175;Q264118
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.;Q180983;P2175;Q29496
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.;Q180983;P2175;Q954625
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.;Q411659;P2175;Q264118
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.;Q203174;P2175;Q954625
Streptomycetes producing daunomycin and related compounds: do we know enough about them after 25 years?;Q183290;P31;Q11173
Streptomycetes producing daunomycin and related compounds: do we know enough about them after 25 years?;Q411659;P31;Q11173
Proton nuclear magnetic resonance study of the self-complementary hexanucleotide d(pTpA)3 and its interaction with daunomycin;Q218642;P703;Q2046782
Different effects of metabolic inhibitors and cyclosporin A on daunorubicin transport in leukemia cells from patients with AML.;Q411659;P361;Q22290410
Free energy calculation on base specificity of drug--DNA interactions: application to daunomycin and acridine intercalation into DNA.;Q218642;P31;Q12140
Free energy calculation on base specificity of drug--DNA interactions: application to daunomycin and acridine intercalation into DNA.;Q411659;P31;Q12140
Free energy calculation on base specificity of drug--DNA interactions: application to daunomycin and acridine intercalation into DNA.;Q191924;P31;Q12140
Free energy calculation on base specificity of drug--DNA interactions: application to daunomycin and acridine intercalation into DNA.;Q170545;P31;Q12140
Free energy calculation on base specificity of drug--DNA interactions: application to daunomycin and acridine intercalation into DNA.;Q178450;P31;Q12140
Circumvention of daunorubicin resistance by a new tamoxifen derivative, toremifene, in multidrug-resistant cell line.;Q186474;P31;Q12140
Circumvention of daunorubicin resistance by a new tamoxifen derivative, toremifene, in multidrug-resistant cell line.;Q411659;P31;Q12140
Circumvention of daunorubicin resistance by a new tamoxifen derivative, toremifene, in multidrug-resistant cell line.;Q412178;P31;Q12140
Circumvention of daunorubicin resistance by a new tamoxifen derivative, toremifene, in multidrug-resistant cell line.;Q3993743;P31;Q12140
A proton nuclear magnetic resonance investigation of the conformation of daunomycin;Q218642;P703;Q2046782
A differential interaction of doxorubicin and daunorubicin with human serum proteins;Q218642;P703;Q15978631
Topoisomerase IIalpha expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C.;Q411659;P2175;Q264118
Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia.;Q411659;P2175;Q264118
Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia.;Q16965066;P527;Q411659
Liposomal daunorubicin in tumor stage cutaneous T-cell lymphoma: report of three cases;Q16965066;P527;Q411659
Hyaluronic acid modified daunorubicin plus honokiol cationic liposomes for the treatment of breast cancer along with the elimination vasculogenic mimicry channels.;Q3143635;P3781;Q337231
Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study;Q180983;P2175;Q29496
Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study;Q180983;P2175;Q264118
Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study;Q411659;P2175;Q264118
High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot study;Q180983;P2175;Q29496
High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot study;Q411659;P2175;Q6708277
Specific interaction of 4'-O-(a-l-Cladinosyl) daunorubicin with human serum albumin: The binding site II on HSA molecular using spectroscopy and modeling.;Q218642;P703;Q15978631
Specific interaction of 4'-O-(a-l-Cladinosyl) daunorubicin with human serum albumin: The binding site II on HSA molecular using spectroscopy and modeling.;Q183290;P703;Q15978631
Specific interaction of 4'-O-(a-l-Cladinosyl) daunorubicin with human serum albumin: The binding site II on HSA molecular using spectroscopy and modeling.;Q186474;P703;Q15978631
Specific interaction of 4'-O-(a-l-Cladinosyl) daunorubicin with human serum albumin: The binding site II on HSA molecular using spectroscopy and modeling.;Q186521;P703;Q15978631
Specific interaction of 4'-O-(a-l-Cladinosyl) daunorubicin with human serum albumin: The binding site II on HSA molecular using spectroscopy and modeling.;Q485277;P703;Q15978631
Specific interaction of 4'-O-(a-l-Cladinosyl) daunorubicin with human serum albumin: The binding site II on HSA molecular using spectroscopy and modeling.;Q484940;P703;Q15978631
Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.;Q186474;P31;Q12140
Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.;Q411659;P31;Q12140
Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.;Q1063862;P31;Q12140
Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.;Q620730;P31;Q12140
[Study on the sensitization of acute myeloid leukemia cell to daunorubicin by recombinant human interleukin-3];Q183290;P703;Q15978631
[Study on the sensitization of acute myeloid leukemia cell to daunorubicin by recombinant human interleukin-3];Q411659;P2175;Q264118
Intercalation of daunomycin into stacked DNA base pairs. DFT study of an anticancer drug;Q218642;P31;Q12140
Intercalation of daunomycin into stacked DNA base pairs. DFT study of an anticancer drug;Q186521;P31;Q12140
Intercalation of daunomycin into stacked DNA base pairs. DFT study of an anticancer drug;Q411659;P31;Q12140
Intercalation of daunomycin into stacked DNA base pairs. DFT study of an anticancer drug;Q191924;P366;Q8386
Intercalation of daunomycin into stacked DNA base pairs. DFT study of an anticancer drug;Q170545;P31;Q12140
Intercalation of daunomycin into stacked DNA base pairs. DFT study of an anticancer drug;Q178450;P31;Q12140
Intercalation of daunomycin into stacked DNA base pairs. DFT study of an anticancer drug;Q484940;P31;Q12140
Pharmacological and therapeutic efficacy of rubidazone in mice. Comparison with daunomycin and adriamycin.;Q186474;P703;Q177932
Pharmacological and therapeutic efficacy of rubidazone in mice. Comparison with daunomycin and adriamycin.;Q186474;P703;Q83310
Pharmacological and therapeutic efficacy of rubidazone in mice. Comparison with daunomycin and adriamycin.;Q20035886;P703;Q177932
Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.;Q218642;P31;Q12140
Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.;Q411659;P31;Q12140
Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.;Q20035886;P31;Q12140
Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.;Q1063862;P31;Q12140
Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells.;Q218642;P31;Q12140
Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells.;Q186521;P31;Q12140
Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells.;Q411659;P31;Q12140
Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells.;Q411659;P31;Q109603820
Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells.;Q485277;P31;Q12140
Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells.;Q80863;P31;Q12140
Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells.;Q20035886;P31;Q12140
Inhibitors of vacuolar H+-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells.;Q484940;P31;Q12140
Continuous intravenous administration of daunorubicin and cytarabine for remission induction of poor risk acute myelogenous leukaemias and myelodysplastic syndromes.;Q180983;P2175;Q29496
Continuous intravenous administration of daunorubicin and cytarabine for remission induction of poor risk acute myelogenous leukaemias and myelodysplastic syndromes.;Q180983;P2175;Q954625
High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults;Q180983;P2175;Q264118
High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults;Q180983;P2175;Q29496
High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults;Q411659;P2175;Q264118
Modulation of drug resistance in a daunorubicin resistant subline with oligonucleoside methylphosphonates.;Q411659;P31;Q12140
Modulation of drug resistance in a daunorubicin resistant subline with oligonucleoside methylphosphonates.;Q191924;P31;Q12140
Modulation of drug resistance in a daunorubicin resistant subline with oligonucleoside methylphosphonates.;Q22124685;P31;Q12140
Comparative metabolism of daunorubicin and 4-demethoxydaunorubicin in mice and rabbits;Q186474;P703;Q83310
Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia.;Q180983;P2175;Q29496
Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia.;Q186474;P1889;Q178425
IT-143, A Polymer Micelle Nanoparticle, Widens Therapeutic Window of Daunorubicin;Q218642;P703;Q177932
IT-143, A Polymer Micelle Nanoparticle, Widens Therapeutic Window of Daunorubicin;Q186521;P703;Q177932
IT-143, A Polymer Micelle Nanoparticle, Widens Therapeutic Window of Daunorubicin;Q178450;P703;Q177932
IT-143, A Polymer Micelle Nanoparticle, Widens Therapeutic Window of Daunorubicin;Q20035886;P703;Q177932
IT-143, A Polymer Micelle Nanoparticle, Widens Therapeutic Window of Daunorubicin;Q22124685;P703;Q177932
IT-143, A Polymer Micelle Nanoparticle, Widens Therapeutic Window of Daunorubicin;Q484940;P703;Q177932
Synergistic effect of ricin in combination with daunorubicin, cis-dichlorodiammineplatinum(II) and vincristine in systemic L1210 leukemia.;Q408977;P2175;Q29496
Plasma levels of daunorubicin metabolites and the outcome of ANLL therapy.;Q218642;P31;Q407595
Plasma levels of daunorubicin metabolites and the outcome of ANLL therapy.;Q411659;P2175;Q264118
The effect of thioguanine on a combination of daunorubicine, cytarabine and prednisone in the treatment of acute leukaemia in adults. The Finnish Leukaemia Group;Q180983;P2175;Q29496
Daunorubicin efflux against a concentration gradient in non-P-glycoprotein multidrug-resistant lung-cancer cells.;Q153;P31;Q12140
[Influence of cytochrome C on apoptosis induced by daunorubicine in acute myeloid leukemia (AML) cells].;Q411659;P2175;Q264118
Novel SAHAbendamustine hybrid NL101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia;Q411659;P2175;Q264118
Novel SAHAbendamustine hybrid NL101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia;Q905901;P2175;Q264118
Laser scanning and confocal microscopy of daunorubicin, doxorubicin, and rhodamine 123 in multidrug-resistant cells;Q18936;P31;Q12140
Laser scanning and confocal microscopy of daunorubicin, doxorubicin, and rhodamine 123 in multidrug-resistant cells;Q411659;P31;Q12140
Laser scanning and confocal microscopy of daunorubicin, doxorubicin, and rhodamine 123 in multidrug-resistant cells;Q483745;P31;Q12140
Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy;Q183290;P31;Q12140
Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy;Q411659;P31;Q12140
Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy;Q20035886;P31;Q12140
Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.;Q180983;P2175;Q29496
Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.;Q180983;P2175;Q264118
Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.;Q186474;P1889;Q178425
Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.;Q411659;P2175;Q264118
Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.;Q239426;P2175;Q264118
Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.;Q418817;P2175;Q264118
Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.;Q411659;P2175;Q264118
Daunorubicin, cytosine arabinoside and 6-thioguanine (DAT) combination chemotherapy for the treatment of acute non-lymphocytic leukemia.;Q180983;P2175;Q29496
Daunorubicin, cytosine arabinoside and 6-thioguanine (DAT) combination chemotherapy for the treatment of acute non-lymphocytic leukemia.;Q411659;P2175;Q6708277
Combined antitumoral effects of pretubulysin and methotrexate;Q422232;P636;Q285166
A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.;Q418817;P2175;Q208414
A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.;Q422232;P2175;Q208414
A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.;Q422232;P2175;Q7667896
Hyperhomocysteinemia in children with juvenile idiopathic arthritis is not influenced by methotrexate treatment and folic acid supplementation: a pilot study.;Q422232;P2868;Q127060
Hyperhomocysteinemia in children with juvenile idiopathic arthritis is not influenced by methotrexate treatment and folic acid supplementation: a pilot study.;Q422232;P2175;Q170990
Hyperhomocysteinemia in children with juvenile idiopathic arthritis is not influenced by methotrexate treatment and folic acid supplementation: a pilot study.;Q422232;P2175;Q861224
The effect of methotrexate on the folate coenzyme pools in human hepatoma cells in culture;Q186521;P703;Q15978631
A pilot study of intermediate-dose methotrexate and cytosine arabinoside, "spread-out" or "up-front," in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study.;Q180983;P2175;Q29496
A pilot study of intermediate-dose methotrexate and cytosine arabinoside, "spread-out" or "up-front," in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study.;Q422232;P2175;Q29496
Nephrotoxicity due to intermediate-dose methotrexate without rescue in an obese adolescent with acute lymphoblastic leukemia.;Q191924;P2175;Q12174
Nephrotoxicity due to intermediate-dose methotrexate without rescue in an obese adolescent with acute lymphoblastic leukemia.;Q422232;P2175;Q29496
Towards personalized medicine - the role of methotrexate;Q186521;P31;Q12140
Towards personalized medicine - the role of methotrexate;Q191924;P31;Q12140
Towards personalized medicine - the role of methotrexate;Q422232;P31;Q12140
Relations of serum COMP to cardiovascular risk factors and endothelial function in patients with rheumatoid arthritis treated with methotrexate and TNF- inhibitors;Q422232;P2175;Q170990
Relations of serum COMP to cardiovascular risk factors and endothelial function in patients with rheumatoid arthritis treated with methotrexate and TNF- inhibitors;Q422232;P2175;Q187255
[Cutaneous lymphoma associated with methotrexate in a patient with rheumatoid arthritis].;Q422232;P2175;Q170990
[Cutaneous lymphoma associated with methotrexate in a patient with rheumatoid arthritis].;Q422232;P2175;Q208414
[Cutaneous lymphoma associated with methotrexate in a patient with rheumatoid arthritis].;Q422232;P2175;Q187255
Superselective uterine arterial embolization combined with transcatheter intra-arterial methotrexate infusion in 40 cases with fallopian tube ectopic pregnancy.;Q422232;P2175;Q207087
Weekly split-dose regimen for oral methotrexate reduced polyglutamation in red blood cells in patients with rheumatoid arthritis compared with single-dose regimen: Results from a multicentered randomized control trial;Q422232;P636;Q285166
Weekly split-dose regimen for oral methotrexate reduced polyglutamation in red blood cells in patients with rheumatoid arthritis compared with single-dose regimen: Results from a multicentered randomized control trial;Q422232;P2175;Q170990
Weekly split-dose regimen for oral methotrexate reduced polyglutamation in red blood cells in patients with rheumatoid arthritis compared with single-dose regimen: Results from a multicentered randomized control trial;Q422232;P2175;Q187255
Cervical pregnancy treated with a single intravenous administration of methotrexate plus oral folinic acid.;Q422232;P636;Q285166
Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin for locally advanced transitional cell carcinoma of the bladder.;Q18936;P2175;Q2501186
Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin for locally advanced transitional cell carcinoma of the bladder.;Q412415;P2175;Q2501186
Comparison of 2-methoxyestradiol and methotrexate effects on non-Hodgkin's B-cell lymphoma.;Q422232;P2175;Q208414
Comparison of 2-methoxyestradiol and methotrexate effects on non-Hodgkin's B-cell lymphoma.;Q422232;P2175;Q1138590
Comparison of 2-methoxyestradiol and methotrexate effects on non-Hodgkin's B-cell lymphoma.;Q422232;P2175;Q4833719
Subacute quadriplegic myelopathy following intrathecal methotrexate;Q422232;P636;Q1320251
White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab;Q412323;P2175;Q136312
White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab;Q412323;P2175;Q208414
White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab;Q422232;P2175;Q136312
White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab;Q422232;P2175;Q208414
Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations;Q422232;P2175;Q29496
The relevance of cell kinetics for optimal scheduling of 1-beta-D-arabinofuranosyl cytosine and methotrexate in a slow growing acute myeloid leukemia (BNML).;Q422232;P2175;Q29496
The relevance of cell kinetics for optimal scheduling of 1-beta-D-arabinofuranosyl cytosine and methotrexate in a slow growing acute myeloid leukemia (BNML).;Q422232;P2175;Q264118
Increment in beta-hCG in the 48-h period prior to treatment: a new variable predictive of therapeutic success in the treatment of ectopic pregnancy with methotrexate;Q186474;P703;Q177932
Increment in beta-hCG in the 48-h period prior to treatment: a new variable predictive of therapeutic success in the treatment of ectopic pregnancy with methotrexate;Q620730;P703;Q177932
Increment in beta-hCG in the 48-h period prior to treatment: a new variable predictive of therapeutic success in the treatment of ectopic pregnancy with methotrexate;Q484940;P703;Q177932
Increment in beta-hCG in the 48-h period prior to treatment: a new variable predictive of therapeutic success in the treatment of ectopic pregnancy with methotrexate;Q422232;P2175;Q207087
PReS-FINAL-2162: Development of a risk model to predict methotrexate intolerance in juvenile idiopathic arthritis.;Q422232;P2175;Q170990
PReS-FINAL-2162: Development of a risk model to predict methotrexate intolerance in juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Primary cauda equina lymphoma treated with high-dose methotrexate;Q422232;P2175;Q208414
[Reactivation of hepatitis B in a patient with spondyloarthritis after the suspension of methotrexate and efficacy of treatment with antivirals in association to adalimumab];Q348260;P2175;Q170990
[Reactivation of hepatitis B in a patient with spondyloarthritis after the suspension of methotrexate and efficacy of treatment with antivirals in association to adalimumab];Q422232;P2175;Q170990
Functionalisation of carbon nanotubes by methotrexate and study of synchronous photothermal effect of carbon nanotube and anticancer drug on cancer cell death;Q191924;P527;Q623
Functionalisation of carbon nanotubes by methotrexate and study of synchronous photothermal effect of carbon nanotube and anticancer drug on cancer cell death;Q191924;P31;Q12140
Functionalisation of carbon nanotubes by methotrexate and study of synchronous photothermal effect of carbon nanotube and anticancer drug on cancer cell death;Q170545;P31;Q12140
Functionalisation of carbon nanotubes by methotrexate and study of synchronous photothermal effect of carbon nanotube and anticancer drug on cancer cell death;Q170545;P527;Q623
Functionalisation of carbon nanotubes by methotrexate and study of synchronous photothermal effect of carbon nanotube and anticancer drug on cancer cell death;Q422232;P31;Q12140
Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells.;Q178450;P703;Q15978631
Immunosuppressive activity of methotrexate and arabinosyl cytosine in mice bearing L1210 leukaemia;Q422232;P2175;Q29496
Transfection with a cDNA encoding a Ser31 or Ser34 mutant human dihydrofolate reductase into Chinese hamster ovary and mouse marrow progenitor cells confers methotrexate resistance.;Q218642;P703;Q15978631
Transfection with a cDNA encoding a Ser31 or Ser34 mutant human dihydrofolate reductase into Chinese hamster ovary and mouse marrow progenitor cells confers methotrexate resistance.;Q183290;P703;Q15978631
Transfection with a cDNA encoding a Ser31 or Ser34 mutant human dihydrofolate reductase into Chinese hamster ovary and mouse marrow progenitor cells confers methotrexate resistance.;Q186474;P703;Q15978631
Transfection with a cDNA encoding a Ser31 or Ser34 mutant human dihydrofolate reductase into Chinese hamster ovary and mouse marrow progenitor cells confers methotrexate resistance.;Q186474;P703;Q83310
Transfection with a cDNA encoding a Ser31 or Ser34 mutant human dihydrofolate reductase into Chinese hamster ovary and mouse marrow progenitor cells confers methotrexate resistance.;Q186521;P703;Q15978631
Transfection with a cDNA encoding a Ser31 or Ser34 mutant human dihydrofolate reductase into Chinese hamster ovary and mouse marrow progenitor cells confers methotrexate resistance.;Q178450;P703;Q15978631
High-dose methotrexate for advanced breast cancer.;Q422232;P2175;Q128581
Pegloticase in combination with methotrexate in patients with uncontrolled gout: A multicenter, open-label study (MIRROR);Q7160794;P2175;Q133087
Etanercept and methotrexate combination in rheumatoid arthritis;Q415343;P2175;Q170990
Etanercept and methotrexate combination in rheumatoid arthritis;Q415343;P2175;Q187255
Etanercept and methotrexate combination in rheumatoid arthritis;Q422232;P2175;Q170990
Etanercept and methotrexate combination in rheumatoid arthritis;Q422232;P2175;Q187255
Comparison of combination therapy with methotrexate and sinomenine or leflunomide for active rheumatoid arthritis: A randomized controlled clinical trial;Q248550;P2175;Q170990
Comparison of combination therapy with methotrexate and sinomenine or leflunomide for active rheumatoid arthritis: A randomized controlled clinical trial;Q248550;P2175;Q187255
Comparison of combination therapy with methotrexate and sinomenine or leflunomide for active rheumatoid arthritis: A randomized controlled clinical trial;Q422232;P2175;Q170990
Comparison of combination therapy with methotrexate and sinomenine or leflunomide for active rheumatoid arthritis: A randomized controlled clinical trial;Q422232;P2175;Q187255
A comparison between ozonolysis and sonolysis/ozonolysis treatments for the degradation of the cytostatic drugs methotrexate and doxorubicin: Kinetic and efficiency approaches.;Q218642;P31;Q12140
A comparison between ozonolysis and sonolysis/ozonolysis treatments for the degradation of the cytostatic drugs methotrexate and doxorubicin: Kinetic and efficiency approaches.;Q18936;P31;Q12140
A comparison between ozonolysis and sonolysis/ozonolysis treatments for the degradation of the cytostatic drugs methotrexate and doxorubicin: Kinetic and efficiency approaches.;Q191924;P366;Q8386
A comparison between ozonolysis and sonolysis/ozonolysis treatments for the degradation of the cytostatic drugs methotrexate and doxorubicin: Kinetic and efficiency approaches.;Q20816880;P31;Q12140
A comparison between ozonolysis and sonolysis/ozonolysis treatments for the degradation of the cytostatic drugs methotrexate and doxorubicin: Kinetic and efficiency approaches.;Q422232;P31;Q12140
Folate analogues. 33. Synthesis of folate and antifolate poly-gamma-glutamates by [(9-fluorenylmethoxy)oxy]carbonyl chemistry and biological evaluation of certain methotrexate polyglutamate polylysine conjugates as inhibitors of the growth of H35 he;Q183290;P527;Q623
Folate analogues. 33. Synthesis of folate and antifolate poly-gamma-glutamates by [(9-fluorenylmethoxy)oxy]carbonyl chemistry and biological evaluation of certain methotrexate polyglutamate polylysine conjugates as inhibitors of the growth of H35 he;Q191924;P527;Q623
Folate analogues. 33. Synthesis of folate and antifolate poly-gamma-glutamates by [(9-fluorenylmethoxy)oxy]carbonyl chemistry and biological evaluation of certain methotrexate polyglutamate polylysine conjugates as inhibitors of the growth of H35 he;Q485277;P527;Q623
Folate analogues. 33. Synthesis of folate and antifolate poly-gamma-glutamates by [(9-fluorenylmethoxy)oxy]carbonyl chemistry and biological evaluation of certain methotrexate polyglutamate polylysine conjugates as inhibitors of the growth of H35 he;Q170545;P527;Q623
Folate analogues. 33. Synthesis of folate and antifolate poly-gamma-glutamates by [(9-fluorenylmethoxy)oxy]carbonyl chemistry and biological evaluation of certain methotrexate polyglutamate polylysine conjugates as inhibitors of the growth of H35 he;Q20816880;P31;Q178430
High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience;Q422232;P2175;Q136312
High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience;Q422232;P2175;Q208414
Fatal methotrexate toxicity in a patient treated for an ectopic pregnancy.;Q422232;P2175;Q207087
Concurrent radiotherapy and capecitabine, followed by high-dose methotrexate consolidation, provided effective palliation in a patient with leptomeningeal metastases from breast cancer;Q420207;P2175;Q128581
Concurrent radiotherapy and capecitabine, followed by high-dose methotrexate consolidation, provided effective palliation in a patient with leptomeningeal metastases from breast cancer;Q422232;P2175;Q128581
Highly sensitive determination of methotrexate at poly (l-lysine) modified electrode in the presence of sodium dodecyl benzene sulfonate;Q20816880;P31;Q178430
Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy s;Q422232;P636;Q285166
Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy s;Q422232;P2175;Q187255
Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy s;Q422232;P2175;Q170990
Cost analysis of biologic drugs in rheumatoid arthritis first line treatment after methotrexate failure according to patients' body weight.;Q186474;P31;Q12140
Cost analysis of biologic drugs in rheumatoid arthritis first line treatment after methotrexate failure according to patients' body weight.;Q191924;P366;Q8386
Cost analysis of biologic drugs in rheumatoid arthritis first line treatment after methotrexate failure according to patients' body weight.;Q422232;P31;Q12140
Cost analysis of biologic drugs in rheumatoid arthritis first line treatment after methotrexate failure according to patients' body weight.;Q422232;P2175;Q170990
Cost analysis of biologic drugs in rheumatoid arthritis first line treatment after methotrexate failure according to patients' body weight.;Q422232;P2175;Q187255
High-Dose Methotrexate and Cytarabine-Based Multi-Agent Chemotherapy (Modified Bonn Protocol) for Systemic Lymphoma with CNS Involvement;Q180983;P2175;Q208414
High-Dose Methotrexate and Cytarabine-Based Multi-Agent Chemotherapy (Modified Bonn Protocol) for Systemic Lymphoma with CNS Involvement;Q422232;P2175;Q208414
Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: A single-center, randomized, double-blind clinical trial;Q421094;P1889;Q422438
Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: A single-center, randomized, double-blind clinical trial;Q421094;P2175;Q170990
Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: A single-center, randomized, double-blind clinical trial;Q421094;P2175;Q187255
Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: A single-center, randomized, double-blind clinical trial;Q422438;P2175;Q187255
Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: A single-center, randomized, double-blind clinical trial;Q422438;P1889;Q421094
Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: A single-center, randomized, double-blind clinical trial;Q422232;P2175;Q170990
Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: A single-center, randomized, double-blind clinical trial;Q422232;P2175;Q187255
Lung function in children and adolescents with juvenile idiopathic arthritis during long-term treatment with methotrexate: a retrospective study.;Q422232;P2175;Q861224
Lung function in children and adolescents with juvenile idiopathic arthritis during long-term treatment with methotrexate: a retrospective study.;Q422232;P2175;Q170990
Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials;Q422232;P2175;Q170990
Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials;Q422232;P2175;Q187255
Methotrexate and rheumatoid arthritis;Q422232;P2175;Q170990
Methotrexate and rheumatoid arthritis;Q422232;P2175;Q187255
Analytical methodologies for determination of methotrexate and its metabolites in pharmaceutical, biological and environmental samples;Q218642;P31;Q407595
Analytical methodologies for determination of methotrexate and its metabolites in pharmaceutical, biological and environmental samples;Q218642;P31;Q12140
Analytical methodologies for determination of methotrexate and its metabolites in pharmaceutical, biological and environmental samples;Q191924;P31;Q12140
Analytical methodologies for determination of methotrexate and its metabolites in pharmaceutical, biological and environmental samples;Q422232;P31;Q12140
Effective transdermal delivery of methotrexate through nanostructured lipid carriers in an experimentally induced arthritis model.;Q422232;P2175;Q170990
A new regimen of cisplatin, epirubicin and methotrexate (PEM-3) as primary chemotherapy for locally advanced bladder cancer;Q412415;P2175;Q504775
Methotrexate in oligoarticular persistent juvenile idiopathic arthritis.;Q422232;P2175;Q170990
Methotrexate in oligoarticular persistent juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux.;Q153;P31;Q12140
Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux.;Q186474;P31;Q12140
Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux.;Q170545;P31;Q12140
Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux.;Q239426;P31;Q12140
Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux.;Q239426;P2175;Q128581
Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux.;Q22124685;P31;Q12140
Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux.;Q422232;P31;Q12140
Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux.;Q422232;P2175;Q128581
Sequential methotrexate treatment with and estrogen and progestin in a retained adhesive placenta.;Q422416;P279;Q277954
Pulmonary Mycobacterium abscessus disease in a patient receiving low-dose methotrexate for treatment of early rheumatoid arthritis.;Q422232;P2175;Q170990
Pulmonary Mycobacterium abscessus disease in a patient receiving low-dose methotrexate for treatment of early rheumatoid arthritis.;Q422232;P2175;Q187255
Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis;Q422232;P2175;Q170990
Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis;Q422232;P2175;Q187255
Primary mediastinal large B-cell lymphoma: Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20.;Q180983;P2175;Q208414
Primary mediastinal large B-cell lymphoma: Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20.;Q422232;P2175;Q208414
Primary mediastinal large B-cell lymphoma: Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20.;Q422232;P2175;Q4833719
Anti-TNF agents and methotrexate in spondyloarthritis related uveitis in a Chinese population;Q422232;P2175;Q280027
Anti-TNF agents and methotrexate in spondyloarthritis related uveitis in a Chinese population;Q422232;P2175;Q170990
Effects of methotrexate use in a patient with rheumatoid arthritis and multiple sclerosis.;Q422232;P2175;Q187255
Effects of methotrexate use in a patient with rheumatoid arthritis and multiple sclerosis.;Q422232;P2175;Q170990
[Methotrexate and its drug resistance];Q22124685;P31;Q12140
[Methotrexate and its drug resistance];Q422232;P31;Q12140
[Methotrexate and salazosulfapyridine in the long-term treatment of rheumatoid arthritis];Q422232;P2175;Q170990
[Methotrexate and salazosulfapyridine in the long-term treatment of rheumatoid arthritis];Q422232;P2175;Q187255
Genetic determinants of methotrexate treatment efficacy in patients with juvenile idiopathic arthritis.;Q422232;P2175;Q170990
Genetic determinants of methotrexate treatment efficacy in patients with juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study;Q422232;P361;Q14819383
Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study;Q422232;P2175;Q170990
Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study;Q422232;P2175;Q187255
Methotrexate in rheumatoid arthritis: a 2 year experience at a university hospital in Pakistan.;Q422232;P2175;Q170990
Methotrexate in rheumatoid arthritis: a 2 year experience at a university hospital in Pakistan.;Q422232;P2175;Q187255
In-vitro cell growth of human urothelial tumor cell lines under exposure with IL-3, GM-CSF, G-CSF and by combined administration with methotrexate, vinblastine, adriamycin and cisplatin;Q183290;P703;Q15978631
In-vitro cell growth of human urothelial tumor cell lines under exposure with IL-3, GM-CSF, G-CSF and by combined administration with methotrexate, vinblastine, adriamycin and cisplatin;Q186474;P703;Q15978631
In-vitro cell growth of human urothelial tumor cell lines under exposure with IL-3, GM-CSF, G-CSF and by combined administration with methotrexate, vinblastine, adriamycin and cisplatin;Q170545;P703;Q15978631
In-vitro cell growth of human urothelial tumor cell lines under exposure with IL-3, GM-CSF, G-CSF and by combined administration with methotrexate, vinblastine, adriamycin and cisplatin;Q1592932;P279;Q50229794
In-vitro cell growth of human urothelial tumor cell lines under exposure with IL-3, GM-CSF, G-CSF and by combined administration with methotrexate, vinblastine, adriamycin and cisplatin;Q22124685;P703;Q15978631
In-vitro cell growth of human urothelial tumor cell lines under exposure with IL-3, GM-CSF, G-CSF and by combined administration with methotrexate, vinblastine, adriamycin and cisplatin;Q620730;P703;Q15978631
In-vitro cell growth of human urothelial tumor cell lines under exposure with IL-3, GM-CSF, G-CSF and by combined administration with methotrexate, vinblastine, adriamycin and cisplatin;Q483745;P703;Q15978631
In-vitro cell growth of human urothelial tumor cell lines under exposure with IL-3, GM-CSF, G-CSF and by combined administration with methotrexate, vinblastine, adriamycin and cisplatin;Q484940;P703;Q15978631
Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs.;Q248550;P31;Q12140
Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs.;Q248550;P2175;Q187255
Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs.;Q248550;P2175;Q170990
Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs.;Q218642;P31;Q12140
Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs.;Q191924;P31;Q12140
Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs.;Q191924;P366;Q8386
Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs.;Q421094;P31;Q12140
Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs.;Q421094;P2175;Q170990
Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs.;Q421094;P1889;Q422438
Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs.;Q421094;P2175;Q187255
Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs.;Q422438;P2175;Q187255
Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs.;Q422438;P31;Q12140
Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs.;Q422438;P1889;Q421094
Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs.;Q422232;P31;Q12140
Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs.;Q422232;P2175;Q170990
Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs.;Q422232;P2175;Q187255
High-dose methotrexate and asparaginase for the treatment of children with acute lymphoblastic leukemia: why and how?;Q422232;P2175;Q29496
Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug;Q191924;P366;Q8386
Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug;Q20035886;P31;Q12140
Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug;Q422232;P31;Q12140
Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug;Q422232;P2175;Q170990
Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug;Q422232;P2175;Q187255
[The effect of comedication with folic or folinic acid on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a randomized, double blind, placebo controlled study of 48 weeks].;Q23118;P31;Q12140
[The effect of comedication with folic or folinic acid on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a randomized, double blind, placebo controlled study of 48 weeks].;Q186521;P31;Q12140
[The effect of comedication with folic or folinic acid on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a randomized, double blind, placebo controlled study of 48 weeks].;Q191924;P31;Q12140
[The effect of comedication with folic or folinic acid on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a randomized, double blind, placebo controlled study of 48 weeks].;Q422232;P31;Q12140
[The effect of comedication with folic or folinic acid on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a randomized, double blind, placebo controlled study of 48 weeks].;Q422232;P2175;Q170990
[The effect of comedication with folic or folinic acid on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a randomized, double blind, placebo controlled study of 48 weeks].;Q422232;P2175;Q187255
Clearing up potential misconceptions about the treatment of rheumatoid arthritis and the use of methotrexate in combination therapy.;Q422232;P2175;Q187255
Clearing up potential misconceptions about the treatment of rheumatoid arthritis and the use of methotrexate in combination therapy.;Q422232;P2175;Q170990
Combination of oral methotrexate and oral mini-pulse dexamethasone versus either agent alone in vitiligo treatment with follow up by dermoscope;Q422232;P636;Q285166
Azathioprine in combination with methotrexate: a therapeutic alternative in severe and recalcitrant forms of alopecia areata?;Q218642;P703;Q177932
Pharmacokinetik population of methotrexate in tunisian population with acute lymphoblastic leukemia.;Q422232;P2175;Q29496
Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer;Q412415;P2175;Q1783924
Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer;Q238512;P2175;Q1783924
Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer;Q422232;P2175;Q1783924
Systematic review of recommendations on the use of methotrexate in rheumatoid arthritis;Q422232;P2175;Q170990
Systematic review of recommendations on the use of methotrexate in rheumatoid arthritis;Q422232;P2175;Q187255
Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer.;Q422232;P2175;Q1783924
[Infliximab combined with methotrexate in the treatment of rheumatoid arthritis].;Q422232;P2175;Q170990
[Infliximab combined with methotrexate in the treatment of rheumatoid arthritis].;Q422232;P2175;Q187255
Yellapragada SubbaRow - The unsung Indian biochemist behind methotrexate and other drugs.;Q188017;P31;Q12140
Yellapragada SubbaRow - The unsung Indian biochemist behind methotrexate and other drugs.;Q183290;P31;Q12140
Yellapragada SubbaRow - The unsung Indian biochemist behind methotrexate and other drugs.;Q186521;P31;Q12140
Yellapragada SubbaRow - The unsung Indian biochemist behind methotrexate and other drugs.;Q191924;P366;Q8386
Yellapragada SubbaRow - The unsung Indian biochemist behind methotrexate and other drugs.;Q173670;P31;Q12140
Yellapragada SubbaRow - The unsung Indian biochemist behind methotrexate and other drugs.;Q484940;P31;Q12140
Yellapragada SubbaRow - The unsung Indian biochemist behind methotrexate and other drugs.;Q422232;P31;Q12140
Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy;Q422232;P2175;Q29496
Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.;Q180983;P2175;Q208414
Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.;Q408977;P2175;Q208414
Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.;Q191924;P769;Q418656
Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.;Q418656;P2175;Q208414
Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.;Q418656;P2175;Q136312
Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.;Q422232;P2175;Q208414
Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.;Q422232;P2175;Q136312
Sequential combination of methotrexate and 1-beta-D-arabinofuranosylcytosine shows synergistic effect on the generation of DNA strand breaks in a human promyelocytic leukemia cell line;Q218642;P703;Q15978631
Sequential combination of methotrexate and 1-beta-D-arabinofuranosylcytosine shows synergistic effect on the generation of DNA strand breaks in a human promyelocytic leukemia cell line;Q183290;P703;Q15978631
Sequential combination of methotrexate and 1-beta-D-arabinofuranosylcytosine shows synergistic effect on the generation of DNA strand breaks in a human promyelocytic leukemia cell line;Q178450;P703;Q15978631
Sequential combination of methotrexate and 1-beta-D-arabinofuranosylcytosine shows synergistic effect on the generation of DNA strand breaks in a human promyelocytic leukemia cell line;Q422232;P2175;Q29496
The bioavailability of oral methotrexate in children with inflammatory bowel disease;Q422232;P636;Q285166
Investigation of kinetics of methotrexate for therapeutic treatment of intraocular lymphoma.;Q484940;P703;Q177932
Investigation of kinetics of methotrexate for therapeutic treatment of intraocular lymphoma.;Q422232;P2175;Q208414
Safety of intrathecal administration of cytosine arabinoside and methotrexate in dogs and cats.;Q422232;P636;Q1320251
[A case of intraocular lymphoma having retinal adverse events associated with intravitreal methotrexate];Q422232;P2175;Q208414
Influence of Reduced Folate Carrier and Aminoimidazole Carboxamide Ribonucleotide Transformylase gene polymorphisms on the efficacy of methotrexate in juvenile idiopathic arthritis.;Q422232;P2175;Q170990
Influence of Reduced Folate Carrier and Aminoimidazole Carboxamide Ribonucleotide Transformylase gene polymorphisms on the efficacy of methotrexate in juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Non-steroidal anti-inflammatory drugs affect the methotrexate transport in IEC-6 cells.;Q186474;P31;Q12140
Non-steroidal anti-inflammatory drugs affect the methotrexate transport in IEC-6 cells.;Q191924;P366;Q8386
Non-steroidal anti-inflammatory drugs affect the methotrexate transport in IEC-6 cells.;Q484940;P31;Q12140
Non-steroidal anti-inflammatory drugs affect the methotrexate transport in IEC-6 cells.;Q422232;P31;Q12140
[Experiences with high dose methotrexate treatments within the framework of polychemotherapy in osteosarcoma (proceedings)];Q422232;P2175;Q549534
Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate;Q348260;P2175;Q170990
Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate;Q422232;P2175;Q170990
Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate;Q422232;P2175;Q861224
Intermediate dose methotrexate (IDM) in children with acute lymphocytic leukemia (ALL). An update;Q422232;P2175;Q29496
Good clinical response to methotrexate treatment in a patient with fibroblastic rheumatism.;Q422232;P361;Q14819383
Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.;Q422232;P2175;Q187255
Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.;Q422232;P2175;Q170990
Accumulation of methotrexate polyglutamates, ploidy and trisomies of both chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group Study;Q422232;P2175;Q29496
Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.;Q130336;P4149;Q27122100
Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.;Q130336;P31;Q407142
High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG.;Q422232;P2175;Q29496
PReS-FINAL-2048: Treatment with methotrexate plus leflunomide for juvenile idiopathic arthritis.;Q248550;P2175;Q170990
PReS-FINAL-2048: Treatment with methotrexate plus leflunomide for juvenile idiopathic arthritis.;Q422232;P2175;Q861224
PReS-FINAL-2048: Treatment with methotrexate plus leflunomide for juvenile idiopathic arthritis.;Q422232;P2175;Q170990
Methotrexate in acute persistent humoral rejection: an option for graft rescue;Q422232;P636;Q285166
Methotrexate binds in a non-productive orientation to human dihydrofolate reductase in solution, based on NMR spectroscopy.;Q173670;P703;Q15978631
Methotrexate binds in a non-productive orientation to human dihydrofolate reductase in solution, based on NMR spectroscopy.;Q22124685;P703;Q15978631
Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018;Q422232;P2175;Q208414
The evaluation of red blood cell folate and methotrexate levels during protocol M in childhood acute lymphoblastic leukemia;Q422232;P2175;Q29496
Primary intraocular lymphoma arising during methotrexate treatment of temporal arteritis.;Q422232;P636;Q285166
Primary intraocular lymphoma arising during methotrexate treatment of temporal arteritis.;Q422232;P2175;Q208414
Hemostatic side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia.;Q422232;P2175;Q29496
Activity measurements in human tissues of the methotrexate molecular target: a novel fluorometric assay.;Q218642;P703;Q15978631
Comment on: Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy;Q422232;P2175;Q170990
Mycophenolic acid and methotrexate inhibit lymphocyte cytokine production via different mechanisms.;Q130336;P31;Q407142
MR findings in Balint's syndrome, following intrathecal methotrexate and cytarabine therapy in adult acute lymphoblastic leukemia.;Q180983;P2175;Q29496
MR findings in Balint's syndrome, following intrathecal methotrexate and cytarabine therapy in adult acute lymphoblastic leukemia.;Q422232;P2175;Q29496
MR findings in Balint's syndrome, following intrathecal methotrexate and cytarabine therapy in adult acute lymphoblastic leukemia.;Q422232;P636;Q1320251
Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies;Q223600;P1889;Q426660
Effects of folate receptor expression following stable transfection into wild type and methotrexate transport-deficient ZR-75-1 human breast cancer cells.;Q173670;P703;Q15978631
Effects of folate receptor expression following stable transfection into wild type and methotrexate transport-deficient ZR-75-1 human breast cancer cells.;Q422232;P2175;Q128581
Efficacy of high dose methotrexate in pediatric auto-immune uveitis.;Q422232;P2175;Q280027
First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine;Q218642;P31;Q12140
First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine;Q407781;P31;Q12140
First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine;Q191924;P31;Q12140
First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine;Q170545;P31;Q12140
First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine;Q173670;P31;Q12140
First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine;Q178450;P31;Q12140
First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine;Q420035;P31;Q12140
First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine;Q420035;P2175;Q170990
First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine;Q420035;P2868;Q810254
First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine;Q22124685;P31;Q12140
First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine;Q422232;P31;Q12140
First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine;Q422232;P2868;Q810254
First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine;Q422232;P2175;Q170990
[Reduced central nervous system leukemia by prophylaxis with intermittent intrathecal methotrexate and prednisolone in adults with acute leukemia];Q422232;P2175;Q29496
[Reduced central nervous system leukemia by prophylaxis with intermittent intrathecal methotrexate and prednisolone in adults with acute leukemia];Q422232;P636;Q1320251
A non-interventional retrospective cohort study of the interaction between methotrexate and proton pump inhibitors or aspirin;Q18216;P1889;Q10420388
A non-interventional retrospective cohort study of the interaction between methotrexate and proton pump inhibitors or aspirin;Q18216;P769;Q422232
Self-microemulsifying drug delivery system (SMEDDS) for improved oral delivery and photostability of methotrexate;Q183290;P31;Q12140
Self-microemulsifying drug delivery system (SMEDDS) for improved oral delivery and photostability of methotrexate;Q191924;P31;Q12140
Self-microemulsifying drug delivery system (SMEDDS) for improved oral delivery and photostability of methotrexate;Q192717;P31;Q12140
Self-microemulsifying drug delivery system (SMEDDS) for improved oral delivery and photostability of methotrexate;Q178450;P31;Q12140
Self-microemulsifying drug delivery system (SMEDDS) for improved oral delivery and photostability of methotrexate;Q22124685;P31;Q12140
Self-microemulsifying drug delivery system (SMEDDS) for improved oral delivery and photostability of methotrexate;Q422226;P31;Q12140
Self-microemulsifying drug delivery system (SMEDDS) for improved oral delivery and photostability of methotrexate;Q422232;P31;Q12140
Self-microemulsifying drug delivery system (SMEDDS) for improved oral delivery and photostability of methotrexate;Q422232;P636;Q285166
Down-regulation of reduced folate carrier gene (RFC1) expression after exposure to methotrexate in ZR-75-1 breast cancer cells.;Q422232;P2175;Q128581
[Clinical efficacy of idarubicin combined with methotrexate for treatment of patients with central nervous system diffuse large B cell lymphoma].;Q422232;P2175;Q208414
Lessons from the initial adjuvant cyclophosphamide, methotrexate, and fluorouracil studies in operable breast cancer.;Q238512;P2175;Q128581
Lessons from the initial adjuvant cyclophosphamide, methotrexate, and fluorouracil studies in operable breast cancer.;Q422232;P2175;Q128581
Experience of the concentration of methotrexate evaluation in children with juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Experience of the concentration of methotrexate evaluation in children with juvenile idiopathic arthritis.;Q422232;P2175;Q170990
Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus;Q18939;P2175;Q1485
Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus;Q130336;P31;Q407142
Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T-cell leukemia xenograft, LALW-2.;Q181003;P31;Q12140
Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T-cell leukemia xenograft, LALW-2.;Q181003;P703;Q15978631
Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T-cell leukemia xenograft, LALW-2.;Q218642;P703;Q15978631
Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T-cell leukemia xenograft, LALW-2.;Q218642;P31;Q12140
Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T-cell leukemia xenograft, LALW-2.;Q186521;P31;Q12140
Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T-cell leukemia xenograft, LALW-2.;Q186521;P703;Q15978631
Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T-cell leukemia xenograft, LALW-2.;Q191924;P366;Q8386
Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T-cell leukemia xenograft, LALW-2.;Q173670;P31;Q12140
Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T-cell leukemia xenograft, LALW-2.;Q173670;P703;Q15978631
Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T-cell leukemia xenograft, LALW-2.;Q483745;P31;Q12140
Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T-cell leukemia xenograft, LALW-2.;Q483745;P703;Q15978631
Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T-cell leukemia xenograft, LALW-2.;Q422232;P31;Q12140
Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T-cell leukemia xenograft, LALW-2.;Q422232;P2175;Q29496
EEG with extreme delta brush in young female with methotrexate neurotoxicity supports NMDA receptor involvement.;Q191924;P2868;Q407752
Microbiologic assay for cytosine arabinoside (NSC-63878): the use of a mutant of streptococcus faecium var. durans resistant to methotrexate (NSC-740) and 6-mercaptopurine (NSC-755);Q186474;P1889;Q178425
Pharmacogenetic aspects of methotrexate in a cohort of Colombian patients with rheumatoid arthritis;Q422232;P2175;Q170990
Pharmacogenetic aspects of methotrexate in a cohort of Colombian patients with rheumatoid arthritis;Q422232;P2175;Q187255
Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis;Q422232;P2175;Q187255
Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis;Q422232;P2175;Q170990
Bayesian calculation of methotrexate clearance after low dose intramuscular administration in patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Bayesian calculation of methotrexate clearance after low dose intramuscular administration in patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.;Q415343;P2175;Q170990
Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.;Q415343;P2175;Q187255
Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Lipophilic Prodrug of Methotrexate in the Membrane of Liposomes Promotes Their Uptake by Human Blood Phagocytes;Q186521;P31;Q12140
Lipophilic Prodrug of Methotrexate in the Membrane of Liposomes Promotes Their Uptake by Human Blood Phagocytes;Q485277;P31;Q12140
Lipophilic Prodrug of Methotrexate in the Membrane of Liposomes Promotes Their Uptake by Human Blood Phagocytes;Q20035886;P31;Q12140
Lipophilic Prodrug of Methotrexate in the Membrane of Liposomes Promotes Their Uptake by Human Blood Phagocytes;Q22124685;P31;Q12140
Lipophilic Prodrug of Methotrexate in the Membrane of Liposomes Promotes Their Uptake by Human Blood Phagocytes;Q422232;P31;Q12140
Lipophilic Prodrug of Methotrexate in the Membrane of Liposomes Promotes Their Uptake by Human Blood Phagocytes;Q483745;P31;Q12140
Combination of -cyclodextrin inclusion complex and self-microemulsifying drug delivery system for photostability and enhanced oral bioavailability of methotrexate: novel technique.;Q186474;P31;Q12140
Combination of -cyclodextrin inclusion complex and self-microemulsifying drug delivery system for photostability and enhanced oral bioavailability of methotrexate: novel technique.;Q191924;P31;Q12140
Combination of -cyclodextrin inclusion complex and self-microemulsifying drug delivery system for photostability and enhanced oral bioavailability of methotrexate: novel technique.;Q422232;P31;Q12140
Combination of -cyclodextrin inclusion complex and self-microemulsifying drug delivery system for photostability and enhanced oral bioavailability of methotrexate: novel technique.;Q422232;P636;Q285166
Adherence to methotrexate in juvenile idiopathic arthritis;Q422232;P2175;Q170990
Adherence to methotrexate in juvenile idiopathic arthritis;Q422232;P2175;Q861224
Selection and perception of methotrexate treatment information in people with rheumatoid arthritis;Q422232;P2175;Q187255
Selection and perception of methotrexate treatment information in people with rheumatoid arthritis;Q422232;P2175;Q170990
Clinical evaluation of severe toxicity in two patients with acute lymphoblastic leukemia receiving outpatient methotrexate therapy;Q422232;P2175;Q29496
Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis.;Q422232;P2175;Q170990
Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis.;Q422232;P2175;Q187255
SLCO1B1 rs4149056 genetic polymorphism predicting methotrexate toxicity in Chinese patients with non-Hodgkin lymphoma.;Q422232;P2175;Q208414
SLCO1B1 rs4149056 genetic polymorphism predicting methotrexate toxicity in Chinese patients with non-Hodgkin lymphoma.;Q422232;P2175;Q1138590
Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: a prognostic value?;Q422232;P2175;Q29496
Effect of methotrexate combined with Sanhuang Yilong decoction on serum and synovial fluid aquaporin levels in rheumatoid arthritis dampness-heat blockage syndrome;Q422232;P2175;Q170990
Effect of methotrexate combined with Sanhuang Yilong decoction on serum and synovial fluid aquaporin levels in rheumatoid arthritis dampness-heat blockage syndrome;Q422232;P2175;Q187255
Mechanism of leucovorin reversal of methotrexate cytotoxicity in human MCF-7 breast cancer cells.;Q186474;P703;Q15978631
Mechanism of leucovorin reversal of methotrexate cytotoxicity in human MCF-7 breast cancer cells.;Q170545;P703;Q15978631
Mechanism of leucovorin reversal of methotrexate cytotoxicity in human MCF-7 breast cancer cells.;Q22124685;P703;Q15978631
Mechanism of leucovorin reversal of methotrexate cytotoxicity in human MCF-7 breast cancer cells.;Q483745;P703;Q15978631
Mechanism of leucovorin reversal of methotrexate cytotoxicity in human MCF-7 breast cancer cells.;Q422232;P2175;Q128581
Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice.;Q422232;P2175;Q170990
Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice.;Q422232;P2175;Q187255
Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation;Q411648;P2175;Q1194520
Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation;Q32089;P2175;Q1194520
Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis.;Q422232;P2175;Q170990
Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis.;Q422232;P361;Q14819383
Methotrexate cytotoxicity on MCF-7 breast cancer cells is not altered by exposure to 25 Hz, 1.5 mT magnetic field and iron (III) chloride hexahydrate.;Q422232;P2175;Q128581
Severe secondary bone marrow aplasia due to methotrexate in a patient with late onset rheumatoid arthritis;Q422232;P2175;Q170990
Severe secondary bone marrow aplasia due to methotrexate in a patient with late onset rheumatoid arthritis;Q422232;P2175;Q187255
Caesarean scar ectopic pregnancy successfully treated with methotrexate and mifepristone;Q411240;P2175;Q207087
Caesarean scar ectopic pregnancy successfully treated with methotrexate and mifepristone;Q422232;P2175;Q207087
Gynecomastia associated with low-dose methotrexate therapy for rheumatoid arthritis.;Q422232;P2175;Q170990
Gynecomastia associated with low-dose methotrexate therapy for rheumatoid arthritis.;Q422232;P2175;Q187255
Induction of cytogenetic damage in human lymphocytes in vitro and of antineoplastic effects in Ehrlich ascites tumor cells in vivo treated by methotrexate, hyperthermia and/or caffeine;Q60235;P703;Q15978631
Induction of cytogenetic damage in human lymphocytes in vitro and of antineoplastic effects in Ehrlich ascites tumor cells in vivo treated by methotrexate, hyperthermia and/or caffeine;Q484940;P703;Q15978631
Synoviocyte apoptosis may differentiate responder and non-responder patients to methotrexate treatment in rheumatoid arthritis.;Q422232;P2175;Q187255
Synoviocyte apoptosis may differentiate responder and non-responder patients to methotrexate treatment in rheumatoid arthritis.;Q422232;P2175;Q170990
Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry;Q348260;P2175;Q170990
Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry;Q422232;P2175;Q170990
Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry;Q422232;P2175;Q861224
Distinct genetic profile in peripheral blood mononuclear cells of psoriatic arthritis patients treated with methotrexate and TNF-inhibitors.;Q422232;P2175;Q170990
[Relative sensitivity of acute leukemia cells to methotrexate in vitro and the rescue effects of folates];Q422232;P2175;Q29496
[Effect of folic acid and methotrexate on the reproduction of the Rauscher leukemia virus];Q422232;P2175;Q29496
[Effect of folic acid and methotrexate on the reproduction of the Rauscher leukemia virus];Q422232;P2868;Q127060
[Treatment with methotrexate for tubal pregnancy];Q422232;P2175;Q207087
[Clinical symptoms effect of Tripterygium Glycosides Tablets alone or combined with methotrexate in treatment of rheumatoid arthritis: a Meta-analysis];Q422232;P2175;Q170990
[Clinical symptoms effect of Tripterygium Glycosides Tablets alone or combined with methotrexate in treatment of rheumatoid arthritis: a Meta-analysis];Q422232;P2175;Q187255
Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity.;Q191924;P31;Q12140
Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity.;Q20035886;P31;Q12140
Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity.;Q422232;P31;Q12140
Idiopathic peripheral ulcerative keratitis with good response to methotrexate;Q422232;P361;Q14819383
Clinical correlates of in vitro effect of methotrexate on acute leukemia blasts.;Q422232;P2175;Q29496
Modulation of methotrexate resistance by genistein in murine leukemia L1210 cells.;Q422232;P2175;Q29496
Multimodal image-guided folic acid targeted Ag-based quantum dots for the combination of selective methotrexate delivery and photothermal therapy;Q422232;P2868;Q127060
Efficacy of Methotrexate on Pain Severity Reduction and Improvement of Quality of Life in Patients with Moderate to Severe Knee Osteoarthritis;Q422232;P2175;Q170990
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU: CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.;Q218642;P31;Q12140
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU: CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.;Q183290;P31;Q12140
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU: CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.;Q18936;P31;Q12140
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU: CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.;Q186474;P31;Q12140
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU: CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.;Q244150;P31;Q12140
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU: CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.;Q191924;P31;Q12140
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU: CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.;Q485277;P31;Q12140
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU: CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.;Q412415;P31;Q12140
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU: CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.;Q170545;P31;Q12140
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU: CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.;Q238512;P31;Q12140
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU: CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.;Q20035886;P31;Q12140
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU: CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.;Q22124685;P31;Q12140
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU: CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.;Q422232;P31;Q12140
[A Case of Small Bowel Perforation Caused by Malignant Lymphoma after Methotrexate Therapy for Rheumatoid Arthritis];Q422232;P2175;Q208414
The effect of methotrexate on neutrophil reactive oxygen species and CD177 expression in rheumatoid arthritis;Q422232;P2175;Q170990
The effect of methotrexate on neutrophil reactive oxygen species and CD177 expression in rheumatoid arthritis;Q422232;P2175;Q187255
Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation.;Q367700;P2175;Q1194520
Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation.;Q130336;P31;Q407142
Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation.;Q130336;P4149;Q27122100
Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation.;Q4567614;P2175;Q1194520
Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.;Q180983;P2175;Q208414
Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.;Q412323;P2175;Q136312
Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.;Q412323;P2175;Q208414
Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.;Q418817;P2175;Q208414
Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.;Q422232;P2175;Q208414
Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.;Q422232;P2175;Q136312
Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients;Q422232;P2175;Q208414
[High dose methotrexate in children with acute lymphocytic leukemia];Q422232;P2175;Q29496
Liquid chromatographic methods for the therapeutic drug monitoring of methotrexate as clinical decision support for personalized medicine: A brief review.;Q218642;P31;Q12140
Liquid chromatographic methods for the therapeutic drug monitoring of methotrexate as clinical decision support for personalized medicine: A brief review.;Q218642;P703;Q177932
Liquid chromatographic methods for the therapeutic drug monitoring of methotrexate as clinical decision support for personalized medicine: A brief review.;Q191924;P31;Q12140
Liquid chromatographic methods for the therapeutic drug monitoring of methotrexate as clinical decision support for personalized medicine: A brief review.;Q483745;P31;Q12140
Liquid chromatographic methods for the therapeutic drug monitoring of methotrexate as clinical decision support for personalized medicine: A brief review.;Q483745;P703;Q177932
Liquid chromatographic methods for the therapeutic drug monitoring of methotrexate as clinical decision support for personalized medicine: A brief review.;Q422232;P31;Q12140
[Effect of methotrexate on the activity of DNA-dependent RNA polymerases (A and B) in the spleen of mice infected with Rauscher leukemia virus and on the development of virus-induced leukemia];Q422232;P2175;Q29496
[Chemotherapy combining vindesine, thiotepa and methotrexate in metastatic breast cancer after failure of a combination containing anthracycline. Results of a prospective phase II trial];Q422232;P2175;Q128581
[The effect of low dose methotrexate treatment on bone mineral density in patients with rheumatoid arthritis].;Q422232;P2175;Q170990
[The effect of low dose methotrexate treatment on bone mineral density in patients with rheumatoid arthritis].;Q422232;P2175;Q187255
Tamoxifen and conjugated estrogens (Premarin) followed by sequenced methotrexate and 5-FU in refractory advanced breast cancer;Q412178;P2175;Q128581
Tamoxifen and conjugated estrogens (Premarin) followed by sequenced methotrexate and 5-FU in refractory advanced breast cancer;Q238512;P2175;Q128581
Tamoxifen and conjugated estrogens (Premarin) followed by sequenced methotrexate and 5-FU in refractory advanced breast cancer;Q4118295;P3780;Q47522014
Tamoxifen and conjugated estrogens (Premarin) followed by sequenced methotrexate and 5-FU in refractory advanced breast cancer;Q422416;P2175;Q128581
Tamoxifen and conjugated estrogens (Premarin) followed by sequenced methotrexate and 5-FU in refractory advanced breast cancer;Q422416;P279;Q277954
Tamoxifen and conjugated estrogens (Premarin) followed by sequenced methotrexate and 5-FU in refractory advanced breast cancer;Q422232;P2175;Q128581
Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results;Q18936;P3780;Q47520887
Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA;Q420035;P2868;Q810254
Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA;Q422232;P2868;Q810254
The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors;Q186521;P31;Q12140
The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors;Q191924;P366;Q8386
The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors;Q422232;P31;Q12140
The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors;Q422232;P2175;Q170990
The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors;Q422232;P2175;Q187255
Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: significance of the time between initiation of adjuvant therapy and of therapy for metastatic breast cancer.;Q238512;P2175;Q128581
Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: significance of the time between initiation of adjuvant therapy and of therapy for metastatic breast cancer.;Q422232;P2175;Q128581
Combination chemotherapy with high-dose methotrexate and cytarabine with or without brain irradiation for primary central nervous system lymphomas.;Q180983;P2175;Q208414
Combination chemotherapy with high-dose methotrexate and cytarabine with or without brain irradiation for primary central nervous system lymphomas.;Q422232;P2175;Q136312
Combination chemotherapy with high-dose methotrexate and cytarabine with or without brain irradiation for primary central nervous system lymphomas.;Q422232;P2175;Q208414
High-dose methotrexate in the treatment of adult acute lymphoblastic leukemia.;Q422232;P2175;Q29496
[Treatment with the immunosuppressive agents methotrexate and chlorambucil of patients with progessive chronic polyarthritis];Q422232;P2175;Q1274464
[Treatment with the immunosuppressive agents methotrexate and chlorambucil of patients with progessive chronic polyarthritis];Q422232;P2175;Q170990
ABC transporter genes and methotrexate response in rheumatoid arthritis;Q422232;P2175;Q170990
ABC transporter genes and methotrexate response in rheumatoid arthritis;Q422232;P2175;Q187255
Combination chemotherapy for small cell carcinoma of the lung: evaluation of four-drug combination of cyclophosphamide, vincristine, methotrexate, and procarbazine;Q186474;P31;Q12140
Combination chemotherapy for small cell carcinoma of the lung: evaluation of four-drug combination of cyclophosphamide, vincristine, methotrexate, and procarbazine;Q408977;P31;Q12140
Combination chemotherapy for small cell carcinoma of the lung: evaluation of four-drug combination of cyclophosphamide, vincristine, methotrexate, and procarbazine;Q191924;P366;Q8386
Combination chemotherapy for small cell carcinoma of the lung: evaluation of four-drug combination of cyclophosphamide, vincristine, methotrexate, and procarbazine;Q191924;P769;Q418656
Combination chemotherapy for small cell carcinoma of the lung: evaluation of four-drug combination of cyclophosphamide, vincristine, methotrexate, and procarbazine;Q418656;P31;Q12140
Combination chemotherapy for small cell carcinoma of the lung: evaluation of four-drug combination of cyclophosphamide, vincristine, methotrexate, and procarbazine;Q422232;P31;Q12140
Cost-effectiveness analysis of laparoscopic surgery versus methotrexate: comparison of data recorded in an ectopic pregnancy registry;Q422232;P2175;Q207087
[Treatment of medium and highly malignant non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisone and bleomycin (protocol MACOP-B)];Q408977;P2175;Q1138590
[Treatment of medium and highly malignant non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisone and bleomycin (protocol MACOP-B)];Q408977;P2175;Q208414
[Treatment of medium and highly malignant non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisone and bleomycin (protocol MACOP-B)];Q424972;P2175;Q1138590
[Treatment of medium and highly malignant non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisone and bleomycin (protocol MACOP-B)];Q422232;P2175;Q208414
[Treatment of medium and highly malignant non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisone and bleomycin (protocol MACOP-B)];Q422232;P2175;Q1138590
Removal of the anti-cancer drug methotrexate from water by advanced oxidation processes: Aerobic biodegradation and toxicity studies after treatment.;Q218642;P31;Q12140
Removal of the anti-cancer drug methotrexate from water by advanced oxidation processes: Aerobic biodegradation and toxicity studies after treatment.;Q191924;P366;Q8386
Removal of the anti-cancer drug methotrexate from water by advanced oxidation processes: Aerobic biodegradation and toxicity studies after treatment.;Q173670;P31;Q12140
Removal of the anti-cancer drug methotrexate from water by advanced oxidation processes: Aerobic biodegradation and toxicity studies after treatment.;Q29053744;P366;Q7892
Removal of the anti-cancer drug methotrexate from water by advanced oxidation processes: Aerobic biodegradation and toxicity studies after treatment.;Q29053744;P31;Q12140
Removal of the anti-cancer drug methotrexate from water by advanced oxidation processes: Aerobic biodegradation and toxicity studies after treatment.;Q422232;P31;Q12140
A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical;Q422232;P2175;Q208414
A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical;Q422232;P2175;Q136312
Erratum: Hyperosmolar and methotrexate therapy avoiding surgery in the acute presentation of primary central nervous system lymphoma: Erratum;Q422232;P2175;Q208414
Erratum: Hyperosmolar and methotrexate therapy avoiding surgery in the acute presentation of primary central nervous system lymphoma: Erratum;Q422232;P2175;Q136312
Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial;Q180983;P2175;Q208414
Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial;Q418011;P2175;Q208414
Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial;Q422252;P2175;Q208414
Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial;Q422232;P2175;Q208414
Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial;Q422232;P2175;Q136312
Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4.;Q422232;P2175;Q187255
Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4.;Q422232;P2175;Q170990
7.5 Safety data from over 1,200 patients-years of methotrexate and/or etanercept treatment in children with polyarticular or systemic juvenile rheumatoid arthritis.;Q422232;P2175;Q170990
7.5 Safety data from over 1,200 patients-years of methotrexate and/or etanercept treatment in children with polyarticular or systemic juvenile rheumatoid arthritis.;Q422232;P2175;Q187255
7.5 Safety data from over 1,200 patients-years of methotrexate and/or etanercept treatment in children with polyarticular or systemic juvenile rheumatoid arthritis.;Q422232;P2175;Q861224
Higher maximal serum concentration of methotrexate predicts the incidence of adverse reactions in Japanese rheumatoid arthritis patients;Q422232;P2175;Q170990
Higher maximal serum concentration of methotrexate predicts the incidence of adverse reactions in Japanese rheumatoid arthritis patients;Q422232;P2175;Q187255
Reduced folate carrier 1 gene expression levels are correlated with methotrexate efficacy in Japanese patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Reduced folate carrier 1 gene expression levels are correlated with methotrexate efficacy in Japanese patients with rheumatoid arthritis.;Q422232;P2175;Q187255
High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement.;Q422232;P2175;Q208414
High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement.;Q422232;P2175;Q1138590
Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort;Q183290;P31;Q12140
Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort;Q191924;P31;Q12140
Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort;Q173670;P31;Q12140
Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort;Q20035886;P31;Q12140
Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort;Q484940;P31;Q12140
Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort;Q422232;P31;Q12140
Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort;Q422232;P2175;Q187255
Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort;Q422232;P2175;Q170990
Effect of methotrexate treatment on expression levels of organic anion transporter polypeptide 2, P-glycoprotein and bile salt export pump in rats.;Q2314;P1889;Q12370
Neoadjuvant medium-dose methotrexate, cisplatin in category T3b-T4a (N0M0) bladder cancer.;Q412415;P2175;Q504775
Differential binding of plasma proteins by liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the bilayer.;Q191924;P31;Q12140
Differential binding of plasma proteins by liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the bilayer.;Q191924;P366;Q8386
Differential binding of plasma proteins by liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the bilayer.;Q2298283;P31;Q12140
Differential binding of plasma proteins by liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the bilayer.;Q178450;P31;Q12140
Differential binding of plasma proteins by liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the bilayer.;Q422232;P31;Q12140
Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first;Q422232;P2175;Q170990
Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first;Q422232;P2175;Q187255
Pharmacokinetics of folinic acid and 5-methyltetrahydrofolic metabolite after repeated oral administration of calcium folinate following methotrexate treatment;Q422232;P636;Q285166
Can the association of Ciclosporine A and Methotrexate maintain remission/low disease activity induced by etanercept in early Rheumatoid Arthritis patients? Evaluation by Magnetic Resonance Imaging.;Q218642;P703;Q2046782
Epstein-Barr virus infection associated hepatic lymphoma in a patient treated with methotrexate for rheumatoid arthritis.;Q422232;P2175;Q170990
Epstein-Barr virus infection associated hepatic lymphoma in a patient treated with methotrexate for rheumatoid arthritis.;Q422232;P2175;Q187255
Epstein-Barr virus infection associated hepatic lymphoma in a patient treated with methotrexate for rheumatoid arthritis.;Q422232;P2175;Q208414
Intracellular pharmacology and biochemistry of methotrexate and 6-mercaptopurine in childhood acute lymphoblastic leukemia;Q422232;P2175;Q29496
Traditional Chinese medicine Biqi capsule compared with leflunomide in combination with methotrexate in patients with rheumatoid arthritis: a randomized controlled trial;Q248550;P31;Q12140
Traditional Chinese medicine Biqi capsule compared with leflunomide in combination with methotrexate in patients with rheumatoid arthritis: a randomized controlled trial;Q248550;P2175;Q187255
Traditional Chinese medicine Biqi capsule compared with leflunomide in combination with methotrexate in patients with rheumatoid arthritis: a randomized controlled trial;Q248550;P2175;Q170990
Traditional Chinese medicine Biqi capsule compared with leflunomide in combination with methotrexate in patients with rheumatoid arthritis: a randomized controlled trial;Q186474;P31;Q12140
Traditional Chinese medicine Biqi capsule compared with leflunomide in combination with methotrexate in patients with rheumatoid arthritis: a randomized controlled trial;Q186521;P31;Q12140
Traditional Chinese medicine Biqi capsule compared with leflunomide in combination with methotrexate in patients with rheumatoid arthritis: a randomized controlled trial;Q191924;P31;Q12140
Traditional Chinese medicine Biqi capsule compared with leflunomide in combination with methotrexate in patients with rheumatoid arthritis: a randomized controlled trial;Q422232;P31;Q12140
Traditional Chinese medicine Biqi capsule compared with leflunomide in combination with methotrexate in patients with rheumatoid arthritis: a randomized controlled trial;Q422232;P2175;Q187255
Traditional Chinese medicine Biqi capsule compared with leflunomide in combination with methotrexate in patients with rheumatoid arthritis: a randomized controlled trial;Q422232;P2175;Q170990
Dose-intense weekly cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisolone (CMFP) in advanced breast cancer.;Q238512;P2175;Q128581
Dose-intense weekly cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisolone (CMFP) in advanced breast cancer.;Q11426176;P2175;Q12078
Dose-intense weekly cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisolone (CMFP) in advanced breast cancer.;Q422232;P2175;Q128581
Chemoradiotherapy with temozolomide after high-dose methotrexate for primary CNS lymphoma: a multicenter phase I study of a response-adapted strategy;Q422232;P2175;Q136312
Chemoradiotherapy with temozolomide after high-dose methotrexate for primary CNS lymphoma: a multicenter phase I study of a response-adapted strategy;Q422232;P2175;Q208414
Evaluation of possible interference of anti-inflammatory drugs upon scintigraphic imaging with macrophage targeting 99mTc-J001X: effects of methylprednisolone, dexamethasone, indomethacin and methotrexate;Q186521;P31;Q12140
Evaluation of possible interference of anti-inflammatory drugs upon scintigraphic imaging with macrophage targeting 99mTc-J001X: effects of methylprednisolone, dexamethasone, indomethacin and methotrexate;Q409231;P31;Q12140
Evaluation of possible interference of anti-inflammatory drugs upon scintigraphic imaging with macrophage targeting 99mTc-J001X: effects of methylprednisolone, dexamethasone, indomethacin and methotrexate;Q191924;P366;Q8386
Evaluation of possible interference of anti-inflammatory drugs upon scintigraphic imaging with macrophage targeting 99mTc-J001X: effects of methylprednisolone, dexamethasone, indomethacin and methotrexate;Q11426176;P2868;Q581996
Evaluation of possible interference of anti-inflammatory drugs upon scintigraphic imaging with macrophage targeting 99mTc-J001X: effects of methylprednisolone, dexamethasone, indomethacin and methotrexate;Q11426176;P31;Q12140
Evaluation of possible interference of anti-inflammatory drugs upon scintigraphic imaging with macrophage targeting 99mTc-J001X: effects of methylprednisolone, dexamethasone, indomethacin and methotrexate;Q422252;P31;Q12140
Evaluation of possible interference of anti-inflammatory drugs upon scintigraphic imaging with macrophage targeting 99mTc-J001X: effects of methylprednisolone, dexamethasone, indomethacin and methotrexate;Q422252;P2868;Q581996
Evaluation of possible interference of anti-inflammatory drugs upon scintigraphic imaging with macrophage targeting 99mTc-J001X: effects of methylprednisolone, dexamethasone, indomethacin and methotrexate;Q417222;P31;Q12140
Evaluation of possible interference of anti-inflammatory drugs upon scintigraphic imaging with macrophage targeting 99mTc-J001X: effects of methylprednisolone, dexamethasone, indomethacin and methotrexate;Q417222;P2868;Q581996
Evaluation of possible interference of anti-inflammatory drugs upon scintigraphic imaging with macrophage targeting 99mTc-J001X: effects of methylprednisolone, dexamethasone, indomethacin and methotrexate;Q422232;P31;Q12140
A randomized comparative trial of sequential versus alternating cyclophosphamide, doxorubicin, and cisplatin and mitomycin, lomustine, and methotrexate in metastatic non-small-cell lung cancer.;Q19856779;P1889;Q417625
False-photosensitivity and transient hemiparesis following high-dose intravenous and intrathecal methotrexate for treatment of acute lymphoblastic leukemia.;Q422232;P2175;Q29496
False-photosensitivity and transient hemiparesis following high-dose intravenous and intrathecal methotrexate for treatment of acute lymphoblastic leukemia.;Q422232;P636;Q1320251
[Combination of methotrexate injection through hysteroscopic tubal catheterization and mifepristone per os in the conservative treatment of tubal pregnancy];Q411240;P2175;Q207087
[Combination of methotrexate injection through hysteroscopic tubal catheterization and mifepristone per os in the conservative treatment of tubal pregnancy];Q422232;P636;Q285166
[Combination of methotrexate injection through hysteroscopic tubal catheterization and mifepristone per os in the conservative treatment of tubal pregnancy];Q422232;P2175;Q207087
TGF- signalling defect is linked to low CD39 expression on regulatory T cells and methotrexate resistance in rheumatoid arthritis.;Q422232;P2175;Q187255
TGF- signalling defect is linked to low CD39 expression on regulatory T cells and methotrexate resistance in rheumatoid arthritis.;Q422232;P2175;Q170990
Treatment strategies in early rheumatoid arthritis methotrexate management: Results from a prospective cohort;Q422232;P2175;Q187255
Treatment strategies in early rheumatoid arthritis methotrexate management: Results from a prospective cohort;Q422232;P2175;Q170990
Role of mean platelet volume and neutrophil/lymphocyte ratio to predict single-dose methotrexate treatment success in tubal ectopic pregnancy;Q422232;P2175;Q207087
Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft versus host disease: low incidence of lower gastrointestinal tract disease.;Q411648;P2175;Q1194520
Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft versus host disease: low incidence of lower gastrointestinal tract disease.;Q411648;P2175;Q56014460
Folic acid and methotrexate in rheumatoid arthritis;Q422232;P2175;Q170990
Folic acid and methotrexate in rheumatoid arthritis;Q422232;P2175;Q187255
Purulent pericarditis in rheumatoid arthritis treated with rituximab and methotrexate;Q412323;P2175;Q170990
Purulent pericarditis in rheumatoid arthritis treated with rituximab and methotrexate;Q422232;P2175;Q170990
Purulent pericarditis in rheumatoid arthritis treated with rituximab and methotrexate;Q422232;P2175;Q187255
Endogenous sialic acid-engineered micelles: a multifunctional platform for on-demand methotrexate delivery and bone repair of rheumatoid arthritis.;Q422232;P2175;Q170990
Endogenous sialic acid-engineered micelles: a multifunctional platform for on-demand methotrexate delivery and bone repair of rheumatoid arthritis.;Q422232;P2175;Q187255
Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines.;Q191924;P31;Q12140
Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines.;Q178450;P31;Q12140
Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines.;Q422232;P31;Q12140
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register.;Q412323;P2175;Q170990
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register.;Q422232;P2175;Q170990
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register.;Q422232;P2175;Q187255
The impact on health-related quality of life from non-steroidal anti-inflammatory drugs, methotrexate, or steroids in treatment for juvenile idiopathic arthritis.;Q186521;P31;Q12140
The impact on health-related quality of life from non-steroidal anti-inflammatory drugs, methotrexate, or steroids in treatment for juvenile idiopathic arthritis.;Q191924;P366;Q8386
The impact on health-related quality of life from non-steroidal anti-inflammatory drugs, methotrexate, or steroids in treatment for juvenile idiopathic arthritis.;Q422232;P31;Q12140
The impact on health-related quality of life from non-steroidal anti-inflammatory drugs, methotrexate, or steroids in treatment for juvenile idiopathic arthritis.;Q422232;P2175;Q861224
The impact on health-related quality of life from non-steroidal anti-inflammatory drugs, methotrexate, or steroids in treatment for juvenile idiopathic arthritis.;Q422232;P2175;Q170990
High-dose methotrexate and temozolomide associated with intrathecal liposomal cytarabine for the treatment of primary or secondary central nervous system lymphoma: a preliminary experience.;Q180983;P2175;Q208414
High-dose methotrexate and temozolomide associated with intrathecal liposomal cytarabine for the treatment of primary or secondary central nervous system lymphoma: a preliminary experience.;Q422232;P636;Q1320251
High-dose methotrexate and temozolomide associated with intrathecal liposomal cytarabine for the treatment of primary or secondary central nervous system lymphoma: a preliminary experience.;Q422232;P2175;Q136312
High-dose methotrexate and temozolomide associated with intrathecal liposomal cytarabine for the treatment of primary or secondary central nervous system lymphoma: a preliminary experience.;Q422232;P2175;Q208414
[Evaluation of methotrexate effect on the acute-phase response in rheumatoid arthritis after 12-week treatment];Q422232;P2175;Q187255
[Evaluation of methotrexate effect on the acute-phase response in rheumatoid arthritis after 12-week treatment];Q422232;P2175;Q170990
Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial;Q415264;P2175;Q170990
Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial;Q422232;P2175;Q170990
ATIC missense variant affects response to methotrexate treatment in rheumatoid arthritis patients;Q422232;P2175;Q170990
ATIC missense variant affects response to methotrexate treatment in rheumatoid arthritis patients;Q422232;P361;Q14819383
ATIC missense variant affects response to methotrexate treatment in rheumatoid arthritis patients;Q422232;P2175;Q187255
[Effect of methotrexate on the leukemic cell cycle in mouse ascitic leukemia L1210];Q422232;P2175;Q29496
Trans-stimulation effects of folic acid derivatives on methotrexate transport by rat renal organic anion transporter, OAT-K1.;Q422232;P2868;Q127060
Methotrexate therapy for persistent ectopic pregnancy after conservative laparoscopic management.;Q422232;P2175;Q207087
Fucose decorated solid-lipid nanocarriers mediate efficient delivery of methotrexate in breast cancer therapeutics.;Q422232;P2175;Q128581
Hematology. Individualized methotrexate dosing in primary CNS lymphoma.;Q422232;P2175;Q136312
Hematology. Individualized methotrexate dosing in primary CNS lymphoma.;Q422232;P2175;Q208414
Methotrexate might increase mortality from interstitial lung disease in rheumatoid arthritis;Q422232;P2175;Q187255
Methotrexate might increase mortality from interstitial lung disease in rheumatoid arthritis;Q422232;P2175;Q170990
Low-dose oral methotrexate for the management of childhood Cogan's syndrome: a case report.;Q422232;P636;Q285166
Adverse effects of methotrexate in three psoriatic arthritis patients.;Q422232;P2175;Q170990
Treatment of a viable caesarean scar pregnancy with transvaginal methotrexate and potassium chloride injection;Q184630;P527;Q703
Treatment of a viable caesarean scar pregnancy with transvaginal methotrexate and potassium chloride injection;Q184630;P527;Q108200
Tocilizumab versus methotrexate in moderate to severe rheumatoid arthritis.;Q422232;P2175;Q187255
Tocilizumab versus methotrexate in moderate to severe rheumatoid arthritis.;Q422232;P2175;Q170990
[Synthesis of a fluorescent analog of methotrexate lipophilic prodrug];Q183290;P31;Q12140
[Synthesis of a fluorescent analog of methotrexate lipophilic prodrug];Q191924;P31;Q12140
[Synthesis of a fluorescent analog of methotrexate lipophilic prodrug];Q422232;P31;Q12140
Spinal epidural abscess following minimally invasive dental examination in a rheumatoid arthritis patient receiving methotrexate, glucocorticoids, and anti-tumor necrosis factor therapy.;Q422232;P2175;Q187255
Spinal epidural abscess following minimally invasive dental examination in a rheumatoid arthritis patient receiving methotrexate, glucocorticoids, and anti-tumor necrosis factor therapy.;Q422232;P2175;Q170990
Risk of higher dose methotrexate for renal impairment in patients with rheumatoid arthritis;Q422232;P2175;Q187255
Risk of higher dose methotrexate for renal impairment in patients with rheumatoid arthritis;Q422232;P2175;Q170990
Phase II study of sequential methotrexate and 5-FU plus mitomycin and leucovorin in patients with disseminated large bowel cancer: a Northern California Oncology Group study;Q19856779;P1889;Q417625
An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma.;Q422232;P2175;Q549534
Chemometrics-assisted Spectrofluorimetric Determination of Two Co-administered Drugs of Major Interaction, Methotrexate and Aspirin, in Human Urine Following Acid-induced Hydrolysis.;Q18216;P769;Q422232
Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.;Q367700;P2175;Q1194520
Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.;Q424972;P2175;Q1194520
Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors.;Q422232;P2175;Q170990
Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors.;Q422232;P2175;Q187255
In vitro and in vivo interactions of methotrexate and other antimetabolites with the oestrogen high affinity receptors of the rat uterus.;Q422416;P279;Q277954
Activity of adriamycin in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prdnisone.;Q238512;P2175;Q128581
Activity of adriamycin in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prdnisone.;Q422232;P2175;Q128581
FRI0194A phase IB clinical trial with dekavil (F8-IL10), an anti-inflammatory immunocytokine for the treatment of rheumatoid arthritis, used in combination with methotrexate;Q422232;P2175;Q170990
FRI0194A phase IB clinical trial with dekavil (F8-IL10), an anti-inflammatory immunocytokine for the treatment of rheumatoid arthritis, used in combination with methotrexate;Q422232;P2175;Q187255
[p73 gene expression in apoptotic process of acute myeloid leukemia cell line U937 induced by methotrexate];Q422232;P2175;Q29496
[p73 gene expression in apoptotic process of acute myeloid leukemia cell line U937 induced by methotrexate];Q422232;P2175;Q264118
Effects of progressive muscle relaxation training on anxiety and quality of life of inpatients with ectopic pregnancy receiving methotrexate treatment.;Q422232;P2175;Q207087
Hepatorenal protective effects of protocatechuic acid in rats administered with anticancer drug methotrexate;Q23118;P31;Q12140
Hepatorenal protective effects of protocatechuic acid in rats administered with anticancer drug methotrexate;Q191924;P366;Q8386
Hepatorenal protective effects of protocatechuic acid in rats administered with anticancer drug methotrexate;Q485277;P31;Q12140
Hepatorenal protective effects of protocatechuic acid in rats administered with anticancer drug methotrexate;Q422232;P31;Q12140
[Reccomendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of methotrexate in inflammatory bowel disease].;Q422232;P2175;Q1477
Effect of sequence of administration of methotrexate, leucovorin, and 5-fluorouracil on mammary tumor growth and survival in syngeneic C3H mice.;Q186474;P703;Q83310
[Szary syndrome showing a stable clinical course for more than four years after oral administration of etoposide and methotrexate];Q418817;P636;Q285166
[Szary syndrome showing a stable clinical course for more than four years after oral administration of etoposide and methotrexate];Q422232;P636;Q285166
Human chorionic gonadotropin value and its change prior to methotrexate treatment can predict the prognosis in ectopic tubal pregnancies;Q407172;P279;Q409770
Effects of germline variants in DHFR and FPGS on methotrexate metabolism and relapse of leukemia;Q422232;P2175;Q29496
The efficacy of the traditional Chinese medicine Jia Wei Niu Bang Zi granule combined with methotrexate in treating active rheumatoid arthritis: A multicenter, randomized, double-blinded controlled clinical trial;Q181003;P31;Q12140
The efficacy of the traditional Chinese medicine Jia Wei Niu Bang Zi granule combined with methotrexate in treating active rheumatoid arthritis: A multicenter, randomized, double-blinded controlled clinical trial;Q218642;P31;Q12140
The efficacy of the traditional Chinese medicine Jia Wei Niu Bang Zi granule combined with methotrexate in treating active rheumatoid arthritis: A multicenter, randomized, double-blinded controlled clinical trial;Q186474;P31;Q12140
The efficacy of the traditional Chinese medicine Jia Wei Niu Bang Zi granule combined with methotrexate in treating active rheumatoid arthritis: A multicenter, randomized, double-blinded controlled clinical trial;Q186521;P31;Q12140
The efficacy of the traditional Chinese medicine Jia Wei Niu Bang Zi granule combined with methotrexate in treating active rheumatoid arthritis: A multicenter, randomized, double-blinded controlled clinical trial;Q191924;P31;Q12140
The efficacy of the traditional Chinese medicine Jia Wei Niu Bang Zi granule combined with methotrexate in treating active rheumatoid arthritis: A multicenter, randomized, double-blinded controlled clinical trial;Q422232;P31;Q12140
The efficacy of the traditional Chinese medicine Jia Wei Niu Bang Zi granule combined with methotrexate in treating active rheumatoid arthritis: A multicenter, randomized, double-blinded controlled clinical trial;Q422232;P2175;Q187255
The efficacy of the traditional Chinese medicine Jia Wei Niu Bang Zi granule combined with methotrexate in treating active rheumatoid arthritis: A multicenter, randomized, double-blinded controlled clinical trial;Q422232;P2175;Q170990
Erythrocyte concentrations of metabolites or cumulative doses of 6-mercaptopurine and methotrexate do not predict liver changes in children treated for acute lymphoblastic leukemia.;Q422232;P2175;Q29496
A CD30(-) Transformed Mycosis Fungoides Case Responding Very Well to Systemic Bexarotene and Methotrexate;Q418192;P2175;Q1891209
A CD30(-) Transformed Mycosis Fungoides Case Responding Very Well to Systemic Bexarotene and Methotrexate;Q422232;P2175;Q1891209
Efficacy and selectivity of monoclonal-antibody-targeted drugs and free methotrexate in fluorescence-labelled mixed tumour-cell monolayer cultures and multicellular spheroids.;Q191924;P31;Q12140
Efficacy and selectivity of monoclonal-antibody-targeted drugs and free methotrexate in fluorescence-labelled mixed tumour-cell monolayer cultures and multicellular spheroids.;Q191924;P366;Q8386
Efficacy and selectivity of monoclonal-antibody-targeted drugs and free methotrexate in fluorescence-labelled mixed tumour-cell monolayer cultures and multicellular spheroids.;Q422232;P31;Q12140
[Population pharmacokinetics of high-dose methotrexate administered in 329 children with acute lymphoblastic leukemia].;Q422232;P2175;Q29496
[Comparative study on clinical efficacy of using methotrexate singly or combined with total glucosides of Paeony in treating rheumatoid arthritis];Q422232;P2175;Q170990
[Comparative study on clinical efficacy of using methotrexate singly or combined with total glucosides of Paeony in treating rheumatoid arthritis];Q422232;P2175;Q187255
Multifunctional N,S co-doped carbon dots for sensitive probing of temperature, ferric ion, and methotrexate;Q183290;P527;Q623
Multifunctional N,S co-doped carbon dots for sensitive probing of temperature, ferric ion, and methotrexate;Q23118;P527;Q623
Multifunctional N,S co-doped carbon dots for sensitive probing of temperature, ferric ion, and methotrexate;Q191924;P527;Q623
Multifunctional N,S co-doped carbon dots for sensitive probing of temperature, ferric ion, and methotrexate;Q60168;P527;Q623
A combination of oral azathioprine and methotrexate in difficult to treat dermatoses;Q422232;P636;Q285166
[Nonadherence and ineffective methotrexate treatment of inflammatory arthritis].;Q422232;P2175;Q170990
Methotrexate treatment and mortality in rheumatoid arthritis.;Q422232;P2175;Q187255
Methotrexate treatment and mortality in rheumatoid arthritis.;Q422232;P2175;Q170990
Combination chemotherapy with cyclophosphamide (NSC-26271), cytosine arabinoside (NSC-63878), and methotrexate (NSC-740) in advanced solid tumors.;Q186474;P1889;Q178425
Methotrexate in polymyalgia rheumatica: kernel of truth or curse of Tantalus?;Q422232;P2175;Q1752891
Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences;Q186474;P31;Q12140
Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences;Q191924;P31;Q12140
Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences;Q191924;P366;Q8386
Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences;Q422232;P31;Q12140
Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences;Q422232;P2175;Q170990
Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences;Q422232;P2868;Q810254
Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences;Q422232;P2175;Q187255
Methotrexate treatment for ectopic pregnancy after assisted reproductive technology: A case-control study.;Q422232;P2175;Q207087
Intra-arterial versus intravenous cisplatinum (in addition to systemic Adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. results of a randomized study;Q18936;P3780;Q47520887
Intra-arterial versus intravenous cisplatinum (in addition to systemic Adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. results of a randomized study;Q412415;P527;Q880
Intra-arterial versus intravenous cisplatinum (in addition to systemic Adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. results of a randomized study;Q412415;P2175;Q549534
Intra-arterial versus intravenous cisplatinum (in addition to systemic Adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. results of a randomized study;Q422232;P2175;Q549534
[A comparison of leflunomide and subcutaneous methotrexate in the treatment of rheumatoid arthritis: an approximation based on the number needed to treat].;Q248550;P2175;Q170990
[A comparison of leflunomide and subcutaneous methotrexate in the treatment of rheumatoid arthritis: an approximation based on the number needed to treat].;Q248550;P2175;Q187255
[A comparison of leflunomide and subcutaneous methotrexate in the treatment of rheumatoid arthritis: an approximation based on the number needed to treat].;Q422232;P2175;Q170990
[A comparison of leflunomide and subcutaneous methotrexate in the treatment of rheumatoid arthritis: an approximation based on the number needed to treat].;Q422232;P2175;Q187255
Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis.;Q422232;P361;Q14819383
Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Phaeohyphomycotic tenosynovitis after local steroid injection during methotrexate therapy for rheumatoid arthritis: A case-report.;Q422232;P2175;Q170990
Phaeohyphomycotic tenosynovitis after local steroid injection during methotrexate therapy for rheumatoid arthritis: A case-report.;Q422232;P2175;Q187255
First-pass uptake of methotrexate after intra-arterial bolus injection in human head and neck cancers;Q170545;P703;Q15978631
First-pass uptake of methotrexate after intra-arterial bolus injection in human head and neck cancers;Q422232;P2175;Q1783924
Acute inflammatory arthritis: Methotrexate for chronic chikungunya arthritis?;Q422232;P2175;Q170990
Potentiation of etoposide cytotoxicity against a human ovarian cancer cell line by pretreatment with non-toxic concentrations of methotrexate or aphidicolin.;Q20035886;P703;Q15978631
Evaluation of microvessel density with CD31 and CD105 in patients with psoriasis under methotrexate and acitretin therapy;Q341500;P31;Q106040601
Changes in cognition and dendritic complexity following intrathecal methotrexate and cytarabine treatment in a juvenile murine model.;Q422232;P636;Q1320251
Methotrexate enhances 5-aminolevulinic acid-mediated photodynamic therapy-induced killing of human SCC4 cells by upregulation of coproporphyrinogen oxidase;Q183290;P703;Q15978631
Methotrexate enhances 5-aminolevulinic acid-mediated photodynamic therapy-induced killing of human SCC4 cells by upregulation of coproporphyrinogen oxidase;Q186474;P703;Q15978631
Methotrexate enhances 5-aminolevulinic acid-mediated photodynamic therapy-induced killing of human SCC4 cells by upregulation of coproporphyrinogen oxidase;Q139347;P703;Q15978631
Methotrexate enhances 5-aminolevulinic acid-mediated photodynamic therapy-induced killing of human SCC4 cells by upregulation of coproporphyrinogen oxidase;Q238474;P703;Q15978631
Methotrexate enhances 5-aminolevulinic acid-mediated photodynamic therapy-induced killing of human SCC4 cells by upregulation of coproporphyrinogen oxidase;Q238474;P279;Q49917009
Methotrexate enhances 5-aminolevulinic acid-mediated photodynamic therapy-induced killing of human SCC4 cells by upregulation of coproporphyrinogen oxidase;Q22124685;P703;Q15978631
Quantitative correlations of biological activities of dactinomycin analogs and methotrexate derivatives with van der Waals volume.;Q186127;P279;Q343465
The unclear role of methotrexate in the treatment of diffuse large-cell lymphoma.;Q422232;P2175;Q208414
Prospective monitoring of Epstein-Barr virus and other herpesviruses in patients with juvenile idiopathic arthritis treated with methotrexate and tocilizumab.;Q425154;P2175;Q170990
Prospective monitoring of Epstein-Barr virus and other herpesviruses in patients with juvenile idiopathic arthritis treated with methotrexate and tocilizumab.;Q422232;P2175;Q170990
Prospective monitoring of Epstein-Barr virus and other herpesviruses in patients with juvenile idiopathic arthritis treated with methotrexate and tocilizumab.;Q422232;P2175;Q861224
Cyclosporine and methotrexate for severe rheumatoid arthritis;Q422232;P2175;Q170990
Cyclosporine and methotrexate for severe rheumatoid arthritis;Q422232;P2175;Q187255
Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer.;Q2298283;P2175;Q172341
A case of delayed methotrexate clearance following administration of a complementary medication containing chlorophyll;Q218642;P31;Q12140
A case of delayed methotrexate clearance following administration of a complementary medication containing chlorophyll;Q191924;P31;Q12140
A case of delayed methotrexate clearance following administration of a complementary medication containing chlorophyll;Q422232;P31;Q12140
Response time and safety profile of pulsed oral methotrexate therapy in idiopathic retinal periphlebitis.;Q422232;P636;Q285166
Treatment of psoriatic arthritis with etanercept, methotrexate, and cyclosporin A.;Q422232;P2175;Q170990
Conservative management of ectopic pregnancy with fetal cardiac activity by combined local (sonographically guided) and systemic injection of methotrexate;Q422232;P2175;Q207087
Successful treatment of persistent partial mole with oral methotrexate therapy.;Q422232;P636;Q285166
PReS-FINAL-2030: Treatment with leflunomide results in a higher flare rate of chronic uveitis compared to methotrexate in patients with juvenile idiopathic arthritis treated with both drugs.;Q248550;P31;Q12140
PReS-FINAL-2030: Treatment with leflunomide results in a higher flare rate of chronic uveitis compared to methotrexate in patients with juvenile idiopathic arthritis treated with both drugs.;Q248550;P2175;Q170990
PReS-FINAL-2030: Treatment with leflunomide results in a higher flare rate of chronic uveitis compared to methotrexate in patients with juvenile idiopathic arthritis treated with both drugs.;Q218642;P31;Q12140
PReS-FINAL-2030: Treatment with leflunomide results in a higher flare rate of chronic uveitis compared to methotrexate in patients with juvenile idiopathic arthritis treated with both drugs.;Q183290;P31;Q12140
PReS-FINAL-2030: Treatment with leflunomide results in a higher flare rate of chronic uveitis compared to methotrexate in patients with juvenile idiopathic arthritis treated with both drugs.;Q186521;P31;Q12140
PReS-FINAL-2030: Treatment with leflunomide results in a higher flare rate of chronic uveitis compared to methotrexate in patients with juvenile idiopathic arthritis treated with both drugs.;Q191924;P31;Q12140
PReS-FINAL-2030: Treatment with leflunomide results in a higher flare rate of chronic uveitis compared to methotrexate in patients with juvenile idiopathic arthritis treated with both drugs.;Q191924;P366;Q8386
PReS-FINAL-2030: Treatment with leflunomide results in a higher flare rate of chronic uveitis compared to methotrexate in patients with juvenile idiopathic arthritis treated with both drugs.;Q170545;P31;Q12140
PReS-FINAL-2030: Treatment with leflunomide results in a higher flare rate of chronic uveitis compared to methotrexate in patients with juvenile idiopathic arthritis treated with both drugs.;Q173670;P31;Q12140
PReS-FINAL-2030: Treatment with leflunomide results in a higher flare rate of chronic uveitis compared to methotrexate in patients with juvenile idiopathic arthritis treated with both drugs.;Q20035886;P31;Q12140
PReS-FINAL-2030: Treatment with leflunomide results in a higher flare rate of chronic uveitis compared to methotrexate in patients with juvenile idiopathic arthritis treated with both drugs.;Q483745;P31;Q12140
PReS-FINAL-2030: Treatment with leflunomide results in a higher flare rate of chronic uveitis compared to methotrexate in patients with juvenile idiopathic arthritis treated with both drugs.;Q484940;P31;Q12140
PReS-FINAL-2030: Treatment with leflunomide results in a higher flare rate of chronic uveitis compared to methotrexate in patients with juvenile idiopathic arthritis treated with both drugs.;Q422232;P31;Q12140
PReS-FINAL-2030: Treatment with leflunomide results in a higher flare rate of chronic uveitis compared to methotrexate in patients with juvenile idiopathic arthritis treated with both drugs.;Q422232;P2175;Q280027
PReS-FINAL-2030: Treatment with leflunomide results in a higher flare rate of chronic uveitis compared to methotrexate in patients with juvenile idiopathic arthritis treated with both drugs.;Q422232;P2175;Q170990
PReS-FINAL-2030: Treatment with leflunomide results in a higher flare rate of chronic uveitis compared to methotrexate in patients with juvenile idiopathic arthritis treated with both drugs.;Q422232;P2175;Q861224
[Methotrexate in the treatment of rheumatoid arthritis];Q422232;P2175;Q170990
[Methotrexate in the treatment of rheumatoid arthritis];Q422232;P2175;Q187255
Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice;Q183290;P31;Q12140
Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice;Q186521;P31;Q12140
Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice;Q191924;P366;Q8386
Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice;Q425154;P31;Q12140
Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice;Q425154;P2175;Q170990
Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice;Q422232;P31;Q12140
Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice;Q422232;P2175;Q170990
Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice;Q422232;P2175;Q187255
Is methotrexate contra-indicated in lung involvement of rheumatoid arthritis?;Q422232;P2175;Q170990
Is methotrexate contra-indicated in lung involvement of rheumatoid arthritis?;Q422232;P2175;Q187255
Cell cycle kinetics of uninfected and feline leukemia virus-infected canine lymphoma cell lines: effects of methotrexate treatment.;Q422232;P2175;Q29496
Cell cycle kinetics of uninfected and feline leukemia virus-infected canine lymphoma cell lines: effects of methotrexate treatment.;Q422232;P2175;Q208414
Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register;Q218642;P31;Q12140
Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register;Q183290;P31;Q12140
Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register;Q186474;P31;Q12140
Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register;Q186521;P31;Q12140
Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register;Q191924;P366;Q8386
Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register;Q170545;P31;Q12140
Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register;Q173670;P31;Q12140
Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register;Q484940;P31;Q12140
Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register;Q422232;P31;Q12140
Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register;Q422232;P2175;Q170990
Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register;Q422232;P2175;Q187255
Genetic variants in the human SLCO1B1 gene and individual variations in methotrexate clearance;Q183290;P703;Q15978631
Genetic variants in the human SLCO1B1 gene and individual variations in methotrexate clearance;Q186474;P703;Q15978631
Genetic variants in the human SLCO1B1 gene and individual variations in methotrexate clearance;Q620730;P703;Q15978631
Genetic variants in the human SLCO1B1 gene and individual variations in methotrexate clearance;Q483745;P703;Q15978631
[Studies on concentrations and interactions of drugs in patients with administration of high-dose of cytosine arabinoside and methotrexate];Q180983;P31;Q12140
[Studies on concentrations and interactions of drugs in patients with administration of high-dose of cytosine arabinoside and methotrexate];Q183290;P31;Q12140
[Studies on concentrations and interactions of drugs in patients with administration of high-dose of cytosine arabinoside and methotrexate];Q191924;P366;Q8386
[Studies on concentrations and interactions of drugs in patients with administration of high-dose of cytosine arabinoside and methotrexate];Q422232;P31;Q12140
-hCG and prediction of therapeutic success in ectopic pregnancies treated with methotrexate, results from a prospective observational study.;Q186474;P703;Q177932
-hCG and prediction of therapeutic success in ectopic pregnancies treated with methotrexate, results from a prospective observational study.;Q620730;P703;Q177932
Maintenance of differential methotrexate toxicity between cells expressing drug-resistant and wild-type dihydrofolate reductase activities in the presence of nucleosides through nucleoside transport inhibition.;Q191924;P366;Q8386
Maintenance of differential methotrexate toxicity between cells expressing drug-resistant and wild-type dihydrofolate reductase activities in the presence of nucleosides through nucleoside transport inhibition.;Q22124685;P31;Q12140
Maintenance of differential methotrexate toxicity between cells expressing drug-resistant and wild-type dihydrofolate reductase activities in the presence of nucleosides through nucleoside transport inhibition.;Q422232;P31;Q12140
The long-term outcome of hip replacement in adults with juvenile idiopathic arthritis: the influence of steroids and methotrexate;Q422232;P2175;Q170990
The long-term outcome of hip replacement in adults with juvenile idiopathic arthritis: the influence of steroids and methotrexate;Q422232;P2175;Q861224
Methotrexate therapy of oral corticosteroid-dependent asthmatics reduces serum immunoglobulins: correlation with clinical response to therapy.;Q422232;P636;Q285166
The use of intravenous methotrexate in the treatment of ectopic pregnancy.;Q422232;P2175;Q207087
Effect of charcoal hemoperfusion for removal of plasma methotrexate in a patient with acute renal failure.;Q422232;P636;Q640448
Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and D-penicillamine.;Q191924;P31;Q12140
Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and D-penicillamine.;Q191924;P366;Q8386
Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and D-penicillamine.;Q178450;P31;Q12140
Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and D-penicillamine.;Q420035;P31;Q12140
Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and D-penicillamine.;Q420035;P2868;Q810254
Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and D-penicillamine.;Q421239;P31;Q12140
Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and D-penicillamine.;Q421239;P2868;Q810254
Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and D-penicillamine.;Q422232;P31;Q12140
Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and D-penicillamine.;Q422232;P2868;Q810254
Randomized comparison of health-related quality of life in women with ectopic pregnancy or pregnancy of unknown location treated with systemic methotrexate or expectant management.;Q422232;P2175;Q207087
Effect of methotrexate therapy on bone mineral density and body composition in rat adjuvant arthritis;Q422232;P2175;Q170990
Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial.;Q422232;P2175;Q170990
Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial.;Q422232;P2868;Q810254
Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial.;Q422232;P2175;Q187255
Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab;Q412323;P2175;Q208414
Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab;Q412323;P2175;Q170990
Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab;Q422232;P2175;Q208414
Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab;Q422232;P2175;Q170990
Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab;Q422232;P2175;Q187255
miR-192 enhances sensitivity of methotrexate drug to MG-63 osteosarcoma cancer cells;Q191924;P31;Q12140
miR-192 enhances sensitivity of methotrexate drug to MG-63 osteosarcoma cancer cells;Q173670;P31;Q12140
miR-192 enhances sensitivity of methotrexate drug to MG-63 osteosarcoma cancer cells;Q22124685;P31;Q12140
miR-192 enhances sensitivity of methotrexate drug to MG-63 osteosarcoma cancer cells;Q620730;P31;Q12140
miR-192 enhances sensitivity of methotrexate drug to MG-63 osteosarcoma cancer cells;Q422232;P31;Q12140
miR-192 enhances sensitivity of methotrexate drug to MG-63 osteosarcoma cancer cells;Q422232;P2175;Q549534
Time course of methotrexate polyglutamate formation and degradation in the pre-B-leukaemia cell line Nalm6 and in lymphoblasts from children with leukaemia.;Q422232;P2175;Q29496
Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer.;Q238512;P2175;Q128581
Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer.;Q420532;P2175;Q128581
Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer.;Q425122;P2175;Q128581
Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer.;Q423762;P2175;Q128581
Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer.;Q422232;P2175;Q128581
Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks.;Q422232;P2175;Q170990
Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks.;Q422232;P2175;Q187255
Low-dose methotrexate - a therapeutical kick in TNF-alpha antagonist treatment for recalcitrant psoriasis vulgaris.;Q186521;P703;Q177932
Low-dose methotrexate - a therapeutical kick in TNF-alpha antagonist treatment for recalcitrant psoriasis vulgaris.;Q483745;P703;Q177932
Seesaw nystagmus following whole brain irradiation and intrathecal methotrexate;Q422232;P636;Q1320251
Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation.;Q3530324;P2175;Q170990
Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation.;Q422232;P2175;Q170990
Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation.;Q422232;P2175;Q187255
Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis;Q422232;P2175;Q170990
Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.;Q18936;P2175;Q208414
Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.;Q18936;P2175;Q1138590
Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.;Q180983;P2175;Q208414
Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.;Q180983;P2175;Q1138590
Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.;Q408977;P2175;Q208414
Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.;Q408977;P2175;Q1138590
Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.;Q239426;P2175;Q208414
Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.;Q418817;P2175;Q208414
Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.;Q418817;P2175;Q1138590
Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.;Q418011;P2175;Q208414
Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.;Q422232;P2175;Q1138590
Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.;Q422232;P2175;Q208414
Pneumonitis induced by methotrexate in a patient with seronegative rheumatoid arthritis;Q422232;P2175;Q170990
Pneumonitis induced by methotrexate in a patient with seronegative rheumatoid arthritis;Q422232;P2175;Q187255
Efficacy and Safety of Second-Line 5-Day Dactinomycin in Case of Methotrexate Failure for Gestational Trophoblastic Neoplasia.;Q186127;P279;Q343465
The METEOR Trial: The Burial of Methotrexate in Ulcerative Colitis?;Q422232;P2175;Q1477
Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: A systematic review and meta-analysis;Q422232;P2175;Q170990
Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: A systematic review and meta-analysis;Q422232;P2175;Q187255
Effects of methotrexate and phenobarbital on the hepatic microsomal drug-metabolizing enzymes in normal rat.;Q407241;P31;Q12140
Effects of methotrexate and phenobarbital on the hepatic microsomal drug-metabolizing enzymes in normal rat.;Q191924;P31;Q12140
Effects of methotrexate and phenobarbital on the hepatic microsomal drug-metabolizing enzymes in normal rat.;Q422232;P31;Q12140
Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis.;Q411648;P2175;Q1194520
Clinical predictors of failing one dose of methotrexate for ectopic pregnancy after in vitro fertilization.;Q422232;P2175;Q207087
Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3.;Q411159;P31;Q12140
Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3.;Q191924;P366;Q8386
Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3.;Q422232;P31;Q12140
Chemotherapy for esophageal cancer with mitoguazone, methotrexate, bleomycin, and cisplatin.;Q412415;P2175;Q372701
Chemotherapy for esophageal cancer with mitoguazone, methotrexate, bleomycin, and cisplatin.;Q422232;P2175;Q372701
Role of methotrexate chronotherapy in collagen-induced rheumatoid arthritis inrats.;Q422232;P2175;Q187255
Role of methotrexate chronotherapy in collagen-induced rheumatoid arthritis inrats.;Q422232;P2175;Q170990
Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma;Q422232;P2175;Q136312
Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma;Q422232;P2175;Q208414
Synthesis and characterization of novel P(HEMA-LA-MADQUAT) micelles for co-delivery of methotrexate and Chrysin in combination cancer chemotherapy.;Q186474;P703;Q83310
Combination chemotherapy with mitomycin C, methotrexate, and vincristine (MMV) for metastatic breast cancer refractory to adriamycin;Q19856779;P1889;Q417625
Combination chemotherapy with mitomycin C, methotrexate, and vincristine (MMV) for metastatic breast cancer refractory to adriamycin;Q422232;P2175;Q128581
Pre-treatment X-rays for rheumatoid arthritis treated with methotrexate;Q422232;P2175;Q187255
Pre-treatment X-rays for rheumatoid arthritis treated with methotrexate;Q422232;P2175;Q170990
[Cutaneous pseudolymphoma during treatment of rheumatoid polyarthritis with low-dose methotrexate];Q422232;P2175;Q170990
[Cutaneous pseudolymphoma during treatment of rheumatoid polyarthritis with low-dose methotrexate];Q422232;P2175;Q208414
[Cutaneous pseudolymphoma during treatment of rheumatoid polyarthritis with low-dose methotrexate];Q422232;P2175;Q1274464
[Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients];Q191924;P31;Q12140
[Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients];Q422232;P31;Q12140
[Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients];Q422232;P2175;Q208414
Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study;Q425154;P2175;Q170990
Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study;Q422232;P2175;Q187255
Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study;Q422232;P2175;Q170990
[Methotrexate treatment in refractory juvenile rheumatoid arthritis];Q422232;P2175;Q170990
[Methotrexate treatment in refractory juvenile rheumatoid arthritis];Q422232;P2175;Q187255
[Methotrexate treatment in refractory juvenile rheumatoid arthritis];Q422232;P2175;Q861224
Utility and Safety of Intrathecal Methotrexate Treatment in Severe Anti-N-methyl-D-aspartate Receptor Encephalitis: A Pilot Study.;Q178450;P3364;Q27076990
Selectively weakened binding of methotrexate by human dihydrofolate reductase allows rapid ex vivo selection of mammalian cells;Q183290;P703;Q15978631
[Multidose treatment of methotrexate in cornual ectopic pregnancy];Q422232;P2175;Q207087
Comparative analysis of graft-versus-host disease prophylaxis with tacrolimus in combination with methylprednisolone or methotrexate after umbilical cord blood transplantation;Q411648;P2175;Q1194520
Comparative analysis of graft-versus-host disease prophylaxis with tacrolimus in combination with methylprednisolone or methotrexate after umbilical cord blood transplantation;Q11426176;P2175;Q1194520
Comparative analysis of graft-versus-host disease prophylaxis with tacrolimus in combination with methylprednisolone or methotrexate after umbilical cord blood transplantation;Q417222;P2175;Q1194520
Activation by peptidases and cytotoxicity of 2-(L-alpha-aminoacyl) prodrugs of methotrexate;Q218642;P31;Q12140
Activation by peptidases and cytotoxicity of 2-(L-alpha-aminoacyl) prodrugs of methotrexate;Q191924;P366;Q8386
Activation by peptidases and cytotoxicity of 2-(L-alpha-aminoacyl) prodrugs of methotrexate;Q483745;P31;Q12140
Activation by peptidases and cytotoxicity of 2-(L-alpha-aminoacyl) prodrugs of methotrexate;Q422232;P31;Q12140
Low-dose methotrexate treatment for oligoarticular juvenile idiopathic arthritis nonresponsive to intra-articular corticosteroids.;Q422232;P2175;Q170990
Low-dose methotrexate treatment for oligoarticular juvenile idiopathic arthritis nonresponsive to intra-articular corticosteroids.;Q422232;P2175;Q861224
Factors associated with drug survival of methotrexate and acitretin in patients with psoriasis.;Q191924;P31;Q12140
Factors associated with drug survival of methotrexate and acitretin in patients with psoriasis.;Q341500;P31;Q12140
Factors associated with drug survival of methotrexate and acitretin in patients with psoriasis.;Q341500;P31;Q106040601
Factors associated with drug survival of methotrexate and acitretin in patients with psoriasis.;Q170545;P31;Q12140
Factors associated with drug survival of methotrexate and acitretin in patients with psoriasis.;Q422232;P31;Q12140
Combination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia.;Q422232;P2175;Q29496
High-dose methotrexate plus temozolomide as a salvage treatment in metastatic central nervous system Lymphoma: two cases report and review of literature;Q422232;P2175;Q208414
Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.;Q422232;P2175;Q208414
Cytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis;Q422232;P2175;Q170990
Cytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis;Q422232;P2175;Q187255
[Usefulness of local administration of methotrexate bound to activated carbon particles (MTX-CH)];Q186474;P527;Q623
[Usefulness of local administration of methotrexate bound to activated carbon particles (MTX-CH)];Q186521;P527;Q623
[Usefulness of local administration of methotrexate bound to activated carbon particles (MTX-CH)];Q191924;P527;Q623
[Usefulness of local administration of methotrexate bound to activated carbon particles (MTX-CH)];Q485277;P527;Q623
Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.;Q238512;P2175;Q128581
Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.;Q422232;P2175;Q128581
Intravenous methotrexate at a dose of 1 g/m2 incorporated into RCHOP prevented CNS relapse in high-risk DLBCL patients: A prospective, historic controlled study;Q422232;P2175;Q2626074
[Treatment of childhood acute lymphoblastic leukemia: efficacy of intermittent pulses of 6-mercaptopurine and methotrexate for maintenance chemotherapy, CCLSG-S811 (phase III study). Children's Cancer and Leukemia Study Group];Q422232;P2175;Q29496
Myelosuppressive and hepatotoxic potential of leflunomide and methotrexate combination in a rat model of rheumatoid arthritis.;Q248550;P2175;Q187255
Myelosuppressive and hepatotoxic potential of leflunomide and methotrexate combination in a rat model of rheumatoid arthritis.;Q248550;P2175;Q170990
Myelosuppressive and hepatotoxic potential of leflunomide and methotrexate combination in a rat model of rheumatoid arthritis.;Q422232;P2175;Q187255
Myelosuppressive and hepatotoxic potential of leflunomide and methotrexate combination in a rat model of rheumatoid arthritis.;Q422232;P2175;Q170990
[Combination therapy by bleomycin, methotrexate, and telecobalt irradiation in carcinoma of the oral cavity (author's transl)];Q422232;P636;Q285166
[Adjuvant chemotherapy with MVP-CAB (methotrexate, vincristine, cisplatinum, cyclophosphamide, adriamycin and bleomycin) for epithelial tumors of the upper urinary tract];Q412415;P527;Q880
[Stage IV gastric cancer patient who underwent palliative gastrectomy showing complete response to induction therapy with methotrexate plus 5-fluorouracil and secondary treatment with oral TS-1].;Q238512;P2175;Q189588
[Stage IV gastric cancer patient who underwent palliative gastrectomy showing complete response to induction therapy with methotrexate plus 5-fluorouracil and secondary treatment with oral TS-1].;Q422232;P636;Q285166
[Stage IV gastric cancer patient who underwent palliative gastrectomy showing complete response to induction therapy with methotrexate plus 5-fluorouracil and secondary treatment with oral TS-1].;Q422232;P2175;Q189588
Does concomitant methotrexate confer clinical benefits in patients treated with prior biologic therapy? Analysis of data from a noninterventional study of rheumatoid arthritis patients initiating treatment with adalimumab;Q348260;P2175;Q170990
Does concomitant methotrexate confer clinical benefits in patients treated with prior biologic therapy? Analysis of data from a noninterventional study of rheumatoid arthritis patients initiating treatment with adalimumab;Q348260;P2175;Q187255
Does concomitant methotrexate confer clinical benefits in patients treated with prior biologic therapy? Analysis of data from a noninterventional study of rheumatoid arthritis patients initiating treatment with adalimumab;Q422232;P2175;Q187255
Does concomitant methotrexate confer clinical benefits in patients treated with prior biologic therapy? Analysis of data from a noninterventional study of rheumatoid arthritis patients initiating treatment with adalimumab;Q422232;P2175;Q170990
A fluorine-labeled methotrexate as a probe for monitoring tumor antifolate pharmacokinetics: synthesis, in vitro cytotoxicity, and pilot in vivo 19F magnetic resonance spectra.;Q218642;P703;Q2046782
Conservative management of live tubal pregnancies by ultrasound guided potassium chloride injection and systemic methotrexate treatment;Q184630;P527;Q703
Conservative management of live tubal pregnancies by ultrasound guided potassium chloride injection and systemic methotrexate treatment;Q184630;P527;Q108200
Protection against methotrexate toxicity by a soybean protein- and omega-3 fatty acid-containing diet: comparative study with a casein-containing diet.;Q20035886;P361;Q193970
[Clinical observation on treatment of rheumatoid arthritis by combined therapy with methotrexate, sulfasalazine and Chinese herbal medicine].;Q186474;P31;Q12140
[Clinical observation on treatment of rheumatoid arthritis by combined therapy with methotrexate, sulfasalazine and Chinese herbal medicine].;Q191924;P31;Q12140
[Clinical observation on treatment of rheumatoid arthritis by combined therapy with methotrexate, sulfasalazine and Chinese herbal medicine].;Q420035;P31;Q12140
[Clinical observation on treatment of rheumatoid arthritis by combined therapy with methotrexate, sulfasalazine and Chinese herbal medicine].;Q420035;P2175;Q170990
[Clinical observation on treatment of rheumatoid arthritis by combined therapy with methotrexate, sulfasalazine and Chinese herbal medicine].;Q420035;P2175;Q187255
[Clinical observation on treatment of rheumatoid arthritis by combined therapy with methotrexate, sulfasalazine and Chinese herbal medicine].;Q422232;P2175;Q170990
[Clinical observation on treatment of rheumatoid arthritis by combined therapy with methotrexate, sulfasalazine and Chinese herbal medicine].;Q422232;P2175;Q187255
[Clinical observation on treatment of rheumatoid arthritis by combined therapy with methotrexate, sulfasalazine and Chinese herbal medicine].;Q422232;P31;Q12140
Periodontal treatment prevents arthritis in mice and methotrexate ameliorates periodontal bone loss.;Q422232;P2175;Q170990
Frequent amplification of a short chain dehydrogenase gene in methotrexate resistant Leishmania.;Q170545;P527;Q556
Resistance of mammalian tumour cells to anticancer drugs: mechanisms and concepts relating specifically to methotrexate and vincristine.;Q408977;P31;Q12140
Resistance of mammalian tumour cells to anticancer drugs: mechanisms and concepts relating specifically to methotrexate and vincristine.;Q191924;P31;Q12140
Resistance of mammalian tumour cells to anticancer drugs: mechanisms and concepts relating specifically to methotrexate and vincristine.;Q191924;P366;Q8386
Resistance of mammalian tumour cells to anticancer drugs: mechanisms and concepts relating specifically to methotrexate and vincristine.;Q173670;P31;Q12140
Resistance of mammalian tumour cells to anticancer drugs: mechanisms and concepts relating specifically to methotrexate and vincristine.;Q422232;P31;Q12140
Induction of drug-resistant bladder carcinoma cells in vitro: impact on polychemotherapy with cisplatin, methotrexate and vinblastine (CMV).;Q186474;P31;Q12140
Induction of drug-resistant bladder carcinoma cells in vitro: impact on polychemotherapy with cisplatin, methotrexate and vinblastine (CMV).;Q191924;P366;Q8386
Induction of drug-resistant bladder carcinoma cells in vitro: impact on polychemotherapy with cisplatin, methotrexate and vinblastine (CMV).;Q412415;P31;Q12140
Induction of drug-resistant bladder carcinoma cells in vitro: impact on polychemotherapy with cisplatin, methotrexate and vinblastine (CMV).;Q22124685;P31;Q12140
Induction of drug-resistant bladder carcinoma cells in vitro: impact on polychemotherapy with cisplatin, methotrexate and vinblastine (CMV).;Q483752;P31;Q12140
Induction of drug-resistant bladder carcinoma cells in vitro: impact on polychemotherapy with cisplatin, methotrexate and vinblastine (CMV).;Q484940;P31;Q12140
Induction of drug-resistant bladder carcinoma cells in vitro: impact on polychemotherapy with cisplatin, methotrexate and vinblastine (CMV).;Q422232;P31;Q12140
Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use.;Q422232;P2175;Q170990
Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use.;Q422232;P2175;Q187255
Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use.;Q422232;P2868;Q810254
Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.;Q422232;P636;Q285166
Predictive ability, validity, and responsiveness of the multi-biomarker disease activity score in patients with rheumatoid arthritis initiating methotrexate;Q422232;P2175;Q187255
Predictive ability, validity, and responsiveness of the multi-biomarker disease activity score in patients with rheumatoid arthritis initiating methotrexate;Q422232;P2175;Q170990
Antioxidant and anti-inflammatory effects of virgin coconut oil supplementation abrogate acute chemotherapy oxidative nephrotoxicity induced by anticancer drug methotrexate in rats.;Q218642;P31;Q12140
Antioxidant and anti-inflammatory effects of virgin coconut oil supplementation abrogate acute chemotherapy oxidative nephrotoxicity induced by anticancer drug methotrexate in rats.;Q191924;P31;Q12140
Antioxidant and anti-inflammatory effects of virgin coconut oil supplementation abrogate acute chemotherapy oxidative nephrotoxicity induced by anticancer drug methotrexate in rats.;Q422232;P31;Q12140
Methotrexate for rheumatoid arthritis;Q422232;P2175;Q170990
Methotrexate for rheumatoid arthritis;Q422232;P2175;Q187255
Trends towards more active introduction of drug therapy, emphasizing methotrexate and biologic agents, for juvenile idiopathic arthritis;Q186521;P31;Q12140
Trends towards more active introduction of drug therapy, emphasizing methotrexate and biologic agents, for juvenile idiopathic arthritis;Q191924;P366;Q8386
Trends towards more active introduction of drug therapy, emphasizing methotrexate and biologic agents, for juvenile idiopathic arthritis;Q422232;P31;Q12140
Trends towards more active introduction of drug therapy, emphasizing methotrexate and biologic agents, for juvenile idiopathic arthritis;Q422232;P2175;Q170990
Trends towards more active introduction of drug therapy, emphasizing methotrexate and biologic agents, for juvenile idiopathic arthritis;Q422232;P2175;Q861224
Pathological responses to preoperative high-dose methotrexate chemotherapy in osteosarcoma--experience in Korea cancer hospital;Q422232;P2175;Q549534
The effect of methotrexate (MTX) on expression of signalling lymphocytic activation molecule (SLAM) in patients with rheumatoid arthritis (RA) and its role in the regulation of cytokine production;Q422232;P2175;Q170990
The effect of methotrexate (MTX) on expression of signalling lymphocytic activation molecule (SLAM) in patients with rheumatoid arthritis (RA) and its role in the regulation of cytokine production;Q422232;P2175;Q187255
Methotrexate sodium-associated UV reactivation in a patient with acute lymphoblastic leukemia;Q422232;P2175;Q29496
Genotoxic activity of the anti-cancer drug methotrexate in somatic cells of Drosophila melanogaster.;Q191924;P31;Q12140
Genotoxic activity of the anti-cancer drug methotrexate in somatic cells of Drosophila melanogaster.;Q178450;P31;Q12140
Genotoxic activity of the anti-cancer drug methotrexate in somatic cells of Drosophila melanogaster.;Q620730;P31;Q12140
Genotoxic activity of the anti-cancer drug methotrexate in somatic cells of Drosophila melanogaster.;Q620730;P703;Q130888
Genotoxic activity of the anti-cancer drug methotrexate in somatic cells of Drosophila melanogaster.;Q422232;P31;Q12140
Summer-type hypersensitivity pneumonitis in a patient with rheumatoid arthritis on methotrexate and tacrolimus.;Q422232;P2175;Q187255
Summer-type hypersensitivity pneumonitis in a patient with rheumatoid arthritis on methotrexate and tacrolimus.;Q422232;P2175;Q170990
Methotrexate provides significant cost savings for the treatment of unruptured ectopic pregnancy.;Q422232;P2175;Q207087
Analogues of methotrexate in rheumatoid arthritis. 1. Effects of 10-deazaaminopterin analogues on type II collagen-induced arthritis in mice.;Q422232;P2175;Q170990
Analogues of methotrexate in rheumatoid arthritis. 1. Effects of 10-deazaaminopterin analogues on type II collagen-induced arthritis in mice.;Q422232;P2175;Q187255
A case of rheumatoid arthritis exhibiting accelerating rheumatoid pleurisy during low-dose weekly methotrexate therapy;Q422232;P2175;Q187255
A case of rheumatoid arthritis exhibiting accelerating rheumatoid pleurisy during low-dose weekly methotrexate therapy;Q422232;P2175;Q170990
Can low-dose methotrexate reduce effusion-synovitis and symptoms in patients with mid- to late-stage knee osteoarthritis? Study protocol for a randomised, double-blind, and placebo-controlled trial;Q422232;P2175;Q170990
Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats.;Q422232;P2175;Q170990
Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis;Q422232;P2175;Q170990
Methotrexate and rheumatoid arthritis.;Q422232;P2175;Q170990
Methotrexate and rheumatoid arthritis.;Q422232;P2175;Q187255
Predictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Predictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis.;Q422232;P2175;Q170990
MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma;Q408977;P2175;Q208414
MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma;Q408977;P2175;Q1138590
MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma;Q190875;P2959;Q26981430
MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma;Q418817;P2175;Q208414
MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma;Q418817;P2175;Q1138590
MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma;Q422232;P2175;Q1138590
MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma;Q422232;P2175;Q208414
Liver cirrhosis due to methotrexate in a patient with rheumatoid arthritis;Q422232;P2175;Q187255
Liver cirrhosis due to methotrexate in a patient with rheumatoid arthritis;Q422232;P2175;Q170990
Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.;Q186521;P31;Q12140
Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.;Q191924;P366;Q8386
Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.;Q22124685;P31;Q12140
Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.;Q422232;P2175;Q170990
Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.;Q422232;P31;Q12140
Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.;Q422232;P2175;Q187255
Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.;Q422232;P2868;Q810254
Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.;Q483745;P31;Q12140
Change in serum beta-human chorionic gonadotropin after abortion with methotrexate and misoprostol.;Q407172;P279;Q409770
Change in serum beta-human chorionic gonadotropin after abortion with methotrexate and misoprostol.;Q407172;P703;Q15978631
Change in serum beta-human chorionic gonadotropin after abortion with methotrexate and misoprostol.;Q186474;P703;Q15978631
Compliance with follow-up in an inner-city population treated with intramuscular methotrexate for suspected ectopic pregnancy.;Q422232;P2175;Q207087
Brainstem auditory pathway of children with acute lymphoid leukemia on chemotherapy with methotrexate;Q422232;P2175;Q29496
Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.;Q412415;P2175;Q549534
Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.;Q422232;P2175;Q549534
A pilot study of sequential combination chemotherapy with adriamycin and cyclophosphamide, and methotrexate, 5-fluorouracil and prednisolone in advanced breast cancer.;Q238512;P2175;Q128581
A pilot study of sequential combination chemotherapy with adriamycin and cyclophosphamide, and methotrexate, 5-fluorouracil and prednisolone in advanced breast cancer.;Q11426176;P2175;Q12078
A pilot study of sequential combination chemotherapy with adriamycin and cyclophosphamide, and methotrexate, 5-fluorouracil and prednisolone in advanced breast cancer.;Q422232;P2175;Q128581
Therapeutic outcomes of methotrexate injection in unruptured interstitial pregnancy.;Q186521;P703;Q177932
Phase II study of mitomycin C, cyclophosphamide, and methotrexate in drug-resistant colorectal carcinoma.;Q186474;P31;Q12140
Phase II study of mitomycin C, cyclophosphamide, and methotrexate in drug-resistant colorectal carcinoma.;Q191924;P366;Q8386
Phase II study of mitomycin C, cyclophosphamide, and methotrexate in drug-resistant colorectal carcinoma.;Q19856779;P31;Q12140
Phase II study of mitomycin C, cyclophosphamide, and methotrexate in drug-resistant colorectal carcinoma.;Q19856779;P1889;Q417625
Phase II study of mitomycin C, cyclophosphamide, and methotrexate in drug-resistant colorectal carcinoma.;Q20035886;P31;Q12140
Phase II study of mitomycin C, cyclophosphamide, and methotrexate in drug-resistant colorectal carcinoma.;Q484940;P31;Q12140
Phase II study of mitomycin C, cyclophosphamide, and methotrexate in drug-resistant colorectal carcinoma.;Q422232;P31;Q12140
Conservative treatment of ectopic pregnancy with intramuscular administration of methotrexate (MTX/CV).;Q422232;P2175;Q207087
Pharmacological conditioning for juvenile idiopathic arthritis: a potential solution to reduce methotrexate intolerance;Q422232;P2175;Q861224
Pharmacological conditioning for juvenile idiopathic arthritis: a potential solution to reduce methotrexate intolerance;Q422232;P2175;Q170990
Transport of the folate compound methotrexate decreases during differentiation of murine erythroleukemia cells.;Q186521;P31;Q11173
Transport of the folate compound methotrexate decreases during differentiation of murine erythroleukemia cells.;Q191924;P31;Q11173
Transport of the folate compound methotrexate decreases during differentiation of murine erythroleukemia cells.;Q422232;P2175;Q29496
Transport of the folate compound methotrexate decreases during differentiation of murine erythroleukemia cells.;Q422232;P31;Q11173
Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia;Q422232;P636;Q285166
Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia;Q422232;P2175;Q29496
Methotrexate pneumonitis after systemic treatment for ectopic pregnancy.;Q422232;P2175;Q207087
Management of separation pain after single-dose methotrexate therapy for ectopic pregnancy.;Q422232;P2175;Q207087
Possible mechanisms of action of methotrexate in patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Possible mechanisms of action of methotrexate in patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Comment on: A randomized placebo-controlled trial of methotrexate in psoriatic arthritis: reply.;Q422232;P2175;Q170990
The sequence of application of methotrexate and histone deacetylase inhibitors determines either a synergistic or an antagonistic response in childhood acute lymphoblastic leukemia cells.;Q422232;P2175;Q29496
Treatment of Primary Central Nervous System Lymphoma with High-dose Methotrexate and Radiotherapy in HIV-negative Patients.;Q422232;P2175;Q136312
Treatment of Primary Central Nervous System Lymphoma with High-dose Methotrexate and Radiotherapy in HIV-negative Patients.;Q422232;P2175;Q208414
Methotrexate dose-escalation studies in transgenic mice and marrow transplant recipients expressing drug-resistant dihydrofolate reductase activity.;Q191924;P31;Q12140
Methotrexate dose-escalation studies in transgenic mice and marrow transplant recipients expressing drug-resistant dihydrofolate reductase activity.;Q22124685;P31;Q12140
Methotrexate dose-escalation studies in transgenic mice and marrow transplant recipients expressing drug-resistant dihydrofolate reductase activity.;Q422232;P31;Q12140
Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line.;Q218642;P703;Q15978631
Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line.;Q186474;P703;Q15978631
Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line.;Q173670;P703;Q15978631
Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line.;Q20035886;P703;Q15978631
Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line.;Q620730;P703;Q15978631
Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line.;Q483745;P703;Q15978631
Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line.;Q422232;P2175;Q128581
[Treatment with methotrexate in a patient with subglottic stenosis as initial manifestation of limited Wegener granulomatosis].;Q422232;P2175;Q1161568
Reversal of methotrexate toxicity in mice by 5-methyltetrahydrofolic acid.;Q422232;P2868;Q127060
Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis.;Q422232;P2175;Q170990
Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis.;Q422232;P2175;Q187255
Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy;Q422232;P2175;Q208414
Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy;Q422232;P2175;Q136312
Efficacy of methotrexate and tumor necrosis factor inhibitors in Japanese patients with active psoriatic arthritis.;Q422232;P2175;Q170990
Burgdorf's reaction (painful acral erythema) in patients with acute lymphoblastic leukemia following medium-dose methotrexate therapy;Q422232;P2175;Q29496
Temporal profiles of synaptic plasticity-related signals in adult mouse hippocampus with methotrexate treatment.;Q422232;P636;Q285166
Uracil-tegafur and tamoxifen versus cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in postoperative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study.;Q412178;P2175;Q128581
Uracil-tegafur and tamoxifen versus cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in postoperative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study.;Q238512;P2175;Q128581
Uracil-tegafur and tamoxifen versus cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in postoperative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study.;Q422232;P2175;Q128581
[Induction of sister chromatid exchange (SCE) and incorporation of BUdR in mouse cells treated with methotrexate];Q186474;P703;Q83310
Treatment for Low-Risk Gestational Trophoblastic Disease: Comparison of Single-Agent Methotrexate, Dactinomycin and Combination Regimens;Q186127;P279;Q343465
Development of myeloid sarcoma after long-term methotrexate use for rheumatoid arthritis.;Q422232;P2175;Q187255
Development of myeloid sarcoma after long-term methotrexate use for rheumatoid arthritis.;Q422232;P2175;Q170990
Coexistence of reversible cerebral neurotoxicity and irreversible cerebellar atrophy following an intrathecal methotrexate chemotherapy: two case reports.;Q191924;P2868;Q407752
Coexistence of reversible cerebral neurotoxicity and irreversible cerebellar atrophy following an intrathecal methotrexate chemotherapy: two case reports.;Q422232;P636;Q1320251
Identification of impurities in methotrexate drug substances using high-performance liquid chromatography coupled with a photodiode array detector and Fourier transform ion cyclotron resonance mass spectrometry.;Q191924;P366;Q8386
Identification of impurities in methotrexate drug substances using high-performance liquid chromatography coupled with a photodiode array detector and Fourier transform ion cyclotron resonance mass spectrometry.;Q170545;P31;Q12140
Identification of impurities in methotrexate drug substances using high-performance liquid chromatography coupled with a photodiode array detector and Fourier transform ion cyclotron resonance mass spectrometry.;Q484940;P31;Q12140
Identification of impurities in methotrexate drug substances using high-performance liquid chromatography coupled with a photodiode array detector and Fourier transform ion cyclotron resonance mass spectrometry.;Q422232;P31;Q12140
Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Re;Q18936;P2175;Q208414
Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Re;Q18936;P2175;Q53660452
Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Re;Q18936;P2175;Q4833719
Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Re;Q408977;P2175;Q208414
Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Re;Q408977;P2175;Q4833719
Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Re;Q412323;P2175;Q208414
Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Re;Q412323;P2175;Q4833719
Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Re;Q424972;P2175;Q12078
Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Re;Q424972;P2175;Q4833719
Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Re;Q422232;P2175;Q208414
Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Re;Q422232;P2175;Q4833719
Effects of acute or chronic exposure to dietary organic anions on secretion of methotrexate and salicylate by Malpighian tubules of Drosophila melanogaster larvae.;Q193572;P4149;Q3469744
Methotrexate in childhood arthritis: effects on gene expression.;Q422232;P2175;Q170990
[The risk profile of low-dose methotrexate in the therapy of chronic polyarthritis];Q422232;P2175;Q170990
[The risk profile of low-dose methotrexate in the therapy of chronic polyarthritis];Q422232;P2175;Q1274464
Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure.;Q186474;P31;Q12140
Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure.;Q186474;P703;Q15978631
Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure.;Q191924;P31;Q12140
Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure.;Q170545;P31;Q12140
Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure.;Q170545;P703;Q15978631
Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure.;Q139347;P31;Q12140
Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure.;Q139347;P703;Q15978631
Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure.;Q173670;P31;Q12140
Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure.;Q173670;P703;Q15978631
Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure.;Q22124685;P31;Q12140
Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure.;Q22124685;P703;Q15978631
Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure.;Q422232;P2175;Q29496
Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure.;Q422232;P31;Q12140
Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?;Q23118;P31;Q8386
Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?;Q191924;P31;Q12140
Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?;Q191924;P366;Q8386
Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?;Q178450;P31;Q12140
Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?;Q484940;P31;Q12140
Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?;Q422232;P31;Q12140
It's not all about the CNS. High dose methotrexate in DLBCL;Q422232;P2175;Q2626074
Should methotrexate be a first-line treatment for rheumatoid arthritis?;Q422232;P2175;Q170990
Should methotrexate be a first-line treatment for rheumatoid arthritis?;Q422232;P2175;Q187255
Reprint of: The medical treatment of unruptured ectopic pregnancy with methotrexate and citrovorum rescue: preliminary experience;Q422232;P2175;Q207087
Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study;Q422232;P2175;Q187255
Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study;Q422232;P2175;Q170990
GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis;Q422232;P2175;Q170990
A low-affinity binder for methotrexate in human leukaemia cells.;Q218642;P703;Q15978631
A low-affinity binder for methotrexate in human leukaemia cells.;Q422232;P2175;Q29496
Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial;Q422232;P2175;Q170990
Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial;Q422232;P2175;Q187255
Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study;Q422232;P2175;Q29496
Initial experience combining methotrexate with biologic agents for treating rheumatoid arthritis.;Q422232;P2175;Q170990
Initial experience combining methotrexate with biologic agents for treating rheumatoid arthritis.;Q422232;P2175;Q187255
Prospective study of methotrexate treatment for rheumatoid arthritis treated legitimately according to the government recommended 8 mg/week dose.;Q422232;P2175;Q170990
Prospective study of methotrexate treatment for rheumatoid arthritis treated legitimately according to the government recommended 8 mg/week dose.;Q422232;P2175;Q187255
Implementation study of patient-ready syringes containing 25 mg/mL methotrexate solution for use in treating ectopic pregnancy;Q422232;P2175;Q207087
The DNA damage checkpoint is activated during residual tumour cell survival to methotrexate treatment as an initial step of acquired drug resistance.;Q218642;P31;Q12140
The DNA damage checkpoint is activated during residual tumour cell survival to methotrexate treatment as an initial step of acquired drug resistance.;Q186521;P31;Q12140
The DNA damage checkpoint is activated during residual tumour cell survival to methotrexate treatment as an initial step of acquired drug resistance.;Q191924;P366;Q8386
The DNA damage checkpoint is activated during residual tumour cell survival to methotrexate treatment as an initial step of acquired drug resistance.;Q178450;P31;Q12140
The DNA damage checkpoint is activated during residual tumour cell survival to methotrexate treatment as an initial step of acquired drug resistance.;Q422232;P31;Q12140
Methotrexate : Side effects and the role of folic acid supplementation in psoriasis - A study;Q422232;P2868;Q127060
Notch-1 siRNA and Methotrexate towards a Multifunctional Approach in Rhematoid Arthritis Management: a Nanomedicine Approach;Q218642;P31;Q12140
Notch-1 siRNA and Methotrexate towards a Multifunctional Approach in Rhematoid Arthritis Management: a Nanomedicine Approach;Q173670;P31;Q12140
Notch-1 siRNA and Methotrexate towards a Multifunctional Approach in Rhematoid Arthritis Management: a Nanomedicine Approach;Q22124685;P31;Q12140
Notch-1 siRNA and Methotrexate towards a Multifunctional Approach in Rhematoid Arthritis Management: a Nanomedicine Approach;Q422232;P31;Q12140
Sarcoidal anemia and leukopenia treated with methotrexate and mycophenolate mofetil.;Q130336;P31;Q407142
Sarcoidal anemia and leukopenia treated with methotrexate and mycophenolate mofetil.;Q130336;P4149;Q27122100
Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis.;Q422232;P2175;Q170990
Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis.;Q422232;P2175;Q187255
[Increased secretion of vasopressin and edema formation in high dosage methotrexate therapy];Q183011;P31;Q66571917
Bilateral tubal ectopic pregnancy and failed methotrexate therapy: a case report;Q422232;P2175;Q207087
Low-voltage electrochemotherapy with low-dose methotrexate enhances survival in mice with osteosarcoma;Q422232;P2175;Q549534
Methotrexate and rheumatoid arthritis associated interstitial lung disease;Q422232;P2175;Q187255
Methotrexate and rheumatoid arthritis associated interstitial lung disease;Q422232;P2175;Q170990
No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis;Q422232;P2175;Q170990
No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis;Q422232;P2175;Q187255
No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis;Q422232;P2868;Q810254
Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false-positive report probability;Q422232;P2175;Q170990
Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false-positive report probability;Q422232;P2175;Q187255
[Conservative treatment of ectopic pregnancy with methotrexate];Q422232;P2175;Q207087
Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Szary Syndrome;Q422232;P2175;Q1891209
Patient with rheumatoid arthritis on methotrexate with multiple infecting organisms causing gastritis.;Q422232;P2175;Q187255
Patient with rheumatoid arthritis on methotrexate with multiple infecting organisms causing gastritis.;Q422232;P2175;Q170990
[How to effectively use methotrexate in rheumatoid arthritis?];Q422232;P2175;Q170990
[How to effectively use methotrexate in rheumatoid arthritis?];Q422232;P2175;Q187255
[The importance of dose intensity in preoperative chemotherapy for osteosarcoma--retrospective analysis of a short intensive chemotherapy regimen preoperatively using high-dose methotrexate and cisplatinum];Q412415;P527;Q880
[The importance of dose intensity in preoperative chemotherapy for osteosarcoma--retrospective analysis of a short intensive chemotherapy regimen preoperatively using high-dose methotrexate and cisplatinum];Q412415;P2175;Q549534
[The importance of dose intensity in preoperative chemotherapy for osteosarcoma--retrospective analysis of a short intensive chemotherapy regimen preoperatively using high-dose methotrexate and cisplatinum];Q422232;P2175;Q549534
Effect of ursodeoxycholic acid and vitamin E in the prevention of liver injury from methotrexate in pediatric leukemia;Q422232;P2175;Q29496
Regression of human melanoma xenografts in nude mice injected with methotrexate linked to monoclonal antibody 225.28 to human high molecular weight-melanoma associated antigen.;Q173670;P703;Q15978631
Impact of methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy in patients with lymph node metastases from transitional cell carcinoma of the lower urinary tract.;Q412415;P2175;Q2501186
Xenobiotics or biological response modifiers? Methotrexate remains the anchor drug for rheumatoid arthritis;Q22124685;P31;Q12140
Xenobiotics or biological response modifiers? Methotrexate remains the anchor drug for rheumatoid arthritis;Q422232;P31;Q12140
Xenobiotics or biological response modifiers? Methotrexate remains the anchor drug for rheumatoid arthritis;Q422232;P2175;Q187255
Xenobiotics or biological response modifiers? Methotrexate remains the anchor drug for rheumatoid arthritis;Q422232;P2175;Q170990
Cytotoxicity, uptake, polyglutamate formation, and antileukemic effects of 8-deaza analogues of methotrexate and aminopterin in mice.;Q186474;P703;Q83310
[Personal experience with methotrexate in the treatment of idiopathic juvenile arthritis];Q422232;P2175;Q170990
Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats.;Q422232;P2175;Q170990
Comparative study on methotrexate and hydroxychloroquine in the treatment of rheumatoid arthritis.;Q421094;P1889;Q422438
Comparative study on methotrexate and hydroxychloroquine in the treatment of rheumatoid arthritis.;Q421094;P2175;Q170990
Comparative study on methotrexate and hydroxychloroquine in the treatment of rheumatoid arthritis.;Q421094;P2175;Q187255
Comparative study on methotrexate and hydroxychloroquine in the treatment of rheumatoid arthritis.;Q422438;P1889;Q421094
Comparative study on methotrexate and hydroxychloroquine in the treatment of rheumatoid arthritis.;Q422438;P2175;Q187255
Comparative study on methotrexate and hydroxychloroquine in the treatment of rheumatoid arthritis.;Q422232;P2175;Q170990
Comparative study on methotrexate and hydroxychloroquine in the treatment of rheumatoid arthritis.;Q422232;P2175;Q187255
High methotrexate exposure and toxicity in children with t(9:22) positive acute lymphoblastic leukaemia treated with imatinib;Q177094;P2175;Q29496
High methotrexate exposure and toxicity in children with t(9:22) positive acute lymphoblastic leukaemia treated with imatinib;Q422232;P2175;Q29496
Methotrexate versus combination methotrexate and etanercept for rheumatoid arthritis.;Q422232;P2175;Q187255
Methotrexate versus combination methotrexate and etanercept for rheumatoid arthritis.;Q422232;P2175;Q170990
Ultrasound assessment of enthesis thickening in psoriatic arthritis patients treated with adalimumab compared to methotrexate;Q348260;P2175;Q170990
Ultrasound assessment of enthesis thickening in psoriatic arthritis patients treated with adalimumab compared to methotrexate;Q422232;P2175;Q170990
Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis;Q422232;P361;Q14819383
Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis;Q422232;P2175;Q170990
Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis;Q422232;P2175;Q187255
Methotrexate exacerbates tumor progression in a murine model of chronic myeloid leukemia.;Q422232;P2175;Q29496
[Combination chemotherapy with methotrexate, endoxan, and vincristine (M.E.V.) in the treatment of non-Hodgkin's lymphoma (author's transl)].;Q408977;P2175;Q208414
[Combination chemotherapy with methotrexate, endoxan, and vincristine (M.E.V.) in the treatment of non-Hodgkin's lymphoma (author's transl)].;Q408977;P2175;Q1138590
[Combination chemotherapy with methotrexate, endoxan, and vincristine (M.E.V.) in the treatment of non-Hodgkin's lymphoma (author's transl)].;Q422232;P2175;Q208414
[Combination chemotherapy with methotrexate, endoxan, and vincristine (M.E.V.) in the treatment of non-Hodgkin's lymphoma (author's transl)].;Q422232;P2175;Q1138590
Schedule-dependent in vitro combination effects of methotrexate and 5-fluorouracil in human tumor cell lines.;Q183290;P703;Q15978631
An EORTC gastrointestinal (GI) group randomized evaluation of the toxicity of sequential high dose methotrexate and 5-fluorouracil combined with adriamycin (FAMTX) vs 5-fluorouracil, adriamycin and mitomycin (FAM) in advanced gastric cancer.;Q238512;P2175;Q189588
An EORTC gastrointestinal (GI) group randomized evaluation of the toxicity of sequential high dose methotrexate and 5-fluorouracil combined with adriamycin (FAMTX) vs 5-fluorouracil, adriamycin and mitomycin (FAM) in advanced gastric cancer.;Q19856779;P1889;Q417625
An EORTC gastrointestinal (GI) group randomized evaluation of the toxicity of sequential high dose methotrexate and 5-fluorouracil combined with adriamycin (FAMTX) vs 5-fluorouracil, adriamycin and mitomycin (FAM) in advanced gastric cancer.;Q422232;P2175;Q189588
Adverse drug reaction to methotrexate: pharmacogenetic origin.;Q218642;P31;Q12140
Adverse drug reaction to methotrexate: pharmacogenetic origin.;Q191924;P31;Q12140
Adverse drug reaction to methotrexate: pharmacogenetic origin.;Q422232;P31;Q12140
Mitoxantrone, methotrexate, and 5-fluorouracil combination chemotherapy as first-line treatment in stage IV breast cancer.;Q238512;P2175;Q128581
Mitoxantrone, methotrexate, and 5-fluorouracil combination chemotherapy as first-line treatment in stage IV breast cancer.;Q239426;P2175;Q128581
Mitoxantrone, methotrexate, and 5-fluorouracil combination chemotherapy as first-line treatment in stage IV breast cancer.;Q422232;P2175;Q128581
Mild preconditioning and low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate reductase activity.;Q191924;P31;Q12140
Mild preconditioning and low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate reductase activity.;Q22124685;P31;Q12140
Mild preconditioning and low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate reductase activity.;Q422232;P31;Q12140
MTHFR polymorphism and red cell folate levels are not useful as biomarkers of methotrexate efficacy and toxicity in children with juvenile idiopathic arthritis.;Q422232;P2175;Q170990
MTHFR polymorphism and red cell folate levels are not useful as biomarkers of methotrexate efficacy and toxicity in children with juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Methotrexate in rheumatoid arthritis: an update.;Q422232;P2175;Q170990
Methotrexate in rheumatoid arthritis: an update.;Q422232;P2175;Q187255
Treatment of refractory and relapsed non-Hodgkin's lymphoma with ifosfamide, methotrexate and etoposide.;Q418817;P2175;Q208414
Treatment of refractory and relapsed non-Hodgkin's lymphoma with ifosfamide, methotrexate and etoposide.;Q418817;P2175;Q1138590
Treatment of refractory and relapsed non-Hodgkin's lymphoma with ifosfamide, methotrexate and etoposide.;Q422232;P2175;Q208414
Treatment of refractory and relapsed non-Hodgkin's lymphoma with ifosfamide, methotrexate and etoposide.;Q422232;P2175;Q1138590
Methotrexate in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatoid and nonrheumatic disorders.;Q422232;P2175;Q170990
Methotrexate in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatoid and nonrheumatic disorders.;Q422232;P2175;Q861224
Methotrexate in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatoid and nonrheumatic disorders.;Q422232;P2175;Q187255
The role of day 0 and day 4 -human chorionic gonadotropin values and initial ultrasound findings in predicting the success of methotrexate treatment in ectopic pregnancy;Q407172;P279;Q409770
The role of day 0 and day 4 -human chorionic gonadotropin values and initial ultrasound findings in predicting the success of methotrexate treatment in ectopic pregnancy;Q407172;P703;Q15978631
The role of day 0 and day 4 -human chorionic gonadotropin values and initial ultrasound findings in predicting the success of methotrexate treatment in ectopic pregnancy;Q186521;P703;Q15978631
The role of day 0 and day 4 -human chorionic gonadotropin values and initial ultrasound findings in predicting the success of methotrexate treatment in ectopic pregnancy;Q422232;P2175;Q207087
Methotrexate and Thioguanine Rescue Therapy for Conventional Thiopurine Failing Ulcerative Colitis Patients: A Multi-center Database Study on Tolerability and Effectiveness;Q422232;P2175;Q1477
Adverse effects of intrathecal methotrexate in children with acute leukemia in remission.;Q422232;P2175;Q29496
Adverse effects of intrathecal methotrexate in children with acute leukemia in remission.;Q422232;P636;Q1320251
A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line che;Q412323;P2175;Q208414
A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line che;Q11426176;P2175;Q208414
A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line che;Q418817;P2175;Q208414
A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line che;Q422232;P2175;Q208414
Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritis.;Q422232;P2175;Q170990
Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritis.;Q422232;P2175;Q187255
Leukoencephalopathy in a patient taking low dose oral methotrexate therapy for rheumatoid arthritis.;Q422232;P636;Q285166
Leukoencephalopathy in a patient taking low dose oral methotrexate therapy for rheumatoid arthritis.;Q422232;P2175;Q170990
Leukoencephalopathy in a patient taking low dose oral methotrexate therapy for rheumatoid arthritis.;Q422232;P2175;Q187255
Intra-articular treatment of inflammatory arthritis with microsphere formulations of methotrexate: pharmacokinetics and efficacy determination in antigen-induced arthritic rabbits.;Q422232;P2175;Q170990
Palliative low dose fortnightly methotrexate in oral cancer.;Q422232;P636;Q285166
Composite Cutaneous Lymphoma (Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorder) in a Patient with Rheumatoid Arthritis Treated with Methotrexate: Staging and Evaluation of Response to Therapy with 18F-FDG PET/CT.;Q422232;P2175;Q208414
Association of altered folylpolyglutamate synthetase pre-mRNA splicing with methotrexate unresponsiveness in early rheumatoid arthritis;Q422232;P2175;Q170990
Association of altered folylpolyglutamate synthetase pre-mRNA splicing with methotrexate unresponsiveness in early rheumatoid arthritis;Q422232;P2175;Q187255
Immunogenicity and safety of the inactivated hepatitis A vaccine in children with juvenile idiopathic arthritis on methotrexate treatment: a matched case-control study.;Q422232;P2175;Q170990
Immunogenicity and safety of the inactivated hepatitis A vaccine in children with juvenile idiopathic arthritis on methotrexate treatment: a matched case-control study.;Q422232;P2175;Q861224
Methotrexate upregulates circadian transcriptional factors PAR bZIP to induce apoptosis on rheumatoid arthritis synovial fibroblasts.;Q422232;P2175;Q170990
Methotrexate upregulates circadian transcriptional factors PAR bZIP to induce apoptosis on rheumatoid arthritis synovial fibroblasts.;Q422232;P2175;Q187255
Adjuvant cyclophosphamide, methotrexate and 5-fluorouracil versus cyclophosphamide plus futraful for premenopausal patients with stage I-II and one- to three-node-positive breast cancer: results of a prospective randomized study;Q238512;P2175;Q128581
Adjuvant cyclophosphamide, methotrexate and 5-fluorouracil versus cyclophosphamide plus futraful for premenopausal patients with stage I-II and one- to three-node-positive breast cancer: results of a prospective randomized study;Q422232;P2175;Q128581
Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate;Q191924;P31;Q12140
Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate;Q173670;P31;Q12140
Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate;Q20035886;P31;Q12140
Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate;Q22124685;P31;Q12140
Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate;Q484940;P31;Q12140
Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate;Q422232;P31;Q12140
Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate;Q422232;P636;Q285166
Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate;Q422232;P2175;Q128581
[Radiological case of the month. Leukoencephalopathy caused by methotrexate in a child treated for acute lymphoblastic leukemia];Q422232;P2175;Q29496
Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin.;Q412415;P2175;Q18348812
Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin.;Q238512;P2175;Q18348812
Low dose methotrexate osteopathy in a patient with polyarticular juvenile idiopathic arthritis.;Q422232;P2175;Q170990
Low dose methotrexate osteopathy in a patient with polyarticular juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma.;Q422232;P2175;Q549534
[Efficacy and side effects of methotrexate in the treatment of ectopic pregnancy].;Q422232;P2175;Q207087
Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.;Q420035;P2175;Q170990
Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.;Q420035;P2175;Q187255
Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.;Q422232;P2175;Q170990
Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.;Q422232;P2175;Q187255
Degradation and clearance of methotrexate in children with osteosarcoma receiving high-dose infusion.;Q422232;P2175;Q549534
Association of MTHFR C677T and A1298C gene polymorphisms with methotrexate efficiency and toxicity in Algerian rheumatoid arthritis patients.;Q422232;P2175;Q187255
Association of MTHFR C677T and A1298C gene polymorphisms with methotrexate efficiency and toxicity in Algerian rheumatoid arthritis patients.;Q422232;P2175;Q170990
Is concomitant use of methotrexate and oral retinoids dangerous? A review of the data regarding this combination.;Q422232;P636;Q285166
Cytomegalovirus pneumonia in a patient with rheumatoid arthritis treated with low dose methotrexate and prednisone.;Q424972;P2175;Q170990
Cytomegalovirus pneumonia in a patient with rheumatoid arthritis treated with low dose methotrexate and prednisone.;Q422232;P2175;Q170990
Cytomegalovirus pneumonia in a patient with rheumatoid arthritis treated with low dose methotrexate and prednisone.;Q422232;P2175;Q187255
Methotrexate intolerance in oral and subcutaneous administration in patients with juvenile idiopathic arthritis: a cross-sectional, observational study.;Q422232;P636;Q285166
Methotrexate intolerance in oral and subcutaneous administration in patients with juvenile idiopathic arthritis: a cross-sectional, observational study.;Q422232;P2175;Q861224
Methotrexate intolerance in oral and subcutaneous administration in patients with juvenile idiopathic arthritis: a cross-sectional, observational study.;Q422232;P2175;Q170990
Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M);Q18936;P2175;Q208414
Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M);Q18936;P2175;Q4833719
Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M);Q408977;P2175;Q4833719
Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M);Q408977;P2175;Q208414
Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M);Q424972;P2175;Q4833719
Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M);Q422232;P2175;Q4833719
Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M);Q422232;P2175;Q208414
Maintenance therapy of intermittent high-dose methotrexate in acute childhood leukemia--4-year survivals.;Q422232;P2175;Q29496
Methotrexate and trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis;Q422665;P2175;Q7205993
Fertility outcome following combined methotrexate treatment of unruptured extrauterine pregnancy.;Q422232;P2175;Q207087
[Controlled ultra-high dosage methotrexate therapy in three patients with metastatic osteosarcoma (author's transl)];Q422232;P2175;Q549534
[Combination chemotherapy with methotrexate (MTX), vincristine (VCR), cisplatinum (CDDP), cyclophosphamide (CPM), adriamycin (ADM), and bleomycin (BLM): MVP-CAB in patients with advanced urothelial tract cancer];Q412415;P527;Q880
Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience;Q422232;P2175;Q208414
Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience;Q422232;P2175;Q136312
Significant interaction between high-dose methotrexate and high-dose piperacillin-tazobactam causing reversible neurotoxicity and renal failure in an osteosarcoma patient;Q191924;P2868;Q407752
Significant interaction between high-dose methotrexate and high-dose piperacillin-tazobactam causing reversible neurotoxicity and renal failure in an osteosarcoma patient;Q422232;P2175;Q549534
Lipophilic conjugates of methotrexate with short-chain alkylamino acids as DHFR inhibitors. Synthesis, biological evaluation, and molecular modeling.;Q485277;P279;Q8066
Lipophilic conjugates of methotrexate with short-chain alkylamino acids as DHFR inhibitors. Synthesis, biological evaluation, and molecular modeling.;Q173670;P31;Q8066
Lipophilic conjugates of methotrexate with short-chain alkylamino acids as DHFR inhibitors. Synthesis, biological evaluation, and molecular modeling.;Q178450;P31;Q8066
A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities.;Q191924;P2868;Q407752
Etoposide, Methotrexate, and Dactinomycin Alternating With Cyclophosphamide and Vincristine (EMACO) for Male Patients With HCG-expressing, Chemoresistant Germ Cell Tumors;Q186127;P279;Q343465
Branch retinal artery occlusion in a patient undergoing Methotrexate therapy for ectopic pregnancy: A case report;Q422232;P2175;Q207087
Flow cytometric studies of methotrexate resistance in human squamous carcinoma cell cultures.;Q170545;P703;Q15978631
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 tria;Q18936;P2175;Q208414
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 tria;Q18936;P2175;Q4833719
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 tria;Q408977;P2175;Q208414
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 tria;Q408977;P2175;Q4833719
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 tria;Q11426176;P2175;Q4833719
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 tria;Q11426176;P2175;Q208414
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 tria;Q422232;P2175;Q208414
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 tria;Q422232;P2175;Q4833719
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 tria;Q422232;P636;Q1320251
Recommendations by the Spanish Society of Rheumatology for the management of patients diagnosed with rheumatoid arthritis who cannot be treated with methotrexate;Q422232;P2175;Q170990
Recommendations by the Spanish Society of Rheumatology for the management of patients diagnosed with rheumatoid arthritis who cannot be treated with methotrexate;Q422232;P2175;Q187255
The effect of methotrexate and sulfasalazine on the course of HLA-B27-positive anterior uveitis: results from a retrospective cohort study;Q422232;P2175;Q280027
AZT: a biochemical response modifier of methotrexate and 5-fluorouracil cytotoxicity in human ovarian and pancreatic carcinoma cells.;Q218642;P703;Q15978631
AZT: a biochemical response modifier of methotrexate and 5-fluorouracil cytotoxicity in human ovarian and pancreatic carcinoma cells.;Q186521;P703;Q15978631
[Methotrexate combined with leflunomide or hydroxychloroquine in the treatment of rheumatoid arteritis].;Q421094;P1889;Q422438
[Methotrexate combined with leflunomide or hydroxychloroquine in the treatment of rheumatoid arteritis].;Q422438;P1889;Q421094
Intrarticular methotrexate in the therapy of rheumatoid arthritis.;Q422232;P2175;Q170990
Intrarticular methotrexate in the therapy of rheumatoid arthritis.;Q422232;P2175;Q187255
Sarcoidosis following adjuvant high-dose methotrexate therapy for osteosarcoma.;Q422232;P2175;Q549534
Methotrexate use, not interleukin 33, is associated with lower carotid intima-media thickness in patients with rheumatoid arthritis;Q422232;P2175;Q170990
Methotrexate use, not interleukin 33, is associated with lower carotid intima-media thickness in patients with rheumatoid arthritis;Q422232;P2175;Q187255
[Relapsed primary intraocular lymphoma treated with intravitreal methotrexate and high-dose chemotherapy followed by autologous stem cell rescue];Q422232;P2175;Q208414
Ruptured ectopic pregnancy with a negative urinary pregnancy test after methotrexate treatment - challenges of diagnosis in the emergency department;Q422232;P2175;Q207087
Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone;Q18936;P3780;Q47520887
Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone;Q19856779;P1889;Q417625
Methotrexate infusions as central nervous system prophylaxis in children with acute lymphocytic leukemia: the Norwegian experience;Q422232;P2175;Q29496
Severe intra-abdominal bleeding from neglected omental implantation of ectopic tissue after methotrexate treatment for persistent ectopic pregnancy;Q422232;P2175;Q207087
Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma melatonin and chosen hormones in breast cancer premenopausal patients.;Q238512;P2175;Q128581
Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma melatonin and chosen hormones in breast cancer premenopausal patients.;Q180912;P31;Q11364
Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma melatonin and chosen hormones in breast cancer premenopausal patients.;Q422232;P2175;Q128581
[Combination chemotherapy with cisplatin and methotrexate in advanced bladder cancer];Q412415;P2175;Q504775
Bilateral septic knee arthritis after treatment of an ectopic pregnancy with methotrexate;Q422232;P2175;Q207087
Bilateral septic knee arthritis after treatment of an ectopic pregnancy with methotrexate;Q422232;P2175;Q170990
Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis.;Q180983;P2175;Q208414
Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis.;Q422232;P2175;Q208414
A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in postmenopausal female patients with rheumatoid arthritis taking methotrexate;Q422232;P636;Q285166
A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in postmenopausal female patients with rheumatoid arthritis taking methotrexate;Q422232;P2175;Q187255
A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in postmenopausal female patients with rheumatoid arthritis taking methotrexate;Q422232;P2175;Q170990
The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in normal and tumor-bearing mice: a microdialysis study.;Q186521;P31;Q12140
The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in normal and tumor-bearing mice: a microdialysis study.;Q191924;P366;Q8386
The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in normal and tumor-bearing mice: a microdialysis study.;Q422232;P31;Q12140
Comparison of methotrexate (NSC-740) and testosterone propionate (NSC-9166) in the treatment of breast cancer.;Q422232;P2175;Q128581
[Adverse effects of methotrexate in the treatment of acute lymphoblastic leukemia in Uyghur and Han children].;Q422232;P2175;Q29496
Population pharmacokinetic study of methotrexate in children with acute lymphoblastic leukemia.;Q422232;P2175;Q29496
Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation.;Q411648;P2175;Q1194520
Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation.;Q11426176;P2175;Q1194520
Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation.;Q417222;P2175;Q1194520
Histological and biochemical considerations in the treatment of oral cancer with preoperative methotrexate infusion.;Q422232;P636;Q285166
Renal impairment following the combined use of high-dose methotrexate and procarbazine.;Q191924;P769;Q418656
Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate;Q422232;P2175;Q170990
APL-1, an altered peptide ligand derived from heat-shock protein, alone or combined with methotrexate attenuates murine collagen-induced arthritis.;Q422232;P2175;Q170990
[Clinical Therapeutic Efficacy of Rituximab Combined with Methotrexate on Primary Central Nervous System Lymphoma].;Q183290;P703;Q177932
[Clinical Therapeutic Efficacy of Rituximab Combined with Methotrexate on Primary Central Nervous System Lymphoma].;Q186474;P703;Q177932
[Clinical Therapeutic Efficacy of Rituximab Combined with Methotrexate on Primary Central Nervous System Lymphoma].;Q186521;P703;Q177932
[Clinical Therapeutic Efficacy of Rituximab Combined with Methotrexate on Primary Central Nervous System Lymphoma].;Q173670;P703;Q177932
[Clinical Therapeutic Efficacy of Rituximab Combined with Methotrexate on Primary Central Nervous System Lymphoma].;Q20035886;P703;Q177932
[Clinical Therapeutic Efficacy of Rituximab Combined with Methotrexate on Primary Central Nervous System Lymphoma].;Q22124685;P703;Q177932
[Clinical Therapeutic Efficacy of Rituximab Combined with Methotrexate on Primary Central Nervous System Lymphoma].;Q422232;P2175;Q136312
[Clinical Therapeutic Efficacy of Rituximab Combined with Methotrexate on Primary Central Nervous System Lymphoma].;Q422232;P2175;Q208414
[Clinical Therapeutic Efficacy of Rituximab Combined with Methotrexate on Primary Central Nervous System Lymphoma].;Q483745;P703;Q177932
Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia;Q422232;P2175;Q29496
Effect of immunosuppressive drugs (6-mercaptopurine and methotrexate) on resistance of Chinese hamsters to the tissue phase of Trichinella spiralis.;Q186474;P31;Q12140
Effect of immunosuppressive drugs (6-mercaptopurine and methotrexate) on resistance of Chinese hamsters to the tissue phase of Trichinella spiralis.;Q186521;P31;Q12140
Effect of immunosuppressive drugs (6-mercaptopurine and methotrexate) on resistance of Chinese hamsters to the tissue phase of Trichinella spiralis.;Q191924;P366;Q8386
Effect of immunosuppressive drugs (6-mercaptopurine and methotrexate) on resistance of Chinese hamsters to the tissue phase of Trichinella spiralis.;Q418529;P31;Q12140
Effect of immunosuppressive drugs (6-mercaptopurine and methotrexate) on resistance of Chinese hamsters to the tissue phase of Trichinella spiralis.;Q418529;P2868;Q249619
Effect of immunosuppressive drugs (6-mercaptopurine and methotrexate) on resistance of Chinese hamsters to the tissue phase of Trichinella spiralis.;Q422232;P31;Q12140
Effect of immunosuppressive drugs (6-mercaptopurine and methotrexate) on resistance of Chinese hamsters to the tissue phase of Trichinella spiralis.;Q422232;P2868;Q249619
Reduced time for urinary alkalinization before high-dose methotrexate with preadmission oral bicarbonate.;Q191924;P527;Q623
Reduced time for urinary alkalinization before high-dose methotrexate with preadmission oral bicarbonate.;Q173670;P527;Q623
Reduced time for urinary alkalinization before high-dose methotrexate with preadmission oral bicarbonate.;Q422232;P636;Q285166
Sequential methotrexate, 5-fluorouracil (high-dose), and doxorubicin for advanced gastric cancer.;Q238512;P2175;Q189588
Sequential methotrexate, 5-fluorouracil (high-dose), and doxorubicin for advanced gastric cancer.;Q422232;P2175;Q189588
Treatment of four patients with erythrophagocytic lymphohistiocytosis by a combination of epipodophyllotoxin, steroids, intrathecal methotrexate, and cranial irradiation.;Q422232;P636;Q1320251
Low-dose oral methotrexate management of patients with bilateral Mnire's disease.;Q422232;P636;Q285166
Single-dose systemic methotrexate for the treatment of persistent ectopic pregnancy after conservative surgery.;Q422232;P2175;Q207087
[Late sequelae of central nervous system prophylaxis in children with acute lymphoblastic leukemia: high doses of intravenous methotrexate versus radiotherapy of the central nervous system--review of literature];Q422232;P2175;Q29496
[The treatment of severe psoriatic arthritis with methotrexate in a weekly "mini-pulse" dosage plan];Q422232;P2175;Q170990
Bilateral subdural hygromas following administration of intrathecal methotrexate chemotherapy;Q422232;P636;Q1320251
Atypical multidrug resistance in CCRF-CEM cells selected for high level methotrexate resistance: reactivity to monoclonal antibody C219 in the absence of P-glycoprotein expression.;Q218642;P31;Q12140
Atypical multidrug resistance in CCRF-CEM cells selected for high level methotrexate resistance: reactivity to monoclonal antibody C219 in the absence of P-glycoprotein expression.;Q186474;P31;Q12140
Atypical multidrug resistance in CCRF-CEM cells selected for high level methotrexate resistance: reactivity to monoclonal antibody C219 in the absence of P-glycoprotein expression.;Q191924;P31;Q12140
Atypical multidrug resistance in CCRF-CEM cells selected for high level methotrexate resistance: reactivity to monoclonal antibody C219 in the absence of P-glycoprotein expression.;Q170545;P31;Q12140
Atypical multidrug resistance in CCRF-CEM cells selected for high level methotrexate resistance: reactivity to monoclonal antibody C219 in the absence of P-glycoprotein expression.;Q139347;P31;Q12140
Atypical multidrug resistance in CCRF-CEM cells selected for high level methotrexate resistance: reactivity to monoclonal antibody C219 in the absence of P-glycoprotein expression.;Q173670;P31;Q12140
Atypical multidrug resistance in CCRF-CEM cells selected for high level methotrexate resistance: reactivity to monoclonal antibody C219 in the absence of P-glycoprotein expression.;Q20035886;P31;Q12140
Atypical multidrug resistance in CCRF-CEM cells selected for high level methotrexate resistance: reactivity to monoclonal antibody C219 in the absence of P-glycoprotein expression.;Q22124685;P31;Q12140
Atypical multidrug resistance in CCRF-CEM cells selected for high level methotrexate resistance: reactivity to monoclonal antibody C219 in the absence of P-glycoprotein expression.;Q422232;P31;Q12140
A rare complication of intrathecal methotrexate in a child with acute lymphoblastic leukemia.;Q422232;P2175;Q29496
A rare complication of intrathecal methotrexate in a child with acute lymphoblastic leukemia.;Q422232;P636;Q1320251
MTHFR, TYMS and SLCO1B1 polymorphisms and adverse liver effects of methotrexate in rheumatoid arthritis;Q422232;P2175;Q187255
MTHFR, TYMS and SLCO1B1 polymorphisms and adverse liver effects of methotrexate in rheumatoid arthritis;Q422232;P2175;Q170990
Severe apoptotic enteropathy caused by methotrexate treatment for rheumatoid arthritis.;Q422232;P2175;Q187255
Severe apoptotic enteropathy caused by methotrexate treatment for rheumatoid arthritis.;Q422232;P2175;Q170990
The ligand (s) anchored lipobrid nanoconstruct mediated delivery of methotrexate: an effective approach in breast cancer therapeutics.;Q186521;P703;Q177932
The ligand (s) anchored lipobrid nanoconstruct mediated delivery of methotrexate: an effective approach in breast cancer therapeutics.;Q422232;P2175;Q128581
Discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab: An interventional study;Q425154;P2175;Q170990
Discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab: An interventional study;Q422232;P2175;Q187255
Discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab: An interventional study;Q422232;P2175;Q170990
Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add?;Q422232;P2175;Q170990
Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add?;Q422232;P2175;Q187255
Gene expression regulated by abatacept associated with methotrexate and correlation with disease activity in rheumatoid arthritis;Q422232;P2175;Q187255
Gene expression regulated by abatacept associated with methotrexate and correlation with disease activity in rheumatoid arthritis;Q422232;P2175;Q170990
Phenotypic and cytogenetic analysis of atypical multidrug resistance in human leukaemic cells selected with methotrexate at high concentration.;Q191924;P31;Q12140
Phenotypic and cytogenetic analysis of atypical multidrug resistance in human leukaemic cells selected with methotrexate at high concentration.;Q170545;P31;Q12140
Phenotypic and cytogenetic analysis of atypical multidrug resistance in human leukaemic cells selected with methotrexate at high concentration.;Q170545;P703;Q15978631
Phenotypic and cytogenetic analysis of atypical multidrug resistance in human leukaemic cells selected with methotrexate at high concentration.;Q20035886;P31;Q12140
Phenotypic and cytogenetic analysis of atypical multidrug resistance in human leukaemic cells selected with methotrexate at high concentration.;Q20035886;P703;Q15978631
Phenotypic and cytogenetic analysis of atypical multidrug resistance in human leukaemic cells selected with methotrexate at high concentration.;Q422232;P31;Q12140
Long-term follow-up of refractory mycosis fungoides which achieved remission with the addision of isotretinoin to methotrexate and psoralen plus ultraviolat a therapy;Q287029;P636;Q285166
Long-term follow-up of refractory mycosis fungoides which achieved remission with the addision of isotretinoin to methotrexate and psoralen plus ultraviolat a therapy;Q422232;P636;Q285166
Long-term follow-up of refractory mycosis fungoides which achieved remission with the addision of isotretinoin to methotrexate and psoralen plus ultraviolat a therapy;Q422232;P2175;Q1891209
Mucoadhesive and pH responsive fucoidan-chitosan nanoparticles for the oral delivery of methotrexate;Q422232;P636;Q285166
[Bone marrow necrosis in a patient with metastatic breast cancer in chemotherapy with chlorambucil, methotrexate and prednisone];Q424972;P2175;Q12078
[Bone marrow necrosis in a patient with metastatic breast cancer in chemotherapy with chlorambucil, methotrexate and prednisone];Q415939;P2175;Q128581
[Bone marrow necrosis in a patient with metastatic breast cancer in chemotherapy with chlorambucil, methotrexate and prednisone];Q422232;P2175;Q128581
Efficacy of add-on tacrolimus on methotrexate to maintain clinical remission after rediscontinuation of a tumor necrosis factor inhibitor in rheumatoid arthritis patients who relapsed shortly after discontinuation of the same tumor necrosis factor i;Q422232;P2175;Q170990
Efficacy of add-on tacrolimus on methotrexate to maintain clinical remission after rediscontinuation of a tumor necrosis factor inhibitor in rheumatoid arthritis patients who relapsed shortly after discontinuation of the same tumor necrosis factor i;Q422232;P2175;Q187255
[Therapeutic effect and impact on cytokine production by methotrexate in rheumatoid arthritis];Q186521;P703;Q177932
[Therapeutic effect and impact on cytokine production by methotrexate in rheumatoid arthritis];Q422232;P2175;Q187255
[Therapeutic effect and impact on cytokine production by methotrexate in rheumatoid arthritis];Q422232;P2175;Q170990
[Evaluation of severe side effects of high-dose methotrexate in osteosarcoma];Q422232;P2175;Q549534
In vitro investigation on the magnetic thermochemotherapy mediated by magnetic nanoparticles combined with methotrexate for breast cancer treatment.;Q422232;P2175;Q128581
Methotrexate in the treatment of mycosis fungoides - a multicenter observational study in 79 patients;Q422232;P2175;Q1891209
Relationship between 5,10-methylenetetrahydrofolate reductase C677T gene polymorphism and methotrexate related toxicity in patients with autoimmune diseases receiving folic acid supplementation.;Q422232;P2868;Q127060
Patient self-injection of methotrexate for inflammatory arthritis: a study evaluating the introduction of a new type of syringe and exploring patients' sense of empowerment.;Q422232;P2175;Q170990
Refractory optic perineuritis due to granulomatosis with polyangiitis successfully treated with methotrexate and mycophenolate mofetil combination therapy.;Q130336;P31;Q407142
Refractory optic perineuritis due to granulomatosis with polyangiitis successfully treated with methotrexate and mycophenolate mofetil combination therapy.;Q130336;P4149;Q27122100
Refractory optic perineuritis due to granulomatosis with polyangiitis successfully treated with methotrexate and mycophenolate mofetil combination therapy.;Q4567614;P2175;Q1161568
Refractory optic perineuritis due to granulomatosis with polyangiitis successfully treated with methotrexate and mycophenolate mofetil combination therapy.;Q422232;P2175;Q1161568
Ogilvie's syndrome during chemotherapy with high-dose methotrexate for primary CNS lymphoma.;Q422232;P2175;Q136312
Ogilvie's syndrome during chemotherapy with high-dose methotrexate for primary CNS lymphoma.;Q422232;P2175;Q208414
Factors Predicting the Therapeutic Response to Methotrexate in Japanese Patients with Rheumatoid Arthritis: A Hospital-Based Cohort Study;Q218642;P703;Q177932
Factors Predicting the Therapeutic Response to Methotrexate in Japanese Patients with Rheumatoid Arthritis: A Hospital-Based Cohort Study;Q183290;P703;Q177932
Factors Predicting the Therapeutic Response to Methotrexate in Japanese Patients with Rheumatoid Arthritis: A Hospital-Based Cohort Study;Q186474;P703;Q177932
Factors Predicting the Therapeutic Response to Methotrexate in Japanese Patients with Rheumatoid Arthritis: A Hospital-Based Cohort Study;Q186521;P703;Q177932
Factors Predicting the Therapeutic Response to Methotrexate in Japanese Patients with Rheumatoid Arthritis: A Hospital-Based Cohort Study;Q485277;P703;Q177932
Factors Predicting the Therapeutic Response to Methotrexate in Japanese Patients with Rheumatoid Arthritis: A Hospital-Based Cohort Study;Q173670;P703;Q177932
Factors Predicting the Therapeutic Response to Methotrexate in Japanese Patients with Rheumatoid Arthritis: A Hospital-Based Cohort Study;Q20035886;P703;Q177932
Factors Predicting the Therapeutic Response to Methotrexate in Japanese Patients with Rheumatoid Arthritis: A Hospital-Based Cohort Study;Q22124685;P703;Q177932
Methotrexate use in psoriasis and psoriatic arthritis.;Q422232;P2175;Q170990
Safety considerations regarding Methotrexate off-label use in tubal ectopic pregnancy;Q422232;P2175;Q207087
What is the optimal dose of high-dose methotrexate in the initial treatment of primary central nervous system lymphoma?;Q422232;P2175;Q136312
What is the optimal dose of high-dose methotrexate in the initial treatment of primary central nervous system lymphoma?;Q422232;P2175;Q208414
An economic evaluation of single dose systemic methotrexate and laparoscopic surgery for the treatment of unruptured ectopic pregnancy;Q422232;P2175;Q207087
Methotrexate therapy impacts on red cell distribution width and its predictive value for cardiovascular events in patients with rheumatoid arthritis;Q422232;P2175;Q170990
Methotrexate therapy impacts on red cell distribution width and its predictive value for cardiovascular events in patients with rheumatoid arthritis;Q422232;P2175;Q187255
Nilotinib-induced psoriasis in a patient of chronic myeloid leukemia responding to methotrexate;Q412327;P2175;Q29496
Nilotinib-induced psoriasis in a patient of chronic myeloid leukemia responding to methotrexate;Q422232;P2175;Q29496
Methotrexate affects HMGB1 expression in rheumatoid arthritis, and the downregulation of HMGB1 prevents rheumatoid arthritis progression.;Q422232;P2175;Q170990
Methotrexate affects HMGB1 expression in rheumatoid arthritis, and the downregulation of HMGB1 prevents rheumatoid arthritis progression.;Q422232;P2175;Q187255
Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival;Q422232;P2175;Q136312
Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival;Q422232;P2175;Q208414
Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL);Q422232;P2175;Q208414
Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL);Q422232;P2175;Q136312
Concomitant administration of methotrexate does not improve efficacy of intra-articular joint injections in patients with oligoarticular juvenile idiopathic arthritis.;Q422232;P2175;Q170990
Concomitant administration of methotrexate does not improve efficacy of intra-articular joint injections in patients with oligoarticular juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Self-aggregates of hyperbranched epoxidized 2-hydroxyethyl methacrylate conjugates of methotrexate: Synthesis and in vitro drug delivery.;Q183290;P31;Q12140
Self-aggregates of hyperbranched epoxidized 2-hydroxyethyl methacrylate conjugates of methotrexate: Synthesis and in vitro drug delivery.;Q191924;P366;Q8386
Self-aggregates of hyperbranched epoxidized 2-hydroxyethyl methacrylate conjugates of methotrexate: Synthesis and in vitro drug delivery.;Q422232;P31;Q12140
Oropharyngeal carcinoma arising after methotrexate and etanercept therapy for rheumatoid arthritis.;Q422232;P2175;Q170990
Oropharyngeal carcinoma arising after methotrexate and etanercept therapy for rheumatoid arthritis.;Q422232;P2175;Q187255
Success rate of methotrexate treatment for recurrent vs. primary ectopic pregnancy: a case-control study;Q422232;P2175;Q207087
Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis.;Q422232;P2175;Q170990
Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis.;Q422232;P361;Q14819383
Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis.;Q422232;P2175;Q187255
[Why we recommend parenteral methotrexate for the treatment of rheumatoid arthritis: a response and overview of the literature];Q422232;P2175;Q187255
[Why we recommend parenteral methotrexate for the treatment of rheumatoid arthritis: a response and overview of the literature];Q422232;P2175;Q170990
Bleomycin, vincristine, and methotrexate (BOM) in squamous cell carcinoma of the lung: a phase II study;Q415571;P2175;Q681817
Chemotherapy for osteosarcoma without high-dose methotrexate: another piece in the puzzle.;Q422232;P2175;Q549534
Circulating levels of soluble E-selectin, ICAM-1 and VCAM-1 in bullous pemphigoid during low-dose methotrexate therapy. A prospective study.;Q422232;P2175;Q1004647
[Results of 30 perfusions of the external carotid. (Value of methotrexate)];Q422232;P636;Q640448
Effects and safety of Sinomenine in treatment of rheumatoid arthritis contrast to methotrexate: a systematic review and Meta-analysis;Q422232;P2175;Q170990
Effects and safety of Sinomenine in treatment of rheumatoid arthritis contrast to methotrexate: a systematic review and Meta-analysis;Q422232;P2175;Q187255
Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNFalpha production without decreasing TNFalpha mRNA levels. An in vivo and in vitro study.;Q367700;P2175;Q187255
Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNFalpha production without decreasing TNFalpha mRNA levels. An in vivo and in vitro study.;Q422232;P2175;Q170990
Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNFalpha production without decreasing TNFalpha mRNA levels. An in vivo and in vitro study.;Q422232;P2175;Q187255
Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World;Q421094;P1889;Q422438
Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World;Q422438;P1889;Q421094
Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring-A nationwide cohort study.;Q18939;P279;Q3360898
Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: a dose-finding study for ambulatory patients with breast cancer;Q238512;P2175;Q128581
Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: a dose-finding study for ambulatory patients with breast cancer;Q422232;P2175;Q128581
Folic acid supplements are good (not bad) for rheumatoid arthritis patients treated with low-dose methotrexate;Q422232;P2175;Q187255
Folic acid supplements are good (not bad) for rheumatoid arthritis patients treated with low-dose methotrexate;Q422232;P2175;Q170990
Double modulation with methotrexate and L-leucovorin of weekly 24- hour fluorouracil infusion in fluorouracil-refractory colorectal cancer;Q192464;P31;Q45435667
Double modulation with methotrexate and L-leucovorin of weekly 24- hour fluorouracil infusion in fluorouracil-refractory colorectal cancer;Q238512;P2175;Q2739660
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.;Q18936;P2175;Q4833719
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.;Q18936;P2175;Q208414
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.;Q18936;P2175;Q2626074
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.;Q408977;P2175;Q2626074
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.;Q408977;P2175;Q208414
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.;Q408977;P2175;Q4833719
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.;Q412323;P2175;Q208414
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.;Q412323;P2175;Q2626074
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.;Q412323;P2175;Q4833719
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.;Q424972;P2175;Q2626074
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.;Q424972;P2175;Q4833719
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.;Q422232;P2175;Q4833719
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.;Q422232;P2175;Q208414
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.;Q422232;P2175;Q2626074
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma;Q180983;P2175;Q208414
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma;Q180983;P2175;Q268713
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma;Q412323;P2175;Q268713
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma;Q412323;P2175;Q208414
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma;Q422232;P2175;Q208414
Epstein-Barr virus-associated mononucleosis caused by weekly low-dose methotrexate therapy in a rheumatoid arthritis patient.;Q422232;P2175;Q170990
Epstein-Barr virus-associated mononucleosis caused by weekly low-dose methotrexate therapy in a rheumatoid arthritis patient.;Q422232;P2175;Q187255
Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer;Q422232;P2175;Q128581
Extremely slow methotrexate elimination in a patient with t(9:22) positive acute lymphoblastic leukemia treated with imatinib.;Q177094;P2175;Q29496
Extremely slow methotrexate elimination in a patient with t(9:22) positive acute lymphoblastic leukemia treated with imatinib.;Q422232;P2175;Q29496
PReS-FINAL-2100: Methotrexate treatment affects effector, but not regulatory T cells in juvenile idiopathic arthritis.;Q422232;P2175;Q861224
PReS-FINAL-2100: Methotrexate treatment affects effector, but not regulatory T cells in juvenile idiopathic arthritis.;Q422232;P2175;Q170990
Efficacy of intralesional methotrexate in specific cutaneous involvement of B-cell chronic lymphocytic leukaemia;Q422232;P2175;Q29496
Efficacy evaluation of methotrexate in the treatment of ankylosing spondylitis using meta-analysis.;Q422232;P2175;Q52849
[Prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation--combination protocol of high dose methylprednisolone, prednisolone and methotrexate];Q11426176;P2175;Q1194520
[Prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation--combination protocol of high dose methylprednisolone, prednisolone and methotrexate];Q417222;P2175;Q1194520
Genetic polymorphism of the methotrexate transporter ABCG2, blood pressure and markers of arterial function in patients with rheumatoid arthritis: repeated cross-sectional study;Q422232;P2175;Q187255
Genetic polymorphism of the methotrexate transporter ABCG2, blood pressure and markers of arterial function in patients with rheumatoid arthritis: repeated cross-sectional study;Q422232;P2175;Q170990
Multidrug resistance protein-1 expression, function and polymorphisms in patients with rheumatoid arthritis not responding to methotrexate;Q191924;P31;Q12140
Multidrug resistance protein-1 expression, function and polymorphisms in patients with rheumatoid arthritis not responding to methotrexate;Q22124685;P31;Q12140
Multidrug resistance protein-1 expression, function and polymorphisms in patients with rheumatoid arthritis not responding to methotrexate;Q422232;P31;Q12140
Multidrug resistance protein-1 expression, function and polymorphisms in patients with rheumatoid arthritis not responding to methotrexate;Q422232;P2175;Q170990
Multidrug resistance protein-1 expression, function and polymorphisms in patients with rheumatoid arthritis not responding to methotrexate;Q422232;P2175;Q187255
Induction chemotherapy with methotrexate, bleomycin and hydroxyurea with or without cisplatin in advanced squamous cell carcinoma of the head and neck: a study of the Swiss Group for Clinical Cancer Research (SAKK).;Q412415;P2175;Q18348812
Induction chemotherapy with methotrexate, bleomycin and hydroxyurea with or without cisplatin in advanced squamous cell carcinoma of the head and neck: a study of the Swiss Group for Clinical Cancer Research (SAKK).;Q212272;P279;Q48318
The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.;Q411648;P2175;Q1194520
Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?;Q422232;P2175;Q187255
Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?;Q422232;P2175;Q170990
Treatment of metastatic colorectal carcinoma with 5-FU, mitomycin, vincristine, and methotrexate;Q19856779;P1889;Q417625
Whole brain magnetization transfer histogram analysis of pediatric acute lymphoblastic leukemia patients receiving intrathecal methotrexate therapy.;Q422232;P2175;Q29496
Whole brain magnetization transfer histogram analysis of pediatric acute lymphoblastic leukemia patients receiving intrathecal methotrexate therapy.;Q422232;P636;Q1320251
Predicting methotrexate resistance in rheumatoid arthritis patients.;Q422232;P2175;Q170990
Predicting methotrexate resistance in rheumatoid arthritis patients.;Q422232;P2175;Q187255
Methotrexate concentrations in cerebrospinal fluid and serum, and the risk of central nervous system relapse in children with acute lymphoblastic leukaemia.;Q422232;P2175;Q29496
Does intraperitoneal medical ozone preconditioning and treatment ameliorate the methotrexate induced nephrotoxicity in rats?;Q178450;P703;Q177932
Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis;Q422232;P2175;Q170990
Methotrexate utilization in Rheumatoid arthritis. A register-based cohort-study of treatment re-starts after gabs of at least 90days;Q422232;P2175;Q170990
Methotrexate utilization in Rheumatoid arthritis. A register-based cohort-study of treatment re-starts after gabs of at least 90days;Q422232;P2175;Q187255
Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis;Q348260;P2175;Q170990
Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis;Q348260;P2175;Q187255
Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis;Q425154;P2175;Q170990
Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis;Q422232;P2175;Q187255
Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis;Q422232;P2175;Q170990
The effect of methotrexate on transformation and mitosis of normal human blood lymphocytes in vitro.;Q186521;P703;Q15978631
Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collab;Q238512;P2175;Q128581
Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collab;Q425122;P2175;Q128581
Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collab;Q422232;P2175;Q128581
Azathioprine or methotrexate maintenance for ANCA-associated vasculitis;Q218642;P703;Q2046782
Azathioprine or methotrexate maintenance for ANCA-associated vasculitis;Q422232;P2175;Q1161568
Association of MTHFR and RFC1 gene polymorphisms with methotrexate efficacy and toxicity in Chinese Han patients with rheumatoid arthritis;Q422232;P2175;Q187255
Association of MTHFR and RFC1 gene polymorphisms with methotrexate efficacy and toxicity in Chinese Han patients with rheumatoid arthritis;Q422232;P2175;Q170990
[Effects of different first dose calcium tetrahydro-folate on toxicity and side effects of large dose methotrexate treated standard risk group children with acute lymphoblastic leukemia].;Q422232;P2175;Q29496
[The effect of mitomycin C and methotrexate on the reappearing of T-lymphocyte membrane receptors for sheep red cells (author's transl)];Q19856779;P1889;Q417625
Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.;Q422232;P2175;Q187255
Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.;Q422232;P2175;Q170990
Pseudoleukemia during recovery from methotrexate toxicity in psoriasis.;Q422232;P2175;Q29496
Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics;Q422232;P2175;Q29496
Recommendations for treatment of lymphomatoid papulosis with methotrexate: a report from the Dutch Cutaneous Lymphoma Group;Q422232;P2175;Q208414
Effect of methotrexate and sulphasalazine on UMR 106 rat osteosarcoma cells.;Q422232;P2175;Q549534
[Results of 5-fluorouracil, methotrexate, cyclophosphamide and prednisone combination therapy in the treatment of advanced breast cancer];Q238512;P2175;Q128581
[Results of 5-fluorouracil, methotrexate, cyclophosphamide and prednisone combination therapy in the treatment of advanced breast cancer];Q424972;P2175;Q12078
[Results of 5-fluorouracil, methotrexate, cyclophosphamide and prednisone combination therapy in the treatment of advanced breast cancer];Q422232;P2175;Q128581
Oral versus intramuscular methotrexate in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group.;Q422232;P2175;Q170990
Prediction of response of collagen-induced arthritis rats to methotrexate: an (1)H-NMR-based urine metabolomic analysis;Q422232;P2175;Q170990
Changes in the illness perceptions of patients with rheumatoid arthritis over the first year of methotrexate therapy;Q422232;P2175;Q170990
Changes in the illness perceptions of patients with rheumatoid arthritis over the first year of methotrexate therapy;Q422232;P2175;Q187255
A case of acne fulminans with sacroiliitis successfully treated with methotrexate and isotretinoin;Q29417;P2175;Q79928
A case of acne fulminans with sacroiliitis successfully treated with methotrexate and isotretinoin;Q287029;P2175;Q79928
Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis;Q422232;P2175;Q170990
Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis;Q422232;P2175;Q187255
Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis;Q422232;P361;Q14819383
[Neuropsychiatric manifestations in systemic lupus erythematosus and the treatment of intrathecal methotrexate plus dexamethasone];Q422232;P636;Q1320251
[Ventriculo-lumbar perfusion chemotherapy with methotrexate and cytosine arabinoside for meningeal dissemination of malignant disease];Q422232;P636;Q640448
A patient-initiated DMARD self-monitoring service for people with rheumatoid or psoriatic arthritis on methotrexate: a randomised controlled trial.;Q422232;P2868;Q810254
A patient-initiated DMARD self-monitoring service for people with rheumatoid or psoriatic arthritis on methotrexate: a randomised controlled trial.;Q422232;P2175;Q170990
Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP).;Q412415;P2175;Q2501186
Medical abortion with oral methotrexate and vaginal misoprostol.;Q416025;P636;Q285166
Medical abortion with oral methotrexate and vaginal misoprostol.;Q416025;P636;Q4112929
Medical abortion with oral methotrexate and vaginal misoprostol.;Q422232;P636;Q285166
The Association of Methotrexate, Sulfasalazine, and Hydroxychloroquine Use With Fracture in Postmenopausal Women With Rheumatoid Arthritis: Findings From the Women's Health Initiative;Q421094;P1889;Q422438
The Association of Methotrexate, Sulfasalazine, and Hydroxychloroquine Use With Fracture in Postmenopausal Women With Rheumatoid Arthritis: Findings From the Women's Health Initiative;Q422438;P1889;Q421094
Why subcutaneous methotrexate should be a prerequisite to biologic use in patients with rheumatoid arthritis;Q422232;P2175;Q170990
Why subcutaneous methotrexate should be a prerequisite to biologic use in patients with rheumatoid arthritis;Q422232;P2175;Q187255
Cutaneous Kaposi sarcoma during treatment with superpotent topical steroids and methotrexate for bullous pemphigoid: three cases.;Q422232;P2175;Q1004647
[The need for a better definition of therapeutic indications of carboxypeptidase in delayed elimination of methotrexate];Q186521;P703;Q177932
Transport of methotrexate into LNCaP human prostate cancer cells.;Q186474;P703;Q15978631
Transport of methotrexate into LNCaP human prostate cancer cells.;Q186521;P703;Q15978631
Transport of methotrexate into LNCaP human prostate cancer cells.;Q20035886;P703;Q15978631
Transport of methotrexate into LNCaP human prostate cancer cells.;Q483745;P703;Q15978631
The effect of sequential methotrexate and 5-fluorouracil in patients with recurrent head and neck cancer.;Q238512;P2175;Q1783924
The effect of sequential methotrexate and 5-fluorouracil in patients with recurrent head and neck cancer.;Q422232;P2175;Q1783924
Osteogenic sarcoma: state of the art with high-dose methotrexate treatment.;Q422232;P2175;Q549534
Coexistence of psoriasis and bullous pemphigoid: remission with low-dose methotrexate;Q422232;P2175;Q1004647
Laparoscopic methotrexate instillation in unruptured tubal pregnancy--is it worthwhile?;Q422232;P2175;Q207087
Immobilization of methotrexate anticancer drug onto the graphene surface and interaction with calf thymus DNA and 4T1 cancer cells.;Q218642;P31;Q12140
Immobilization of methotrexate anticancer drug onto the graphene surface and interaction with calf thymus DNA and 4T1 cancer cells.;Q186521;P31;Q12140
Immobilization of methotrexate anticancer drug onto the graphene surface and interaction with calf thymus DNA and 4T1 cancer cells.;Q191924;P31;Q12140
Immobilization of methotrexate anticancer drug onto the graphene surface and interaction with calf thymus DNA and 4T1 cancer cells.;Q178450;P31;Q12140
Immobilization of methotrexate anticancer drug onto the graphene surface and interaction with calf thymus DNA and 4T1 cancer cells.;Q484940;P31;Q12140
Immobilization of methotrexate anticancer drug onto the graphene surface and interaction with calf thymus DNA and 4T1 cancer cells.;Q422232;P31;Q12140
Synthesis of PPEGMEA-g-PDEAEMA Double Hydrophilic Graft Copolymer and Studies on Controlled Drug Release in vitro of Loaded Methotrexate;Q410083;P31;Q81163
Beta carotene-loaded zein nanoparticles to improve the biopharmaceutical attributes and to abolish the toxicity of methotrexate: a preclinical study for breast cancer;Q191924;P31;Q12140
Beta carotene-loaded zein nanoparticles to improve the biopharmaceutical attributes and to abolish the toxicity of methotrexate: a preclinical study for breast cancer;Q422232;P31;Q12140
Beta carotene-loaded zein nanoparticles to improve the biopharmaceutical attributes and to abolish the toxicity of methotrexate: a preclinical study for breast cancer;Q422232;P2175;Q128581
Comparison of efficacy and safety of tacrolimus and methotrexate in combination with abatacept in patients with rheumatoid arthritis: a retrospective observational study in the TBC Registry;Q422232;P2175;Q187255
Comparison of efficacy and safety of tacrolimus and methotrexate in combination with abatacept in patients with rheumatoid arthritis: a retrospective observational study in the TBC Registry;Q422232;P2175;Q170990
Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis;Q422232;P361;Q14819383
Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis;Q422232;P2175;Q170990
Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis;Q422232;P2175;Q861224
Toxic corneal epitheliopathy after intravitreal methotrexate and its treatment with oral folic acid.;Q422232;P2868;Q127060
Toxic corneal epitheliopathy after intravitreal methotrexate and its treatment with oral folic acid.;Q422232;P636;Q285166
Right bundle branch block induced by low-dose methotrexate in a patient with rheumatoid arthritis;Q422232;P2175;Q187255
Right bundle branch block induced by low-dose methotrexate in a patient with rheumatoid arthritis;Q422232;P2175;Q170990
[Treatment of rheumatoid polyarthritis with methotrexate in Dakar: efficacy, tolerance and cost];Q422232;P2175;Q170990
[Treatment of rheumatoid polyarthritis with methotrexate in Dakar: efficacy, tolerance and cost];Q422232;P2175;Q1274464
A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.;Q418817;P2175;Q208414
A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.;Q422252;P2175;Q208414
A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.;Q422232;P2175;Q7667896
A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.;Q422232;P2175;Q208414
Cerebral calcifications associated with intrathecal methotrexate therapy in acute lymphocytic leukemia;Q422232;P2175;Q29496
Cerebral calcifications associated with intrathecal methotrexate therapy in acute lymphocytic leukemia;Q422232;P636;Q1320251
[Serial spectral EEG analysis in a patient with non-Hodgkin's lymphoma complicated by leukoencephalopathy induced by high-dose methotrexate];Q422232;P2175;Q208414
[Serial spectral EEG analysis in a patient with non-Hodgkin's lymphoma complicated by leukoencephalopathy induced by high-dose methotrexate];Q422232;P2175;Q1138590
Predictors of disease flare after discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab;Q425154;P2175;Q170990
Predictors of disease flare after discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab;Q422232;P2175;Q187255
Predictors of disease flare after discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab;Q422232;P2175;Q170990
Radiologic damage at baseline predicts patient-related outcomes 18 years after the initiation of methotrexate therapy in patients with severe rheumatoid arthritis.;Q422232;P2175;Q170990
Radiologic damage at baseline predicts patient-related outcomes 18 years after the initiation of methotrexate therapy in patients with severe rheumatoid arthritis.;Q422232;P2175;Q187255
Multiple-dose and double-dose versus single-dose administration of methotrexate for the treatment of ectopic pregnancy: a systematic review and meta-analysis.;Q422232;P2175;Q207087
Addition of cyclosporine-A (Neoral) in patients on anti-TNF and methotrexate therapy improves disease activity: an open-label, pilot study.;Q367700;P3780;Q47521884
Addition of cyclosporine-A (Neoral) in patients on anti-TNF and methotrexate therapy improves disease activity: an open-label, pilot study.;Q422232;P636;Q285166
Vinblastine, methotrexate, bleomycin, in the management of head and neck cancer;Q282629;P2175;Q1783924
Vinblastine, methotrexate, bleomycin, in the management of head and neck cancer;Q422232;P2175;Q1783924
Therapeutic role of methotrexate in pediatric Crohn's disease.;Q186474;P703;Q177932
Therapeutic role of methotrexate in pediatric Crohn's disease.;Q186521;P703;Q177932
[Preventive therapy of central nervous system leukemia in children. Effects of cranial irradiation plus intrathecal methotrexate and hydrocortisone (author's transl)];Q190875;P2959;Q26981430
[Preventive therapy of central nervous system leukemia in children. Effects of cranial irradiation plus intrathecal methotrexate and hydrocortisone (author's transl)];Q422232;P2175;Q29496
[Preventive therapy of central nervous system leukemia in children. Effects of cranial irradiation plus intrathecal methotrexate and hydrocortisone (author's transl)];Q422232;P636;Q1320251
[Therapeutic maintenance level of methotrexate in rheumatoid arthritis].;Q186521;P703;Q177932
[Therapeutic maintenance level of methotrexate in rheumatoid arthritis].;Q422232;P2175;Q170990
[Therapeutic maintenance level of methotrexate in rheumatoid arthritis].;Q422232;P2175;Q187255
Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid.;Q422232;P2175;Q549534
Duration of methotrexate treatment until partial and total remission of refractory juvenile rheumatoid arthritis.;Q422232;P2175;Q187255
Duration of methotrexate treatment until partial and total remission of refractory juvenile rheumatoid arthritis.;Q422232;P2175;Q861224
Duration of methotrexate treatment until partial and total remission of refractory juvenile rheumatoid arthritis.;Q422232;P2175;Q170990
Decline in hCG levels between days 0 and 4 after a single dose of methotrexate for ectopic pregnancy predicts treatment success: a retrospective cohort study;Q422232;P2175;Q207087
Possible survival benefit of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin combination therapy (HD-MVAC) over conventional MVAC in metastatic urothelial carcinoma patients.;Q18936;P2175;Q2501186
Possible survival benefit of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin combination therapy (HD-MVAC) over conventional MVAC in metastatic urothelial carcinoma patients.;Q412415;P2175;Q2501186
Sequential treatment with high-dose methotrexate and fluorouracil in advanced colorectal cancer. Experience of the Southern Italian Oncology Group (GOIM);Q238512;P2175;Q2739660
[A device for rapid elevation of plasma methotrexate (MTX) concentration and its maintenance in high-dose MTX therapy];Q218642;P703;Q2046782
The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and [...];Q238512;P2175;Q128581
The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and [...];Q422232;P2175;Q128581
Methotrexate selection of long-term culture initiating cells following transduction of CD34(+) cells with a retrovirus containing a mutated human dihydrofolate reductase gene.;Q186474;P703;Q15978631
Methotrexate selection of long-term culture initiating cells following transduction of CD34(+) cells with a retrovirus containing a mutated human dihydrofolate reductase gene.;Q178450;P703;Q15978631
Methotrexate selection of long-term culture initiating cells following transduction of CD34(+) cells with a retrovirus containing a mutated human dihydrofolate reductase gene.;Q22124685;P703;Q15978631
Sequential combination of methotrexate (MTX), 5-fluorouracil (FU), and high-dose folinic acid (FA) in advanced colorectal cancer: double biochemical modulation?;Q238512;P2175;Q2739660
Combined cytotoxic and endocrine treatment of postmenopausal patients with advanced breast cancer: preliminary results of a phase II study of the combination of prednimustine, novantrone, methotrexate, 5-fluorouracil, and tamoxifen;Q412178;P2175;Q128581
Combined cytotoxic and endocrine treatment of postmenopausal patients with advanced breast cancer: preliminary results of a phase II study of the combination of prednimustine, novantrone, methotrexate, 5-fluorouracil, and tamoxifen;Q238512;P2175;Q128581
Combined cytotoxic and endocrine treatment of postmenopausal patients with advanced breast cancer: preliminary results of a phase II study of the combination of prednimustine, novantrone, methotrexate, 5-fluorouracil, and tamoxifen;Q422232;P2175;Q128581
[Comparison of hormone therapy alone and in combination with chemotherapy of cisplatin and methotrexate in newly diagnosed patients with stage D2 prostatic cancer].;Q412415;P2175;Q181257
Methotrexate for juvenile rheumatoid arthritis;Q422232;P2175;Q861224
Methotrexate for juvenile rheumatoid arthritis;Q422232;P2175;Q170990
Methotrexate for juvenile rheumatoid arthritis;Q422232;P2175;Q187255
Comparison of prednisolone, vincristine, methotrexate and 6-mercaptopurine vs. 6-mercaptopurine and prednisone maintenance therapy in childhood acute leukemia: a Southwest Oncology Group Study;Q408977;P2175;Q29496
Comparison of prednisolone, vincristine, methotrexate and 6-mercaptopurine vs. 6-mercaptopurine and prednisone maintenance therapy in childhood acute leukemia: a Southwest Oncology Group Study;Q11426176;P1889;Q424972
Comparison of prednisolone, vincristine, methotrexate and 6-mercaptopurine vs. 6-mercaptopurine and prednisone maintenance therapy in childhood acute leukemia: a Southwest Oncology Group Study;Q424972;P1889;Q11426176
Comparison of prednisolone, vincristine, methotrexate and 6-mercaptopurine vs. 6-mercaptopurine and prednisone maintenance therapy in childhood acute leukemia: a Southwest Oncology Group Study;Q422232;P2175;Q29496
Use of methotrexate in the management of rheumatoid arthritis in Dakar. Potential pitfalls.;Q422232;P2175;Q187255
Use of methotrexate in the management of rheumatoid arthritis in Dakar. Potential pitfalls.;Q422232;P2175;Q170990
Methotrexate and bone marrow suppression: drug errors may be implicated in death.;Q22124685;P31;Q12140
Methotrexate and bone marrow suppression: drug errors may be implicated in death.;Q422232;P31;Q12140
Methotrexate induces apoptosis of human choriocarcinoma cell line JAR via a mitochondrial pathway.;Q218642;P703;Q15978631
Methotrexate induces apoptosis of human choriocarcinoma cell line JAR via a mitochondrial pathway.;Q173670;P703;Q15978631
Methotrexate induces apoptosis of human choriocarcinoma cell line JAR via a mitochondrial pathway.;Q22124685;P703;Q15978631
Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the Hoosier Oncology Group.;Q18936;P2175;Q128581
Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the Hoosier Oncology Group.;Q412415;P2175;Q128581
Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the Hoosier Oncology Group.;Q422232;P2175;Q128581
Oral methotrexate for treatment of ectopic pregnancy.;Q422232;P2175;Q207087
Short Communication: Lack of association between MTHFR gene polymorphisms and response to methotrexate treatment in Pakistani patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Short Communication: Lack of association between MTHFR gene polymorphisms and response to methotrexate treatment in Pakistani patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Short Communication: Lack of association between MTHFR gene polymorphisms and response to methotrexate treatment in Pakistani patients with rheumatoid arthritis.;Q422232;P361;Q14819383
Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Drug survival and post-drug survival of first-line immunosuppressive treatments for atopic dermatitis: comparison between methotrexate and cyclosporine.;Q191924;P366;Q8386
Drug survival and post-drug survival of first-line immunosuppressive treatments for atopic dermatitis: comparison between methotrexate and cyclosporine.;Q367700;P31;Q12140
Drug survival and post-drug survival of first-line immunosuppressive treatments for atopic dermatitis: comparison between methotrexate and cyclosporine.;Q178450;P31;Q12140
Drug survival and post-drug survival of first-line immunosuppressive treatments for atopic dermatitis: comparison between methotrexate and cyclosporine.;Q422232;P31;Q12140
Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China;Q414143;P2175;Q208414
Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China;Q422252;P2175;Q208414
Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China;Q422232;P2175;Q208414
[Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis];Q420035;P2175;Q170990
[Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis];Q420035;P2175;Q187255
[Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis];Q421094;P2175;Q170990
[Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis];Q421094;P1889;Q422438
[Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis];Q421094;P2175;Q187255
[Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis];Q422438;P1889;Q421094
[Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis];Q422438;P2175;Q187255
[Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis];Q422232;P2175;Q170990
[Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis];Q422232;P2175;Q187255
Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma after failure of the LNH 84 regimen.;Q418817;P2175;Q1138590
Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma after failure of the LNH 84 regimen.;Q418817;P2175;Q208414
Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma after failure of the LNH 84 regimen.;Q422232;P2175;Q208414
Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma after failure of the LNH 84 regimen.;Q422232;P2175;Q1138590
Adherence to current recommendations on the use of methotrexate in rheumatoid arthritis in Italy: results from the MARI study.;Q422232;P2175;Q170990
Adherence to current recommendations on the use of methotrexate in rheumatoid arthritis in Italy: results from the MARI study.;Q422232;P2175;Q187255
Methotrexate for assisted reproductive technology (ART) ectopic pregnancy.;Q422232;P2175;Q207087
Methotrexate and cytosine arabinoside modulation of thymidylate synthetase activity in CCRF-CEM cells.;Q186474;P1889;Q178425
Adjuvant cyclophosphamide, methotrexate and fluorouracil for node-positive breast cancer: a lifetime cost-utility analysis based on a modified Q-TWIST method.;Q238512;P2175;Q128581
Adjuvant cyclophosphamide, methotrexate and fluorouracil for node-positive breast cancer: a lifetime cost-utility analysis based on a modified Q-TWIST method.;Q422232;P2175;Q128581
A prospective, crossover randomized trial of the optimal timing for leucovorin rescue after high-dose methotrexate management in adult non-Hodgkin's lymphoma patients;Q422232;P2175;Q208414
A prospective, crossover randomized trial of the optimal timing for leucovorin rescue after high-dose methotrexate management in adult non-Hodgkin's lymphoma patients;Q422232;P2175;Q1138590
Local and systemic diffusion of antineoplastic drugs following vertebroplasty using acrylic cement mixed with cisplatin or methotrexate: experimental study in pigs.;Q191924;P366;Q8386
Local and systemic diffusion of antineoplastic drugs following vertebroplasty using acrylic cement mixed with cisplatin or methotrexate: experimental study in pigs.;Q412415;P31;Q12140
Local and systemic diffusion of antineoplastic drugs following vertebroplasty using acrylic cement mixed with cisplatin or methotrexate: experimental study in pigs.;Q412415;P2868;Q2853144
Local and systemic diffusion of antineoplastic drugs following vertebroplasty using acrylic cement mixed with cisplatin or methotrexate: experimental study in pigs.;Q483745;P31;Q12140
Local and systemic diffusion of antineoplastic drugs following vertebroplasty using acrylic cement mixed with cisplatin or methotrexate: experimental study in pigs.;Q422232;P31;Q12140
Synthesis and preliminary in vitro screening of lipophilic alpha, gamma-bis(amides) as potential prodrugs of methotrexate;Q183290;P31;Q12140
Synthesis and preliminary in vitro screening of lipophilic alpha, gamma-bis(amides) as potential prodrugs of methotrexate;Q191924;P366;Q8386
Synthesis and preliminary in vitro screening of lipophilic alpha, gamma-bis(amides) as potential prodrugs of methotrexate;Q422232;P31;Q12140
Monitoring methotrexate therapy in patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Monitoring methotrexate therapy in patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Concomitant use of low-dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis;Q422232;P2175;Q170990
Concomitant use of low-dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis;Q422232;P2175;Q187255
Re: Treatment of accidental intrathecal methotrexate overdose.;Q422232;P636;Q1320251
Successful salvage treatment of blastic natural killer cell lymphoma with methotrexate;Q422232;P2175;Q208414
Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene.;Q183290;P703;Q15978631
Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene.;Q186474;P703;Q15978631
Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene.;Q186474;P703;Q83310
Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene.;Q180983;P2175;Q208414
Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene.;Q207843;P703;Q15978631
Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene.;Q178450;P703;Q15978631
Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene.;Q22124685;P703;Q15978631
Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene.;Q422232;P2175;Q208414
Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene.;Q484940;P703;Q15978631
Effect of folate status and methylenetetrahydrofolate reductase genotypes on the complications and outcome of high dose methotrexate chemotherapy in north Indian children with acute lymphoblastic leukemia;Q422232;P2175;Q29496
Comparison study on treatment of acute graft-versus-host disease with low-dose methotrexate in combination with low-dose methylprednisolone or standard-dose methylprednisolone;Q11426176;P2175;Q1194520
Comparison study on treatment of acute graft-versus-host disease with low-dose methotrexate in combination with low-dose methylprednisolone or standard-dose methylprednisolone;Q417222;P2175;Q1194520
The role of folates in the development of methotrexate resistance in human leukemia cell line K562.;Q186521;P703;Q15978631
The role of folates in the development of methotrexate resistance in human leukemia cell line K562.;Q20816880;P703;Q15978631
The role of folates in the development of methotrexate resistance in human leukemia cell line K562.;Q422232;P2175;Q29496
Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.;Q218642;P31;Q12140
Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.;Q191924;P31;Q12140
Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.;Q191924;P366;Q8386
Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.;Q173670;P31;Q12140
Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.;Q484940;P31;Q12140
Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.;Q422232;P31;Q12140
Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.;Q422232;P2175;Q170990
Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.;Q422232;P2175;Q187255
Hexamethylmelamine, bleomycin, and CCNU chemotherapy for patients with squamous cell carcinoma, large cell carcinoma, and adenocarcinoma of the lung unresponsive to cyclophosphamide, adriamycin, methotrexate, and procarbazine.;Q191924;P769;Q418656
No correlation between MTHFR c.677 C>T, MTHFR c.1298 A>C, and ABCB1 c.3435 C>T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population.;Q218642;P703;Q177932
No correlation between MTHFR c.677 C>T, MTHFR c.1298 A>C, and ABCB1 c.3435 C>T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population.;Q186474;P703;Q177932
No correlation between MTHFR c.677 C>T, MTHFR c.1298 A>C, and ABCB1 c.3435 C>T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population.;Q186521;P703;Q177932
No correlation between MTHFR c.677 C>T, MTHFR c.1298 A>C, and ABCB1 c.3435 C>T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population.;Q485277;P703;Q177932
No correlation between MTHFR c.677 C>T, MTHFR c.1298 A>C, and ABCB1 c.3435 C>T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population.;Q173670;P703;Q177932
No correlation between MTHFR c.677 C>T, MTHFR c.1298 A>C, and ABCB1 c.3435 C>T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population.;Q22124685;P703;Q177932
No correlation between MTHFR c.677 C>T, MTHFR c.1298 A>C, and ABCB1 c.3435 C>T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population.;Q422232;P2175;Q187255
No correlation between MTHFR c.677 C>T, MTHFR c.1298 A>C, and ABCB1 c.3435 C>T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population.;Q422232;P2175;Q170990
Herpes simplex type 2 encephalitis and methotrexate medication: a fortuitous or causative association in a patient with spondyloarthritis?;Q191924;P31;Q12140
Herpes simplex type 2 encephalitis and methotrexate medication: a fortuitous or causative association in a patient with spondyloarthritis?;Q485277;P31;Q12140
Herpes simplex type 2 encephalitis and methotrexate medication: a fortuitous or causative association in a patient with spondyloarthritis?;Q422232;P31;Q12140
Herpes simplex type 2 encephalitis and methotrexate medication: a fortuitous or causative association in a patient with spondyloarthritis?;Q422232;P2175;Q170990
Words of wisdom. Re: International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastin chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial;Q412415;P2175;Q504775
Polymeric Nanoscale Drug Carriers Mediate the Delivery of Methotrexate for Developing Therapeutic Interventions Against Cancer and Rheumatoid Arthritis;Q218642;P703;Q177932
Polymeric Nanoscale Drug Carriers Mediate the Delivery of Methotrexate for Developing Therapeutic Interventions Against Cancer and Rheumatoid Arthritis;Q186474;P703;Q177932
Polymeric Nanoscale Drug Carriers Mediate the Delivery of Methotrexate for Developing Therapeutic Interventions Against Cancer and Rheumatoid Arthritis;Q186521;P703;Q177932
Polymeric Nanoscale Drug Carriers Mediate the Delivery of Methotrexate for Developing Therapeutic Interventions Against Cancer and Rheumatoid Arthritis;Q173670;P703;Q177932
Polymeric Nanoscale Drug Carriers Mediate the Delivery of Methotrexate for Developing Therapeutic Interventions Against Cancer and Rheumatoid Arthritis;Q178450;P703;Q177932
Polymeric Nanoscale Drug Carriers Mediate the Delivery of Methotrexate for Developing Therapeutic Interventions Against Cancer and Rheumatoid Arthritis;Q20035886;P703;Q177932
Polymeric Nanoscale Drug Carriers Mediate the Delivery of Methotrexate for Developing Therapeutic Interventions Against Cancer and Rheumatoid Arthritis;Q22124685;P703;Q177932
Polymeric Nanoscale Drug Carriers Mediate the Delivery of Methotrexate for Developing Therapeutic Interventions Against Cancer and Rheumatoid Arthritis;Q484940;P703;Q177932
Pancytopenia in a patient with psoriatic arthritis treated with methotrexate and concomitant lithium.;Q422232;P2175;Q170990
High Efficacy of Methotrexate in Patients with Recurrent Idiopathic Acute Anterior Uveitis: a Prospective Study.;Q422232;P2175;Q280027
Does methotrexate improve TNF inhibitor drug survival in elderly patients with RA?;Q218642;P31;Q12140
Does methotrexate improve TNF inhibitor drug survival in elderly patients with RA?;Q186521;P31;Q12140
Does methotrexate improve TNF inhibitor drug survival in elderly patients with RA?;Q191924;P366;Q8386
Does methotrexate improve TNF inhibitor drug survival in elderly patients with RA?;Q170545;P31;Q12140
Does methotrexate improve TNF inhibitor drug survival in elderly patients with RA?;Q173670;P31;Q12140
Does methotrexate improve TNF inhibitor drug survival in elderly patients with RA?;Q178450;P31;Q12140
Does methotrexate improve TNF inhibitor drug survival in elderly patients with RA?;Q422232;P31;Q12140
Sugarcane bagasse lignin, and silica gel and magneto-silica as drug vehicles for development of innocuous methotrexate drug against rheumatoid arthritis disease in albino rats.;Q183290;P31;Q12140
Sugarcane bagasse lignin, and silica gel and magneto-silica as drug vehicles for development of innocuous methotrexate drug against rheumatoid arthritis disease in albino rats.;Q191924;P366;Q8386
Sugarcane bagasse lignin, and silica gel and magneto-silica as drug vehicles for development of innocuous methotrexate drug against rheumatoid arthritis disease in albino rats.;Q422232;P31;Q12140
Sugarcane bagasse lignin, and silica gel and magneto-silica as drug vehicles for development of innocuous methotrexate drug against rheumatoid arthritis disease in albino rats.;Q422232;P2175;Q170990
Sugarcane bagasse lignin, and silica gel and magneto-silica as drug vehicles for development of innocuous methotrexate drug against rheumatoid arthritis disease in albino rats.;Q422232;P2175;Q187255
On the treatment of rheumatoid arthritis with M&Ms (Motrin & methotrexate);Q422232;P2175;Q170990
On the treatment of rheumatoid arthritis with M&Ms (Motrin & methotrexate);Q422232;P2175;Q187255
Methotrexate in neutrophils in children with acute lymphoblastic leukemia.;Q422232;P2175;Q29496
Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate;Q412415;P2175;Q1783924
Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate;Q238512;P2175;Q1783924
Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate;Q422232;P2175;Q1783924
Correlation between plasma glucagon-like peptide 2 levels and proliferative makers in small intestinal injury in rats induced by methotrexate administration;Q28163629;P3781;Q170617
Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine.;Q18939;P2175;Q187255
Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine.;Q422232;P2175;Q187255
Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine.;Q422232;P2175;Q170990
Re: High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphatic leukemia.;Q422232;P2175;Q29496
Predictors and clinical features of methotrexate (MTX) therapy for ectopic pregnancy;Q422232;P2175;Q207087
Tuberculosis osteomyelitis in an old fused hip: activated by prednisolone, salazosulfapyridine, and low-dose methotrexate therapy in a patient with rheumatoid arthritis;Q422232;P2175;Q170990
Tuberculosis osteomyelitis in an old fused hip: activated by prednisolone, salazosulfapyridine, and low-dose methotrexate therapy in a patient with rheumatoid arthritis;Q422232;P2175;Q187255
Methotrexate and radiographic disease progression in patients with rheumatoid arthritis;Q422232;P2175;Q170990
Methotrexate and radiographic disease progression in patients with rheumatoid arthritis;Q422232;P2175;Q187255
Selected applications of methotrexate alone and in combination in osteosarcoma.;Q422232;P2175;Q549534
Investigation of ultrafine gold nanoparticles (AuNPs) based nanoformulation as single conjugates target delivery for improved methotrexate chemotherapy in breast cancer;Q422232;P2175;Q128581
Folliculotropic mycosis fungoides in a psoriatic patient under methotrexate treatment;Q422232;P2175;Q1891209
Safety and efficacy of leflunomide and infliximab versus methotrexate and infliximab combination therapy in rheumatoid arthritis.;Q248550;P2175;Q187255
Safety and efficacy of leflunomide and infliximab versus methotrexate and infliximab combination therapy in rheumatoid arthritis.;Q248550;P2175;Q170990
Safety and efficacy of leflunomide and infliximab versus methotrexate and infliximab combination therapy in rheumatoid arthritis.;Q415264;P2175;Q170990
Safety and efficacy of leflunomide and infliximab versus methotrexate and infliximab combination therapy in rheumatoid arthritis.;Q422232;P2175;Q170990
Safety and efficacy of leflunomide and infliximab versus methotrexate and infliximab combination therapy in rheumatoid arthritis.;Q422232;P2175;Q187255
Malignancy in patients with rheumatoid arthritis treated with methotrexate;Q422232;P2175;Q170990
Malignancy in patients with rheumatoid arthritis treated with methotrexate;Q422232;P2175;Q187255
Methotrexate and low-dose prednisolone downregulate osteoclast function by decreasing receptor activator of nuclear factor- expression in monocytes from patients with early rheumatoid arthritis.;Q422232;P2175;Q187255
Methotrexate and low-dose prednisolone downregulate osteoclast function by decreasing receptor activator of nuclear factor- expression in monocytes from patients with early rheumatoid arthritis.;Q422232;P2175;Q170990
Relationship between the methylenetetrahydrofolate reductase gene polymorphism and adverse reactions of high-dose methotrexate in children with acute lymphocytic leukemia;Q422232;P2175;Q29496
[Pneumonitis as a complication of low-dose methotrexate therapy in chronic polyarthritis];Q422232;P2175;Q170990
[Pneumonitis as a complication of low-dose methotrexate therapy in chronic polyarthritis];Q422232;P2175;Q1274464
Resistance of the human colon carcinoma cell line HCT-8 to methotrexate results in selection of cells with features of enterocytic differentiation.;Q186474;P703;Q15978631
Resistance of the human colon carcinoma cell line HCT-8 to methotrexate results in selection of cells with features of enterocytic differentiation.;Q186521;P703;Q15978631
Resistance of the human colon carcinoma cell line HCT-8 to methotrexate results in selection of cells with features of enterocytic differentiation.;Q190875;P703;Q15978631
Resistance of the human colon carcinoma cell line HCT-8 to methotrexate results in selection of cells with features of enterocytic differentiation.;Q485277;P703;Q15978631
Resistance of the human colon carcinoma cell line HCT-8 to methotrexate results in selection of cells with features of enterocytic differentiation.;Q173670;P703;Q15978631
Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults;Q422232;P2175;Q549534
Endemic Burkitt lymphoma of maxillofacial region: results of induction treatment with cyclophosphamide plus methotrexate in West Africa.;Q422232;P2175;Q208414
A Rare Case of Primary Central Nervous System Lymphoma in an Adolescent Female Treated with High-Dose Methotrexate and Rituximab-Based Chemoimmunotherapy and Consolidation Whole Brain Radiotherapy;Q422232;P2175;Q208414
A Rare Case of Primary Central Nervous System Lymphoma in an Adolescent Female Treated with High-Dose Methotrexate and Rituximab-Based Chemoimmunotherapy and Consolidation Whole Brain Radiotherapy;Q422232;P2175;Q136312
Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer.;Q412178;P2175;Q128581
Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer.;Q412178;P129;Q5401858
Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer.;Q238512;P2175;Q128581
Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer.;Q422416;P2175;Q128581
Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer.;Q422416;P279;Q277954
Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer.;Q422416;P129;Q5401858
Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer.;Q422232;P2175;Q128581
Ifosfamide, methotrexate, and 5-fluorouracil: effective combination in resistant breast cancer.;Q238512;P2175;Q128581
Ifosfamide, methotrexate, and 5-fluorouracil: effective combination in resistant breast cancer.;Q418560;P2175;Q128581
Ifosfamide, methotrexate, and 5-fluorouracil: effective combination in resistant breast cancer.;Q422232;P2175;Q128581
Hydroxychloroquine does not decrease serum methotrexate concentrations in children with juvenile idiopathic arthritis.;Q421094;P2175;Q170990
Hydroxychloroquine does not decrease serum methotrexate concentrations in children with juvenile idiopathic arthritis.;Q421094;P1889;Q422438
Hydroxychloroquine does not decrease serum methotrexate concentrations in children with juvenile idiopathic arthritis.;Q422438;P1889;Q421094
Hydroxychloroquine does not decrease serum methotrexate concentrations in children with juvenile idiopathic arthritis.;Q422232;P2175;Q170990
Hydroxychloroquine does not decrease serum methotrexate concentrations in children with juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Combination benefit of a pyrimidylpiperazine derivative (Y-40138) and methotrexate in arthritic rats.;Q422232;P2175;Q170990
Molecular events in the membrane transport of methotrexate in human CCRF-CEM leukemia cell lines.;Q186474;P703;Q15978631
Molecular events in the membrane transport of methotrexate in human CCRF-CEM leukemia cell lines.;Q170545;P703;Q15978631
Molecular events in the membrane transport of methotrexate in human CCRF-CEM leukemia cell lines.;Q139347;P703;Q15978631
Molecular events in the membrane transport of methotrexate in human CCRF-CEM leukemia cell lines.;Q173670;P703;Q15978631
Molecular events in the membrane transport of methotrexate in human CCRF-CEM leukemia cell lines.;Q22124685;P703;Q15978631
Molecular events in the membrane transport of methotrexate in human CCRF-CEM leukemia cell lines.;Q422232;P2175;Q29496
Comparison of paclitaxel-cetuximab chemotherapy versus metronomic chemotherapy consisting of methotrexate and celecoxib as palliative chemotherapy in head and neck cancers.;Q422232;P2175;Q1783924
Significant increase in serum hCG levels following methotrexate therapy is associated with lower treatment success rates in ectopic pregnancy patients;Q422232;P2175;Q207087
[A new method for treating ectopic pregnancy with methotrexate];Q422232;P2175;Q207087
Analysis of methotrexate in human plasma by high-pressure liquid chromatography with fluorescence detection.;Q218642;P703;Q15978631
Lymphoma with regression after methotrexate withdrawal in a patient with rheumatoid arthritis. Role for the Epstein-Barr virus.;Q422232;P2175;Q208414
Lymphoma with regression after methotrexate withdrawal in a patient with rheumatoid arthritis. Role for the Epstein-Barr virus.;Q422232;P2175;Q170990
Lymphoma with regression after methotrexate withdrawal in a patient with rheumatoid arthritis. Role for the Epstein-Barr virus.;Q422232;P2175;Q187255
Comparison of prednisolone, vincristine, methotrexate, and 6-mercaptopurine vs. vincristine and prednisone induction therapy in childhood acute leukemia.;Q408977;P2175;Q29496
Comparison of prednisolone, vincristine, methotrexate, and 6-mercaptopurine vs. vincristine and prednisone induction therapy in childhood acute leukemia.;Q11426176;P1889;Q424972
Comparison of prednisolone, vincristine, methotrexate, and 6-mercaptopurine vs. vincristine and prednisone induction therapy in childhood acute leukemia.;Q424972;P1889;Q11426176
Comparison of prednisolone, vincristine, methotrexate, and 6-mercaptopurine vs. vincristine and prednisone induction therapy in childhood acute leukemia.;Q422232;P2175;Q29496
Effects of combined treatments with CTLA4-IG (abatacept), dexamethasone and methotrexate on cultured human macrophages.;Q218642;P703;Q15978631
Effects of combined treatments with CTLA4-IG (abatacept), dexamethasone and methotrexate on cultured human macrophages.;Q186474;P703;Q15978631
Effects of combined treatments with CTLA4-IG (abatacept), dexamethasone and methotrexate on cultured human macrophages.;Q186521;P703;Q15978631
Effects of combined treatments with CTLA4-IG (abatacept), dexamethasone and methotrexate on cultured human macrophages.;Q620730;P703;Q15978631
Effects of combined treatments with CTLA4-IG (abatacept), dexamethasone and methotrexate on cultured human macrophages.;Q483745;P703;Q15978631
Effects of combined treatments with CTLA4-IG (abatacept), dexamethasone and methotrexate on cultured human macrophages.;Q484940;P703;Q15978631
[Methotrexate in conjunction with meloxicam for treating ankylosing spondylitis: a clinical observation of the efficacy and safety].;Q422232;P2175;Q52849
Six-month flare risk after discontinuing long-term methotrexate treatment in patients having rheumatoid arthritis with low disease activity;Q422232;P2175;Q170990
Six-month flare risk after discontinuing long-term methotrexate treatment in patients having rheumatoid arthritis with low disease activity;Q422232;P2175;Q187255
Effects of long-term administration of methotrexate on bone mineral density in rheumatoid arthritis;Q422232;P2175;Q170990
Effects of long-term administration of methotrexate on bone mineral density in rheumatoid arthritis;Q422232;P2175;Q187255
Convulsions and intracranial calcifications in a leukemic infant receiving only intrathecal methotrexate as central nervous system prophylaxis.;Q422232;P636;Q1320251
Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy.;Q422232;P636;Q640448
Efficacy and safety of a combination therapy of methotrexate, chloroquine and cyclophosphamide in patients with refractory rheumatoid arthritis: results of an observational study with matched-pair analysis.;Q422438;P2175;Q187255
Efficacy and safety of a combination therapy of methotrexate, chloroquine and cyclophosphamide in patients with refractory rheumatoid arthritis: results of an observational study with matched-pair analysis.;Q422232;P2175;Q187255
Efficacy and safety of a combination therapy of methotrexate, chloroquine and cyclophosphamide in patients with refractory rheumatoid arthritis: results of an observational study with matched-pair analysis.;Q422232;P2175;Q170990
Methotrexate in patients with rheumatoid arthritis in Spain: Subanalysis of the AR Excellence project.;Q422232;P2175;Q170990
Methotrexate in patients with rheumatoid arthritis in Spain: Subanalysis of the AR Excellence project.;Q422232;P2175;Q187255
[Metabolism of monocarbons and trisomy 21: sensitivity to methotrexate];Q191924;P527;Q623
[Metabolism of monocarbons and trisomy 21: sensitivity to methotrexate];Q413961;P527;Q623
Phase 1/2 study of synchronous methotrexate, cisplatin, vincristine (MOPq10) chemotherapy and radiation for patients with locally advanced bladder cancer.;Q412415;P2175;Q504775
Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients.;Q248550;P2175;Q187255
Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients.;Q248550;P2175;Q170990
Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients.;Q422232;P2175;Q170990
Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients.;Q422232;P2175;Q187255
Conservative management of cervical ectopic pregnancy: systemic methotrexate followed by curettage.;Q422232;P2175;Q207087
ACP Journal Club. Review: Methotrexate does not increase risk for lung disease in psoriasis, psoriatic arthritis, or IBD.;Q422232;P2175;Q170990
[Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug];Q186474;P31;Q12140
[Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug];Q191924;P366;Q8386
[Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug];Q422232;P31;Q12140
Methotrexate efficacy and tolerability after switching from oral to subcutaneous route of administration in juvenile idiopathic arthritis.;Q422232;P636;Q285166
Methotrexate efficacy and tolerability after switching from oral to subcutaneous route of administration in juvenile idiopathic arthritis.;Q422232;P2175;Q170990
Methotrexate efficacy and tolerability after switching from oral to subcutaneous route of administration in juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Antigenic changes associated with resistance to methotrexate and 6-mercaptopurine in L1210 ascites lymphoma.;Q422232;P2175;Q208414
[Remission maintenance with methotrexate, azathioprine or mycophenolate-mofetil after induction therapy with rituximab for granulomatosis with polyangiitis];Q412323;P2175;Q1161568
[Remission maintenance with methotrexate, azathioprine or mycophenolate-mofetil after induction therapy with rituximab for granulomatosis with polyangiitis];Q130336;P4149;Q27122100
[Remission maintenance with methotrexate, azathioprine or mycophenolate-mofetil after induction therapy with rituximab for granulomatosis with polyangiitis];Q130336;P31;Q407142
[Remission maintenance with methotrexate, azathioprine or mycophenolate-mofetil after induction therapy with rituximab for granulomatosis with polyangiitis];Q422232;P2175;Q1161568
Transport of methotrexate and other folate compounds: components, mechanism and regulation by cyclic nucleotides.;Q186521;P31;Q11173
Transport of methotrexate and other folate compounds: components, mechanism and regulation by cyclic nucleotides.;Q191924;P31;Q11173
Transport of methotrexate and other folate compounds: components, mechanism and regulation by cyclic nucleotides.;Q422232;P31;Q11173
[Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].;Q422232;P2175;Q29496
Retrospective analysis of factors that affect the success of single-dose methotrexate treatment in ectopic pregnancy;Q422232;P2175;Q207087
[Clinical evaluation of intra-arterial methotrexate, vinblastine, doxorubicin and cis-platinum for bladder cancer];Q18936;P2175;Q504775
Influence of plasma methotrexate level and MTHFR genotype in Korean paediatric patients with acute lymphoblastic leukaemia;Q422232;P2175;Q29496
Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study;Q422232;P2175;Q170990
Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study;Q422232;P361;Q14819383
Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study;Q422232;P2175;Q187255
Intermittent therapy with 6-mercaptopurine (NSC-755) and methotrexate (NSC-740) given intravenously to adults with acute leukemia;Q422232;P2175;Q29496
[Intracerebral calcifications associated with intrathecal methotrexate therapy in acute lymphocytic leukemia (author's transl)];Q422232;P2175;Q29496
[Intracerebral calcifications associated with intrathecal methotrexate therapy in acute lymphocytic leukemia (author's transl)];Q422232;P636;Q1320251
[Low-dose oral methotrexate in the treatment of rheumatoid polyarthritis];Q422232;P636;Q285166
[Low-dose oral methotrexate in the treatment of rheumatoid polyarthritis];Q422232;P2175;Q170990
[Low-dose oral methotrexate in the treatment of rheumatoid polyarthritis];Q422232;P2175;Q1274464
Primary Cutaneous Follicle Center Lymphoma in a 16-Year-old boy With Crohn Disease Exposed to Infliximab and Methotrexate;Q422232;P2175;Q208414
Methods for methotrexate determination in macromolecular conjugates drug carrier;Q191924;P31;Q12140
Methods for methotrexate determination in macromolecular conjugates drug carrier;Q22124685;P31;Q12140
Methods for methotrexate determination in macromolecular conjugates drug carrier;Q422232;P31;Q12140
Retrospective clinical study of the efficacy of lower-dose methotrexate and infliximab therapy in patients with rheumatoid arthritis;Q415264;P2175;Q170990
Retrospective clinical study of the efficacy of lower-dose methotrexate and infliximab therapy in patients with rheumatoid arthritis;Q422232;P2175;Q170990
Retrospective clinical study of the efficacy of lower-dose methotrexate and infliximab therapy in patients with rheumatoid arthritis;Q422232;P2175;Q187255
Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH.;Q183290;P703;Q15978631
Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH.;Q485277;P703;Q15978631
Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH.;Q178450;P703;Q15978631
Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH.;Q20816880;P703;Q15978631
Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH.;Q20035886;P703;Q15978631
Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH.;Q22124685;P703;Q15978631
Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH.;Q484940;P703;Q15978631
Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH.;Q422232;P2175;Q29496
A randomized, double-blind, and placebo-controlled multicenter clinical trial of a novel cytotoxic T-lymphocyte antigen-4 fusion protein, Leining, in Chinese active rheumatoid arthritis patients with an inadequate response to methotrexate;Q422232;P2175;Q187255
A randomized, double-blind, and placebo-controlled multicenter clinical trial of a novel cytotoxic T-lymphocyte antigen-4 fusion protein, Leining, in Chinese active rheumatoid arthritis patients with an inadequate response to methotrexate;Q422232;P361;Q14819383
A randomized, double-blind, and placebo-controlled multicenter clinical trial of a novel cytotoxic T-lymphocyte antigen-4 fusion protein, Leining, in Chinese active rheumatoid arthritis patients with an inadequate response to methotrexate;Q422232;P2175;Q170990
Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis: comment on the article by Gutierrez-Urea et al.;Q422232;P2175;Q170990
Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis: comment on the article by Gutierrez-Urea et al.;Q422232;P2175;Q187255
Despite some expression of folate receptor alpha in human mesothelioma cells, internalization of methotrexate is predominantly carrier mediated.;Q178450;P703;Q15978631
Low efficacy of methotrexate in childhood acute myeloid leukemia (AML): single-agent therapeutic window study in relapsed AML;Q218642;P703;Q177932
Low efficacy of methotrexate in childhood acute myeloid leukemia (AML): single-agent therapeutic window study in relapsed AML;Q22124685;P703;Q177932
Low efficacy of methotrexate in childhood acute myeloid leukemia (AML): single-agent therapeutic window study in relapsed AML;Q483745;P703;Q177932
Low efficacy of methotrexate in childhood acute myeloid leukemia (AML): single-agent therapeutic window study in relapsed AML;Q422232;P2175;Q264118
Low efficacy of methotrexate in childhood acute myeloid leukemia (AML): single-agent therapeutic window study in relapsed AML;Q422232;P2175;Q29496
[Primary malignant lymphoma in the central nervous system treated with high dose methotrexate (MTX)-CHOP (M-CHOP)];Q422232;P2175;Q208414
Capillary electrophoretic determination of triamterene, methotrexate, and creatinine in human urine.;Q186474;P703;Q15978631
Methotrexate reduces keratinocyte proliferation, migration and induces apoptosis in HaCaT keratinocytes in vitro and reduces wound closure in Skh1 mice in vivo;Q186474;P703;Q83310
Early prediction of methotrexate treatment outcome in tubal ectopic pregnancy based on days 0 and 4 human chorionic gonadotropin levels;Q407172;P703;Q15978631
Early prediction of methotrexate treatment outcome in tubal ectopic pregnancy based on days 0 and 4 human chorionic gonadotropin levels;Q407172;P279;Q409770
Early prediction of methotrexate treatment outcome in tubal ectopic pregnancy based on days 0 and 4 human chorionic gonadotropin levels;Q422232;P2175;Q207087
Monitoring the cytotoxic potential of a sequential polychemotherapy (adriamycin/cisplatin-vincristine/cyclophosphamide-high dose methotrexate) in patients with advanced ovarian cancer with the tumor marker CA-125;Q412415;P2175;Q172341
Protective effects of amifostine and cyclooxygenase-1 inhibitor against normal human epidermal keratinocyte toxicity induced by methotrexate and 5-fluorouracil.;Q20035886;P703;Q15978631
Additive combination of actarit and methotrexate in the treatment of refractory rheumatoid arthritis.;Q422232;P2175;Q170990
Additive combination of actarit and methotrexate in the treatment of refractory rheumatoid arthritis.;Q422232;P2175;Q187255
[An extremely high serum methotrexate concentration associated with acute renal failure in a patient with acute lymphoblastic leukemia after conduction of high dose consolidation];Q422232;P2175;Q29496
Management of interstitial ectopic pregnancy with intravenous methotrexate: An extended study of a standardised regimen;Q422232;P2175;Q207087
Enhanced cytotoxicity and apoptosis by raloxifene in combination with estrogen and methotrexate in human endometrial stromal cells.;Q422416;P703;Q15978631
Enhanced cytotoxicity and apoptosis by raloxifene in combination with estrogen and methotrexate in human endometrial stromal cells.;Q422416;P279;Q277954
Cutaneous Breast Cancer Metastases Successfully Treated Using an Oxygen Flow Assisted Topical Administration of Methotrexate (OFAMTX);Q170545;P527;Q629
Development and Validation of UHPLC-MS/MS Assay for Therapeutic Drug Monitoring of High-dose Methotrexate in Children with Acute Lymphoblastic Leukemia;Q218642;P703;Q177932
Development and Validation of UHPLC-MS/MS Assay for Therapeutic Drug Monitoring of High-dose Methotrexate in Children with Acute Lymphoblastic Leukemia;Q183290;P703;Q177932
Development and Validation of UHPLC-MS/MS Assay for Therapeutic Drug Monitoring of High-dose Methotrexate in Children with Acute Lymphoblastic Leukemia;Q186474;P703;Q177932
Development and Validation of UHPLC-MS/MS Assay for Therapeutic Drug Monitoring of High-dose Methotrexate in Children with Acute Lymphoblastic Leukemia;Q186521;P703;Q177932
Development and Validation of UHPLC-MS/MS Assay for Therapeutic Drug Monitoring of High-dose Methotrexate in Children with Acute Lymphoblastic Leukemia;Q485277;P703;Q177932
Development and Validation of UHPLC-MS/MS Assay for Therapeutic Drug Monitoring of High-dose Methotrexate in Children with Acute Lymphoblastic Leukemia;Q178450;P703;Q177932
Development and Validation of UHPLC-MS/MS Assay for Therapeutic Drug Monitoring of High-dose Methotrexate in Children with Acute Lymphoblastic Leukemia;Q20035886;P703;Q177932
Development and Validation of UHPLC-MS/MS Assay for Therapeutic Drug Monitoring of High-dose Methotrexate in Children with Acute Lymphoblastic Leukemia;Q22124685;P703;Q177932
Development and Validation of UHPLC-MS/MS Assay for Therapeutic Drug Monitoring of High-dose Methotrexate in Children with Acute Lymphoblastic Leukemia;Q483745;P703;Q177932
Development and Validation of UHPLC-MS/MS Assay for Therapeutic Drug Monitoring of High-dose Methotrexate in Children with Acute Lymphoblastic Leukemia;Q483752;P703;Q177932
Medical ozone increases methotrexate clinical response and improves cellular redox balance in patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Medical ozone increases methotrexate clinical response and improves cellular redox balance in patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Successful treatment of methotrexate intolerance in juvenile idiopathic arthritis using eye movement desensitization and reprocessing - treatment protocol and preliminary results.;Q422232;P2175;Q861224
Successful treatment of methotrexate intolerance in juvenile idiopathic arthritis using eye movement desensitization and reprocessing - treatment protocol and preliminary results.;Q422232;P2175;Q170990
Synergistic interaction of methotrexate and 6-mercaptopurine in human derived malignant T-ALL and CALLA+ cell lines.;Q218642;P703;Q15978631
Synergistic interaction of methotrexate and 6-mercaptopurine in human derived malignant T-ALL and CALLA+ cell lines.;Q183290;P703;Q15978631
Synergistic interaction of methotrexate and 6-mercaptopurine in human derived malignant T-ALL and CALLA+ cell lines.;Q186474;P703;Q15978631
Synergistic interaction of methotrexate and 6-mercaptopurine in human derived malignant T-ALL and CALLA+ cell lines.;Q287415;P703;Q15978631
Synergistic interaction of methotrexate and 6-mercaptopurine in human derived malignant T-ALL and CALLA+ cell lines.;Q186521;P703;Q15978631
Synergistic interaction of methotrexate and 6-mercaptopurine in human derived malignant T-ALL and CALLA+ cell lines.;Q483745;P703;Q15978631
Synergistic interaction of methotrexate and 6-mercaptopurine in human derived malignant T-ALL and CALLA+ cell lines.;Q422232;P2175;Q55789426
Effectiveness of cytosine arabinoside therapy on leukemia (L-1210) of the central nervous system in mice arising during methotrexate treatment.;Q180983;P2175;Q29496
Effectiveness of cytosine arabinoside therapy on leukemia (L-1210) of the central nervous system in mice arising during methotrexate treatment.;Q422232;P2175;Q29496
Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.;Q422232;P2175;Q549534
Large scale synthesis of recombinant human thyrotropin using methotrexate amplification: chromatographic, immunological, and biological characterization.;Q483745;P703;Q15978631
Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis;Q422232;P2175;Q170990
Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis;Q422232;P2175;Q17148432
Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis;Q422232;P2175;Q861224
Study of neoadjuvant chemotherapy for invasive bladder cancer with MEC (methotrexate, epirubicin, cisplatin) therapy;Q412415;P2175;Q504775
Intermittent intrathecal methotrexate and fractional radiation (M-IMFRA) plus chemotherapy in childhood leukemia.;Q422232;P2175;Q29496
Intermittent intrathecal methotrexate and fractional radiation (M-IMFRA) plus chemotherapy in childhood leukemia.;Q422232;P636;Q1320251
[Rheumatoid arthritis: what to do if methotrexate fails?].;Q422232;P2175;Q170990
[Rheumatoid arthritis: what to do if methotrexate fails?].;Q422232;P2175;Q187255
Methotrexate pneumonia lacking dyspnea and radiographic interstitial patterns during treatment for early rheumatoid arthritis: bronchoalveolar lavage and transbronchial lung biopsy in a differential diagnosis.;Q422232;P2175;Q187255
Methotrexate pneumonia lacking dyspnea and radiographic interstitial patterns during treatment for early rheumatoid arthritis: bronchoalveolar lavage and transbronchial lung biopsy in a differential diagnosis.;Q422232;P2175;Q170990
Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: A retrospective chart review;Q218642;P703;Q15978631
Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: A retrospective chart review;Q415264;P2175;Q1526459
Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: A retrospective chart review;Q483745;P703;Q15978631
Phase II study of tacrolimus and methotrexate for prophylaxis of acute graft-versus-host disease after HLA-A, B, and DRB1 genotypically mismatched unrelated bone marrow transplantation among Japanese patients.;Q411648;P2175;Q1194520
The association of aberrant folylpolyglutamate synthetase splicing with ex vivo methotrexate resistance and clinical outcome in childhood acute lymphoblastic leukemia;Q422232;P2175;Q29496
Juvenile idiopathic arthritis: updated guide to administering methotrexate;Q422232;P2175;Q170990
Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: the Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results;Q2858961;P2175;Q170990
Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: the Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results;Q422232;P2175;Q170990
Evaluation of serum and urine fetuin-A levels in children with acute lymphoblastic leukemia during and after high-dose methotrexate therapy: Relation to toxicity.;Q422232;P2175;Q29496
Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes;Q238512;P2175;Q128581
Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes;Q425122;P2175;Q128581
Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes;Q423762;P2175;Q128581
Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes;Q422232;P2175;Q128581
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.;Q415264;P2175;Q170990
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.;Q422232;P2175;Q187255
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.;Q422232;P2175;Q170990
Rheumatologists' recommended patient information when prescribing methotrexate for rheumatoid arthritis.;Q422232;P2175;Q187255
Rheumatologists' recommended patient information when prescribing methotrexate for rheumatoid arthritis.;Q422232;P2175;Q170990
[Effects of sinomenine and methotrexate on fibroblast-like synoviocytes in rheumatoid arthritis];Q422232;P2175;Q187255
[Effects of sinomenine and methotrexate on fibroblast-like synoviocytes in rheumatoid arthritis];Q422232;P2175;Q170990
[A case of Borrmann type 4 gastric cancer responding to sequential methotrexate and 5-fluorouracil combined with CDDP];Q412415;P2175;Q189588
[A case of Borrmann type 4 gastric cancer responding to sequential methotrexate and 5-fluorouracil combined with CDDP];Q238512;P2175;Q189588
[A case of Borrmann type 4 gastric cancer responding to sequential methotrexate and 5-fluorouracil combined with CDDP];Q422232;P2175;Q189588
MiR-595 Suppresses the Cellular Uptake and Cytotoxic Effects of Methotrexate by Targeting SLC19A1 in CEM/C1 Cells.;Q422232;P129;Q21126218
Aim for remission or "personal best" using combination DMARD therapy with methotrexate and hydroxychloroquine;Q421094;P1889;Q422438
Aim for remission or "personal best" using combination DMARD therapy with methotrexate and hydroxychloroquine;Q421094;P2868;Q810254
Aim for remission or "personal best" using combination DMARD therapy with methotrexate and hydroxychloroquine;Q422438;P2868;Q810254
Aim for remission or "personal best" using combination DMARD therapy with methotrexate and hydroxychloroquine;Q422438;P1889;Q421094
Aim for remission or "personal best" using combination DMARD therapy with methotrexate and hydroxychloroquine;Q422232;P2868;Q810254
Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib.;Q3011604;P2175;Q180614
Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia.;Q422232;P2175;Q29496
Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia.;Q422232;P129;Q21126218
Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis.;Q422232;P2175;Q187255
Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis.;Q422232;P2175;Q170990
TYMS polymorphisms and responsiveness to or toxicity of methotrexate in rheumatoid arthritis.;Q422232;P2175;Q170990
TYMS polymorphisms and responsiveness to or toxicity of methotrexate in rheumatoid arthritis.;Q422232;P2175;Q187255
Combination D-penicillamine and methotrexate therapy: proposal for early and aggressive treatment for rheumatoid arthritis.;Q421239;P2175;Q187255
Combination D-penicillamine and methotrexate therapy: proposal for early and aggressive treatment for rheumatoid arthritis.;Q422232;P2175;Q187255
Combination D-penicillamine and methotrexate therapy: proposal for early and aggressive treatment for rheumatoid arthritis.;Q422232;P2175;Q170990
Recommendations for the use of methotrexate in psoriatic arthritis.;Q422232;P2175;Q170990
Salvage treatment with intermediate-dose methotrexate and 5-fluorouracil in metastatic breast cancer.;Q238512;P2175;Q128581
Salvage treatment with intermediate-dose methotrexate and 5-fluorouracil in metastatic breast cancer.;Q422232;P2175;Q128581
Methotrexate with citrovorum factor rescue for nonmetastatic gestational trophoblastic neoplasms.;Q422232;P2175;Q7845637
Acute methotrexate neurotoxicity revealed by a cerebellar syndrome.;Q191924;P2868;Q407752
Treatment of ectopic pregnancy with methotrexate;Q422232;P2175;Q207087
CD8(+) T-cell lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis during methotrexate therapy.;Q422232;P2175;Q187255
CD8(+) T-cell lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis during methotrexate therapy.;Q422232;P2175;Q170990
[Clinical Analysis of Combination Chemotherapy Using High Dose Methotrexate, Rituximab, and Vincristine with or without Procarbazine for Elderly Patients with Diffuse Large B-Cell Lymphoma of the Central Nervous System].;Q408977;P2175;Q208414
[Clinical Analysis of Combination Chemotherapy Using High Dose Methotrexate, Rituximab, and Vincristine with or without Procarbazine for Elderly Patients with Diffuse Large B-Cell Lymphoma of the Central Nervous System].;Q418656;P2175;Q208414
[Clinical Analysis of Combination Chemotherapy Using High Dose Methotrexate, Rituximab, and Vincristine with or without Procarbazine for Elderly Patients with Diffuse Large B-Cell Lymphoma of the Central Nervous System].;Q422232;P2175;Q208414
Cytological changes in the cerebrospinal fluid following intrathecal methotrexate treatment. I. Observations in adult meningeal leukemia.;Q422232;P2175;Q29496
Cytological changes in the cerebrospinal fluid following intrathecal methotrexate treatment. I. Observations in adult meningeal leukemia.;Q422232;P636;Q1320251
Methylenetetrahydrofolate reductase and reduced folate carrier-1 genotypes and methotrexate serum concentrations in patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Methylenetetrahydrofolate reductase and reduced folate carrier-1 genotypes and methotrexate serum concentrations in patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind stud;Q422232;P2175;Q187255
Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind stud;Q422232;P361;Q14819383
Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind stud;Q422232;P2175;Q170990
Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative;Q18936;P2175;Q128581
Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative;Q412178;P2175;Q128581
Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative;Q238512;P2175;Q128581
Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative;Q422232;P2175;Q128581
[Clinical study of Biqi Capsule combined with methotrexate for treatment of rheumatoid arthritis];Q422232;P2175;Q187255
[Clinical study of Biqi Capsule combined with methotrexate for treatment of rheumatoid arthritis];Q422232;P2175;Q170990
Decrease of adenosine deaminase activity and increase of the lipid peroxidation after acute methotrexate treatment in young rats: protective effects of grape seed extract.;Q190012;P361;Q14864762
Decrease of adenosine deaminase activity and increase of the lipid peroxidation after acute methotrexate treatment in young rats: protective effects of grape seed extract.;Q178450;P703;Q177932
Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients;Q422232;P2175;Q187255
Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients;Q422232;P2175;Q170990
Effect of Sanhuangyilong decoction plus methotrexate on tumor necrosis factor alpha and interferon gamma in serum and synovial fluid in rheumatoid arthritis patients with symptom pattern of damp heat obstruction;Q422232;P2175;Q170990
Effect of Sanhuangyilong decoction plus methotrexate on tumor necrosis factor alpha and interferon gamma in serum and synovial fluid in rheumatoid arthritis patients with symptom pattern of damp heat obstruction;Q422232;P2175;Q187255
Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.;Q248550;P2175;Q170990
Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.;Q248550;P2175;Q187255
Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.;Q412323;P2175;Q170990
Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.;Q422232;P2175;Q170990
Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.;Q422232;P2175;Q187255
[Moderate dose methotrexate with citrovorum factor rescue therapy in the treatment of head and neck cancer];Q422232;P2175;Q1783924
Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy;Q218642;P31;Q407595
Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy;Q218642;P703;Q2046782
Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy;Q422232;P2175;Q29496
Microbubble-enhanced ultrasound exposure promotes uptake of methotrexate into synovial cells and enhanced antiinflammatory effects in the knees of rabbits with antigen-induced arthritis.;Q422232;P2175;Q170990
Interferon (IFN)-alpha and IFN-gamma in combination with methotrexate: in vitro sensitivity studies in four human mesothelioma cell lines.;Q170545;P703;Q15978631
Interferon (IFN)-alpha and IFN-gamma in combination with methotrexate: in vitro sensitivity studies in four human mesothelioma cell lines.;Q484940;P703;Q15978631
Low-dose Methotrexate Treatment for Solitary or Localized Primary Cutaneous Anaplastic Large Cell Lymphoma: A Long-term Follow-up Study;Q422232;P2175;Q208414
The impact on disability of initial treatment with methotrexate in patients with rheumatoid arthritis: results from the MARI study.;Q422232;P2175;Q170990
The impact on disability of initial treatment with methotrexate in patients with rheumatoid arthritis: results from the MARI study.;Q422232;P2175;Q187255
[Studies of methotrexate pharmacokinetics in children with neoplasms of the hematopoietic system after administration of different doses of the drug];Q183290;P31;Q12140
[Studies of methotrexate pharmacokinetics in children with neoplasms of the hematopoietic system after administration of different doses of the drug];Q191924;P366;Q8386
[Studies of methotrexate pharmacokinetics in children with neoplasms of the hematopoietic system after administration of different doses of the drug];Q422232;P31;Q12140
Effectiveness of tacrolimus in comparison with methotrexate or biologics in propensity score-matched patients with rheumatoid arthritis;Q422232;P2175;Q170990
Effectiveness of tacrolimus in comparison with methotrexate or biologics in propensity score-matched patients with rheumatoid arthritis;Q422232;P2175;Q187255
Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.;Q425154;P2175;Q170990
Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.;Q422232;P2175;Q170990
Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.;Q422232;P2175;Q187255
Natural resistance to methotrexate in human acute nonlymphocytic leukemia.;Q422232;P2175;Q29496
Comparison of methotrexate polyglutamylation in L1210 leukemia cells when influx is mediated by the reduced folate carrier or the folate receptor. Lack of evidence for influx route-specific effects.;Q422232;P2175;Q29496
High-dose methotrexate in the mobilization of hematopoietic stem cells for patients with non-Hodgkin's lymphoma: a twelve-year study in a single center.;Q422232;P2175;Q208414
High-dose methotrexate in the mobilization of hematopoietic stem cells for patients with non-Hodgkin's lymphoma: a twelve-year study in a single center.;Q422232;P2175;Q1138590
Therapeutic drug monitoring of methotrexate on the pediatric oncology ward: can blood sampling from central venous accesses substitute for capillary finger punctures?;Q186521;P31;Q12140
Therapeutic drug monitoring of methotrexate on the pediatric oncology ward: can blood sampling from central venous accesses substitute for capillary finger punctures?;Q186521;P703;Q177932
Therapeutic drug monitoring of methotrexate on the pediatric oncology ward: can blood sampling from central venous accesses substitute for capillary finger punctures?;Q191924;P31;Q12140
Therapeutic drug monitoring of methotrexate on the pediatric oncology ward: can blood sampling from central venous accesses substitute for capillary finger punctures?;Q422232;P31;Q12140
The relationship of the immune response mediator genes polymorphic variants with the methotrexate efficacy in juvenile idiopathic arthritis;Q422232;P2175;Q170990
The relationship of the immune response mediator genes polymorphic variants with the methotrexate efficacy in juvenile idiopathic arthritis;Q422232;P2175;Q861224
[Increasing the radioprotective therapeutic efficacy of typhoid vaccine using sexta-anatoxin in combination with the antimetabolite methotrexate];Q484940;P703;Q177932
Oral methotrexate in the treatment of rheumatoid arthritis: allergic agranulocytosis?;Q422232;P2175;Q187255
Oral methotrexate in the treatment of rheumatoid arthritis: allergic agranulocytosis?;Q422232;P2175;Q170990
Intermediate dose methotrexate (IDM) in childhood acute lymphocytic leukemia (ALL).;Q422232;P2175;Q29496
[Efficacy and safety of treatment with methotrexate, leflunomide, detralex, and their combination of patients with rheumatoid arthritis].;Q248550;P2175;Q170990
[Efficacy and safety of treatment with methotrexate, leflunomide, detralex, and their combination of patients with rheumatoid arthritis].;Q248550;P2175;Q187255
[Efficacy and safety of treatment with methotrexate, leflunomide, detralex, and their combination of patients with rheumatoid arthritis].;Q422232;P2175;Q187255
[Efficacy and safety of treatment with methotrexate, leflunomide, detralex, and their combination of patients with rheumatoid arthritis].;Q422232;P2175;Q170990
Effects of naproxen and sulphasalazine or methotrexate on hypothalamic-pituitary-adrenal axis activity in patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Effects of naproxen and sulphasalazine or methotrexate on hypothalamic-pituitary-adrenal axis activity in patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Effects of naproxen and sulphasalazine or methotrexate on hypothalamic-pituitary-adrenal axis activity in patients with rheumatoid arthritis.;Q1215575;P2175;Q187255
Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia.;Q422232;P2175;Q29496
Doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil for breast cancer;Q18936;P2175;Q128581
Doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil for breast cancer;Q238512;P2175;Q128581
Doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil for breast cancer;Q422232;P2175;Q128581
[Cost of medical treatment with methotrexate for ectopic pregnancy. Study comparing medical treatment versus laparoscopy. Experience of Aziza Othmana Hospital].;Q422232;P2175;Q207087
Protein binding of methotrexate to human albumin and serum. A first derivative spectroscopic analysis.;Q218642;P703;Q15978631
Protein binding of methotrexate to human albumin and serum. A first derivative spectroscopic analysis.;Q20035886;P703;Q15978631
[An open-label, multicentric clinical trial to evaluate the efficacy and impact on bone metabolism of recombinant human tumor necrosis factor- receptor II IgG Fc fusion protein with methotrexate in active rheumatoid arthritis: 24-week clinical and;Q218642;P703;Q15978631
[An open-label, multicentric clinical trial to evaluate the efficacy and impact on bone metabolism of recombinant human tumor necrosis factor- receptor II IgG Fc fusion protein with methotrexate in active rheumatoid arthritis: 24-week clinical and;Q415343;P2175;Q170990
[An open-label, multicentric clinical trial to evaluate the efficacy and impact on bone metabolism of recombinant human tumor necrosis factor- receptor II IgG Fc fusion protein with methotrexate in active rheumatoid arthritis: 24-week clinical and;Q415343;P2175;Q187255
[An open-label, multicentric clinical trial to evaluate the efficacy and impact on bone metabolism of recombinant human tumor necrosis factor- receptor II IgG Fc fusion protein with methotrexate in active rheumatoid arthritis: 24-week clinical and;Q170545;P703;Q15978631
[An open-label, multicentric clinical trial to evaluate the efficacy and impact on bone metabolism of recombinant human tumor necrosis factor- receptor II IgG Fc fusion protein with methotrexate in active rheumatoid arthritis: 24-week clinical and;Q620730;P703;Q15978631
[An open-label, multicentric clinical trial to evaluate the efficacy and impact on bone metabolism of recombinant human tumor necrosis factor- receptor II IgG Fc fusion protein with methotrexate in active rheumatoid arthritis: 24-week clinical and;Q484940;P703;Q15978631
[An open-label, multicentric clinical trial to evaluate the efficacy and impact on bone metabolism of recombinant human tumor necrosis factor- receptor II IgG Fc fusion protein with methotrexate in active rheumatoid arthritis: 24-week clinical and;Q422232;P2175;Q170990
[An open-label, multicentric clinical trial to evaluate the efficacy and impact on bone metabolism of recombinant human tumor necrosis factor- receptor II IgG Fc fusion protein with methotrexate in active rheumatoid arthritis: 24-week clinical and;Q422232;P2175;Q187255
[The influence of IL-6 polymorphism on efficacy of treatment of rheumatoid arthritis patients with methotrexate and prednisone].;Q424972;P2175;Q170990
[The influence of IL-6 polymorphism on efficacy of treatment of rheumatoid arthritis patients with methotrexate and prednisone].;Q422232;P2175;Q187255
[The influence of IL-6 polymorphism on efficacy of treatment of rheumatoid arthritis patients with methotrexate and prednisone].;Q422232;P2175;Q170990
Oral tuberculosis in a patient with rheumatoid arthritis after long treatment with methotrexate and adalimumab;Q348260;P2175;Q170990
Oral tuberculosis in a patient with rheumatoid arthritis after long treatment with methotrexate and adalimumab;Q348260;P2175;Q187255
Oral tuberculosis in a patient with rheumatoid arthritis after long treatment with methotrexate and adalimumab;Q422232;P2175;Q187255
Oral tuberculosis in a patient with rheumatoid arthritis after long treatment with methotrexate and adalimumab;Q422232;P2175;Q170990
Secondary acute myelocytic leukemia after adjuvant therapy for early-stage breast carcinoma. A new complication of cyclophosphamide, methotrexate, and 5-fluorouracil therapy.;Q422232;P2175;Q29496
Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis.;Q422232;P2175;Q170990
Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis.;Q422232;P2175;Q187255
Lack of interaction between flucloxacillin and methotrexate in patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Lack of interaction between flucloxacillin and methotrexate in patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Increased activity of gamma-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate (MTX).;Q186521;P703;Q15978631
Increased activity of gamma-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate (MTX).;Q22124685;P703;Q15978631
Increased activity of gamma-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate (MTX).;Q484940;P703;Q15978631
Laparoscopic salpingocentesis using methotrexate in combination with oral mifepristone for successful treatment of interstitial pregnancy: a case report;Q422232;P636;Q285166
A targeted nanocarrier based on polyspermine for the effective delivery of methotrexate in nasopharyngeal carcinoma.;Q424597;P31;Q109379097
Life-threatening pneumonitis complicating low-dose methotrexate treatment for juvenile idiopathic arthritis in a child.;Q422232;P2175;Q170990
Life-threatening pneumonitis complicating low-dose methotrexate treatment for juvenile idiopathic arthritis in a child.;Q422232;P2175;Q861224
Methotrexate induced seizures associated with acute reversible magnetic resonance imaging (MRI) changes in a patient with acute lymphoblastic leukemia.;Q422232;P2175;Q29496
[Pembrolizumab is more effective and better tolerable than methotrexate, docetaxel, or cetuximab in recurrent or metastatic HNSCC (KEYNOTE-040)];Q420296;P2175;Q18348812
Methotrexate ultraviolet reactivation reaction in the setting of voriconazole-induced phototoxicity;Q412236;P279;Q419639
Membrane-Spanning Protein Genetic Polymorphisms Related to Methotrexate Therapeutic Outcomes in a Chinese Rheumatoid Arthritis Population;Q218642;P703;Q177932
Membrane-Spanning Protein Genetic Polymorphisms Related to Methotrexate Therapeutic Outcomes in a Chinese Rheumatoid Arthritis Population;Q183290;P703;Q177932
Membrane-Spanning Protein Genetic Polymorphisms Related to Methotrexate Therapeutic Outcomes in a Chinese Rheumatoid Arthritis Population;Q186474;P703;Q177932
Membrane-Spanning Protein Genetic Polymorphisms Related to Methotrexate Therapeutic Outcomes in a Chinese Rheumatoid Arthritis Population;Q186521;P703;Q177932
Membrane-Spanning Protein Genetic Polymorphisms Related to Methotrexate Therapeutic Outcomes in a Chinese Rheumatoid Arthritis Population;Q173670;P703;Q177932
Membrane-Spanning Protein Genetic Polymorphisms Related to Methotrexate Therapeutic Outcomes in a Chinese Rheumatoid Arthritis Population;Q20035886;P703;Q177932
Membrane-Spanning Protein Genetic Polymorphisms Related to Methotrexate Therapeutic Outcomes in a Chinese Rheumatoid Arthritis Population;Q22124685;P703;Q177932
Membrane-Spanning Protein Genetic Polymorphisms Related to Methotrexate Therapeutic Outcomes in a Chinese Rheumatoid Arthritis Population;Q620730;P703;Q177932
Noncardiogenic pulmonary edema in low-dose oral methotrexate therapy.;Q422232;P636;Q285166
Protective effect of a synthetic analog of prostaglandin E(1) on the small intestinal damage induced by the administration of methotrexate to rats.;Q4860325;P279;Q209717
Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA.;Q418817;P2175;Q208414
Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA.;Q422252;P2175;Q208414
Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA.;Q422232;P2175;Q208414
Efficacy of pegaspargase, etoposide, methotrexate and dexamethasone in newly diagnosed advanced-stage extra-nodal natural killer/T-cell lymphoma with the analysis of the prognosis of whole blood EBV-DNA.;Q422232;P2175;Q7667896
The Temporal Relationship between Arterial Stiffening and Blood Pressure Is Modified by Methotrexate Treatment in Patients with Rheumatoid Arthritis.;Q422232;P636;Q285166
High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group.;Q256502;P2175;Q12078
High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group.;Q238512;P2175;Q2739660
High-dose methotrexate for the remission induction of refractory adult acute lymphocytic leukemia.;Q422232;P2175;Q29496
Efficacy of concurrent administration of cilostazol and methotrexate in rheumatoid arthritis: pharmacologic and clinical significance.;Q422232;P2175;Q170990
Efficacy of concurrent administration of cilostazol and methotrexate in rheumatoid arthritis: pharmacologic and clinical significance.;Q422232;P2175;Q187255
[Preliminary results of a chemotherapy study of patients with squamous cell carcinoma in the head and neck region. Comparison of 2 therapeutic regimens: cis-diamminodichloroplatinum (II) and bleomycin compared to methotrexate and vindesine];Q186474;P703;Q177932
[Preliminary results of a chemotherapy study of patients with squamous cell carcinoma in the head and neck region. Comparison of 2 therapeutic regimens: cis-diamminodichloroplatinum (II) and bleomycin compared to methotrexate and vindesine];Q20035886;P703;Q177932
[Preliminary results of a chemotherapy study of patients with squamous cell carcinoma in the head and neck region. Comparison of 2 therapeutic regimens: cis-diamminodichloroplatinum (II) and bleomycin compared to methotrexate and vindesine];Q484940;P703;Q177932
Differential modulation of human chorionic gonadotropin production by methotrexate in normal and malignant placental cultures and its increase by dibutyryl cyclic adenosine monophosphate and/or actinomycin D in normal cultures.;Q407172;P279;Q409770
Differential modulation of human chorionic gonadotropin production by methotrexate in normal and malignant placental cultures and its increase by dibutyryl cyclic adenosine monophosphate and/or actinomycin D in normal cultures.;Q407172;P703;Q15978631
Differential modulation of human chorionic gonadotropin production by methotrexate in normal and malignant placental cultures and its increase by dibutyryl cyclic adenosine monophosphate and/or actinomycin D in normal cultures.;Q190012;P703;Q15978631
Differential modulation of human chorionic gonadotropin production by methotrexate in normal and malignant placental cultures and its increase by dibutyryl cyclic adenosine monophosphate and/or actinomycin D in normal cultures.;Q318369;P703;Q15978631
Differential modulation of human chorionic gonadotropin production by methotrexate in normal and malignant placental cultures and its increase by dibutyryl cyclic adenosine monophosphate and/or actinomycin D in normal cultures.;Q178450;P703;Q15978631
Further insight into the markers of methotrexate resistance in childhood acute lymphoblastic leukemia patients;Q422232;P2175;Q29496
Encapsulation of methotrexate and cyclophosphamide in interpolymer complexes formed between poly acrylic acid and poly ethylene glycol on multi-walled carbon nanotubes as drug delivery systems.;Q23118;P31;Q8386
Encapsulation of methotrexate and cyclophosphamide in interpolymer complexes formed between poly acrylic acid and poly ethylene glycol on multi-walled carbon nanotubes as drug delivery systems.;Q23118;P527;Q623
Encapsulation of methotrexate and cyclophosphamide in interpolymer complexes formed between poly acrylic acid and poly ethylene glycol on multi-walled carbon nanotubes as drug delivery systems.;Q191924;P527;Q623
Encapsulation of methotrexate and cyclophosphamide in interpolymer complexes formed between poly acrylic acid and poly ethylene glycol on multi-walled carbon nanotubes as drug delivery systems.;Q191924;P366;Q8386
Encapsulation of methotrexate and cyclophosphamide in interpolymer complexes formed between poly acrylic acid and poly ethylene glycol on multi-walled carbon nanotubes as drug delivery systems.;Q422232;P31;Q12140
Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.;Q420035;P2175;Q170990
Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.;Q420035;P2175;Q187255
Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.;Q422232;P2175;Q170990
Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.;Q422232;P2175;Q187255
Factors associated with radiographic progression in patients with rheumatoid arthritis who were treated with methotrexate;Q422232;P2175;Q170990
Factors associated with radiographic progression in patients with rheumatoid arthritis who were treated with methotrexate;Q422232;P2175;Q187255
Pharmacokinetics of nimustine, methotrexate, and cytosine arabinoside during cerebrospinal fluid perfusion chemotherapy in patients with disseminated brain tumors.;Q422232;P636;Q640448
Treatment of unruptured cornual pregnancies by local injections of methotrexate or potassium chloride under transvaginal ultrasonographic guidance.;Q184630;P527;Q703
Treatment of unruptured cornual pregnancies by local injections of methotrexate or potassium chloride under transvaginal ultrasonographic guidance.;Q184630;P527;Q108200
Severe oral ulceration in a patient taking low-dose methotrexate for rheumatoid arthritis.;Q422232;P2175;Q170990
Severe oral ulceration in a patient taking low-dose methotrexate for rheumatoid arthritis.;Q422232;P636;Q285166
Severe oral ulceration in a patient taking low-dose methotrexate for rheumatoid arthritis.;Q422232;P2175;Q187255
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma;Q180983;P2175;Q208414
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma;Q180983;P2175;Q1138590
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma;Q408977;P2175;Q208414
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma;Q408977;P2175;Q1138590
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma;Q422252;P2175;Q208414
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma;Q422252;P2175;Q1138590
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma;Q422232;P2175;Q208414
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma;Q422232;P2175;Q1138590
Brain tumor chemotherapy with methotrexate given intrathecally. A new technique.;Q422232;P636;Q1320251
Methotrexate accumulates to similar levels in animals transplanted with normal versus drug-resistant transgenic marrow.;Q22124685;P31;Q12140
Methotrexate accumulates to similar levels in animals transplanted with normal versus drug-resistant transgenic marrow.;Q422232;P31;Q12140
Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world.;Q18936;P2175;Q504775
Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world.;Q412415;P2175;Q504775
Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma by combined methotrexate and prednisone.;Q422232;P2175;Q7667896
Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma by combined methotrexate and prednisone.;Q422232;P2175;Q208414
[The efficacy of combination therapy with prednisolone (PSL) and methotrexate (MTX) on radiographic progression in patients with rheumatoid arthritis (RA)];Q422232;P2175;Q187255
[The efficacy of combination therapy with prednisolone (PSL) and methotrexate (MTX) on radiographic progression in patients with rheumatoid arthritis (RA)];Q422232;P2175;Q170990
A dexamethasone, vinblastine, cyclophosphamide, etoposide, methotrexate and bleomycin (D-VICEMB) protocol as first-line treatment of patients aged 70 years or older affected by intermediate/high grade non-Hodgkin's lymphoma.;Q418817;P2175;Q208414
A dexamethasone, vinblastine, cyclophosphamide, etoposide, methotrexate and bleomycin (D-VICEMB) protocol as first-line treatment of patients aged 70 years or older affected by intermediate/high grade non-Hodgkin's lymphoma.;Q418817;P2175;Q1138590
A dexamethasone, vinblastine, cyclophosphamide, etoposide, methotrexate and bleomycin (D-VICEMB) protocol as first-line treatment of patients aged 70 years or older affected by intermediate/high grade non-Hodgkin's lymphoma.;Q422252;P2175;Q208414
A dexamethasone, vinblastine, cyclophosphamide, etoposide, methotrexate and bleomycin (D-VICEMB) protocol as first-line treatment of patients aged 70 years or older affected by intermediate/high grade non-Hodgkin's lymphoma.;Q422252;P2175;Q1138590
A dexamethasone, vinblastine, cyclophosphamide, etoposide, methotrexate and bleomycin (D-VICEMB) protocol as first-line treatment of patients aged 70 years or older affected by intermediate/high grade non-Hodgkin's lymphoma.;Q422232;P2175;Q1138590
A dexamethasone, vinblastine, cyclophosphamide, etoposide, methotrexate and bleomycin (D-VICEMB) protocol as first-line treatment of patients aged 70 years or older affected by intermediate/high grade non-Hodgkin's lymphoma.;Q422232;P2175;Q208414
Collateral sensitivity to azidothymidine in methotrexate resistant human leukemia cells.;Q186474;P703;Q15978631
Collateral sensitivity to azidothymidine in methotrexate resistant human leukemia cells.;Q422232;P2175;Q29496
A painful inflammatory lesion on the dorsum of the hand of a patient with rheumatoid arthritis treated with methotrexate;Q422232;P2175;Q187255
A painful inflammatory lesion on the dorsum of the hand of a patient with rheumatoid arthritis treated with methotrexate;Q422232;P2175;Q170990
Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis;Q422232;P2175;Q170990
Methotrexate induces interleukin-8 production by human bronchial and alveolar epithelial cells.;Q22124685;P703;Q15978631
Effects of methotrexate, sulphasalazine and aurothiomalate on polymorphonuclear leucocytes in rheumatoid arthritis.;Q422232;P2175;Q170990
Effects of methotrexate, sulphasalazine and aurothiomalate on polymorphonuclear leucocytes in rheumatoid arthritis.;Q422232;P2175;Q187255
MMP-8 and TIMP-1 are associated to periodontal inflammation in patients with rheumatoid arthritis under methotrexate immunosuppression - First results of a cross-sectional study.;Q422232;P2175;Q187255
MMP-8 and TIMP-1 are associated to periodontal inflammation in patients with rheumatoid arthritis under methotrexate immunosuppression - First results of a cross-sectional study.;Q422232;P2175;Q170990
Differential influences of bucillamine and methotrexate on the generation of fibroblast-like cells from bone marrow CD34+ cells of rheumatoid arthritis patients.;Q422232;P2175;Q170990
Differential influences of bucillamine and methotrexate on the generation of fibroblast-like cells from bone marrow CD34+ cells of rheumatoid arthritis patients.;Q422232;P2175;Q187255
Efficacy of methotrexate in the treatment of nonruptured ectopic pregnancy. A six year experience at Polish Mother's Memorial Institute.;Q422232;P2175;Q207087
Evaluation of the concomitant use of methotrexate and curcumin on Freund's complete adjuvant-induced arthritis and hematological indices in rats;Q422232;P2175;Q170990
Methotrexate induces high level of apoptosis in canine lymphoma/leukemia cell lines.;Q422232;P2175;Q29496
Methotrexate induces high level of apoptosis in canine lymphoma/leukemia cell lines.;Q422232;P2175;Q208414
[Combination chemotherapy with methotrexate, vincristine, cisplatinum, cyclophosphamide, adriamycin, and bleomycin (MVP-CAB) for metastatic urothelial cancer].;Q412415;P527;Q880
Sequential methotrexate, 5-fluorouracil, and leucovorin in metastatic measurable colorectal cancer. Does it work?;Q238512;P2175;Q2739660
Divergent effects of methotrexate on the clonal growth of T and B lymphocytes and synovial adherent cells from patients with rheumatoid arthritis;Q422232;P2175;Q170990
Divergent effects of methotrexate on the clonal growth of T and B lymphocytes and synovial adherent cells from patients with rheumatoid arthritis;Q422232;P2175;Q187255
[Methotrexate pneumonitis arising during the treatment of non-Hodgkin's lymphomas with the m-BACOD protocol].;Q422232;P2175;Q1138590
[Methotrexate pneumonitis arising during the treatment of non-Hodgkin's lymphomas with the m-BACOD protocol].;Q422232;P2175;Q208414
Short-chain methotrexate polyglutamate MTXPG2 as outcome parameter in rheumatoid arthritis.;Q422232;P2175;Q187255
Short-chain methotrexate polyglutamate MTXPG2 as outcome parameter in rheumatoid arthritis.;Q422232;P2175;Q170990
[Studies on the mechanism of action of methotrexate on blast cells in acute leukemia];Q422232;P2175;Q29496
[A case of an antalgic-induced (Phenacetin + Acetanilid) sulf and methemoglobinemia in a woman receiving an antimetabolite (Methotrexate) (author's transl)];Q218642;P31;Q407595
Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis;Q422232;P2175;Q1477
Real-world experiences of folic acid supplementation (5 versus 30 mg/week) with methotrexate in rheumatoid arthritis patients: a comparison study.;Q422232;P2868;Q127060
Real-world experiences of folic acid supplementation (5 versus 30 mg/week) with methotrexate in rheumatoid arthritis patients: a comparison study.;Q422232;P2175;Q170990
Real-world experiences of folic acid supplementation (5 versus 30 mg/week) with methotrexate in rheumatoid arthritis patients: a comparison study.;Q422232;P2175;Q187255
Letter: oral low-dose methotrexate for collagenous colitis.;Q422232;P636;Q285166
Collateral methotrexate resistance in cultured human head and neck carcinoma cells selected for resistance to cis-diamminedichloroplatinum(II).;Q186474;P703;Q15978631
Collateral methotrexate resistance in cultured human head and neck carcinoma cells selected for resistance to cis-diamminedichloroplatinum(II).;Q412415;P527;Q880
Collateral methotrexate resistance in cultured human head and neck carcinoma cells selected for resistance to cis-diamminedichloroplatinum(II).;Q484940;P703;Q15978631
A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia.;Q422232;P2175;Q29496
A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia.;Q422232;P2175;Q264118
[A case of advanced gastric cancer with multiple bone metastasis successfully treated by both methotrexate and 5-fluorouracil sequential therapy, and endoscopic intratumoral injection of 5-fluorouracil];Q238512;P2175;Q189588
[A case of advanced gastric cancer with multiple bone metastasis successfully treated by both methotrexate and 5-fluorouracil sequential therapy, and endoscopic intratumoral injection of 5-fluorouracil];Q422232;P636;Q285166
[A case of advanced gastric cancer with multiple bone metastasis successfully treated by both methotrexate and 5-fluorouracil sequential therapy, and endoscopic intratumoral injection of 5-fluorouracil];Q422232;P2175;Q189588
Methotrexate in rheumatoid arthritis;Q422232;P2175;Q170990
Methotrexate in rheumatoid arthritis;Q422232;P2175;Q187255
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response;Q348260;P2175;Q170990
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response;Q348260;P2175;Q187255
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response;Q422232;P2175;Q170990
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response;Q422232;P2175;Q187255
Transverse myelitis following methotrexate treatment of ectopic pregnancy: a case report.;Q422232;P2175;Q207087
Acute toxicity of five insect chemosterilants, hemel, hempa, tepa, metepa, and methotrexate, for cockerels.;Q218642;P703;Q26726
A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy.;Q415264;P2175;Q170990
A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy.;Q422232;P2175;Q170990
Methotrexate pharmacokinetic is influenced by co-administration of cyclosporin in rheumatoid arthritis patients. Results from a randomized clinical trial;Q422232;P2175;Q170990
Methotrexate pharmacokinetic is influenced by co-administration of cyclosporin in rheumatoid arthritis patients. Results from a randomized clinical trial;Q422232;P2175;Q187255
Aspirin antagonizes the cytotoxic effect of methotrexate in lung cancer cells.;Q18216;P769;Q422232
Is methotrexate effective and safe in patients with psoriatic arthritis? A Cochrane Review summary with commentary;Q422232;P2175;Q170990
31P NMR study of the impact of dietary manipulation on tumor metabolism and response to methotrexate;Q422232;P361;Q14819383
Acute leukoencephalopathy due to pyrimethamine. An insight into methotrexate neurotoxicity?;Q191924;P2868;Q407752
Preservation of tubal function following methotrexate treatment for ectopic pregnancy;Q422232;P2175;Q207087
Novel methotrexate prodrug-targeted drug delivery system based on PEG-lipid-PLA hybrid nanoparticles for enhanced anticancer efficacy and reduced toxicity of mitomycin C;Q218642;P31;Q12140
Novel methotrexate prodrug-targeted drug delivery system based on PEG-lipid-PLA hybrid nanoparticles for enhanced anticancer efficacy and reduced toxicity of mitomycin C;Q186474;P31;Q12140
Novel methotrexate prodrug-targeted drug delivery system based on PEG-lipid-PLA hybrid nanoparticles for enhanced anticancer efficacy and reduced toxicity of mitomycin C;Q191924;P31;Q12140
Novel methotrexate prodrug-targeted drug delivery system based on PEG-lipid-PLA hybrid nanoparticles for enhanced anticancer efficacy and reduced toxicity of mitomycin C;Q410083;P31;Q12140
Novel methotrexate prodrug-targeted drug delivery system based on PEG-lipid-PLA hybrid nanoparticles for enhanced anticancer efficacy and reduced toxicity of mitomycin C;Q19856779;P31;Q12140
Novel methotrexate prodrug-targeted drug delivery system based on PEG-lipid-PLA hybrid nanoparticles for enhanced anticancer efficacy and reduced toxicity of mitomycin C;Q19856779;P1889;Q417625
Novel methotrexate prodrug-targeted drug delivery system based on PEG-lipid-PLA hybrid nanoparticles for enhanced anticancer efficacy and reduced toxicity of mitomycin C;Q20035886;P31;Q12140
Novel methotrexate prodrug-targeted drug delivery system based on PEG-lipid-PLA hybrid nanoparticles for enhanced anticancer efficacy and reduced toxicity of mitomycin C;Q620730;P31;Q12140
Novel methotrexate prodrug-targeted drug delivery system based on PEG-lipid-PLA hybrid nanoparticles for enhanced anticancer efficacy and reduced toxicity of mitomycin C;Q483745;P31;Q12140
Novel methotrexate prodrug-targeted drug delivery system based on PEG-lipid-PLA hybrid nanoparticles for enhanced anticancer efficacy and reduced toxicity of mitomycin C;Q422232;P31;Q12140
[Experiences with 6-mercaptopurine and methotrexate in primary chronic polyarthritis and other collagen diseases];Q422232;P2175;Q170990
[Experiences with 6-mercaptopurine and methotrexate in primary chronic polyarthritis and other collagen diseases];Q422232;P2175;Q1274464
Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study.;Q422232;P2175;Q187255
Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study.;Q422232;P2868;Q810254
Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study.;Q422232;P2175;Q170990
[Bone marrow aplasia in rheumatoid polyarthritis treated with low-dose methotrexate];Q422232;P2175;Q170990
[Bone marrow aplasia in rheumatoid polyarthritis treated with low-dose methotrexate];Q422232;P2175;Q1274464
Assessment of brain perfusion by 99mTc-HMPAO SPECT in akinetic mutism due to high-dose intravenous methotrexate therapy.;Q422232;P636;Q640448
RETRACTED ARTICLE: Safety and effectiveness of high-dose methotrexate (over 8mg/week) in 2838 Japanese patients with rheumatoid arthritis: A postmarketing surveillance report.;Q422232;P2175;Q170990
RETRACTED ARTICLE: Safety and effectiveness of high-dose methotrexate (over 8mg/week) in 2838 Japanese patients with rheumatoid arthritis: A postmarketing surveillance report.;Q422232;P2175;Q187255
Four-way calibration applied to the simultaneous determination of folic acid and methotrexate in urine samples;Q422232;P2868;Q127060
Methotrexate therapy of tubal pregnancy.;Q422232;P2175;Q207087
A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion.;Q416025;P636;Q4112929
(1)H NMR-based metabolomic analysis for identifying serum biomarkers to evaluate methotrexate treatment in patients with early rheumatoid arthritis.;Q422232;P2175;Q170990
(1)H NMR-based metabolomic analysis for identifying serum biomarkers to evaluate methotrexate treatment in patients with early rheumatoid arthritis.;Q422232;P2175;Q187255
[Security of the combined treatment of methotrexate and leflunomide in patients with rheumatoid arthritis].;Q248550;P2175;Q170990
[Security of the combined treatment of methotrexate and leflunomide in patients with rheumatoid arthritis].;Q248550;P2175;Q187255
[Security of the combined treatment of methotrexate and leflunomide in patients with rheumatoid arthritis].;Q422232;P2175;Q187255
[Security of the combined treatment of methotrexate and leflunomide in patients with rheumatoid arthritis].;Q422232;P2175;Q170990
Uterine artery embolization combined with local infusion of methotrexate and 5- fluorouracil in treating ectopic pregnancy: A CONSORT-compliant article.;Q422232;P2175;Q207087
A novel combination of astilbin and low-dose methotrexate respectively targeting A2AAR and its ligand adenosine for the treatment of collagen-induced arthritis.;Q422232;P2175;Q170990
Radiological and clinical results of longterm treatment of rheumatoid arthritis with methotrexate and azathioprine.;Q18939;P2175;Q187255
Radiological and clinical results of longterm treatment of rheumatoid arthritis with methotrexate and azathioprine.;Q422232;P2175;Q187255
Radiological and clinical results of longterm treatment of rheumatoid arthritis with methotrexate and azathioprine.;Q422232;P2175;Q170990
Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group.;Q238512;P2175;Q128581
Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group.;Q422232;P2175;Q128581
The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models;Q28209496;P366;Q846227
The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models;Q28209496;P2175;Q84263196
Methotrexate preconditioning allows sufficient engraftment to confer drug resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate reductase activity.;Q191924;P366;Q8386
Methotrexate preconditioning allows sufficient engraftment to confer drug resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate reductase activity.;Q22124685;P31;Q12140
Methotrexate preconditioning allows sufficient engraftment to confer drug resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate reductase activity.;Q422232;P31;Q12140
Effect of folic acid supplementation on the efficacy of methotrexate treatment in rheumatoid arthritis: comment on the article by Khanna et al.;Q422232;P2868;Q127060
Effect of folic acid supplementation on the efficacy of methotrexate treatment in rheumatoid arthritis: comment on the article by Khanna et al.;Q422232;P2175;Q187255
Effect of folic acid supplementation on the efficacy of methotrexate treatment in rheumatoid arthritis: comment on the article by Khanna et al.;Q422232;P2175;Q170990
Methotrexate as an oral corticosteroid-sparing agent in severe asthma: the emergence of a responder asthma endotype.;Q422232;P636;Q285166
Association between MTHFR microRNA binding site polymorphisms and methotrexate concentrations in Chinese pediatric patients with acute lymphoblastic leukemia.;Q422232;P2175;Q29496
Combination chemotherapy with methotrexate, adriamycin, cyclophosphamide and CCNU (MACC) for nonsmall cell lung cancer. 4-year experience with 92 patients.;Q139347;P2175;Q12078
High dose methotrexate with citrovorum factor in adult resistant lymphoma.;Q422232;P2175;Q208414
Pulmonary Intravascular Large B-cell Lymphoma in a Patient Administered Methotrexate for Rheumatoid Arthritis;Q422232;P2175;Q208414
A pilot study of the safety and efficacy of dexamethasone, ifosfamide, methotrexate and gemcitabine chemotherapy for natural killer/T-cell lymphoma.;Q414143;P2175;Q208414
A pilot study of the safety and efficacy of dexamethasone, ifosfamide, methotrexate and gemcitabine chemotherapy for natural killer/T-cell lymphoma.;Q422252;P2175;Q208414
A pilot study of the safety and efficacy of dexamethasone, ifosfamide, methotrexate and gemcitabine chemotherapy for natural killer/T-cell lymphoma.;Q422232;P2175;Q208414
A pilot study of the safety and efficacy of dexamethasone, ifosfamide, methotrexate and gemcitabine chemotherapy for natural killer/T-cell lymphoma.;Q422232;P2175;Q7667896
Poly (L-lysine) and poly (D-lysine) conjugates of methotrexate: different inhibitory effect on drug resistant cells.;Q191924;P366;Q8386
Poly (L-lysine) and poly (D-lysine) conjugates of methotrexate: different inhibitory effect on drug resistant cells.;Q178450;P31;Q12140
Poly (L-lysine) and poly (D-lysine) conjugates of methotrexate: different inhibitory effect on drug resistant cells.;Q20816880;P31;Q12140
Poly (L-lysine) and poly (D-lysine) conjugates of methotrexate: different inhibitory effect on drug resistant cells.;Q20816880;P31;Q178430
Poly (L-lysine) and poly (D-lysine) conjugates of methotrexate: different inhibitory effect on drug resistant cells.;Q20035886;P31;Q12140
Poly (L-lysine) and poly (D-lysine) conjugates of methotrexate: different inhibitory effect on drug resistant cells.;Q483745;P31;Q12140
Poly (L-lysine) and poly (D-lysine) conjugates of methotrexate: different inhibitory effect on drug resistant cells.;Q422232;P31;Q12140
Reversal of methotrexate resistance in human squamous carcinoma cells by SQM1-liposome.;Q181619;P703;Q15978631
Reversal of methotrexate resistance in human squamous carcinoma cells by SQM1-liposome.;Q183290;P703;Q15978631
Reversal of methotrexate resistance in human squamous carcinoma cells by SQM1-liposome.;Q173670;P703;Q15978631
Reversal of methotrexate resistance in human squamous carcinoma cells by SQM1-liposome.;Q22124685;P703;Q15978631
Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis;Q422232;P2175;Q170990
Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis;Q422232;P2175;Q187255
Metronomic cyclophosphamide and methotrexate for breast cancer: enhanced efficacy by adding dalteparin and low-dose prednisone?;Q424972;P2175;Q12078
Metronomic cyclophosphamide and methotrexate for breast cancer: enhanced efficacy by adding dalteparin and low-dose prednisone?;Q422232;P2175;Q128581
[Methotrexate in ectopic pregnancy is almost allowed!].;Q422232;P2175;Q207087
Methotrexate based oral chemotherapy for advanced oral cancer during COVID-19 pandemic: Another option in the therapeutic armamentarium;Q218642;P703;Q177932
Methotrexate based oral chemotherapy for advanced oral cancer during COVID-19 pandemic: Another option in the therapeutic armamentarium;Q186474;P703;Q177932
Methotrexate based oral chemotherapy for advanced oral cancer during COVID-19 pandemic: Another option in the therapeutic armamentarium;Q178450;P703;Q177932
Methotrexate based oral chemotherapy for advanced oral cancer during COVID-19 pandemic: Another option in the therapeutic armamentarium;Q22124685;P703;Q177932
Methotrexate based oral chemotherapy for advanced oral cancer during COVID-19 pandemic: Another option in the therapeutic armamentarium;Q422232;P636;Q285166
Methotrexate based oral chemotherapy for advanced oral cancer during COVID-19 pandemic: Another option in the therapeutic armamentarium;Q483752;P703;Q177932
Methotrexate based oral chemotherapy for advanced oral cancer during COVID-19 pandemic: Another option in the therapeutic armamentarium;Q484940;P703;Q177932
Use of methotrexate, vinblastine, adriamycin, and cisplatin in combination with radiation and hyperthermia as neo-adjuvant therapy for bladder cancer.;Q412415;P2175;Q504775
Fulminant hepatic failure induced by intermediate dose methotrexate in a case of non-Hodgkin's lymphoma;Q422232;P2175;Q208414
Fulminant hepatic failure induced by intermediate dose methotrexate in a case of non-Hodgkin's lymphoma;Q422232;P2175;Q1138590
Severe methotrexate toxicity after treatment for ectopic pregnancy: A case report;Q422232;P2175;Q207087
The reproducibility and use of the tritiated folic acid urinary excretion test as a measure of folate absorption in clinical practice: effect of methotrexate on absorption of folic acid.;Q422232;P2868;Q127060
Postoperative results of rheumatoid arthritis patients on methotrexate at the time of reconstructive surgery of the hand.;Q422232;P2175;Q170990
Postoperative results of rheumatoid arthritis patients on methotrexate at the time of reconstructive surgery of the hand.;Q422232;P2175;Q187255
Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.;Q422232;P2175;Q170990
Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.;Q422232;P2175;Q187255
A phase II trial of carboplatin, methotrexate and fluorouracil in fluorouracil-pretreated colorectal cancer;Q238512;P2175;Q2739660
Cavitary lung tuberculosis in a rheumatoid arthritis patient treated with low-dose methotrexate and steroid pulse therapy;Q422232;P2175;Q170990
Cavitary lung tuberculosis in a rheumatoid arthritis patient treated with low-dose methotrexate and steroid pulse therapy;Q422232;P2175;Q187255
Mitoxantrone and methotrexate chemotherapy with and without mitomycin C in the regional treatment of locally advanced breast cancer.;Q239426;P2175;Q128581
Mitoxantrone and methotrexate chemotherapy with and without mitomycin C in the regional treatment of locally advanced breast cancer.;Q19856779;P1889;Q417625
Mitoxantrone and methotrexate chemotherapy with and without mitomycin C in the regional treatment of locally advanced breast cancer.;Q422232;P2175;Q128581
Cord blood transplantation from unrelated donors for children with acute lymphoblastic leukemia in Japan: the impact of methotrexate on clinical outcomes.;Q422232;P2175;Q29496
Methotrexate and Curcumin co-encapsulated PLGA nanoparticles as a potential breast cancer therapeutic system: In vitro and in vivo evaluation;Q218642;P703;Q177932
Methotrexate and Curcumin co-encapsulated PLGA nanoparticles as a potential breast cancer therapeutic system: In vitro and in vivo evaluation;Q186474;P703;Q177932
Methotrexate and Curcumin co-encapsulated PLGA nanoparticles as a potential breast cancer therapeutic system: In vitro and in vivo evaluation;Q20035886;P703;Q177932
Methotrexate and Curcumin co-encapsulated PLGA nanoparticles as a potential breast cancer therapeutic system: In vitro and in vivo evaluation;Q22124685;P703;Q177932
Methotrexate and Curcumin co-encapsulated PLGA nanoparticles as a potential breast cancer therapeutic system: In vitro and in vivo evaluation;Q422232;P2175;Q128581
Methotrexate and Curcumin co-encapsulated PLGA nanoparticles as a potential breast cancer therapeutic system: In vitro and in vivo evaluation;Q620730;P703;Q177932
Methotrexate and Curcumin co-encapsulated PLGA nanoparticles as a potential breast cancer therapeutic system: In vitro and in vivo evaluation;Q483745;P703;Q177932
Methotrexate and Curcumin co-encapsulated PLGA nanoparticles as a potential breast cancer therapeutic system: In vitro and in vivo evaluation;Q484940;P703;Q177932
A clinical and biochemical assessment of methotrexate in rheumatoid arthritis.;Q422232;P2175;Q170990
A clinical and biochemical assessment of methotrexate in rheumatoid arthritis.;Q422232;P2175;Q187255
Evaluation of unfolded-partial least-squares coupled to residual trilinearization for four-way calibration of folic acid and methotrexate in human serum samples.;Q127060;P703;Q15978631
Evaluation of unfolded-partial least-squares coupled to residual trilinearization for four-way calibration of folic acid and methotrexate in human serum samples.;Q422232;P2868;Q127060
[Treatment of ectopic pregnancy by transvaginal ultrasonography-guided puncture and local application of methotrexate];Q422232;P2175;Q207087
[A case of iatrogenic immunodeficiency-associated lymphoproliferative disease in a patient treated with methotrexate for rheumatoid arthritis for 9 consecutive years, which Showed natural remission after discontinuation of MTX therapy].;Q422232;P2175;Q187255
[A case of iatrogenic immunodeficiency-associated lymphoproliferative disease in a patient treated with methotrexate for rheumatoid arthritis for 9 consecutive years, which Showed natural remission after discontinuation of MTX therapy].;Q422232;P2175;Q170990
Methotrexate and Cytarabine-Loaded Nanocarriers for Multidrug Cancer Therapy. Spectroscopic Study.;Q180983;P31;Q12140
Methotrexate and Cytarabine-Loaded Nanocarriers for Multidrug Cancer Therapy. Spectroscopic Study.;Q183290;P31;Q12140
Methotrexate and Cytarabine-Loaded Nanocarriers for Multidrug Cancer Therapy. Spectroscopic Study.;Q186474;P31;Q12140
Methotrexate and Cytarabine-Loaded Nanocarriers for Multidrug Cancer Therapy. Spectroscopic Study.;Q186521;P31;Q12140
Methotrexate and Cytarabine-Loaded Nanocarriers for Multidrug Cancer Therapy. Spectroscopic Study.;Q22124685;P31;Q12140
Methotrexate and Cytarabine-Loaded Nanocarriers for Multidrug Cancer Therapy. Spectroscopic Study.;Q422232;P31;Q12140
Methotrexate and Cytarabine-Loaded Nanocarriers for Multidrug Cancer Therapy. Spectroscopic Study.;Q483745;P31;Q12140
The value of an initial drop in human Chorionic gonadotropin levels in predicting a response to methotrexate in women with low-risk gestational trophoblastic neoplasia;Q186474;P703;Q15978631
The value of an initial drop in human Chorionic gonadotropin levels in predicting a response to methotrexate in women with low-risk gestational trophoblastic neoplasia;Q186521;P703;Q15978631
The value of an initial drop in human Chorionic gonadotropin levels in predicting a response to methotrexate in women with low-risk gestational trophoblastic neoplasia;Q422232;P361;Q14819383
Factors that may influence the choice for initiating apremilast or methotrexate treatment for psoriasis in real-world clinical setting;Q2858961;P2175;Q179945
Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and Tandem TS Repeats Influence Pharmacokinetics, Acute Liver Toxicity, and Vomiting in Children With Acute Lymphoblastic Leukemia Treated With High Doses of Methotrexate;Q422232;P129;Q21126218
Methotrexate as a preferential cyclooxygenase 2 inhibitor in whole blood of patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Methotrexate as a preferential cyclooxygenase 2 inhibitor in whole blood of patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Cervical pregnancy after in vitro fertilization and embryo transfer successfully treated with methotrexate and intracervical injection of vasopressin.;Q183011;P31;Q66571917
Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation;Q218642;P703;Q2046782
Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation;Q422232;P2175;Q264118
Etoposide, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.;Q418817;P2175;Q1138590
Etoposide, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.;Q418817;P2175;Q208414
Etoposide, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.;Q422232;P2175;Q208414
Etoposide, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.;Q422232;P2175;Q1138590
Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis.;Q422232;P2175;Q187255
Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis.;Q422232;P2175;Q861224
Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis.;Q422232;P2175;Q170990
Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim-Chester disease.;Q422232;P636;Q285166
Anticancer medicines (Doxorubicin and methotrexate) conjugated with magnetic nanoparticles for targeting drug delivery through iron.;Q218642;P31;Q12140
Anticancer medicines (Doxorubicin and methotrexate) conjugated with magnetic nanoparticles for targeting drug delivery through iron.;Q18936;P31;Q12140
Anticancer medicines (Doxorubicin and methotrexate) conjugated with magnetic nanoparticles for targeting drug delivery through iron.;Q191924;P31;Q12140
Anticancer medicines (Doxorubicin and methotrexate) conjugated with magnetic nanoparticles for targeting drug delivery through iron.;Q178450;P31;Q12140
Anticancer medicines (Doxorubicin and methotrexate) conjugated with magnetic nanoparticles for targeting drug delivery through iron.;Q422232;P31;Q12140
Remobilization of hematopoietic stem cells with high-dose methotrexate and cytarabine in patients with non-Hodgkin's lymphoma and multiple myeloma after failure to mobilize with chemotherapy and cytokines.;Q180983;P2175;Q208414
Remobilization of hematopoietic stem cells with high-dose methotrexate and cytarabine in patients with non-Hodgkin's lymphoma and multiple myeloma after failure to mobilize with chemotherapy and cytokines.;Q180983;P2175;Q1138590
Remobilization of hematopoietic stem cells with high-dose methotrexate and cytarabine in patients with non-Hodgkin's lymphoma and multiple myeloma after failure to mobilize with chemotherapy and cytokines.;Q422232;P2175;Q1138590
Remobilization of hematopoietic stem cells with high-dose methotrexate and cytarabine in patients with non-Hodgkin's lymphoma and multiple myeloma after failure to mobilize with chemotherapy and cytokines.;Q422232;P2175;Q208414
Evidence for negative feedback of extracellular methotrexate on blasts of acute lymphoblastic leukemia in vitro;Q422232;P2175;Q29496
Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results;Q413879;P2175;Q170990
Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results;Q422232;P2175;Q170990
Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results;Q422232;P2175;Q187255
Perioperative use of methotrexate in patients with rheumatoid arthritis undergoing orthopedic surgery.;Q422232;P2175;Q170990
Perioperative use of methotrexate in patients with rheumatoid arthritis undergoing orthopedic surgery.;Q422232;P2175;Q187255
Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis.;Q422232;P2175;Q170990
Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis.;Q422232;P2175;Q187255
Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis.;Q422232;P2175;Q861224
Prolonged survival of neoplastic meningitis from breast cancer with letrozole and intrathecal methotrexate: a case report;Q194974;P2175;Q128581
Prolonged survival of neoplastic meningitis from breast cancer with letrozole and intrathecal methotrexate: a case report;Q422232;P2175;Q128581
Prolonged survival of neoplastic meningitis from breast cancer with letrozole and intrathecal methotrexate: a case report;Q422232;P636;Q1320251
Treatment of rheumatoid arthritis with methotrexate in Congolese patients.;Q422232;P2175;Q170990
Treatment of rheumatoid arthritis with methotrexate in Congolese patients.;Q422232;P2175;Q187255
[Treatment of gestational trophoblastic neoplasms with methotrexate and citrovorum factor rescue: analysis of 43 cases];Q422232;P2175;Q7845637
[Cost effectiveness of methotrexate treatment of ectopic pregnancy];Q422232;P2175;Q207087
Reduced elimination of Methotrexate in an adult with trisomy 21 and acute lymphoblastic leukaemia;Q422232;P2175;Q29496
Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.;Q218642;P703;Q2046782
Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.;Q422232;P2175;Q1161568
Massive myelinolytic leukoencephalopathy in a patient medicated with low-dose oral methotrexate for rheumatoid arthritis: an autopsy report.;Q422232;P636;Q285166
Massive myelinolytic leukoencephalopathy in a patient medicated with low-dose oral methotrexate for rheumatoid arthritis: an autopsy report.;Q422232;P2175;Q187255
Massive myelinolytic leukoencephalopathy in a patient medicated with low-dose oral methotrexate for rheumatoid arthritis: an autopsy report.;Q422232;P2175;Q170990
Therapeutic consequences of antitumour drug interactions: methotrexate and 5-fluorouracil in the chemotherapy of C3H mice with transplanted mammary adenocarcinoma.;Q186474;P703;Q177932
Therapeutic consequences of antitumour drug interactions: methotrexate and 5-fluorouracil in the chemotherapy of C3H mice with transplanted mammary adenocarcinoma.;Q186474;P31;Q12140
Therapeutic consequences of antitumour drug interactions: methotrexate and 5-fluorouracil in the chemotherapy of C3H mice with transplanted mammary adenocarcinoma.;Q186474;P703;Q83310
Therapeutic consequences of antitumour drug interactions: methotrexate and 5-fluorouracil in the chemotherapy of C3H mice with transplanted mammary adenocarcinoma.;Q186521;P31;Q12140
Therapeutic consequences of antitumour drug interactions: methotrexate and 5-fluorouracil in the chemotherapy of C3H mice with transplanted mammary adenocarcinoma.;Q186521;P703;Q177932
Therapeutic consequences of antitumour drug interactions: methotrexate and 5-fluorouracil in the chemotherapy of C3H mice with transplanted mammary adenocarcinoma.;Q191924;P31;Q12140
Therapeutic consequences of antitumour drug interactions: methotrexate and 5-fluorouracil in the chemotherapy of C3H mice with transplanted mammary adenocarcinoma.;Q485277;P31;Q12140
Therapeutic consequences of antitumour drug interactions: methotrexate and 5-fluorouracil in the chemotherapy of C3H mice with transplanted mammary adenocarcinoma.;Q485277;P703;Q177932
Therapeutic consequences of antitumour drug interactions: methotrexate and 5-fluorouracil in the chemotherapy of C3H mice with transplanted mammary adenocarcinoma.;Q238512;P31;Q12140
Therapeutic consequences of antitumour drug interactions: methotrexate and 5-fluorouracil in the chemotherapy of C3H mice with transplanted mammary adenocarcinoma.;Q422232;P31;Q12140
[Untoward effects of low dose methotrexate therapy in rheumatoid arthritis].;Q422232;P2175;Q187255
[Untoward effects of low dose methotrexate therapy in rheumatoid arthritis].;Q422232;P2175;Q170990
OP0289A Prospective, Randomized, Open-Label, Assessor-Blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids versus Glucocorticoids Alone in Patients with Polymyositis and Dermatomyositis (Prometheu;Q422232;P2175;Q980926
Cross resistance to esters of methotrexate in a doxorubicin-resistant subline of P388 murine leukemia.;Q422232;P2175;Q29496
Methotrexate: vital new information about a middle aged drug.;Q22124685;P31;Q12140
Methotrexate: vital new information about a middle aged drug.;Q422232;P31;Q12140
Folinic acid alleviates side effects of methotrexate in arthritis patients with side effects despite folic acid supplementation: an observational cohort study;Q422232;P2175;Q170990
Folinic acid alleviates side effects of methotrexate in arthritis patients with side effects despite folic acid supplementation: an observational cohort study;Q422232;P2868;Q127060
A preliminary prospective non-randomized controlled trial to compare the efficacy of subcutaneous etanercept versus oral methotrexate in moderate-to-severe chronic plaque psoriasis and correlation of response with T helper (th) 1, th2, th17 and T re;Q422232;P636;Q285166
Auxiliary in vitro and in vivo biological evaluation of hydrogen peroxide sensitive prodrugs of methotrexate and aminopterin for the treatment of rheumatoid arthritis;Q218642;P31;Q12140
Auxiliary in vitro and in vivo biological evaluation of hydrogen peroxide sensitive prodrugs of methotrexate and aminopterin for the treatment of rheumatoid arthritis;Q191924;P366;Q8386
Auxiliary in vitro and in vivo biological evaluation of hydrogen peroxide sensitive prodrugs of methotrexate and aminopterin for the treatment of rheumatoid arthritis;Q415734;P31;Q12140
Auxiliary in vitro and in vivo biological evaluation of hydrogen peroxide sensitive prodrugs of methotrexate and aminopterin for the treatment of rheumatoid arthritis;Q422232;P31;Q12140
Auxiliary in vitro and in vivo biological evaluation of hydrogen peroxide sensitive prodrugs of methotrexate and aminopterin for the treatment of rheumatoid arthritis;Q422232;P2175;Q187255
Auxiliary in vitro and in vivo biological evaluation of hydrogen peroxide sensitive prodrugs of methotrexate and aminopterin for the treatment of rheumatoid arthritis;Q422232;P2175;Q170990
[Adriamycin, cyclophosphamide, vincristine and methotrexate combination chemotherapy of small cell lung cancer];Q18936;P3780;Q47520887
Prophylactic and therapeutic activity of alkaline phosphatase in arthritic rats: single-agent effects of alkaline phosphatase and synergistic effects in combination with methotrexate;Q20035886;P703;Q177932
Prophylactic and therapeutic activity of alkaline phosphatase in arthritic rats: single-agent effects of alkaline phosphatase and synergistic effects in combination with methotrexate;Q422232;P2175;Q170990
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer.;Q238512;P2175;Q128581
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer.;Q422232;P2175;Q128581
Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer;Q422232;P2175;Q128581
Loeffler's Syndrome Secondary to Hyperinfection by Strongyloides stercoralis Associated with Methotrexate in a Patient with Rheumatoid Arthritis.;Q422232;P636;Q285166
In Silico Study Identified Methotrexate Analog as Potential Inhibitor of Drug Resistant Human Dihydrofolate Reductase for Cancer Therapeutics;Q218642;P703;Q177932
In Silico Study Identified Methotrexate Analog as Potential Inhibitor of Drug Resistant Human Dihydrofolate Reductase for Cancer Therapeutics;Q183290;P703;Q177932
In Silico Study Identified Methotrexate Analog as Potential Inhibitor of Drug Resistant Human Dihydrofolate Reductase for Cancer Therapeutics;Q186474;P703;Q177932
In Silico Study Identified Methotrexate Analog as Potential Inhibitor of Drug Resistant Human Dihydrofolate Reductase for Cancer Therapeutics;Q186521;P703;Q177932
In Silico Study Identified Methotrexate Analog as Potential Inhibitor of Drug Resistant Human Dihydrofolate Reductase for Cancer Therapeutics;Q485277;P703;Q177932
In Silico Study Identified Methotrexate Analog as Potential Inhibitor of Drug Resistant Human Dihydrofolate Reductase for Cancer Therapeutics;Q173670;P703;Q177932
In Silico Study Identified Methotrexate Analog as Potential Inhibitor of Drug Resistant Human Dihydrofolate Reductase for Cancer Therapeutics;Q178450;P703;Q177932
In Silico Study Identified Methotrexate Analog as Potential Inhibitor of Drug Resistant Human Dihydrofolate Reductase for Cancer Therapeutics;Q20035886;P703;Q177932
In Silico Study Identified Methotrexate Analog as Potential Inhibitor of Drug Resistant Human Dihydrofolate Reductase for Cancer Therapeutics;Q22124685;P703;Q177932
In Silico Study Identified Methotrexate Analog as Potential Inhibitor of Drug Resistant Human Dihydrofolate Reductase for Cancer Therapeutics;Q484940;P703;Q177932
Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.;Q218642;P31;Q12140
Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.;Q191924;P366;Q8386
Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.;Q415264;P31;Q12140
Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.;Q415264;P2175;Q170990
Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.;Q422232;P31;Q12140
Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.;Q422232;P2175;Q170990
Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.;Q422232;P2175;Q187255
Resistance to methotrexate is associated with selective changes of alpha 2,6- and alpha 2,3-sialyltransferase activities toward N-acetyllactosaminic sequences in human colon cancer cell line HT-29.;Q186521;P703;Q15978631
Resistance to methotrexate is associated with selective changes of alpha 2,6- and alpha 2,3-sialyltransferase activities toward N-acetyllactosaminic sequences in human colon cancer cell line HT-29.;Q485277;P703;Q15978631
Resistance to methotrexate is associated with selective changes of alpha 2,6- and alpha 2,3-sialyltransferase activities toward N-acetyllactosaminic sequences in human colon cancer cell line HT-29.;Q173670;P703;Q15978631
Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases.;Q422232;P636;Q1320251
Second-dose methotrexate in ectopic pregnancies: the role of beta human chorionic gonadotropin.;Q407172;P279;Q409770
Second-dose methotrexate in ectopic pregnancies: the role of beta human chorionic gonadotropin.;Q407172;P703;Q15978631
Second-dose methotrexate in ectopic pregnancies: the role of beta human chorionic gonadotropin.;Q183290;P703;Q15978631
A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey.;Q411648;P2175;Q1194520
A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey.;Q367700;P2175;Q1194520
[Adjuvant chemotherapy (MVP-CAB: methotrexate, vincristine, cisplatinum, cyclophosphamide, adriamycin, and bleomycin) for bladder cancer];Q412415;P527;Q880
[Adjuvant chemotherapy (MVP-CAB: methotrexate, vincristine, cisplatinum, cyclophosphamide, adriamycin, and bleomycin) for bladder cancer];Q412415;P2175;Q504775
Weak Interaction of the Antimetabolite Drug Methotrexate with a Cavitand Derivative;Q218642;P31;Q407595
Cytomegalovirus retinitis followed by immune recovery uveitis in an elderly patient with rheumatoid arthritis undergoing administration of methotrexate and tofacitinib combination therapy.;Q3530324;P2175;Q170990
Cytomegalovirus retinitis followed by immune recovery uveitis in an elderly patient with rheumatoid arthritis undergoing administration of methotrexate and tofacitinib combination therapy.;Q422232;P2175;Q170990
Cytomegalovirus retinitis followed by immune recovery uveitis in an elderly patient with rheumatoid arthritis undergoing administration of methotrexate and tofacitinib combination therapy.;Q422232;P2175;Q187255
Cytomegalovirus retinitis followed by immune recovery uveitis in an elderly patient with rheumatoid arthritis undergoing administration of methotrexate and tofacitinib combination therapy.;Q422232;P2175;Q280027
Listeria monocytogenes infection in a patient treated with methotrexate for rheumatoid arthritis;Q422232;P2175;Q187255
Listeria monocytogenes infection in a patient treated with methotrexate for rheumatoid arthritis;Q422232;P2175;Q170990
Stability study of methotrexate in 0.9% sodium chloride injection and 5% dextrose injection with limit tests for impurities.;Q2314;P1889;Q11254
Stability study of methotrexate in 0.9% sodium chloride injection and 5% dextrose injection with limit tests for impurities.;Q2314;P31;Q44791900
Interaction of methotrexate and betamethasone with experimental phototoxic inflammation to PUVA (Psoralen and UVA) in mice.;Q416132;P2175;Q101991
Interaction of methotrexate and betamethasone with experimental phototoxic inflammation to PUVA (Psoralen and UVA) in mice.;Q422232;P636;Q285166
Prevention of the progressive biochemical cartilage destruction under methotrexate therapy in early rheumatoid arthritis;Q422232;P2175;Q170990
Prevention of the progressive biochemical cartilage destruction under methotrexate therapy in early rheumatoid arthritis;Q422232;P2175;Q187255
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study;Q422232;P2175;Q170990
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study;Q422232;P2175;Q187255
Risk of hematological events and preventive effect of folic acid in methotrexate users with chronic kidney disease and rheumatoid arthritis: analysis of the Japanese Adverse Event Report database;Q422232;P2175;Q170990
Risk of hematological events and preventive effect of folic acid in methotrexate users with chronic kidney disease and rheumatoid arthritis: analysis of the Japanese Adverse Event Report database;Q422232;P2175;Q187255
Risk of hematological events and preventive effect of folic acid in methotrexate users with chronic kidney disease and rheumatoid arthritis: analysis of the Japanese Adverse Event Report database;Q422232;P2868;Q127060
Low-dose methotrexate use and safety for older patients with bullous pemphigoid and impaired renal function: a cohort study;Q422232;P2175;Q1004647
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.;Q186521;P31;Q12140
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.;Q186521;P703;Q15978631
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.;Q191924;P31;Q12140
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.;Q191924;P366;Q8386
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.;Q485277;P31;Q12140
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.;Q485277;P703;Q15978631
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.;Q327362;P703;Q15978631
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.;Q327362;P31;Q12140
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.;Q412415;P31;Q12140
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.;Q170545;P31;Q12140
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.;Q170545;P703;Q15978631
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.;Q15304877;P31;Q12140
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.;Q419953;P3780;Q29005939
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.;Q419953;P31;Q12140
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.;Q620730;P703;Q15978631
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.;Q620730;P31;Q12140
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.;Q422252;P31;Q12140
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.;Q422232;P31;Q12140
Treatment of peritoneal dissemination of gastric cancer with sequential methotrexate and 5-fluorouracil;Q238512;P2175;Q189588
Treatment of peritoneal dissemination of gastric cancer with sequential methotrexate and 5-fluorouracil;Q422232;P2175;Q189588
A randomised trial comparing single dose systemic methotrexate and laparoscopic surgery for the treatment of unruptured tubal pregnancy;Q422232;P2175;Q207087
Successful Immunochemotherapy for Burkitt Lymphoma During Pregnancy as a Bridge to Postpartum High-Dose Methotrexate Therapy: A Case Report and Review of the Literature;Q422232;P2175;Q208414
Rapid healing of peripheral ulcerative keratitis in rheumatoid arthritis with prednisone, methotrexate and adalimumab combination therapy.;Q348260;P2175;Q170990
Rapid healing of peripheral ulcerative keratitis in rheumatoid arthritis with prednisone, methotrexate and adalimumab combination therapy.;Q348260;P2175;Q187255
Rapid healing of peripheral ulcerative keratitis in rheumatoid arthritis with prednisone, methotrexate and adalimumab combination therapy.;Q424972;P2175;Q170990
Rapid healing of peripheral ulcerative keratitis in rheumatoid arthritis with prednisone, methotrexate and adalimumab combination therapy.;Q422232;P2175;Q187255
Rapid healing of peripheral ulcerative keratitis in rheumatoid arthritis with prednisone, methotrexate and adalimumab combination therapy.;Q422232;P2175;Q170990
[Bufalin induces apoptosis in osteosarcoma U-2OS and U-2OS methotrexate 300-resistant cell lines in vitro].;Q422232;P2175;Q549534
[Methotrexate in rheumatoid arthritis];Q422232;P2175;Q170990
[Methotrexate in rheumatoid arthritis];Q422232;P2175;Q187255
Low-Risk Gestational Trophoblastic Neoplasia in Manitoba: Experience With Alternating Methotrexate and Dactinomycin;Q186127;P279;Q343465
Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.;Q484940;P703;Q15978631
Neoadjuvant M-VAC (methotrexate, vinblastine, adriamycin, and cisplatin) chemotherapy and bladder preservation for muscle-infiltrating transitional cell carcinoma of the bladder;Q412415;P2175;Q2501186
Interaction of methotrexate polyglutamates and dihydrofolate during leucovorin rescue in a human breast cancer cell line (MCF-7).;Q186474;P703;Q15978631
Interaction of methotrexate polyglutamates and dihydrofolate during leucovorin rescue in a human breast cancer cell line (MCF-7).;Q170545;P703;Q15978631
Interaction of methotrexate polyglutamates and dihydrofolate during leucovorin rescue in a human breast cancer cell line (MCF-7).;Q22124685;P703;Q15978631
Interaction of methotrexate polyglutamates and dihydrofolate during leucovorin rescue in a human breast cancer cell line (MCF-7).;Q483745;P703;Q15978631
Interaction of methotrexate polyglutamates and dihydrofolate during leucovorin rescue in a human breast cancer cell line (MCF-7).;Q484940;P703;Q15978631
Interaction of methotrexate polyglutamates and dihydrofolate during leucovorin rescue in a human breast cancer cell line (MCF-7).;Q422232;P2175;Q128581
The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials.;Q422232;P2868;Q127060
The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials.;Q422232;P2175;Q170990
The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials.;Q422232;P2175;Q187255
Rituximab after methotrexate failure in rheumatoid arthritis: evaluation of the SERENE trial;Q422232;P2175;Q187255
Rituximab after methotrexate failure in rheumatoid arthritis: evaluation of the SERENE trial;Q422232;P2175;Q170990
Role of methotrexate in the treatment of bullous pemphigoid in the elderly.;Q422232;P2175;Q1004647
Interaction between methotrexate and indomethacin on a human normal haemopoietic cell line;Q484940;P703;Q15978631
Adaptation of the methotrexate in rheumatoid arthritis knowledge questionnaire (MiRAK) for use with parents of children with juvenile idiopathic arthritis: a qualitative study.;Q422232;P2175;Q170990
Adaptation of the methotrexate in rheumatoid arthritis knowledge questionnaire (MiRAK) for use with parents of children with juvenile idiopathic arthritis: a qualitative study.;Q422232;P2175;Q187255
Adaptation of the methotrexate in rheumatoid arthritis knowledge questionnaire (MiRAK) for use with parents of children with juvenile idiopathic arthritis: a qualitative study.;Q422232;P2175;Q861224
[A phosphorescence method for the determination of 4-amino-4-deoxy-N-10-methyl-P teroylglutamic acid (methotrexate) and folic acid];Q422232;P2868;Q127060
Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III,;Q218642;P703;Q2046782
Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III,;Q178450;P703;Q2046782
Methotrexate pharmacokinetics and survival in osteosarcoma.;Q422232;P2175;Q549534
Methotrexate, an attractive agent for palliation in head and neck cancers.;Q422232;P2175;Q1783924
The H(+)-dependent reduced folate carrier 1 of humans and the sodium-dependent methotrexate carrier-1 of the rat are orthologs.;Q186521;P703;Q15978631
The H(+)-dependent reduced folate carrier 1 of humans and the sodium-dependent methotrexate carrier-1 of the rat are orthologs.;Q485277;P703;Q15978631
The H(+)-dependent reduced folate carrier 1 of humans and the sodium-dependent methotrexate carrier-1 of the rat are orthologs.;Q422232;P129;Q21126218
Response to methotrexate predicts long-term patient-related outcomes in rheumatoid arthritis.;Q422232;P2175;Q170990
Response to methotrexate predicts long-term patient-related outcomes in rheumatoid arthritis.;Q422232;P2175;Q187255
Methotrexate loaded on magnetite iron nanoparticles coated with chitosan: Biosynthesis, characterization, and impact on human breast cancer MCF-7 cell line;Q186474;P703;Q15978631
Methotrexate loaded on magnetite iron nanoparticles coated with chitosan: Biosynthesis, characterization, and impact on human breast cancer MCF-7 cell line;Q170545;P703;Q15978631
Methotrexate loaded on magnetite iron nanoparticles coated with chitosan: Biosynthesis, characterization, and impact on human breast cancer MCF-7 cell line;Q22124685;P703;Q15978631
Methotrexate loaded on magnetite iron nanoparticles coated with chitosan: Biosynthesis, characterization, and impact on human breast cancer MCF-7 cell line;Q422232;P2175;Q128581
Ultrasound liver elastography for the detection of liver fibrosis in patients with psoriasis and reactive arthritis on long-term methotrexate therapy: A cross-sectional study;Q422232;P2175;Q170990
The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.;Q422232;P2175;Q29496
Anal submucosal injection: a new route for drug administration in pelvic malignancies. II. Methotrexate anal injection in the treatment of advanced bladder cancer. Preliminary study.;Q218642;P31;Q12140
Anal submucosal injection: a new route for drug administration in pelvic malignancies. II. Methotrexate anal injection in the treatment of advanced bladder cancer. Preliminary study.;Q20035886;P31;Q12140
Anal submucosal injection: a new route for drug administration in pelvic malignancies. II. Methotrexate anal injection in the treatment of advanced bladder cancer. Preliminary study.;Q22124685;P31;Q12140
Anal submucosal injection: a new route for drug administration in pelvic malignancies. II. Methotrexate anal injection in the treatment of advanced bladder cancer. Preliminary study.;Q422232;P31;Q12140
Anal submucosal injection: a new route for drug administration in pelvic malignancies. II. Methotrexate anal injection in the treatment of advanced bladder cancer. Preliminary study.;Q484940;P31;Q12140
Increased baseline RUNX2, caspase 3 and p21 gene expressions in the peripheral blood of disease-modifying anti-rheumatic drug-nave rheumatoid arthritis patients are associated with improved clinical response to methotrexate therapy.;Q191924;P366;Q8386
Increased baseline RUNX2, caspase 3 and p21 gene expressions in the peripheral blood of disease-modifying anti-rheumatic drug-nave rheumatoid arthritis patients are associated with improved clinical response to methotrexate therapy.;Q173670;P31;Q12140
Increased baseline RUNX2, caspase 3 and p21 gene expressions in the peripheral blood of disease-modifying anti-rheumatic drug-nave rheumatoid arthritis patients are associated with improved clinical response to methotrexate therapy.;Q484940;P31;Q12140
Increased baseline RUNX2, caspase 3 and p21 gene expressions in the peripheral blood of disease-modifying anti-rheumatic drug-nave rheumatoid arthritis patients are associated with improved clinical response to methotrexate therapy.;Q422232;P31;Q12140
Increased baseline RUNX2, caspase 3 and p21 gene expressions in the peripheral blood of disease-modifying anti-rheumatic drug-nave rheumatoid arthritis patients are associated with improved clinical response to methotrexate therapy.;Q422232;P2175;Q170990
Increased baseline RUNX2, caspase 3 and p21 gene expressions in the peripheral blood of disease-modifying anti-rheumatic drug-nave rheumatoid arthritis patients are associated with improved clinical response to methotrexate therapy.;Q422232;P361;Q14819383
Increased baseline RUNX2, caspase 3 and p21 gene expressions in the peripheral blood of disease-modifying anti-rheumatic drug-nave rheumatoid arthritis patients are associated with improved clinical response to methotrexate therapy.;Q422232;P2175;Q187255
Drug/antibody conjugates. In vitro cytotoxicity of a human serum albumin-mediated conjugate of methotrexate with anti-MM46 monoclonal antibody;Q178450;P703;Q15978631
Drug/antibody conjugates. In vitro cytotoxicity of a human serum albumin-mediated conjugate of methotrexate with anti-MM46 monoclonal antibody;Q22124685;P703;Q15978631
Drug/antibody conjugates. In vitro cytotoxicity of a human serum albumin-mediated conjugate of methotrexate with anti-MM46 monoclonal antibody;Q484940;P703;Q15978631
Unilateral tubal twin ectopic pregnancy treated with single-dose methotrexate;Q422232;P2175;Q207087
Decreased risk of acute gastrointestinal toxicity when substituting methotrexate with mycophenolate mofetil in the prevention of graft-versus-host disease in stem cell transplantation following myeloablative conditioning regimens.;Q130336;P31;Q407142
Decreased risk of acute gastrointestinal toxicity when substituting methotrexate with mycophenolate mofetil in the prevention of graft-versus-host disease in stem cell transplantation following myeloablative conditioning regimens.;Q130336;P4149;Q27122100
Decreased risk of acute gastrointestinal toxicity when substituting methotrexate with mycophenolate mofetil in the prevention of graft-versus-host disease in stem cell transplantation following myeloablative conditioning regimens.;Q4567614;P2175;Q1194520
Real-life practice of methotrexate toxicity monitoring in juvenile idiopathic arthritis in Germany, Switzerland and Austria: results of a cross-sectional assessment conducted in 2012.;Q422232;P2175;Q170990
Real-life practice of methotrexate toxicity monitoring in juvenile idiopathic arthritis in Germany, Switzerland and Austria: results of a cross-sectional assessment conducted in 2012.;Q422232;P2175;Q861224
Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine.;Q422232;P2175;Q187255
Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine.;Q422232;P2175;Q170990
Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage;Q218642;P527;Q623
Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage;Q218642;P31;Q12140
Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage;Q191924;P527;Q623
Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage;Q191924;P366;Q8386
Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage;Q179731;P527;Q623
Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage;Q179731;P527;Q658
Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage;Q179731;P31;Q12140
Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage;Q178450;P527;Q623
Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage;Q178450;P31;Q12140
Do intravenous fluid substitutions influence methotrexate clearance? An unanticipated impact of an intravenous sodium bicarbonate drug shortage;Q422232;P31;Q12140
A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors.;Q1592932;P279;Q50229794
Methotrexate and etanercept-induced primary cutaneous CD4 positive small/medium-sized pleomorphic T-cell lymphoma;Q422232;P2175;Q208414
Methotrexate and etanercept-induced primary cutaneous CD4 positive small/medium-sized pleomorphic T-cell lymphoma;Q422232;P2175;Q7667896
Gamma knife stereotactic radiosurgery as an effective tool in primary CNS lymphoma: Evaluation of stereotactic radiosurgery and methotrexate treatment in a prospective and observational clinical research study;Q422232;P2175;Q136312
Gamma knife stereotactic radiosurgery as an effective tool in primary CNS lymphoma: Evaluation of stereotactic radiosurgery and methotrexate treatment in a prospective and observational clinical research study;Q422232;P2175;Q208414
A Northern California Oncology Group randomized trial of leucovorin plus 5-fluorouracil versus sequential methotrexate, 5-fluorouracil, and leucovorin in patients with advanced colorectal cancer who failed treatment with 5-fluorouracil or 5-fluorode;Q238512;P2175;Q2739660
[Outcomes of primary central nervous system lymphoma patients treated with high-dose methotrexate and rituximab];Q412323;P2175;Q136312
[Outcomes of primary central nervous system lymphoma patients treated with high-dose methotrexate and rituximab];Q412323;P2175;Q208414
[Outcomes of primary central nervous system lymphoma patients treated with high-dose methotrexate and rituximab];Q422232;P2175;Q136312
[Outcomes of primary central nervous system lymphoma patients treated with high-dose methotrexate and rituximab];Q422232;P2175;Q208414
Radiation development of pH-responsive (xanthan-acrylic acid)/MgO nanocomposite hydrogels for controlled delivery of methotrexate anticancer drug;Q23118;P31;Q12140
Radiation development of pH-responsive (xanthan-acrylic acid)/MgO nanocomposite hydrogels for controlled delivery of methotrexate anticancer drug;Q191924;P366;Q8386
Radiation development of pH-responsive (xanthan-acrylic acid)/MgO nanocomposite hydrogels for controlled delivery of methotrexate anticancer drug;Q485277;P31;Q12140
Radiation development of pH-responsive (xanthan-acrylic acid)/MgO nanocomposite hydrogels for controlled delivery of methotrexate anticancer drug;Q214769;P31;Q12140
Radiation development of pH-responsive (xanthan-acrylic acid)/MgO nanocomposite hydrogels for controlled delivery of methotrexate anticancer drug;Q173670;P31;Q12140
Radiation development of pH-responsive (xanthan-acrylic acid)/MgO nanocomposite hydrogels for controlled delivery of methotrexate anticancer drug;Q22124685;P31;Q12140
Radiation development of pH-responsive (xanthan-acrylic acid)/MgO nanocomposite hydrogels for controlled delivery of methotrexate anticancer drug;Q422232;P31;Q12140
[A randomized trial comparing ACF (adriamycin, cyclophosphamide, ftorafur) and ACF/MVMF (mitomycin C, vincristine, methotrexate, ftorafur)--a non-cross-resistant alternating chemotherapy of recurrent and advanced breast cancer].;Q19856779;P1889;Q417625
[A randomized trial comparing ACF (adriamycin, cyclophosphamide, ftorafur) and ACF/MVMF (mitomycin C, vincristine, methotrexate, ftorafur)--a non-cross-resistant alternating chemotherapy of recurrent and advanced breast cancer].;Q422232;P2175;Q128581
Enhancement of methotrexate cytotoxicity by modulation of proliferative activity in normal and neoplastic T lymphocytes and in a myeloid leukemia cell line.;Q422232;P2175;Q29496
A multifunctional nanomedicine platform for co-delivery of methotrexate and mild hyperthermia towards breast cancer therapy;Q218642;P31;Q12140
A multifunctional nanomedicine platform for co-delivery of methotrexate and mild hyperthermia towards breast cancer therapy;Q191924;P31;Q12140
A multifunctional nanomedicine platform for co-delivery of methotrexate and mild hyperthermia towards breast cancer therapy;Q422232;P31;Q12140
A multifunctional nanomedicine platform for co-delivery of methotrexate and mild hyperthermia towards breast cancer therapy;Q422232;P2175;Q128581
The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis;Q186521;P703;Q177932
The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis;Q412415;P2175;Q549534
The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis;Q422232;P2175;Q549534
Lymphomas during long-term methotrexate therapy.;Q422232;P2175;Q208414
Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.;Q180983;P2175;Q268713
Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.;Q180983;P2175;Q208414
Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.;Q412323;P2175;Q208414
Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.;Q412323;P2175;Q268713
Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.;Q422232;P2175;Q208414
[Development of a novel drug dilivery system based on calcium phosphate cement with methotrexate and its drug release test in vitro].;Q191924;P366;Q8386
[Development of a novel drug dilivery system based on calcium phosphate cement with methotrexate and its drug release test in vitro].;Q178450;P31;Q12140
[Development of a novel drug dilivery system based on calcium phosphate cement with methotrexate and its drug release test in vitro].;Q422232;P31;Q12140
Assessing joint destruction in the knees of patients with rheumatoid arthritis by using a semi-automated software for magnetic resonance imaging: therapeutic effect of methotrexate plus etanercept compared with methotrexate monotherapy.;Q218642;P703;Q2046782
Assessing joint destruction in the knees of patients with rheumatoid arthritis by using a semi-automated software for magnetic resonance imaging: therapeutic effect of methotrexate plus etanercept compared with methotrexate monotherapy.;Q218642;P703;Q177932
Assessing joint destruction in the knees of patients with rheumatoid arthritis by using a semi-automated software for magnetic resonance imaging: therapeutic effect of methotrexate plus etanercept compared with methotrexate monotherapy.;Q422232;P2175;Q187255
Assessing joint destruction in the knees of patients with rheumatoid arthritis by using a semi-automated software for magnetic resonance imaging: therapeutic effect of methotrexate plus etanercept compared with methotrexate monotherapy.;Q422232;P2175;Q170990
Epstein-Barr virus-related primary central nervous system lymphoma after cadaveric renal transplantation improved by treatment with high-dose methotrexate followed by irradiation.;Q422232;P2175;Q136312
Epstein-Barr virus-related primary central nervous system lymphoma after cadaveric renal transplantation improved by treatment with high-dose methotrexate followed by irradiation.;Q422232;P2175;Q208414
Triple DMARD combination for rheumatoid arthritis resistant to methotrexate and steroid combination: a single-center experience.;Q422232;P2175;Q170990
Triple DMARD combination for rheumatoid arthritis resistant to methotrexate and steroid combination: a single-center experience.;Q422232;P2175;Q187255
Triple DMARD combination for rheumatoid arthritis resistant to methotrexate and steroid combination: a single-center experience.;Q422232;P2868;Q810254
Central nervous system prophylaxis with high-dose methotrexate does not give rise to significant electroencephalographic changes in children with acute lymphoblastic leukemia.;Q422232;P2175;Q29496
Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis;Q422232;P2175;Q187255
Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis;Q422232;P2175;Q170990
Interaction of Folic Acid with Nanocrystalline Apatites and Extension to Methotrexate (Antifolate) in View of Anticancer Applications;Q422232;P2868;Q50573407
Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.;Q1592932;P2175;Q208414
Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.;Q1592932;P279;Q50229794
Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.;Q418817;P2175;Q208414
Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.;Q422232;P2175;Q208414
Intracerebral hematoma as a complication of intrathecal methotrexate administration.;Q422232;P636;Q1320251
Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study;Q422232;P2175;Q128581
HSH2D contributes to methotrexate resistance inhuman Tcell acute lymphoblastic leukaemia;Q183290;P703;Q15978631
HSH2D contributes to methotrexate resistance inhuman Tcell acute lymphoblastic leukaemia;Q186521;P703;Q15978631
HSH2D contributes to methotrexate resistance inhuman Tcell acute lymphoblastic leukaemia;Q485277;P703;Q15978631
HSH2D contributes to methotrexate resistance inhuman Tcell acute lymphoblastic leukaemia;Q178450;P703;Q15978631
HSH2D contributes to methotrexate resistance inhuman Tcell acute lymphoblastic leukaemia;Q422232;P2175;Q29496
[Use of methotrexate in the treatment of rheumatoid arthritis];Q422232;P2175;Q187255
[Use of methotrexate in the treatment of rheumatoid arthritis];Q422232;P2175;Q170990
The effect of asparaginase therapy on methotrexate toxicity and efficacy in children with acute lymphoblastic leukemia;Q422232;P2175;Q29496
Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate;Q422232;P2175;Q170990
Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate;Q422232;P2175;Q187255
Methotrexate in peripheral spondyloarthritis including psoriatic arthritis: a need for further evaluation;Q422232;P2175;Q170990
Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis.;Q415264;P2175;Q170990
Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis.;Q2697833;P2175;Q170990
Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis.;Q422232;P2175;Q187255
Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis.;Q422232;P2175;Q170990
Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis.;Q422232;P361;Q14819383
Response to D.M. Marcus's comment on the TRIFRA study (comparison ofTripterygium wilfordiiHook F vs methotrexate in the treatment of active rheumatoid arthritis);Q422232;P2175;Q187255
Response to D.M. Marcus's comment on the TRIFRA study (comparison ofTripterygium wilfordiiHook F vs methotrexate in the treatment of active rheumatoid arthritis);Q422232;P2175;Q170990
Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study.;Q415343;P2175;Q170990
Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study.;Q415343;P2175;Q187255
Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study.;Q422232;P2175;Q187255
Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study.;Q422232;P2175;Q170990
Intra-vitreal methotrexate leads to resolution of intraocular chronic lymphocytic leukaemia;Q422232;P2175;Q29496
The effect of gender on methotrexate prescription attitudes in Italian rheumatoid arthritis patients: the MARI study;Q422232;P2175;Q187255
The effect of gender on methotrexate prescription attitudes in Italian rheumatoid arthritis patients: the MARI study;Q422232;P2175;Q170990
[Clinical application of the simultaneous detection of methotrexate and 7-hydroxymethotrexate in the delayed elimination for pediatric acute lymphoblastic leukemia];Q422232;P2175;Q29496
Association between a microRNA binding site polymorphism in SLCO1A2 and the risk of delayed methotrexate elimination in Chinese children with acute lymphoblastic leukemia.;Q422232;P2175;Q29496
Serial changes in the aqueous IL-10 level after intravitreal methotrexate injection as an indicator of primary vitreoretinal lymphoma recurrence;Q422232;P2175;Q208414
Intracranial tumor lysis and cerebral edema after administration of intrathecal methotrexate: a case report and discussion.;Q422232;P636;Q1320251
Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis;Q422232;P2175;Q187255
Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis;Q422232;P2175;Q170990
Fatal pulmonary lymphomatoid granulomatosis in a patient taking methotrexate for rheumatoid arthritis;Q422232;P2175;Q187255
Fatal pulmonary lymphomatoid granulomatosis in a patient taking methotrexate for rheumatoid arthritis;Q422232;P2175;Q208414
Fatal pulmonary lymphomatoid granulomatosis in a patient taking methotrexate for rheumatoid arthritis;Q422232;P2175;Q170990
Are gene polymorphisms related to adverse events of methotrexate in patients with rheumatoid arthritis? A retrospective cohort study based on an updated meta-analysis;Q422232;P2175;Q187255
Are gene polymorphisms related to adverse events of methotrexate in patients with rheumatoid arthritis? A retrospective cohort study based on an updated meta-analysis;Q422232;P2175;Q170990
Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia of childhood.;Q422232;P2175;Q29496
Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings: possible role of genetic homoge;Q367700;P2175;Q1194520
Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings: possible role of genetic homoge;Q367700;P703;Q15978631
Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings: possible role of genetic homoge;Q483745;P703;Q15978631
Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings: possible role of genetic homoge;Q422232;P2175;Q29496
Stevens-Johnson Syndrome associated with methotrexate treatment for acute lymphoblastic leukemia: a case report;Q422232;P2175;Q29496
Is Methotrexate as efficacious as etanercept in psoriatic arthritis patients ? comment on the article by Mease Et Al;Q422232;P2175;Q170990
Can early hCG change and baseline progesterone level predict treatment outcome in patients receiving single dose Methotrexate protocol for tubal ectopic pregnancy?;Q422232;P2175;Q207087
Subtherapeutic dosing of methotrexate in rheumatoid arthritis trials;Q183290;P703;Q177932
Subtherapeutic dosing of methotrexate in rheumatoid arthritis trials;Q422232;P2175;Q170990
Subtherapeutic dosing of methotrexate in rheumatoid arthritis trials;Q422232;P2175;Q187255
Future refinement of methotrexate treatment in rheumatoid arthritis: comment on the article by Yazdany et al.;Q422232;P2175;Q187255
Future refinement of methotrexate treatment in rheumatoid arthritis: comment on the article by Yazdany et al.;Q422232;P2175;Q170990
Bilateral sensorineural hearing loss after adjuvant treatment with cyclophosphamide, methotrexate, Fluorouracil and alternative oral medications in a male with breast cancer.;Q191924;P31;Q12140
Bilateral sensorineural hearing loss after adjuvant treatment with cyclophosphamide, methotrexate, Fluorouracil and alternative oral medications in a male with breast cancer.;Q170545;P31;Q12140
Bilateral sensorineural hearing loss after adjuvant treatment with cyclophosphamide, methotrexate, Fluorouracil and alternative oral medications in a male with breast cancer.;Q238512;P31;Q12140
Bilateral sensorineural hearing loss after adjuvant treatment with cyclophosphamide, methotrexate, Fluorouracil and alternative oral medications in a male with breast cancer.;Q238512;P2175;Q128581
Bilateral sensorineural hearing loss after adjuvant treatment with cyclophosphamide, methotrexate, Fluorouracil and alternative oral medications in a male with breast cancer.;Q422232;P31;Q12140
Bilateral sensorineural hearing loss after adjuvant treatment with cyclophosphamide, methotrexate, Fluorouracil and alternative oral medications in a male with breast cancer.;Q422232;P2175;Q128581
Bilateral sensorineural hearing loss after adjuvant treatment with cyclophosphamide, methotrexate, Fluorouracil and alternative oral medications in a male with breast cancer.;Q422232;P636;Q285166
Impact of genetic variants of ATP binding cassette B1, AICAR transformylase/IMP cyclohydrolase, folyl-polyglutamatesynthetase, and methylenetetrahydrofolatereductase on methotrexate toxicity.;Q80863;P361;Q14817981
Porphyria cutanea tarda affecting a rheumatoid arthritis patient treated with methotrexate: association or coincidence?;Q422232;P2175;Q170990
Porphyria cutanea tarda affecting a rheumatoid arthritis patient treated with methotrexate: association or coincidence?;Q422232;P2175;Q187255
Downregulation of xIAP expression by small interfering RNA inhibits cellular viability and increases chemosensitivity to methotrexate in human hepatoma cell line HepG2.;Q218642;P703;Q15978631
Downregulation of xIAP expression by small interfering RNA inhibits cellular viability and increases chemosensitivity to methotrexate in human hepatoma cell line HepG2.;Q485277;P703;Q15978631
Downregulation of xIAP expression by small interfering RNA inhibits cellular viability and increases chemosensitivity to methotrexate in human hepatoma cell line HepG2.;Q173670;P703;Q15978631
Downregulation of xIAP expression by small interfering RNA inhibits cellular viability and increases chemosensitivity to methotrexate in human hepatoma cell line HepG2.;Q178450;P703;Q15978631
Downregulation of xIAP expression by small interfering RNA inhibits cellular viability and increases chemosensitivity to methotrexate in human hepatoma cell line HepG2.;Q20035886;P703;Q15978631
Downregulation of xIAP expression by small interfering RNA inhibits cellular viability and increases chemosensitivity to methotrexate in human hepatoma cell line HepG2.;Q620730;P703;Q15978631
Downregulation of xIAP expression by small interfering RNA inhibits cellular viability and increases chemosensitivity to methotrexate in human hepatoma cell line HepG2.;Q484940;P703;Q15978631
Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis;Q422232;P2175;Q170990
Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis;Q422232;P2175;Q187255
Changes in the pyrimidine deoxynucleoside triphosphate pools of L5178Y cells after their exposure to methotrexate and 5-fluorouracil.;Q238512;P31;Q47069735
Measurement of methotrexate in human cerebrospinal fluid using a chemiluminescence immunoassay intended for serum and plasma matrices;Q22124685;P703;Q15978631
Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study;Q424972;P2175;Q18554512
Outcome of methotrexate treatment for ectopic pregnancies among obese women;Q191924;P2175;Q12174
Methotrexate treatment of pityriasis lichenoides and lymphomatoid papulosis.;Q422232;P2175;Q208414
Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study;Q422232;P2175;Q170990
Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study;Q422232;P361;Q14819383
Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study;Q422232;P2175;Q187255
Chemotherapy of advanced head and neck cancer: updated results of a randomized trial of the order of administration of sequential methotrexate and 5-fluorouracil;Q238512;P2175;Q1783924
Chemotherapy of advanced head and neck cancer: updated results of a randomized trial of the order of administration of sequential methotrexate and 5-fluorouracil;Q422232;P2175;Q1783924
[Psoriasis. Treatment with methylaminopterin (Methotrexate) in weekly oral doses];Q422232;P636;Q285166
Treatment of primary cutaneous CD30+ anaplastic large cell lymphoma with intralesional methotrexate;Q422232;P2175;Q208414
Genetic variants influencing response to methotrexate in juvenile idiopathic arthritis and rheumatoid arthritis;Q422232;P2175;Q170990
Genetic variants influencing response to methotrexate in juvenile idiopathic arthritis and rheumatoid arthritis;Q422232;P361;Q14819383
Genetic variants influencing response to methotrexate in juvenile idiopathic arthritis and rheumatoid arthritis;Q422232;P2175;Q861224
Genetic variants influencing response to methotrexate in juvenile idiopathic arthritis and rheumatoid arthritis;Q422232;P2175;Q187255
Methotrexate analogues. 8. Synthesis and biological evaluation of bisamide derivatives as potential prodrugs.;Q183290;P31;Q12140
Methotrexate analogues. 8. Synthesis and biological evaluation of bisamide derivatives as potential prodrugs.;Q22124685;P31;Q12140
Methotrexate analogues. 8. Synthesis and biological evaluation of bisamide derivatives as potential prodrugs.;Q422232;P31;Q12140
Pityriasis lichenoides chronica induced by infliximab, with response to methotrexate;Q422232;P361;Q14819383
[Randomized multicenter trial of sequential methotrexate and 5-fluorouracil versus 5-fluorouracil alone in advanced gastric cancer];Q238512;P2175;Q189588
[Randomized multicenter trial of sequential methotrexate and 5-fluorouracil versus 5-fluorouracil alone in advanced gastric cancer];Q422232;P2175;Q189588
Understanding the variation in response to methotrexate;Q422232;P361;Q14819383
PReS-FINAL-2155: Genetic variability of methotrexate transporters in patients with juvenile idiopathic arthritis.;Q422232;P2175;Q170990
PReS-FINAL-2155: Genetic variability of methotrexate transporters in patients with juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Mycophenolate mofetil versus methotrexate for prevention of acute graft-versus-host disease in patients receiving allogeneic hematopoietic stem cell transplantation;Q130336;P4149;Q27122100
Mycophenolate mofetil versus methotrexate for prevention of acute graft-versus-host disease in patients receiving allogeneic hematopoietic stem cell transplantation;Q130336;P31;Q407142
Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Factors influencing length of time taking methotrexate in rheumatoid arthritis.;Q422232;P2175;Q170990
Factors influencing length of time taking methotrexate in rheumatoid arthritis.;Q422232;P2175;Q187255
Corneal Epithelial Toxicity after Intravitreal Methotrexate Injection for Vitreoretinal Lymphoma: Clinical and In Vitro Studies;Q422232;P2175;Q208414
DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 study;Q422232;P2175;Q208414
DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 study;Q422232;P2175;Q4833719
DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 study;Q422232;P2175;Q2626074
Nimesulide improves the disease modifying anti-rheumatic profile of methotrexate in mice with collagen-induced arthritis.;Q422232;P2175;Q170990
Development of pylomatrixoma after the subcutaneous injection of methotrexate for the treatment of juvenile idiopathic arthritis;Q422232;P2175;Q861224
Development of pylomatrixoma after the subcutaneous injection of methotrexate for the treatment of juvenile idiopathic arthritis;Q422232;P2175;Q170990
[Prospective clinical study of the combination therapy of auranofin and methotrexate for rheumatoid arthritis--a multi-center study];Q421230;P2175;Q187255
[Prospective clinical study of the combination therapy of auranofin and methotrexate for rheumatoid arthritis--a multi-center study];Q422232;P2175;Q187255
[Prospective clinical study of the combination therapy of auranofin and methotrexate for rheumatoid arthritis--a multi-center study];Q422232;P2175;Q170990
Methotrexate in early inflammatory arthritis;Q422232;P2175;Q170990
Error in the dosage of Methotrexate in the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis;Q408032;P1889;Q99239607
Error in the dosage of Methotrexate in the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis;Q422232;P2175;Q1161568
Methotrexate pharmacogenetics in the treatment of rheumatoid arthritis;Q422232;P2175;Q187255
Methotrexate pharmacogenetics in the treatment of rheumatoid arthritis;Q422232;P2175;Q170990
[Effects of low dose methotrexate therapy in rheumatoid arthritis: a comparison of three different dosage regimens];Q422232;P2175;Q170990
[Effects of low dose methotrexate therapy in rheumatoid arthritis: a comparison of three different dosage regimens];Q422232;P2175;Q187255
Pilot study using the combination of methotrexate and thalidomide in the treatment of rheumatoid arthritis.;Q203174;P2175;Q187255
Pilot study using the combination of methotrexate and thalidomide in the treatment of rheumatoid arthritis.;Q422232;P2175;Q187255
Pilot study using the combination of methotrexate and thalidomide in the treatment of rheumatoid arthritis.;Q422232;P2175;Q170990
[Therapy of refractory rheumatoid arthritis. Cyclosporin and methotrexate combination];Q422232;P2175;Q170990
[Therapy of refractory rheumatoid arthritis. Cyclosporin and methotrexate combination];Q422232;P2175;Q187255
Management of Caesarean scar pregnancy with or without methotrexate before curettage: human chorionic gonadotropin trends and patient outcomes.;Q407172;P279;Q409770
Management of Caesarean scar pregnancy with or without methotrexate before curettage: human chorionic gonadotropin trends and patient outcomes.;Q407172;P703;Q15978631
Management of Caesarean scar pregnancy with or without methotrexate before curettage: human chorionic gonadotropin trends and patient outcomes.;Q186474;P703;Q15978631
Management of Caesarean scar pregnancy with or without methotrexate before curettage: human chorionic gonadotropin trends and patient outcomes.;Q22124685;P703;Q15978631
[Treatment of chronic polyarthritis with low-dose methotrexate];Q422232;P2175;Q170990
[Treatment of chronic polyarthritis with low-dose methotrexate];Q422232;P2175;Q1274464
[Weekly high-dose methotrexate with citrovorum factor rescue for non-Hodgkin's lymphoma--serum methotrexate level and safety administration (author's transl)];Q422232;P2175;Q208414
[Weekly high-dose methotrexate with citrovorum factor rescue for non-Hodgkin's lymphoma--serum methotrexate level and safety administration (author's transl)];Q422232;P2175;Q1138590
Biologic treatment in comparison to methotrexate has positive effect on trabecular bone score in rheumatoid arthritis patients: 1-year follow-up;Q422232;P2175;Q170990
Biologic treatment in comparison to methotrexate has positive effect on trabecular bone score in rheumatoid arthritis patients: 1-year follow-up;Q422232;P2175;Q187255
Correction: Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study;Q2697833;P2175;Q170990
Correction: Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study;Q422232;P2175;Q170990
Correction: Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study;Q422232;P2175;Q187255
Oral low-dose methotrexate (MTX) to be efficient in refractory rheumatoid arthritis and adult-onset Still's disease.;Q422232;P2175;Q170990
Oral low-dose methotrexate (MTX) to be efficient in refractory rheumatoid arthritis and adult-onset Still's disease.;Q422232;P2175;Q187255
Phase II study of 'high-dose' celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma.;Q422232;P2175;Q208414
Subcutaneous methotrexate versus oral form for the treatment and prophylaxis of chronic plaque psoriasis;Q422232;P636;Q285166
Childhood dermatomyositis and polymyositis. Treatment with methotrexate and prednisone.;Q422232;P2175;Q980926
In vitro inhibition of human erythrocyte acetylcholinesterase (EC3.1.1.7) by an antineoplastic drug methotrexate;Q186474;P31;Q12140
In vitro inhibition of human erythrocyte acetylcholinesterase (EC3.1.1.7) by an antineoplastic drug methotrexate;Q186474;P703;Q15978631
In vitro inhibition of human erythrocyte acetylcholinesterase (EC3.1.1.7) by an antineoplastic drug methotrexate;Q191924;P31;Q12140
In vitro inhibition of human erythrocyte acetylcholinesterase (EC3.1.1.7) by an antineoplastic drug methotrexate;Q193166;P31;Q12140
In vitro inhibition of human erythrocyte acetylcholinesterase (EC3.1.1.7) by an antineoplastic drug methotrexate;Q193166;P703;Q15978631
In vitro inhibition of human erythrocyte acetylcholinesterase (EC3.1.1.7) by an antineoplastic drug methotrexate;Q180623;P31;Q12140
In vitro inhibition of human erythrocyte acetylcholinesterase (EC3.1.1.7) by an antineoplastic drug methotrexate;Q180623;P703;Q15978631
In vitro inhibition of human erythrocyte acetylcholinesterase (EC3.1.1.7) by an antineoplastic drug methotrexate;Q484940;P703;Q15978631
In vitro inhibition of human erythrocyte acetylcholinesterase (EC3.1.1.7) by an antineoplastic drug methotrexate;Q484940;P31;Q12140
In vitro inhibition of human erythrocyte acetylcholinesterase (EC3.1.1.7) by an antineoplastic drug methotrexate;Q422232;P31;Q12140
Serum levels of methotrexate by the ligand-binding assay after "high-dose" therapy for osteosarcoma.;Q422232;P2175;Q549534
[Combination of mycophenolate mofetil with cyclosporine A and methotrexate as acute GVHD prophylaxis after unrelated donor allogeneic bone marrow transplantation].;Q367700;P2175;Q1194520
[Combination of mycophenolate mofetil with cyclosporine A and methotrexate as acute GVHD prophylaxis after unrelated donor allogeneic bone marrow transplantation].;Q130336;P4149;Q27122100
[Combination of mycophenolate mofetil with cyclosporine A and methotrexate as acute GVHD prophylaxis after unrelated donor allogeneic bone marrow transplantation].;Q130336;P31;Q407142
[Combination of mycophenolate mofetil with cyclosporine A and methotrexate as acute GVHD prophylaxis after unrelated donor allogeneic bone marrow transplantation].;Q4567614;P2175;Q1194520
Suboptimal methotrexate use in rheumatoid arthritis patients in Italy: the MARI study.;Q422232;P2175;Q170990
Suboptimal methotrexate use in rheumatoid arthritis patients in Italy: the MARI study.;Q422232;P2175;Q187255
Role of the E45K-reduced folate carrier gene mutation in methotrexate resistance in human leukemia cells.;Q173670;P703;Q15978631
Role of the E45K-reduced folate carrier gene mutation in methotrexate resistance in human leukemia cells.;Q20816880;P703;Q15978631
Role of the E45K-reduced folate carrier gene mutation in methotrexate resistance in human leukemia cells.;Q422232;P2175;Q29496
Exclusive use of intrasac potassium chloride and methotrexate for treating cesarean scar pregnancy: effectiveness and subsequent fecundity;Q184630;P527;Q703
Exclusive use of intrasac potassium chloride and methotrexate for treating cesarean scar pregnancy: effectiveness and subsequent fecundity;Q184630;P527;Q108200
Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study;Q422232;P2175;Q170990
Cis-dichlorodiammineplatinum(II), methotrexate, bleomycin, and vincristine in head and neck cancer: a pilot study;Q422232;P2175;Q1783924
[Preliminary evaluation of individualized use of large doses of methotrexate for treatment of osteosarcoma in children and adolescents];Q422232;P2175;Q549534
The role of methotrexate and low-dose prednisolone on adiponectine levels and insulin resistance in patients with rheumatoid arthritis nave to disease-modifying antirheumatic drugs.;Q186521;P31;Q12140
The role of methotrexate and low-dose prednisolone on adiponectine levels and insulin resistance in patients with rheumatoid arthritis nave to disease-modifying antirheumatic drugs.;Q191924;P366;Q8386
The role of methotrexate and low-dose prednisolone on adiponectine levels and insulin resistance in patients with rheumatoid arthritis nave to disease-modifying antirheumatic drugs.;Q11426176;P31;Q12140
The role of methotrexate and low-dose prednisolone on adiponectine levels and insulin resistance in patients with rheumatoid arthritis nave to disease-modifying antirheumatic drugs.;Q50265665;P31;Q12140
The role of methotrexate and low-dose prednisolone on adiponectine levels and insulin resistance in patients with rheumatoid arthritis nave to disease-modifying antirheumatic drugs.;Q422232;P31;Q12140
The role of methotrexate and low-dose prednisolone on adiponectine levels and insulin resistance in patients with rheumatoid arthritis nave to disease-modifying antirheumatic drugs.;Q422232;P2175;Q187255
The role of methotrexate and low-dose prednisolone on adiponectine levels and insulin resistance in patients with rheumatoid arthritis nave to disease-modifying antirheumatic drugs.;Q422232;P2868;Q810254
The role of methotrexate and low-dose prednisolone on adiponectine levels and insulin resistance in patients with rheumatoid arthritis nave to disease-modifying antirheumatic drugs.;Q422232;P2175;Q170990
High level resistance to glucocorticoids, associated with a dysfunctional glucocorticoid receptor, in childhood acute lymphoblastic leukemia cells selected for methotrexate resistance.;Q422232;P2175;Q29496
Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.;Q191924;P366;Q8386
Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.;Q422232;P31;Q12140
Methotrexate in tubal pregnancy;Q422232;P2175;Q207087
Recommendations for the therapeutics of methotrexate in rheumatoid arthritis;Q173670;P703;Q177932
Recommendations for the therapeutics of methotrexate in rheumatoid arthritis;Q422232;P2175;Q170990
Recommendations for the therapeutics of methotrexate in rheumatoid arthritis;Q422232;P2175;Q187255
High dose methotrexate treatment in children with acute lymphoblastic leukaemia may be optimised by a weight-based dose calculation.;Q422232;P2175;Q29496
[Therapeutic effectiveness of carminomycin (CRM) in combination with dibromodulcitol (DBD) compared with the combination vincristine, cyclophosphamide, methotrexate, 5-fluorouracil (VCMF) on some tumor systems (author's transl)];Q186474;P703;Q177932
[Therapeutic effectiveness of carminomycin (CRM) in combination with dibromodulcitol (DBD) compared with the combination vincristine, cyclophosphamide, methotrexate, 5-fluorouracil (VCMF) on some tumor systems (author's transl)];Q186521;P703;Q177932
[Therapeutic effectiveness of carminomycin (CRM) in combination with dibromodulcitol (DBD) compared with the combination vincristine, cyclophosphamide, methotrexate, 5-fluorouracil (VCMF) on some tumor systems (author's transl)];Q173670;P703;Q177932
[Therapeutic effectiveness of carminomycin (CRM) in combination with dibromodulcitol (DBD) compared with the combination vincristine, cyclophosphamide, methotrexate, 5-fluorouracil (VCMF) on some tumor systems (author's transl)];Q178450;P703;Q177932
[Therapeutic effectiveness of carminomycin (CRM) in combination with dibromodulcitol (DBD) compared with the combination vincristine, cyclophosphamide, methotrexate, 5-fluorouracil (VCMF) on some tumor systems (author's transl)];Q22124685;P703;Q177932
[Therapeutic effectiveness of carminomycin (CRM) in combination with dibromodulcitol (DBD) compared with the combination vincristine, cyclophosphamide, methotrexate, 5-fluorouracil (VCMF) on some tumor systems (author's transl)];Q483752;P703;Q177932
[Prophylactic CNS therapy in childhood leukemia--randomized controlled study of high-dose intravenous methotrexate and cranial irradiation];Q422232;P2175;Q29496
Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis;Q422232;P2175;Q170990
Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis;Q422232;P2175;Q187255
Validation of the Fibrosis-4 (FIB-4) index in the diagnosis of liver disease of rheumatoid arthritis patients treated with methotrexate;Q422232;P2175;Q170990
Validation of the Fibrosis-4 (FIB-4) index in the diagnosis of liver disease of rheumatoid arthritis patients treated with methotrexate;Q422232;P2175;Q187255
Evaluation of the effect of andrographolide and methotrexate combined therapy in complete Freund's adjuvant induced arthritis with reduced hepatotoxicity;Q422232;P2175;Q170990
[analysis of adherence and compliance to methotrexate therapy in rheumatoid arthritis patients].;Q422232;P2175;Q187255
[analysis of adherence and compliance to methotrexate therapy in rheumatoid arthritis patients].;Q422232;P2175;Q170990
Acute myeloid leukemia following 3M (mitoxantrone, mitomycin and methotrexate) chemotherapy for advanced breast cancer;Q239426;P2175;Q128581
Acute myeloid leukemia following 3M (mitoxantrone, mitomycin and methotrexate) chemotherapy for advanced breast cancer;Q19856779;P1889;Q417625
Acute myeloid leukemia following 3M (mitoxantrone, mitomycin and methotrexate) chemotherapy for advanced breast cancer;Q422232;P2175;Q29496
Acute myeloid leukemia following 3M (mitoxantrone, mitomycin and methotrexate) chemotherapy for advanced breast cancer;Q422232;P2175;Q128581
Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis;Q248550;P2175;Q170990
Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis;Q248550;P2175;Q187255
Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis;Q422232;P2175;Q187255
Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis;Q422232;P2175;Q170990
A prospective study on urine alkalization with an oral regimen consisting of sodium bicarbonate and acetazolamide in patients receiving high-dose methotrexate;Q218642;P527;Q623
A prospective study on urine alkalization with an oral regimen consisting of sodium bicarbonate and acetazolamide in patients receiving high-dose methotrexate;Q191924;P527;Q623
A prospective study on urine alkalization with an oral regimen consisting of sodium bicarbonate and acetazolamide in patients receiving high-dose methotrexate;Q413690;P636;Q285166
A prospective study on urine alkalization with an oral regimen consisting of sodium bicarbonate and acetazolamide in patients receiving high-dose methotrexate;Q179731;P527;Q623
A prospective study on urine alkalization with an oral regimen consisting of sodium bicarbonate and acetazolamide in patients receiving high-dose methotrexate;Q179731;P527;Q658
A prospective study on urine alkalization with an oral regimen consisting of sodium bicarbonate and acetazolamide in patients receiving high-dose methotrexate;Q422232;P636;Q285166
Role of nail bed methotrexate injections in isolated nail psoriasis: conventional drug via an unconventional route;Q191924;P366;Q8386
Role of nail bed methotrexate injections in isolated nail psoriasis: conventional drug via an unconventional route;Q173670;P31;Q12140
Role of nail bed methotrexate injections in isolated nail psoriasis: conventional drug via an unconventional route;Q422232;P31;Q12140
Methotrexate and folic acid: what is the optimal combination?;Q422232;P2868;Q127060
Giant-cell pneumonia caused by measles and methotrexate in childhood leukaemia in remission.;Q422232;P2175;Q29496
A systemic review and meta-analysis of the clinical efficacy and safety of total glucosides of peony combined with methotrexate in rheumatoid arthritis.;Q422232;P2175;Q170990
A systemic review and meta-analysis of the clinical efficacy and safety of total glucosides of peony combined with methotrexate in rheumatoid arthritis.;Q422232;P2175;Q187255
Examination of the rescue effects of folic acid on derangement of the tubo-ovarian ultrastructural architecture caused by methotrexate;Q422232;P2868;Q127060
Large diversity in transport-mediated methotrexate resistance in human leukemia cell line CCRF-CEM established in a high concentration of leucovorin.;Q186474;P703;Q15978631
Large diversity in transport-mediated methotrexate resistance in human leukemia cell line CCRF-CEM established in a high concentration of leucovorin.;Q170545;P703;Q15978631
Large diversity in transport-mediated methotrexate resistance in human leukemia cell line CCRF-CEM established in a high concentration of leucovorin.;Q139347;P703;Q15978631
Large diversity in transport-mediated methotrexate resistance in human leukemia cell line CCRF-CEM established in a high concentration of leucovorin.;Q173670;P703;Q15978631
Large diversity in transport-mediated methotrexate resistance in human leukemia cell line CCRF-CEM established in a high concentration of leucovorin.;Q22124685;P703;Q15978631
Large diversity in transport-mediated methotrexate resistance in human leukemia cell line CCRF-CEM established in a high concentration of leucovorin.;Q483745;P703;Q15978631
Large diversity in transport-mediated methotrexate resistance in human leukemia cell line CCRF-CEM established in a high concentration of leucovorin.;Q422232;P2175;Q29496
Methotrexate for maintenance of remission in ulcerative colitis;Q422232;P2175;Q1477
Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia.;Q422232;P2175;Q29496
Light activates reduction of methotrexate by NADPH in the ternary complex with Escherichia coli dihydrofolate reductase.;Q218642;P703;Q25419
Light activates reduction of methotrexate by NADPH in the ternary complex with Escherichia coli dihydrofolate reductase.;Q485277;P703;Q25419
Light activates reduction of methotrexate by NADPH in the ternary complex with Escherichia coli dihydrofolate reductase.;Q178450;P703;Q25419
Light activates reduction of methotrexate by NADPH in the ternary complex with Escherichia coli dihydrofolate reductase.;Q20035886;P703;Q25419
Light activates reduction of methotrexate by NADPH in the ternary complex with Escherichia coli dihydrofolate reductase.;Q483745;P703;Q25419
Effect of treatment with methotrexate, hydroxychloroquine, and prednisone on lymphocyte polyamine levels in rheumatoid arthritis: correlation with the clinical response and rheumatoid factor synthesis.;Q421094;P2175;Q187255
Effect of treatment with methotrexate, hydroxychloroquine, and prednisone on lymphocyte polyamine levels in rheumatoid arthritis: correlation with the clinical response and rheumatoid factor synthesis.;Q421094;P2175;Q170990
Effect of treatment with methotrexate, hydroxychloroquine, and prednisone on lymphocyte polyamine levels in rheumatoid arthritis: correlation with the clinical response and rheumatoid factor synthesis.;Q421094;P1889;Q422438
Effect of treatment with methotrexate, hydroxychloroquine, and prednisone on lymphocyte polyamine levels in rheumatoid arthritis: correlation with the clinical response and rheumatoid factor synthesis.;Q424972;P2175;Q170990
Effect of treatment with methotrexate, hydroxychloroquine, and prednisone on lymphocyte polyamine levels in rheumatoid arthritis: correlation with the clinical response and rheumatoid factor synthesis.;Q422438;P2175;Q187255
Effect of treatment with methotrexate, hydroxychloroquine, and prednisone on lymphocyte polyamine levels in rheumatoid arthritis: correlation with the clinical response and rheumatoid factor synthesis.;Q422438;P1889;Q421094
Effect of treatment with methotrexate, hydroxychloroquine, and prednisone on lymphocyte polyamine levels in rheumatoid arthritis: correlation with the clinical response and rheumatoid factor synthesis.;Q422232;P2175;Q170990
Effect of treatment with methotrexate, hydroxychloroquine, and prednisone on lymphocyte polyamine levels in rheumatoid arthritis: correlation with the clinical response and rheumatoid factor synthesis.;Q422232;P2175;Q187255
Effect of methotrexate on the survival of human lymphocyte cultures carrying MTHFR 677 (C>T) and MTHFR 1298 (A>C) mutations.;Q218642;P703;Q15978631
Effect of methotrexate on the survival of human lymphocyte cultures carrying MTHFR 677 (C>T) and MTHFR 1298 (A>C) mutations.;Q186474;P703;Q15978631
Effect of methotrexate on the survival of human lymphocyte cultures carrying MTHFR 677 (C>T) and MTHFR 1298 (A>C) mutations.;Q186521;P703;Q15978631
Effect of methotrexate on the survival of human lymphocyte cultures carrying MTHFR 677 (C>T) and MTHFR 1298 (A>C) mutations.;Q485277;P703;Q15978631
Effect of methotrexate on the survival of human lymphocyte cultures carrying MTHFR 677 (C>T) and MTHFR 1298 (A>C) mutations.;Q170545;P703;Q15978631
Effect of methotrexate on the survival of human lymphocyte cultures carrying MTHFR 677 (C>T) and MTHFR 1298 (A>C) mutations.;Q173670;P703;Q15978631
Effect of methotrexate on the survival of human lymphocyte cultures carrying MTHFR 677 (C>T) and MTHFR 1298 (A>C) mutations.;Q22124685;P703;Q15978631
Effect of SLCO1B1 Polymorphisms on High-Dose Methotrexate Clearance in Children and Young Adults with Leukemia and Lymphoblastic Lymphoma;Q422232;P2175;Q208414
A phase II study of high-dose celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma.;Q422232;P2175;Q208414
Single-dose methotrexate for the management of interstitial ectopic pregnancy;Q422232;P2175;Q207087
Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905;Q422232;P2175;Q56014449
Remission maintenance therapy for meningeal leukemia: intrathecal methotrexate vs. intravenous bis-nitrosourea.;Q422232;P2175;Q29496
Remission maintenance therapy for meningeal leukemia: intrathecal methotrexate vs. intravenous bis-nitrosourea.;Q422232;P636;Q1320251
High-dose methotrexate in fibroblastic osteosarcoma;Q422232;P2175;Q549534
Transforming activities of methotrexate, hydroxyurea and 5-fluorouracil in different cell systems.;Q212272;P279;Q48318
Methotrexate reduces withdrawal rates of TNF inhibitors due to ineffectiveness in rheumatoid arthritis but only in patients who are seropositive;Q422232;P2175;Q170990
Methotrexate reduces withdrawal rates of TNF inhibitors due to ineffectiveness in rheumatoid arthritis but only in patients who are seropositive;Q422232;P2175;Q187255
Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?;Q422232;P2175;Q707816
Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?;Q422232;P2175;Q1752891
[A case of advanced thoracic esophageal cancer with marked response to bleomycin absorbed on activated carbon particles (BLM-CH44), methotrexate, and cisplatin];Q218642;P527;Q623
[A case of advanced thoracic esophageal cancer with marked response to bleomycin absorbed on activated carbon particles (BLM-CH44), methotrexate, and cisplatin];Q186474;P527;Q623
[A case of advanced thoracic esophageal cancer with marked response to bleomycin absorbed on activated carbon particles (BLM-CH44), methotrexate, and cisplatin];Q191924;P527;Q623
[A case of advanced thoracic esophageal cancer with marked response to bleomycin absorbed on activated carbon particles (BLM-CH44), methotrexate, and cisplatin];Q485277;P527;Q623
[A case of advanced thoracic esophageal cancer with marked response to bleomycin absorbed on activated carbon particles (BLM-CH44), methotrexate, and cisplatin];Q412415;P2175;Q372701
[A case of advanced thoracic esophageal cancer with marked response to bleomycin absorbed on activated carbon particles (BLM-CH44), methotrexate, and cisplatin];Q415571;P361;Q24460804
[A case of advanced thoracic esophageal cancer with marked response to bleomycin absorbed on activated carbon particles (BLM-CH44), methotrexate, and cisplatin];Q483745;P527;Q623
[A case of advanced thoracic esophageal cancer with marked response to bleomycin absorbed on activated carbon particles (BLM-CH44), methotrexate, and cisplatin];Q422232;P2175;Q372701
Etoposide, carmustine, bleomycin, and methotrexate with leucovorin rescue as re-treatment for unfavorable non-Hodgkin's lymphoma.;Q418817;P2175;Q208414
Etoposide, carmustine, bleomycin, and methotrexate with leucovorin rescue as re-treatment for unfavorable non-Hodgkin's lymphoma.;Q418817;P2175;Q1138590
Etoposide, carmustine, bleomycin, and methotrexate with leucovorin rescue as re-treatment for unfavorable non-Hodgkin's lymphoma.;Q418011;P2175;Q208414
Etoposide, carmustine, bleomycin, and methotrexate with leucovorin rescue as re-treatment for unfavorable non-Hodgkin's lymphoma.;Q422232;P2175;Q1138590
Etoposide, carmustine, bleomycin, and methotrexate with leucovorin rescue as re-treatment for unfavorable non-Hodgkin's lymphoma.;Q422232;P2175;Q208414
Population Pharmacokinetics of High-Dose Methotrexate in Patients With Primary Central Nervous System Lymphoma.;Q422232;P2175;Q136312
Population Pharmacokinetics of High-Dose Methotrexate in Patients With Primary Central Nervous System Lymphoma.;Q422232;P2175;Q208414
Influence of methotrexate on purine and pyrimidine pools and on cell phase distribution of cultured human lymphoblasts.;Q484940;P703;Q15978631
Effects of purified micronized flavonoid fraction (Detralex) on prophylactic treatment of adjuvant arthritis with methotrexate in rats;Q422232;P2175;Q170990
PReS-FINAL-2054: Latent tuberculosis infection in patients with juvenile idiopathic arthritis undergoing methotrexate therapy: a longitudinal study with TST and ELISPOT.;Q422232;P2175;Q170990
PReS-FINAL-2054: Latent tuberculosis infection in patients with juvenile idiopathic arthritis undergoing methotrexate therapy: a longitudinal study with TST and ELISPOT.;Q422232;P2175;Q861224
Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system;Q412323;P2175;Q208414
Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system;Q422232;P2175;Q208414
Relationship of peak serum methotrexate concentration to prognosis and drug tolerance in non-metastatic extremity osteosarcomas;Q191924;P31;Q12140
Relationship of peak serum methotrexate concentration to prognosis and drug tolerance in non-metastatic extremity osteosarcomas;Q173670;P31;Q12140
Relationship of peak serum methotrexate concentration to prognosis and drug tolerance in non-metastatic extremity osteosarcomas;Q422232;P31;Q12140
Relationship of peak serum methotrexate concentration to prognosis and drug tolerance in non-metastatic extremity osteosarcomas;Q422232;P2175;Q549534
Histological changes following high-dose methotrexate and cisplatinum administration and the influence of dosage scheduling.;Q412415;P527;Q880
Reasons for stopping methotrexate treatment in patients with juvenile idiopathic arthritis.;Q422232;P2175;Q170990
Reasons for stopping methotrexate treatment in patients with juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs.;Q420035;P31;Q12140
Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs.;Q420035;P2175;Q170990
Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs.;Q420035;P2175;Q187255
Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs.;Q22124685;P31;Q12140
Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs.;Q422232;P2175;Q170990
Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs.;Q422232;P31;Q12140
Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs.;Q422232;P2175;Q187255
[Meta-analysis of RCT studies on clinical efficacy of single administration of Tripterygium Glycosides Tablets or combined administration with methotrexate against rheumatoid arthritis];Q422232;P2175;Q187255
[Meta-analysis of RCT studies on clinical efficacy of single administration of Tripterygium Glycosides Tablets or combined administration with methotrexate against rheumatoid arthritis];Q422232;P2175;Q170990
Dihydrofolate Reductase Genetic Polymorphisms Affect Methotrexate Dose Requirements in Pediatric Patients With Acute Lymphoblastic Leukemia on Maintenance Therapy.;Q218642;P703;Q2046782
Dihydrofolate Reductase Genetic Polymorphisms Affect Methotrexate Dose Requirements in Pediatric Patients With Acute Lymphoblastic Leukemia on Maintenance Therapy.;Q178450;P703;Q2046782
DNA ploidy and S-phase fraction as predictive factors of response and outcome following neoadjuvant methotrexate, vinblastine, epirubicin and cisplatin (M-VEC) chemotherapy for invasive bladder cancer.;Q412415;P2175;Q504775
Methotrexate induced early onset pancytopenia in rheumatoid arthritis: drug allergy? Idiosyncrasy?;Q22124685;P31;Q12140
Methotrexate induced early onset pancytopenia in rheumatoid arthritis: drug allergy? Idiosyncrasy?;Q422232;P31;Q12140
Methotrexate induced early onset pancytopenia in rheumatoid arthritis: drug allergy? Idiosyncrasy?;Q422232;P2175;Q170990
Methotrexate induced early onset pancytopenia in rheumatoid arthritis: drug allergy? Idiosyncrasy?;Q422232;P2175;Q187255
Methotrexate induced early onset pancytopenia in rheumatoid arthritis: drug allergy? Idiosyncrasy?;Q484940;P31;Q12140
Enhanced production of intracellular ara-CTP after sequential use of methotrexate and 1-beta-D-arabinofuranosylcytosine.;Q186474;P1889;Q178425
Preliminary study for predicting better methotrexate efficacy in Japanese patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Preliminary study for predicting better methotrexate efficacy in Japanese patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Laparoscopic excision of coexisting left tubal and right pseudotubal pregnancy after conservative management of previous ectopic pregnancy with methotrexate: an unusual clinical entity.;Q422232;P2175;Q207087
Are haplotypes in a single methotrexate pathway more predictive for response in rheumatoid arthritis than in different pathways?;Q422232;P2175;Q170990
Are haplotypes in a single methotrexate pathway more predictive for response in rheumatoid arthritis than in different pathways?;Q422232;P2175;Q187255
ACP Journal Club. Methotrexate reduced pain and improved function in symptomatic knee osteoarthritis;Q422232;P2175;Q170990
PT716. Treatment with the Chemotherapeutic Drug Methotrexate Impairs Long-Term Potentiation in the Hippocampus.;Q186474;P703;Q177932
PT716. Treatment with the Chemotherapeutic Drug Methotrexate Impairs Long-Term Potentiation in the Hippocampus.;Q186521;P703;Q177932
PT716. Treatment with the Chemotherapeutic Drug Methotrexate Impairs Long-Term Potentiation in the Hippocampus.;Q485277;P703;Q177932
PT716. Treatment with the Chemotherapeutic Drug Methotrexate Impairs Long-Term Potentiation in the Hippocampus.;Q178450;P703;Q177932
PT716. Treatment with the Chemotherapeutic Drug Methotrexate Impairs Long-Term Potentiation in the Hippocampus.;Q20035886;P703;Q177932
PT716. Treatment with the Chemotherapeutic Drug Methotrexate Impairs Long-Term Potentiation in the Hippocampus.;Q22124685;P703;Q177932
PT716. Treatment with the Chemotherapeutic Drug Methotrexate Impairs Long-Term Potentiation in the Hippocampus.;Q483745;P703;Q177932
PT716. Treatment with the Chemotherapeutic Drug Methotrexate Impairs Long-Term Potentiation in the Hippocampus.;Q484940;P703;Q177932
Multiple cerebral hemorrhages as a possible complication of antiblastic treatment with cyclophosphamide, methotrexate and fluoruracil (CMF) for breast cancer;Q422232;P2175;Q128581
[In vivo 31P-NMR studies on energy metabolism and the effect of methotrexate in murine implanted osteosarcoma];Q422232;P2175;Q549534
Culture Conditions Affect Chemical-Induced Developmental Toxicity In Vitro: The Case of Folic Acid, Methionine and Methotrexate in the Neural Embryonic Stem Cell Test;Q22124685;P31;Q180341
[Isoniazid prophylaxis for pulmonary tuberculosis in Chinese patients with rheumatoid arthritis receiving long-term methotrexate therapy].;Q423169;P2175;Q12204
[Isoniazid prophylaxis for pulmonary tuberculosis in Chinese patients with rheumatoid arthritis receiving long-term methotrexate therapy].;Q423169;P2175;Q13046587
[Isoniazid prophylaxis for pulmonary tuberculosis in Chinese patients with rheumatoid arthritis receiving long-term methotrexate therapy].;Q422232;P2175;Q170990
[Isoniazid prophylaxis for pulmonary tuberculosis in Chinese patients with rheumatoid arthritis receiving long-term methotrexate therapy].;Q422232;P2175;Q187255
High-dose methotrexate in acute lymphocytic leukemia.;Q422232;P2175;Q29496
Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system lymphoma;Q180983;P2175;Q208414
Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system lymphoma;Q412323;P2175;Q136312
Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system lymphoma;Q412323;P2175;Q208414
Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system lymphoma;Q416507;P2175;Q208414
Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system lymphoma;Q422232;P2175;Q208414
Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system lymphoma;Q422232;P2175;Q136312
Etanercept plus methotrexate reduced symptoms and disease activity in adult-onset rheumatoid arthritis.;Q415343;P2175;Q170990
Etanercept plus methotrexate reduced symptoms and disease activity in adult-onset rheumatoid arthritis.;Q415343;P2175;Q187255
Etanercept plus methotrexate reduced symptoms and disease activity in adult-onset rheumatoid arthritis.;Q422232;P2175;Q187255
Etanercept plus methotrexate reduced symptoms and disease activity in adult-onset rheumatoid arthritis.;Q422232;P2175;Q170990
Rapid regression of cystoid macular edema associated with cytomegalovirus retinitis in adult acute myeloid leukemia by intravitreal methotrexate combined with oral valganciclovir: A case report with comparison of binocular outcome.;Q417640;P636;Q285166
Rapid regression of cystoid macular edema associated with cytomegalovirus retinitis in adult acute myeloid leukemia by intravitreal methotrexate combined with oral valganciclovir: A case report with comparison of binocular outcome.;Q422232;P636;Q285166
Rapid regression of cystoid macular edema associated with cytomegalovirus retinitis in adult acute myeloid leukemia by intravitreal methotrexate combined with oral valganciclovir: A case report with comparison of binocular outcome.;Q422232;P2175;Q29496
Rapid regression of cystoid macular edema associated with cytomegalovirus retinitis in adult acute myeloid leukemia by intravitreal methotrexate combined with oral valganciclovir: A case report with comparison of binocular outcome.;Q422232;P2175;Q264118
Strategy to minimize radiation burden in infants and high-risk medulloblastoma using intrathecal methotrexate and high-dose chemotherapy: A prospective registry study in Japan;Q422232;P636;Q1320251
Luteal blood flow as a predictive factor for methotrexate treatment outcomes in women with unruptured tubal pregnancy;Q422232;P2175;Q207087
The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis.;Q341500;P31;Q106040601
[Cellular immunity during and after high-dose methotrexate therapy in patients with osteosarcoma (author's transl)];Q422232;P2175;Q549534
Right on target: coupling methotrexate to albumin to treat rheumatoid arthritis.;Q422232;P2175;Q187255
Right on target: coupling methotrexate to albumin to treat rheumatoid arthritis.;Q422232;P2175;Q170990
Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.;Q238512;P2175;Q128581
Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.;Q425122;P2175;Q128581
Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.;Q422232;P2175;Q128581
Primary cutaneous CD30+ anaplastic large cell lymphoma treated with radiotherapy and methotrexate with development of xanthomas at the sites of prior disease;Q422232;P2175;Q208414
The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis.;Q422232;P2175;Q170990
The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis.;Q422232;P2175;Q187255
Absence of Pharmacokinetic Interactions between the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate;Q188017;P31;Q27102882
Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial.;Q422232;P2175;Q170990
Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial.;Q422232;P2175;Q187255
Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial.;Q422232;P361;Q14819383
Clinical and radiological dissociation of anti-TNF plus methotrexate treatment in early rheumatoid arthritis in routine care: results from the ABRAB study;Q422232;P2175;Q187255
Clinical and radiological dissociation of anti-TNF plus methotrexate treatment in early rheumatoid arthritis in routine care: results from the ABRAB study;Q422232;P2175;Q170990
Low-dose methotrexate combined with superficial X-ray in the treatment of folliculotropic mycosis fungoides: A case report.;Q422232;P2175;Q1891209
The concomitant use of meloxicam and methotrexate does not clearly increase the risk of silent kidney and liver damages in patients with rheumatoid arthritis.;Q414028;P2175;Q170990
The concomitant use of meloxicam and methotrexate does not clearly increase the risk of silent kidney and liver damages in patients with rheumatoid arthritis.;Q422232;P2175;Q187255
The concomitant use of meloxicam and methotrexate does not clearly increase the risk of silent kidney and liver damages in patients with rheumatoid arthritis.;Q422232;P2175;Q170990
High-dose cyclophosphamide-high-dose methotrexate with coordinated intrathecal therapy for advanced nonlymphoblastic lymphoma of childhood: results of a Pediatric Oncology Group study.;Q422232;P636;Q1320251
High-dose cyclophosphamide-high-dose methotrexate with coordinated intrathecal therapy for advanced nonlymphoblastic lymphoma of childhood: results of a Pediatric Oncology Group study.;Q422232;P2175;Q208414
Single-dose intramuscular methotrexate treatment of cervical ectopic pregnancy. A case report.;Q422232;P2175;Q207087
Folic and folinic acid supplementation reduces methotrexate gastrointestinal side effects in rheumatoid arthritis;Q422232;P2175;Q187255
Folic and folinic acid supplementation reduces methotrexate gastrointestinal side effects in rheumatoid arthritis;Q422232;P2175;Q170990
Imported case of visceral leishmaniasis presenting as pancytopenia in a Norwegian patient treated with methotrexate and etanercept for psoriasis arthritis.;Q422232;P2175;Q170990
Interstitial ectopic pregnancy--management with laparoscopically-guided local methotrexate infiltration;Q422232;P2175;Q207087
Association between malignancy and methotrexate and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis;Q218642;P31;Q12140
Association between malignancy and methotrexate and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis;Q191924;P31;Q12140
Association between malignancy and methotrexate and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis;Q191924;P366;Q8386
Association between malignancy and methotrexate and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis;Q422232;P31;Q12140
Association between malignancy and methotrexate and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis;Q422232;P2175;Q170990
Association between malignancy and methotrexate and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis;Q422232;P2868;Q810254
Association between malignancy and methotrexate and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis;Q422232;P2175;Q187255
Increased growth of tumor isotransplants after immunosuppression of the recipient mice by methotrexate or 5-fluoro-2'-deoxyuridine.;Q5462356;P279;Q419140
A comparison of the biological effects of dichloromethotrexate and methotrexate on human leukemic cells in culture.;Q218642;P703;Q15978631
Pharmacokinetics of nimustine, cytosine arabinoside, and methotrexate in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy.;Q422232;P636;Q640448
Headache after diagnostic lumbar puncture. Doctors given intrathecal methotrexate had headache when 20 gauge standard needle was used.;Q422232;P636;Q1320251
Toxicity study of cytosine arabinoside and methotrexate in the maintenance therapy of childhood leukemia. A Southwest Oncology Group study.;Q180983;P2175;Q29496
Toxicity study of cytosine arabinoside and methotrexate in the maintenance therapy of childhood leukemia. A Southwest Oncology Group study.;Q218642;P703;Q2046782
Toxicity study of cytosine arabinoside and methotrexate in the maintenance therapy of childhood leukemia. A Southwest Oncology Group study.;Q422232;P2175;Q29496
Methotrexate analogues. 31. Meta and ortho isomers of aminopterin, compounds with a double bond in the side chain, and a novel analogue modified at the alpha-carbon: chemical and in vitro biological studies.;Q415734;P31;Q11173
Methotrexate analogues. 31. Meta and ortho isomers of aminopterin, compounds with a double bond in the side chain, and a novel analogue modified at the alpha-carbon: chemical and in vitro biological studies.;Q22124685;P31;Q11173
Methotrexate analogues. 31. Meta and ortho isomers of aminopterin, compounds with a double bond in the side chain, and a novel analogue modified at the alpha-carbon: chemical and in vitro biological studies.;Q422232;P31;Q11173
[Successful treatment with administration of systemic high dose methotrexate and intraarterial carboplatin for osteosarcoma of the skull: a case report];Q415588;P2175;Q549534
[Successful treatment with administration of systemic high dose methotrexate and intraarterial carboplatin for osteosarcoma of the skull: a case report];Q422232;P2175;Q549534
Progression of myelodysplasia during low-dose methotrexate therapy in rheumatoid arthritis;Q422232;P2175;Q170990
Progression of myelodysplasia during low-dose methotrexate therapy in rheumatoid arthritis;Q422232;P2175;Q187255
Methotrexate pharmacology in leukaemia cells -letter to the editor.;Q422232;P2175;Q29496
Methotrexate treatment of ectopic pregnancy: observations on the medical literature.;Q422232;P2175;Q207087
Raman spectroscopy as a potential tool for label free therapeutic drug monitoring in human serum: the case of busulfan and methotrexate;Q191924;P366;Q8386
Raman spectroscopy as a potential tool for label free therapeutic drug monitoring in human serum: the case of busulfan and methotrexate;Q348922;P31;Q12140
Raman spectroscopy as a potential tool for label free therapeutic drug monitoring in human serum: the case of busulfan and methotrexate;Q173670;P31;Q12140
Raman spectroscopy as a potential tool for label free therapeutic drug monitoring in human serum: the case of busulfan and methotrexate;Q173670;P703;Q15978631
Raman spectroscopy as a potential tool for label free therapeutic drug monitoring in human serum: the case of busulfan and methotrexate;Q173670;P703;Q177932
Raman spectroscopy as a potential tool for label free therapeutic drug monitoring in human serum: the case of busulfan and methotrexate;Q422232;P31;Q12140
Mycophenolate mofetil combined with tacrolimus and minidose methotrexate after unrelated donor bone marrow transplantation with reduced-intensity conditioning.;Q130336;P4149;Q27122100
Mycophenolate mofetil combined with tacrolimus and minidose methotrexate after unrelated donor bone marrow transplantation with reduced-intensity conditioning.;Q130336;P31;Q407142
pH and salivary sodium bicarbonate during the administration protocol for methotrexate in children with leukemia.;Q191924;P527;Q623
pH and salivary sodium bicarbonate during the administration protocol for methotrexate in children with leukemia.;Q485277;P527;Q623
pH and salivary sodium bicarbonate during the administration protocol for methotrexate in children with leukemia.;Q179731;P527;Q623
pH and salivary sodium bicarbonate during the administration protocol for methotrexate in children with leukemia.;Q179731;P527;Q658
pH and salivary sodium bicarbonate during the administration protocol for methotrexate in children with leukemia.;Q422232;P2175;Q29496
Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment.;Q412323;P2175;Q208414
Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment.;Q412323;P2175;Q4833719
Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment.;Q422232;P2175;Q56014449
Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment.;Q422232;P2175;Q208414
Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment.;Q422232;P2175;Q4833719
What is the role of primary methotrexate treatment in scar ectopic pregnancy?;Q422232;P2175;Q207087
[A survey of the doses of methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis];Q422232;P2175;Q170990
[A survey of the doses of methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis];Q422232;P2175;Q187255
Effect of folic acid on methotrexate induction of sulfotransferases in rats;Q422232;P2868;Q127060
Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs.;Q422232;P636;Q285166
Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.;Q422232;P2175;Q29496
Effect of iguratimod and methotrexate on RANKL and OPG expression in serum and IL-1-induced fibroblast-like synoviocytes from patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Effect of iguratimod and methotrexate on RANKL and OPG expression in serum and IL-1-induced fibroblast-like synoviocytes from patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Diffuse Large B-Cell Lymphoma of the Gingiva in a Patient on Long-Term Use of Methotrexate Being Treated for Psoriasis.;Q422232;P2175;Q208414
Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T-cell leukemia Jurkat cells.;Q183290;P703;Q15978631
Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T-cell leukemia Jurkat cells.;Q186474;P703;Q15978631
Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T-cell leukemia Jurkat cells.;Q186521;P703;Q15978631
Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T-cell leukemia Jurkat cells.;Q422232;P2175;Q29496
[The treatment of tubal pregnancy with methotrexate];Q422232;P2175;Q207087
Thymidylate synthase genetic polymorphism and plasma total homocysteine level in a group of Turkish patients with rheumatoid arthritis: relationship with disease activity and methotrexate toxicity;Q422232;P2175;Q170990
Thymidylate synthase genetic polymorphism and plasma total homocysteine level in a group of Turkish patients with rheumatoid arthritis: relationship with disease activity and methotrexate toxicity;Q422232;P2175;Q187255
Outcomes of conception subsequent to methotrexate treatment for an unruptured ectopic pregnancy.;Q422232;P2175;Q207087
A physiologically-based pharmacokinetic model of methotrexate incorporating hepatic excretion via multidrug-resistance-associated protein 2 (Mrp2) in mice, rats, dogs, and humans.;Q218642;P703;Q15978631
A physiologically-based pharmacokinetic model of methotrexate incorporating hepatic excretion via multidrug-resistance-associated protein 2 (Mrp2) in mice, rats, dogs, and humans.;Q218642;P31;Q12140
A physiologically-based pharmacokinetic model of methotrexate incorporating hepatic excretion via multidrug-resistance-associated protein 2 (Mrp2) in mice, rats, dogs, and humans.;Q191924;P31;Q12140
A physiologically-based pharmacokinetic model of methotrexate incorporating hepatic excretion via multidrug-resistance-associated protein 2 (Mrp2) in mice, rats, dogs, and humans.;Q20817118;P31;Q12140
A physiologically-based pharmacokinetic model of methotrexate incorporating hepatic excretion via multidrug-resistance-associated protein 2 (Mrp2) in mice, rats, dogs, and humans.;Q22124685;P31;Q12140
A physiologically-based pharmacokinetic model of methotrexate incorporating hepatic excretion via multidrug-resistance-associated protein 2 (Mrp2) in mice, rats, dogs, and humans.;Q22124685;P703;Q15978631
A physiologically-based pharmacokinetic model of methotrexate incorporating hepatic excretion via multidrug-resistance-associated protein 2 (Mrp2) in mice, rats, dogs, and humans.;Q422232;P31;Q12140
Maxillary angiocentric EBV-associated large B cell lymphoma associated with methotrexate treatment.;Q422232;P2175;Q208414
Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids.;Q422232;P2175;Q280027
Effects of non-steroidal anti-inflammatory drugs on the methotrexate transport in rat small intestine.;Q191924;P366;Q8386
Effects of non-steroidal anti-inflammatory drugs on the methotrexate transport in rat small intestine.;Q422232;P31;Q12140
Two cases of primary intraocular lymphoma: fine needle aspiration diagnosis and intravitreal methotrexate treatment;Q422232;P2175;Q208414
Folic acid and folinic acid supplementation during low-dose methotrexate therapy for rheumatoid arthritis: comment on the article by van Ede et al.;Q422232;P2175;Q187255
Folic acid and folinic acid supplementation during low-dose methotrexate therapy for rheumatoid arthritis: comment on the article by van Ede et al.;Q422232;P2175;Q170990
Myelopathy mimicking subacute combined degeneration in a Down syndrome patient with methotrexate treatment for B lymphoblastic leukemia: report of an autopsy case.;Q422232;P2175;Q29496
Methotrexate treatment suppresses local cytokine and chemokine production in rat adjuvant arthritis;Q422232;P2175;Q170990
[Neoadjuvant treatment of osteosarcoma and malignant fibrous histiocytoma of the bones of the extremities: preliminary results in 76 cases treated preoperatively with a methotrexate and cisplatin combination];Q412415;P2175;Q549534
[Neoadjuvant treatment of osteosarcoma and malignant fibrous histiocytoma of the bones of the extremities: preliminary results in 76 cases treated preoperatively with a methotrexate and cisplatin combination];Q422232;P2175;Q549534
[Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].;Q367700;P2175;Q1194520
[Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].;Q130336;P4149;Q27122100
[Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].;Q130336;P31;Q407142
[Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].;Q4567614;P2175;Q1194520
Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis.;Q422232;P2175;Q170990
Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis.;Q422232;P361;Q14819383
Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis.;Q422232;P2175;Q187255
Immediate treatment effects of high-dose methotrexate and cranial irradiation on neuropsychological functions of children treated for acute lymphoblastic leukemia at a regional cancer center;Q422232;P2175;Q29496
Peroxisome proliferator receptor (PPAR) / in psoriatic patients before and after two conventional therapeutic modalities: methotrexate and PUVA.;Q218642;P703;Q177932
Peroxisome proliferator receptor (PPAR) / in psoriatic patients before and after two conventional therapeutic modalities: methotrexate and PUVA.;Q173670;P703;Q177932
Peroxisome proliferator receptor (PPAR) / in psoriatic patients before and after two conventional therapeutic modalities: methotrexate and PUVA.;Q20035886;P703;Q177932
Peroxisome proliferator receptor (PPAR) / in psoriatic patients before and after two conventional therapeutic modalities: methotrexate and PUVA.;Q483752;P703;Q177932
The safety and effectiveness of a chloroform/methanol extract of Tripterygium wilfordii Hook F (T2) plus methotrexate in treating rheumatoid arthritis.;Q422232;P2175;Q187255
The safety and effectiveness of a chloroform/methanol extract of Tripterygium wilfordii Hook F (T2) plus methotrexate in treating rheumatoid arthritis.;Q422232;P2175;Q170990
Multidrug chemotherapy (vincristine, bleomycin, and methotrexate [VBM]) with radiotherapy in stage III-IV squamous cell carcinoma of the head and neck;Q408977;P31;Q12140
Multidrug chemotherapy (vincristine, bleomycin, and methotrexate [VBM]) with radiotherapy in stage III-IV squamous cell carcinoma of the head and neck;Q191924;P31;Q12140
Multidrug chemotherapy (vincristine, bleomycin, and methotrexate [VBM]) with radiotherapy in stage III-IV squamous cell carcinoma of the head and neck;Q22124685;P31;Q12140
Multidrug chemotherapy (vincristine, bleomycin, and methotrexate [VBM]) with radiotherapy in stage III-IV squamous cell carcinoma of the head and neck;Q483752;P31;Q12140
Multidrug chemotherapy (vincristine, bleomycin, and methotrexate [VBM]) with radiotherapy in stage III-IV squamous cell carcinoma of the head and neck;Q484940;P31;Q12140
Multidrug chemotherapy (vincristine, bleomycin, and methotrexate [VBM]) with radiotherapy in stage III-IV squamous cell carcinoma of the head and neck;Q422232;P31;Q12140
The impact of salpingectomy and single-dose systemic methotrexate treatments on ovarian reserve in ectopic pregnancy;Q422232;P2175;Q207087
Primary CNS lymphoma: 5-year survival in relation to dosage of methotrexate and radiation.;Q422232;P2175;Q208414
Do infliximab and methotrexate act synergistically in the treatment of rheumatoid arthritis? Comment on the article by Maini et al;Q415264;P2175;Q170990
Do infliximab and methotrexate act synergistically in the treatment of rheumatoid arthritis? Comment on the article by Maini et al;Q422232;P2175;Q187255
Do infliximab and methotrexate act synergistically in the treatment of rheumatoid arthritis? Comment on the article by Maini et al;Q422232;P2175;Q170990
Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.;Q218642;P703;Q15978631
Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.;Q186474;P703;Q15978631
Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.;Q186474;P703;Q83310
Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.;Q20035886;P703;Q15978631
Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.;Q22124685;P703;Q15978631
Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.;Q484940;P703;Q15978631
Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.;Q186474;P31;Q12140
Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.;Q191924;P31;Q12140
Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.;Q170545;P31;Q12140
Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.;Q139347;P31;Q12140
Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.;Q173670;P31;Q12140
Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.;Q15304877;P31;Q12140
Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.;Q22124685;P31;Q12140
Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.;Q484940;P31;Q12140
Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.;Q422232;P31;Q12140
[Assessment of elimination and tolerance of high dose of methotrexate (3 g/m2) in children with standard-risk acute lymphoblastic leukemia];Q422232;P2175;Q29496
Studies on preoperative cancer chemotherapy. Effects of preoperative intra-arterial infusion of methotrexate and mitomycin C on stomach cancer.;Q19856779;P1889;Q417625
Studies on preoperative cancer chemotherapy. Effects of preoperative intra-arterial infusion of methotrexate and mitomycin C on stomach cancer.;Q422232;P2175;Q189588
Sequential use of hemoperfusion and single-pass albumin dialysis can safely reverse methotrexate nephrotoxicity.;Q422232;P636;Q640448
Synthesis and antifolate properties of 10-alkyl-5,10-dideaza analogues of methotrexate and tetrahydrofolic acid.;Q422232;P2868;Q127060
Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Methotrexate inhibition of CCRF-CEM cultures of human lymphoblasts.;Q186474;P703;Q15978631
Methotrexate inhibition of CCRF-CEM cultures of human lymphoblasts.;Q170545;P703;Q15978631
Methotrexate inhibition of CCRF-CEM cultures of human lymphoblasts.;Q139347;P703;Q15978631
Methotrexate inhibition of CCRF-CEM cultures of human lymphoblasts.;Q173670;P703;Q15978631
Methotrexate inhibition of CCRF-CEM cultures of human lymphoblasts.;Q22124685;P703;Q15978631
A phase I study of cisplatin, methotrexate, levofolinic acid and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck;Q412415;P2175;Q18348812
A phase I study of cisplatin, methotrexate, levofolinic acid and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck;Q238512;P2175;Q18348812
AAAP (ACNU, adriamycin, methotrexate, prednisolone) therapy for adult erythroleukemia.;Q422232;P2175;Q29496
[Initial experience with a minidose of methotrexate in the management of unruptured ectopic pregnancy];Q422232;P2175;Q207087
Abatacept versus other biologics in methotrexate inadequate responders with rheumatoid arthritis: you like tomato and I like tomahto... let's call the whole thing off.;Q218642;P703;Q23501
Abatacept versus other biologics in methotrexate inadequate responders with rheumatoid arthritis: you like tomato and I like tomahto... let's call the whole thing off.;Q2697833;P2175;Q170990
Abatacept versus other biologics in methotrexate inadequate responders with rheumatoid arthritis: you like tomato and I like tomahto... let's call the whole thing off.;Q422232;P2175;Q170990
Abatacept versus other biologics in methotrexate inadequate responders with rheumatoid arthritis: you like tomato and I like tomahto... let's call the whole thing off.;Q422232;P2175;Q187255
Phenotypic heterogeneity in cultured human head and neck squamous cell carcinoma lines with low-level methotrexate resistance.;Q170545;P703;Q15978631
Phenotypic heterogeneity in cultured human head and neck squamous cell carcinoma lines with low-level methotrexate resistance.;Q20035886;P703;Q15978631
Random serum methotrexate determinations for assessing compliance with maintenance therapy for childhood acute lymphoblastic leukemia.;Q422232;P2175;Q29496
[Neoadjuvant chemotherapy with MVC (methotrexate, vinblastine, cisplatin)in the treatment of infiltrating transitional carcinoma of the bladder].;Q412415;P2175;Q2501186
Proceedings: Clinico-pharmacological aspects of methotrexate therapy in humans.;Q186474;P703;Q15978631
Proceedings: Clinico-pharmacological aspects of methotrexate therapy in humans.;Q20035886;P703;Q15978631
The effect of parental 5,10-methylenetetrahydrofolate reductase 677C/T and 1298A/C gene polymorphisms on response to single-dose methotrexate in tubal ectopic pregnancy.;Q422232;P2175;Q207087
Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis;Q424972;P2175;Q170990
Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis;Q422232;P2175;Q861224
Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis;Q422232;P2175;Q170990
Refractory Kawasaki disease: infliximab or methotrexate therapy?;Q415264;P2175;Q265936
Induction by estrogens of methotrexate resistance in MCF-7 breast cancer cells.;Q422416;P2175;Q128581
Induction by estrogens of methotrexate resistance in MCF-7 breast cancer cells.;Q422416;P279;Q277954
Induction by estrogens of methotrexate resistance in MCF-7 breast cancer cells.;Q422232;P2175;Q128581
Effect of a 3-hour interval between methotrexate and 5-fluorouracil in the treatment of metastatic colorectal cancer.;Q238512;P2175;Q2739660
Risk factors and human chorionic gonadotropin trends in patients with ruptured tubal ectopic pregnancies despite methotrexate treatment;Q407172;P703;Q15978631
Risk factors and human chorionic gonadotropin trends in patients with ruptured tubal ectopic pregnancies despite methotrexate treatment;Q407172;P279;Q409770
Risk factors and human chorionic gonadotropin trends in patients with ruptured tubal ectopic pregnancies despite methotrexate treatment;Q173670;P703;Q15978631
Synthesis and colloidal characterization of folic acid-modified PEG-b-PCL Micelles for methotrexate delivery;Q422232;P2868;Q127060
Comment on: Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false positive report probability;Q422232;P2175;Q187255
Comment on: Methotrexate pharmacogenomics in rheumatoid arthritis: introducing false positive report probability;Q422232;P2175;Q170990
A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis.;Q218642;P31;Q12140
A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis.;Q191924;P366;Q8386
A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis.;Q244150;P31;Q12140
A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis.;Q20035886;P31;Q12140
A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis.;Q22124685;P31;Q12140
A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis.;Q422232;P31;Q12140
A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis.;Q422232;P2175;Q170990
A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer.;Q412415;P2175;Q1783924
Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer.;Q238512;P2175;Q1783924
Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer.;Q422232;P2175;Q1783924
Early treatment with addition of low dose prednisolone to methotrexate improves therapeutic outcome in severe psoriatic arthritis.;Q422232;P2175;Q170990
Dual role of vitamin C on lipid profile and combined application of cyclophosphamide, methotrexate and 5-fluorouracil treatment in fibrosarcoma-bearing rats.;Q199678;P31;Q34956
A rare case of pulmonary toxoplasmosis in a patient with undifferentiated inflammatory arthritis on chronic methotrexate and corticosteroid therapy.;Q422232;P2175;Q170990
Risk of serious infection among initiators of TNF inhibitors plus methotrexate versus triple therapy for rheumatoid arthritis: a cohort study;Q422232;P2175;Q170990
Risk of serious infection among initiators of TNF inhibitors plus methotrexate versus triple therapy for rheumatoid arthritis: a cohort study;Q422232;P2175;Q187255
Intolerance in oral versus subcutaneous administration of methotrexate in patients with juvenile idiopathic arthritis: a cross-sectional, observational study.;Q422232;P2175;Q170990
Intolerance in oral versus subcutaneous administration of methotrexate in patients with juvenile idiopathic arthritis: a cross-sectional, observational study.;Q422232;P636;Q285166
Intolerance in oral versus subcutaneous administration of methotrexate in patients with juvenile idiopathic arthritis: a cross-sectional, observational study.;Q422232;P2175;Q861224
Mitoxantrone, methotrexate, and 5-fluorouracil (MMF) in hormone-refractory advanced breast cancer.;Q238512;P2175;Q128581
Mitoxantrone, methotrexate, and 5-fluorouracil (MMF) in hormone-refractory advanced breast cancer.;Q239426;P2175;Q128581
Mitoxantrone, methotrexate, and 5-fluorouracil (MMF) in hormone-refractory advanced breast cancer.;Q422232;P2175;Q128581
Subcutaneous or intramuscular methotrexate for rheumatoid arthritis;Q422232;P2175;Q187255
Subcutaneous or intramuscular methotrexate for rheumatoid arthritis;Q422232;P2175;Q170990
Sister chromatid exchange in methotrexate resistant and sensitive C3H10T1/2 mouse cells.;Q186474;P703;Q83310
Leiomyosarcoma, rheumatoid arthritis and methotrexate: an association?;Q422232;P2175;Q187255
Leiomyosarcoma, rheumatoid arthritis and methotrexate: an association?;Q422232;P2175;Q170990
Combination chemotherapy for mycosis fungoides with cyclophosphamide, vincristine, methotrexate, and prednisone.;Q422232;P2175;Q1891209
Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population-based retrospective cohort study.;Q422232;P2175;Q187255
Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population-based retrospective cohort study.;Q422232;P2175;Q170990
Frequency and related factors of tubal patency after methotrexate treatment in women with ectopic pregnancy.;Q422232;P2175;Q207087
Successful treatment of pemphigus foliaceous and ankylosing spondylitis with infliximab and methotrexate: A case report;Q415264;P2175;Q52849
Successful treatment of pemphigus foliaceous and ankylosing spondylitis with infliximab and methotrexate: A case report;Q415264;P2175;Q2165411
Successful treatment of pemphigus foliaceous and ankylosing spondylitis with infliximab and methotrexate: A case report;Q422232;P2175;Q52849
Long-term continuation of methotrexate therapy in giant cell arteritis patients in clinical practice;Q422232;P2175;Q707816
Neo-adjuvant M-VAC (methotrexate, vinblastine, adriamycin, and cisplatin) for infiltrating bladder cancer: initial results in Italy.;Q412415;P2175;Q504775
Methotrexate in rheumatoid arthritis: studies with animal models.;Q422232;P2175;Q170990
Methotrexate in rheumatoid arthritis: studies with animal models.;Q422232;P2175;Q187255
Methotrexate in juvenile rheumatoid arthritis. Do the benefits outweigh the risks?;Q422232;P2175;Q187255
Methotrexate in juvenile rheumatoid arthritis. Do the benefits outweigh the risks?;Q422232;P2175;Q170990
Methotrexate in juvenile rheumatoid arthritis. Do the benefits outweigh the risks?;Q422232;P2175;Q861224
Intralesional Methotrexate for Treatment of Invasive Squamous Cell Carcinomas in a Patient Taking Vemurafenib for Treatment of Metastatic Melanoma;Q423111;P2175;Q180614
Intralesional Methotrexate for Treatment of Invasive Squamous Cell Carcinomas in a Patient Taking Vemurafenib for Treatment of Metastatic Melanoma;Q423111;P2175;Q18975855
Antiapoptosis action of aged garlic extract (AGE) protects epithelial cells from methotrexate induced injury.;Q218642;P703;Q23400
Antiapoptosis action of aged garlic extract (AGE) protects epithelial cells from methotrexate induced injury.;Q620730;P703;Q23400
Methotrexate increases incidence of melanoma in rheumatoid arthritis patients;Q422232;P2175;Q170990
Methotrexate increases incidence of melanoma in rheumatoid arthritis patients;Q422232;P2175;Q187255
The role of early determination of -human chorionic gonadotropin levels in predicting the success of single-dose methotrexate treatment in ectopic pregnancy.;Q407172;P703;Q15978631
The role of early determination of -human chorionic gonadotropin levels in predicting the success of single-dose methotrexate treatment in ectopic pregnancy.;Q407172;P279;Q409770
The role of early determination of -human chorionic gonadotropin levels in predicting the success of single-dose methotrexate treatment in ectopic pregnancy.;Q186521;P703;Q15978631
The role of early determination of -human chorionic gonadotropin levels in predicting the success of single-dose methotrexate treatment in ectopic pregnancy.;Q422232;P2175;Q207087
Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia;Q422232;P2175;Q29496
Clinical Review Report: Baricitinib (Olumiant): (Eli Lilly Canada Inc.): Indication: For use in combination with methotrexate (MTX) for the treatment of adult patients with moderate to severe rheumatoid arthritis who have responded inadequately to o;Q422232;P2175;Q170990
Clinical Review Report: Baricitinib (Olumiant): (Eli Lilly Canada Inc.): Indication: For use in combination with methotrexate (MTX) for the treatment of adult patients with moderate to severe rheumatoid arthritis who have responded inadequately to o;Q422232;P2175;Q187255
Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients;Q348260;P2175;Q187255
Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients;Q348260;P2175;Q170990
Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients;Q422232;P2175;Q170990
Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients;Q422232;P2175;Q187255
Differential toxicity of carrier-bound methotrexate toward human lymphocytes, marrow and tumor cells.;Q178450;P703;Q15978631
Serum profiles of methotrexate after its administration in children with acute lymphoblastic leukaemia.;Q422232;P2175;Q29496
[Pelvic lymph node metastasis from bladder cancer markedly responsive to methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy followed by radiotherapy: a case report];Q18936;P2175;Q504775
[Pelvic lymph node metastasis from bladder cancer markedly responsive to methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy followed by radiotherapy: a case report];Q412415;P2175;Q504775
Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.;Q422232;P2175;Q29496
Venipuncture versus central venous access: a comparison of methotrexate levels in pediatric leukemia patients.;Q422232;P2175;Q29496
[Pancytopenia and opportunistic infections in rheumatoid arthritis treated with methotrexate];Q422232;P2175;Q170990
[Pancytopenia and opportunistic infections in rheumatoid arthritis treated with methotrexate];Q422232;P2175;Q187255
Combination therapy of ginsenoside compound K and methotrexate was efficient in elimination of anaemia and reduction of disease activity in adjuvant-induced arthritis rats;Q186474;P31;Q11173
Combination therapy of ginsenoside compound K and methotrexate was efficient in elimination of anaemia and reduction of disease activity in adjuvant-induced arthritis rats;Q191924;P31;Q11173
Combination therapy of ginsenoside compound K and methotrexate was efficient in elimination of anaemia and reduction of disease activity in adjuvant-induced arthritis rats;Q20816880;P31;Q11173
Combination therapy of ginsenoside compound K and methotrexate was efficient in elimination of anaemia and reduction of disease activity in adjuvant-induced arthritis rats;Q422232;P2175;Q170990
Combination therapy of ginsenoside compound K and methotrexate was efficient in elimination of anaemia and reduction of disease activity in adjuvant-induced arthritis rats;Q422232;P31;Q11173
Antiepileptic drugs reduce efficacy of methotrexate chemotherapy by downregulation of Reduced folate carrier transport activity.;Q218642;P31;Q12140
Antiepileptic drugs reduce efficacy of methotrexate chemotherapy by downregulation of Reduced folate carrier transport activity.;Q191924;P31;Q12140
Antiepileptic drugs reduce efficacy of methotrexate chemotherapy by downregulation of Reduced folate carrier transport activity.;Q191924;P366;Q8386
Antiepileptic drugs reduce efficacy of methotrexate chemotherapy by downregulation of Reduced folate carrier transport activity.;Q173670;P31;Q12140
Antiepileptic drugs reduce efficacy of methotrexate chemotherapy by downregulation of Reduced folate carrier transport activity.;Q422232;P31;Q12140
Effectiveness and safety of initiating adalimumab plus 12mg/week methotrexate with adjustable dosing in biologic-nave patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan;Q348260;P2175;Q170990
Effectiveness and safety of initiating adalimumab plus 12mg/week methotrexate with adjustable dosing in biologic-nave patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan;Q348260;P2175;Q187255
Effectiveness and safety of initiating adalimumab plus 12mg/week methotrexate with adjustable dosing in biologic-nave patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan;Q422232;P2175;Q187255
Effectiveness and safety of initiating adalimumab plus 12mg/week methotrexate with adjustable dosing in biologic-nave patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan;Q422232;P2175;Q170990
Cutaneous side effects of medium dose methotrexate in children with acute lymphoblastic leukaemia;Q422232;P2175;Q29496
Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Involving the Colon in a Patient With Ulcerative Pancolitis and Polymyositis on Long-Term Methotrexate Therapy.;Q422232;P2175;Q208414
Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Involving the Colon in a Patient With Ulcerative Pancolitis and Polymyositis on Long-Term Methotrexate Therapy.;Q422232;P2175;Q980926
Effect of oral colestimide on the elimination of high-dose methotrexate in patients with primary central nervous system lymphoma--case report.;Q422232;P636;Q285166
Effect of oral colestimide on the elimination of high-dose methotrexate in patients with primary central nervous system lymphoma--case report.;Q422232;P2175;Q136312
Effect of oral colestimide on the elimination of high-dose methotrexate in patients with primary central nervous system lymphoma--case report.;Q422232;P2175;Q208414
Kinetic fluorimetric determination of the antineoplastic methotrexate (MTX) in human serum.;Q186521;P703;Q15978631
Kinetic fluorimetric determination of the antineoplastic methotrexate (MTX) in human serum.;Q20816880;P703;Q15978631
Kinetic fluorimetric determination of the antineoplastic methotrexate (MTX) in human serum.;Q22124685;P703;Q15978631
Induction of hyperchromic microcytic anaemia by repeated oral administration of methotrexate in rats;Q422232;P636;Q285166
[A comparative evaluation of the treatment results with cyclosporin A, methotrexate and azathioprine in rheumatoid arthritis patients (a preliminary report)];Q18939;P2175;Q187255
[A comparative evaluation of the treatment results with cyclosporin A, methotrexate and azathioprine in rheumatoid arthritis patients (a preliminary report)];Q367700;P2175;Q187255
[A comparative evaluation of the treatment results with cyclosporin A, methotrexate and azathioprine in rheumatoid arthritis patients (a preliminary report)];Q422232;P2175;Q170990
[A comparative evaluation of the treatment results with cyclosporin A, methotrexate and azathioprine in rheumatoid arthritis patients (a preliminary report)];Q422232;P2175;Q187255
Methotrexate for psoriatic arthritis;Q422232;P2175;Q170990
Intravitreal methotrexate and fluocinolone acetonide implantation for Vogt-Koyanagi-Harada uveitis;Q422232;P2175;Q280027
Methotrexate treatment for rheumatoid arthritis in Poland: Retrospective analysis of patients in routine clinical practice.;Q422232;P2175;Q170990
Methotrexate treatment for rheumatoid arthritis in Poland: Retrospective analysis of patients in routine clinical practice.;Q422232;P2175;Q187255
Intratumoral administration of methotrexate bound to activated carbon particles: antitumor effectiveness against human colon carcinoma xenografts and acute toxicity in mice;Q191924;P527;Q623
Intratumoral administration of methotrexate bound to activated carbon particles: antitumor effectiveness against human colon carcinoma xenografts and acute toxicity in mice;Q484940;P527;Q623
Intratumoral administration of methotrexate bound to activated carbon particles: antitumor effectiveness against human colon carcinoma xenografts and acute toxicity in mice;Q484940;P703;Q15978631
Intratumoral administration of methotrexate bound to activated carbon particles: antitumor effectiveness against human colon carcinoma xenografts and acute toxicity in mice;Q422232;P636;Q285166
Single-nucleotide polymorphisms in the folate pathway are associated with response to methotrexate treatment in juvenile idiopathic arthritis.;Q422232;P2175;Q170990
Single-nucleotide polymorphisms in the folate pathway are associated with response to methotrexate treatment in juvenile idiopathic arthritis.;Q422232;P361;Q14819383
Single-nucleotide polymorphisms in the folate pathway are associated with response to methotrexate treatment in juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Fibrosing cholestatic hepatitis after methotrexate and prednisone therapy for rheumatoid arthritis.;Q424972;P2175;Q170990
Fibrosing cholestatic hepatitis after methotrexate and prednisone therapy for rheumatoid arthritis.;Q422232;P2175;Q170990
Fibrosing cholestatic hepatitis after methotrexate and prednisone therapy for rheumatoid arthritis.;Q422232;P2175;Q187255
Development and in vitro evaluation of mucoadhesive patches of methotrexate for targeted delivery in oral cancer.;Q422232;P636;Q285166
Schedule-dependent synergism and antagonism between methotrexate and 6-mercaptopurine in a human acute lymphoblastic cell line.;Q183290;P703;Q15978631
[Long-term follow-up of the efficacy of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia areata totalis or universalis].;Q422232;P636;Q285166
Neoadjuvant chemotherapy for the treatment of osteosarcoma of the limbs. Preliminary results in 100 patients treated preoperatively with high doses of methotrexate i.v. followed by cisplatin (i.a.) and adriamycin.;Q412415;P2175;Q549534
Neoadjuvant chemotherapy for the treatment of osteosarcoma of the limbs. Preliminary results in 100 patients treated preoperatively with high doses of methotrexate i.v. followed by cisplatin (i.a.) and adriamycin.;Q422232;P2175;Q549534
Combination chemotherapy with cisplatin, bleomycin, and methotrexate in patients with advanced head and neck cancer;Q412415;P2175;Q1783924
Combination chemotherapy with cisplatin, bleomycin, and methotrexate in patients with advanced head and neck cancer;Q422232;P2175;Q1783924
IOIBD questionnaire on the clinical use of azathioprine, 6-mercaptopurine, cyclosporin A and methotrexate in the treatment of inflammatory bowel diseases.;Q18939;P279;Q3360898
Erratum corrige: "Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study". J.L. Pablos et al;Q425154;P2175;Q170990
Erratum corrige: "Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study". J.L. Pablos et al;Q422232;P2175;Q187255
Erratum corrige: "Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study". J.L. Pablos et al;Q422232;P2175;Q170990
[Intratumoral administration of methotrexate bound to activated carbon particles (MTX-CH) inducing antitumor effect in vivo];Q186474;P527;Q623
[Intratumoral administration of methotrexate bound to activated carbon particles (MTX-CH) inducing antitumor effect in vivo];Q186521;P527;Q623
[Intratumoral administration of methotrexate bound to activated carbon particles (MTX-CH) inducing antitumor effect in vivo];Q191924;P527;Q623
[Intratumoral administration of methotrexate bound to activated carbon particles (MTX-CH) inducing antitumor effect in vivo];Q485277;P527;Q623
[Intratumoral administration of methotrexate bound to activated carbon particles (MTX-CH) inducing antitumor effect in vivo];Q422232;P636;Q285166
[Intratumoral administration of methotrexate bound to activated carbon particles (MTX-CH) inducing antitumor effect in vivo];Q484940;P527;Q623
Case report on hypersensitivity to methotrexate infusion in a pediatric acute lymphoblastic leukaemia patient;Q422232;P2175;Q29496
Safety and efficacy profile of oral cyclosporine versus oral methotrexate versus oral acitretin in palmoplantar psoriasis - A hospital based prospective investigator blind randomized controlled comparative study;Q341500;P31;Q106040601
Safety and efficacy profile of oral cyclosporine versus oral methotrexate versus oral acitretin in palmoplantar psoriasis - A hospital based prospective investigator blind randomized controlled comparative study;Q422232;P636;Q285166
Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland;Q186474;P31;Q12140
Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland;Q191924;P366;Q8386
Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland;Q178450;P31;Q12140
Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland;Q20035886;P31;Q12140
Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland;Q483752;P31;Q12140
Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland;Q484940;P31;Q12140
Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland;Q422232;P31;Q12140
Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland;Q422232;P2868;Q810254
[Cancer chemotherapy for lymph nodal metastases using activated carbon particles adsorbing methotrexate];Q186474;P527;Q623
[Cancer chemotherapy for lymph nodal metastases using activated carbon particles adsorbing methotrexate];Q191924;P527;Q623
The advances of methotrexate resistance in rheumatoid arthritis;Q422232;P2175;Q170990
The advances of methotrexate resistance in rheumatoid arthritis;Q422232;P2175;Q187255
Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier.;Q181619;P31;Q12140
Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier.;Q191924;P366;Q8386
Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier.;Q422232;P31;Q12140
Real-time intracranial pressure monitoring during high-dose methotrexate treatment for primary central nervous system lymphoma;Q422232;P2175;Q136312
Real-time intracranial pressure monitoring during high-dose methotrexate treatment for primary central nervous system lymphoma;Q422232;P2175;Q208414
Insights into the interaction of methotrexate and human serum albumin: A spectroscopic and molecular modeling approach.;Q218642;P703;Q15978631
Insights into the interaction of methotrexate and human serum albumin: A spectroscopic and molecular modeling approach.;Q484940;P703;Q15978631
The effect of methotrexate and mycophenolic acid on monokine production in vitro.;Q130336;P31;Q407142
[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].;Q422232;P2175;Q29496
High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease.;Q422232;P2175;Q208414
High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease.;Q422232;P2175;Q136312
Methotrexate for suspected cerebral lymphoma in AIDS.;Q422232;P2175;Q208414
Acute spontaneous hematotrachelos following methotrexate treatment of a suspected tubal pregnancy;Q422232;P2175;Q207087
[Change in the sensitivity to methotrexate of neoplastic cells cultivated in the presence of folic acid];Q422232;P2868;Q127060
[Pharmacokinetics of methotrexate in rheumatoid arthritis: therapeutic implications];Q20035886;P703;Q177932
[Pharmacokinetics of methotrexate in rheumatoid arthritis: therapeutic implications];Q422232;P2175;Q187255
[Pharmacokinetics of methotrexate in rheumatoid arthritis: therapeutic implications];Q422232;P2175;Q170990
Sequence- and time-dependent antagonism between raloxifene and methotrexate in human breast cancer cells.;Q183290;P703;Q15978631
Sequence- and time-dependent antagonism between raloxifene and methotrexate in human breast cancer cells.;Q422232;P2175;Q128581
[Methotrexate - anchor drug in the treament of rheumatoid arthritis];Q22124685;P31;Q12140
[Methotrexate - anchor drug in the treament of rheumatoid arthritis];Q422232;P31;Q12140
[Methotrexate - anchor drug in the treament of rheumatoid arthritis];Q422232;P2175;Q170990
[Methotrexate - anchor drug in the treament of rheumatoid arthritis];Q422232;P2175;Q187255
Concentration- and time-dependent cytostatic effects of methotrexate and etoposide on L1210 leukemic cells in vitro demonstrated by a new microperfusion method.;Q418817;P636;Q640448
Concentration- and time-dependent cytostatic effects of methotrexate and etoposide on L1210 leukemic cells in vitro demonstrated by a new microperfusion method.;Q422232;P636;Q640448
Bioanalytical method development for a generation 5 polyamidoamine folic acid methotrexate conjugated nanoparticle.;Q422232;P2868;Q127060
Rational design of metal-organic frameworks to deliver methotrexate for targeted rheumatoid arthritis therapy;Q422232;P2175;Q170990
Rational design of metal-organic frameworks to deliver methotrexate for targeted rheumatoid arthritis therapy;Q422232;P2175;Q187255
Ifosfamide, methotrexate and 5-fluorouracil for pretreated advanced breast cancer;Q238512;P2175;Q128581
Ifosfamide, methotrexate and 5-fluorouracil for pretreated advanced breast cancer;Q418560;P2175;Q128581
Ifosfamide, methotrexate and 5-fluorouracil for pretreated advanced breast cancer;Q422232;P2175;Q128581
Synthesis of non-cytotoxic poly(ester-amine) dendrimers as potential solubility enhancers for drugs: methotrexate as a case study.;Q183290;P31;Q12140
Synthesis of non-cytotoxic poly(ester-amine) dendrimers as potential solubility enhancers for drugs: methotrexate as a case study.;Q191924;P366;Q8386
Synthesis of non-cytotoxic poly(ester-amine) dendrimers as potential solubility enhancers for drugs: methotrexate as a case study.;Q422232;P31;Q12140
Methotrexate inhibits effects of platelet-derived growth factor and interleukin-1 on rheumatoid arthritis fibroblast-like synoviocytes.;Q422232;P2175;Q170990
Methotrexate inhibits effects of platelet-derived growth factor and interleukin-1 on rheumatoid arthritis fibroblast-like synoviocytes.;Q422232;P2175;Q187255
Concurrent use of methotrexate and celecoxib increases risk of silent liver fibrosis in rheumatoid arthritis patients with subclinical reduced kidney function.;Q408801;P2175;Q170990
Concurrent use of methotrexate and celecoxib increases risk of silent liver fibrosis in rheumatoid arthritis patients with subclinical reduced kidney function.;Q408801;P2175;Q187255
Concurrent use of methotrexate and celecoxib increases risk of silent liver fibrosis in rheumatoid arthritis patients with subclinical reduced kidney function.;Q422232;P2175;Q170990
Concurrent use of methotrexate and celecoxib increases risk of silent liver fibrosis in rheumatoid arthritis patients with subclinical reduced kidney function.;Q422232;P2175;Q187255
Methotrexate: new indication. Psoriatic arthritis: approved at last;Q422232;P2175;Q170990
Methotrexate treatment for tubal pregnancy. Criteria for medical approach;Q422232;P2175;Q207087
Ocular surface findings in patients with rheumatoid arthritis under methotrexate or biological agent therapy.;Q422232;P2175;Q187255
Ocular surface findings in patients with rheumatoid arthritis under methotrexate or biological agent therapy.;Q422232;P2175;Q170990
The efficacy of multiple-dose methotrexate treatment for unruptured tubal ectopic pregnancy and conversion rate to surgery: a study on 294 cases.;Q422232;P2175;Q207087
Bleomycin, vincristine, and mitomycin C with or without methotrexate in the treatment of squamous cell carcinoma.;Q415571;P2175;Q681817
Bleomycin, vincristine, and mitomycin C with or without methotrexate in the treatment of squamous cell carcinoma.;Q19856779;P1889;Q417625
Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report;Q191924;P769;Q418656
Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report;Q412323;P2175;Q136312
Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report;Q412323;P2175;Q208414
Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report;Q418656;P2175;Q136312
Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report;Q418656;P2175;Q208414
Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report;Q422232;P2175;Q208414
Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report;Q422232;P2175;Q136312
Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation;Q183290;P31;Q12140
Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation;Q183290;P703;Q177932
Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation;Q186521;P31;Q12140
Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation;Q186521;P703;Q177932
Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation;Q191924;P366;Q8386
Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation;Q22124685;P31;Q12140
Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation;Q22124685;P703;Q177932
Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation;Q422232;P31;Q12140
Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation;Q620730;P31;Q12140
Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation;Q620730;P703;Q177932
Reduced-dose methotrexate in combination with tacrolimus was associated with rapid engraftment and recovery from oral mucositis without affecting the incidence of GVHD.;Q411648;P636;Q285166
Reduced-dose methotrexate in combination with tacrolimus was associated with rapid engraftment and recovery from oral mucositis without affecting the incidence of GVHD.;Q411648;P2175;Q1194520
Reduced-dose methotrexate in combination with tacrolimus was associated with rapid engraftment and recovery from oral mucositis without affecting the incidence of GVHD.;Q422232;P636;Q285166
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and [...];Q412415;P2175;Q372701
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and [...];Q422232;P2175;Q372701
Is mega dose of methotrexate beneficial to patients with acute lymphoblastic leukemia?;Q422232;P2175;Q29496
A comparative study of histopathological findings in skin biopsies from patients with psoriasis before and after treatment with acitretin, methotrexate and phototherapy;Q341500;P31;Q106040601
Effect of golimumab combined with methotrexate on radiographic progression in rheumatoid arthritis: comment on the article by Emery et al;Q413879;P2175;Q170990
Effect of golimumab combined with methotrexate on radiographic progression in rheumatoid arthritis: comment on the article by Emery et al;Q422232;P2175;Q187255
Effect of golimumab combined with methotrexate on radiographic progression in rheumatoid arthritis: comment on the article by Emery et al;Q422232;P2175;Q170990
Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer.;Q18936;P2175;Q128581
Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer.;Q238512;P2175;Q128581
Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer.;Q422232;P2175;Q128581
[Clinical relapse of rheumatoid arthritis (escape phenomenon) during low-dose methotrexate therapy];Q422232;P2175;Q187255
[Clinical relapse of rheumatoid arthritis (escape phenomenon) during low-dose methotrexate therapy];Q422232;P2175;Q170990
Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial;Q130336;P31;Q407142
Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial;Q130336;P4149;Q27122100
Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial;Q422232;P2175;Q280027
[Preventive therapy of central nervous system leukemia in children. II. Results of CNS-prophylaxis with 2,400 rads of cranial irradiation and intrathecal injection of methotrexate and hydrocortisone (author's transl)];Q190875;P2959;Q26981430
[Preventive therapy of central nervous system leukemia in children. II. Results of CNS-prophylaxis with 2,400 rads of cranial irradiation and intrathecal injection of methotrexate and hydrocortisone (author's transl)];Q422232;P2175;Q29496
[Preventive therapy of central nervous system leukemia in children. II. Results of CNS-prophylaxis with 2,400 rads of cranial irradiation and intrathecal injection of methotrexate and hydrocortisone (author's transl)];Q422232;P636;Q1320251
Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review.;Q422232;P2175;Q170990
Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review.;Q422232;P2175;Q861224
Tolerability of methotrexate and leflunomide combination therapy for inflammatory arthritis in routine clinical practice: results of a four-centre study.;Q248550;P2175;Q170990
Tolerability of methotrexate and leflunomide combination therapy for inflammatory arthritis in routine clinical practice: results of a four-centre study.;Q422232;P2175;Q170990
Association of methotrexate effects and single-nucleotide polymorphisms in the folate pathway in rheumatoid arthritis: comment on the article by Wessels et al;Q422232;P2175;Q187255
Association of methotrexate effects and single-nucleotide polymorphisms in the folate pathway in rheumatoid arthritis: comment on the article by Wessels et al;Q422232;P2175;Q170990
Genomic stratification by expression of HLA-DRB4 alleles identifies differential innate and adaptive immune transcriptional patterns - A strategy to detect predictors of methotrexate response in early rheumatoid arthritis.;Q422232;P2175;Q170990
Genomic stratification by expression of HLA-DRB4 alleles identifies differential innate and adaptive immune transcriptional patterns - A strategy to detect predictors of methotrexate response in early rheumatoid arthritis.;Q422232;P2175;Q187255
Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis.;Q421094;P1889;Q422438
Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis.;Q421094;P2175;Q170990
Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis.;Q421094;P2175;Q187255
Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis.;Q422232;P2175;Q187255
Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis.;Q422232;P2175;Q170990
Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis.;Q422438;P2175;Q187255
Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis.;Q422438;P1889;Q421094
Superior outcome using cyclosporin A alone versus cyclosporin A plus methotrexate for post-transplant immunosuppression in children with acute leukemia undergoing sibling hematopoietic stem cell transplantation;Q422232;P2175;Q29496
A refractory anti-NMDA receptor encephalitis successfully treated by bilateral salpingo-oophorectomy and intrathecal injection of methotrexate and dexamethasone: a case report;Q422232;P636;Q1320251
Re: international phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.;Q412415;P2175;Q504775
Methotrexate kinetics: effect of subdividing an oral dose [proceedings];Q422232;P636;Q285166
Endogenous metabolites that are substrates of organic anion transporter's (OATs) predict methotrexate clearance.;Q218642;P31;Q407595
Effect of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a human tumor necrosis factor alpha-converting enzyme inhibitor, on the disposition of methotrexate: a transport;Q186474;P703;Q15978631
Effect of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a human tumor necrosis factor alpha-converting enzyme inhibitor, on the disposition of methotrexate: a transport;Q173670;P703;Q15978631
Effect of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a human tumor necrosis factor alpha-converting enzyme inhibitor, on the disposition of methotrexate: a transport;Q178450;P703;Q15978631
Effect of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a human tumor necrosis factor alpha-converting enzyme inhibitor, on the disposition of methotrexate: a transport;Q419164;P2868;Q427492
Effect of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a human tumor necrosis factor alpha-converting enzyme inhibitor, on the disposition of methotrexate: a transport;Q20035886;P703;Q15978631
Effect of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a human tumor necrosis factor alpha-converting enzyme inhibitor, on the disposition of methotrexate: a transport;Q422232;P2868;Q427492
[Effect of 3 different antiblastic agents on the intact and regenerating liver. Adriamycin, cyclophosphamide, methotrexate (experimental study in the rat). II];Q18936;P3780;Q47520887
The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts.;Q181003;P703;Q15978631
The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts.;Q183290;P703;Q15978631
The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts.;Q186521;P703;Q15978631
The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts.;Q484940;P703;Q15978631
P15.04 Treatment results of combination chemotherapy with high-dose methotrexate and procarbazine for primary CNS lymphoma: Asingle institution experience.;Q191924;P769;Q418656
P15.04 Treatment results of combination chemotherapy with high-dose methotrexate and procarbazine for primary CNS lymphoma: Asingle institution experience.;Q418656;P2175;Q136312
P15.04 Treatment results of combination chemotherapy with high-dose methotrexate and procarbazine for primary CNS lymphoma: Asingle institution experience.;Q418656;P2175;Q208414
P15.04 Treatment results of combination chemotherapy with high-dose methotrexate and procarbazine for primary CNS lymphoma: Asingle institution experience.;Q422232;P2175;Q136312
P15.04 Treatment results of combination chemotherapy with high-dose methotrexate and procarbazine for primary CNS lymphoma: Asingle institution experience.;Q422232;P2175;Q208414
Venetoclax with high-dose methotrexate and rituximab seem effective and well-tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report;Q412323;P2175;Q29496
Venetoclax with high-dose methotrexate and rituximab seem effective and well-tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report;Q412323;P2175;Q1088156
Venetoclax with high-dose methotrexate and rituximab seem effective and well-tolerated in the treatment of central nervous system involvement of chronic lymphocytic leukemia: A case report;Q422232;P2175;Q29496
Effective salvage chemotherapy with etoposide, dactinomycin, and methotrexate in refractory germ cell cancer. Australasian Germ Cell Trial Group.;Q186127;P279;Q343465
Effective salvage chemotherapy with etoposide, dactinomycin, and methotrexate in refractory germ cell cancer. Australasian Germ Cell Trial Group.;Q418817;P2175;Q18555254
Different methotrexate effects in cultured normal and leukaemic human leukocytes.;Q178450;P703;Q15978631
M-EA (methotrexate, etoposide, dactinomycin) and EMA-CO (methotrexate, etoposide, dactinomycin / cyclophosphamide, vincristine) regimens as first line treatment of high-risk Gestational Trophoblastic Neoplasia;Q186127;P279;Q343465
Intermediate-dose methotrexate and intravenous 6-mercaptopurine chemotherapy for children with acute lymphoblastic leukemia who did not respond to initial induction therapy.;Q422232;P2175;Q29496
Prognostic value of human chorionic gonadotropin levels 4days after a single dose of methotrexate for ectopic pregnancy;Q407172;P703;Q15978631
Prognostic value of human chorionic gonadotropin levels 4days after a single dose of methotrexate for ectopic pregnancy;Q407172;P279;Q409770
Prognostic value of human chorionic gonadotropin levels 4days after a single dose of methotrexate for ectopic pregnancy;Q20035886;P703;Q15978631
Prognostic value of human chorionic gonadotropin levels 4days after a single dose of methotrexate for ectopic pregnancy;Q422232;P2175;Q207087
A case of spontaneous regression of pulmonary mucosa-associated lymphoid tissue (MALT) type lymphoma with Sjgren's syndrome treated with methotrexate for rheumatoid arthritis;Q422232;P2175;Q170990
A case of spontaneous regression of pulmonary mucosa-associated lymphoid tissue (MALT) type lymphoma with Sjgren's syndrome treated with methotrexate for rheumatoid arthritis;Q422232;P2175;Q187255
A case of spontaneous regression of pulmonary mucosa-associated lymphoid tissue (MALT) type lymphoma with Sjgren's syndrome treated with methotrexate for rheumatoid arthritis;Q422232;P2175;Q208414
Treatment of acute lymphoblastic leukemia in childreq with "prophylactic" intrathecal methotrexate and intensive systemic chemotherapy.;Q422232;P2175;Q29496
Treatment of acute lymphoblastic leukemia in childreq with "prophylactic" intrathecal methotrexate and intensive systemic chemotherapy.;Q422232;P636;Q1320251
Necrotising leucoencephalopathy associated with intrathecal/intraventricular methotrexate therapy.;Q422232;P636;Q1320251
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups.;Q239426;P2175;Q128581
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups.;Q238512;P2175;Q128581
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups.;Q422232;P2175;Q128581
[Regulation mechanism of autophagy-related protein LC3 by c-Jun in methotrexate resistant human choriocarcinoma JEG-3 cells].;Q186474;P703;Q15978631
[Regulation mechanism of autophagy-related protein LC3 by c-Jun in methotrexate resistant human choriocarcinoma JEG-3 cells].;Q173670;P703;Q15978631
[Regulation mechanism of autophagy-related protein LC3 by c-Jun in methotrexate resistant human choriocarcinoma JEG-3 cells].;Q620730;P703;Q15978631
[Regulation mechanism of autophagy-related protein LC3 by c-Jun in methotrexate resistant human choriocarcinoma JEG-3 cells].;Q483745;P703;Q15978631
M-VEC (methotrexate, vinblastine, 4'-epirubicin and cisplatin) combined with glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the treatment of transitional cell carcinoma of urothelium: reduction in toxicity produce;Q183290;P703;Q15978631
M-VEC (methotrexate, vinblastine, 4'-epirubicin and cisplatin) combined with glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the treatment of transitional cell carcinoma of urothelium: reduction in toxicity produce;Q186474;P703;Q15978631
M-VEC (methotrexate, vinblastine, 4'-epirubicin and cisplatin) combined with glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the treatment of transitional cell carcinoma of urothelium: reduction in toxicity produce;Q412415;P2175;Q2501186
M-VEC (methotrexate, vinblastine, 4'-epirubicin and cisplatin) combined with glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the treatment of transitional cell carcinoma of urothelium: reduction in toxicity produce;Q170545;P703;Q15978631
M-VEC (methotrexate, vinblastine, 4'-epirubicin and cisplatin) combined with glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the treatment of transitional cell carcinoma of urothelium: reduction in toxicity produce;Q1592932;P279;Q50229794
M-VEC (methotrexate, vinblastine, 4'-epirubicin and cisplatin) combined with glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the treatment of transitional cell carcinoma of urothelium: reduction in toxicity produce;Q22124685;P703;Q15978631
M-VEC (methotrexate, vinblastine, 4'-epirubicin and cisplatin) combined with glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the treatment of transitional cell carcinoma of urothelium: reduction in toxicity produce;Q620730;P703;Q15978631
M-VEC (methotrexate, vinblastine, 4'-epirubicin and cisplatin) combined with glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the treatment of transitional cell carcinoma of urothelium: reduction in toxicity produce;Q483752;P703;Q15978631
Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study;Q218642;P31;Q12140
Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study;Q186474;P31;Q12140
Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study;Q186521;P31;Q12140
Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study;Q407781;P31;Q12140
Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study;Q191924;P31;Q12140
Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study;Q191924;P366;Q8386
Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study;Q173670;P31;Q12140
Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study;Q178450;P31;Q12140
Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study;Q22124685;P31;Q12140
Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study;Q422232;P31;Q12140
Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study;Q422232;P2175;Q187255
Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study;Q422232;P2868;Q810254
Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study;Q422232;P2175;Q170990
Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: what can we learn from small studies?;Q422232;P2175;Q29496
[Recent progress of diagnosis and treatment for immune-mediated hematological diseases. Topics: IV. Recent topics: 3. Methotrexate related malignant lymphoma].;Q422232;P2175;Q208414
Therapeutic efficacy and safety of methotrexate + leflunomide in Colombian patients with active rheumatoid arthritis refractory to conventional treatment;Q248550;P2175;Q187255
Therapeutic efficacy and safety of methotrexate + leflunomide in Colombian patients with active rheumatoid arthritis refractory to conventional treatment;Q248550;P2175;Q170990
Therapeutic efficacy and safety of methotrexate + leflunomide in Colombian patients with active rheumatoid arthritis refractory to conventional treatment;Q186474;P703;Q177932
Therapeutic efficacy and safety of methotrexate + leflunomide in Colombian patients with active rheumatoid arthritis refractory to conventional treatment;Q186521;P703;Q177932
Therapeutic efficacy and safety of methotrexate + leflunomide in Colombian patients with active rheumatoid arthritis refractory to conventional treatment;Q422232;P2175;Q170990
Therapeutic efficacy and safety of methotrexate + leflunomide in Colombian patients with active rheumatoid arthritis refractory to conventional treatment;Q422232;P2175;Q187255
Pharmacokinetic interaction between methotrexate and chloral hydrate.;Q422232;P636;Q285166
Peritoneal tuberculosis mimicking advanced ovarian cancer in a patient treated with methotrexate for chronic rheumatoid arthritis.;Q422232;P2175;Q187255
Peritoneal tuberculosis mimicking advanced ovarian cancer in a patient treated with methotrexate for chronic rheumatoid arthritis.;Q422232;P2175;Q170990
Correction: Patient-derived oral mucosa organoids as an in vitro model for methotrexate induced toxicity in pediatric acute lymphoblastic leukemia;Q422232;P2175;Q29496
Correction: Patient-derived oral mucosa organoids as an in vitro model for methotrexate induced toxicity in pediatric acute lymphoblastic leukemia;Q422232;P636;Q285166
Large intravenous dose of methotrexate and radiotherapy in the treatment of advanced oral cancers.;Q422232;P636;Q285166
Primary Adrenal Lymphoma Possibly Associated With Epstein-Barr Virus Reactivation Due to Immunosuppression Under Methotrexate Therapy;Q422232;P2175;Q208414
Does Concomitant Methotrexate During Rituximab Treatment in Granulomatosis With Polyangiitis (Wegener's) Increase the Risk of Severe Infection? Comment on the Article by Azar et al;Q422232;P2175;Q1161568
[Primary intraocular lymphoma invaded to the central nervous system after successful treatment with intraocular methotrexate injection];Q422232;P2175;Q208414
Connexin 26 in psoriatic skin before and after two conventional therapeutic modalities: methotrexate and PUVA;Q218642;P703;Q177932
Connexin 26 in psoriatic skin before and after two conventional therapeutic modalities: methotrexate and PUVA;Q186474;P703;Q177932
Connexin 26 in psoriatic skin before and after two conventional therapeutic modalities: methotrexate and PUVA;Q20035886;P703;Q177932
Connexin 26 in psoriatic skin before and after two conventional therapeutic modalities: methotrexate and PUVA;Q483752;P703;Q177932
Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data;Q3530324;P2175;Q170990
Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data;Q422232;P2175;Q187255
Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data;Q422232;P2175;Q170990
A randomized study of cyclosporine and methotrexate with or without methylprednisolone for the prevention of graft-versus-host disease: Improved long-term survival with triple prophylaxis.;Q367700;P2175;Q1194520
A randomized study of cyclosporine and methotrexate with or without methylprednisolone for the prevention of graft-versus-host disease: Improved long-term survival with triple prophylaxis.;Q11426176;P2175;Q1194520
A randomized study of cyclosporine and methotrexate with or without methylprednisolone for the prevention of graft-versus-host disease: Improved long-term survival with triple prophylaxis.;Q417222;P2175;Q1194520
Differential methotrexate toxicity between two human oral squamous carcinoma cell lines.;Q178450;P703;Q15978631
Differential methotrexate toxicity between two human oral squamous carcinoma cell lines.;Q422232;P636;Q285166
[Pneumocystis carinii pneumopathy in rheumatoid polyarthritis treated by methotrexate in a patient with pulmonary asbestosis];Q422232;P2175;Q170990
[Pneumocystis carinii pneumopathy in rheumatoid polyarthritis treated by methotrexate in a patient with pulmonary asbestosis];Q422232;P2175;Q1274464
Combination of Mangifera indica L. extract supplementation plus methotrexate in rheumatoid arthritis patients: a pilot study.;Q422232;P2175;Q187255
Combination of Mangifera indica L. extract supplementation plus methotrexate in rheumatoid arthritis patients: a pilot study.;Q422232;P2175;Q170990
The impact of expectant management, systemic methotrexate and surgery on subsequent pregnancy outcomes in tubal ectopic pregnancy;Q422232;P2175;Q207087
In vitro and ex vivo evaluation of methotrexate removal by different sorbents haemoperfusion.;Q422232;P636;Q640448
Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients;Q422232;P361;Q14819383
Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients;Q422232;P2175;Q187255
Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients;Q422232;P2175;Q170990
Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis.;Q422232;P2175;Q170990
Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma;Q418560;P2175;Q12284921
Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma;Q418817;P2175;Q208414
Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma;Q422252;P2175;Q208414
Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma;Q422232;P2175;Q208414
A controlled trial of intra-articular corticosteroids with or without methotrexate in oligoarticular juvenile idiopathic arthritis.;Q422232;P2175;Q170990
A controlled trial of intra-articular corticosteroids with or without methotrexate in oligoarticular juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Effect of nitrous oxide and methotrexate on folate coenzyme pools of blast cells from leukemia patients.;Q422232;P2175;Q29496
Are serum human chorionic gonadotropin clearance curves of use in monitoring methotrexate treatment in cervical pregnancy?;Q218642;P703;Q15978631
Are serum human chorionic gonadotropin clearance curves of use in monitoring methotrexate treatment in cervical pregnancy?;Q407172;P279;Q409770
Are serum human chorionic gonadotropin clearance curves of use in monitoring methotrexate treatment in cervical pregnancy?;Q407172;P703;Q15978631
[Clinical analysis of 82 cases of ectopic pregnancy treated by methotrexate combined with traditional Chinese recipe];Q422232;P2175;Q207087
Varicella pneumonia in a woman receiving methotrexate for psoriatic arthritis.;Q422232;P2175;Q170990
Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.;Q422232;P2175;Q187255
Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.;Q422232;P2175;Q170990
MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial.;Q248550;P2175;Q187255
MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial.;Q248550;P2175;Q170990
MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial.;Q422232;P2175;Q170990
MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial.;Q422232;P2175;Q187255
[A case of rheumatoid arthritis complicated with pseudotumor around odontoid process successfully treated by methotrexate];Q422232;P2175;Q170990
[A case of rheumatoid arthritis complicated with pseudotumor around odontoid process successfully treated by methotrexate];Q422232;P2175;Q187255
Adjuvant chemotherapy with a combination of mitoxantrone, methotrexate, 5-fluorouracil for node-positive breast cancer: phase II pilot study;Q239426;P2175;Q128581
Adjuvant chemotherapy with a combination of mitoxantrone, methotrexate, 5-fluorouracil for node-positive breast cancer: phase II pilot study;Q238512;P2175;Q128581
Adjuvant chemotherapy with a combination of mitoxantrone, methotrexate, 5-fluorouracil for node-positive breast cancer: phase II pilot study;Q422232;P2175;Q128581
Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis.;Q248550;P2175;Q170990
Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis.;Q248550;P2175;Q187255
Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis.;Q422232;P2175;Q170990
Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis.;Q422232;P2175;Q187255
Neoadjuvant chemotherapy with cisplatin, methotrexate, bleomycin and vincristine (CABO) in patients with stage III and IV squamous cell carcinoma of the head and neck;Q412415;P2175;Q18348812
[High-dose methotrexate with blood monitoring in patients with osteosarcoma];Q422232;P2175;Q549534
Oligosymptomatic herpetic hepatitis in a patient with rheumatoid arthritis using corticosteroid and methotrexate;Q422232;P2175;Q170990
Oligosymptomatic herpetic hepatitis in a patient with rheumatoid arthritis using corticosteroid and methotrexate;Q422232;P2175;Q187255
[High methotrexate doses in the treatment program for acute lymphoblastic leukemia and lymphosarcoma in children];Q422232;P2175;Q29496
Low-dose methotrexate inhibits lung metastasis and lengthens survival in rat osteosarcoma.;Q422232;P2175;Q549534
Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review;Q422232;P2175;Q187255
Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review;Q422232;P2175;Q170990
Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study;Q186521;P703;Q177932
Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study;Q422232;P2175;Q170990
Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study;Q422232;P2175;Q187255
Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis.;Q348260;P2175;Q170990
Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis.;Q348260;P2175;Q187255
Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Management of uterine ectopic pregnancy - local vs. systemic methotrexate;Q422232;P2175;Q207087
The Influence of Race and Sex on the Side Effect Profile of Methotrexate in the Treatment of Uveitis;Q422232;P2175;Q280027
Reflections on Peter Clark's Moral Analysis of the Use of Methotrexate in Ectopic Pregnancies.;Q422232;P636;Q285166
Combination of Low-Dose, Short-Course Mycophenolate Mofetil With Cyclosporine and Methotrexate for Graft-Versus-Host Disease Prophylaxis in Allogeneic Stem Cell Transplant;Q130336;P31;Q407142
Combination of Low-Dose, Short-Course Mycophenolate Mofetil With Cyclosporine and Methotrexate for Graft-Versus-Host Disease Prophylaxis in Allogeneic Stem Cell Transplant;Q130336;P4149;Q27122100
Rheumatoid arthritis. Triple therapy or etanercept after methotrexate failure in RA?;Q422232;P2175;Q170990
Rheumatoid arthritis. Triple therapy or etanercept after methotrexate failure in RA?;Q422232;P2175;Q187255
Nodules in patients with rheumatoid arthritis and methotrexate treatment;Q422232;P2175;Q187255
Nodules in patients with rheumatoid arthritis and methotrexate treatment;Q422232;P2175;Q170990
Methotrexate versus hyperosomolar glucose in the treatment of extrauterine pregnancy.;Q422232;P2175;Q207087
OS08.8 A head-to-head comparison of two different high dose methotrexate (HDMTX) - and high dose cytarabin (HDAraC)-based chemotherapy regimens in younger patients with primary central nervous system lymphoma (PCNSL).;Q422232;P2175;Q136312
OS08.8 A head-to-head comparison of two different high dose methotrexate (HDMTX) - and high dose cytarabin (HDAraC)-based chemotherapy regimens in younger patients with primary central nervous system lymphoma (PCNSL).;Q422232;P2175;Q208414
Topical methotrexate pretreatment enhances the therapeutic effect of topical 5-aminolevulinic acid-mediated photodynamic therapy on hamster buccal pouch precancers.;Q186521;P703;Q177932
Impairment of methotrexate transport is common in osteosarcoma tumor samples;Q422232;P2175;Q549534
Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy.;Q218642;P703;Q2046782
Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy.;Q178450;P703;Q2046782
Treatment of patients with refractory myelogenous leukemia with BCOMM[1,3-bis-chloro(2-chloroethyl)-1-nitrosourea (BCNU), oncovin (vincristine), cyclophosphamide, high-dose methotrexate and methyl-glyoxal bis-guanylhydrazone (MGBG)].;Q408977;P2175;Q29496
Treatment of patients with refractory myelogenous leukemia with BCOMM[1,3-bis-chloro(2-chloroethyl)-1-nitrosourea (BCNU), oncovin (vincristine), cyclophosphamide, high-dose methotrexate and methyl-glyoxal bis-guanylhydrazone (MGBG)].;Q422232;P2175;Q29496
Induction chemotherapy of dibromodulcitol, Adriamycin, vincristine, tamoxifen, and Halotestin with methotrexate in metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1181).;Q18936;P2175;Q128581
Induction chemotherapy of dibromodulcitol, Adriamycin, vincristine, tamoxifen, and Halotestin with methotrexate in metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1181).;Q18936;P3780;Q47520887
Induction chemotherapy of dibromodulcitol, Adriamycin, vincristine, tamoxifen, and Halotestin with methotrexate in metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1181).;Q412178;P2175;Q128581
Induction chemotherapy of dibromodulcitol, Adriamycin, vincristine, tamoxifen, and Halotestin with methotrexate in metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1181).;Q422232;P2175;Q128581
Long-term third chronic phase of chronic myelogenous leukemia maintained by interferon-alpha and methotrexate;Q422232;P2175;Q29496
The radiotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin treatment is an effective therapeutic option in patients with advanced or metastatic bladder cancer.;Q18936;P2175;Q504775
The radiotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin treatment is an effective therapeutic option in patients with advanced or metastatic bladder cancer.;Q186521;P703;Q177932
The radiotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin treatment is an effective therapeutic option in patients with advanced or metastatic bladder cancer.;Q412415;P2175;Q504775
Glutamic Acid Increased Methotrexate Polyglutamation and Cytotoxicity in a CCRF-SB Acute Lymphoblastic Leukemia Cell Line;Q422232;P2175;Q56014449
Methotrexate therapy in rheumatoid arthritis.;Q422232;P2175;Q170990
Methotrexate therapy in rheumatoid arthritis.;Q422232;P2175;Q187255
Human chorionic gonadotropin (hCG) regression normograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy.;Q407172;P279;Q409770
Clarithromycin in rheumatoid arthritis: the addition to methotrexate and low-dose methylprednisolone induces a significant additive value--a 24-month single-blind pilot study.;Q118551;P3780;Q118551
Clarithromycin in rheumatoid arthritis: the addition to methotrexate and low-dose methylprednisolone induces a significant additive value--a 24-month single-blind pilot study.;Q417222;P2175;Q187255
Clarithromycin in rheumatoid arthritis: the addition to methotrexate and low-dose methylprednisolone induces a significant additive value--a 24-month single-blind pilot study.;Q417222;P2175;Q170990
Clarithromycin in rheumatoid arthritis: the addition to methotrexate and low-dose methylprednisolone induces a significant additive value--a 24-month single-blind pilot study.;Q422232;P2175;Q170990
Clarithromycin in rheumatoid arthritis: the addition to methotrexate and low-dose methylprednisolone induces a significant additive value--a 24-month single-blind pilot study.;Q422232;P2175;Q187255
Mangosteen ethanol extract alleviated the severity of collagen-induced arthritis in rats and produced synergistic effects with methotrexate;Q422232;P2175;Q170990
Autoantibodies against a novel citrullinated fibrinogen peptide related to smoking status, disease activity and therapeutic response to methotrexate in cuban patients with early rheumatoid arthritis;Q218642;P703;Q177932
Autoantibodies against a novel citrullinated fibrinogen peptide related to smoking status, disease activity and therapeutic response to methotrexate in cuban patients with early rheumatoid arthritis;Q422232;P2175;Q187255
Autoantibodies against a novel citrullinated fibrinogen peptide related to smoking status, disease activity and therapeutic response to methotrexate in cuban patients with early rheumatoid arthritis;Q422232;P2175;Q170990
Autoantibodies against a novel citrullinated fibrinogen peptide related to smoking status, disease activity and therapeutic response to methotrexate in cuban patients with early rheumatoid arthritis;Q422232;P361;Q14819383
Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis.;Q422232;P2175;Q170990
Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis.;Q422232;P2175;Q187255
Methotrexate for high-grade osteosarcoma in children and young adults;Q422232;P2175;Q549534
Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions;Q2603363;P279;Q665843
Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions;Q424952;P636;Q285166
Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions;Q416331;P636;Q285166
Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions;Q423930;P279;Q665843
Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions;Q422232;P2868;Q127060
Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions;Q422232;P636;Q285166
Studies on Controlled Drug Release in vitro of Methotrexate Loaded by PPEGMEA-g-PMAA Double Hydrophilic Graft Copolymer;Q410083;P31;Q81163
Intermediate dose of methotrexate toxicity in non-Hodgkin lymphoma;Q422232;P2175;Q208414
Intermediate dose of methotrexate toxicity in non-Hodgkin lymphoma;Q422232;P2175;Q1138590
Reduced-dose whole-brain radiotherapy with tumor bed boost after upfront high-dose methotrexate for primary central nervous system lymphoma;Q422232;P2175;Q208414
Reduced-dose whole-brain radiotherapy with tumor bed boost after upfront high-dose methotrexate for primary central nervous system lymphoma;Q422232;P2175;Q136312
Lack of therapeutic synergism between vincristine and methotrexate in L1210 murine leukemia in vivo.;Q408977;P2175;Q29496
Lack of therapeutic synergism between vincristine and methotrexate in L1210 murine leukemia in vivo.;Q483745;P703;Q177932
Lack of therapeutic synergism between vincristine and methotrexate in L1210 murine leukemia in vivo.;Q422232;P2175;Q29496
Combination therapy with hydroxychloroquine and methotrexate in rheumatoid arthritis.;Q421094;P2175;Q170990
Combination therapy with hydroxychloroquine and methotrexate in rheumatoid arthritis.;Q421094;P2175;Q187255
Combination therapy with hydroxychloroquine and methotrexate in rheumatoid arthritis.;Q421094;P1889;Q422438
Combination therapy with hydroxychloroquine and methotrexate in rheumatoid arthritis.;Q422438;P2175;Q187255
Combination therapy with hydroxychloroquine and methotrexate in rheumatoid arthritis.;Q422438;P1889;Q421094
Combination therapy with hydroxychloroquine and methotrexate in rheumatoid arthritis.;Q422232;P2175;Q170990
Combination therapy with hydroxychloroquine and methotrexate in rheumatoid arthritis.;Q422232;P2175;Q187255
[Combination chemotherapy with MOPP and intrathecal methotrexate in children with brain tumors].;Q422232;P636;Q1320251
Subcellular localization of folate and effect of methotrexate on the incorporation of radioactive folic acid into guinea-pig liver folate.;Q422232;P2868;Q127060
Collateral sensitivity to methotrexate and dichloromethotrexate of cultured lymphocytic leukemia L1210 cells resistant to 6-mercaptopurine.;Q418529;P2175;Q6708277
Collateral sensitivity to methotrexate and dichloromethotrexate of cultured lymphocytic leukemia L1210 cells resistant to 6-mercaptopurine.;Q422232;P2175;Q29496
-Lipoic acid ameliorates oral mucositis and oxidative stress induced by methotrexate in rats. Histological and immunohistochemical study.;Q422232;P636;Q285166
TwHF versus methotrexate in the treatment of rheumatoid arthritis: response to Landewe's comment on the TRIFRA study;Q422232;P2175;Q187255
TwHF versus methotrexate in the treatment of rheumatoid arthritis: response to Landewe's comment on the TRIFRA study;Q422232;P2175;Q170990
Methotrexate chronotherapy is effective against rheumatoid arthritis.;Q422232;P2175;Q170990
Methotrexate chronotherapy is effective against rheumatoid arthritis.;Q422232;P2175;Q187255
Prolonged methotrexate infusions in children with acute leukemia in relapse and in remission and with medulloblastoma. Pharmacokinetics, toxicity and clinical results.;Q422232;P2175;Q29496
L-asparaginase-induced modulation of methotrexate polyglutamylation in murine leukemia L5178Y.;Q422232;P2175;Q29496
A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group.;Q422232;P636;Q285166
Methotrexate and folic acid effect in normal and sarcoma 180 bearing mice.;Q422232;P2868;Q127060
Ultrasensitive SERS detection of antitumor drug methotrexate based on modified Ag substrate;Q218642;P31;Q12140
Ultrasensitive SERS detection of antitumor drug methotrexate based on modified Ag substrate;Q183290;P31;Q12140
Ultrasensitive SERS detection of antitumor drug methotrexate based on modified Ag substrate;Q191924;P31;Q12140
Ultrasensitive SERS detection of antitumor drug methotrexate based on modified Ag substrate;Q173670;P31;Q12140
Ultrasensitive SERS detection of antitumor drug methotrexate based on modified Ag substrate;Q422232;P31;Q12140
Chemotherapy of metastatic breast cancer in postmenopausal women: a controlled trial of cyclophosphamide versus a five-drug combination of cyclophosphamide, vincristine, methotrexate, 5-fluorouracil and prednisone.;Q186474;P31;Q12140
Chemotherapy of metastatic breast cancer in postmenopausal women: a controlled trial of cyclophosphamide versus a five-drug combination of cyclophosphamide, vincristine, methotrexate, 5-fluorouracil and prednisone.;Q408977;P31;Q12140
Chemotherapy of metastatic breast cancer in postmenopausal women: a controlled trial of cyclophosphamide versus a five-drug combination of cyclophosphamide, vincristine, methotrexate, 5-fluorouracil and prednisone.;Q191924;P31;Q12140
Chemotherapy of metastatic breast cancer in postmenopausal women: a controlled trial of cyclophosphamide versus a five-drug combination of cyclophosphamide, vincristine, methotrexate, 5-fluorouracil and prednisone.;Q238512;P31;Q12140
Chemotherapy of metastatic breast cancer in postmenopausal women: a controlled trial of cyclophosphamide versus a five-drug combination of cyclophosphamide, vincristine, methotrexate, 5-fluorouracil and prednisone.;Q238512;P2175;Q128581
Chemotherapy of metastatic breast cancer in postmenopausal women: a controlled trial of cyclophosphamide versus a five-drug combination of cyclophosphamide, vincristine, methotrexate, 5-fluorouracil and prednisone.;Q424972;P2175;Q12078
Chemotherapy of metastatic breast cancer in postmenopausal women: a controlled trial of cyclophosphamide versus a five-drug combination of cyclophosphamide, vincristine, methotrexate, 5-fluorouracil and prednisone.;Q424972;P31;Q12140
Chemotherapy of metastatic breast cancer in postmenopausal women: a controlled trial of cyclophosphamide versus a five-drug combination of cyclophosphamide, vincristine, methotrexate, 5-fluorouracil and prednisone.;Q422232;P31;Q12140
Chemotherapy of metastatic breast cancer in postmenopausal women: a controlled trial of cyclophosphamide versus a five-drug combination of cyclophosphamide, vincristine, methotrexate, 5-fluorouracil and prednisone.;Q422232;P2175;Q128581
Letter: Antagonism between cranial irradiation and intrathecal methotrexate in meningeal leukaemia;Q422232;P2175;Q29496
Letter: Antagonism between cranial irradiation and intrathecal methotrexate in meningeal leukaemia;Q422232;P636;Q1320251
Sequential chemotherapy of advanced colorectal cancer with standard or high-dose methotrexate followed by 5-fluorouracil.;Q238512;P2175;Q2739660
Methods to evaluate the effect of ethanol on the folate analogue: fluorescein methotrexate uptake in human proximal tubular cells;Q153;P703;Q15978631
Methods to evaluate the effect of ethanol on the folate analogue: fluorescein methotrexate uptake in human proximal tubular cells;Q22124685;P703;Q15978631
The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma.;Q422232;P636;Q285166
Resistance to methotrexate and multidrug resistance in childhood malignancies.;Q191924;P366;Q8386
Resistance to methotrexate and multidrug resistance in childhood malignancies.;Q173670;P31;Q12140
Resistance to methotrexate and multidrug resistance in childhood malignancies.;Q422232;P31;Q12140
On the safety of perioperative adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil in breast cancer.;Q238512;P2175;Q128581
On the safety of perioperative adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil in breast cancer.;Q422232;P2175;Q128581
Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence;Q412415;P2175;Q18348812
Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence;Q420296;P2175;Q18348812
The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial.;Q415264;P2175;Q170990
The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial.;Q422232;P2175;Q170990
The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial.;Q422232;P2175;Q861224
Angio-neurotic oedema associated with methotrexate treatment in rheumatoid arthritis;Q422232;P2175;Q170990
Angio-neurotic oedema associated with methotrexate treatment in rheumatoid arthritis;Q422232;P2175;Q187255
Hepatotoxicity in patients with juvenile idiopathic arthritis receiving longterm methotrexate therapy;Q422232;P2175;Q170990
Hepatotoxicity in patients with juvenile idiopathic arthritis receiving longterm methotrexate therapy;Q422232;P2175;Q861224
Advanced mycosis fungoides: chemotherapy with etoposide, methotrexate, bleomycin, and prednimustine;Q418817;P2175;Q1891209
Advanced mycosis fungoides: chemotherapy with etoposide, methotrexate, bleomycin, and prednimustine;Q418011;P2175;Q1891209
Advanced mycosis fungoides: chemotherapy with etoposide, methotrexate, bleomycin, and prednimustine;Q422232;P2175;Q1891209
Patient-derived oral mucosa organoids as an in vitro model for methotrexate induced toxicity in pediatric acute lymphoblastic leukemia;Q422232;P636;Q285166
Patient-derived oral mucosa organoids as an in vitro model for methotrexate induced toxicity in pediatric acute lymphoblastic leukemia;Q422232;P2175;Q29496
A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis;Q422232;P2175;Q170990
A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis;Q422232;P2175;Q861224
Liposomal methotrexate in the treatment of murine L1210 leukemia.;Q422232;P2175;Q29496
Risk factors for abnormal hepatic enzyme elevation by methotrexate treatment in patients with rheumatoid arthritis: A hospital based-cohort study.;Q422232;P2175;Q170990
Risk factors for abnormal hepatic enzyme elevation by methotrexate treatment in patients with rheumatoid arthritis: A hospital based-cohort study.;Q422232;P2175;Q187255
Outcomes of intravitreal methotrexate to salvage eyes with relapsed primary intraocular lymphoma;Q422232;P2175;Q208414
Alteration of the organ uptake of the (99m)Tc-radiopharmaceuticals, (99m)Tc-DPD, (99m)Tc-DMSA, (99m)Tc-tin colloid and (99m)Tc-MAA, induced by the applied cytotoxic drugs methotrexate sodium and cyclophosphamide.;Q218642;P31;Q12140
Alteration of the organ uptake of the (99m)Tc-radiopharmaceuticals, (99m)Tc-DPD, (99m)Tc-DMSA, (99m)Tc-tin colloid and (99m)Tc-MAA, induced by the applied cytotoxic drugs methotrexate sodium and cyclophosphamide.;Q183290;P31;Q12140
Alteration of the organ uptake of the (99m)Tc-radiopharmaceuticals, (99m)Tc-DPD, (99m)Tc-DMSA, (99m)Tc-tin colloid and (99m)Tc-MAA, induced by the applied cytotoxic drugs methotrexate sodium and cyclophosphamide.;Q186521;P31;Q12140
Alteration of the organ uptake of the (99m)Tc-radiopharmaceuticals, (99m)Tc-DPD, (99m)Tc-DMSA, (99m)Tc-tin colloid and (99m)Tc-MAA, induced by the applied cytotoxic drugs methotrexate sodium and cyclophosphamide.;Q407781;P31;Q12140
Alteration of the organ uptake of the (99m)Tc-radiopharmaceuticals, (99m)Tc-DPD, (99m)Tc-DMSA, (99m)Tc-tin colloid and (99m)Tc-MAA, induced by the applied cytotoxic drugs methotrexate sodium and cyclophosphamide.;Q191924;P366;Q8386
Alteration of the organ uptake of the (99m)Tc-radiopharmaceuticals, (99m)Tc-DPD, (99m)Tc-DMSA, (99m)Tc-tin colloid and (99m)Tc-MAA, induced by the applied cytotoxic drugs methotrexate sodium and cyclophosphamide.;Q191924;P31;Q12140
Alteration of the organ uptake of the (99m)Tc-radiopharmaceuticals, (99m)Tc-DPD, (99m)Tc-DMSA, (99m)Tc-tin colloid and (99m)Tc-MAA, induced by the applied cytotoxic drugs methotrexate sodium and cyclophosphamide.;Q178450;P31;Q12140
Alteration of the organ uptake of the (99m)Tc-radiopharmaceuticals, (99m)Tc-DPD, (99m)Tc-DMSA, (99m)Tc-tin colloid and (99m)Tc-MAA, induced by the applied cytotoxic drugs methotrexate sodium and cyclophosphamide.;Q20035886;P31;Q12140
Alteration of the organ uptake of the (99m)Tc-radiopharmaceuticals, (99m)Tc-DPD, (99m)Tc-DMSA, (99m)Tc-tin colloid and (99m)Tc-MAA, induced by the applied cytotoxic drugs methotrexate sodium and cyclophosphamide.;Q22124685;P31;Q12140
Alteration of the organ uptake of the (99m)Tc-radiopharmaceuticals, (99m)Tc-DPD, (99m)Tc-DMSA, (99m)Tc-tin colloid and (99m)Tc-MAA, induced by the applied cytotoxic drugs methotrexate sodium and cyclophosphamide.;Q423814;P31;Q12140
Alteration of the organ uptake of the (99m)Tc-radiopharmaceuticals, (99m)Tc-DPD, (99m)Tc-DMSA, (99m)Tc-tin colloid and (99m)Tc-MAA, induced by the applied cytotoxic drugs methotrexate sodium and cyclophosphamide.;Q423423;P31;Q12140
Alteration of the organ uptake of the (99m)Tc-radiopharmaceuticals, (99m)Tc-DPD, (99m)Tc-DMSA, (99m)Tc-tin colloid and (99m)Tc-MAA, induced by the applied cytotoxic drugs methotrexate sodium and cyclophosphamide.;Q422232;P31;Q12140
Impact of methotrexate dose on efficacy of adalimumab in Japanese patients with rheumatoid arthritis: Results from registered data analyses;Q348260;P2175;Q187255
Impact of methotrexate dose on efficacy of adalimumab in Japanese patients with rheumatoid arthritis: Results from registered data analyses;Q348260;P2175;Q170990
Impact of methotrexate dose on efficacy of adalimumab in Japanese patients with rheumatoid arthritis: Results from registered data analyses;Q422232;P2175;Q187255
Impact of methotrexate dose on efficacy of adalimumab in Japanese patients with rheumatoid arthritis: Results from registered data analyses;Q422232;P2175;Q170990
[New concept of a classical antirheumatic drug methotrexate];Q191924;P31;Q12140
[New concept of a classical antirheumatic drug methotrexate];Q422232;P31;Q12140
[Compared bioavailability of methotrexate administered orally or intramuscularly in rheumatoid arthritis].;Q422232;P636;Q285166
[Compared bioavailability of methotrexate administered orally or intramuscularly in rheumatoid arthritis].;Q422232;P2175;Q170990
[Compared bioavailability of methotrexate administered orally or intramuscularly in rheumatoid arthritis].;Q422232;P2175;Q187255
Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT;Q248550;P31;Q12140
Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT;Q218642;P31;Q12140
Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT;Q218642;P703;Q2046782
Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT;Q186474;P31;Q12140
Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT;Q186521;P31;Q12140
Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT;Q191924;P31;Q12140
Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT;Q191924;P366;Q8386
Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT;Q173670;P31;Q12140
Effectiveness of maintenance therapy with methotrexate compared with leflunomide for patients with RA having achieved disease control with both these drugs: results of a predefined sub-analysis of CareRA, a pragmatic RCT;Q422232;P31;Q12140
Membrane transport of methotrexate in human lymphoblastoid cells.;Q22124685;P703;Q15978631
Analysis of hair and plasma samples for methotrexate (MTX) and metabolite using high-performance liquid chromatography triple quadrupole mass spectrometry (LC-MS/MS) detection;Q218642;P31;Q407595
Efficacy of intrathecal methotrexate with and without cranial radiotherapy in preventing central nervous system relapses in acute lymphocytic leukemia.;Q422232;P2175;Q29496
Efficacy of intrathecal methotrexate with and without cranial radiotherapy in preventing central nervous system relapses in acute lymphocytic leukemia.;Q422232;P636;Q1320251
Cerebral glucose metabolic change after high-dose methotrexate treatment in patients with acute lymphocytic leukemia.;Q422232;P2175;Q29496
Two pediatric osteosarcoma cases with delayed methotrexate excretion: its clinical course and management.;Q422232;P2175;Q549534
Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era;Q422232;P2175;Q170990
Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era;Q422232;P2175;Q861224
High grade follicular lymphoma in a patient receiving adalimumab and methotrexate for pityriasis rubra pilaris;Q348260;P2175;Q766856
High grade follicular lymphoma in a patient receiving adalimumab and methotrexate for pityriasis rubra pilaris;Q422232;P2175;Q208414
TT genotype of rs10036748 in TNIP1 shows better response to methotrexate in a Chinese population: a prospective cohort study;Q422232;P361;Q14819383
Response-adapted treatment with upfront high-dose chemotherapy followed by autologous stem-cell transplantation rescue or consolidation phase high-dose methotrexate for primary central nervous system lymphoma: a long-term mono-center study;Q422232;P2175;Q208414
Response-adapted treatment with upfront high-dose chemotherapy followed by autologous stem-cell transplantation rescue or consolidation phase high-dose methotrexate for primary central nervous system lymphoma: a long-term mono-center study;Q422232;P2175;Q136312
Hyperfractionated cyclophosphamide with high-doses of arabinosylcytosine and methotrexate (HyperCHiDAM Verona 897).;Q186474;P1889;Q178425
Combination therapy for rheumatoid arthritis with methotrexate and cyclosporine.;Q367700;P2175;Q187255
Combination therapy for rheumatoid arthritis with methotrexate and cyclosporine.;Q422232;P2175;Q187255
Combination therapy for rheumatoid arthritis with methotrexate and cyclosporine.;Q422232;P2175;Q170990
Pharmacoeconomic Review Report: Baricitinib (Olumiant): (Eli Lilly Canada Inc.): Indication: For use in combination with methotrexate (MTX) for the treatment of adult patients with moderate to severe rheumatoid arthritis who have responded inadequat;Q422232;P2175;Q170990
Pharmacoeconomic Review Report: Baricitinib (Olumiant): (Eli Lilly Canada Inc.): Indication: For use in combination with methotrexate (MTX) for the treatment of adult patients with moderate to severe rheumatoid arthritis who have responded inadequat;Q422232;P2175;Q187255
Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.;Q422232;P2175;Q29496
Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.;Q422232;P2175;Q187255
Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.;Q422232;P2868;Q810254
Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.;Q422232;P2175;Q170990
mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL.;Q422232;P2175;Q56014449
[Effect of methotrexate in treating patients with rheumatoid arthritis of different Chinese medical syndrome patterns];Q422232;P2175;Q170990
[Effect of methotrexate in treating patients with rheumatoid arthritis of different Chinese medical syndrome patterns];Q422232;P2175;Q187255
Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules.;Q11426176;P2175;Q12078
Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules.;Q417222;P2175;Q12078
Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules.;Q417222;P2868;Q575136
The efficacy of methotrexate for lymphomatoid papulosis;Q422232;P2175;Q208414
[Case of disseminated necrotizing leukoencephalopathy following intrathecal methotrexate in acute lymphocytic leukemia];Q422232;P2175;Q29496
[Case of disseminated necrotizing leukoencephalopathy following intrathecal methotrexate in acute lymphocytic leukemia];Q422232;P636;Q1320251
Characterization of the coexisting multiple mechanisms of methotrexate resistance in mouse 3T6 R50 fibroblasts.;Q186474;P703;Q83310
One-third of patients are low-adherent to methotrexate for rheumatoid arthritis at the initiation of a first biologic. A cross-sectional study investigating adherence rate and factors;Q422232;P2175;Q170990
One-third of patients are low-adherent to methotrexate for rheumatoid arthritis at the initiation of a first biologic. A cross-sectional study investigating adherence rate and factors;Q422232;P2175;Q187255
Effects of vitamin B12 on methotrexate hepatotoxicity: evaluation of receptor-interacting protein (RIP) kinase;Q83187;P2868;Q183206
Effects of vitamin B12 on methotrexate hepatotoxicity: evaluation of receptor-interacting protein (RIP) kinase;Q83187;P361;Q27115611
Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study.;Q422232;P2175;Q208414
Salpingoscopy after a single dose of methotrexate for treatment of tubal pregnancy.;Q422232;P2175;Q207087
Methotrexate in crohn's disease: a new face for an old drug?;Q22124685;P31;Q12140
Methotrexate in crohn's disease: a new face for an old drug?;Q422232;P31;Q12140
The effects of cisplatin and methotrexate on the expression of human immunodeficiency virus type 1 long terminal repeat.;Q186521;P703;Q15978631
Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.;Q420035;P2175;Q170990
Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.;Q420035;P2175;Q187255
Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.;Q422232;P2175;Q170990
Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.;Q422232;P2175;Q187255
Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: retrospective study.;Q418817;P2175;Q1138590
Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: retrospective study.;Q418817;P2175;Q208414
Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: retrospective study.;Q422232;P2175;Q1138590
Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: retrospective study.;Q422232;P2175;Q208414
Safe administration of high-dose methotrexate with minimal drug level monitoring: Experience from a center in north India;Q183290;P31;Q12140
Safe administration of high-dose methotrexate with minimal drug level monitoring: Experience from a center in north India;Q191924;P31;Q12140
Safe administration of high-dose methotrexate with minimal drug level monitoring: Experience from a center in north India;Q484940;P31;Q12140
Safe administration of high-dose methotrexate with minimal drug level monitoring: Experience from a center in north India;Q422232;P31;Q12140
[Treatment of acute childhood leukemia: dosage schedule of 6-mercaptopurine and methotrexate for maintenance of remission (author's transl)];Q422232;P2175;Q29496
Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis;Q22124685;P31;Q12140
Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis;Q422232;P31;Q12140
Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis;Q422232;P2175;Q861224
Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis;Q422232;P2175;Q170990
Plasma homocysteine, methionine and S-adenosylhomocysteine levels following high-dose methotrexate treatment in pediatric patients with acute lymphoblastic leukemia or Burkitt lymphoma: association with hepatotoxicity.;Q422232;P2175;Q29496
Plasma homocysteine, methionine and S-adenosylhomocysteine levels following high-dose methotrexate treatment in pediatric patients with acute lymphoblastic leukemia or Burkitt lymphoma: association with hepatotoxicity.;Q422232;P2175;Q208414
Can inflammatory markers predict response to methotrexate in JIA? Results from the CHARM study.;Q422232;P361;Q14819383
Methotrexate vs bleomycin experiences in advanced oral malignancies.;Q422232;P636;Q285166
Comment on: A randomized placebo-controlled trial of methotrexate in psoriatic arthritis.;Q422232;P2175;Q170990
[Relative efficacy of neoadjuvant gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management for muscle-invasive bladder cancer].;Q412415;P2175;Q504775
[Relative efficacy of neoadjuvant gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management for muscle-invasive bladder cancer].;Q414143;P2175;Q504775
Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European p;Q348260;P2175;Q170990
Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European p;Q348260;P2175;Q187255
Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European p;Q422232;P361;Q14819383
Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European p;Q422232;P2175;Q170990
Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European p;Q422232;P2175;Q187255
Myelotoxicity of methotrexate, mitozantrone, and mitomycin C.;Q19856779;P1889;Q417625
LAPONITE nanoplatform functionalized with histidine modified oligomeric hyaluronic acid as an effective vehicle for the anticancer drug methotrexate;Q218642;P31;Q12140
LAPONITE nanoplatform functionalized with histidine modified oligomeric hyaluronic acid as an effective vehicle for the anticancer drug methotrexate;Q23118;P31;Q8386
LAPONITE nanoplatform functionalized with histidine modified oligomeric hyaluronic acid as an effective vehicle for the anticancer drug methotrexate;Q186521;P31;Q12140
LAPONITE nanoplatform functionalized with histidine modified oligomeric hyaluronic acid as an effective vehicle for the anticancer drug methotrexate;Q191924;P31;Q12140
LAPONITE nanoplatform functionalized with histidine modified oligomeric hyaluronic acid as an effective vehicle for the anticancer drug methotrexate;Q244150;P31;Q12140
LAPONITE nanoplatform functionalized with histidine modified oligomeric hyaluronic acid as an effective vehicle for the anticancer drug methotrexate;Q20035886;P31;Q12140
LAPONITE nanoplatform functionalized with histidine modified oligomeric hyaluronic acid as an effective vehicle for the anticancer drug methotrexate;Q485277;P31;Q12140
LAPONITE nanoplatform functionalized with histidine modified oligomeric hyaluronic acid as an effective vehicle for the anticancer drug methotrexate;Q483745;P31;Q12140
LAPONITE nanoplatform functionalized with histidine modified oligomeric hyaluronic acid as an effective vehicle for the anticancer drug methotrexate;Q484940;P31;Q12140
LAPONITE nanoplatform functionalized with histidine modified oligomeric hyaluronic acid as an effective vehicle for the anticancer drug methotrexate;Q422232;P31;Q12140
Stereotactic radiosurgery in combination with up-front high-dose methotrexate as a first-line treatment for newly diagnosed primary central nervous system lymphoma.;Q422232;P2175;Q136312
Stereotactic radiosurgery in combination with up-front high-dose methotrexate as a first-line treatment for newly diagnosed primary central nervous system lymphoma.;Q422232;P2175;Q208414
[Level of evidence for therapeutic drug monitoring of low dose methotrexate in inflammatory diseases].;Q191924;P366;Q8386
[Level of evidence for therapeutic drug monitoring of low dose methotrexate in inflammatory diseases].;Q483745;P31;Q12140
[Level of evidence for therapeutic drug monitoring of low dose methotrexate in inflammatory diseases].;Q483745;P703;Q177932
[Level of evidence for therapeutic drug monitoring of low dose methotrexate in inflammatory diseases].;Q422232;P31;Q12140
Randomized trial comparing adriamycin vincristine (av) cyclophosphamide methotrexate 5-Fluorouracil prednisone (cmfp) hybrid versus av-cmfp monthly alternated in metastatic breast-cancer.;Q424972;P2175;Q12078
Phase II study of low-dose methotrexate in advanced osteosarcoma followed by escalation after disease progression: a study of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research on Treatment of Cancer;Q422232;P2175;Q549534
Phase II study of low-dose methotrexate in advanced osteosarcoma followed by escalation after disease progression: a study of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research on Treatment of Cancer;Q422232;P2175;Q56014469
Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin.;Q422232;P636;Q285166
Phase II trial of pre- and postoperative cisplatin, methotrexate and vinblastine in infiltrating bladder cancer: a three year experience.;Q412415;P2175;Q504775
Treatment with methotrexate and risk of relapses in patients with giant cell arteritis in clinical practice.;Q422232;P2175;Q707816
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.;Q238512;P2175;Q2739660
Should methotrexate be added to prednisone therapy for temporal arteritis?;Q422232;P636;Q285166
Methotrexate in psoriatic arthritis;Q422232;P2175;Q170990
Combination sulfasalazine and methotrexate in the management of rheumatoid arthritis.;Q420035;P2175;Q187255
Combination sulfasalazine and methotrexate in the management of rheumatoid arthritis.;Q420035;P2175;Q170990
Combination sulfasalazine and methotrexate in the management of rheumatoid arthritis.;Q422232;P2175;Q170990
Combination sulfasalazine and methotrexate in the management of rheumatoid arthritis.;Q422232;P2175;Q187255
Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients;Q422232;P2175;Q170990
Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients;Q422232;P2175;Q187255
[Correlation study of blood drug concentration and nephrotoxicity on high dose methotrexate therapy in suggestion of diagnosis and treatment of childhood acute lymphoblastic leukemia in the 4th revised edition].;Q186474;P31;Q12140
[Correlation study of blood drug concentration and nephrotoxicity on high dose methotrexate therapy in suggestion of diagnosis and treatment of childhood acute lymphoblastic leukemia in the 4th revised edition].;Q191924;P31;Q12140
[Correlation study of blood drug concentration and nephrotoxicity on high dose methotrexate therapy in suggestion of diagnosis and treatment of childhood acute lymphoblastic leukemia in the 4th revised edition].;Q422232;P2175;Q29496
[Correlation study of blood drug concentration and nephrotoxicity on high dose methotrexate therapy in suggestion of diagnosis and treatment of childhood acute lymphoblastic leukemia in the 4th revised edition].;Q422232;P31;Q12140
Efficacy of methotrexate and etanercept biosimilar rhTNFR:Fc in Chinese patients with active rheumatoid arthritis: A controlled, randomized and multicenter study;Q415343;P2175;Q170990
Efficacy of methotrexate and etanercept biosimilar rhTNFR:Fc in Chinese patients with active rheumatoid arthritis: A controlled, randomized and multicenter study;Q415343;P2175;Q187255
Efficacy of methotrexate and etanercept biosimilar rhTNFR:Fc in Chinese patients with active rheumatoid arthritis: A controlled, randomized and multicenter study;Q422232;P2175;Q170990
Efficacy of methotrexate and etanercept biosimilar rhTNFR:Fc in Chinese patients with active rheumatoid arthritis: A controlled, randomized and multicenter study;Q422232;P2175;Q187255
Combination of cyclosporine and methotrexate for prophylaxis of acute graft versus host disease after allogeneic bone marrow transplantation for leukaemias.;Q367700;P2175;Q1194520
Combination of cyclosporine and methotrexate for prophylaxis of acute graft versus host disease after allogeneic bone marrow transplantation for leukaemias.;Q422232;P2175;Q29496
Mycobacterium avium-intracellulare (MAI) liver abscess mimicking liver metastasis in a patient with rheumatoid arthritis on adalimumab and methotrexate;Q348260;P2175;Q170990
Mycobacterium avium-intracellulare (MAI) liver abscess mimicking liver metastasis in a patient with rheumatoid arthritis on adalimumab and methotrexate;Q348260;P2175;Q187255
Mycobacterium avium-intracellulare (MAI) liver abscess mimicking liver metastasis in a patient with rheumatoid arthritis on adalimumab and methotrexate;Q422232;P2175;Q170990
Mycobacterium avium-intracellulare (MAI) liver abscess mimicking liver metastasis in a patient with rheumatoid arthritis on adalimumab and methotrexate;Q422232;P2175;Q187255
Analysis of arthritis flares after achievement of inactive disease with methotrexate monotherapy in juvenile idiopathic arthritis;Q422232;P2175;Q170990
Analysis of arthritis flares after achievement of inactive disease with methotrexate monotherapy in juvenile idiopathic arthritis;Q422232;P2175;Q861224
Inhibition of human renal cancer by monoclonal-anti-body-linked methotrexate in an ascites tumor model.;Q484940;P703;Q15978631
Medical management of ectopic pregnancy with single-dose and 2-dose methotrexate protocols: human chorionic gonadotropin trends and patient outcomes;Q407172;P703;Q15978631
Medical management of ectopic pregnancy with single-dose and 2-dose methotrexate protocols: human chorionic gonadotropin trends and patient outcomes;Q407172;P279;Q409770
Medical management of ectopic pregnancy with single-dose and 2-dose methotrexate protocols: human chorionic gonadotropin trends and patient outcomes;Q22124685;P703;Q15978631
Medical management of ectopic pregnancy with single-dose and 2-dose methotrexate protocols: human chorionic gonadotropin trends and patient outcomes;Q422232;P2175;Q207087
Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies;Q411648;P2175;Q1194520
Leukocytoclastic Vasculitis and Desensitization to High-dose Methotrexate in Primary Central Nervous System Lymphoma;Q422232;P2175;Q208414
Leukocytoclastic Vasculitis and Desensitization to High-dose Methotrexate in Primary Central Nervous System Lymphoma;Q422232;P2175;Q136312
The issue of bioavailability of oral low dose methotrexate: should we choose only 10mg of MTX a week in conjunction with anti-TNF therapy?;Q422232;P636;Q285166
[Value of combining biologics with methotrexate for treatment of psoriatic arthritis-questions remain];Q422232;P2175;Q170990
Repeated IL-10 measurement in aqueous humor and OCT imaging are valuable tools to monitor intraocular lymphoma treated with intravitreal injections of methotrexate;Q422232;P2175;Q208414
Methotrexate as an alternative to surgery in ectopic pregnancy: a new role for an old drug.;Q22124685;P31;Q12140
Methotrexate as an alternative to surgery in ectopic pregnancy: a new role for an old drug.;Q422232;P31;Q12140
Methotrexate as an alternative to surgery in ectopic pregnancy: a new role for an old drug.;Q422232;P2175;Q207087
Daily oral administration of low-dose methotrexate has greater antirheumatic effects in collagen-induced arthritis rats;Q422232;P636;Q285166
Daily oral administration of low-dose methotrexate has greater antirheumatic effects in collagen-induced arthritis rats;Q422232;P2175;Q170990
Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates;Q191924;P366;Q8386
Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates;Q421094;P31;Q12140
Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates;Q421094;P1889;Q422438
Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates;Q422438;P31;Q12140
Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates;Q422438;P1889;Q421094
Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates;Q422232;P31;Q12140
Poisoning related to therapeutic error in prolonged low-dose methotrexate treatment;Q20035886;P703;Q177932
Treatment of HIV-associated Primary CNS Lymphoma with Antiretroviral Therapy, Rituximab, and High-Dose Methotrexate;Q422232;P2175;Q136312
Treatment of HIV-associated Primary CNS Lymphoma with Antiretroviral Therapy, Rituximab, and High-Dose Methotrexate;Q422232;P2175;Q208414
Methotrexate in ectopic pregnancy.;Q422232;P2175;Q207087
[Subacute encephalopathy after high-dose methotrexate as prophylaxis for central nervous system relapse in a patient with intravascular large B-cell lymphoma];Q422232;P2175;Q208414
[Subacute encephalopathy after high-dose methotrexate as prophylaxis for central nervous system relapse in a patient with intravascular large B-cell lymphoma];Q422232;P2175;Q4833719
Effect of methotrexate on the mandibular development of arthritic rabbits;Q422232;P2175;Q170990
Methotrexate resistance in relapsed childhood acute lymphoblastic leukaemia;Q422232;P2175;Q29496
Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study).;Q218642;P703;Q177932
Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study).;Q188017;P703;Q177932
Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study).;Q183290;P703;Q177932
Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study).;Q186521;P703;Q177932
Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study).;Q485277;P703;Q177932
Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study).;Q173670;P703;Q177932
Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study).;Q178450;P703;Q177932
Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study).;Q20035886;P703;Q177932
Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study).;Q22124685;P703;Q177932
Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study).;Q620730;P703;Q177932
Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study).;Q483745;P703;Q177932
High-dose methotrexate monotherapy followed by radiation for CD30-positive, anaplastic lymphoma kinase-1-positive anaplastic large-cell lymphoma in the brain of a child.;Q422232;P2175;Q208414
Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B);Q408977;P2175;Q208414
Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B);Q408977;P2175;Q1138590
Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B);Q11426176;P2175;Q1138590
Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B);Q11426176;P2175;Q208414
Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B);Q422232;P2175;Q208414
Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B);Q422232;P2175;Q1138590
Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study;Q414143;P2175;Q208414
Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study;Q422252;P2175;Q208414
Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study;Q422232;P2175;Q208414
Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real-world data analyses and experience of one center;Q422232;P2175;Q128581
Methotrexate polyglutamate concentrations and association with disease control in rheumatoid arthritis: comment on the article by Stamp et al;Q422232;P2175;Q187255
Methotrexate polyglutamate concentrations and association with disease control in rheumatoid arthritis: comment on the article by Stamp et al;Q422232;P2175;Q170990
Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent patients;Q422232;P2175;Q208414
Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent patients;Q422232;P2175;Q136312
Delayed elimination of methotrexate by cola beverages in a pediatric acute lymphoblastic leukemia population.;Q422232;P2175;Q29496
Effect of short-term methotrexate discontinuation on rheumatoid arthritis disease activity: post-hoc analysis of two randomized trials;Q422232;P2175;Q170990
Effect of short-term methotrexate discontinuation on rheumatoid arthritis disease activity: post-hoc analysis of two randomized trials;Q422232;P2175;Q187255
Evaluation of methotrexate sensitivity in human leukemia cell lines by an adenosine triphosphate bioluminescence assay;Q190012;P703;Q15978631
Evaluation of methotrexate sensitivity in human leukemia cell lines by an adenosine triphosphate bioluminescence assay;Q80863;P703;Q15978631
Evaluation of methotrexate sensitivity in human leukemia cell lines by an adenosine triphosphate bioluminescence assay;Q422232;P2175;Q29496
Acute myeloid leukemia with t(3:21)(q26.2:q22) developing following low-dose methotrexate therapy for rheumatoid arthritis and expressing two AML1/MDS1/EVI1 fusion proteins: A case report.;Q422232;P2175;Q29496
Acute myeloid leukemia with t(3:21)(q26.2:q22) developing following low-dose methotrexate therapy for rheumatoid arthritis and expressing two AML1/MDS1/EVI1 fusion proteins: A case report.;Q422232;P2175;Q170990
Acute myeloid leukemia with t(3:21)(q26.2:q22) developing following low-dose methotrexate therapy for rheumatoid arthritis and expressing two AML1/MDS1/EVI1 fusion proteins: A case report.;Q422232;P2175;Q187255
Prediction of response to methotrexate in rheumatoid arthritis.;Q422232;P361;Q14819383
Prediction of response to methotrexate in rheumatoid arthritis.;Q422232;P2175;Q170990
Prediction of response to methotrexate in rheumatoid arthritis.;Q422232;P2175;Q187255
Etanercept and methotrexate in rheumatoid arthritis.;Q415343;P2175;Q170990
Etanercept and methotrexate in rheumatoid arthritis.;Q415343;P2175;Q187255
Etanercept and methotrexate in rheumatoid arthritis.;Q422232;P2175;Q187255
Etanercept and methotrexate in rheumatoid arthritis.;Q422232;P2175;Q170990
Elevated level of serum cystatin-C concentration is a useful predictor for myelosuppression induced by methotrexate for treatment of rheumatoid arthritis.;Q422232;P2175;Q170990
Elevated level of serum cystatin-C concentration is a useful predictor for myelosuppression induced by methotrexate for treatment of rheumatoid arthritis.;Q422232;P2175;Q187255
Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine;Q238512;P2175;Q128581
Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine;Q422232;P2175;Q128581
Synergy of methotrexate and 6-mercaptopurine on cell growth and clonogenicity of cultured human T-lymphoblasts;Q183290;P703;Q15978631
Synergy of methotrexate and 6-mercaptopurine on cell growth and clonogenicity of cultured human T-lymphoblasts;Q186521;P703;Q15978631
N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.;Q186474;P703;Q15978631
N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.;Q127060;P703;Q15978631
N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.;Q422232;P2175;Q29496
N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.;Q422232;P2868;Q127060
Smilax glabra Rhizoma affects the pharmacokinetics and tissue distribution of methotrexate by increasing the Pglycoprotein mRNA expression in rats after oral administration.;Q422232;P636;Q285166
Liver biopsy with the use of methotrexate for juvenile rheumatoid arthritis.;Q422232;P2175;Q187255
Liver biopsy with the use of methotrexate for juvenile rheumatoid arthritis.;Q422232;P2175;Q861224
Liver biopsy with the use of methotrexate for juvenile rheumatoid arthritis.;Q422232;P2175;Q170990
Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-nave Japanese patients with rheumatoid arthritis: A sub-analysis of the Phase 3 SELECT-EARLY study;Q422232;P2175;Q170990
Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-nave Japanese patients with rheumatoid arthritis: A sub-analysis of the Phase 3 SELECT-EARLY study;Q422232;P2175;Q187255
Real-world utilization of methotrexate or prednisone co-therapy with etanercept among Canadian patients with rheumatoid arthritis: a retrospective cohort study;Q424972;P2175;Q170990
Real-world utilization of methotrexate or prednisone co-therapy with etanercept among Canadian patients with rheumatoid arthritis: a retrospective cohort study;Q422232;P2175;Q170990
Real-world utilization of methotrexate or prednisone co-therapy with etanercept among Canadian patients with rheumatoid arthritis: a retrospective cohort study;Q422232;P2175;Q187255
Methotrexate, cytosine arabinoside, and BCNU concentration in brain after ventriculocisternal perfusion.;Q186474;P1889;Q178425
Methotrexate, cytosine arabinoside, and BCNU concentration in brain after ventriculocisternal perfusion.;Q422232;P636;Q640448
Small cell osteosarcoma successfully treated by high-dose ifosfamide and methotrexate, combined with carboplatin and pirarubicin;Q415588;P2175;Q549534
Small cell osteosarcoma successfully treated by high-dose ifosfamide and methotrexate, combined with carboplatin and pirarubicin;Q422232;P2175;Q549534
[Treatment results in children with the standard risk acute lymphoblastic leukemia treated with high dose of methotrexate (5.0 g/m2). 11 years of the Polish Pediatric Leukemia/Lymphoma Study Group experience];Q422232;P2175;Q29496
[Treatment results in children with the standard risk acute lymphoblastic leukemia treated with high dose of methotrexate (5.0 g/m2). 11 years of the Polish Pediatric Leukemia/Lymphoma Study Group experience];Q422232;P2175;Q208414
Biased assessment of blinding in a randomized placebo-controlled trial of oral methotrexate in chronic progressive multiple sclerosis.;Q422232;P636;Q285166
[Serious neurological syndrome observed after first intraspinal administration of methotrexate in a child with acute lymphatic leukemia];Q422232;P2175;Q29496
Making rational treatment decisions in rheumatoid arthritis when methotrexate fails.;Q422232;P2175;Q170990
Making rational treatment decisions in rheumatoid arthritis when methotrexate fails.;Q422232;P2175;Q187255
[Case of central nervous system lymphoma metastasized to breast after remission by methotrexate chemotherapy].;Q422232;P2175;Q136312
[Case of central nervous system lymphoma metastasized to breast after remission by methotrexate chemotherapy].;Q422232;P2175;Q208414
Race and methotrexate pharmacogenetics in rheumatoid arthritis.;Q422232;P2175;Q187255
Race and methotrexate pharmacogenetics in rheumatoid arthritis.;Q422232;P2175;Q170990
Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?;Q218642;P31;Q12140
Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?;Q186474;P31;Q12140
Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?;Q191924;P31;Q12140
Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?;Q173670;P31;Q12140
Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?;Q3530324;P31;Q12140
Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?;Q3530324;P2175;Q170990
Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?;Q422232;P31;Q12140
Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?;Q422232;P636;Q285166
Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?;Q422232;P2175;Q170990
Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?;Q422232;P2175;Q187255
Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?;Q422232;P361;Q14819383
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab.;Q348260;P2175;Q170990
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab.;Q348260;P2175;Q187255
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab.;Q422232;P2175;Q170990
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab.;Q422232;P2175;Q187255
Comparative studies of quality and bioavailability of methotrexate in Thai patients with rheumatoid arthritis;Q422232;P2175;Q170990
Comparative studies of quality and bioavailability of methotrexate in Thai patients with rheumatoid arthritis;Q422232;P2175;Q187255
Methylene tetrahydrofolate reductase genotypes frequencies: association with toxicity and response to methotrexate in rheumatoid arthritis patients.;Q422232;P361;Q14819383
Methylene tetrahydrofolate reductase genotypes frequencies: association with toxicity and response to methotrexate in rheumatoid arthritis patients.;Q422232;P2175;Q187255
Methylene tetrahydrofolate reductase genotypes frequencies: association with toxicity and response to methotrexate in rheumatoid arthritis patients.;Q422232;P2175;Q170990
[Methotrexate for therapy of rheumatoid arthritis].;Q422232;P2175;Q187255
[Methotrexate for therapy of rheumatoid arthritis].;Q422232;P2175;Q170990
Chronic hepatitis E in a patient with rheumatoid arthritis treated with adalimumab and methotrexate;Q348260;P2175;Q187255
Chronic hepatitis E in a patient with rheumatoid arthritis treated with adalimumab and methotrexate;Q348260;P2175;Q170990
Chronic hepatitis E in a patient with rheumatoid arthritis treated with adalimumab and methotrexate;Q422232;P2175;Q170990
Chronic hepatitis E in a patient with rheumatoid arthritis treated with adalimumab and methotrexate;Q422232;P2175;Q187255
High-dose methotrexate and HELP [Holoxan (ifosfamide), eldesine (vindesine), platinum]--doxorubicin in non-metastatic osteosarcoma of the extremity: a French multicentre pilot study. Fdration Nationale des Centres de Lutte contre le Cancer and Soc;Q422232;P2175;Q549534
Cirrhosis following prolonged treatment of psoriasis with methotrexate orally.;Q422232;P636;Q285166
Combined chemotherapy for head and neck cancer using cisplatin, methotrexate and continuous subcutaneous infusion of peplomycin;Q412415;P2175;Q1783924
Combined chemotherapy for head and neck cancer using cisplatin, methotrexate and continuous subcutaneous infusion of peplomycin;Q422232;P2175;Q1783924
An 19F magnetic resonance-based in vivo assay of solid tumor methotrexate resistance: proof of principle.;Q218642;P703;Q2046782
Successful treatment of extranodal natural killer/T-cell lymphoma, nasal type, complicated by severe hemophagocytic syndrome, with dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide chemotherapy followed by autologous stem cell t;Q418817;P2175;Q208414
Successful treatment of extranodal natural killer/T-cell lymphoma, nasal type, complicated by severe hemophagocytic syndrome, with dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide chemotherapy followed by autologous stem cell t;Q422252;P2175;Q208414
Successful treatment of extranodal natural killer/T-cell lymphoma, nasal type, complicated by severe hemophagocytic syndrome, with dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide chemotherapy followed by autologous stem cell t;Q422232;P2175;Q7667896
Successful treatment of extranodal natural killer/T-cell lymphoma, nasal type, complicated by severe hemophagocytic syndrome, with dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide chemotherapy followed by autologous stem cell t;Q422232;P2175;Q208414
Early therapeutic intervention with methotrexate prevents the development of rheumatoid arthritis in patients with recent-onset undifferentiated arthritis: A prospective cohort study.;Q218642;P703;Q177932
Early therapeutic intervention with methotrexate prevents the development of rheumatoid arthritis in patients with recent-onset undifferentiated arthritis: A prospective cohort study.;Q422232;P2175;Q187255
Early therapeutic intervention with methotrexate prevents the development of rheumatoid arthritis in patients with recent-onset undifferentiated arthritis: A prospective cohort study.;Q422232;P2175;Q170990
The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer;Q238512;P2175;Q128581
The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer;Q11426176;P2175;Q12078
The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer;Q422232;P2175;Q128581
Hydroxyurea, methotrexate and adriblastine can mediate non-enzymatic reduction of nitroblue tetrazolium with NADH which is inhibited by superoxide dismutase.;Q212272;P279;Q48318
Serious pancytopenia from methotrexate treatment of psoriatic arthritis;Q422232;P2175;Q170990
[Treatment of childhood non-Hodgkin's lymphoma with a multi-drug combination protocol including high-dose methotrexate and citrovorum factor rescue. Children's Cancer and Leukemia Study group];Q183290;P31;Q12140
[Treatment of childhood non-Hodgkin's lymphoma with a multi-drug combination protocol including high-dose methotrexate and citrovorum factor rescue. Children's Cancer and Leukemia Study group];Q186474;P31;Q12140
[Treatment of childhood non-Hodgkin's lymphoma with a multi-drug combination protocol including high-dose methotrexate and citrovorum factor rescue. Children's Cancer and Leukemia Study group];Q186521;P31;Q12140
[Treatment of childhood non-Hodgkin's lymphoma with a multi-drug combination protocol including high-dose methotrexate and citrovorum factor rescue. Children's Cancer and Leukemia Study group];Q191924;P31;Q12140
[Treatment of childhood non-Hodgkin's lymphoma with a multi-drug combination protocol including high-dose methotrexate and citrovorum factor rescue. Children's Cancer and Leukemia Study group];Q485277;P31;Q12140
[Treatment of childhood non-Hodgkin's lymphoma with a multi-drug combination protocol including high-dose methotrexate and citrovorum factor rescue. Children's Cancer and Leukemia Study group];Q483745;P31;Q12140
[Treatment of childhood non-Hodgkin's lymphoma with a multi-drug combination protocol including high-dose methotrexate and citrovorum factor rescue. Children's Cancer and Leukemia Study group];Q422232;P31;Q12140
[Treatment of childhood non-Hodgkin's lymphoma with a multi-drug combination protocol including high-dose methotrexate and citrovorum factor rescue. Children's Cancer and Leukemia Study group];Q422232;P2175;Q1138590
[Treatment of childhood non-Hodgkin's lymphoma with a multi-drug combination protocol including high-dose methotrexate and citrovorum factor rescue. Children's Cancer and Leukemia Study group];Q422232;P2175;Q208414
3'-Azido 3'-deoxythymidine + methotrexate as a novel antineoplastic combination in the treatment of human immunodeficiency virus-related non-Hodgkin's lymphomas.;Q218642;P703;Q15978631
3'-Azido 3'-deoxythymidine + methotrexate as a novel antineoplastic combination in the treatment of human immunodeficiency virus-related non-Hodgkin's lymphomas.;Q485277;P703;Q15978631
3'-Azido 3'-deoxythymidine + methotrexate as a novel antineoplastic combination in the treatment of human immunodeficiency virus-related non-Hodgkin's lymphomas.;Q422232;P2175;Q208414
3'-Azido 3'-deoxythymidine + methotrexate as a novel antineoplastic combination in the treatment of human immunodeficiency virus-related non-Hodgkin's lymphomas.;Q422232;P2175;Q1138590
Methotrexate with citrovorum factor rescue for gestational trophoblastic neoplasms.;Q422232;P2175;Q7845637
Simultaneous detection of folic acid and methotrexate by an optical sensor based on molecularly imprinted polymers on dual-color CdTe quantum dots.;Q422232;P2868;Q127060
[Combined basic therapy of rheumatoid arthritis with methotrexate and plaquenil];Q422232;P2175;Q170990
[Combined basic therapy of rheumatoid arthritis with methotrexate and plaquenil];Q422232;P2175;Q187255
Circulating CD19+CD24hiCD38hi regulatory B cells as biomarkers of response to methotrexate in early rheumatoid arthritis;Q422232;P2175;Q170990
Circulating CD19+CD24hiCD38hi regulatory B cells as biomarkers of response to methotrexate in early rheumatoid arthritis;Q422232;P2175;Q187255
Circulating CD19+CD24hiCD38hi regulatory B cells as biomarkers of response to methotrexate in early rheumatoid arthritis;Q422232;P361;Q14819383
Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer.;Q422232;P2175;Q128581
Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone;Q248550;P2175;Q170990
Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone;Q248550;P2175;Q187255
Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone;Q424972;P2175;Q170990
Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone;Q422232;P2175;Q187255
Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone;Q422232;P2175;Q170990
Sinusoidal Obstruction Syndrome During Maintenance Therapy for Acute Lymphoblastic Leukemia With 6-Mercaptopurine and Methotrexate: A Pediatric Case Report.;Q218642;P703;Q2046782
Sinusoidal Obstruction Syndrome During Maintenance Therapy for Acute Lymphoblastic Leukemia With 6-Mercaptopurine and Methotrexate: A Pediatric Case Report.;Q178450;P703;Q2046782
TNF blockers followed by continuation of sulfasalazine and methotrexate combination: a retrospective study on cost saving options of treatment in Spondyloarthritis.;Q420035;P2175;Q170990
TNF blockers followed by continuation of sulfasalazine and methotrexate combination: a retrospective study on cost saving options of treatment in Spondyloarthritis.;Q422232;P2175;Q170990
Methotrexate does not primarily affect Foxp3+ regulatory T cells in poly-articular juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Methotrexate does not primarily affect Foxp3+ regulatory T cells in poly-articular juvenile idiopathic arthritis.;Q422232;P2175;Q170990
Yellow fever vaccine used in a psoriatic arthritis patient treated with methotrexate: a case report.;Q422232;P2175;Q170990
The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritis;Q420035;P2175;Q170990
The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritis;Q420035;P2175;Q187255
The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritis;Q421094;P2175;Q187255
The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritis;Q421094;P1889;Q422438
The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritis;Q421094;P2175;Q170990
The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritis;Q422438;P1889;Q421094
The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritis;Q422438;P2175;Q187255
The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritis;Q422232;P2175;Q187255
The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritis;Q422232;P2175;Q170990
Cisplatin, bleomycin, and methotrexate (PBM) chemotherapy in locally advanced and metastatic head and neck cancer.;Q422232;P2175;Q1783924
Bi-directional effects of vitamin B12 and methotrexate on Daphnia magna fitness and genomic methylation.;Q83187;P2868;Q183206
Bi-directional effects of vitamin B12 and methotrexate on Daphnia magna fitness and genomic methylation.;Q83187;P361;Q27115611
The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients;Q422232;P2175;Q170990
The effect of methotrexate on tumour necrosis factor concentrations in etanercept-treated rheumatoid arthritis patients;Q422232;P2175;Q187255
[A case of multidrug-resistant breast cancer associated with multiple hepatic and bone metastases for which cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy proved effective].;Q218642;P31;Q12140
[A case of multidrug-resistant breast cancer associated with multiple hepatic and bone metastases for which cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy proved effective].;Q191924;P31;Q12140
[A case of multidrug-resistant breast cancer associated with multiple hepatic and bone metastases for which cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy proved effective].;Q238512;P31;Q12140
[A case of multidrug-resistant breast cancer associated with multiple hepatic and bone metastases for which cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy proved effective].;Q238512;P2175;Q128581
[A case of multidrug-resistant breast cancer associated with multiple hepatic and bone metastases for which cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy proved effective].;Q422232;P31;Q12140
[A case of multidrug-resistant breast cancer associated with multiple hepatic and bone metastases for which cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy proved effective].;Q422232;P2175;Q128581
[Effects of zhengqing fengtongning tablet and methotrexate on the serum OPG/RANKL and IL-17 of collagen-induced arthritis rats].;Q620730;P361;Q26868
[Effects of zhengqing fengtongning tablet and methotrexate on the serum OPG/RANKL and IL-17 of collagen-induced arthritis rats].;Q422232;P2175;Q170990
Antimetabolite Therapy for Uveitis: Methotrexate or Mycophenolate?;Q218642;P31;Q407595
Antimetabolite Therapy for Uveitis: Methotrexate or Mycophenolate?;Q130336;P4149;Q27122100
Antimetabolite Therapy for Uveitis: Methotrexate or Mycophenolate?;Q130336;P31;Q407142
Antimetabolite Therapy for Uveitis: Methotrexate or Mycophenolate?;Q422232;P2175;Q280027
Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis;Q422232;P2175;Q208414
Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis;Q422232;P2175;Q1138590
Pulmonary lymphoma developed during long-term methotrexate therapy for psoriasis;Q422232;P2175;Q208414
[Severe pneumonitis as a complication of low-dose methotrexate therapy in psoriasis-associated polyarthritis];Q422232;P2175;Q1274464
[Severe pneumonitis as a complication of low-dose methotrexate therapy in psoriasis-associated polyarthritis];Q422232;P2175;Q170990
Immunologic heterogeneity of dihydrofolate reductase from methotrexate sensitive and resistant L1210 leukemia cells.;Q422232;P2175;Q29496
Response to "Letter to the editor RE: "Conservative management of 11 weeks old cervical ectopic pregnancy with transvaginal ultrasound-guided combined methotrexate injection: Case report and literature review"";Q422232;P2175;Q207087
[A case report: postoperative recurrence of peritoneal dissemination of gastric cancer responding to sequential methotrexate and 5-FU (5-fluorouracil)];Q238512;P2175;Q189588
[A case report: postoperative recurrence of peritoneal dissemination of gastric cancer responding to sequential methotrexate and 5-FU (5-fluorouracil)];Q422232;P2175;Q189588
[Combination therapy using methotrexate with DMARDs or biologics--current status];Q422232;P2868;Q810254
Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia.;Q218642;P703;Q2046782
Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia.;Q408977;P2175;Q29496
Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia.;Q408977;P2175;Q18553852
Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia.;Q422232;P2175;Q29496
Folate binding protein: therapeutic natural nanotechnology for folic acid, methotrexate, and leucovorin.;Q127060;P703;Q177932
Folate binding protein: therapeutic natural nanotechnology for folic acid, methotrexate, and leucovorin.;Q483745;P703;Q177932
Folate binding protein: therapeutic natural nanotechnology for folic acid, methotrexate, and leucovorin.;Q422232;P2868;Q127060
[Methylenetetrahydrofolate reductase polymorphisms in methotrexate treatment of rheumatoid arthritis patients. Review of the literature and personal experience.];Q422232;P2175;Q170990
[Methylenetetrahydrofolate reductase polymorphisms in methotrexate treatment of rheumatoid arthritis patients. Review of the literature and personal experience.];Q422232;P2175;Q187255
Enteric-coated mycophenolate sodium could be an alternative to methotrexate for GVHD prophylaxis;Q130336;P4149;Q27122100
Enteric-coated mycophenolate sodium could be an alternative to methotrexate for GVHD prophylaxis;Q130336;P31;Q407142
Corticosteroids and methotrexate as adjuvants to costimulation blockade in non-human primate renal transplantation;Q186474;P703;Q15978631
Monitoring of Epstein-Barr virus load and killer T cells in patients with juvenile idiopathic arthritis treated with methotrexate or tocilizumab.;Q425154;P2175;Q170990
Monitoring of Epstein-Barr virus load and killer T cells in patients with juvenile idiopathic arthritis treated with methotrexate or tocilizumab.;Q422232;P2175;Q861224
Monitoring of Epstein-Barr virus load and killer T cells in patients with juvenile idiopathic arthritis treated with methotrexate or tocilizumab.;Q422232;P2175;Q170990
High-dose chemotherapy with autologous stem cell transplantation following systemic chemotherapy, prophylactic intrathecal methotrexate, and radiotherapy prevents relapse and improves the outcome of advanced stage primary testicular lymphoma even wi;Q422232;P2175;Q208414
High-dose chemotherapy with autologous stem cell transplantation following systemic chemotherapy, prophylactic intrathecal methotrexate, and radiotherapy prevents relapse and improves the outcome of advanced stage primary testicular lymphoma even wi;Q422232;P636;Q1320251
Response to low-dose oral methotrexate and prednisone in two patients with angio-immunoblastic lymphadenopathy-type T-cell lymphoma.;Q422232;P2175;Q7667896
Response to low-dose oral methotrexate and prednisone in two patients with angio-immunoblastic lymphadenopathy-type T-cell lymphoma.;Q422232;P636;Q285166
Response to low-dose oral methotrexate and prednisone in two patients with angio-immunoblastic lymphadenopathy-type T-cell lymphoma.;Q422232;P2175;Q208414
Anti inflammatory effect of thymoquinone in comparison with methotrexate on pristane induced arthritis in rats.;Q422232;P2175;Q170990
Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.;Q412415;P2175;Q18348812
Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.;Q238512;P2175;Q18348812
Preirradiation chemotherapy including "eight drugs in 1 day" regimen and high-dose methotrexate in childhood medulloblastoma: results of the M7 French Cooperative Study.;Q183290;P31;Q12140
Preirradiation chemotherapy including "eight drugs in 1 day" regimen and high-dose methotrexate in childhood medulloblastoma: results of the M7 French Cooperative Study.;Q186474;P31;Q12140
Preirradiation chemotherapy including "eight drugs in 1 day" regimen and high-dose methotrexate in childhood medulloblastoma: results of the M7 French Cooperative Study.;Q191924;P366;Q8386
Preirradiation chemotherapy including "eight drugs in 1 day" regimen and high-dose methotrexate in childhood medulloblastoma: results of the M7 French Cooperative Study.;Q170545;P31;Q12140
Preirradiation chemotherapy including "eight drugs in 1 day" regimen and high-dose methotrexate in childhood medulloblastoma: results of the M7 French Cooperative Study.;Q20035886;P31;Q12140
Preirradiation chemotherapy including "eight drugs in 1 day" regimen and high-dose methotrexate in childhood medulloblastoma: results of the M7 French Cooperative Study.;Q22124685;P31;Q12140
Preirradiation chemotherapy including "eight drugs in 1 day" regimen and high-dose methotrexate in childhood medulloblastoma: results of the M7 French Cooperative Study.;Q422232;P31;Q12140
Is the combination of mitomycin C, bleomycin and methotrexate effective as a neoadjuvant treatment for cervical cancer in women?;Q19856779;P1889;Q417625
Cost-effectiveness of biological therapy compared with methotrexate in the treatment for rheumatoid arthritis in Colombia.;Q422232;P2175;Q170990
Cost-effectiveness of biological therapy compared with methotrexate in the treatment for rheumatoid arthritis in Colombia.;Q422232;P2175;Q187255
Controlled trial of methotrexate and Bacillus Calmette-Gurin therapy for advanced head and neck cancer.;Q422232;P2175;Q1783924
Monitoring recommendations for oral azathioprine, methotrexate and cyclosporin in a paediatric dermatology clinic and literature review.;Q422232;P636;Q285166
[An alternative therapy in a patient with rheumatoid arthritis with no possibility of treatment with methotrexate as a result of a toxic syndrome due to colza oil];Q422232;P2175;Q170990
[An alternative therapy in a patient with rheumatoid arthritis with no possibility of treatment with methotrexate as a result of a toxic syndrome due to colza oil];Q422232;P2175;Q187255
Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis.;Q248550;P2175;Q187255
Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis.;Q248550;P2175;Q170990
Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis.;Q422232;P2175;Q187255
Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis.;Q422232;P2175;Q170990
Serum soluble interleukin-2 receptor levels in rheumatoid arthritis: effect of methotrexate, sulphasalazine and hydroxychloroquine therapy.;Q421094;P2175;Q187255
Serum soluble interleukin-2 receptor levels in rheumatoid arthritis: effect of methotrexate, sulphasalazine and hydroxychloroquine therapy.;Q421094;P2175;Q170990
Serum soluble interleukin-2 receptor levels in rheumatoid arthritis: effect of methotrexate, sulphasalazine and hydroxychloroquine therapy.;Q421094;P1889;Q422438
Serum soluble interleukin-2 receptor levels in rheumatoid arthritis: effect of methotrexate, sulphasalazine and hydroxychloroquine therapy.;Q422438;P2175;Q187255
Serum soluble interleukin-2 receptor levels in rheumatoid arthritis: effect of methotrexate, sulphasalazine and hydroxychloroquine therapy.;Q422438;P1889;Q421094
Serum soluble interleukin-2 receptor levels in rheumatoid arthritis: effect of methotrexate, sulphasalazine and hydroxychloroquine therapy.;Q422232;P2175;Q170990
Serum soluble interleukin-2 receptor levels in rheumatoid arthritis: effect of methotrexate, sulphasalazine and hydroxychloroquine therapy.;Q422232;P2175;Q187255
[Efficacy, side effects and blood concentration monitoring of high-dose methotrexate in treatment of 180 children with acute lymphoblastic leukemia].;Q422232;P2175;Q29496
Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells.;Q218642;P703;Q15978631
Methotrexate in rheumatoid arthritis: when NSAIDs fail.;Q422232;P2175;Q170990
Methotrexate in rheumatoid arthritis: when NSAIDs fail.;Q422232;P2175;Q187255
Methotrexate and gamma-tert-butyl methotrexate transport in CEM and CEM/MTX human leukemic lymphoblasts.;Q186474;P703;Q15978631
Methotrexate and gamma-tert-butyl methotrexate transport in CEM and CEM/MTX human leukemic lymphoblasts.;Q186521;P703;Q15978631
Methotrexate and gamma-tert-butyl methotrexate transport in CEM and CEM/MTX human leukemic lymphoblasts.;Q22124685;P703;Q15978631
Creating a care-effective cost-effective strategy for methotrexate liver toxicity monitoring in rheumatoid arthritis: comment on the article by Kremer et al;Q422232;P2175;Q187255
Creating a care-effective cost-effective strategy for methotrexate liver toxicity monitoring in rheumatoid arthritis: comment on the article by Kremer et al;Q422232;P2175;Q170990
Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study.;Q248550;P2175;Q187255
Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study.;Q248550;P2175;Q170990
Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study.;Q415411;P2175;Q187255
Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study.;Q422232;P2175;Q170990
Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study.;Q422232;P2175;Q187255
Acute respiratory failure after intrathecal methotrexate administration.;Q422232;P636;Q1320251
Hispanic ethnicity is associated with prolonged clearance of high dose methotrexate and severe nephrotoxicity in children and adolescents with acute lymphoblastic leukemia;Q422232;P2175;Q29496
Efficacy and survival of golimumab with and without methotrexate in patients with psoriatic arthritis: A retrospective study from daily clinical practice;Q413879;P2175;Q170990
Efficacy and survival of golimumab with and without methotrexate in patients with psoriatic arthritis: A retrospective study from daily clinical practice;Q422232;P2175;Q170990
Cell-kinetics and biochemical pharmacology of methotrexate and 6-mercaptopurine in human malignant T-lymphoblasts.;Q186474;P703;Q15978631
Cell-kinetics and biochemical pharmacology of methotrexate and 6-mercaptopurine in human malignant T-lymphoblasts.;Q186521;P703;Q15978631
Successful management of a rudimentary uterine horn ectopic pregnancy by combining methotrexate and surgery: A case report;Q422232;P2175;Q207087
Concomitant methotrexate has little effect on clinical outcomes of abatacept in rheumatoid arthritis: a propensity score matching analysis;Q422232;P2175;Q187255
Concomitant methotrexate has little effect on clinical outcomes of abatacept in rheumatoid arthritis: a propensity score matching analysis;Q422232;P2175;Q170990
Stroke-like encephalopathy following high-dose intravenous methotrexate in an adolescent with osteosarcoma: a case report.;Q422232;P2175;Q549534
Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study.;Q422232;P636;Q285166
Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study.;Q422232;P2175;Q170990
Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study.;Q422232;P2175;Q1274464
The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors.;Q130336;P31;Q407142
The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors.;Q130336;P4149;Q27122100
Azathioprine and methotrexate as combination chemotherapy in rheumatoid arthritis.;Q18939;P2175;Q187255
Azathioprine and methotrexate as combination chemotherapy in rheumatoid arthritis.;Q422232;P2175;Q187255
Azathioprine and methotrexate as combination chemotherapy in rheumatoid arthritis.;Q422232;P2175;Q170990
Multimodal biochemical modulation of 5-fluorouracil by leucovorin, methotrexate, and interferon alpha in patients with advanced colorectal cancer;Q238512;P2175;Q2739660
In vitro transport of methotrexate by Drosophila Multidrug Resistance-associated Protein;Q191924;P31;Q12140
In vitro transport of methotrexate by Drosophila Multidrug Resistance-associated Protein;Q173670;P31;Q12140
In vitro transport of methotrexate by Drosophila Multidrug Resistance-associated Protein;Q178450;P31;Q12140
In vitro transport of methotrexate by Drosophila Multidrug Resistance-associated Protein;Q20035886;P31;Q12140
In vitro transport of methotrexate by Drosophila Multidrug Resistance-associated Protein;Q22124685;P31;Q12140
In vitro transport of methotrexate by Drosophila Multidrug Resistance-associated Protein;Q484940;P31;Q12140
In vitro transport of methotrexate by Drosophila Multidrug Resistance-associated Protein;Q422232;P31;Q12140
Magnetic- and pH-responsive -carrageenan/chitosan complexes for controlled release of methotrexate anticancer drug.;Q191924;P31;Q12140
Magnetic- and pH-responsive -carrageenan/chitosan complexes for controlled release of methotrexate anticancer drug.;Q485277;P31;Q12140
Magnetic- and pH-responsive -carrageenan/chitosan complexes for controlled release of methotrexate anticancer drug.;Q22124685;P31;Q12140
Magnetic- and pH-responsive -carrageenan/chitosan complexes for controlled release of methotrexate anticancer drug.;Q422232;P31;Q12140
Selective intraperitoneal biochemical modulation of methotrexate by dipyridamole.;Q183290;P703;Q177932
Tuberculosis of the tongue in a patient with rheumatoid arthritis treated with methotrexate and adalimumab.;Q348260;P2175;Q170990
Tuberculosis of the tongue in a patient with rheumatoid arthritis treated with methotrexate and adalimumab.;Q348260;P2175;Q187255
Tuberculosis of the tongue in a patient with rheumatoid arthritis treated with methotrexate and adalimumab.;Q422232;P2175;Q187255
Tuberculosis of the tongue in a patient with rheumatoid arthritis treated with methotrexate and adalimumab.;Q422232;P2175;Q170990
Oral Methods of Urinary Alkalinization for High-dose Methotrexate Administration: Alternatives to Intravenous Sodium Bicarbonate During a Critical Drug Shortage;Q218642;P527;Q623
Oral Methods of Urinary Alkalinization for High-dose Methotrexate Administration: Alternatives to Intravenous Sodium Bicarbonate During a Critical Drug Shortage;Q183290;P527;Q623
Oral Methods of Urinary Alkalinization for High-dose Methotrexate Administration: Alternatives to Intravenous Sodium Bicarbonate During a Critical Drug Shortage;Q186474;P527;Q623
Oral Methods of Urinary Alkalinization for High-dose Methotrexate Administration: Alternatives to Intravenous Sodium Bicarbonate During a Critical Drug Shortage;Q485277;P527;Q623
Oral Methods of Urinary Alkalinization for High-dose Methotrexate Administration: Alternatives to Intravenous Sodium Bicarbonate During a Critical Drug Shortage;Q179731;P527;Q623
Oral Methods of Urinary Alkalinization for High-dose Methotrexate Administration: Alternatives to Intravenous Sodium Bicarbonate During a Critical Drug Shortage;Q178450;P527;Q623
Oral Methods of Urinary Alkalinization for High-dose Methotrexate Administration: Alternatives to Intravenous Sodium Bicarbonate During a Critical Drug Shortage;Q484940;P527;Q623
Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials.;Q422232;P361;Q14819383
Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial.;Q425154;P2175;Q170990
Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial.;Q422232;P2175;Q187255
Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial.;Q422232;P2175;Q170990
Traditional herbal medicines (Kampo) for patients with rheumatoid arthritis receiving concomitant methotrexate: a preliminary study.;Q186521;P31;Q12140
Traditional herbal medicines (Kampo) for patients with rheumatoid arthritis receiving concomitant methotrexate: a preliminary study.;Q191924;P31;Q12140
Traditional herbal medicines (Kampo) for patients with rheumatoid arthritis receiving concomitant methotrexate: a preliminary study.;Q20816880;P31;Q12140
Traditional herbal medicines (Kampo) for patients with rheumatoid arthritis receiving concomitant methotrexate: a preliminary study.;Q422232;P31;Q12140
Traditional herbal medicines (Kampo) for patients with rheumatoid arthritis receiving concomitant methotrexate: a preliminary study.;Q422232;P2175;Q187255
Traditional herbal medicines (Kampo) for patients with rheumatoid arthritis receiving concomitant methotrexate: a preliminary study.;Q422232;P2175;Q170990
Topical methotrexate alters solute and water transport in the rat jejunum in vivo and rabbit ileum in vitro.;Q29053744;P366;Q7892
Topical methotrexate alters solute and water transport in the rat jejunum in vivo and rabbit ileum in vitro.;Q29053744;P361;Q14820652
Intrinsic resistance to methotrexate in human soft tissue sarcoma cell lines.;Q484940;P703;Q15978631
Will nanobiosensors change therapeutic drug monitoring? The case of methotrexate;Q181003;P31;Q12140
Will nanobiosensors change therapeutic drug monitoring? The case of methotrexate;Q186521;P31;Q12140
Will nanobiosensors change therapeutic drug monitoring? The case of methotrexate;Q186521;P703;Q177932
Will nanobiosensors change therapeutic drug monitoring? The case of methotrexate;Q191924;P366;Q8386
Will nanobiosensors change therapeutic drug monitoring? The case of methotrexate;Q422232;P31;Q12140
Suppression of collagen-induced arthritis by combination cyclosporin A and methotrexate therapy.;Q422232;P2175;Q170990
Cathechol-O-methyltransferase Val158Met polymorphism is associated with nocebo effects, but not with methotrexate intolerance in patients with juvenile idiopathic arthritis.;Q422232;P2175;Q170990
Cathechol-O-methyltransferase Val158Met polymorphism is associated with nocebo effects, but not with methotrexate intolerance in patients with juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Neurotoxicity with leukoencephalopathy after a single intravenous high dose of methotrexate in a patient with lymphoma.;Q422232;P2175;Q208414
Dietary polyphenols influence antimetabolite agents: methotrexate, 6-mercaptopurine and 5-fluorouracil in leukemia cell lines.;Q130336;P31;Q407142
Dietary polyphenols influence antimetabolite agents: methotrexate, 6-mercaptopurine and 5-fluorouracil in leukemia cell lines.;Q238512;P2868;Q50429865
Dietary polyphenols influence antimetabolite agents: methotrexate, 6-mercaptopurine and 5-fluorouracil in leukemia cell lines.;Q418529;P2868;Q50429865
Dietary polyphenols influence antimetabolite agents: methotrexate, 6-mercaptopurine and 5-fluorouracil in leukemia cell lines.;Q422232;P2175;Q29496
[Extra-articular manifestations of rheumatoid arthritis at the time of basic methotrexate treatment: apropos of a case of nodulosis with pericarditis];Q422232;P2175;Q187255
[Extra-articular manifestations of rheumatoid arthritis at the time of basic methotrexate treatment: apropos of a case of nodulosis with pericarditis];Q422232;P2175;Q170990
Direct cost of single dose methotrexate for unruptured ectopic pregnancy. Prospective comparison with laparoscopy.;Q422232;P2175;Q207087
Evaluation of a follow-up customized strategy for women treated with methotrexate for an ectopic pregnancy: An observational study;Q422232;P2175;Q207087
Determination of methotrexate in spiked human urine using SERS-active sorbent;Q183290;P703;Q15978631
Determination of methotrexate in spiked human urine using SERS-active sorbent;Q173670;P703;Q15978631
Determination of methotrexate in spiked human urine using SERS-active sorbent;Q178450;P703;Q15978631
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery;Q422232;P2175;Q2626074
The correlation between dose of folinic acid and neurotoxicity in children and adolescents treated for osteosarcoma with high-dose methotrexate (HDMTX): a neuropsychological and psychosocial study.;Q191924;P2868;Q407752
The correlation between dose of folinic acid and neurotoxicity in children and adolescents treated for osteosarcoma with high-dose methotrexate (HDMTX): a neuropsychological and psychosocial study.;Q422232;P2175;Q549534
Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).;Q412323;P2175;Q208414
Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).;Q412323;P2175;Q136312
Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).;Q422232;P2175;Q136312
Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).;Q422232;P2175;Q208414
Pre- and post-treatment patterns of human chorionic gonadotropin for early detection of persistence after a single dose of methotrexate for ectopic pregnancy;Q407172;P703;Q15978631
Pre- and post-treatment patterns of human chorionic gonadotropin for early detection of persistence after a single dose of methotrexate for ectopic pregnancy;Q407172;P279;Q409770
Pre- and post-treatment patterns of human chorionic gonadotropin for early detection of persistence after a single dose of methotrexate for ectopic pregnancy;Q20035886;P703;Q15978631
Pre- and post-treatment patterns of human chorionic gonadotropin for early detection of persistence after a single dose of methotrexate for ectopic pregnancy;Q422232;P2175;Q207087
Favorable outcomes and reduced toxicity with a novel vinblastine-based non-high dose methotrexate (HDMTX) regimen (modified MCP-842) in pediatric anaplastic large cell lymphoma (ALCL): experience from India;Q422232;P2175;Q208414
[Protective effect of mutant dihydrofolate reductase gene on human peripheral blood CD34+ cells against methotrexate];Q186474;P703;Q15978631
[Protective effect of mutant dihydrofolate reductase gene on human peripheral blood CD34+ cells against methotrexate];Q178450;P703;Q15978631
[Protective effect of mutant dihydrofolate reductase gene on human peripheral blood CD34+ cells against methotrexate];Q20035886;P703;Q15978631
High energy shock waves enhance the cytotoxic effect of doxorubicin and methotrexate to human osteosarcoma cell lines.;Q485277;P703;Q15978631
High energy shock waves enhance the cytotoxic effect of doxorubicin and methotrexate to human osteosarcoma cell lines.;Q422232;P2175;Q549534
[Listeria arthritis in chronic polyarthritis during low dose prednisolone and methotrexate therapy. Case report and review of the literature].;Q422232;P2175;Q170990
[Listeria arthritis in chronic polyarthritis during low dose prednisolone and methotrexate therapy. Case report and review of the literature].;Q422232;P2175;Q1274464
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter study.;Q239426;P2175;Q128581
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter study.;Q238512;P2175;Q128581
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter study.;Q422232;P2175;Q128581
Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma.;Q422232;P2175;Q549534
Repeated infusions of low-dose infliximab plus methotrexate in psoriatic arthritis: immediate benefits are not maintained after discontinuation of infliximab.;Q415264;P2175;Q170990
Repeated infusions of low-dose infliximab plus methotrexate in psoriatic arthritis: immediate benefits are not maintained after discontinuation of infliximab.;Q422232;P2175;Q170990
No benefit of the combination therapy etanercept and methotrexate compared to etanercept mono therapy in juvenile idiopathic arthritis  a matched pair analysis.;Q422232;P2175;Q170990
No benefit of the combination therapy etanercept and methotrexate compared to etanercept mono therapy in juvenile idiopathic arthritis  a matched pair analysis.;Q422232;P2175;Q861224
Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice.;Q218642;P703;Q15978631
Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice.;Q186521;P703;Q15978631
Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice.;Q170545;P703;Q15978631
Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice.;Q20035886;P703;Q15978631
Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice.;Q483745;P703;Q15978631
Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice.;Q422232;P2175;Q29496
Age-depending effects of methotrexate treatment on systemic bone turnover in experimental adjuvant arthritis;Q422232;P2175;Q170990
Acute myeloid leukemia with a cryptic NUP98/PRRX2 rearrangement developing after low-dose methotrexate therapy for rheumatoid arthritis;Q422232;P2175;Q29496
Acute myeloid leukemia with a cryptic NUP98/PRRX2 rearrangement developing after low-dose methotrexate therapy for rheumatoid arthritis;Q422232;P2175;Q187255
Acute myeloid leukemia with a cryptic NUP98/PRRX2 rearrangement developing after low-dose methotrexate therapy for rheumatoid arthritis;Q422232;P2175;Q170990
Successful treatment of recurrent multiple lung metastasis from colon cancer with combination chemotherapy using methotrexate, 5-fluorouracil, and high-dose leucovorin: a case report;Q238512;P2175;Q18555025
Monitoring of methotrexate chlorination in water.;Q29053744;P366;Q7892
Effect of methotrexate alone and in combination with antifungal drugs on the growth of Candida albicans.;Q186474;P31;Q12140
Effect of methotrexate alone and in combination with antifungal drugs on the growth of Candida albicans.;Q186474;P703;Q310443
Effect of methotrexate alone and in combination with antifungal drugs on the growth of Candida albicans.;Q191924;P366;Q8386
Effect of methotrexate alone and in combination with antifungal drugs on the growth of Candida albicans.;Q422232;P31;Q12140
Cytomegalovirus pneumonia in a rheumatoid arthritis patient on low dose methotrexate;Q422232;P2175;Q187255
Cytomegalovirus pneumonia in a rheumatoid arthritis patient on low dose methotrexate;Q422232;P2175;Q170990
Methotrexate resistance conferred by transplantation of drug-resistant transgenic marrow cells fractionated bycounterflow elutriation.;Q22124685;P31;Q12140
Methotrexate resistance conferred by transplantation of drug-resistant transgenic marrow cells fractionated bycounterflow elutriation.;Q422232;P31;Q12140
Influence of methotrexate, leflunomide and tumour necrosis factor alpha inhibitors on immune competence in rheumatoid arthritis patients: a long-run monitoring of EpsteinBarr virus load.;Q248550;P2175;Q170990
Influence of methotrexate, leflunomide and tumour necrosis factor alpha inhibitors on immune competence in rheumatoid arthritis patients: a long-run monitoring of EpsteinBarr virus load.;Q248550;P2175;Q187255
Influence of methotrexate, leflunomide and tumour necrosis factor alpha inhibitors on immune competence in rheumatoid arthritis patients: a long-run monitoring of EpsteinBarr virus load.;Q422232;P2175;Q187255
Influence of methotrexate, leflunomide and tumour necrosis factor alpha inhibitors on immune competence in rheumatoid arthritis patients: a long-run monitoring of EpsteinBarr virus load.;Q422232;P2175;Q170990
Comparison of CD4 Counts with Mycophenolate Mofetil versus Methotrexate from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial;Q218642;P31;Q407595
Comparison of CD4 Counts with Mycophenolate Mofetil versus Methotrexate from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial;Q130336;P31;Q407142
Comparison of CD4 Counts with Mycophenolate Mofetil versus Methotrexate from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial;Q130336;P4149;Q27122100
Comparison of CD4 Counts with Mycophenolate Mofetil versus Methotrexate from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial;Q422232;P2175;Q280027
Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.;Q348260;P2175;Q170990
Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.;Q348260;P2175;Q187255
Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.;Q422232;P2175;Q170990
Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.;Q422232;P2175;Q187255
[Comparative evaluation of thiphosphamide, cyclophosphane, methotrexate and 5-fluorouracil in the treatment of breast cancer];Q238512;P2175;Q128581
[Comparative evaluation of thiphosphamide, cyclophosphane, methotrexate and 5-fluorouracil in the treatment of breast cancer];Q422232;P2175;Q128581
[Treatment of rheumatoid arthritis of senile onset with methotrexate];Q422232;P2175;Q187255
[Treatment of rheumatoid arthritis of senile onset with methotrexate];Q422232;P2175;Q170990
Thymidine enhancement of methotrexate and 5-fluorouracil toxicity in cultured human colon carcinoma.;Q186521;P703;Q15978631
Neurotoxicity in lymphoblastic leukaemia: comparison of oral and intramuscular methotrexate and two doses of radiation.;Q422232;P2175;Q29496
Neurotoxicity in lymphoblastic leukaemia: comparison of oral and intramuscular methotrexate and two doses of radiation.;Q422232;P636;Q285166
Salvage therapy for recurrent or refractory non-Hodgkin's lymphoma with etoposide, methotrexate, vindesine and prednisolone (EMVP);Q11426176;P2175;Q208414
Salvage therapy for recurrent or refractory non-Hodgkin's lymphoma with etoposide, methotrexate, vindesine and prednisolone (EMVP);Q11426176;P2175;Q1138590
Salvage therapy for recurrent or refractory non-Hodgkin's lymphoma with etoposide, methotrexate, vindesine and prednisolone (EMVP);Q418817;P2175;Q208414
Salvage therapy for recurrent or refractory non-Hodgkin's lymphoma with etoposide, methotrexate, vindesine and prednisolone (EMVP);Q418817;P2175;Q1138590
Salvage therapy for recurrent or refractory non-Hodgkin's lymphoma with etoposide, methotrexate, vindesine and prednisolone (EMVP);Q422232;P2175;Q208414
Salvage therapy for recurrent or refractory non-Hodgkin's lymphoma with etoposide, methotrexate, vindesine and prednisolone (EMVP);Q422232;P2175;Q1138590
[Over-expression of mdr1/P-gp is associated with methotrexate resistance in patients with rheumatoid arthritis].;Q422232;P2175;Q187255
[Over-expression of mdr1/P-gp is associated with methotrexate resistance in patients with rheumatoid arthritis].;Q422232;P2175;Q170990
Treatment of adjuvant-induced arthritis with the combination of methotrexate and probiotic bacteria Escherichia coli O83 (Colinfant).;Q186474;P703;Q25419
Treatment of adjuvant-induced arthritis with the combination of methotrexate and probiotic bacteria Escherichia coli O83 (Colinfant).;Q186521;P703;Q25419
Treatment of adjuvant-induced arthritis with the combination of methotrexate and probiotic bacteria Escherichia coli O83 (Colinfant).;Q422232;P2175;Q170990
Recapitulation of methotrexate hepatotoxicity with induced pluripotent stem cell-derived hepatocytes from patients with rheumatoid arthritis;Q422232;P2175;Q170990
Recapitulation of methotrexate hepatotoxicity with induced pluripotent stem cell-derived hepatocytes from patients with rheumatoid arthritis;Q422232;P2175;Q187255
Disease-modifying antirheumatic drugs, including methotrexate, gold, sulfasalazine, antimalarials, and D-penicillamine.;Q191924;P366;Q8386
Disease-modifying antirheumatic drugs, including methotrexate, gold, sulfasalazine, antimalarials, and D-penicillamine.;Q178450;P31;Q12140
Disease-modifying antirheumatic drugs, including methotrexate, gold, sulfasalazine, antimalarials, and D-penicillamine.;Q420035;P2868;Q810254
Disease-modifying antirheumatic drugs, including methotrexate, gold, sulfasalazine, antimalarials, and D-penicillamine.;Q420035;P31;Q12140
Disease-modifying antirheumatic drugs, including methotrexate, gold, sulfasalazine, antimalarials, and D-penicillamine.;Q421239;P31;Q12140
Disease-modifying antirheumatic drugs, including methotrexate, gold, sulfasalazine, antimalarials, and D-penicillamine.;Q421239;P2868;Q810254
Disease-modifying antirheumatic drugs, including methotrexate, gold, sulfasalazine, antimalarials, and D-penicillamine.;Q422232;P31;Q12140
Disease-modifying antirheumatic drugs, including methotrexate, gold, sulfasalazine, antimalarials, and D-penicillamine.;Q422232;P2868;Q810254
Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial.;Q412323;P2175;Q170990
Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial.;Q422232;P2175;Q187255
Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial.;Q422232;P2175;Q170990
Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant;Q367700;P2175;Q1194520
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.;Q415264;P2175;Q170990
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.;Q420035;P2175;Q187255
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.;Q420035;P2175;Q170990
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.;Q421094;P2175;Q170990
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.;Q421094;P2175;Q187255
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.;Q421094;P1889;Q422438
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.;Q422438;P2175;Q187255
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.;Q422438;P1889;Q421094
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.;Q422232;P2175;Q170990
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.;Q422232;P2175;Q187255
Is adalimumab in combination with methotrexate a safe and efficacious treatment for early rheumatoid arthritis?;Q348260;P2175;Q170990
Is adalimumab in combination with methotrexate a safe and efficacious treatment for early rheumatoid arthritis?;Q348260;P2175;Q187255
Is adalimumab in combination with methotrexate a safe and efficacious treatment for early rheumatoid arthritis?;Q422232;P2175;Q187255
Is adalimumab in combination with methotrexate a safe and efficacious treatment for early rheumatoid arthritis?;Q422232;P2175;Q170990
Methotrexate and beta-carotene loaded-lipid polymer hybrid nanoparticles: a preclinical study for breast cancer.;Q422232;P2175;Q128581
Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation;Q367700;P2175;Q1194520
Combined effects of infliximab and methotrexate on rheumatoid arthritis osteoblastic cell metabolism;Q415264;P2175;Q170990
Combined effects of infliximab and methotrexate on rheumatoid arthritis osteoblastic cell metabolism;Q422232;P2175;Q170990
Combined effects of infliximab and methotrexate on rheumatoid arthritis osteoblastic cell metabolism;Q422232;P2175;Q187255
Epstein-Barr virus associated Hodgkin lymphoma in a 9-year-old girl receiving long-term methotrexate therapy for juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Epstein-Barr virus associated Hodgkin lymphoma in a 9-year-old girl receiving long-term methotrexate therapy for juvenile idiopathic arthritis.;Q422232;P2175;Q208414
Epstein-Barr virus associated Hodgkin lymphoma in a 9-year-old girl receiving long-term methotrexate therapy for juvenile idiopathic arthritis.;Q422232;P2175;Q170990
Herpes zoster encephalomyelitis in a patient with rheumatoid arthritis treated with low dose methotrexate;Q422232;P2175;Q187255
Herpes zoster encephalomyelitis in a patient with rheumatoid arthritis treated with low dose methotrexate;Q422232;P2175;Q170990
Efficacy and safety of total glucosides of paeony combined with methotrexate and leflunomide for active rheumatoid arthritis: a meta-analysis;Q248550;P2175;Q187255
Efficacy and safety of total glucosides of paeony combined with methotrexate and leflunomide for active rheumatoid arthritis: a meta-analysis;Q248550;P2175;Q170990
Efficacy and safety of total glucosides of paeony combined with methotrexate and leflunomide for active rheumatoid arthritis: a meta-analysis;Q422232;P2175;Q187255
Efficacy and safety of total glucosides of paeony combined with methotrexate and leflunomide for active rheumatoid arthritis: a meta-analysis;Q422232;P2175;Q170990
[Changes induced in the crystalline lens epithelium with a folic acid antagonist, methotrexate];Q422232;P2868;Q127060
[Changes induced in the crystalline lens epithelium with a folic acid antagonist, methotrexate];Q422232;P2868;Q50573407
[Effectiveness of VM 26, mitomycine C and methotrexate in advanced breast cancer refractory to a four drug combination (author's transl)];Q186474;P31;Q12140
[Effectiveness of VM 26, mitomycine C and methotrexate in advanced breast cancer refractory to a four drug combination (author's transl)];Q191924;P31;Q12140
[Effectiveness of VM 26, mitomycine C and methotrexate in advanced breast cancer refractory to a four drug combination (author's transl)];Q19856779;P31;Q12140
[Effectiveness of VM 26, mitomycine C and methotrexate in advanced breast cancer refractory to a four drug combination (author's transl)];Q19856779;P1889;Q417625
[Effectiveness of VM 26, mitomycine C and methotrexate in advanced breast cancer refractory to a four drug combination (author's transl)];Q22124685;P31;Q12140
[Effectiveness of VM 26, mitomycine C and methotrexate in advanced breast cancer refractory to a four drug combination (author's transl)];Q483752;P31;Q12140
[Effectiveness of VM 26, mitomycine C and methotrexate in advanced breast cancer refractory to a four drug combination (author's transl)];Q422232;P31;Q12140
[Effectiveness of VM 26, mitomycine C and methotrexate in advanced breast cancer refractory to a four drug combination (author's transl)];Q422232;P2175;Q128581
Computerized image-analysis quantitation of heterogeneity of response in k562 human leukemia-cells after methotrexate exposure.;Q186474;P703;Q15978631
Computerized image-analysis quantitation of heterogeneity of response in k562 human leukemia-cells after methotrexate exposure.;Q422232;P2175;Q29496
Meta-analysis and meta-regression analysis to compare the outcomes of chemotherapy for T- and B-lineage acute lymphoblastic leukemia (ALL): the use of dexamethasone, L-asparaginase, and/or methotrexate may improve the outcome of T-lineage ALL.;Q422232;P2175;Q29496
2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension.;Q415264;P2175;Q170990
2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension.;Q422232;P2175;Q861224
2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension.;Q422232;P2175;Q187255
2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension.;Q422232;P2175;Q170990
Cyclic post methotrexate dosing arthritis in systemic lupus erythematosus;Q422232;P2175;Q170990
Transformation of Grade I Follicular Lymphoma to Anaplastic Large Cell Lymphoma CD30+ ALK1- with Complete Response to Brentuximab Vedotin and High-Dose Methotrexate;Q422232;P2175;Q208414
Predictive factors for the methotrexate treatment outcome in ectopic pregnancy: A comparative study of 400 cases.;Q422232;P2175;Q207087
Molecularly imprinted solid-phase extraction combined with electrochemical oxidation fluorimetry for the determination of methotrexate in human serum and urine.;Q22124685;P703;Q15978631
High dose methotrexate with leucovorin rescue in the treatment of malignant lymphoma;Q422232;P2175;Q208414
Therapy: oral or subcutaneous methotrexate for rheumatoid arthritis?;Q422232;P636;Q285166
Therapy: oral or subcutaneous methotrexate for rheumatoid arthritis?;Q422232;P2175;Q170990
Therapy: oral or subcutaneous methotrexate for rheumatoid arthritis?;Q422232;P2175;Q187255
Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy.;Q422232;P2175;Q549534
5-Fluorouracil, methotrexate, leucovorin, CDDP and epirubicin (FEPMTX): a wide-spectrum regimen of salvage chemotherapy for high-grade advanced gastric cancer.;Q412415;P2175;Q189588
5-Fluorouracil, methotrexate, leucovorin, CDDP and epirubicin (FEPMTX): a wide-spectrum regimen of salvage chemotherapy for high-grade advanced gastric cancer.;Q238512;P2175;Q189588
5-Fluorouracil, methotrexate, leucovorin, CDDP and epirubicin (FEPMTX): a wide-spectrum regimen of salvage chemotherapy for high-grade advanced gastric cancer.;Q422232;P2175;Q189588
Solid lipid nanoparticles by coacervation loaded with a methotrexate prodrug: preliminary study for glioma treatment.;Q183290;P31;Q12140
Solid lipid nanoparticles by coacervation loaded with a methotrexate prodrug: preliminary study for glioma treatment.;Q191924;P366;Q8386
Solid lipid nanoparticles by coacervation loaded with a methotrexate prodrug: preliminary study for glioma treatment.;Q422232;P31;Q12140
Subcutaneous panniculitis-like T-cell lymphoma : complete sustained remission with corticosteroids and methotrexate;Q422232;P2175;Q208414
Subcutaneous panniculitis-like T-cell lymphoma : complete sustained remission with corticosteroids and methotrexate;Q422232;P2175;Q7667896
Trophoblastic tumors of the uterus-problems of methotrexate therapy;Q422232;P2175;Q7845637
[Effect of nonsteroidal anti-inflammatory drugs on pharmacokinetics of methotrexate: a meta-analysis];Q191924;P31;Q12140
[Effect of nonsteroidal anti-inflammatory drugs on pharmacokinetics of methotrexate: a meta-analysis];Q191924;P366;Q8386
[Effect of nonsteroidal anti-inflammatory drugs on pharmacokinetics of methotrexate: a meta-analysis];Q422232;P31;Q12140
Methotrexate intercalated calcium carbonate nanostructures: Synthesis, phase transformation and bioassay study.;Q183290;P527;Q623
Methotrexate intercalated calcium carbonate nanostructures: Synthesis, phase transformation and bioassay study.;Q23767;P527;Q623
Methotrexate intercalated calcium carbonate nanostructures: Synthesis, phase transformation and bioassay study.;Q23767;P527;Q706
Methotrexate intercalated calcium carbonate nanostructures: Synthesis, phase transformation and bioassay study.;Q23767;P31;Q56810798
Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report;Q218642;P31;Q11173
Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report;Q186474;P31;Q11173
Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report;Q186521;P31;Q11173
Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report;Q191924;P31;Q11173
Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report;Q485277;P31;Q11173
Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report;Q170545;P31;Q11173
Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report;Q173670;P31;Q11173
Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report;Q178450;P31;Q11173
Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report;Q22124685;P31;Q11173
Complete clinical and functional recovery following low-dose methotrexate related paraparesis in a patient with compound c.1298A>C AND c.677C>T MTHFR polymorphism: A case report;Q422232;P31;Q11173
Methotrexate with N5-methyl-tetrahydrofolic acid in the treatment of non-Hodgkin's lymphomas and acute leukemias;Q422232;P2175;Q29496
Methotrexate with N5-methyl-tetrahydrofolic acid in the treatment of non-Hodgkin's lymphomas and acute leukemias;Q422232;P2868;Q127060
Methotrexate with N5-methyl-tetrahydrofolic acid in the treatment of non-Hodgkin's lymphomas and acute leukemias;Q422232;P2175;Q1138590
Methotrexate with N5-methyl-tetrahydrofolic acid in the treatment of non-Hodgkin's lymphomas and acute leukemias;Q422232;P2175;Q208414
High-dose methotrexate and primary central nervous system lymphoma.;Q422232;P2175;Q136312
High-dose methotrexate and primary central nervous system lymphoma.;Q422232;P2175;Q208414
The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8mg/week in patients with rheumatoid arthritis;Q422232;P2175;Q187255
The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8mg/week in patients with rheumatoid arthritis;Q422232;P2175;Q170990
Up-regulated transport of methotrexate and 5-methyl-tetrahydrofolate in a human breast cancer cell line.;Q422232;P2175;Q128581
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.;Q18936;P2175;Q208414
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.;Q18936;P2175;Q2626074
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.;Q18936;P2175;Q4833719
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.;Q408977;P2175;Q2626074
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.;Q408977;P2175;Q208414
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.;Q408977;P2175;Q4833719
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.;Q412323;P2175;Q208414
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.;Q412323;P2175;Q2626074
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.;Q412323;P2175;Q4833719
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.;Q424972;P2175;Q4833719
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.;Q424972;P2175;Q2626074
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.;Q422232;P2175;Q4833719
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.;Q422232;P2175;Q2626074
Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.;Q422232;P2175;Q208414
[Association of VM26, mitomycine C, methotrexate in patients with metastatic carcinoma of the breast resistant to a combination of 4 drugs including adriamycin. Results of a type II study (autohr's transl)];Q218642;P31;Q12140
[Association of VM26, mitomycine C, methotrexate in patients with metastatic carcinoma of the breast resistant to a combination of 4 drugs including adriamycin. Results of a type II study (autohr's transl)];Q186474;P31;Q12140
[Association of VM26, mitomycine C, methotrexate in patients with metastatic carcinoma of the breast resistant to a combination of 4 drugs including adriamycin. Results of a type II study (autohr's transl)];Q191924;P366;Q8386
[Association of VM26, mitomycine C, methotrexate in patients with metastatic carcinoma of the breast resistant to a combination of 4 drugs including adriamycin. Results of a type II study (autohr's transl)];Q173670;P31;Q12140
[Association of VM26, mitomycine C, methotrexate in patients with metastatic carcinoma of the breast resistant to a combination of 4 drugs including adriamycin. Results of a type II study (autohr's transl)];Q19856779;P31;Q12140
[Association of VM26, mitomycine C, methotrexate in patients with metastatic carcinoma of the breast resistant to a combination of 4 drugs including adriamycin. Results of a type II study (autohr's transl)];Q19856779;P1889;Q417625
[Association of VM26, mitomycine C, methotrexate in patients with metastatic carcinoma of the breast resistant to a combination of 4 drugs including adriamycin. Results of a type II study (autohr's transl)];Q22124685;P31;Q12140
[Association of VM26, mitomycine C, methotrexate in patients with metastatic carcinoma of the breast resistant to a combination of 4 drugs including adriamycin. Results of a type II study (autohr's transl)];Q483752;P31;Q12140
[Association of VM26, mitomycine C, methotrexate in patients with metastatic carcinoma of the breast resistant to a combination of 4 drugs including adriamycin. Results of a type II study (autohr's transl)];Q484940;P31;Q12140
[Association of VM26, mitomycine C, methotrexate in patients with metastatic carcinoma of the breast resistant to a combination of 4 drugs including adriamycin. Results of a type II study (autohr's transl)];Q422232;P31;Q12140
PLGA-soya lecithin based micelles for enhanced delivery of methotrexate: Cellular uptake, cytotoxic and pharmacokinetic evidences.;Q218642;P703;Q11006
PLGA-soya lecithin based micelles for enhanced delivery of methotrexate: Cellular uptake, cytotoxic and pharmacokinetic evidences.;Q186474;P703;Q83310
PLGA-soya lecithin based micelles for enhanced delivery of methotrexate: Cellular uptake, cytotoxic and pharmacokinetic evidences.;Q20035886;P703;Q11006
PLGA-soya lecithin based micelles for enhanced delivery of methotrexate: Cellular uptake, cytotoxic and pharmacokinetic evidences.;Q620730;P703;Q11006
PLGA-soya lecithin based micelles for enhanced delivery of methotrexate: Cellular uptake, cytotoxic and pharmacokinetic evidences.;Q483745;P703;Q11006
Phase II study of epirubicin sequential methotrexate and 5-fluorouracil for advanced colorectal cancer.;Q238512;P2175;Q2739660
Successful salvage therapy of resistant gestational trophoblastic disease with etoposide, methotrexate, dactinomycin, vincristine, and cyclophosphamide.;Q186127;P279;Q343465
Recurrent childhood lymphocytic leukemia: clinical and cytokinetic studies of cytosine arabinoside and methotrexate for maintenance of second hematologic remission.;Q180983;P2175;Q29496
Recurrent childhood lymphocytic leukemia: clinical and cytokinetic studies of cytosine arabinoside and methotrexate for maintenance of second hematologic remission.;Q422232;P2175;Q29496
A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer;Q18936;P2175;Q128581
A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer;Q238512;P2175;Q128581
A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer;Q11426176;P2175;Q12078
A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer;Q422232;P2175;Q128581
Determination of methotrexate in spiked human blood serum using multi-frequency electrochemical immittance spectroscopy and multivariate data analysis.;Q178450;P703;Q15978631
Methyl-CCNU and methotrexate therapy in patients with advanced colorectal cancer after failure of 5-fluorouracil chemotherapy.;Q139347;P2175;Q12078
Methyl-CCNU and methotrexate therapy in patients with advanced colorectal cancer after failure of 5-fluorouracil chemotherapy.;Q238512;P2175;Q2739660
A new myeloblastic leukemia cell line with double minute chromosomes. Induction of methotrexate resistance and dihydrofolate reductase gene amplification.;Q422232;P2175;Q29496
Methotrexate therapy in rheumatoid arthritis patients diminishes lectin-induced mononuclear cell proliferation.;Q422232;P2175;Q170990
Methotrexate therapy in rheumatoid arthritis patients diminishes lectin-induced mononuclear cell proliferation.;Q422232;P2175;Q187255
Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data;Q248550;P31;Q12140
Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data;Q248550;P2175;Q187255
Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data;Q248550;P2175;Q170990
Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data;Q186521;P31;Q12140
Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data;Q191924;P31;Q12140
Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data;Q191924;P366;Q8386
Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data;Q173670;P31;Q12140
Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data;Q422232;P31;Q12140
Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data;Q422232;P2175;Q170990
Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data;Q422232;P2175;Q187255
[A Case of Crohn's Disease Showing Favorable Response to Induction and Maintenance Therapy with Methotrexate after Failure of Anti-tumor Necrosis Factor Therapy].;Q218642;P703;Q2046782
[A Case of Crohn's Disease Showing Favorable Response to Induction and Maintenance Therapy with Methotrexate after Failure of Anti-tumor Necrosis Factor Therapy].;Q178450;P703;Q2046782
[Evaluation of two methods of maintenance chemotherapy with methotrexate and 6-mercaptopurine for childhood acute lymphoblastic leukemia];Q422232;P2175;Q29496
The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry.;Q348260;P2175;Q170990
The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry.;Q348260;P2175;Q187255
The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry.;Q422232;P2175;Q170990
The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry.;Q422232;P2175;Q187255
[CMF (cyclophosphamide, methotrexate, ftorafur) chemotherapy in advanced breast cancer];Q422232;P2175;Q128581
Tolerability and safety of classic cyclophosphamide, methotrexate, and fluorouracil treatment in Japanese patients with early breast cancer.;Q238512;P2175;Q128581
Tolerability and safety of classic cyclophosphamide, methotrexate, and fluorouracil treatment in Japanese patients with early breast cancer.;Q422232;P2175;Q128581
[Methotrexate in the therapy of juvenile idiopathic arthritis].;Q422232;P2175;Q170990
[Methotrexate in the therapy of juvenile idiopathic arthritis].;Q422232;P2175;Q861224
Folate Receptor-Targeting and Reactive Oxygen Species-Responsive Liposomal Formulation of Methotrexate for Treatment of Rheumatoid Arthritis;Q170545;P527;Q629
The Efficacy and Safety of Methotrexate versus Interferon in Cutaneous T-cell Lymphomas.;Q422232;P2175;Q208414
Improved therapeutic index with high-dose methotrexate: comparison of thymidine-purine rescue with citrovorum factor rescue in mice.;Q484940;P703;Q177932
An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis.;Q367700;P2175;Q187255
An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis.;Q421094;P2175;Q170990
An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis.;Q421094;P1889;Q422438
An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis.;Q421094;P2175;Q187255
An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis.;Q422438;P2175;Q187255
An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis.;Q422438;P1889;Q421094
An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis.;Q422232;P2175;Q170990
An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis.;Q422232;P2175;Q187255
The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial.;Q186474;P31;Q12140
The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial.;Q186521;P31;Q12140
The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial.;Q191924;P31;Q12140
The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial.;Q422232;P31;Q12140
The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial.;Q422232;P2175;Q170990
The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial.;Q422232;P2175;Q187255
[Pancytopenia in rheumatoid arthritis treated with methotrexate];Q422232;P2175;Q187255
[Pancytopenia in rheumatoid arthritis treated with methotrexate];Q422232;P2175;Q170990
[Disseminated pneumoperitoneum during the therapy of lymphoma with methotrexate and cytosine arabinoside];Q180983;P2175;Q208414
[Disseminated pneumoperitoneum during the therapy of lymphoma with methotrexate and cytosine arabinoside];Q422232;P2175;Q208414
[Study on targeting drug delivery system--the characteristics of methotrexate microsphere and experimental treatment of hepatic tumor in rats by arterial embolization];Q183290;P31;Q12140
[Study on targeting drug delivery system--the characteristics of methotrexate microsphere and experimental treatment of hepatic tumor in rats by arterial embolization];Q191924;P366;Q8386
[Study on targeting drug delivery system--the characteristics of methotrexate microsphere and experimental treatment of hepatic tumor in rats by arterial embolization];Q422232;P31;Q12140
Conventional and diffusion-weighted MRI findings of methotrexate related sub-acute neurotoxicity.;Q191924;P2868;Q407752
5-aminoimidazole-4-carboxamide ribonucleotide-transformylase and inosine-triphosphate-pyrophosphatase genes variants predict remission rate during methotrexate therapy in patients with juvenile idiopathic arthritis.;Q422232;P2175;Q861224
5-aminoimidazole-4-carboxamide ribonucleotide-transformylase and inosine-triphosphate-pyrophosphatase genes variants predict remission rate during methotrexate therapy in patients with juvenile idiopathic arthritis.;Q422232;P2175;Q170990
Leptomeningeal carcinomatosis from gastric cancer successfully treated by the intrathecal methotrexate plus temozolomide and simultaneous radiotherapy: Case report and literatures review.;Q422232;P636;Q1320251
Leptomeningeal carcinomatosis from gastric cancer successfully treated by the intrathecal methotrexate plus temozolomide and simultaneous radiotherapy: Case report and literatures review.;Q422232;P2175;Q189588
Synthesis and in vitro biological activity of new deaza analogues of folic acid, aminopterin, and methotrexate with an L-ornithine side chain.;Q422232;P2868;Q127060
Future refinement of methotrexate  treatment in rheumatoid arthritis: comment  on the article by Yazdany et al.;Q422232;P2175;Q170990
Future refinement of methotrexate  treatment in rheumatoid arthritis: comment  on the article by Yazdany et al.;Q422232;P2175;Q187255
A prospective observational study to compare efficacy of topical triamcinolone acetonide 0.1% oral paste, oral methotrexate, and a combination of topical triamcinolone acetonide 0.1% and oral methotrexate in moderate to severe oral lichen planus.;Q422232;P636;Q285166
A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents;Q218642;P703;Q177932
A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents;Q422232;P2175;Q170990
A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents;Q422232;P2175;Q861224
Decreased expression of the human folate receptor mediates transport-defective methotrexate resistance in KB cells.;Q178450;P703;Q15978631
Decreased expression of the human folate receptor mediates transport-defective methotrexate resistance in KB cells.;Q20816880;P703;Q15978631
Treatment of ectopic pregnancy with a single intramuscular dose of methotrexate;Q422232;P2175;Q207087
Methotrexate treatment of ectopic pregnancy.;Q422232;P2175;Q207087
[Long-term survival of methotrexate in psoriatic arthritis];Q422232;P2175;Q170990
Concurrent administration of intravenous systemic and intravitreal methotrexate for intraocular lymphoma with central nervous system involvement.;Q422232;P2175;Q208414
[News on the impact of Methotrexate astherapeutic option in patients with ulcerative colitis];Q22124685;P703;Q177932
[News on the impact of Methotrexate astherapeutic option in patients with ulcerative colitis];Q422232;P2175;Q1477
The treatment of childhood acute lymphoblastic leukemia based on the pharmacokinetics of methotrexate in serum and cerebrospinal fluid.;Q422232;P2175;Q29496
[Methotrexate treatment of rheumatoid arthritis in Denmark].;Q422232;P2175;Q187255
[Methotrexate treatment of rheumatoid arthritis in Denmark].;Q422232;P2175;Q170990
Differential usage of the transport systems for folic acid and methotrexate in normal human T-lymphocytes and leukemic cells.;Q186521;P703;Q15978631
Differential usage of the transport systems for folic acid and methotrexate in normal human T-lymphocytes and leukemic cells.;Q127060;P703;Q15978631
Differential usage of the transport systems for folic acid and methotrexate in normal human T-lymphocytes and leukemic cells.;Q178450;P703;Q15978631
Differential usage of the transport systems for folic acid and methotrexate in normal human T-lymphocytes and leukemic cells.;Q422232;P2868;Q127060
Retrospective analysis of the usefulness of a protocol with high-dose methotrexate in polymyalgia rheumatica: Results of a single-center cohort of 100 patients;Q422232;P2175;Q1752891
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials;Q238512;P2175;Q128581
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials;Q425122;P2175;Q128581
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials;Q422232;P2175;Q128581
Letrozole: future alternative to methotrexate for treatment of ectopic pregnancy?;Q422232;P2175;Q207087
Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology;Q191924;P366;Q8386
Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology;Q425154;P31;Q12140
Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology;Q425154;P2175;Q170990
Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology;Q422232;P31;Q12140
Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology;Q422232;P2175;Q170990
Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology;Q422232;P2175;Q187255
Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience.;Q180983;P2175;Q208414
Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience.;Q412323;P2175;Q136312
Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience.;Q412323;P2175;Q208414
Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience.;Q422232;P2175;Q136312
Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience.;Q422232;P2175;Q208414
Can a fifty-year-old medication find happiness treating a 63-year-old disease process? Methotrexate for refractory Crohn's disease.;Q186474;P31;Q12140
Can a fifty-year-old medication find happiness treating a 63-year-old disease process? Methotrexate for refractory Crohn's disease.;Q22124685;P31;Q12140
Can a fifty-year-old medication find happiness treating a 63-year-old disease process? Methotrexate for refractory Crohn's disease.;Q422232;P31;Q12140
Synthesis and in vitro cytotoxicity evaluation of star-shaped polymethacrylic conjugates with methotrexate or acitretin as potential antipsoriatic prodrugs;Q183290;P31;Q12140
Synthesis and in vitro cytotoxicity evaluation of star-shaped polymethacrylic conjugates with methotrexate or acitretin as potential antipsoriatic prodrugs;Q191924;P366;Q8386
Synthesis and in vitro cytotoxicity evaluation of star-shaped polymethacrylic conjugates with methotrexate or acitretin as potential antipsoriatic prodrugs;Q341500;P31;Q106040601
Synthesis and in vitro cytotoxicity evaluation of star-shaped polymethacrylic conjugates with methotrexate or acitretin as potential antipsoriatic prodrugs;Q341500;P31;Q12140
Synthesis and in vitro cytotoxicity evaluation of star-shaped polymethacrylic conjugates with methotrexate or acitretin as potential antipsoriatic prodrugs;Q4775140;P31;Q12140
Synthesis and in vitro cytotoxicity evaluation of star-shaped polymethacrylic conjugates with methotrexate or acitretin as potential antipsoriatic prodrugs;Q422232;P31;Q12140
Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo.;Q218642;P703;Q15978631
Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo.;Q186474;P703;Q15978631
Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo.;Q186521;P703;Q15978631
Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo.;Q190875;P703;Q15978631
Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo.;Q485277;P703;Q15978631
Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo.;Q178450;P703;Q15978631
Alterations in the matrix metalloproteinase-3 promoter methylation after common chemotherapeutics: in vitro study of paclitaxel, cisplatin and methotrexate in the MCF-7 and SH-SY5Y cell lines;Q218642;P703;Q177932
Alterations in the matrix metalloproteinase-3 promoter methylation after common chemotherapeutics: in vitro study of paclitaxel, cisplatin and methotrexate in the MCF-7 and SH-SY5Y cell lines;Q188017;P703;Q177932
Alterations in the matrix metalloproteinase-3 promoter methylation after common chemotherapeutics: in vitro study of paclitaxel, cisplatin and methotrexate in the MCF-7 and SH-SY5Y cell lines;Q183290;P703;Q177932
Alterations in the matrix metalloproteinase-3 promoter methylation after common chemotherapeutics: in vitro study of paclitaxel, cisplatin and methotrexate in the MCF-7 and SH-SY5Y cell lines;Q186474;P703;Q177932
Alterations in the matrix metalloproteinase-3 promoter methylation after common chemotherapeutics: in vitro study of paclitaxel, cisplatin and methotrexate in the MCF-7 and SH-SY5Y cell lines;Q485277;P703;Q177932
Alterations in the matrix metalloproteinase-3 promoter methylation after common chemotherapeutics: in vitro study of paclitaxel, cisplatin and methotrexate in the MCF-7 and SH-SY5Y cell lines;Q22124685;P703;Q177932
[Abdominal actinomycosis after stomach surgery in a patient with long-term rheumatoid arthritis treated with methotrexate];Q422232;P2175;Q170990
[Abdominal actinomycosis after stomach surgery in a patient with long-term rheumatoid arthritis treated with methotrexate];Q422232;P2175;Q187255
Impact of 24months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study.;Q422232;P2175;Q170990
Impact of 24months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study.;Q422232;P2175;Q187255
Multifunctional folate receptor-targeting and pH-responsive nanocarriers loaded with methotrexate for treatment of rheumatoid arthritis.;Q422232;P2175;Q187255
Multifunctional folate receptor-targeting and pH-responsive nanocarriers loaded with methotrexate for treatment of rheumatoid arthritis.;Q422232;P2175;Q170990
The positive influence of methotrexate on the mortality of patients with rheumatoid arthritis is partly independent of its effect on disease activity: results of a re-evaluation 18 years after baseline.;Q422232;P2175;Q170990
The positive influence of methotrexate on the mortality of patients with rheumatoid arthritis is partly independent of its effect on disease activity: results of a re-evaluation 18 years after baseline.;Q422232;P2175;Q187255
The in vivo effect of nonsteroidal anti-inflammatory drugs, gold sodium thiomalate and methotrexate on neutrophil superoxide radical generation.;Q186521;P31;Q12140
The in vivo effect of nonsteroidal anti-inflammatory drugs, gold sodium thiomalate and methotrexate on neutrophil superoxide radical generation.;Q191924;P366;Q8386
The in vivo effect of nonsteroidal anti-inflammatory drugs, gold sodium thiomalate and methotrexate on neutrophil superoxide radical generation.;Q422232;P31;Q12140
Diacerein for the treatment of rheumatoid arthritis in patients with inadequate response to methotrexate: a pilot randomized, double-blind, placebo-controlled add-on trial;Q422232;P2175;Q170990
Diacerein for the treatment of rheumatoid arthritis in patients with inadequate response to methotrexate: a pilot randomized, double-blind, placebo-controlled add-on trial;Q422232;P361;Q14819383
Diacerein for the treatment of rheumatoid arthritis in patients with inadequate response to methotrexate: a pilot randomized, double-blind, placebo-controlled add-on trial;Q422232;P2175;Q187255
Increased methotrexate intolerance in juvenile idiopathic arthritis compared to acute lymphoblastic leukaemia in children;Q422232;P2175;Q170990
Increased methotrexate intolerance in juvenile idiopathic arthritis compared to acute lymphoblastic leukaemia in children;Q422232;P2175;Q29496
Increased methotrexate intolerance in juvenile idiopathic arthritis compared to acute lymphoblastic leukaemia in children;Q422232;P2175;Q861224
Tocilizumab has no clinically relevant effects on methotrexate pharmacokinetics in patients with rheumatoid arthritis;Q422232;P2175;Q170990
Tocilizumab has no clinically relevant effects on methotrexate pharmacokinetics in patients with rheumatoid arthritis;Q422232;P2175;Q187255
[Methotrexate in the treatment of peripheral arthritis in ulcerative colitis];Q422232;P2175;Q1477
[Methotrexate in the treatment of peripheral arthritis in ulcerative colitis];Q422232;P2175;Q170990
Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates.;Q183290;P703;Q15978631
Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates.;Q186474;P703;Q15978631
Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates.;Q170545;P703;Q15978631
Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates.;Q139347;P703;Q15978631
Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates.;Q173670;P703;Q15978631
Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates.;Q22124685;P703;Q15978631
Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates.;Q422232;P2175;Q29496
Mechanism of the discrepant effect of a combination of methotrexate plus dipyridamole on human hematologic cell lines.;Q22124685;P703;Q15978631
Role of initial and day 4 human chorionic gonadotropin levels in predicting the outcome of single-dose methotrexate treatment in women with tubal ectopic pregnancy.;Q407172;P703;Q15978631
Role of initial and day 4 human chorionic gonadotropin levels in predicting the outcome of single-dose methotrexate treatment in women with tubal ectopic pregnancy.;Q407172;P279;Q409770
Role of initial and day 4 human chorionic gonadotropin levels in predicting the outcome of single-dose methotrexate treatment in women with tubal ectopic pregnancy.;Q173670;P703;Q15978631
Role of initial and day 4 human chorionic gonadotropin levels in predicting the outcome of single-dose methotrexate treatment in women with tubal ectopic pregnancy.;Q422232;P2175;Q207087
Combination of 6-mercaptopurine, vincristine, methotrexate, and prednisone in resistant or relapsed acute nonlymphoid leukemia;Q408977;P2175;Q29496
Combination of 6-mercaptopurine, vincristine, methotrexate, and prednisone in resistant or relapsed acute nonlymphoid leukemia;Q408977;P2175;Q18553852
Combination of 6-mercaptopurine, vincristine, methotrexate, and prednisone in resistant or relapsed acute nonlymphoid leukemia;Q418529;P2175;Q6708277
Combination of 6-mercaptopurine, vincristine, methotrexate, and prednisone in resistant or relapsed acute nonlymphoid leukemia;Q422232;P2175;Q29496
Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero's adalimumab (Mabura, Hetero Biopharma Ltd.) and reference adalimumab (Humira, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy;Q348260;P2175;Q170990
Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero's adalimumab (Mabura, Hetero Biopharma Ltd.) and reference adalimumab (Humira, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy;Q348260;P2175;Q187255
Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero's adalimumab (Mabura, Hetero Biopharma Ltd.) and reference adalimumab (Humira, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy;Q348260;P3780;Q29005938
Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero's adalimumab (Mabura, Hetero Biopharma Ltd.) and reference adalimumab (Humira, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy;Q422232;P2175;Q170990
Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero's adalimumab (Mabura, Hetero Biopharma Ltd.) and reference adalimumab (Humira, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy;Q422232;P2175;Q187255
Methotrexate in the treatment of ankylosing spondylitis;Q422232;P2175;Q52849
Alternating hemiparesis and orolingual apraxia as manifestations of methotrexate neurotoxicity in a paediatric case of acute lymphoblastic leukaemia.;Q191924;P2868;Q407752
Alternating hemiparesis and orolingual apraxia as manifestations of methotrexate neurotoxicity in a paediatric case of acute lymphoblastic leukaemia.;Q422232;P2175;Q29496
A new prodrug and bioactivity evaluation of methotrexate based on Chitosan;Q218642;P31;Q12140
A new prodrug and bioactivity evaluation of methotrexate based on Chitosan;Q186474;P31;Q12140
A new prodrug and bioactivity evaluation of methotrexate based on Chitosan;Q191924;P366;Q8386
A new prodrug and bioactivity evaluation of methotrexate based on Chitosan;Q422232;P31;Q12140
Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab.;Q415264;P2175;Q170990
Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab.;Q422232;P2175;Q187255
Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab.;Q422232;P2175;Q170990
Tofacitinib versus methotrexate in rheumatoid arthritis.;Q422232;P2175;Q170990
Tofacitinib versus methotrexate in rheumatoid arthritis.;Q422232;P2175;Q187255
Weekly oral methotrexate therapy: raise awareness of fatal dosing errors;Q422232;P636;Q285166
Sequence-, time- and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts.;Q183290;P703;Q15978631
Sequence-, time- and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts.;Q186521;P703;Q15978631
Mycophenolate Mofetil in severe or methotrexate refractory localized scleroderma.;Q130336;P4149;Q27122100
Mycophenolate Mofetil in severe or methotrexate refractory localized scleroderma.;Q130336;P31;Q407142
Liver toxicity does not have to follow methotrexate therapy of patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Liver toxicity does not have to follow methotrexate therapy of patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Self-assemble Amphiphilic PEO-PPO-PEO Tri-block Co-polymeric Methotrexate Nanomicelles to Combat Against MCF7 Cancer Cells;Q186474;P703;Q83310
Self-assemble Amphiphilic PEO-PPO-PEO Tri-block Co-polymeric Methotrexate Nanomicelles to Combat Against MCF7 Cancer Cells;Q410083;P31;Q81163
Design of pH-sensitive methotrexate prodrug-targeted curcumin nanoparticles for efficient dual-drug delivery and combination cancer therapy.;Q191924;P366;Q8386
Design of pH-sensitive methotrexate prodrug-targeted curcumin nanoparticles for efficient dual-drug delivery and combination cancer therapy.;Q485277;P31;Q12140
Design of pH-sensitive methotrexate prodrug-targeted curcumin nanoparticles for efficient dual-drug delivery and combination cancer therapy.;Q178450;P31;Q12140
Design of pH-sensitive methotrexate prodrug-targeted curcumin nanoparticles for efficient dual-drug delivery and combination cancer therapy.;Q422232;P31;Q12140
Investigating the use of a limited core outcome variable set for the classification of response following methotrexate treatment in juvenile idiopathic arthritis (JIA).;Q422232;P2175;Q170990
Investigating the use of a limited core outcome variable set for the classification of response following methotrexate treatment in juvenile idiopathic arthritis (JIA).;Q422232;P2175;Q861224
Transient cerebral manifestations induced by intrathecal injection of methotrexate;Q422232;P636;Q1320251
Gamma and UV radiations induced treatment of anti-cancer methotrexate drug in aqueous medium: Effect of process variables on radiation efficiency evaluated using bioassays;Q191924;P366;Q8386
Gamma and UV radiations induced treatment of anti-cancer methotrexate drug in aqueous medium: Effect of process variables on radiation efficiency evaluated using bioassays;Q620730;P31;Q12140
Gamma and UV radiations induced treatment of anti-cancer methotrexate drug in aqueous medium: Effect of process variables on radiation efficiency evaluated using bioassays;Q483752;P31;Q12140
Gamma and UV radiations induced treatment of anti-cancer methotrexate drug in aqueous medium: Effect of process variables on radiation efficiency evaluated using bioassays;Q422232;P31;Q12140
Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative Group.;Q422232;P2175;Q29496
Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative Group.;Q422232;P636;Q1320251
[A case of nonresectable gastric cancer treated by sequential methotrexate and 5-fluorouracil];Q238512;P2175;Q189588
[A case of nonresectable gastric cancer treated by sequential methotrexate and 5-fluorouracil];Q422232;P2175;Q189588
Cervical ectopic pregnancy managed with methotrexate and tranexamic acid: A case report;Q422232;P2175;Q207087
Methotrexate neurotoxicity due to drug interactions: an inadequate folinic acid effect?;Q23118;P31;Q8386
Methotrexate neurotoxicity due to drug interactions: an inadequate folinic acid effect?;Q22124685;P31;Q12140
Methotrexate neurotoxicity due to drug interactions: an inadequate folinic acid effect?;Q422232;P31;Q12140
[A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis].;Q248550;P2175;Q170990
[A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis].;Q422232;P2175;Q170990
Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment.;Q2697833;P2175;Q170990
Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment.;Q422232;P2175;Q170990
Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment.;Q422232;P2175;Q187255
[Immune complex formation and complement changes in osteosarcoma patients treated with high-dose methotrexate];Q422232;P2175;Q549534
Co-administration of dexamethasone increases severity and accelerates onset day of neutropenia in bladder cancer patients on methotrexate, vinblastine, adriamycin and cisplatin chemotherapy: a retrospective cohort study.;Q412415;P2175;Q504775
Co-administration of dexamethasone increases severity and accelerates onset day of neutropenia in bladder cancer patients on methotrexate, vinblastine, adriamycin and cisplatin chemotherapy: a retrospective cohort study.;Q422252;P2175;Q12078
P14.01 MTHFR genotype may affect methotrexate toxicity, survival and disease occurrence in patients with central nervous system lymphoma.;Q422232;P2175;Q136312
P14.01 MTHFR genotype may affect methotrexate toxicity, survival and disease occurrence in patients with central nervous system lymphoma.;Q422232;P2175;Q208414
A phase II study of etoposide, cisplatin plus methotrexate in patients with advanced refractory breast cancer;Q412415;P2175;Q128581
A phase II study of etoposide, cisplatin plus methotrexate in patients with advanced refractory breast cancer;Q422232;P2175;Q128581
Double modulation of 5-fluorouracil by methotrexate and high-dose L-leucovorin in advanced colorectal cancer;Q192464;P31;Q45435667
Double modulation of 5-fluorouracil by methotrexate and high-dose L-leucovorin in advanced colorectal cancer;Q238512;P2175;Q2739660
Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.;Q422232;P2175;Q170990
Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.;Q422232;P2175;Q187255
Does methotrexate cause interstitial lung disease in rheumatoid arthritis: What is the evidence?;Q422232;P2175;Q187255
Does methotrexate cause interstitial lung disease in rheumatoid arthritis: What is the evidence?;Q422232;P2175;Q170990
Is high dose methotrexate without irradiation of the brain sufficiently effective in prevention of CNS disease in children with acute lymphoblastic leukemia?;Q422232;P2175;Q29496
Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients.;Q421094;P2175;Q170990
Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients.;Q421094;P2175;Q187255
Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients.;Q421094;P1889;Q422438
Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients.;Q422438;P2175;Q187255
Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients.;Q422438;P1889;Q421094
Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients.;Q422232;P2175;Q187255
Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients.;Q422232;P2175;Q170990
Cytotoxic effect of methotrexate and its solvent on osteosarcoma cells in vitro;Q422232;P2175;Q549534
Methotrexate impact on radiographic progression in biologic-treated rheumatoid arthritis under clinical remission: A case report on monozygotic Caucasian twins.;Q422232;P2175;Q170990
Methotrexate impact on radiographic progression in biologic-treated rheumatoid arthritis under clinical remission: A case report on monozygotic Caucasian twins.;Q422232;P2175;Q187255
Utility of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as biomarker to predict therapeutic response to methotrexate in rheumatoid arthritis.;Q186521;P703;Q177932
Utility of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as biomarker to predict therapeutic response to methotrexate in rheumatoid arthritis.;Q173670;P703;Q177932
Utility of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as biomarker to predict therapeutic response to methotrexate in rheumatoid arthritis.;Q22124685;P703;Q177932
Utility of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as biomarker to predict therapeutic response to methotrexate in rheumatoid arthritis.;Q422232;P2175;Q170990
Utility of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as biomarker to predict therapeutic response to methotrexate in rheumatoid arthritis.;Q422232;P361;Q14819383
Utility of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as biomarker to predict therapeutic response to methotrexate in rheumatoid arthritis.;Q422232;P2175;Q187255
Intra-vitreal injection of methotrexate in experimental endotoxin-induced uveitis in rabbit;Q422232;P2175;Q280027
Effects of treatment of ectopic pregnancy with methotrexate or salpingectomy in the subsequent IVF cycle;Q422232;P2175;Q207087
Treatment of persistent ectopic pregnancy with methotrexate and leukovorum rescue: a case report.;Q422232;P2175;Q207087
The addition of adalimumab to methotrexate reduces rheumatoid arthritis activity in patients with longstanding disease.;Q348260;P2175;Q170990
The addition of adalimumab to methotrexate reduces rheumatoid arthritis activity in patients with longstanding disease.;Q348260;P2175;Q187255
The addition of adalimumab to methotrexate reduces rheumatoid arthritis activity in patients with longstanding disease.;Q422232;P2175;Q170990
The addition of adalimumab to methotrexate reduces rheumatoid arthritis activity in patients with longstanding disease.;Q422232;P2175;Q187255
Effect of high-dose methotrexate chemotherapy on intestinal Bifidobacteria, Lactobacillus and Escherichia coli in children with acute lymphoblastic leukemia.;Q483745;P703;Q25419
Effect of high-dose methotrexate chemotherapy on intestinal Bifidobacteria, Lactobacillus and Escherichia coli in children with acute lymphoblastic leukemia.;Q422232;P2175;Q29496
PReS-FINAL-2095: Older age predicts poor response to 6-months methotrexate therapy in a juvenile idiopathic arthritis cohort of patients.;Q422232;P2175;Q170990
PReS-FINAL-2095: Older age predicts poor response to 6-months methotrexate therapy in a juvenile idiopathic arthritis cohort of patients.;Q422232;P2175;Q861224
Intensive chemotherapy with cisplatin, mitoxantrone, methotrexate and vincristine in metastatic breast cancer;Q412415;P2175;Q128581
Intensive chemotherapy with cisplatin, mitoxantrone, methotrexate and vincristine in metastatic breast cancer;Q239426;P2175;Q128581
Intensive chemotherapy with cisplatin, mitoxantrone, methotrexate and vincristine in metastatic breast cancer;Q422232;P2175;Q128581
Comparison of Body Size, Morphomics, and Kidney Function as Covariates of High-Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma;Q422232;P2175;Q136312
Comparison of Body Size, Morphomics, and Kidney Function as Covariates of High-Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma;Q422232;P2175;Q208414
Comparison of hemodialysis versus hemoperfusion in the clearance of high-dose methotrexate in pigs.;Q422232;P636;Q640448
[Sequential chemotherapy with low-dose methotrexate and 5-fluorouracil in advanced gastric cancer];Q238512;P2175;Q189588
[Sequential chemotherapy with low-dose methotrexate and 5-fluorouracil in advanced gastric cancer];Q422232;P2175;Q189588
Fertility and reproductive outcome after tubal ectopic pregnancy: comparison among methotrexate, surgery and expectant management;Q422232;P2175;Q207087
Efficacy of vitamin D in patients with active rheumatoid arthritis receiving methotrexate therapy.;Q422232;P2175;Q187255
Efficacy of vitamin D in patients with active rheumatoid arthritis receiving methotrexate therapy.;Q422232;P2175;Q170990
[A preliminary study of vincristine, methotrexate, and prednisolone (VM*P) combination chemotherapy for advanced adult non-Hodgkin's lymphoma];Q408977;P2175;Q208414
[A preliminary study of vincristine, methotrexate, and prednisolone (VM*P) combination chemotherapy for advanced adult non-Hodgkin's lymphoma];Q408977;P2175;Q1138590
[A preliminary study of vincristine, methotrexate, and prednisolone (VM*P) combination chemotherapy for advanced adult non-Hodgkin's lymphoma];Q11426176;P2175;Q1138590
[A preliminary study of vincristine, methotrexate, and prednisolone (VM*P) combination chemotherapy for advanced adult non-Hodgkin's lymphoma];Q11426176;P2175;Q208414
[A preliminary study of vincristine, methotrexate, and prednisolone (VM*P) combination chemotherapy for advanced adult non-Hodgkin's lymphoma];Q422232;P2175;Q1138590
[A preliminary study of vincristine, methotrexate, and prednisolone (VM*P) combination chemotherapy for advanced adult non-Hodgkin's lymphoma];Q422232;P2175;Q208414
Methotrexate polyglutamate synthesis in lymphoblasts from children with acute lymphoblastic leukemia.;Q422232;P2175;Q29496
[A case of rheumatoid arthritis complicated with a pneumonitis during concomitant treatment with methotrexate and bucillamine].;Q422232;P2175;Q170990
[A case of rheumatoid arthritis complicated with a pneumonitis during concomitant treatment with methotrexate and bucillamine].;Q422232;P2175;Q187255
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis.;Q241374;P2175;Q1072420
Inadequate folinic acid rescue after methotrexate causing neurocognitive and neuroradiological central nervous system late effects in children with acute lymphatic leukemia;Q422232;P2175;Q29496
Prognostic factors for the outcome of methotrexate treatment in rheumatoid arthritis;Q422232;P2175;Q170990
Prognostic factors for the outcome of methotrexate treatment in rheumatoid arthritis;Q422232;P2175;Q187255
Variability of oral bioavailability for low dose methotrexate in rats.;Q422232;P636;Q285166
[Immunodeficiency-associated Burkitt lymphoma developed in a patient receiving a long-term methotrexate therapy for rheumatoid arthritis].;Q422232;P2175;Q208414
[Immunodeficiency-associated Burkitt lymphoma developed in a patient receiving a long-term methotrexate therapy for rheumatoid arthritis].;Q422232;P2175;Q170990
[Immunodeficiency-associated Burkitt lymphoma developed in a patient receiving a long-term methotrexate therapy for rheumatoid arthritis].;Q422232;P2175;Q187255
A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.;Q238512;P2175;Q189588
A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.;Q422232;P2175;Q189588
Cytomegalovirus-induced infectious mononucleosis-like syndrome in a rheumatoid arthritis patient treated with methotrexate and infliximab.;Q415264;P2175;Q170990
Cytomegalovirus-induced infectious mononucleosis-like syndrome in a rheumatoid arthritis patient treated with methotrexate and infliximab.;Q422232;P2175;Q170990
Cytomegalovirus-induced infectious mononucleosis-like syndrome in a rheumatoid arthritis patient treated with methotrexate and infliximab.;Q422232;P2175;Q187255
Stability of four standardized preparations of methotrexate, cytarabine, and hydrocortisone for intrathecal use;Q190875;P2959;Q26981430
Stability of four standardized preparations of methotrexate, cytarabine, and hydrocortisone for intrathecal use;Q422232;P636;Q1320251
Methotrexate and its effect on the anti-GAD titre in two patients with rheumatoid arthritis and diabetes mellitus;Q422232;P2175;Q187255
Methotrexate and its effect on the anti-GAD titre in two patients with rheumatoid arthritis and diabetes mellitus;Q422232;P2175;Q170990
A case of acute diffuse large B cell lymphoma in an anti-human T-cell leukaemia virus type 1-positive rheumatoid arthritis patient treated with methotrexate, who died;Q218642;P703;Q15978631
A case of acute diffuse large B cell lymphoma in an anti-human T-cell leukaemia virus type 1-positive rheumatoid arthritis patient treated with methotrexate, who died;Q186521;P703;Q15978631
A case of acute diffuse large B cell lymphoma in an anti-human T-cell leukaemia virus type 1-positive rheumatoid arthritis patient treated with methotrexate, who died;Q422232;P2175;Q170990
A case of acute diffuse large B cell lymphoma in an anti-human T-cell leukaemia virus type 1-positive rheumatoid arthritis patient treated with methotrexate, who died;Q422232;P2175;Q187255
A case of acute diffuse large B cell lymphoma in an anti-human T-cell leukaemia virus type 1-positive rheumatoid arthritis patient treated with methotrexate, who died;Q422232;P2175;Q208414
A case of acute diffuse large B cell lymphoma in an anti-human T-cell leukaemia virus type 1-positive rheumatoid arthritis patient treated with methotrexate, who died;Q422232;P2175;Q29496
Comparison of the impact of Tripterygium wilfordii Hook F and Methotrexate treatment on radiological progression in active rheumatoid arthritis: 2-year followup of a randomized, non-blinded, controlled study.;Q422232;P2175;Q170990
Comparison of the impact of Tripterygium wilfordii Hook F and Methotrexate treatment on radiological progression in active rheumatoid arthritis: 2-year followup of a randomized, non-blinded, controlled study.;Q422232;P2175;Q187255
Treatment of advanced mycosis fungoides and Szary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.;Q422232;P2175;Q1891209
A Case of Bullous Morphea Resistant to Methotrexate and Phototherapy Successfully Treated With Mycophenolate Mofetil;Q130336;P4149;Q27122100
A Case of Bullous Morphea Resistant to Methotrexate and Phototherapy Successfully Treated With Mycophenolate Mofetil;Q130336;P31;Q407142
High serum level of haptoglobin is associated with the response of 12weeks methotrexate therapy in recent-onset rheumatoid arthritis patients;Q422232;P2175;Q170990
High serum level of haptoglobin is associated with the response of 12weeks methotrexate therapy in recent-onset rheumatoid arthritis patients;Q422232;P2175;Q187255
The effect of tryptophan plus methionine, 5-azacytidine, and methotrexate on adjuvant arthritis of rat.;Q422232;P2175;Q170990
Influence of biological variables upon pharmacokinetic parameters of intramuscular methotrexate in rheumatoid arthritis.;Q422232;P2175;Q187255
Influence of biological variables upon pharmacokinetic parameters of intramuscular methotrexate in rheumatoid arthritis.;Q422232;P2175;Q170990
Dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide (SMILE) chemotherapy for relapsed or refractory adult lymphoblastic lymphoma.;Q418817;P2175;Q208414
Dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide (SMILE) chemotherapy for relapsed or refractory adult lymphoblastic lymphoma.;Q422232;P2175;Q208414
Beyond methotrexate monotherapy for early rheumatoid arthritis.;Q422232;P2175;Q187255
Beyond methotrexate monotherapy for early rheumatoid arthritis.;Q422232;P2175;Q170990
Requirement of methotrexate in combination with anti-tumor necrosis factor-alpha therapy for adequate suppression of osteoclastogenesis in rheumatoid arthritis;Q422232;P2175;Q170990
Requirement of methotrexate in combination with anti-tumor necrosis factor-alpha therapy for adequate suppression of osteoclastogenesis in rheumatoid arthritis;Q422232;P2175;Q187255
Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis.;Q422232;P2175;Q170990
Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis.;Q422232;P2175;Q187255
[Study on targeting drug delivery system--the animal behavior in vivo after hepatic arterial embolization of methotrexate microsphere];Q183290;P31;Q12140
[Study on targeting drug delivery system--the animal behavior in vivo after hepatic arterial embolization of methotrexate microsphere];Q191924;P366;Q8386
[Study on targeting drug delivery system--the animal behavior in vivo after hepatic arterial embolization of methotrexate microsphere];Q422232;P31;Q12140
Re: Effect of nitrous oxide on human bone marrow cells and its synergistic effect with methionine and methotrexate on functional folate deficiency.;Q173670;P703;Q15978631
Cutaneous S100-negative, CD1a-positive histiocytosis successfully treated with combination therapy of oral methotrexate and corticosteroid;Q422232;P636;Q285166
Comparison of golimumab 100-mg monotherapy to golimumab 50 mg plus methotrexate in patients with rheumatoid arthritis: Results from a multicenter, cohort study;Q413879;P2175;Q170990
Comparison of golimumab 100-mg monotherapy to golimumab 50 mg plus methotrexate in patients with rheumatoid arthritis: Results from a multicenter, cohort study;Q422232;P2175;Q187255
Comparison of golimumab 100-mg monotherapy to golimumab 50 mg plus methotrexate in patients with rheumatoid arthritis: Results from a multicenter, cohort study;Q422232;P2175;Q170990
A randomized comparison of cyclophosphamide, Adriamycin, and 5-fluorouracil with triethylenethiophosphoramide and methotrexate, both as sequential and as fixed rotational treatment in patients with advanced ovarian cancer;Q18936;P2175;Q172341
A randomized comparison of cyclophosphamide, Adriamycin, and 5-fluorouracil with triethylenethiophosphoramide and methotrexate, both as sequential and as fixed rotational treatment in patients with advanced ovarian cancer;Q18936;P3780;Q47520887
Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP).;Q18936;P3780;Q47520887
Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP).;Q412415;P527;Q880
Suppression of expulsion of Aspiculuris tetraptera in hydrocortisone and methotrexate treated mice.;Q190875;P2959;Q26981430
Vinorelbine, epirubicin, and methotrexate (VEM) as primary treatment in locally advanced breast cancer.;Q425122;P2175;Q128581
Vinorelbine, epirubicin, and methotrexate (VEM) as primary treatment in locally advanced breast cancer.;Q422232;P2175;Q128581
Synergistic action of taxol with tiazofurin and methotrexate in human breast cancer cells: schedule-dependence.;Q183290;P703;Q15978631
Synergistic action of taxol with tiazofurin and methotrexate in human breast cancer cells: schedule-dependence.;Q422232;P2175;Q128581
[Hypertransaminemia and methotrexate: not always a toxic effect?];Q191924;P769;Q420885
Saddle pulmonary embolus and bronchiolitis obliterans with organizing pneumonia develop simultaneously after first cyclophosphamide, methotrexate, 5FU chemotherapy for breast cancer.;Q238512;P2175;Q128581
Saddle pulmonary embolus and bronchiolitis obliterans with organizing pneumonia develop simultaneously after first cyclophosphamide, methotrexate, 5FU chemotherapy for breast cancer.;Q422232;P2175;Q128581
Methotrexate therapy is not associated with increased liver stiffness and significant liver fibrosis in rheumatoid arthritis patients: A cross-sectional controlled study with real-time two-dimensional shear wave elastography;Q422232;P2175;Q187255
Methotrexate therapy is not associated with increased liver stiffness and significant liver fibrosis in rheumatoid arthritis patients: A cross-sectional controlled study with real-time two-dimensional shear wave elastography;Q422232;P2175;Q170990
Oral toxicity of isotretinoin, misoprostol, methotrexate, mifepristone and levonorgestrel as pregnancy category X medications in female mice;Q411240;P31;Q12140
Oral toxicity of isotretinoin, misoprostol, methotrexate, mifepristone and levonorgestrel as pregnancy category X medications in female mice;Q29417;P31;Q12140
Oral toxicity of isotretinoin, misoprostol, methotrexate, mifepristone and levonorgestrel as pregnancy category X medications in female mice;Q287029;P31;Q12140
Oral toxicity of isotretinoin, misoprostol, methotrexate, mifepristone and levonorgestrel as pregnancy category X medications in female mice;Q191924;P31;Q12140
Oral toxicity of isotretinoin, misoprostol, methotrexate, mifepristone and levonorgestrel as pregnancy category X medications in female mice;Q416025;P31;Q12140
Oral toxicity of isotretinoin, misoprostol, methotrexate, mifepristone and levonorgestrel as pregnancy category X medications in female mice;Q416950;P31;Q12140
Oral toxicity of isotretinoin, misoprostol, methotrexate, mifepristone and levonorgestrel as pregnancy category X medications in female mice;Q422232;P31;Q12140
Mechanisms of acquired resistance to methotrexate in a human squamous carcinoma cell line of the head and neck, exposed to different treatment schedules.;Q22124685;P703;Q15978631
The place of methotrexate in the treatment of rheumatoid arthritis. Introduction.;Q422232;P2175;Q170990
The place of methotrexate in the treatment of rheumatoid arthritis. Introduction.;Q422232;P2175;Q187255
VP-16, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.;Q418817;P2175;Q1138590
VP-16, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.;Q418817;P2175;Q208414
VP-16, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.;Q422232;P2175;Q208414
VP-16, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.;Q422232;P2175;Q1138590
Summaries for patients. Adding low-dose prednisone to methotrexate therapy for early rheumatoid arthritis;Q424972;P2175;Q170990
Summaries for patients. Adding low-dose prednisone to methotrexate therapy for early rheumatoid arthritis;Q422232;P2175;Q170990
Summaries for patients. Adding low-dose prednisone to methotrexate therapy for early rheumatoid arthritis;Q422232;P2175;Q187255
Experience with methotrexate, 5-fluorouracil, and leucovorin (MFL): a first line effective, minimally toxic regimen for metastatic breast cancer.;Q238512;P2175;Q128581
Experience with methotrexate, 5-fluorouracil, and leucovorin (MFL): a first line effective, minimally toxic regimen for metastatic breast cancer.;Q422232;P2175;Q128581
[Delayed clearance of methotrexate in a patient with malignant lymphoma who developed renal failure].;Q422232;P2175;Q208414
Carboplatin, continuous infusion fluorouracil and mid-cycle high-dose methotrexate as initial treatment in patients with locally advanced head and neck cancer. Hellenic Co-operative Oncology Group Study.;Q238512;P2175;Q1783924
Carboplatin, continuous infusion fluorouracil and mid-cycle high-dose methotrexate as initial treatment in patients with locally advanced head and neck cancer. Hellenic Co-operative Oncology Group Study.;Q422232;P2175;Q1783924
Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma.;Q422232;P2175;Q136312
Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma.;Q422232;P2175;Q208414
Bioreducible cross-linked core polymer micelles enhance in vitro activity of methotrexate in breast cancer cells.;Q422232;P2175;Q128581
Cyclosporine Plus Methotrexate or Cyclosporine Plus Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis in Acute Leukemia Transplant: Comparison of Toxicity, Engraftment Kinetics and Transplant Outcome.;Q130336;P4149;Q27122100
Cyclosporine Plus Methotrexate or Cyclosporine Plus Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis in Acute Leukemia Transplant: Comparison of Toxicity, Engraftment Kinetics and Transplant Outcome.;Q130336;P31;Q407142
Combined radiotherapy and chemotherapy with cyclophosphamide, adriamycin, methotrexate, procarbazine (CAMP) in 64 consecutive patients with epidermoid bronchogenic carcinoma, limited disease: a prospective study;Q191924;P769;Q418656
CADTH Canadian Drug Expert Committee Recommendation: Baricitinib (Olumiant  Eli Lilly Canada Inc.): Indication: For use in combination with methotrexate (MTX) for the treatment of adult patients with moderate to severe rheumatoid arthritis (RA) who;Q422232;P2175;Q170990
CADTH Canadian Drug Expert Committee Recommendation: Baricitinib (Olumiant  Eli Lilly Canada Inc.): Indication: For use in combination with methotrexate (MTX) for the treatment of adult patients with moderate to severe rheumatoid arthritis (RA) who;Q422232;P2175;Q187255
Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged <65years and those 65years of age;Q413879;P2175;Q170990
Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged <65years and those 65years of age;Q422232;P2175;Q170990
Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged <65years and those 65years of age;Q422232;P2175;Q187255
[Psoriatic arthritis: combined treatment with prospidin and methotrexate];Q422232;P2175;Q170990
Methotrexate treatment of unruptured ectopic pregnancy: a report of 100 cases.;Q422232;P2175;Q207087
The effect of colchicine and low-dose methotrexate on intestinal ischemia/reperfusion injury in an experimental model;Q422232;P636;Q640448
Association between SLC19A1 Gene Polymorphism and High Dose Methotrexate Toxicity in Childhood Acute Lymphoblastic Leukaemia and Non Hodgkin Malignant Lymphoma: Introducing a Haplotype based Approach.;Q422232;P2175;Q208414
Association between SLC19A1 Gene Polymorphism and High Dose Methotrexate Toxicity in Childhood Acute Lymphoblastic Leukaemia and Non Hodgkin Malignant Lymphoma: Introducing a Haplotype based Approach.;Q422232;P129;Q21126218
Preclinical trials using an immunoconjugate of T101 and methotrexate in an athymic mouse/human T-cell tumor model.;Q186521;P703;Q15978631
Preclinical trials using an immunoconjugate of T101 and methotrexate in an athymic mouse/human T-cell tumor model.;Q20035886;P703;Q15978631
Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice;Q218642;P31;Q12140
Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice;Q183290;P31;Q12140
Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice;Q191924;P31;Q12140
Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice;Q178450;P31;Q12140
Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice;Q707939;P31;Q12140
Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice;Q484940;P31;Q12140
Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice;Q422232;P31;Q12140
Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice;Q422232;P2868;Q810254
Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice;Q422232;P2175;Q187255
Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice;Q422232;P2175;Q170990
Further studies on the pharmacologic effects of the 7-hydroxy catabolite of methotrexate in the L1210 murine leukemia cell.;Q422232;P2175;Q29496
Selection of the wavelength range and spectrophotometric determination of leucovorin and methotrexate in human serum by a net analyte signal based method;Q183290;P703;Q15978631
Selection of the wavelength range and spectrophotometric determination of leucovorin and methotrexate in human serum by a net analyte signal based method;Q483745;P703;Q15978631
[Combined drug treatment of pemphigus using corticosteroids and methotrexate];Q186474;P31;Q12140
[Combined drug treatment of pemphigus using corticosteroids and methotrexate];Q191924;P31;Q12140
[Combined drug treatment of pemphigus using corticosteroids and methotrexate];Q210420;P31;Q12140
[Combined drug treatment of pemphigus using corticosteroids and methotrexate];Q422232;P31;Q12140
New aspects of clinical and cellular pharmacodynamics of methotrexate with special emphasis on its role in the treatment of acute lymphoblastic leukemia in children.;Q422232;P2175;Q29496
Dihydrofolate reductase activity of leukemia L1210 during development of methotrexate resistance.;Q422232;P2175;Q29496
Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study;Q422232;P636;Q285166
Combination chemotherapy for metastatic urinary bladder cancer with 5-FU, vincristine, bleomycin, cyclophosphamide, mitomycin, and methotrexate;Q19856779;P2175;Q504775
Combination chemotherapy for metastatic urinary bladder cancer with 5-FU, vincristine, bleomycin, cyclophosphamide, mitomycin, and methotrexate;Q19856779;P1889;Q417625
The mechanism of differential sensitivity to methotrexate of normal and malignant human epidermal cells.;Q186521;P703;Q15978631
A rare case of methotrexate and primaquine co-administration in a mantle cell lymphoma patient;Q422232;P2175;Q208414
Systematic review and meta-analysis of single-dose and non-single-dose methotrexate protocols in the treatment of ectopic pregnancy;Q422232;P2175;Q207087
Tolerance of parenteral, higher dose methotrexate in children with juvenile chronic arthritis;Q422232;P2175;Q170990
Disparate results in studies of methotrexate plus corticosteroids in the treatment of giant cell arteritis: comment on the article by Hoffman et al.;Q422232;P2175;Q707816
[Clinical efficacy of a quadruple combination chemotherapy with ACNU, adriamycin, methotrexate, and prednisolone for patients with non-Hodgkin's lymphoma, who were refractory to VEPA (P) treatment];Q11426176;P2175;Q1138590
[Clinical efficacy of a quadruple combination chemotherapy with ACNU, adriamycin, methotrexate, and prednisolone for patients with non-Hodgkin's lymphoma, who were refractory to VEPA (P) treatment];Q11426176;P2175;Q208414
[Clinical efficacy of a quadruple combination chemotherapy with ACNU, adriamycin, methotrexate, and prednisolone for patients with non-Hodgkin's lymphoma, who were refractory to VEPA (P) treatment];Q422232;P2175;Q208414
[Clinical efficacy of a quadruple combination chemotherapy with ACNU, adriamycin, methotrexate, and prednisolone for patients with non-Hodgkin's lymphoma, who were refractory to VEPA (P) treatment];Q422232;P2175;Q1138590
13C NMR studies of complexes of Escherichia coli dihydrofolate reductase formed with methotrexate and with folic acid.;Q186474;P703;Q25419
13C NMR studies of complexes of Escherichia coli dihydrofolate reductase formed with methotrexate and with folic acid.;Q173670;P703;Q25419
13C NMR studies of complexes of Escherichia coli dihydrofolate reductase formed with methotrexate and with folic acid.;Q22124685;P703;Q25419
13C NMR studies of complexes of Escherichia coli dihydrofolate reductase formed with methotrexate and with folic acid.;Q422232;P2868;Q127060
Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practice;Q422232;P2175;Q170990
Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practice;Q422232;P2175;Q187255
Response to methotrexate predicts long-term mortality of patients with rheumatoid arthritis independent of the degree of response: results of a re-evaluation 30 years after baseline.;Q422232;P2175;Q170990
Response to methotrexate predicts long-term mortality of patients with rheumatoid arthritis independent of the degree of response: results of a re-evaluation 30 years after baseline.;Q422232;P2175;Q187255
Self-targeted, bacillus-shaped, and controlled-release methotrexate prodrug polymeric nanoparticles for intratumoral administration with improved therapeutic efficacy in tumor-bearing mice;Q183290;P31;Q12140
Self-targeted, bacillus-shaped, and controlled-release methotrexate prodrug polymeric nanoparticles for intratumoral administration with improved therapeutic efficacy in tumor-bearing mice;Q183290;P703;Q177932
Self-targeted, bacillus-shaped, and controlled-release methotrexate prodrug polymeric nanoparticles for intratumoral administration with improved therapeutic efficacy in tumor-bearing mice;Q191924;P31;Q12140
Self-targeted, bacillus-shaped, and controlled-release methotrexate prodrug polymeric nanoparticles for intratumoral administration with improved therapeutic efficacy in tumor-bearing mice;Q422232;P31;Q12140
Self-targeted, bacillus-shaped, and controlled-release methotrexate prodrug polymeric nanoparticles for intratumoral administration with improved therapeutic efficacy in tumor-bearing mice;Q422232;P636;Q285166
Analysis of association of ADORA2A and ADORA3 polymorphisms genotypes/haplotypes with efficacy and toxicity of methotrexate in patients with Rheumatoid arthritis;Q422232;P2175;Q170990
Analysis of association of ADORA2A and ADORA3 polymorphisms genotypes/haplotypes with efficacy and toxicity of methotrexate in patients with Rheumatoid arthritis;Q422232;P2175;Q187255
SLC04A1, SLC22A2 and SLC28A2 variants not related to methotrexate efficacy or toxicity in rheumatoid arthritis patients;Q422232;P2175;Q170990
SLC04A1, SLC22A2 and SLC28A2 variants not related to methotrexate efficacy or toxicity in rheumatoid arthritis patients;Q422232;P2175;Q187255
Results of Medical Research Council phase II study of low dose cisplatin and methotrexate in the primary treatment of locally advanced (T3 and T4) transitional cell carcinoma of the bladder.;Q412415;P2175;Q2501186
Treatment of metastatic gestational choriocarcinoma with oral methotrexate in a combat environment;Q422232;P636;Q285166
High level expression of human proteins in murine hybridoma cells: induction by methotrexate in the absence of gene amplification.;Q485277;P703;Q15978631
Effect of downregulation of serum MMP-3 levels by traditional Chinese medicine ingredients combined with methotrexate on the progression of bone injury in patients with rheumatoid arthritis: A protocol for a systematic review and meta-analysis;Q218642;P31;Q12140
Effect of downregulation of serum MMP-3 levels by traditional Chinese medicine ingredients combined with methotrexate on the progression of bone injury in patients with rheumatoid arthritis: A protocol for a systematic review and meta-analysis;Q186474;P31;Q12140
Effect of downregulation of serum MMP-3 levels by traditional Chinese medicine ingredients combined with methotrexate on the progression of bone injury in patients with rheumatoid arthritis: A protocol for a systematic review and meta-analysis;Q191924;P31;Q12140
Effect of downregulation of serum MMP-3 levels by traditional Chinese medicine ingredients combined with methotrexate on the progression of bone injury in patients with rheumatoid arthritis: A protocol for a systematic review and meta-analysis;Q20035886;P31;Q12140
Effect of downregulation of serum MMP-3 levels by traditional Chinese medicine ingredients combined with methotrexate on the progression of bone injury in patients with rheumatoid arthritis: A protocol for a systematic review and meta-analysis;Q22124685;P31;Q12140
Effect of downregulation of serum MMP-3 levels by traditional Chinese medicine ingredients combined with methotrexate on the progression of bone injury in patients with rheumatoid arthritis: A protocol for a systematic review and meta-analysis;Q422232;P2175;Q187255
Effect of downregulation of serum MMP-3 levels by traditional Chinese medicine ingredients combined with methotrexate on the progression of bone injury in patients with rheumatoid arthritis: A protocol for a systematic review and meta-analysis;Q422232;P31;Q12140
Effect of downregulation of serum MMP-3 levels by traditional Chinese medicine ingredients combined with methotrexate on the progression of bone injury in patients with rheumatoid arthritis: A protocol for a systematic review and meta-analysis;Q422232;P2175;Q170990
Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).;Q412415;P2175;Q549534
Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).;Q422232;P2175;Q549534
Delayed methotrexate clearance and acute kidney injury after high-dose methotrexate chemotherapy concurrent with dasatinib in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia: A case report;Q422232;P2175;Q29496
ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial;Q218642;P703;Q15978631
ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial;Q183290;P703;Q15978631
ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial;Q178450;P703;Q15978631
ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial;Q20035886;P703;Q15978631
ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial;Q422232;P2175;Q170990
ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial;Q422232;P2175;Q187255
CAMP (cyclophosphamide, doxorubicin, methotrexate, and procarbazine) for epidermoid and large cell anaplastic carcinoma of the lung;Q191924;P769;Q418656
Dose response relationship of methotrexate in combination with cisplatin in murine bladder cancer;Q412415;P2175;Q504775
Methotrexate in superficial bladder cancer--what happens to the drug?;Q22124685;P31;Q12140
Methotrexate in superficial bladder cancer--what happens to the drug?;Q422232;P31;Q12140
Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate;Q415343;P2868;Q810254
Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate;Q422232;P2868;Q810254
[Pancytopenia induced by two low-dose injections of methotrexate in a patient treated for ulcerative colitis].;Q422232;P2175;Q1477
25 mg or 50 mg of oral methotrexate followed by vaginal misoprostol 7 days after for early abortion: a randomized trial;Q416025;P636;Q285166
25 mg or 50 mg of oral methotrexate followed by vaginal misoprostol 7 days after for early abortion: a randomized trial;Q416025;P636;Q4112929
25 mg or 50 mg of oral methotrexate followed by vaginal misoprostol 7 days after for early abortion: a randomized trial;Q422232;P636;Q285166
Ultrasound-detected activity in rheumatoid arthritis on methotrexate therapy: Which joints and tendons should be assessed to predict unstable remission?;Q422232;P2175;Q170990
Ultrasound-detected activity in rheumatoid arthritis on methotrexate therapy: Which joints and tendons should be assessed to predict unstable remission?;Q422232;P2175;Q187255
Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis.;Q367700;P2175;Q187255
Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis.;Q421094;P1889;Q422438
Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis.;Q421094;P2175;Q187255
Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis.;Q421094;P2175;Q170990
Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis.;Q422438;P2175;Q187255
Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis.;Q422438;P1889;Q421094
Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis.;Q422232;P2175;Q170990
Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis.;Q422232;P2175;Q187255
Therapeutic benefits of Indole-3-Carbinol in adjuvant-induced arthritis and its protective effect against methotrexate induced-hepatic toxicity;Q186474;P703;Q177932
Therapeutic benefits of Indole-3-Carbinol in adjuvant-induced arthritis and its protective effect against methotrexate induced-hepatic toxicity;Q186521;P703;Q177932
Therapeutic benefits of Indole-3-Carbinol in adjuvant-induced arthritis and its protective effect against methotrexate induced-hepatic toxicity;Q484940;P703;Q177932
Therapeutic benefits of Indole-3-Carbinol in adjuvant-induced arthritis and its protective effect against methotrexate induced-hepatic toxicity;Q422232;P2175;Q170990
Acute encephalomyelitis complicated with severe neurological sequelae after intrathecal administration of methotrexate in a patient with acute lymphoblastic leukemia.;Q422232;P636;Q1320251
Acute encephalomyelitis complicated with severe neurological sequelae after intrathecal administration of methotrexate in a patient with acute lymphoblastic leukemia.;Q422232;P2175;Q29496
Trends in serum human chorionic gonadotropin levels 0-4days after methotrexate administration for predicting tubal ectopic pregnancy treatment success.;Q407172;P703;Q15978631
Trends in serum human chorionic gonadotropin levels 0-4days after methotrexate administration for predicting tubal ectopic pregnancy treatment success.;Q407172;P279;Q409770
Trends in serum human chorionic gonadotropin levels 0-4days after methotrexate administration for predicting tubal ectopic pregnancy treatment success.;Q186521;P703;Q15978631
Trends in serum human chorionic gonadotropin levels 0-4days after methotrexate administration for predicting tubal ectopic pregnancy treatment success.;Q422232;P2175;Q207087
Low-dose mitomycin and weekly low-dose doxorubicin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, and 5-fluorouracil;Q19856779;P1889;Q417625
Physical Compatibility of Micafungin With Sodium Bicarbonate Hydration Fluids Commonly Used With High-Dose Methotrexate Chemotherapy;Q181003;P527;Q623
Physical Compatibility of Micafungin With Sodium Bicarbonate Hydration Fluids Commonly Used With High-Dose Methotrexate Chemotherapy;Q183290;P527;Q623
Physical Compatibility of Micafungin With Sodium Bicarbonate Hydration Fluids Commonly Used With High-Dose Methotrexate Chemotherapy;Q186474;P527;Q623
Physical Compatibility of Micafungin With Sodium Bicarbonate Hydration Fluids Commonly Used With High-Dose Methotrexate Chemotherapy;Q485277;P527;Q623
Physical Compatibility of Micafungin With Sodium Bicarbonate Hydration Fluids Commonly Used With High-Dose Methotrexate Chemotherapy;Q170545;P527;Q623
Physical Compatibility of Micafungin With Sodium Bicarbonate Hydration Fluids Commonly Used With High-Dose Methotrexate Chemotherapy;Q179731;P527;Q623
Physical Compatibility of Micafungin With Sodium Bicarbonate Hydration Fluids Commonly Used With High-Dose Methotrexate Chemotherapy;Q178450;P527;Q623
Intolerance of folic acid in a patient receiving methotrexate for Crohn's disease;Q422232;P2868;Q127060
Leukoencephalopathy and cortical laminar necrosis associated with intrathecal methotrexate and cranial irradiation;Q422232;P636;Q1320251
Liver disease, erroneously attributed to methotrexate, in a patient with rheumatoid arthritis.;Q422232;P2175;Q187255
Liver disease, erroneously attributed to methotrexate, in a patient with rheumatoid arthritis.;Q422232;P2175;Q170990
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation;Q130336;P4149;Q27122100
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation;Q130336;P31;Q407142
[Cerebral complications after irradiation and administration of methotrexate in lymphatic leukemia in the computerized tomography picture];Q422232;P2175;Q29496
Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy;Q218642;P703;Q2046782
Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy;Q178450;P703;Q2046782
Hyperosmolar and methotrexate therapy avoiding surgery in the acute presentation of primary central nervous system lymphoma.;Q422232;P2175;Q136312
Hyperosmolar and methotrexate therapy avoiding surgery in the acute presentation of primary central nervous system lymphoma.;Q422232;P2175;Q208414
Methotrexate for ankylosing spondylitis;Q422232;P2175;Q52849
PReS-FINAL-2165: Pharmacogenetic determinants of response to methotrexate in juvenile idiopathic arthritis.;Q422232;P2175;Q170990
PReS-FINAL-2165: Pharmacogenetic determinants of response to methotrexate in juvenile idiopathic arthritis.;Q422232;P2175;Q861224
PReS-FINAL-2165: Pharmacogenetic determinants of response to methotrexate in juvenile idiopathic arthritis.;Q422232;P361;Q14819383
[Radiotherapy-oral methotrexate association in cancers of the head and neck];Q422232;P636;Q285166
Efficacy and safety of Ramucirumab and methotrexate co-therapy in rheumatoid arthritis experimental model: Involvement of angiogenic and immunomodulatory signaling;Q422232;P2175;Q170990
Efficacy and safety of Ramucirumab and methotrexate co-therapy in rheumatoid arthritis experimental model: Involvement of angiogenic and immunomodulatory signaling;Q422232;P2175;Q187255
Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic;Q186474;P31;Q12140
Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic;Q186521;P31;Q12140
Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic;Q191924;P31;Q12140
Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic;Q178450;P31;Q12140
Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic;Q2858961;P31;Q12140
Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic;Q2858961;P2175;Q179945
Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic;Q4972934;P31;Q12140
Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic;Q4972934;P2175;Q179945
Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic;Q424972;P31;Q12140
Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic;Q483752;P31;Q12140
Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic;Q484940;P31;Q12140
Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic;Q422232;P31;Q12140
Effect of hydrocortisone, cyclophosphamide, azathioprine and methotrexate on cutaneous delayed and arthus hypersensitivity in the rat.;Q190875;P2959;Q26981430
Successful rapid drug desensitization to methotrexate in a patient with primary central nervous system lymphoma.;Q183290;P31;Q12140
Successful rapid drug desensitization to methotrexate in a patient with primary central nervous system lymphoma.;Q191924;P366;Q8386
Successful rapid drug desensitization to methotrexate in a patient with primary central nervous system lymphoma.;Q422232;P31;Q12140
Successful rapid drug desensitization to methotrexate in a patient with primary central nervous system lymphoma.;Q422232;P2175;Q136312
Successful rapid drug desensitization to methotrexate in a patient with primary central nervous system lymphoma.;Q422232;P2175;Q208414
Effect of lipid-soluble esters of methotrexate on DNA synthesis in human skin.;Q218642;P703;Q15978631
Effect of lipid-soluble esters of methotrexate on DNA synthesis in human skin.;Q178450;P703;Q15978631
[Safety of methotrexate in rheumatoid arthritis: a retrospective cohort study in clinical practice];Q422232;P2175;Q170990
[Safety of methotrexate in rheumatoid arthritis: a retrospective cohort study in clinical practice];Q422232;P2175;Q187255
Effect of etanercept, infliximab and methotrexate in the treatment of arthritis;Q415264;P2175;Q170990
Effect of etanercept, infliximab and methotrexate in the treatment of arthritis;Q422232;P2175;Q170990
Methotrexate released in vitro from bone cement inhibits human stem cell proliferation in S/G2 phase.;Q183290;P703;Q15978631
Methotrexate released in vitro from bone cement inhibits human stem cell proliferation in S/G2 phase.;Q22124685;P703;Q15978631
Methotrexate released in vitro from bone cement inhibits human stem cell proliferation in S/G2 phase.;Q620730;P703;Q15978631
Hepatoprotective effect of gentiopicroside in combination with leflunomide and/or methotrexate in arthritic rats;Q248550;P2175;Q170990
Hepatoprotective effect of gentiopicroside in combination with leflunomide and/or methotrexate in arthritic rats;Q422232;P2175;Q170990
[Renal leiomyosarcoma, rheumatoid arthritis and methotrexate];Q422232;P2175;Q187255
[Renal leiomyosarcoma, rheumatoid arthritis and methotrexate];Q422232;P2175;Q170990
Mechanism of acquired resistance to methotrexate in P388 murine leukemia cells and in their doxorubicin-resistant subline.;Q422232;P2175;Q29496
Methotrexate treatment of tubal pregnancy;Q422232;P2175;Q207087
hCG monitoring after single-dose methotrexate treatment of tubal ectopic pregnancy: is the Day 4 hCG necessary? A retrospective cohort study;Q422232;P2175;Q207087
[Paraplegia after intrathecal injection of methotrexate];Q422232;P636;Q1320251
High-dose intravenous methotrexate in the management of breast cancer with leptomeningeal disease: Case series and review of the literature;Q422232;P2175;Q128581
Phase II study of sequential methotrexate and 5-FU combination in the treatment of advanced colorectal cancer;Q238512;P2175;Q2739660
The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis.;Q218642;P703;Q177932
The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis.;Q186474;P703;Q177932
The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis.;Q186521;P703;Q177932
The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis.;Q173670;P703;Q177932
The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis.;Q178450;P703;Q177932
The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis.;Q20035886;P703;Q177932
The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis.;Q22124685;P703;Q177932
The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis.;Q620730;P703;Q177932
The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis.;Q483745;P703;Q177932
The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis.;Q484940;P703;Q177932
Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.;Q422232;P2175;Q170990
Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.;Q422232;P2175;Q187255
Methotrexate regulates the expression of glucocorticoid receptor alpha and beta isoforms in normal human peripheral mononuclear cells and human lymphocyte cell lines in vitro;Q22124685;P703;Q15978631
Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas;Q418817;P2175;Q208414
Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas;Q422232;P2175;Q208414
Substitutive therapy in a case of methotrexate neurotoxicity;Q191924;P2868;Q407752
[Conservative treatment of interstitial ectopic pregnancy and endometriosis with laparoscopic methotrexate and potassium chloride and complementary management with nasal nafarelin. Report of a case and review of the literature];Q184630;P527;Q703
[Conservative treatment of interstitial ectopic pregnancy and endometriosis with laparoscopic methotrexate and potassium chloride and complementary management with nasal nafarelin. Report of a case and review of the literature];Q184630;P527;Q108200
[Conservative treatment of interstitial ectopic pregnancy and endometriosis with laparoscopic methotrexate and potassium chloride and complementary management with nasal nafarelin. Report of a case and review of the literature];Q3869873;P2175;Q205764
[Conservative treatment of interstitial ectopic pregnancy and endometriosis with laparoscopic methotrexate and potassium chloride and complementary management with nasal nafarelin. Report of a case and review of the literature];Q422232;P2175;Q207087
Characterization of cross-resistance to methotrexate in a human breast cancer cell line selected for resistance to melphalan.;Q186474;P703;Q15978631
Characterization of cross-resistance to methotrexate in a human breast cancer cell line selected for resistance to melphalan.;Q2298283;P2175;Q128581
Characterization of cross-resistance to methotrexate in a human breast cancer cell line selected for resistance to melphalan.;Q422232;P2175;Q128581
Folate-conjugated hydrophobicity modified glycol chitosan nanoparticles for targeted delivery of methotrexate in rheumatoid arthritis;Q422232;P2175;Q170990
Folate-conjugated hydrophobicity modified glycol chitosan nanoparticles for targeted delivery of methotrexate in rheumatoid arthritis;Q422232;P2175;Q187255
Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma.;Q408977;P2175;Q208414
Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma.;Q408977;P2175;Q1138590
Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma.;Q422232;P2175;Q1138590
Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma.;Q422232;P2175;Q208414
Effect of methotrexate upon antigen-induced arthritis of the rabbit temporomandibular joint.;Q422232;P2175;Q170990
[Chemotherapy of advanced head and neck cancer with a combination of bleomycin, vincristine, methotrexate and hydroxyuree or cis-dichloro-diamino-platinium. Analysis of local and general parameters of prognosis (author's transl)];Q422232;P2175;Q1783924
Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report.;Q422232;P2175;Q128581
Methotrexate Monotherapy for Induction and Maintenance of Clinical Remission in Ulcerative Colitis: Dead on Arrival;Q218642;P703;Q2046782
Methotrexate Monotherapy for Induction and Maintenance of Clinical Remission in Ulcerative Colitis: Dead on Arrival;Q178450;P703;Q2046782
Methotrexate Monotherapy for Induction and Maintenance of Clinical Remission in Ulcerative Colitis: Dead on Arrival;Q422232;P2175;Q1477
Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer;Q238512;P2175;Q189588
Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer;Q418817;P636;Q285166
Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer;Q422232;P2175;Q189588
Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer;Q422232;P636;Q285166
Azidothymidine inhibition of thymidine kinase and synergistic cytotoxicity with methotrexate and 5-fluorouracil in rat hepatoma and human colon cancer cells.;Q218642;P703;Q15978631
Azidothymidine inhibition of thymidine kinase and synergistic cytotoxicity with methotrexate and 5-fluorouracil in rat hepatoma and human colon cancer cells.;Q238512;P2175;Q18555025
Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy.;Q139347;P2175;Q12078
Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis.;Q420035;P2175;Q170990
Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis.;Q420035;P2175;Q187255
Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis.;Q421094;P2175;Q170990
Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis.;Q421094;P1889;Q422438
Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis.;Q421094;P2175;Q187255
Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis.;Q422438;P2175;Q187255
Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis.;Q422438;P1889;Q421094
Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study.;Q218642;P703;Q2046782
Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study.;Q425154;P2175;Q170990
Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study.;Q422232;P2175;Q170990
Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study.;Q422232;P2175;Q187255
[Pulse therapy with prospidin and methotrexate: comparative efficacy in rheumatoid arthritis (12-month controlled study)];Q422232;P2175;Q187255
[Pulse therapy with prospidin and methotrexate: comparative efficacy in rheumatoid arthritis (12-month controlled study)];Q422232;P2175;Q170990
Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia.;Q422232;P2175;Q29496
Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.;Q422232;P2175;Q29496
Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: implications for efficacy of methotrexate therapy.;Q422232;P2175;Q29496
Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma.;Q422232;P2175;Q549534
Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients;Q218642;P703;Q2046782
[Convulsions and intrathecal methotrexate];Q422232;P636;Q1320251
Use of mifepristone along with methotrexate in medical management of unruptured ectopic pregnancy;Q411240;P2175;Q207087
Use of mifepristone along with methotrexate in medical management of unruptured ectopic pregnancy;Q422232;P2175;Q207087
Interleukin-10 and interleukin-6 in aqueous humor during treatment of vitreoretinal lymphoma with intravitreally injected methotrexate;Q422232;P2175;Q208414
Aluminum-based metal-organic frameworks for adsorptive removal of anti-cancer (methotrexate) drug from aqueous solutions;Q218642;P31;Q12140
Aluminum-based metal-organic frameworks for adsorptive removal of anti-cancer (methotrexate) drug from aqueous solutions;Q191924;P31;Q12140
Aluminum-based metal-organic frameworks for adsorptive removal of anti-cancer (methotrexate) drug from aqueous solutions;Q422232;P31;Q12140
Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier.;Q422232;P2175;Q29496
Distinct systems mediate the unidirectional efflux of methotrexate and cholate in human CCRF-CEM cells.;Q153;P703;Q15978631
Distinct systems mediate the unidirectional efflux of methotrexate and cholate in human CCRF-CEM cells.;Q186474;P703;Q15978631
Distinct systems mediate the unidirectional efflux of methotrexate and cholate in human CCRF-CEM cells.;Q287415;P703;Q15978631
Distinct systems mediate the unidirectional efflux of methotrexate and cholate in human CCRF-CEM cells.;Q170545;P703;Q15978631
Distinct systems mediate the unidirectional efflux of methotrexate and cholate in human CCRF-CEM cells.;Q139347;P703;Q15978631
Distinct systems mediate the unidirectional efflux of methotrexate and cholate in human CCRF-CEM cells.;Q173670;P703;Q15978631
Distinct systems mediate the unidirectional efflux of methotrexate and cholate in human CCRF-CEM cells.;Q178450;P703;Q15978631
Distinct systems mediate the unidirectional efflux of methotrexate and cholate in human CCRF-CEM cells.;Q22124685;P703;Q15978631
Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.;Q413879;P2175;Q170990
Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.;Q422232;P2175;Q170990
Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.;Q422232;P2175;Q187255
High-dose methotrexate therapy with leucovorin rescue: in vitro investigations on human osteosarcoma cell lines.;Q485277;P703;Q15978631
High-dose methotrexate therapy with leucovorin rescue: in vitro investigations on human osteosarcoma cell lines.;Q483745;P703;Q15978631
High-dose methotrexate therapy with leucovorin rescue: in vitro investigations on human osteosarcoma cell lines.;Q422232;P2175;Q549534
Association of C35T polymorphism in dihydrofolate reductase gene with toxicity of methotrexate in rheumatoid arthritis patients;Q422232;P2175;Q170990
Association of C35T polymorphism in dihydrofolate reductase gene with toxicity of methotrexate in rheumatoid arthritis patients;Q422232;P2175;Q187255
Cyclosporine in addition to infliximab and methotrexate in refractory rheumatoid arthritis;Q415264;P2175;Q170990
Cyclosporine in addition to infliximab and methotrexate in refractory rheumatoid arthritis;Q422232;P2175;Q187255
Cyclosporine in addition to infliximab and methotrexate in refractory rheumatoid arthritis;Q422232;P2175;Q170990
Resolution of pembrolizumab-associated lichenoid dermatitis with a single dose of methotrexate;Q13896859;P3780;Q29006084
Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-c;Q180983;P2175;Q29496
Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-c;Q186474;P1889;Q178425
Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-c;Q422232;P2175;Q29496
Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis;Q420035;P2175;Q170990
Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis;Q420035;P2175;Q187255
Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis;Q422232;P2175;Q170990
Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis;Q422232;P2175;Q187255
Neoadjuvant chemotherapy with sequential methotrexate and 5-fluorouracil scheduling, epirubicin and cisplatin for locally advanced bladder cancer.;Q412415;P2175;Q504775
Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy.;Q422232;P2175;Q29496
Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy.;Q422232;P2175;Q170990
Acute erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy.;Q422232;P2175;Q187255
Time lag between the initiation of adalimumab after methotrexate correlates with the efficacy of adalimumab in rheumatoid arthritis patients.;Q348260;P2175;Q170990
Time lag between the initiation of adalimumab after methotrexate correlates with the efficacy of adalimumab in rheumatoid arthritis patients.;Q348260;P2175;Q187255
Time lag between the initiation of adalimumab after methotrexate correlates with the efficacy of adalimumab in rheumatoid arthritis patients.;Q422232;P2175;Q170990
Time lag between the initiation of adalimumab after methotrexate correlates with the efficacy of adalimumab in rheumatoid arthritis patients.;Q422232;P2175;Q187255
Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck.;Q412415;P2175;Q18348812
Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil;Q130336;P31;Q407142
Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil;Q130336;P4149;Q27122100
Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil;Q4567614;P2175;Q1194520
[Spontaneous regression of immunodeficiency associated plasmablastic lymphoma related to methotrexate after decrease of dosage].;Q422232;P2175;Q208414
[Methotrexate for the treatment of rheumatoid arthritis in Japan--much more still remains to be resolved].;Q422232;P2175;Q170990
[Methotrexate for the treatment of rheumatoid arthritis in Japan--much more still remains to be resolved].;Q422232;P2175;Q187255
Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.;Q18936;P2175;Q208414
Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.;Q408977;P2175;Q208414
Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.;Q191924;P2868;Q407752
Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.;Q11426176;P2175;Q208414
Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.;Q422232;P2175;Q136312
Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.;Q422232;P2175;Q208414
British isles survey of methotrexate monitoring practice during treatment of juvenile idiopathic arthritis.;Q422232;P2175;Q170990
British isles survey of methotrexate monitoring practice during treatment of juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Methotrexate supports in vivo selection of human embryonic stem cell derived-hematopoietic cells expressing dihydrofolate reductase.;Q22124685;P703;Q15978631
Methotrexate loaded gellan gum microparticles for drug delivery.;Q22124685;P31;Q12140
Methotrexate loaded gellan gum microparticles for drug delivery.;Q422232;P31;Q12140
B-cell chronic lymphocytic leukemia followed by mycosis fungoides in a psoriatic patient on long-term methotrexate therapy.;Q422232;P2175;Q29496
B-cell chronic lymphocytic leukemia followed by mycosis fungoides in a psoriatic patient on long-term methotrexate therapy.;Q422232;P2175;Q1891209
MYC/BCL2 Double-hit Lymphoma in a Patient with Rheumatoid Arthritis Associated with Methotrexate Treatment.;Q422232;P2175;Q208414
Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia;Q422232;P2175;Q29496
Circular RNA hsa_circ_0000073 contributes to osteosarcoma cell proliferation, migration, invasion and methotrexate resistance by sponging miR-145-5p and miR-151-3p and upregulating NRAS;Q422232;P2175;Q549534
Interventricular methotrexate therapy for carcinomatous meningitis due to breast cancer: a case with leukoencephalopathy.;Q422232;P2175;Q128581
Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia;Q3088229;P279;Q24770933
Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia;Q422232;P2175;Q29496
Comment on: Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate;Q422232;P2175;Q187255
Comment on: Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate;Q422232;P2175;Q170990
Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.;Q238512;P2175;Q128581
Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.;Q422232;P2175;Q128581
Methotrexate for ectopic pregnancy: success rates and avoidance of embryopathy;Q422232;P2175;Q207087
[Pregnancy outcome after preconceptional exposure to methotrexate for ectopic pregnancy].;Q422232;P2175;Q207087
Comparison Between Methotrexate and Mycophenolate Mofetil Monotherapy for the Control of Noninfectious Ocular Inflammatory Diseases;Q130336;P4149;Q27122100
Comparison Between Methotrexate and Mycophenolate Mofetil Monotherapy for the Control of Noninfectious Ocular Inflammatory Diseases;Q130336;P31;Q407142
Gynecomastia associated with low-dose methotrexate therapy for rheumatoid arthritis ameliorated by folate supplement.;Q422232;P2175;Q170990
Gynecomastia associated with low-dose methotrexate therapy for rheumatoid arthritis ameliorated by folate supplement.;Q422232;P2175;Q187255
Interaction between rhein acyl glucuronide and methotrexate based on human organic anion transporters.;Q484940;P703;Q15978631
Second line chemotherapy with methotrexate and gemcitabine in patients with relapsing head and neck cancer.;Q422232;P2175;Q1783924
Does daily folic acid supplementation reduce methotrexate efficacy?;Q422232;P2868;Q127060
Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects.;Q186521;P703;Q177932
Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects.;Q484940;P703;Q177932
Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects.;Q422232;P2175;Q170990
Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects.;Q422232;P2175;Q187255
Treatment of refractory lymphoma with methotrexate, VM-26 (teniposide), procarbazine, and dexamethasone: Cancer and Leukemia Group B study 7902.;Q191924;P769;Q418656
Treatment of refractory lymphoma with methotrexate, VM-26 (teniposide), procarbazine, and dexamethasone: Cancer and Leukemia Group B study 7902.;Q418656;P2175;Q208414
Treatment of refractory lymphoma with methotrexate, VM-26 (teniposide), procarbazine, and dexamethasone: Cancer and Leukemia Group B study 7902.;Q422252;P2175;Q208414
Treatment of refractory lymphoma with methotrexate, VM-26 (teniposide), procarbazine, and dexamethasone: Cancer and Leukemia Group B study 7902.;Q422232;P2175;Q208414
Comparative study of sequential combinations of paclitaxel and methotrexate on a human bladder cancer cell line.;Q186474;P703;Q15978631
Comparative study of sequential combinations of paclitaxel and methotrexate on a human bladder cancer cell line.;Q423762;P703;Q15978631
Bleomycin, methotrexate, and streptozotocin in epidermoid carcinoma of the lung: an active drug combination with major nonhematologic toxicity.;Q191924;P31;Q12140
Bleomycin, methotrexate, and streptozotocin in epidermoid carcinoma of the lung: an active drug combination with major nonhematologic toxicity.;Q415571;P31;Q12140
Bleomycin, methotrexate, and streptozotocin in epidermoid carcinoma of the lung: an active drug combination with major nonhematologic toxicity.;Q415571;P2175;Q681817
Bleomycin, methotrexate, and streptozotocin in epidermoid carcinoma of the lung: an active drug combination with major nonhematologic toxicity.;Q422232;P31;Q12140
Methotrexate Combined with 4-Hydroperoxycyclophosphamide Downregulates Multidrug-Resistance P-Glycoprotein Expression Induced by Methotrexate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the JAK2/STAT3 Pathway.;Q218642;P31;Q12140
Methotrexate Combined with 4-Hydroperoxycyclophosphamide Downregulates Multidrug-Resistance P-Glycoprotein Expression Induced by Methotrexate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the JAK2/STAT3 Pathway.;Q183290;P31;Q12140
Methotrexate Combined with 4-Hydroperoxycyclophosphamide Downregulates Multidrug-Resistance P-Glycoprotein Expression Induced by Methotrexate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the JAK2/STAT3 Pathway.;Q186474;P31;Q12140
Methotrexate Combined with 4-Hydroperoxycyclophosphamide Downregulates Multidrug-Resistance P-Glycoprotein Expression Induced by Methotrexate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the JAK2/STAT3 Pathway.;Q186521;P31;Q12140
Methotrexate Combined with 4-Hydroperoxycyclophosphamide Downregulates Multidrug-Resistance P-Glycoprotein Expression Induced by Methotrexate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the JAK2/STAT3 Pathway.;Q485277;P31;Q12140
Methotrexate Combined with 4-Hydroperoxycyclophosphamide Downregulates Multidrug-Resistance P-Glycoprotein Expression Induced by Methotrexate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the JAK2/STAT3 Pathway.;Q327362;P31;Q12140
Methotrexate Combined with 4-Hydroperoxycyclophosphamide Downregulates Multidrug-Resistance P-Glycoprotein Expression Induced by Methotrexate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the JAK2/STAT3 Pathway.;Q170545;P31;Q12140
Methotrexate Combined with 4-Hydroperoxycyclophosphamide Downregulates Multidrug-Resistance P-Glycoprotein Expression Induced by Methotrexate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the JAK2/STAT3 Pathway.;Q173670;P31;Q12140
Methotrexate Combined with 4-Hydroperoxycyclophosphamide Downregulates Multidrug-Resistance P-Glycoprotein Expression Induced by Methotrexate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the JAK2/STAT3 Pathway.;Q178450;P31;Q12140
Methotrexate Combined with 4-Hydroperoxycyclophosphamide Downregulates Multidrug-Resistance P-Glycoprotein Expression Induced by Methotrexate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the JAK2/STAT3 Pathway.;Q20816880;P31;Q12140
Methotrexate Combined with 4-Hydroperoxycyclophosphamide Downregulates Multidrug-Resistance P-Glycoprotein Expression Induced by Methotrexate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the JAK2/STAT3 Pathway.;Q20035886;P31;Q12140
Methotrexate Combined with 4-Hydroperoxycyclophosphamide Downregulates Multidrug-Resistance P-Glycoprotein Expression Induced by Methotrexate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the JAK2/STAT3 Pathway.;Q22124685;P31;Q12140
Methotrexate Combined with 4-Hydroperoxycyclophosphamide Downregulates Multidrug-Resistance P-Glycoprotein Expression Induced by Methotrexate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the JAK2/STAT3 Pathway.;Q422232;P31;Q12140
Methotrexate Combined with 4-Hydroperoxycyclophosphamide Downregulates Multidrug-Resistance P-Glycoprotein Expression Induced by Methotrexate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the JAK2/STAT3 Pathway.;Q620730;P31;Q12140
Methotrexate Combined with 4-Hydroperoxycyclophosphamide Downregulates Multidrug-Resistance P-Glycoprotein Expression Induced by Methotrexate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the JAK2/STAT3 Pathway.;Q483745;P31;Q12140
Methotrexate Combined with 4-Hydroperoxycyclophosphamide Downregulates Multidrug-Resistance P-Glycoprotein Expression Induced by Methotrexate in Rheumatoid Arthritis Fibroblast-Like Synoviocytes via the JAK2/STAT3 Pathway.;Q484940;P31;Q12140
Posterior reversible encephalopathy after intrathecal methotrexate therapy in diffuse large B-cell lymphoma.;Q422232;P2175;Q2626074
Posterior reversible encephalopathy after intrathecal methotrexate therapy in diffuse large B-cell lymphoma.;Q422232;P2175;Q208414
Posterior reversible encephalopathy after intrathecal methotrexate therapy in diffuse large B-cell lymphoma.;Q422232;P636;Q1320251
Posterior reversible encephalopathy after intrathecal methotrexate therapy in diffuse large B-cell lymphoma.;Q422232;P2175;Q4833719
[Large doses of cytarabine, etoposide and methotrexate (CEM protocol) in the treatment of lymphoblastic leukemia in adults, resistant to conventional treatment, and of recurrences];Q180983;P2175;Q29496
[Large doses of cytarabine, etoposide and methotrexate (CEM protocol) in the treatment of lymphoblastic leukemia in adults, resistant to conventional treatment, and of recurrences];Q422232;P2175;Q29496
Therapeutic benefits of irsogladine maleate on aphthous stomatitis induced by methotrexate in rheumatoid arthritis.;Q186521;P703;Q177932
Therapeutic benefits of irsogladine maleate on aphthous stomatitis induced by methotrexate in rheumatoid arthritis.;Q422232;P2175;Q170990
Therapeutic benefits of irsogladine maleate on aphthous stomatitis induced by methotrexate in rheumatoid arthritis.;Q422232;P2175;Q187255
Methotrexate resistance in murine and human continuous tumour cell lines: an examination of the different mechanisms involved depending on the order of resistance expressed.;Q22124685;P703;Q15978631
[High-dose methotrexate followed by whole-brain irradiation for primary central nervous system lymphoma patients--a retrospective study in a single institute];Q422232;P2175;Q136312
[High-dose methotrexate followed by whole-brain irradiation for primary central nervous system lymphoma patients--a retrospective study in a single institute];Q422232;P2175;Q208414
Renal function in rheumatoid arthritis patients treated with methotrexate and infliximab.;Q415264;P2175;Q170990
Renal function in rheumatoid arthritis patients treated with methotrexate and infliximab.;Q422232;P2175;Q170990
Renal function in rheumatoid arthritis patients treated with methotrexate and infliximab.;Q422232;P2175;Q187255
[Complete response of lung metastasis from bladder cancer by combination chemotherapy with methotrexate, epirubicin and cisplatin: a case report];Q412415;P2175;Q504775
Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma;Q485277;P703;Q177932
Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma;Q422232;P2175;Q136312
Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma;Q422232;P2175;Q208414
Successful treatment of immunodeficiency-associated EBV-negative lymphoproliferative disorders in rheumatoid arthritis by methotrexate withdrawal and prevention of its relapse by rituximab administration.;Q412323;P2175;Q170990
Successful treatment of immunodeficiency-associated EBV-negative lymphoproliferative disorders in rheumatoid arthritis by methotrexate withdrawal and prevention of its relapse by rituximab administration.;Q422232;P2175;Q187255
Successful treatment of immunodeficiency-associated EBV-negative lymphoproliferative disorders in rheumatoid arthritis by methotrexate withdrawal and prevention of its relapse by rituximab administration.;Q422232;P2175;Q170990
Methotrexate reduces HbA1c concentration but does not produce chronic accumulation of ZMP in patients with rheumatoid or psoriatic arthritis.;Q422232;P2175;Q170990
Interim 18F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine.;Q180983;P2175;Q208414
Interim 18F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine.;Q422232;P2175;Q208414
Interim 18F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine.;Q422232;P2175;Q136312
The use of oral methotrexate (mtx) in the treatment of tumours in the head and neck-region.;Q422232;P636;Q285166
Combined acute interstitial pneumonitis and pancytopenia induced by low-dose methotrexate in a hemodialysis patient treated for bullous pemphigoid.;Q422232;P2175;Q1004647
Intravitreal methotrexate injections for intraocular involvement in primary central nervous system lymphoma.;Q422232;P2175;Q208414
Intravitreal methotrexate injections for intraocular involvement in primary central nervous system lymphoma.;Q422232;P2175;Q136312
Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan;Q238512;P2175;Q128581
Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan;Q422232;P2175;Q128581
Enhancement of the Antitumor Effect of Methotrexate on Colorectal Cancer Cells via Lactate Calcium Salt Targeting Methionine Metabolism.;Q22124685;P31;Q180341
Assessing the impact of adding acetazolamide to oral or intravenous sodium bicarbonate as compared with intravenous bicarbonate monotherapy as urinary alkalinization in adults receiving high-dose methotrexate;Q218642;P527;Q623
Assessing the impact of adding acetazolamide to oral or intravenous sodium bicarbonate as compared with intravenous bicarbonate monotherapy as urinary alkalinization in adults receiving high-dose methotrexate;Q191924;P527;Q623
Assessing the impact of adding acetazolamide to oral or intravenous sodium bicarbonate as compared with intravenous bicarbonate monotherapy as urinary alkalinization in adults receiving high-dose methotrexate;Q413690;P636;Q285166
Assessing the impact of adding acetazolamide to oral or intravenous sodium bicarbonate as compared with intravenous bicarbonate monotherapy as urinary alkalinization in adults receiving high-dose methotrexate;Q179731;P527;Q623
Assessing the impact of adding acetazolamide to oral or intravenous sodium bicarbonate as compared with intravenous bicarbonate monotherapy as urinary alkalinization in adults receiving high-dose methotrexate;Q179731;P527;Q658
Assessing the impact of adding acetazolamide to oral or intravenous sodium bicarbonate as compared with intravenous bicarbonate monotherapy as urinary alkalinization in adults receiving high-dose methotrexate;Q422232;P636;Q285166
Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation;Q422232;P2175;Q29496
Investigating which variables from the core outcome variables in juvenile idiopathic arthritis (JIA) are the best predictors of classification as a responder to treatment with methotrexate (MTX).;Q422232;P2175;Q170990
Investigating which variables from the core outcome variables in juvenile idiopathic arthritis (JIA) are the best predictors of classification as a responder to treatment with methotrexate (MTX).;Q422232;P2175;Q861224
The time course of gastric methotrexate intolerance in patients with rheumatoid arthritis and psoriatic arthritis.;Q422232;P2175;Q170990
The time course of gastric methotrexate intolerance in patients with rheumatoid arthritis and psoriatic arthritis.;Q422232;P2175;Q187255
[Therapeutic drug monitoring of methotrexate after its administration in high-dose protocols].;Q186521;P31;Q12140
[Therapeutic drug monitoring of methotrexate after its administration in high-dose protocols].;Q186521;P703;Q177932
[Therapeutic drug monitoring of methotrexate after its administration in high-dose protocols].;Q191924;P31;Q12140
[Therapeutic drug monitoring of methotrexate after its administration in high-dose protocols].;Q422232;P31;Q12140
[Therapeutic maintenance dose with methotrexate in rheumatoid polyarthritis. Prospective study of 191 cases];Q186521;P703;Q177932
[Therapeutic maintenance dose with methotrexate in rheumatoid polyarthritis. Prospective study of 191 cases];Q20035886;P703;Q177932
[Therapeutic maintenance dose with methotrexate in rheumatoid polyarthritis. Prospective study of 191 cases];Q422232;P2175;Q1274464
[Therapeutic maintenance dose with methotrexate in rheumatoid polyarthritis. Prospective study of 191 cases];Q422232;P2175;Q170990
The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate;Q422232;P2175;Q170990
The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate;Q422232;P2175;Q187255
Treatment of rheumatoid arthritis (RA) in India-how and by whom: results from a speciality clinic-use of low-dose methotrexate (MTX) was inexplicably suboptimal.;Q422232;P2175;Q187255
Treatment of rheumatoid arthritis (RA) in India-how and by whom: results from a speciality clinic-use of low-dose methotrexate (MTX) was inexplicably suboptimal.;Q422232;P2175;Q170990
Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis;Q191924;P31;Q12140
Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis;Q191924;P366;Q8386
Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis;Q422232;P31;Q12140
Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis;Q422232;P2175;Q170990
Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis;Q422232;P2175;Q187255
Molecular interaction of the antineoplastic drug, methotrexate with human brain acetylcholinesterase: a docking study.;Q191924;P366;Q8386
Molecular interaction of the antineoplastic drug, methotrexate with human brain acetylcholinesterase: a docking study.;Q193166;P31;Q12140
Molecular interaction of the antineoplastic drug, methotrexate with human brain acetylcholinesterase: a docking study.;Q193166;P703;Q15978631
Molecular interaction of the antineoplastic drug, methotrexate with human brain acetylcholinesterase: a docking study.;Q180623;P31;Q12140
Molecular interaction of the antineoplastic drug, methotrexate with human brain acetylcholinesterase: a docking study.;Q180623;P703;Q15978631
Molecular interaction of the antineoplastic drug, methotrexate with human brain acetylcholinesterase: a docking study.;Q22124685;P31;Q12140
Molecular interaction of the antineoplastic drug, methotrexate with human brain acetylcholinesterase: a docking study.;Q22124685;P703;Q15978631
Molecular interaction of the antineoplastic drug, methotrexate with human brain acetylcholinesterase: a docking study.;Q422232;P31;Q12140
A preliminary investigation of cognitive function in rheumatoid arthritis patients on long-term methotrexate treatment.;Q422232;P2175;Q187255
A preliminary investigation of cognitive function in rheumatoid arthritis patients on long-term methotrexate treatment.;Q422232;P2175;Q170990
Expression and characterization of mucins associated with the resistance to methotrexate of human colonic adenocarcinoma cell line HT29.;Q186521;P703;Q15978631
Expression and characterization of mucins associated with the resistance to methotrexate of human colonic adenocarcinoma cell line HT29.;Q485277;P703;Q15978631
Should methotrexate be used to treat early rheumatoid arthritis?;Q422232;P2175;Q187255
Should methotrexate be used to treat early rheumatoid arthritis?;Q422232;P2175;Q170990
Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis.;Q422232;P2175;Q170990
Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis.;Q422232;P2175;Q187255
Reumacon (CPH82) showed similar x-ray progression and clinical effects as methotrexate in a two year comparative study on patients with early rheumatoid arthritis;Q421119;P2175;Q187255
Reumacon (CPH82) showed similar x-ray progression and clinical effects as methotrexate in a two year comparative study on patients with early rheumatoid arthritis;Q422232;P2175;Q170990
Reumacon (CPH82) showed similar x-ray progression and clinical effects as methotrexate in a two year comparative study on patients with early rheumatoid arthritis;Q422232;P2175;Q187255
Retrospective analysis of late intensification therapy with high-dose methotrexate for standard-risk acute lymphoblastic leukemia in childhood (CCLSG-S811 study). The Children's Cancer and Leukemia Study Group;Q422232;P2175;Q29496
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.;Q18936;P2175;Q208414
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.;Q18936;P2175;Q268713
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.;Q180983;P2175;Q208414
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.;Q180983;P2175;Q268713
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.;Q408977;P2175;Q208414
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.;Q412323;P2175;Q208414
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.;Q412323;P2175;Q268713
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.;Q419319;P2175;Q268713
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.;Q422252;P2175;Q208414
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.;Q422252;P2175;Q268713
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.;Q422232;P2175;Q208414
I've been taking methotrexate for my rheumatoid arthritis (RA) for several years, but it doesn't seem to be helping my symptoms. My doctor suggested adding a biologic response modifier (BRM) drug, such as etanercept (Enbrel) or adalimumab (Humira) t;Q218642;P31;Q12140
I've been taking methotrexate for my rheumatoid arthritis (RA) for several years, but it doesn't seem to be helping my symptoms. My doctor suggested adding a biologic response modifier (BRM) drug, such as etanercept (Enbrel) or adalimumab (Humira) t;Q191924;P31;Q12140
I've been taking methotrexate for my rheumatoid arthritis (RA) for several years, but it doesn't seem to be helping my symptoms. My doctor suggested adding a biologic response modifier (BRM) drug, such as etanercept (Enbrel) or adalimumab (Humira) t;Q485277;P31;Q12140
I've been taking methotrexate for my rheumatoid arthritis (RA) for several years, but it doesn't seem to be helping my symptoms. My doctor suggested adding a biologic response modifier (BRM) drug, such as etanercept (Enbrel) or adalimumab (Humira) t;Q348260;P31;Q12140
I've been taking methotrexate for my rheumatoid arthritis (RA) for several years, but it doesn't seem to be helping my symptoms. My doctor suggested adding a biologic response modifier (BRM) drug, such as etanercept (Enbrel) or adalimumab (Humira) t;Q348260;P2175;Q170990
I've been taking methotrexate for my rheumatoid arthritis (RA) for several years, but it doesn't seem to be helping my symptoms. My doctor suggested adding a biologic response modifier (BRM) drug, such as etanercept (Enbrel) or adalimumab (Humira) t;Q348260;P2175;Q187255
I've been taking methotrexate for my rheumatoid arthritis (RA) for several years, but it doesn't seem to be helping my symptoms. My doctor suggested adding a biologic response modifier (BRM) drug, such as etanercept (Enbrel) or adalimumab (Humira) t;Q348260;P3780;Q29005938
I've been taking methotrexate for my rheumatoid arthritis (RA) for several years, but it doesn't seem to be helping my symptoms. My doctor suggested adding a biologic response modifier (BRM) drug, such as etanercept (Enbrel) or adalimumab (Humira) t;Q173670;P31;Q12140
I've been taking methotrexate for my rheumatoid arthritis (RA) for several years, but it doesn't seem to be helping my symptoms. My doctor suggested adding a biologic response modifier (BRM) drug, such as etanercept (Enbrel) or adalimumab (Humira) t;Q22124685;P31;Q12140
I've been taking methotrexate for my rheumatoid arthritis (RA) for several years, but it doesn't seem to be helping my symptoms. My doctor suggested adding a biologic response modifier (BRM) drug, such as etanercept (Enbrel) or adalimumab (Humira) t;Q484940;P31;Q12140
I've been taking methotrexate for my rheumatoid arthritis (RA) for several years, but it doesn't seem to be helping my symptoms. My doctor suggested adding a biologic response modifier (BRM) drug, such as etanercept (Enbrel) or adalimumab (Humira) t;Q422232;P31;Q12140
I've been taking methotrexate for my rheumatoid arthritis (RA) for several years, but it doesn't seem to be helping my symptoms. My doctor suggested adding a biologic response modifier (BRM) drug, such as etanercept (Enbrel) or adalimumab (Humira) t;Q422232;P2175;Q187255
I've been taking methotrexate for my rheumatoid arthritis (RA) for several years, but it doesn't seem to be helping my symptoms. My doctor suggested adding a biologic response modifier (BRM) drug, such as etanercept (Enbrel) or adalimumab (Humira) t;Q422232;P2175;Q170990
Pretreatment intratumoral susceptibility signals correlate with response to high-dose methotrexate and progression-free survival in primary central nervous system lymphoma;Q422232;P636;Q285166
Pretreatment intratumoral susceptibility signals correlate with response to high-dose methotrexate and progression-free survival in primary central nervous system lymphoma;Q422232;P2175;Q136312
Pretreatment intratumoral susceptibility signals correlate with response to high-dose methotrexate and progression-free survival in primary central nervous system lymphoma;Q422232;P2175;Q208414
An animal model for the study of chronopharmacokinetics of drugs and application to methotrexate and vinorelbine.;Q218642;P31;Q12140
An animal model for the study of chronopharmacokinetics of drugs and application to methotrexate and vinorelbine.;Q191924;P31;Q12140
An animal model for the study of chronopharmacokinetics of drugs and application to methotrexate and vinorelbine.;Q191924;P366;Q8386
An animal model for the study of chronopharmacokinetics of drugs and application to methotrexate and vinorelbine.;Q420532;P31;Q12140
An animal model for the study of chronopharmacokinetics of drugs and application to methotrexate and vinorelbine.;Q422232;P31;Q12140
Increased resistance to methotrexate in human hematopoietic cells after gene transfer of the Ser31 DHFR mutant.;Q183290;P703;Q15978631
Increased resistance to methotrexate in human hematopoietic cells after gene transfer of the Ser31 DHFR mutant.;Q485277;P703;Q15978631
Increased resistance to methotrexate in human hematopoietic cells after gene transfer of the Ser31 DHFR mutant.;Q170545;P703;Q15978631
Increased resistance to methotrexate in human hematopoietic cells after gene transfer of the Ser31 DHFR mutant.;Q173670;P703;Q15978631
Increased resistance to methotrexate in human hematopoietic cells after gene transfer of the Ser31 DHFR mutant.;Q178450;P703;Q15978631
Increased resistance to methotrexate in human hematopoietic cells after gene transfer of the Ser31 DHFR mutant.;Q484940;P703;Q15978631
Primary malignant melanoma of the urethra in a patient with rheumatoid arthritis treated with methotrexate;Q422232;P2175;Q170990
Primary malignant melanoma of the urethra in a patient with rheumatoid arthritis treated with methotrexate;Q422232;P2175;Q187255
Usefulness of daily folic acid supplementation during methotrexate treatment of Japanese patients with rheumatoid arthritis;Q422232;P2175;Q170990
Usefulness of daily folic acid supplementation during methotrexate treatment of Japanese patients with rheumatoid arthritis;Q422232;P2868;Q127060
Usefulness of daily folic acid supplementation during methotrexate treatment of Japanese patients with rheumatoid arthritis;Q422232;P2175;Q187255
Reponse to methotrexate and reduced mortality in patients with rheumatoid arthritis: comment on the article by Krause et al.;Q422232;P2175;Q170990
Reponse to methotrexate and reduced mortality in patients with rheumatoid arthritis: comment on the article by Krause et al.;Q422232;P2175;Q187255
Methotrexate for nonsurgical treatment of ectopic pregnancy: nursing implications.;Q422232;P2175;Q207087
Mycosis fungoides with CNS involvement: neuropsychiatric manifestations and complications of treatment with intrathecal methotrexate and whole-brain irradiation.;Q422232;P636;Q1320251
Mycosis fungoides with CNS involvement: neuropsychiatric manifestations and complications of treatment with intrathecal methotrexate and whole-brain irradiation.;Q422232;P2175;Q1891209
Effective treatment of early rheumatoid arthritis with a combination of methotrexate, prednisolone and cyclosporin.;Q422232;P2175;Q170990
Effective treatment of early rheumatoid arthritis with a combination of methotrexate, prednisolone and cyclosporin.;Q422232;P2175;Q187255
The safety of weekly low dose oral methotrexate in an Oriental population with rheumatoid arthritis.;Q422232;P636;Q285166
The safety of weekly low dose oral methotrexate in an Oriental population with rheumatoid arthritis.;Q422232;P2175;Q187255
The safety of weekly low dose oral methotrexate in an Oriental population with rheumatoid arthritis.;Q422232;P2175;Q170990
Remission of a primary thyroid lymphoma after methotrexate withdrawal;Q422232;P2175;Q208414
A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients;Q218642;P31;Q12140
A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients;Q191924;P31;Q12140
A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients;Q191924;P366;Q8386
A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients;Q422232;P31;Q12140
A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients;Q422232;P2175;Q170990
A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients;Q422232;P2175;Q187255
Intravenously-administered methotrexate and radiotherapy in the treatment of advanced lesions of the oral cavity and the pharynx.;Q422232;P636;Q285166
Higher average received relative dose intensities of cyclophosphamide, methotrexate and 5-fluorouracil using a 24-hour method: implications for improved cure rates in breast cancer;Q238512;P2175;Q128581
Higher average received relative dose intensities of cyclophosphamide, methotrexate and 5-fluorouracil using a 24-hour method: implications for improved cure rates in breast cancer;Q422232;P2175;Q128581
Safety of limited therapeutic monitoring after high-dose methotrexate in developing countries;Q183290;P703;Q177932
Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis model.;Q186474;P703;Q83310
Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis model.;Q422232;P2175;Q170990
Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis model.;Q422232;P129;Q21126218
Primary transitional cell carcinoma of prostate: case with lymph node metastasis eradicated by neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) therapy.;Q18936;P2175;Q2501186
Primary transitional cell carcinoma of prostate: case with lymph node metastasis eradicated by neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) therapy.;Q412415;P2175;Q2501186
Comparative efficacy of TACI-Ig with TNF-alpha inhibitor and methotrexate in DBA/1 mice with collagen-induced arthritis;Q186474;P703;Q83310
Comparative efficacy of TACI-Ig with TNF-alpha inhibitor and methotrexate in DBA/1 mice with collagen-induced arthritis;Q422232;P2175;Q170990
[Neurological and psychological sequelae in children with acute lymphoblastic leukemia who had received radiotherapy and intrathecal methotrexate];Q422232;P2175;Q29496
[Neurological and psychological sequelae in children with acute lymphoblastic leukemia who had received radiotherapy and intrathecal methotrexate];Q422232;P636;Q1320251
Letter: oral low-dose methotrexate for collagenous colitis - authors' reply.;Q422232;P636;Q285166
Comparison of EBV-positive Mucocutaneous Ulcer (EBVMCU) Associated with Treated Lymphoma or Methotrexate in Japan.;Q422232;P2175;Q208414
Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis;Q421094;P2175;Q170990
Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis;Q421094;P2175;Q187255
Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis;Q421094;P1889;Q422438
Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis;Q422438;P2175;Q187255
Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis;Q422438;P1889;Q421094
Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis;Q422232;P2175;Q187255
Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis;Q422232;P2175;Q170990
KIR2DL2 and KIR2DS2 as genetic markers to the methotrexate response in rheumatoid arthritis patients.;Q422232;P2175;Q170990
KIR2DL2 and KIR2DS2 as genetic markers to the methotrexate response in rheumatoid arthritis patients.;Q422232;P2175;Q187255
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil.;Q238512;P2175;Q2739660
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil.;Q422327;P2175;Q2739660
[A case of pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis and trimethoprim-sulphamethoxazole induced pancytopenia].;Q422232;P2175;Q170990
[A case of pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis and trimethoprim-sulphamethoxazole induced pancytopenia].;Q422232;P2175;Q187255
Low-dose methotrexate in rheumatoid arthritis: a potential risk factor for bisphosphonate-induced osteonecrosis of the jaw.;Q422232;P2175;Q170990
Low-dose methotrexate in rheumatoid arthritis: a potential risk factor for bisphosphonate-induced osteonecrosis of the jaw.;Q422232;P2175;Q187255
A case of pancytopenia secondary to low-dose pulse methotrexate therapy in a patient with rheumatoid arthritis and renal insufficiency;Q422232;P2175;Q187255
A case of pancytopenia secondary to low-dose pulse methotrexate therapy in a patient with rheumatoid arthritis and renal insufficiency;Q422232;P2175;Q170990
[Acute respiratory distress syndrome due to pneumonitis following intrathecal methotrexate administration];Q422232;P636;Q1320251
Modulation of the cytotoxicity of 3'-azido-3'-deoxythymidine and methotrexate after transduction of folate receptor cDNA into human cervical carcinoma: identification of a correlation between folate receptor expression and thymidine kinase activity.;Q218642;P703;Q15978631
Modulation of the cytotoxicity of 3'-azido-3'-deoxythymidine and methotrexate after transduction of folate receptor cDNA into human cervical carcinoma: identification of a correlation between folate receptor expression and thymidine kinase activity.;Q178450;P703;Q15978631
Modulation of the cytotoxicity of 3'-azido-3'-deoxythymidine and methotrexate after transduction of folate receptor cDNA into human cervical carcinoma: identification of a correlation between folate receptor expression and thymidine kinase activity.;Q22124685;P703;Q15978631
Evaluation of drug-drug interaction between the novel cPLA2 inhibitor AK106-001616 and methotrexate in rheumatoid arthritis patients;Q218642;P31;Q12140
Evaluation of drug-drug interaction between the novel cPLA2 inhibitor AK106-001616 and methotrexate in rheumatoid arthritis patients;Q191924;P366;Q8386
Evaluation of drug-drug interaction between the novel cPLA2 inhibitor AK106-001616 and methotrexate in rheumatoid arthritis patients;Q20816880;P31;Q12140
Evaluation of drug-drug interaction between the novel cPLA2 inhibitor AK106-001616 and methotrexate in rheumatoid arthritis patients;Q20035886;P31;Q12140
Evaluation of drug-drug interaction between the novel cPLA2 inhibitor AK106-001616 and methotrexate in rheumatoid arthritis patients;Q483745;P31;Q12140
Evaluation of drug-drug interaction between the novel cPLA2 inhibitor AK106-001616 and methotrexate in rheumatoid arthritis patients;Q422232;P2175;Q170990
Evaluation of drug-drug interaction between the novel cPLA2 inhibitor AK106-001616 and methotrexate in rheumatoid arthritis patients;Q422232;P31;Q12140
Evaluation of drug-drug interaction between the novel cPLA2 inhibitor AK106-001616 and methotrexate in rheumatoid arthritis patients;Q422232;P2175;Q187255
Infliximab, methotrexate and their combination for the treatment of rheumatoid arthritis: a systematic review and meta-analysis.;Q422232;P2175;Q187255
Infliximab, methotrexate and their combination for the treatment of rheumatoid arthritis: a systematic review and meta-analysis.;Q422232;P2175;Q170990
Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphoma;Q422232;P2175;Q208414
Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphoma;Q422232;P2175;Q136312
Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial.;Q238512;P2175;Q128581
Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial.;Q422232;P2175;Q128581
Intrathecal methotrexate versus central nervous system leukemia.;Q422232;P2175;Q29496
Hepatic toxicity by methotrexate with weekly single doses associated with folic acid in rheumatoid and psoriatic arthritis. What is its real frequency?;Q422232;P2175;Q170990
Hepatic toxicity by methotrexate with weekly single doses associated with folic acid in rheumatoid and psoriatic arthritis. What is its real frequency?;Q422232;P2868;Q127060
Long-term continuation of methotrexate therapy in giant cell arteritis patients in clinical practice.;Q422232;P2175;Q707816
Cyclophosphamide, methotrexate, 5-fluorouracil, and folinic acid (CMFF) as first line chemotherapy for treatment of advanced breast cancer. A pilot study.;Q238512;P2175;Q128581
Cyclophosphamide, methotrexate, 5-fluorouracil, and folinic acid (CMFF) as first line chemotherapy for treatment of advanced breast cancer. A pilot study.;Q422232;P2175;Q128581
Dihydrofolate reductase activity and deoxynucleoside incorporation into DNA of human leukocytes. Relation to methotrexate administration.;Q218642;P703;Q15978631
Dihydrofolate reductase activity and deoxynucleoside incorporation into DNA of human leukocytes. Relation to methotrexate administration.;Q173670;P703;Q15978631
Dihydrofolate reductase activity and deoxynucleoside incorporation into DNA of human leukocytes. Relation to methotrexate administration.;Q178450;P703;Q15978631
Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and penicillamine.;Q191924;P366;Q8386
Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and penicillamine.;Q178450;P31;Q12140
Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and penicillamine.;Q420035;P31;Q12140
Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and penicillamine.;Q420035;P2868;Q810254
Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and penicillamine.;Q421239;P31;Q12140
Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and penicillamine.;Q421239;P2868;Q810254
Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and penicillamine.;Q422232;P31;Q12140
Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, antimalarials, and penicillamine.;Q422232;P2868;Q810254
Studies of variation in inherent sensitivities to radiation, 5-fluorouracil and methotrexate in a series of human and murine tumor cell lines in vitro.;Q183290;P703;Q15978631
A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis.;Q412323;P2175;Q170990
A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis.;Q422232;P2175;Q170990
A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis.;Q422232;P2175;Q187255
Methotrexate effect on anti-cyclic citrullinated peptide antibody levels in rheumatoid arthritis.;Q422232;P2175;Q187255
Methotrexate effect on anti-cyclic citrullinated peptide antibody levels in rheumatoid arthritis.;Q422232;P2175;Q170990
Aminosalicylates, thiopurines and methotrexate in inflammatory bowel disease: Is it possible to discontinue the treatment?;Q193572;P4149;Q3469744
Ventriculolumbar perfusion chemotherapy with methotrexate and cytosine arabinoside for meningeal carcinomatosis: a pilot study in 13 patients.;Q422232;P636;Q640448
N-acetylcysteine renoprotection in methotrexate induced nephrotoxicity and its effects on B-cell lymphoma.;Q422232;P2175;Q208414
N-acetylcysteine renoprotection in methotrexate induced nephrotoxicity and its effects on B-cell lymphoma.;Q422232;P2175;Q4833719
Rheumatoid nodulosis during methotrexate therapy in a patient with rheumatoid arthritis;Q422232;P2175;Q187255
Rheumatoid nodulosis during methotrexate therapy in a patient with rheumatoid arthritis;Q422232;P2175;Q170990
ACP Journal Club. Review: In rheumatoid arthritis, adding rituximab to methotrexate improves clinical outcomes.;Q412323;P2175;Q170990
ACP Journal Club. Review: In rheumatoid arthritis, adding rituximab to methotrexate improves clinical outcomes.;Q421119;P2175;Q187255
ACP Journal Club. Review: In rheumatoid arthritis, adding rituximab to methotrexate improves clinical outcomes.;Q422232;P2175;Q170990
ACP Journal Club. Review: In rheumatoid arthritis, adding rituximab to methotrexate improves clinical outcomes.;Q422232;P2175;Q187255
Successful reintroduction of methotrexate after acute pneumonitis in a patient with acute lymphoblastic leukemia.;Q422232;P2175;Q29496
Synthesis and formulation of methotrexate (MTX) conjugated LaF3:Tb(3+)/chitosan nanoparticles for targeted drug delivery applications.;Q183290;P31;Q12140
Synthesis and formulation of methotrexate (MTX) conjugated LaF3:Tb(3+)/chitosan nanoparticles for targeted drug delivery applications.;Q186521;P31;Q12140
Synthesis and formulation of methotrexate (MTX) conjugated LaF3:Tb(3+)/chitosan nanoparticles for targeted drug delivery applications.;Q191924;P366;Q8386
Synthesis and formulation of methotrexate (MTX) conjugated LaF3:Tb(3+)/chitosan nanoparticles for targeted drug delivery applications.;Q170545;P31;Q12140
Synthesis and formulation of methotrexate (MTX) conjugated LaF3:Tb(3+)/chitosan nanoparticles for targeted drug delivery applications.;Q22124685;P31;Q12140
Synthesis and formulation of methotrexate (MTX) conjugated LaF3:Tb(3+)/chitosan nanoparticles for targeted drug delivery applications.;Q422232;P31;Q12140
Synthesis and formulation of methotrexate (MTX) conjugated LaF3:Tb(3+)/chitosan nanoparticles for targeted drug delivery applications.;Q483745;P31;Q12140
Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics.;Q191924;P31;Q12140
Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics.;Q422232;P31;Q12140
Severe multicentric reticulohistiocytosis: disease stabilization achieved with methotrexate and hydroxychloroquine.;Q421094;P1889;Q422438
Severe multicentric reticulohistiocytosis: disease stabilization achieved with methotrexate and hydroxychloroquine.;Q422438;P1889;Q421094
Early predictive factors of single dose methotrexate outcome in patients with ectopic pregnancy;Q422232;P2175;Q207087
Enhancement of the effect of methotrexate on collagen II induced arthritis in mice by nicotinamide.;Q422232;P2175;Q170990
[Treatment of tubal pregnancy with methotrexate in gynecological clinic of MBAL-Pleven during five year period];Q422232;P2175;Q207087
Correction to: Safety considerations regarding Methotrexate of label use in tubal ectopic pregnancy;Q422232;P2175;Q207087
Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse;Q422232;P2175;Q2626074
Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse;Q422232;P2175;Q4833719
Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse;Q422232;P2175;Q208414
Teaching NeuroImages: methotrexate neurotoxicity: resolution and evolution of MRI changes within 48 hours.;Q191924;P2868;Q407752
Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study.;Q422232;P2175;Q170990
Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study.;Q422232;P2175;Q187255
Effects of low-dose tacrolimus therapy in combination with methotrexate in patients with methotrexate-refractory rheumatoid arthritis.;Q422232;P2175;Q170990
Effects of low-dose tacrolimus therapy in combination with methotrexate in patients with methotrexate-refractory rheumatoid arthritis.;Q422232;P2175;Q187255
Coincidence of lymphomatoid granulomatosis, chronic myelomonocytic leukemia, and anaplastic T cell lymphoma after methotrexate therapy for rheumatoid arthritis;Q422232;P2175;Q29496
Coincidence of lymphomatoid granulomatosis, chronic myelomonocytic leukemia, and anaplastic T cell lymphoma after methotrexate therapy for rheumatoid arthritis;Q422232;P2175;Q208414
Coincidence of lymphomatoid granulomatosis, chronic myelomonocytic leukemia, and anaplastic T cell lymphoma after methotrexate therapy for rheumatoid arthritis;Q422232;P2175;Q170990
Coincidence of lymphomatoid granulomatosis, chronic myelomonocytic leukemia, and anaplastic T cell lymphoma after methotrexate therapy for rheumatoid arthritis;Q422232;P2175;Q187255
Kinetics of elimination of methotrexate from the cerebrospinal fluid space of monkeys after ventriculolumbar perfusion.;Q422232;P636;Q640448
P05.90 A prospective phase II study of whole brain radiotherapy concomitant to Temozolomide in primary central nervous system lymphoma after high dose methotrexate;Q422232;P2175;Q136312
P05.90 A prospective phase II study of whole brain radiotherapy concomitant to Temozolomide in primary central nervous system lymphoma after high dose methotrexate;Q422232;P2175;Q208414
[Alternative combination chemotherapy with mitomycin C, vincristine, methotrexate, 5-fluorouracil, cis-platinum and adriamycin for adenocarcinoma of the lung];Q19856779;P1889;Q417625
Efficacy of methotrexate as anti-inflammatory and anti-proliferative drug in dermatology: Three case reports;Q186521;P31;Q12140
Efficacy of methotrexate as anti-inflammatory and anti-proliferative drug in dermatology: Three case reports;Q191924;P366;Q8386
Efficacy of methotrexate as anti-inflammatory and anti-proliferative drug in dermatology: Three case reports;Q422232;P31;Q12140
Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort.;Q422232;P2175;Q170990
[Sequential chemotherapy with methotrexate and 5-fluorouracil for advanced gastric cancer];Q238512;P2175;Q189588
[Sequential chemotherapy with methotrexate and 5-fluorouracil for advanced gastric cancer];Q422232;P2175;Q189588
Synthesis of methotrexate prodrugs as an approach for drug targeting.;Q183290;P31;Q12140
Synthesis of methotrexate prodrugs as an approach for drug targeting.;Q191924;P366;Q8386
Synthesis of methotrexate prodrugs as an approach for drug targeting.;Q422232;P31;Q12140
Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.;Q422232;P2175;Q208414
Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.;Q422232;P2175;Q4833719
Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.;Q422232;P2175;Q2626074
P13.01Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: a prospective and single-arm study.;Q422232;P636;Q1320251
Therapy of PCNSL at the Massachusetts General Hospital with high dose methotrexate and deferred radiotherapy.;Q422232;P2175;Q136312
P13.07Phase II study of systemic high-dose methotrexate and intrathecal liposomal cytarabine for treatment of breast cancer with leptomeningeal metastases.;Q422232;P2175;Q128581
P13.07Phase II study of systemic high-dose methotrexate and intrathecal liposomal cytarabine for treatment of breast cancer with leptomeningeal metastases.;Q422232;P636;Q1320251
Lack of cross-resistance between prednisolone and methotrexate in childhood acute lymphoblastic leukemia? A preliminary analysis.;Q422232;P2175;Q29496
High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?;Q191924;P31;Q12140
High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?;Q485277;P31;Q12140
High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?;Q422232;P31;Q12140
High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?;Q422232;P2175;Q208414
High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?;Q422232;P2175;Q136312
The effect of methotrexate injection for treatment of an ectopic pregnancy on ovarian reserve;Q422232;P2175;Q207087
Methotrexate, combined with cyclophosphamide attenuates murine collagen induced arthritis by modulating the expression level of Breg and DCs.;Q422232;P2175;Q170990
Words of wisdom. Re: International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.;Q412415;P2175;Q504775
[Lung diseases and treatment with methotrexate in rheumatoid arthritis];Q422232;P2175;Q187255
[Lung diseases and treatment with methotrexate in rheumatoid arthritis];Q422232;P2175;Q170990
A case of rheumatoid arthritis with methotrexate related lymphoproliferative diseases of the knee.;Q422232;P2175;Q187255
A case of rheumatoid arthritis with methotrexate related lymphoproliferative diseases of the knee.;Q422232;P2175;Q170990
An alternative monitoring protocol for single-dose methotrexate therapy in ectopic pregnancy.;Q422232;P2175;Q207087
[Management of ectopic pregnancy using methotrexate in Madagascar].;Q422232;P2175;Q207087
Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis;Q348260;P2175;Q170990
Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis;Q348260;P2175;Q187255
Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis;Q422232;P2175;Q170990
Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis;Q422232;P2175;Q187255
Presence of ultrasound subclinical synovitis and increment of serum vascular endothelial growth factor in a patient with rheumatoid arthritis achieved in sustained clinical remission by treatment with adalimumab and methotrexate;Q348260;P2175;Q170990
Presence of ultrasound subclinical synovitis and increment of serum vascular endothelial growth factor in a patient with rheumatoid arthritis achieved in sustained clinical remission by treatment with adalimumab and methotrexate;Q348260;P2175;Q187255
Presence of ultrasound subclinical synovitis and increment of serum vascular endothelial growth factor in a patient with rheumatoid arthritis achieved in sustained clinical remission by treatment with adalimumab and methotrexate;Q422232;P2175;Q187255
Presence of ultrasound subclinical synovitis and increment of serum vascular endothelial growth factor in a patient with rheumatoid arthritis achieved in sustained clinical remission by treatment with adalimumab and methotrexate;Q422232;P2175;Q170990
Effect of low dose methotrexate on markers of bone metabolism in patients with rheumatoid arthritis;Q422232;P2175;Q187255
Effect of low dose methotrexate on markers of bone metabolism in patients with rheumatoid arthritis;Q422232;P2175;Q170990
Oxaliplatin combined with 5-fluorouracil and methotrexate in advanced colorectal cancer;Q238512;P2175;Q2739660
Treatment of the small unruptured ectopic pregnancy: a cost analysis of methotrexate versus laparoscopy.;Q422232;P2175;Q207087
Cyclophosphamide, vincristine, adriamycin, and prednisone (CHOP) with and without intermediate dose methotrexate for the treatment of non-Hodgkin's lymphomas of diffuse histology.;Q408977;P2175;Q1138590
Cyclophosphamide, vincristine, adriamycin, and prednisone (CHOP) with and without intermediate dose methotrexate for the treatment of non-Hodgkin's lymphomas of diffuse histology.;Q408977;P2175;Q208414
Cyclophosphamide, vincristine, adriamycin, and prednisone (CHOP) with and without intermediate dose methotrexate for the treatment of non-Hodgkin's lymphomas of diffuse histology.;Q424972;P2175;Q1138590
Cyclophosphamide, vincristine, adriamycin, and prednisone (CHOP) with and without intermediate dose methotrexate for the treatment of non-Hodgkin's lymphomas of diffuse histology.;Q422232;P2175;Q208414
Cyclophosphamide, vincristine, adriamycin, and prednisone (CHOP) with and without intermediate dose methotrexate for the treatment of non-Hodgkin's lymphomas of diffuse histology.;Q422232;P2175;Q1138590
Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs.;Q181003;P31;Q12140
Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs.;Q218642;P31;Q12140
Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs.;Q186474;P31;Q12140
Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs.;Q191924;P366;Q8386
Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs.;Q485277;P31;Q12140
Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs.;Q415378;P31;Q12140
Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs.;Q418011;P31;Q12140
Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs.;Q484940;P31;Q12140
Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs.;Q422232;P31;Q12140
Anti-arthritic effect of -caryophyllene and its ameliorative role on methotrexate and/or leflunomide-induced side effects in arthritic rats;Q248550;P2175;Q170990
Anti-arthritic effect of -caryophyllene and its ameliorative role on methotrexate and/or leflunomide-induced side effects in arthritic rats;Q422232;P2175;Q170990
Incorporating Cystatin C to Predict Methotrexate Elimination in Patients with CNS Lymphoma and Suspicious Renal Function.;Q422232;P2175;Q136312
Incorporating Cystatin C to Predict Methotrexate Elimination in Patients with CNS Lymphoma and Suspicious Renal Function.;Q422232;P2175;Q208414
[High dose methotrexate with CF rescue therapy in patients with head and neck cancer];Q422232;P2175;Q1783924
MACC (methotrexate, doxorubicin, cyclophosphamide and lomustine) versus cis-platinum and etoposide in the treatment of advanced non-small cell lung cancer;Q139347;P2175;Q12078
Different switching rate of anti-TNF- drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life;Q186521;P31;Q12140
Different switching rate of anti-TNF- drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life;Q191924;P366;Q8386
Different switching rate of anti-TNF- drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life;Q170545;P31;Q12140
Different switching rate of anti-TNF- drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life;Q178450;P31;Q12140
Different switching rate of anti-TNF- drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life;Q422232;P2175;Q187255
Different switching rate of anti-TNF- drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life;Q422232;P31;Q12140
Different switching rate of anti-TNF- drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life;Q422232;P2175;Q170990
Cytomegalovirus infection in a patient with rheumatoid arthritis on low-dose methotrexate;Q422232;P2175;Q170990
Cytomegalovirus infection in a patient with rheumatoid arthritis on low-dose methotrexate;Q422232;P2175;Q187255
Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis.;Q422232;P2175;Q170990
Intratumoral methotrexate kinetics in a patient with intracranial anaplastic ependymoma.;Q422232;P636;Q285166
Treatment of methotrexate (MTX) intolerance: behavioural therapy, versus switch to parenteral MTX versus oral MTX.;Q422232;P636;Q285166
Calprotectin alone is not sufficient to predict response to methotrexate in early ACR/EULAR 2010 rheumatoid arthritis: Analysis of the ESPOIR cohort;Q422232;P2175;Q170990
Calprotectin alone is not sufficient to predict response to methotrexate in early ACR/EULAR 2010 rheumatoid arthritis: Analysis of the ESPOIR cohort;Q422232;P2175;Q187255
Calprotectin alone is not sufficient to predict response to methotrexate in early ACR/EULAR 2010 rheumatoid arthritis: Analysis of the ESPOIR cohort;Q422232;P361;Q14819383
[Sequential therapy with methotrexate and 5-fluorouracil in patients with advanced colorectal cancer pretreated with 5-fluorouracil plus folinic acid];Q238512;P2175;Q2739660
Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy.;Q422232;P2175;Q170990
Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy.;Q422232;P2175;Q187255
Treatment of mycosis fungoides lymphoma: effectiveness of infusions of methotrexate followed by oral citrovorum factor.;Q422232;P636;Q285166
Treatment of mycosis fungoides lymphoma: effectiveness of infusions of methotrexate followed by oral citrovorum factor.;Q422232;P2175;Q1891209
Treatment of mycosis fungoides lymphoma: effectiveness of infusions of methotrexate followed by oral citrovorum factor.;Q422232;P2175;Q208414
Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis.;Q191924;P366;Q8386
Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis.;Q20035886;P31;Q12140
Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis.;Q422232;P31;Q12140
Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis.;Q422232;P2175;Q170990
Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis.;Q422232;P2175;Q187255
Contribution of genetic polymorphism of methylene tetrahydrofolate reductase on the effect of methotrexate in ectopic pregnancy patients;Q422232;P2175;Q207087
Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.;Q422232;P2175;Q29496
Early prediction for the requirement of second or third dose methotrexate in women with ectopic pregnancy, treated with single-dose regimen.;Q422232;P2175;Q207087
Review: the addition of infliximab and etanercept to methotrexate was effective in the long term for rheumatoid arthritis.;Q415264;P2175;Q170990
Review: the addition of infliximab and etanercept to methotrexate was effective in the long term for rheumatoid arthritis.;Q422232;P2175;Q170990
Review: the addition of infliximab and etanercept to methotrexate was effective in the long term for rheumatoid arthritis.;Q422232;P2175;Q187255
FLR1 gene (ORF YBR008c) is required for benomyl and methotrexate resistance in Saccharomyces cerevisiae and its benomylinduced expression is dependent on Pdr3 transcriptional regulator;Q170545;P703;Q719725
High-dose leucovorin reverses acute high-dose methotrexate neurotoxicity in the rat.;Q191924;P2868;Q407752
[Monitoring high dose methotrexate therapy (HD MTX) in children with osteosarcoma and computer simulation using a pharmacokinetic model];Q422232;P2175;Q549534
An Antibody Specific for the Dog Leukocyte Antigen DR (DLA-DR) and Its Novel Methotrexate Conjugate Inhibit the Growth of Canine B Cell Lymphoma;Q422232;P2175;Q208414
Effectiveness of nanoencapsulated methotrexate against osteosarcoma cells: in vitro cytotoxicity under dynamic conditions.;Q422232;P2175;Q549534
[Severe acute pneumopathy following low-dose methotrexate therapy in chronic polyarthritis];Q422232;P2175;Q170990
[Severe acute pneumopathy following low-dose methotrexate therapy in chronic polyarthritis];Q422232;P2175;Q1274464
Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNF Monoclonal Antibody;Q218642;P703;Q177932
Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNF Monoclonal Antibody;Q186521;P703;Q177932
Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNF Monoclonal Antibody;Q178450;P703;Q177932
Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNF Monoclonal Antibody;Q20035886;P703;Q177932
Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNF Monoclonal Antibody;Q22124685;P703;Q177932
Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNF Monoclonal Antibody;Q620730;P703;Q177932
Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNF Monoclonal Antibody;Q484940;P703;Q177932
[Effect of folic acid and methotrexate on the function of the hydroxylating system and the cholesterol and phospholipid content in the liver microsomes of rats];Q422232;P2868;Q127060
Metabolism of anticancer drugs: a rapid and specific enzyme immunoassay for methotrexate [proceedings];Q191924;P366;Q8386
Metabolism of anticancer drugs: a rapid and specific enzyme immunoassay for methotrexate [proceedings];Q22124685;P31;Q12140
Metabolism of anticancer drugs: a rapid and specific enzyme immunoassay for methotrexate [proceedings];Q422232;P31;Q12140
A preliminary report of a pilot randomized trial comparing cyclophosphamide, methotrexate and 5-fluorouracil with cyclophosphamide, mitoxantrone and 5-fluorouracil in the adjuvant therapy of stage II breast cancer with four or more positive axillary;Q239426;P2175;Q128581
A preliminary report of a pilot randomized trial comparing cyclophosphamide, methotrexate and 5-fluorouracil with cyclophosphamide, mitoxantrone and 5-fluorouracil in the adjuvant therapy of stage II breast cancer with four or more positive axillary;Q238512;P2175;Q128581
A preliminary report of a pilot randomized trial comparing cyclophosphamide, methotrexate and 5-fluorouracil with cyclophosphamide, mitoxantrone and 5-fluorouracil in the adjuvant therapy of stage II breast cancer with four or more positive axillary;Q422232;P2175;Q128581
High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL);Q180983;P2175;Q208414
High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL);Q422232;P2175;Q136312
High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL);Q422232;P2175;Q208414
A case of L-dopa-responsive parkinsonian syndrome after low-dose oral methotrexate intake.;Q422232;P636;Q285166
[High-dose methotrexate and cerebral neurotoxicity. Apropos of a case of arachnoiditis].;Q191924;P2868;Q407752
Biopterin and neurotransmitter amine metabolism in children with acute lymphoblastic leukemia receiving methotrexate therapy.;Q422232;P2175;Q29496
The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.;Q218642;P703;Q177932
The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.;Q186474;P703;Q177932
The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.;Q186521;P703;Q177932
The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.;Q485277;P703;Q177932
The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.;Q173670;P703;Q177932
The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.;Q22124685;P703;Q177932
The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.;Q422232;P2175;Q187255
The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.;Q422232;P2175;Q170990
[The short-term efficacy and safety of methotrexate plus low dose prednisone in patients with rheumatoid arthritis].;Q424972;P2175;Q170990
[The short-term efficacy and safety of methotrexate plus low dose prednisone in patients with rheumatoid arthritis].;Q422232;P2175;Q170990
[The short-term efficacy and safety of methotrexate plus low dose prednisone in patients with rheumatoid arthritis].;Q422232;P2175;Q187255
Severe vertigo requiring hospitalization whilst taking low-dose oral methotrexate for psoriasis.;Q422232;P636;Q285166
Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab;Q425154;P2175;Q170990
Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab;Q422232;P2175;Q170990
Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab;Q422232;P2175;Q187255
Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine.;Q421094;P2175;Q170990
Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine.;Q421094;P2175;Q187255
Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine.;Q421094;P1889;Q422438
Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine.;Q422438;P2175;Q187255
Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine.;Q422438;P1889;Q421094
Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine.;Q422232;P2175;Q170990
Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine.;Q422232;P2175;Q187255
Tumour stage of mycosis fungoides treated with bleomycin and methotrexate: report from the Scandinavian mycosis fungoides study group.;Q422232;P2175;Q1891209
A double-blind comparison of parenteral methotrexate and parenteral gold in the treatment of early erosive rheumatoid arthritis: an interim report on 102 patients after 12 months.;Q422232;P2175;Q187255
A double-blind comparison of parenteral methotrexate and parenteral gold in the treatment of early erosive rheumatoid arthritis: an interim report on 102 patients after 12 months.;Q422232;P2175;Q170990
Single-dose versus two-dose administration of methotrexate for the treatment of ectopic pregnancy: a randomized controlled trial;Q422232;P2175;Q207087
Epirubicin, methotrexate and bleomycin in the management of recurrent squamous cell head and neck cancer. A GSTTC randomised phase II study.;Q422232;P2175;Q1783924
Collateral methotrexate resistance in cisplatin-selected murine leukemia cells.;Q422232;P2175;Q29496
Low incidence of CNS relapse with cranial radiotherapy and intrathecal methotrexate in acute lymphoblastic leukemia.;Q422232;P2175;Q29496
Low incidence of CNS relapse with cranial radiotherapy and intrathecal methotrexate in acute lymphoblastic leukemia.;Q422232;P636;Q1320251
Role of amino acid depletion in combined treatment of neoplastic cells with methotrexate and L-asparaginase.;Q173670;P31;Q8066
Modulation of methotrexate cytotoxicity with natural interferon upon human leukemia cell line HL-60.;Q485277;P703;Q15978631
Modulation of methotrexate cytotoxicity with natural interferon upon human leukemia cell line HL-60.;Q22124685;P703;Q15978631
Modulation of methotrexate cytotoxicity with natural interferon upon human leukemia cell line HL-60.;Q483745;P703;Q15978631
Modulation of methotrexate cytotoxicity with natural interferon upon human leukemia cell line HL-60.;Q422232;P2175;Q29496
Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study.;Q415264;P2175;Q170990
Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study.;Q422232;P2175;Q170990
Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study.;Q422232;P2175;Q187255
Efficacy of methotrexate in reducing the risk of bone erosion in patients with rheumatoid arthritis: a systematic review of randomized controlled trials;Q422232;P2175;Q170990
Efficacy of methotrexate in reducing the risk of bone erosion in patients with rheumatoid arthritis: a systematic review of randomized controlled trials;Q422232;P2175;Q187255
Risk factors for recurrent ectopic pregnancy following single-dose methotrexate treatment;Q422232;P2175;Q207087
[Biochemical stigmata of epidermis reactivity. I. Behavior of acid soluble UV-absorbing compounds of guinea pig epidermis under the influence of autolysis, regeneration stimulation, cetan application and methotrexate treatment];Q23118;P31;Q11173
[Biochemical stigmata of epidermis reactivity. I. Behavior of acid soluble UV-absorbing compounds of guinea pig epidermis under the influence of autolysis, regeneration stimulation, cetan application and methotrexate treatment];Q191924;P31;Q11173
[Biochemical stigmata of epidermis reactivity. I. Behavior of acid soluble UV-absorbing compounds of guinea pig epidermis under the influence of autolysis, regeneration stimulation, cetan application and methotrexate treatment];Q483752;P31;Q11173
[Biochemical stigmata of epidermis reactivity. I. Behavior of acid soluble UV-absorbing compounds of guinea pig epidermis under the influence of autolysis, regeneration stimulation, cetan application and methotrexate treatment];Q484940;P31;Q11173
[Biochemical stigmata of epidermis reactivity. I. Behavior of acid soluble UV-absorbing compounds of guinea pig epidermis under the influence of autolysis, regeneration stimulation, cetan application and methotrexate treatment];Q422232;P31;Q11173
Efficacy of methotrexate in management of peripheral psoriatic arthritis - a systematic review;Q422232;P2175;Q170990
[Methotrexate: mainstay of rheumatoid arthritis treatment];Q422232;P2175;Q170990
[Methotrexate: mainstay of rheumatoid arthritis treatment];Q422232;P2175;Q187255
Comparison of single-dose and two-dose methotrexate protocols for the treatment of unruptured ectopic pregnancy;Q422232;P2175;Q207087
Effectiveness of and factors associated with clinical response to methotrexate under daily life conditions in Asian patients with psoriasis: A retrospective cohort study.;Q422232;P361;Q14819383
Severe phototoxicity associated with concomitant use of methotrexate and voriconazole, an overlooked drug-drug interaction;Q183290;P31;Q12140
Severe phototoxicity associated with concomitant use of methotrexate and voriconazole, an overlooked drug-drug interaction;Q191924;P31;Q12140
Severe phototoxicity associated with concomitant use of methotrexate and voriconazole, an overlooked drug-drug interaction;Q412236;P31;Q12140
Severe phototoxicity associated with concomitant use of methotrexate and voriconazole, an overlooked drug-drug interaction;Q412236;P279;Q419639
Severe phototoxicity associated with concomitant use of methotrexate and voriconazole, an overlooked drug-drug interaction;Q422232;P31;Q12140
Pulmonary coinfection by Pneumocystis carinii and Aspegillus fumigatus in a seronegative arthritis patient treated with low-dose methotrexate;Q422232;P2175;Q170990
Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis.;Q422232;P2175;Q170990
Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis.;Q422232;P361;Q14819383
Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Interaction of anticancer drug methotrexate with nucleic acids analyzed by multi-spectroscopic method.;Q23118;P31;Q8386
Interaction of anticancer drug methotrexate with nucleic acids analyzed by multi-spectroscopic method.;Q191924;P31;Q12140
Interaction of anticancer drug methotrexate with nucleic acids analyzed by multi-spectroscopic method.;Q484940;P31;Q12140
Interaction of anticancer drug methotrexate with nucleic acids analyzed by multi-spectroscopic method.;Q422232;P31;Q12140
Impact on costs and quality-adjusted-life-years of treat-to-target treatment strategies initiating methotrexate, or tocilizumab, or their combination in early rheumatoid arthritis. 5 year economic evaluation;Q425154;P2175;Q170990
Impact on costs and quality-adjusted-life-years of treat-to-target treatment strategies initiating methotrexate, or tocilizumab, or their combination in early rheumatoid arthritis. 5 year economic evaluation;Q422232;P2175;Q187255
Impact on costs and quality-adjusted-life-years of treat-to-target treatment strategies initiating methotrexate, or tocilizumab, or their combination in early rheumatoid arthritis. 5 year economic evaluation;Q422232;P2175;Q170990
Methotrexate (MTX)-associated malignant lymphoma of the bilateral breast: imaging features in comparison to other nipple-areolar tumors;Q422232;P2175;Q208414
Umbilical cord blood transplantation for adults using tacrolimus with two-day very-short-term methotrexate for graft-versus-host disease prophylaxis.;Q411648;P2175;Q1194520
The effect of the rate of cell proliferation on the synthesis of methotrexate poly-gamma-glutamates in two human breast cancer cell lines.;Q186521;P703;Q15978631
The effect of the rate of cell proliferation on the synthesis of methotrexate poly-gamma-glutamates in two human breast cancer cell lines.;Q422232;P2175;Q128581
Caffeine consumption and methotrexate dosing requirement in psoriasis and psoriatic arthritis;Q422232;P2175;Q170990
Modulation of fluorouracil by methotrexate, leucovorin, and cisplatin (M-FLP) in the treatment of advanced pancreatic cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC).;Q238512;P2175;Q212961
[Methotrexate and 5-fluorouracil with leucovorin therapy in advanced gastric cancer: the enhancement of 5-fluorouracil antitumor activity by leucovorin];Q238512;P2175;Q189588
[Methotrexate and 5-fluorouracil with leucovorin therapy in advanced gastric cancer: the enhancement of 5-fluorouracil antitumor activity by leucovorin];Q422232;P2175;Q189588
Pregnancy in a rheumatoid arthritis patient on infliximab and methotrexate;Q415264;P2175;Q170990
Pregnancy in a rheumatoid arthritis patient on infliximab and methotrexate;Q422232;P2175;Q170990
Pregnancy in a rheumatoid arthritis patient on infliximab and methotrexate;Q422232;P2175;Q187255
[Juvenile idiopathic arthritis treated by methotrexate: result of treatment and tolerance];Q422232;P2175;Q170990
[B-cell lymphoma possessing t(14:18)(q32:q21)in a patient with rheumatoid arthritis receiving methotrexate treatment].;Q422232;P2175;Q170990
[B-cell lymphoma possessing t(14:18)(q32:q21)in a patient with rheumatoid arthritis receiving methotrexate treatment].;Q422232;P2175;Q187255
[B-cell lymphoma possessing t(14:18)(q32:q21)in a patient with rheumatoid arthritis receiving methotrexate treatment].;Q422232;P2175;Q208414
[B-cell lymphoma possessing t(14:18)(q32:q21)in a patient with rheumatoid arthritis receiving methotrexate treatment].;Q422232;P2175;Q4833719
Adjuvant sequential methotrexate  5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer.;Q238512;P2175;Q18555025
[Prevention of central nervous system involvement with intrathecal 198Au colloid and methotrexate in non-Hodgkin lymphoma, acute non-lymphatic leukaemia and Ewing's sarcoma];Q422232;P2175;Q29496
[Prevention of central nervous system involvement with intrathecal 198Au colloid and methotrexate in non-Hodgkin lymphoma, acute non-lymphatic leukaemia and Ewing's sarcoma];Q422232;P2175;Q208414
[Prevention of central nervous system involvement with intrathecal 198Au colloid and methotrexate in non-Hodgkin lymphoma, acute non-lymphatic leukaemia and Ewing's sarcoma];Q422232;P636;Q1320251
[Prevention of central nervous system involvement with intrathecal 198Au colloid and methotrexate in non-Hodgkin lymphoma, acute non-lymphatic leukaemia and Ewing's sarcoma];Q422232;P2175;Q1138590
Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay.;Q422232;P2175;Q29496
Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy.;Q422232;P2175;Q136312
Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy.;Q422232;P2175;Q208414
Comparison of alternative hCG follow-up protocols after single-dose methotrexate therapy for tubal ectopic pregnancy.;Q422232;P2175;Q207087
Effect of folic acid and methotrexate on reproduction of Rauscher leukemia virus.;Q422232;P2175;Q29496
Effect of folic acid and methotrexate on reproduction of Rauscher leukemia virus.;Q422232;P2868;Q127060
A pharmacokinetic model for predicting the concentration of methotrexate in plasma subsequent to intrathecal injection.;Q422232;P636;Q1320251
Treatment patterns in rheumatoid arthritis after discontinuation of methotrexate: data from the Ontario Best Practices Research Initiative (OBRI).;Q422232;P2175;Q187255
Treatment patterns in rheumatoid arthritis after discontinuation of methotrexate: data from the Ontario Best Practices Research Initiative (OBRI).;Q422232;P2175;Q170990
Short term efficacy of methotrexate in the treatment of rheumatoid arthritis.;Q422232;P2175;Q170990
Short term efficacy of methotrexate in the treatment of rheumatoid arthritis.;Q422232;P2175;Q187255
Comparison of the Therapeutic Effects of Thymoquinone and Methotrexate on Renal Injury in Pristane Induced Arthritis in Rats.;Q218642;P703;Q177932
Comparison of the Therapeutic Effects of Thymoquinone and Methotrexate on Renal Injury in Pristane Induced Arthritis in Rats.;Q186474;P703;Q177932
Comparison of the Therapeutic Effects of Thymoquinone and Methotrexate on Renal Injury in Pristane Induced Arthritis in Rats.;Q186521;P703;Q177932
Comparison of the Therapeutic Effects of Thymoquinone and Methotrexate on Renal Injury in Pristane Induced Arthritis in Rats.;Q173670;P703;Q177932
Comparison of the Therapeutic Effects of Thymoquinone and Methotrexate on Renal Injury in Pristane Induced Arthritis in Rats.;Q20035886;P703;Q177932
Comparison of the Therapeutic Effects of Thymoquinone and Methotrexate on Renal Injury in Pristane Induced Arthritis in Rats.;Q22124685;P703;Q177932
Comparison of the Therapeutic Effects of Thymoquinone and Methotrexate on Renal Injury in Pristane Induced Arthritis in Rats.;Q484940;P703;Q177932
Disposition of endogenous homocysteine by mouse fibroblast C3H/10T1/2 Cl 8 and the chemically transformed C3H/10T1/2 MCA Cl 16 cells following methotrexate exposure.;Q186474;P703;Q83310
Development of biopsy-proven giant cell arteritis in a patient with dermatomyositis on methotrexate: comment on the article by Monti et al;Q422232;P2175;Q707816
The Peters anomaly following antenatal exposure to methotrexate and hydroxychloroquine;Q421094;P1889;Q422438
The Peters anomaly following antenatal exposure to methotrexate and hydroxychloroquine;Q422438;P1889;Q421094
Why methotrexate suboptimal dosing is a potential source of bias in biologic drugs clinical trials.;Q181003;P31;Q12140
Why methotrexate suboptimal dosing is a potential source of bias in biologic drugs clinical trials.;Q191924;P31;Q12140
Why methotrexate suboptimal dosing is a potential source of bias in biologic drugs clinical trials.;Q191924;P366;Q8386
Why methotrexate suboptimal dosing is a potential source of bias in biologic drugs clinical trials.;Q422232;P31;Q12140
Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study;Q422232;P2175;Q187255
Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study;Q422232;P2175;Q170990
[Treating rheumatoid arthritis patients of Shen deficiency and cold invading syndrome by bushen quhan zhiwang decoction combined methotrexate: an evaluation of clinical efficacy and safety].;Q422232;P2175;Q170990
[Treating rheumatoid arthritis patients of Shen deficiency and cold invading syndrome by bushen quhan zhiwang decoction combined methotrexate: an evaluation of clinical efficacy and safety].;Q422232;P2175;Q187255
Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy;Q348260;P2175;Q170990
Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy;Q348260;P2175;Q187255
Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy;Q425154;P2175;Q170990
Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy;Q422232;P2175;Q170990
Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy;Q422232;P2175;Q187255
Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (Rituximab) monotherapy.;Q422232;P2175;Q170990
Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (Rituximab) monotherapy.;Q422232;P2175;Q187255
Local management with methotrexate of cesarean scar ectopic pregnancy with live embryo guided by transvaginal ultrasound: A case report.;Q422232;P2175;Q207087
Transcription regulatory polymorphism -43T>C in the 5'-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy;Q422232;P2175;Q187255
Transcription regulatory polymorphism -43T>C in the 5'-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy;Q422232;P361;Q14819383
Transcription regulatory polymorphism -43T>C in the 5'-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy;Q422232;P2175;Q170990
Transcription regulatory polymorphism -43T>C in the 5'-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy;Q422232;P129;Q21126218
[Use of methotrexate and telegammatherapy in esophageal cancer];Q422232;P2175;Q372701
High-dose methotrexate with R-CHOP therapy for the treatment of patients with primary central nervous system lymphoma;Q422232;P2175;Q136312
High-dose methotrexate with R-CHOP therapy for the treatment of patients with primary central nervous system lymphoma;Q422232;P2175;Q208414
Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis.;Q422232;P2175;Q170990
Simple and reliable HPLC method for the monitoring of methotrexate in osteosarcoma patients.;Q422232;P2175;Q549534
Rapidly ascending necrotizing myelopathy with widespread brain white matter involvement following intrathecal methotrexate and cytosine arabinoside treatment in an adult with T cell acute lymphoblastic leukemia;Q180983;P2175;Q29496
Rapidly ascending necrotizing myelopathy with widespread brain white matter involvement following intrathecal methotrexate and cytosine arabinoside treatment in an adult with T cell acute lymphoblastic leukemia;Q422232;P2175;Q29496
Rapidly ascending necrotizing myelopathy with widespread brain white matter involvement following intrathecal methotrexate and cytosine arabinoside treatment in an adult with T cell acute lymphoblastic leukemia;Q422232;P636;Q1320251
Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial;Q348260;P2175;Q170990
Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial;Q422232;P2175;Q170990
Review: adding newer disease-modifying drugs or biological agents to methotrexate improved rheumatoid arthritis symptoms.;Q191924;P31;Q12140
Review: adding newer disease-modifying drugs or biological agents to methotrexate improved rheumatoid arthritis symptoms.;Q191924;P366;Q8386
Review: adding newer disease-modifying drugs or biological agents to methotrexate improved rheumatoid arthritis symptoms.;Q173670;P31;Q12140
Review: adding newer disease-modifying drugs or biological agents to methotrexate improved rheumatoid arthritis symptoms.;Q422232;P31;Q12140
Review: adding newer disease-modifying drugs or biological agents to methotrexate improved rheumatoid arthritis symptoms.;Q422232;P2175;Q170990
Review: adding newer disease-modifying drugs or biological agents to methotrexate improved rheumatoid arthritis symptoms.;Q422232;P2175;Q187255
A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results fr;Q348260;P2175;Q170990
A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results fr;Q348260;P2175;Q187255
A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results fr;Q422232;P2175;Q170990
A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results fr;Q422232;P2175;Q187255
Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patientscompared to cyclosporine A and methotrexate: results from the BioDay registry;Q218642;P31;Q12140
Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patientscompared to cyclosporine A and methotrexate: results from the BioDay registry;Q186521;P31;Q12140
Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patientscompared to cyclosporine A and methotrexate: results from the BioDay registry;Q191924;P366;Q8386
Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patientscompared to cyclosporine A and methotrexate: results from the BioDay registry;Q367700;P31;Q12140
Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patientscompared to cyclosporine A and methotrexate: results from the BioDay registry;Q178450;P31;Q12140
Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patientscompared to cyclosporine A and methotrexate: results from the BioDay registry;Q422232;P31;Q12140
Clearance of methotrexate by means of hemofiltration in a patient with osteosarcoma;Q422232;P2175;Q549534
Understanding the binding interaction between methotrexate and human alpha-2-macroglobulin: Multi-spectroscopic and computational investigation;Q22124685;P703;Q15978631
PRTX-100 and methotrexate in patients with active rheumatoid arthritis: A Phase Ib randomized, double-blind, placebo-controlled, dose-escalation study.;Q422232;P2175;Q170990
PRTX-100 and methotrexate in patients with active rheumatoid arthritis: A Phase Ib randomized, double-blind, placebo-controlled, dose-escalation study.;Q422232;P2175;Q187255
Experimental study on subacute neurotoxicity of methotrexate in cats.;Q191924;P2868;Q407752
Etanercept biosimilar (recombinant human tumor necrosis factor- receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-;Q186474;P703;Q15978631
Etanercept biosimilar (recombinant human tumor necrosis factor- receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-;Q170545;P703;Q15978631
Etanercept biosimilar (recombinant human tumor necrosis factor- receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-;Q620730;P703;Q15978631
Etanercept biosimilar (recombinant human tumor necrosis factor- receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-;Q484940;P703;Q15978631
Suppressive influences of methotrexate on the generation of CD14(+) monocyte-lineage cells from bone marrow of patients with rheumatoid arthritis;Q422232;P2175;Q170990
Suppressive influences of methotrexate on the generation of CD14(+) monocyte-lineage cells from bone marrow of patients with rheumatoid arthritis;Q422232;P2175;Q187255
[Recent views on the use of methotrexate in the treatment of acute lymphoblastic leukemia in childhood];Q422232;P2175;Q29496
Prognostic value of human chorionic gonadotropin levels 4 days after a single dose of methotrexate for ectopic pregnancy;Q407172;P703;Q15978631
Prognostic value of human chorionic gonadotropin levels 4 days after a single dose of methotrexate for ectopic pregnancy;Q407172;P279;Q409770
Prognostic value of human chorionic gonadotropin levels 4 days after a single dose of methotrexate for ectopic pregnancy;Q20035886;P703;Q15978631
Prognostic value of human chorionic gonadotropin levels 4 days after a single dose of methotrexate for ectopic pregnancy;Q422232;P2175;Q207087
Effects of co-treatment with pioglitazone and methotrexate on experimentally induced rheumatoid arthritis in Wistar albino rats;Q422232;P2175;Q170990
Effects of co-treatment with pioglitazone and methotrexate on experimentally induced rheumatoid arthritis in Wistar albino rats;Q422232;P2175;Q187255
ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb;Q186474;P703;Q15978631
Combining sulphasalazine and methotrexate in rheumatoid arthritis: early clinical impressions.;Q422232;P2175;Q170990
Combining sulphasalazine and methotrexate in rheumatoid arthritis: early clinical impressions.;Q422232;P2175;Q187255
Primary cutaneous -T-cell lymphoma treated with low-dose methotrexate and narrowband ultraviolet B irradiation: report of a case with testicular involvement;Q422232;P2175;Q7667896
Primary cutaneous -T-cell lymphoma treated with low-dose methotrexate and narrowband ultraviolet B irradiation: report of a case with testicular involvement;Q422232;P2175;Q208414
Findings in computerized axial tomography after intrathecal methotrexate and radiation.;Q422232;P636;Q1320251
Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.;Q422232;P2175;Q136312
Comparing the Efficacy of DeVIC Therapy and High-dose Methotrexate Monotherapy with Whole-brain Radiation Therapy for Newly-diagnosed Primary Central Nervous System Lymphoma: A Single Institution Study.;Q422232;P2175;Q208414
Treating rheumatoid arthritis with leflunomide monotherapy versus combination therapy with methotrexate;Q248550;P2175;Q170990
Treating rheumatoid arthritis with leflunomide monotherapy versus combination therapy with methotrexate;Q248550;P2175;Q187255
Treating rheumatoid arthritis with leflunomide monotherapy versus combination therapy with methotrexate;Q422232;P2175;Q187255
Treating rheumatoid arthritis with leflunomide monotherapy versus combination therapy with methotrexate;Q422232;P2175;Q170990
[Intrathecal methotrexate in breast cancer meningeal carcinomatosis - Experience with a new administration schedule].;Q422232;P2175;Q128581
Effects of methotrexate on nucleotide pools in normal human T cells and the CEM T cell line.;Q186474;P703;Q15978631
Effects of methotrexate on nucleotide pools in normal human T cells and the CEM T cell line.;Q186521;P703;Q15978631
Effects of methotrexate on nucleotide pools in normal human T cells and the CEM T cell line.;Q22124685;P703;Q15978631
Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome;Q422232;P2175;Q208414
Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome;Q422232;P2175;Q136312
Efficacy of methotrexate in the treatment of a HLA-B27-positive Japanease patient with reactive arthritis.;Q422232;P2175;Q170990
The potential use of methotrexate in the treatment of falciparum malaria: in vitro assays against sensitive and multidrug-resistant falciparum strains.;Q186521;P31;Q12140
The potential use of methotrexate in the treatment of falciparum malaria: in vitro assays against sensitive and multidrug-resistant falciparum strains.;Q191924;P31;Q12140
The potential use of methotrexate in the treatment of falciparum malaria: in vitro assays against sensitive and multidrug-resistant falciparum strains.;Q422232;P31;Q12140
Methotrexate: the emerging drug of choice for serious rheumatoid arthritis.;Q191924;P31;Q12140
Methotrexate: the emerging drug of choice for serious rheumatoid arthritis.;Q22124685;P31;Q12140
Methotrexate: the emerging drug of choice for serious rheumatoid arthritis.;Q422232;P2175;Q170990
Methotrexate: the emerging drug of choice for serious rheumatoid arthritis.;Q422232;P2175;Q187255
Methotrexate: the emerging drug of choice for serious rheumatoid arthritis.;Q422232;P31;Q12140
Association of 63/91 length polymorphism in the DHFR gene major promoter with toxicity of methotrexate in patients with rheumatoid arthritis.;Q422232;P2175;Q187255
Association of 63/91 length polymorphism in the DHFR gene major promoter with toxicity of methotrexate in patients with rheumatoid arthritis.;Q422232;P2175;Q170990
[A new sequential chemotherapy of methotrexate with 5-fluorouracil against advanced colo-rectal cancer];Q238512;P2175;Q2739660
[Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for malignant rheumatoid arthritis];Q422232;P2175;Q170990
[Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for malignant rheumatoid arthritis];Q422232;P2175;Q187255
Pharmacogenomics of intracellular methotrexate polyglutamates in patients' leukemia cells in vivo;Q422232;P2175;Q29496
Phase II study of combined vincristine, adriamycin, cyclophosphamide, and methotrexate with citrovorum factor factor rescue in metastatic breast cancer.;Q422232;P2175;Q128581
Efficacy of leflunomide 100mg weekly compared to low dose methotrexate in patients with active rheumatoid arthritis. Double blind, randomized clinical trial;Q248550;P2175;Q170990
Efficacy of leflunomide 100mg weekly compared to low dose methotrexate in patients with active rheumatoid arthritis. Double blind, randomized clinical trial;Q248550;P2175;Q187255
Efficacy of leflunomide 100mg weekly compared to low dose methotrexate in patients with active rheumatoid arthritis. Double blind, randomized clinical trial;Q422232;P2175;Q170990
Efficacy of leflunomide 100mg weekly compared to low dose methotrexate in patients with active rheumatoid arthritis. Double blind, randomized clinical trial;Q422232;P2175;Q187255
Effects of double filtration plasmapheresis, leflunomide, and methotrexate on inflammatory changes found through magnetic resonance imaging in early rheumatoid arthritis.;Q248550;P2175;Q170990
Effects of double filtration plasmapheresis, leflunomide, and methotrexate on inflammatory changes found through magnetic resonance imaging in early rheumatoid arthritis.;Q248550;P2175;Q187255
Effects of double filtration plasmapheresis, leflunomide, and methotrexate on inflammatory changes found through magnetic resonance imaging in early rheumatoid arthritis.;Q422232;P2175;Q187255
Effects of double filtration plasmapheresis, leflunomide, and methotrexate on inflammatory changes found through magnetic resonance imaging in early rheumatoid arthritis.;Q422232;P2175;Q170990
Intensive care management of multiorgan failure following single low dose methotrexate for ectopic pregnancy: An intriguing case report;Q422232;P2175;Q207087
Polyuria associated with high-dose methotrexate in two patients with acute lymphoblastic leukaemia.;Q422232;P2175;Q29496
Carfilzomib combined with cyclosporine and methotrexate for the prevention of graft-versus-host disease after allogeneic stem-cell transplantation from unrelated donors;Q367700;P2175;Q1194520
[Clinical observation on effect of total glucosides of paeony combined with methotrexate on rheumatoid arthritis].;Q422232;P2175;Q170990
[Clinical observation on effect of total glucosides of paeony combined with methotrexate on rheumatoid arthritis].;Q422232;P2175;Q187255
Reply: The effect of triple therapy versus etanercept plus methotrexate in rheumatoid arthritis: comment on the article by Moreland et al;Q422232;P2175;Q170990
Reply: The effect of triple therapy versus etanercept plus methotrexate in rheumatoid arthritis: comment on the article by Moreland et al;Q422232;P2175;Q187255
[In vitro effects of vinblastine sulfate, methotrexate and alkeran on human chromosomes];Q484940;P703;Q15978631
Microwave-assisted and one-step synthesis of PEG passivated fluorescent carbon dots from gelatin as an efficient nanocarrier for methotrexate delivery;Q23118;P527;Q623
Microwave-assisted and one-step synthesis of PEG passivated fluorescent carbon dots from gelatin as an efficient nanocarrier for methotrexate delivery;Q191924;P527;Q623
Microwave-assisted and one-step synthesis of PEG passivated fluorescent carbon dots from gelatin as an efficient nanocarrier for methotrexate delivery;Q20035886;P361;Q179254
Microwave-assisted and one-step synthesis of PEG passivated fluorescent carbon dots from gelatin as an efficient nanocarrier for methotrexate delivery;Q620730;P527;Q623
Marked effectiveness of low-dose oral methotrexate for steroid-resistant idiopathic hypertrophic pachymeningitis: Case report.;Q422232;P636;Q285166
High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China;Q412323;P2175;Q136312
High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China;Q412323;P2175;Q208414
High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China;Q422232;P2175;Q208414
High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China;Q422232;P2175;Q136312
Neoadjuvant chemotherapy with methotrexate and cisplatin prior to radiotherapy for invasive transitional cell carcinoma of the bladder. Assessment of feasibility and toxicity;Q412415;P2175;Q2501186
IMFRA (intermittent intrathecal methotrexate and fractional radiation) plus chemotherapy in childhood leukemia;Q422232;P2175;Q29496
IMFRA (intermittent intrathecal methotrexate and fractional radiation) plus chemotherapy in childhood leukemia;Q422232;P636;Q1320251
Naked-eye nanobiosensor for therapeutic drug monitoring of methotrexate;Q191924;P31;Q12140
Naked-eye nanobiosensor for therapeutic drug monitoring of methotrexate;Q422232;P31;Q12140
A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851.;Q422232;P2175;Q208414
A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851.;Q422232;P2175;Q1138590
Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS).;Q422232;P361;Q14819383
Combination of sulphasalazine and methotrexate in the treatment of rheumatoid arthritis.;Q422232;P2175;Q187255
Combination of sulphasalazine and methotrexate in the treatment of rheumatoid arthritis.;Q422232;P2175;Q170990
A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.;Q422232;P636;Q285166
Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis.;Q18939;P2175;Q187255
Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis.;Q422232;P2175;Q170990
Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis.;Q422232;P2175;Q187255
[Clinical tolerance of high-dose methotrexate used in consolidation therapy in children with acute lymphoblastic leukemia];Q422232;P2175;Q29496
[Adverse effects of methotrexate: lymphoma and fatigue fractures];Q422232;P2175;Q208414
[Prophylactic CNS-leukemia therapy with cyclic intrathecal methotrexate and hydrocortisone injection (author's transl)];Q190875;P2959;Q26981430
[Prophylactic CNS-leukemia therapy with cyclic intrathecal methotrexate and hydrocortisone injection (author's transl)];Q422232;P2175;Q29496
[Prophylactic CNS-leukemia therapy with cyclic intrathecal methotrexate and hydrocortisone injection (author's transl)];Q422232;P636;Q1320251
Anal submucosal injection: a new route for drug administration in pelvic malignancies. V. Advanced prostatic cancer: results of methotrexate treatment using the anal route--preliminary study.;Q218642;P31;Q12140
Anal submucosal injection: a new route for drug administration in pelvic malignancies. V. Advanced prostatic cancer: results of methotrexate treatment using the anal route--preliminary study.;Q191924;P31;Q12140
Anal submucosal injection: a new route for drug administration in pelvic malignancies. V. Advanced prostatic cancer: results of methotrexate treatment using the anal route--preliminary study.;Q483752;P31;Q12140
Anal submucosal injection: a new route for drug administration in pelvic malignancies. V. Advanced prostatic cancer: results of methotrexate treatment using the anal route--preliminary study.;Q422232;P31;Q12140
Can Cyclosporine-A associated to methotrexate maintain remission induced by anti-TNF agents in rheumatoid arthritis patients? (Cynar pilot study).;Q422232;P2175;Q170990
Can Cyclosporine-A associated to methotrexate maintain remission induced by anti-TNF agents in rheumatoid arthritis patients? (Cynar pilot study).;Q422232;P2175;Q187255
Watson-Crick G[triple bond, length as m-dash]C-inspired supramolecular nanodrug of methotrexate and 5-fluorouracil for tumor microenvironment-activatable self-recognizing synergistic chemotherapy;Q181003;P31;Q12140
Watson-Crick G[triple bond, length as m-dash]C-inspired supramolecular nanodrug of methotrexate and 5-fluorouracil for tumor microenvironment-activatable self-recognizing synergistic chemotherapy;Q186474;P31;Q12140
Watson-Crick G[triple bond, length as m-dash]C-inspired supramolecular nanodrug of methotrexate and 5-fluorouracil for tumor microenvironment-activatable self-recognizing synergistic chemotherapy;Q191924;P31;Q12140
Watson-Crick G[triple bond, length as m-dash]C-inspired supramolecular nanodrug of methotrexate and 5-fluorouracil for tumor microenvironment-activatable self-recognizing synergistic chemotherapy;Q238512;P31;Q12140
Watson-Crick G[triple bond, length as m-dash]C-inspired supramolecular nanodrug of methotrexate and 5-fluorouracil for tumor microenvironment-activatable self-recognizing synergistic chemotherapy;Q620730;P31;Q12140
Watson-Crick G[triple bond, length as m-dash]C-inspired supramolecular nanodrug of methotrexate and 5-fluorouracil for tumor microenvironment-activatable self-recognizing synergistic chemotherapy;Q422232;P31;Q12140
Intravitreal injections of methotrexate in treatment of primary central nervous system lymphoma with intraocular involvement.;Q422232;P2175;Q136312
Intravitreal injections of methotrexate in treatment of primary central nervous system lymphoma with intraocular involvement.;Q422232;P2175;Q208414
Pilot study of low dose oral methotrexate treatment for primary biliary cirrhosis.;Q422232;P636;Q285166
Efficacy of oral versus subcutaneous methotrexate in children with juvenile idiopathic arthritis.;Q422232;P636;Q285166
Efficacy of oral versus subcutaneous methotrexate in children with juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Efficacy of oral versus subcutaneous methotrexate in children with juvenile idiopathic arthritis.;Q422232;P2175;Q170990
[Salvage chemotherapy with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) for refractory malignant lymphoma];Q191924;P769;Q418656
[Salvage chemotherapy with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) for refractory malignant lymphoma];Q418817;P2175;Q208414
[Salvage chemotherapy with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) for refractory malignant lymphoma];Q418656;P2175;Q208414
[Salvage chemotherapy with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) for refractory malignant lymphoma];Q418656;P2175;Q12284921
[Salvage chemotherapy with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) for refractory malignant lymphoma];Q11426176;P2175;Q208414
[Salvage chemotherapy with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) for refractory malignant lymphoma];Q418560;P2175;Q12284921
[Salvage chemotherapy with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) for refractory malignant lymphoma];Q422232;P2175;Q208414
Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.;Q422232;P2175;Q208414
Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.;Q422232;P2175;Q136312
Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis.;Q422232;P2175;Q170990
Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis.;Q422232;P2175;Q861224
Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis.;Q422232;P2175;Q280027
Kinetics of methotrexate uptake by human tumor cells from routine pathological samples.;Q20816880;P703;Q15978631
A case of emphysematous pyelonephritis in a patient with rheumatoid arthritis taking corticosteroid and low-dose methotrexate;Q422232;P2175;Q187255
A case of emphysematous pyelonephritis in a patient with rheumatoid arthritis taking corticosteroid and low-dose methotrexate;Q422232;P2175;Q170990
Pharmacogenomics of methotrexate in rheumatoid arthritis: does race make a difference?;Q422232;P2175;Q170990
Pharmacogenomics of methotrexate in rheumatoid arthritis: does race make a difference?;Q422232;P2175;Q187255
Methotrexate for the treatment of unruptured tubal pregnancy: a prospective nonrandomized study.;Q422232;P2175;Q207087
Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients;Q422232;P2175;Q170990
Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients;Q422232;P2175;Q187255
[Successful methotrexate therapy of tubal pregnancy];Q422232;P2175;Q207087
Highly sensitive electrochemical determination of methotrexate based on a N-doped hollow nanocarbon sphere modified electrode;Q191924;P527;Q623
Highly sensitive electrochemical determination of methotrexate based on a N-doped hollow nanocarbon sphere modified electrode;Q485277;P527;Q623
Highly sensitive electrochemical determination of methotrexate based on a N-doped hollow nanocarbon sphere modified electrode;Q60168;P527;Q623
Intra-articular methotrexate versus corticosteroid injections in medium-sized joints of rheumatoid arthritis patients-an intervention study.;Q422232;P2175;Q170990
Intra-articular methotrexate versus corticosteroid injections in medium-sized joints of rheumatoid arthritis patients-an intervention study.;Q422232;P2175;Q187255
Cell cycle-related expression of p120 nucleolar antigen in normal human lymphocytes and in cells of HL-60 and MOLT-4 leukemic lines: effects of methotrexate, camptothecin, and teniposide.;Q186474;P703;Q15978631
Cell cycle-related expression of p120 nucleolar antigen in normal human lymphocytes and in cells of HL-60 and MOLT-4 leukemic lines: effects of methotrexate, camptothecin, and teniposide.;Q186521;P703;Q15978631
Cell cycle-related expression of p120 nucleolar antigen in normal human lymphocytes and in cells of HL-60 and MOLT-4 leukemic lines: effects of methotrexate, camptothecin, and teniposide.;Q485277;P703;Q15978631
Cell cycle-related expression of p120 nucleolar antigen in normal human lymphocytes and in cells of HL-60 and MOLT-4 leukemic lines: effects of methotrexate, camptothecin, and teniposide.;Q22124685;P703;Q15978631
Cell cycle-related expression of p120 nucleolar antigen in normal human lymphocytes and in cells of HL-60 and MOLT-4 leukemic lines: effects of methotrexate, camptothecin, and teniposide.;Q483745;P703;Q15978631
Methotrexate in rheumatoid arthritis.;Q422232;P2175;Q187255
Methotrexate in rheumatoid arthritis.;Q422232;P2175;Q170990
The effect of triple therapy versus etanercept plus methotrexate in rheumatoid arthritis: comment on the article by Moreland et al.;Q422232;P2175;Q187255
The effect of triple therapy versus etanercept plus methotrexate in rheumatoid arthritis: comment on the article by Moreland et al.;Q422232;P2175;Q170990
The impact of single nucleotide polymorphisms in ADORA2A and ADORA3 genes on the early response to methotrexate and presence of therapy side effects in children with juvenile idiopathic arthritis: Results of a preliminary study;Q422232;P361;Q14819383
The impact of single nucleotide polymorphisms in ADORA2A and ADORA3 genes on the early response to methotrexate and presence of therapy side effects in children with juvenile idiopathic arthritis: Results of a preliminary study;Q422232;P2175;Q861224
The impact of single nucleotide polymorphisms in ADORA2A and ADORA3 genes on the early response to methotrexate and presence of therapy side effects in children with juvenile idiopathic arthritis: Results of a preliminary study;Q422232;P2175;Q170990
Etanercept and methotrexate in rheumatoid arthritis;Q415343;P2175;Q170990
Etanercept and methotrexate in rheumatoid arthritis;Q415343;P2175;Q187255
Etanercept and methotrexate in rheumatoid arthritis;Q422232;P2175;Q187255
Etanercept and methotrexate in rheumatoid arthritis;Q422232;P2175;Q170990
Meningosis prophylaxis with intrathecal 198Au-colloid and methotrexate in childhood acute lymphocytic leukemia.;Q422232;P2175;Q29496
Meningosis prophylaxis with intrathecal 198Au-colloid and methotrexate in childhood acute lymphocytic leukemia.;Q422232;P636;Q1320251
Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency.;Q422232;P2175;Q549534
Effects of methotrexate and of the "nonclassical" folate antagonist trimetrexate on human leukemia cells.;Q422232;P2175;Q29496
Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. A multicenter randomized placebo-controlled trial.;Q422438;P2175;Q187255
Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. A multicenter randomized placebo-controlled trial.;Q422232;P2175;Q187255
Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. A multicenter randomized placebo-controlled trial.;Q422232;P2175;Q170990
Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.;Q421094;P1889;Q422438
Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.;Q421094;P2175;Q187255
Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.;Q421094;P2175;Q170990
Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.;Q422232;P2175;Q170990
Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.;Q422232;P2175;Q187255
Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.;Q422438;P2175;Q187255
Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.;Q422438;P1889;Q421094
Intravitreal methotrexate as adjunctive, palliative therapy in intraocular T-cell lymphoma.;Q422232;P2175;Q208414
Intravitreal methotrexate as adjunctive, palliative therapy in intraocular T-cell lymphoma.;Q422232;P2175;Q7667896
[High-dose methotrexate plus hematopoietic stem cell transplantation supplemented by rituximab intrathecal injection for primary central nervous system lymphoma:two cases report and literature review];Q412323;P2175;Q136312
[High-dose methotrexate plus hematopoietic stem cell transplantation supplemented by rituximab intrathecal injection for primary central nervous system lymphoma:two cases report and literature review];Q412323;P2175;Q208414
[High-dose methotrexate plus hematopoietic stem cell transplantation supplemented by rituximab intrathecal injection for primary central nervous system lymphoma:two cases report and literature review];Q422232;P636;Q1320251
[High-dose methotrexate plus hematopoietic stem cell transplantation supplemented by rituximab intrathecal injection for primary central nervous system lymphoma:two cases report and literature review];Q422232;P2175;Q136312
[High-dose methotrexate plus hematopoietic stem cell transplantation supplemented by rituximab intrathecal injection for primary central nervous system lymphoma:two cases report and literature review];Q422232;P2175;Q208414
Effects on transmethylation by high-dose 6-mercaptopurine and methotrexate infusions during consolidation treatment of acute lymphoblastic leukemia;Q422232;P2175;Q29496
Severe myelotoxicity in rheumatoid arthritis patients treated with oral methotrexate;Q422232;P636;Q285166
Severe myelotoxicity in rheumatoid arthritis patients treated with oral methotrexate;Q422232;P2175;Q170990
Severe myelotoxicity in rheumatoid arthritis patients treated with oral methotrexate;Q422232;P2175;Q187255
Longterm methotrexate therapy in rheumatoid arthritis: a review.;Q422232;P2175;Q170990
Longterm methotrexate therapy in rheumatoid arthritis: a review.;Q422232;P2175;Q187255
High-dose methotrexate is effective in osteosarcoma so what is the problem?;Q422232;P2175;Q549534
Should methotrexate remain the first-line drug for psoriasis?;Q183290;P31;Q12140
Should methotrexate remain the first-line drug for psoriasis?;Q191924;P31;Q12140
Should methotrexate remain the first-line drug for psoriasis?;Q422232;P31;Q12140
Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation.;Q367700;P2175;Q1194520
Correction to: White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab;Q412323;P2175;Q136312
Correction to: White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab;Q412323;P2175;Q208414
Correction to: White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab;Q422232;P2175;Q136312
Correction to: White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab;Q422232;P2175;Q208414
Methotrexate, uracil and tegafur, and leucovorin chemotherapy for patients with breast cancer in progression after high-dose chemotherapy with peripheral blood progenitor cell transplant: a phase II study;Q422232;P2175;Q128581
Demonstration of a schedule-dependent therapeutic synergism utilizing the interacting drugs methotrexate and teniposide in L1210 leukemia.;Q191924;P31;Q12140
Demonstration of a schedule-dependent therapeutic synergism utilizing the interacting drugs methotrexate and teniposide in L1210 leukemia.;Q191924;P366;Q8386
Demonstration of a schedule-dependent therapeutic synergism utilizing the interacting drugs methotrexate and teniposide in L1210 leukemia.;Q178450;P31;Q12140
Demonstration of a schedule-dependent therapeutic synergism utilizing the interacting drugs methotrexate and teniposide in L1210 leukemia.;Q178450;P703;Q177932
Demonstration of a schedule-dependent therapeutic synergism utilizing the interacting drugs methotrexate and teniposide in L1210 leukemia.;Q417555;P31;Q12140
Demonstration of a schedule-dependent therapeutic synergism utilizing the interacting drugs methotrexate and teniposide in L1210 leukemia.;Q483745;P31;Q12140
Demonstration of a schedule-dependent therapeutic synergism utilizing the interacting drugs methotrexate and teniposide in L1210 leukemia.;Q483745;P703;Q177932
Demonstration of a schedule-dependent therapeutic synergism utilizing the interacting drugs methotrexate and teniposide in L1210 leukemia.;Q422232;P31;Q12140
Demonstration of a schedule-dependent therapeutic synergism utilizing the interacting drugs methotrexate and teniposide in L1210 leukemia.;Q422232;P2175;Q29496
Reduced membrane protein associated with resistance of human squamous carcinoma cells to methotrexate and cis-platinum.;Q173670;P703;Q15978631
Multiple fractions of gamma rays induced resistance to cis-dichloro-diammineplatinum (II) and methotrexate in human HeLa cells.;Q485277;P703;Q15978631
Multiple fractions of gamma rays induced resistance to cis-dichloro-diammineplatinum (II) and methotrexate in human HeLa cells.;Q22124685;P703;Q15978631
Multiple fractions of gamma rays induced resistance to cis-dichloro-diammineplatinum (II) and methotrexate in human HeLa cells.;Q483745;P703;Q15978631
Multiple fractions of gamma rays induced resistance to cis-dichloro-diammineplatinum (II) and methotrexate in human HeLa cells.;Q484940;P703;Q15978631
Early development of Hodgkin's lymphoma in association with the use of methotrexate for the treatment of dermatomyositis.;Q422232;P2175;Q208414
Bleomycin, methotrexate and vincristine before irradiation of stage III and IV laryngeal and pharyngeal squamous cell carcinoma. A study initiated by the Danish Society of Head and Neck Cancer.;Q415571;P2175;Q681817
Diffuse large B-cell lymphoma with lung involvement in a psoriatic arthritis patient treated with methotrexate;Q422232;P2175;Q208414
Diffuse large B-cell lymphoma with lung involvement in a psoriatic arthritis patient treated with methotrexate;Q422232;P2175;Q2626074
Diffuse large B-cell lymphoma with lung involvement in a psoriatic arthritis patient treated with methotrexate;Q422232;P2175;Q170990
Diffuse large B-cell lymphoma with lung involvement in a psoriatic arthritis patient treated with methotrexate;Q422232;P2175;Q4833719
[Effects of high-dose methotrexate therapy on intestinal bacterial flora in children with acute lymphoblastic leukemia].;Q422232;P2175;Q29496
Are glucocorticoids a consistent risk factor for infections in rheumatoid arthritis patients under treatment with methotrexate and etanercept?;Q422232;P2175;Q187255
Are glucocorticoids a consistent risk factor for infections in rheumatoid arthritis patients under treatment with methotrexate and etanercept?;Q422232;P2175;Q170990
Effect of ESR1 and ESR2 gene polymorphisms on rheumatoid arthritis treatment with methotrexate;Q422232;P2175;Q170990
Effect of ESR1 and ESR2 gene polymorphisms on rheumatoid arthritis treatment with methotrexate;Q422232;P2175;Q187255
Genetic and clinical prediction models for the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a multicenter cohort study;Q422232;P2175;Q187255
Genetic and clinical prediction models for the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a multicenter cohort study;Q422232;P2175;Q170990
Mechanisms of resistance to methotrexate in childhood acute lymphoblastic leukemia: circumvention of thymidylate synthase inhibition.;Q422232;P2175;Q29496
Methotrexate for bullous pemphigoid: preliminary study;Q422232;P2175;Q1004647
Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. A possible mechanism of reduced hepatotoxicity.;Q422232;P2175;Q170990
Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. A possible mechanism of reduced hepatotoxicity.;Q422232;P2175;Q187255
Stability of cytarabine, methotrexate sodium, and hydrocortisone sodium succinate admixtures;Q190875;P2959;Q26981430
Determination of methotrexate in pharmaceutical formulations by flow injection analysis exploiting the reaction with potassium permanganate.;Q191924;P31;Q12140
Determination of methotrexate in pharmaceutical formulations by flow injection analysis exploiting the reaction with potassium permanganate.;Q28453504;P527;Q190865
Determination of methotrexate in pharmaceutical formulations by flow injection analysis exploiting the reaction with potassium permanganate.;Q28453504;P31;Q12140
Determination of methotrexate in pharmaceutical formulations by flow injection analysis exploiting the reaction with potassium permanganate.;Q178450;P31;Q12140
Determination of methotrexate in pharmaceutical formulations by flow injection analysis exploiting the reaction with potassium permanganate.;Q422232;P31;Q12140
Relationship of high pretreatment folic acid level and failure of methotrexate in ectopic pregnancy: a pilot study.;Q422232;P2868;Q127060
Relationship of high pretreatment folic acid level and failure of methotrexate in ectopic pregnancy: a pilot study.;Q422232;P2175;Q207087
Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate;Q422232;P2175;Q208414
Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate;Q422232;P2175;Q7667896
Increased Efficacy and Tolerability of Pegloticase in Patients With Uncontrolled Gout Co-Treated With Methotrexate: A Retrospective Study;Q7160794;P2175;Q133087
Pulmonary non-Hodgkin's lymphoma developed during long-term methotrexate therapy for rheumatoid arthritis;Q422232;P2175;Q208414
Pulmonary non-Hodgkin's lymphoma developed during long-term methotrexate therapy for rheumatoid arthritis;Q422232;P2175;Q170990
Pulmonary non-Hodgkin's lymphoma developed during long-term methotrexate therapy for rheumatoid arthritis;Q422232;P2175;Q187255
Pulmonary non-Hodgkin's lymphoma developed during long-term methotrexate therapy for rheumatoid arthritis;Q422232;P2175;Q1138590
Methotrexate pneumonitis precipitated by switching from oral to parenteral administration.;Q422232;P636;Q285166
